ANTICANCER RESEARCH VOLUME International Journal of Cancer Research and Treatment. ISSN (print): ; ISSN (online): - PDF Free Download (2023)

Transcription

1 ANTICANCER RESEARCH International Journal of Cancer Research and Treatment ISSN (print): ; ISSN (online): VOLUME

2

3 This volume is dedicated to the memory of GERARD REBEL

4

5 Editorial Board P.A. Abrahamsson Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden B. B. Aggarwal Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA T. Akimoto Division of Partical Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan A. Argiris Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA J. P. Armand Institut Claudius Regaud, Toulouse, France V. I. Avramis Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA R. C. Bast Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA G. Bauer Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany E. E. Baulieu INSERM U488 and College de France, Le Kremlin-Bicetre, France Y. Becker Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel E. J. Benz, Jr. Dana-Farber Cancer Institute, Boston, MA, USA J. Bergh Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden D. D. Bigner Department of Pathology, Duke University Medical Center, Durham, NC, USA A. Böcking Institute for Cytopathology, University of Düsseldorf, Germany G. Bonadonna Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy F. T. Bosman Institute of Pathology, University of Lausanne, Switzerland G. Broich Gruppo Policlinico di Monza, Monza, Italy J. M. Brown Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA Ø. S. Bruland Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway M. M. Burger Novartis, Basel, Switzerland M. Carbone Cancer Research Center of Hawaii, Honolulu, HI, USA C. Carlberg Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland J. Carlsson Department of Biomedical Radiation Sciences, Uppsala University, Sweden A. F. Chambers Department of Oncology, London Regional Cancer Center, London, Ontario, Canada P. Chandra Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany L. Cheng Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA J.-G. Chung Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC E. De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium W. De Loecker Department of Biochemistry, Katholieke Universiteit Leuven, Belgium W. Den Otter VUMC, Department of Urology, Amsterdam, The Netherlands E. P. Diamandis Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada G. Th. Diamandopoulos Department of Pathology, Harvard Medical School, Boston, MA, USA D.W. Felsher Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA J. A. Fernandez-Pol Metalloproteomics, LLC, Chesterfield, MO, USA I. J. Fidler Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA A.P. Fields Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA B. Fuchs Balgrist University Hospital, Zurich, Switzerland G. Gabbiani Department of Pathology, University of Geneva, Switzerland R. Ganapathi Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA A. F. Gazdar Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA J.H. Geschwind Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA A. Giordano Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA G. Gitsch Department of Gynecology and Obstetrics, University of Freiburg, Germany R. H. Goldfarb Trudeau Institute, Saranac Lake, NY, USA 6999

6 S. Hammarström Department of Immunology, University of Umeä, Sweden I. Hellström Harborview Medical Center, Seattle, WA, USA L. Helson Sign Path Pharma, Inc., Quakertown, PA, USA R. M. Hoffman Department of Surgery, University of California, San Diego, CA, USA K.-S. Jeong Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, South Korea S. C. Jhanwar Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA J. V. Johannessen Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway B. Kaina Institute of Toxicology, University of Mainz, Germany P. -L. Kellokumpu-Lehtinen Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland B. K. Keppler School of Medicine, University of Vienna, Austria D. G. Kieback Klinikum Vest, Standort Marl, Marl, Germany R. Klapdor Medical Clinic, University of Hamburg, Germany U. R. Kleeberg Hämatologisch - Onkologisch - Praxis Altona, Hamburg, Germany P. Kleihues Department of Pathology, University Hospital Zürich, Switzerland E. Klein Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden S. D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece G. R. F. Krueger Center of Anatomy II, University of Cologne Medical School, Cologne, Germany D. W. Kufe Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA Pat M. Kumar Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK Shant Kumar Department Pathology, University of Manchester Medical School, Manchester, UK M. Kuroki Department of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan O. D. Laerum Department of Pathology, The Gade Institute, University of Bergen, Norway F. J. Lejeune Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland L. F. Liu Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA D. M. Lopez Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA E. Lundgren Unit of Applied Cell and Molecular Biology, University of Umeä, Sweden H. T. Lynch Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA Y. Maehara Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan J. Maher Department of Research Oncology, Division of Cancer Studies, King s College London School of Medicine, Guy s Hospital Campus, London, UK J. Marescaux IRCAD, University of Strasbourg, France J. Mark Department of Pathology, Kärnsjukhuset, Skövde, Sweden S. Mitra The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA M. Mueller Hochschule Furtwangen University, Villingen-Schwenningen, Germany F. M. Muggia New York University Cancer Institute, School of Medicine, NY, USA M. J. Murphy, Jr. Hipple Cancer Research Center, Dayton, OH, USA M. Namiki Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan R. Narayanan Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA K. Nilsson Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden S. Pathak Department of Cell Biology, University of Texas, Houston, TX, USA J.L. Persson Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden S. Pestka Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA G. J. Pilkington Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK C. D. Platsoucas College of Sciences, Old Dominion University, Norfolk, VA, USA F. Podo Laboratory of Cell Biology, Istituto Superione di Sanità, Rome, Italy 7000

7 A. Polliack Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel G. Rebel IRCAD, Hopitaux Universitaires, Strasbourg, France M. Rigaud Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France U. Ringborg Department of General Oncology, Karolinska Hospital, Stockholm, Sweden M. Roselli Department of Medical Oncology, University of Rome Tor Vergata, Italy A. Schauer Zentrum Pathologie, Georg-August Universität, Göttingen, Germany M. Schneider Department of Organic Chemistry, Bergische University, Wuppertal, Germany A. Seth Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada G. V. Sherbet Cancer Research Unit, University of Newcastle-upon-Tyne, UK G.-I. Soma Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan G. S. Stein Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA T. Stigbrand Department of Immunology, Umeä University, Umeä, Sweden T. M. Theophanides Department of Chemistry, Technical University of Athens, Greece B. Toth The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA P. M. Ueland Clinical Pharmacolocy Unit, Department of Pharmacology, University of Bergen, Norway H. Van Vlierberghe Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium R.G. Vile Department of Immunology, Mayo Clinic, Rochester, MN, USA M. Weller Department of Neurology, University Hospital Zurich, Zurich, Switzerland B. Westermark Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden Y. Yen Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA M.R.I. Young Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA B. Zumoff Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA 7001

8

9 Acknowledgements The IIAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 35, Aage and Johanne Louis-Hansen Fund, Nivå, Denmark Aase and Ejnar Danielsen Fund, Lyngby, Denmark Academia Sinica, Taipei, Taiwan, R.O.C. Academy of Finland, Helsinki, Finland Academy of Sciences of the Czech Republic, Prague, Czech Republic Advanced Research Foundation, U.S.A. Aenorasis SA, Athens, Greece Agence Nationale de la Recherche (ANR), Paris, France Agreement for Doctoral Education, Region Västra Götaland, Sweden Aichi Cancer Research Foundation, Aichi, Japan Akademická prémie - Praemium Academiae, Prague, Czech Republic Albany College of Pharmacy and Health Sciences, Albany, NY, U.S.A. Albany Memorial Hospital, Albany, NY, U.S.A. Albert Hung Foundation, Hong Kong, P.R. China Albertinen-Krankenhaus Zentrallabor, Hamburg, Germany Alere Medical Co., Ltd., Tokyo, Japan Ali s Dream, Brain Tumor Research, London, U.K. Alliance Pour la Recherche En Cancérologie (APREC), Paris, France Alma Toorock Memorial for Cancer Research, Brooklyn, NY, U.S.A. American Brain Tumor Association Medical Student Summer Fellowship in Honor of Paul Fabri, Chicago, IL, U.S.A. American Brain Tumor Association, Chicago, IL, U.S.A. American Physicians Fellowship for Medicine in Israel, Boston, MA, U.S.A. Anthem Biosciences, Bengaluru, India ApotheCom, Yardley, PA, U.S.A. Arbeitsgemeinschaft für medikamentöse Tumortherapie (AGMT), Salzburg, Austria Arnold S. Leonard Cancer Research Fund, Golden Valley, MN, U.S.A. Articulate Science, London, U.K. Asan Institute for Life Science, Seoul, Republic of Korea Assar Gabrielsson Foundation, Gothenburg, Sweden Assistance Publique Hôpitaux de Paris (APHP), Paris, France Association pour la Recherche sur les Tumeurs Cérébrales Sud (ARTC Sud), Marseille, France Associazione Italiana Ricerca Cancro (AIRC), Milan, Italy Astri and Birger Torsteds Legat, Oslo, Norway Austrian Development Cooperation, Vienna, Austria Austrian Exchange Service (OeAD), Austrian Federal Ministry of Education and Women's Affairs (BMBF), Wien, Austria Austrian Science Fund (FWF), Vienna, Austria Avon Foundation, New York, NY, U.S.A. Barcode for Life Foundation, Zeist, the Netherlands Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea Ben-Gurion University of the Negev, Be'er Sheva, Israel Bio & Medical Technology Development Program, National Research Foundation of Korea, Republic of Korea Biological Research Facility, St. George s University of London, London, U.K. Biomedical Science Research Initiative Grant, Biomedical Science Cancer Research Donation Fund, Australia Bio-oriented Technology Research Advancement Institution, NARO, Saitama, Japan Biostatics Task Force, Taichung Veteran General Hospital, Taichung, Taiwan, R.O.C. BK21 Plus Program for Creative Veterinary Science Research, Seoul National University, Seoul, Republic of Korea Brain Tumour Research, Buckingham, U.K. Brainstrust, Cowes, U.K. Breast Cancer Research Foundation (BCRF), New York, NY, U.S.A. Bremer Krebsgesellschaft e.v., Bremen, Germany Bristol-Myers Squibb spol. s.r.o., Prague, Czech Republic Bryer Foundation Medical Research Fund, University of Michigan-Flint, Flint, MI, U.S.A. Buddhist Dalin Tzu Chi Hospital, Dalin, Taiwan, R.O.C. California State University-Fresno, Fresno, CA, U.S.A. Canadian Breast Cancer Foundation (CBCF), Toronto, ON, Canada Cancer Foundation, Gävle Hospital, Gävle, Sweden Cancer Research Funds of Radiumhemmet, Karolinska Institutet, Stockholm, Sweden 7003

10 Cancer Research Wales, Wales, U.K. Cancer Society of Finland, Helsinki, Finland Cancer Society Schleswig-Holstein, Schleswig-Holstein, Germany Cancer Vaccine Institute, London, U.K. Cardiothoracic Center and Transplant Unit, General Hospital G. Papanikolaou, Thessaloniki, Greece Carl Zeiss MicroImaging GmbH, Jena, Germany Cathay General Hospital, Taipei, Taiwan, R.O.C. Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan Center for Translational Molecular Medicine (CTMM), Project for Mammary Carcinoma Molecular Imaging for Diagnosis and Therapeutics (MAMMOTH), Eindhoven, the Netherlands Centre Oscar Lambret, Centre Hospitalier Régional Universitaire de Lille, Lille, France Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C Charles University in Prague, Prague, Czech Republic Charles University Research Fund, Prague, Czech Republic Charlie s Challenge, Heathfield, East Sussex, U.K. Childhood Brain Tumor Foundation, Germantown, MD, U.S.A. Children s Hospital Oakland Research Institute, Oakland, CA, U.S.A. China Medical University Hospital, Taichung, Taiwan, R.O.C. China Medical University, Taichung, Taiwan, R.O.C. China Scholarship Council, Beijing, P.R. China Chinese Scholarship Council (CSC), Beijing, P.R. China Chosun University, Gwangju, Republic of Korea Chungnam National University Hospital Research Fund, Daejeon, Republic of Korea Clinical Research Promotion Foundation, Japan Society for the Promotion of Science (JSPS), Tokyo, Japan Clinical Trial and Research Center of Excellence, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C. College of Engineering, University of Washington, Seattle, WA, U.S.A. Competitive State Research Financing of the Expert Responsibility Area of Tampere and Helsinki University Hospitals, Finland Comprehensive Cancer Centre Netherlands, The Netherlands Cancer Institute, Amsterdam, the Netherlands Confocal Microscopy Laboratory, Institute of Zoology, Jagiellonian University, Kraków, Poland Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brasilia, Brazil Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasilia, Brazil Copenhagen Municipal s 100th Anniversary Foundation, Copenhagen, Denmark COST Consortium ChemBioRadical, Bologna, Italy Council for Science, Technology and Innovation (CSTI), Tokyo, Japan Crafoord Foundation, Lund, Sweden CREST, Tokyo, Japan Cross-ministerial Strategic Innovation Promotion Program (SIP), Tokyo, Japan Cryotherapy Trust Fund, Harefield, U.K. Dabo s All-In Team Foundation, Clemson, SC, U.S.A. Dagmar Marshall s Foundation, Denmark Daiwa Securities Health Foundation, Tokyo, Japan Danish Cancer Research Foundation, Copenhagen, Denmark Danish Cancer Society, Copenhagen, Denmark Danish Council for Independent Research, Copenhagen, Denmark Danish Council for Strategic Research, Copenhagen, Denmark Danish Lung Association, Copenhagen, Denmark Danish Medical Research Council, Copenhagen, Denmark Dankook University, Yongin, Republic of Korea Department of Anesthesiology and Operative Intensive Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C. Department of Biostatistics and Epidemiology, Yokohama City University, Yokohama, Japan Department of Biostatistics and Pharmaceutical Medicine, Yokohama City University of Medicine, Yokohama, Japan Department of Clinical Pathology, University Hospital of North Norway, Tromsoe, Norway Department of Clinical Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland Department of Gastroenterology, University Hospital of Marburg, Marburg, Germany Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland Department of Immunology and Parasitology, Tokushima University, Tokushima, Japan Department of Internal Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, U.S.A. 7004

11 Department of Medical Oncology, UMC Utrecht, Utrecht, the Netherlands Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan, R.O.C. Department of Molecular Medicine, Institute of Health Science, Istanbul University, Istanbul, Turkey Department of Neurosurgery and College of Medicine, Medical University of South Carolina, Charleston, SC, U.S.A. Department of Oncology, Uppsala University Hospital, Uppsala, Sweden Department of Orthodontics and Pediatric Dentistry, University of Michigan, Ann Arbor, MI, U.S.A. Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Center, Munich, Germany Department of Pathology, Oslo University Hospital, Oslo, Norway Department of Pathology, Peking University First Hospital, Beijing, P.R. China Department of Pathology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway Department of Pathology, Rigshospitalet, Copenhagen, Denmark Department of Pathology, Singapore General Hospital, Singapore, Republic of Singapore Department of Pathology, UMC Utrecht, Utrecht, the Netherlands Department of Pathology, University of Lübeck, Lübeck, Germany Department of Pharmaceutical Chemistry and Drug Control, Faculty of Pharmacy, Charles University in Prague, Hradec Králové, Czech Republic Department of Public Health, Experimental Medicine and Forensic, Histology and Embryology Unit, University of Pavia, Pavia, Italy Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C. Department of Statistics, North Carolina State University, Raleigh, NC, U.S.A. Department of Surgery, University of Minnesota, Minneapolis, MN, U.S.A. Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan Department of Transfusion Medicine, The University of Tokyo, Tokyo, Japan Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu, Japan Department of Urology, HELIOS Hospital, Bad Saarow, Germany Department of Urology, Lukaskrankenhaus, Neuss, Germany Department of Visceral Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany Deutsche Krebshilfe, Bonn, Germany District Hospital Akureyri, Akureyri, Iceland Division of Advanced Research Promotion, Aichi Medical University, Nagakute, Japan Division of Cancer Research and Training, Charles R. Drew University, Los Angeles, CA, U.S.A. Division of Hematology-Oncology, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C. Division of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C. Doktor Robert Pfleger-Stiftung, Bamberg, Germany Dong-nam Institute of Radiological & Medical Sciences(DIRAMS), Busan, Repubic of Korea Doppler Laboratory for Molecular Chemoprevention, Medical University of Vienna, Vienna, Austria Eden Therapeutic Solutions, Houston, Texas, U.S.A. Edmonton Civic Employees Charitable Assistance Fund (ECECAF), St. Albert, AB, Canada Eindhoven Cancer Registry Comprehensive Cancer Centre South, Eindhoven, the Netherlands Élan Corporation plc, Perrigo Company PLC, Dublin, Ireland Elna Kaarina Savolainen's Cancer Research Fund, Finland Else-Kröner Fresenius Foundation (EKFS), Bad Homburg vor der Höhe, Germany Emil Aaltonen Foundation, Tampere, Finland Emmerling Fund, The Pittsburgh Foundation, Pittsburgh, PA, U.S.A. Endoscopy Division, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan Endoscopy Unit, St. George Private Hospital, Kogarah, NSW, Australia Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsförderung (ELAN), Universität Erlangen- Nürnberg, Erlangen, Germany Ernst Mach Grant, Wien, Austria European Association for the Study of the Liver (EASL), Geneva, Switzerland European Regional Development Fund, Brussels, Belgium European Social Fund (ESF), European Commission, Brussels, Belgium 7005

12 EuroTransBio, Jülich, Germany EVO Funds, Kuopio University Hospital, Kuopio, Finland F. Hoffmann-La Roche AG, Basel, Switzerland Fabrikant Einar Willumsens Memorial Trust, Broendby, Denmark Faculty Hospital in Pilsen, Pilsen, Czech Republic Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Japan FALCO Biosystems, Kyoto, Japan Federal Ministry of Economics and Energy, Berlin, Germany Federal University of Pará, Belém, Pará, Brazil Finnish Anti-Tuberculosis Foundation, Finland Finnish Cancer Society, Helsinki, Finland Finnish Cultural Foundation, Helsinki, Finland Finnish Foundation for Cardiovascular Research, Helsinki, Finland Finnish Medical Foundation, Helsinki, Finland FIRB Futuro in Ricerca, Ministry of Education, Universities and Research (MIUR), Rome, Italy FIRB/MERIT, Italy Florida A & M University, Tallahassee, FL, U.S.A. Florida Cancer Data System (FCDS), Miami, FL, U.S.A. Flow Cytometry Core Facility, Oslo University Hospital, Oslo, Norway Flow Cytometry, Yale Cancer Center, New Haven, CT, U.S.A. Fondation pour la Recherche Médicale (FRM), Paris, France Fondazione Banca Monte Lombardia, Pavia, Italy Förderverein Hilfe bei Prostatakrebs e.v. (FHbP), Bonn, Germany Forschungsförderungsverein für Rheumatologie und Balneologie, Wien, Austria Forschungsstiftung Medizin, University Hospital Erlangen, Erlangen, Germany Foundation for Cancer Research Szeged, Szeged, Hungary Foundation for the Promotion of Cancer Research, Tokyo, Japan Foundation for the Promotion of Medical Science, Tokyo, Japan Foundation in Memory of Sigvald and Edith Anelise Celine Kristine Rasmussen, Denmark Foundation Living with Cancer (Stiftung Leben mit Krebs), Mainz-Kastel, Germany Foundation of Osaka Cancer Research, Osaka, Japan Founding Program for Next Generation World-leading Researchers, Tokyo, Japan Franz Lanyar Foundation, Medical University of Graz, Graz, Austria Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany Friedrich Baur Stiftung, Altenkunstadt, Germany Fujisawa Municipal Citizen's Hospital, Fujisawa, Japan Fukuoka Foundation for Sound Health Cancer Research Fund, Fukuoka, Japan Fundação Amazônia Paraense do Estado do Pará (FAPESPA), São Paulo, Brazil Fundação para a Ciência e a Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal G.A.E. Nilsson Foundation for Cancer Treatment, Sweden Gaziantep University Research Foundation, Şehitkamil/Gaziantep, Turkey Gene Research Center, Yamaguchi University, Yamaguchi, Japan Gene Research Centre, Yamaguchi University, Yamaguchi, Japan Genekor Medical S.A., Athens, Greece Gen-Probe, San Diego, CA, U.S.A. Georgetown University, Washington, DC, U.S.A. German Academic Exchange Service (DAAD), New York, NY, U.S.A. German Liver Foundation, Essen, Germany GlaxoSmithKline plc, London, U.K. Gothenburg Dental Society, Gothenburg, Sweden Graduate School of Medicine, Chiba University, Chiba, Japan Grand Forks Human Nutrition Research Center, Grand Forks, ND, U.S.A. Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan Gunma Cancer Center, Ohtawara, Japan Gustave Roussy Cancer Campus, Villejuif, France Haematology Unit, Department of Medical and Experimental Oncology, National Cancer Research Centre Giovanni Paolo II, Bari, Italy Hallym University Research Fund, Chuncheon, Republic of Korea Hannover Medical School, Hannover, Germany Harper Cancer Research Institute, University of Notre Dame, South Bend, IN, U.S.A. Health and Labour Sciences Research Grant, Ministry of Health, Labor, and Welfare, Tokyo, Japan Health Sciences Faculty Seed Grant Program, Howard University, Washington, DC, U.S.A. 7006

13 Health Service Center, Tokushima University, Tokushima, Japan Hede Nielsen Foundation, Horsens, Denmark Hellenic Cooperative Oncology Group, Athens, Greece Hellenic Society of Medical Oncology (HeSMO), Athens, Greece Higher KOS Project (Promoting Institutional Development in Higher Education and Research in Kosovo), Prishtina, Republic of Kosovo Histology and Embryology Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Histology Facility for Immunohistochemical Staining, Confocal and High Content Screening Facility of Basement Shared Facilities (BSF), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Sinagapore Howard University ADVANCE-IT, Washington, DC, U.S.A. Howard University Cancer Center/ Johns Hopkins Cancer Center Partnership grant, National Cancer Institute, Bethesda, MD, U.S.A. Howard University, Washington, DC, U.S.A. Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan Hvidovre Hospital, Hvidovre, Denmark Hyogo Scientific and Technology Association, Hyogo Prefecture, Japan Ib Henriksens Foundation, Hørsholm, Denmark Ichiro Kanehara Foundation of the Promotion of Medical Science and Medical Care, Tokyo, Japan Ida Montin Fund, Finland IMK Almene Foundation, Denmark Indian Institute of Science, Bengaluru, India Inger and John Fredriksen Foundation, Norway Innovative Research Institute for Cell Therapy, Seoul, Republic of Korea Institut für Anatomie Experimentelle Morphologie, Universitätsklinikum Eppendorf, Hamburg, Germany Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France Institut National du Cancer, Boulogne-Billancourt, France Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille, France Institute for Biological Interfaces of Engineering, Clemson University, Clemson, SC, U.S.A. Institute of Biometrics and Epidemiology, University of Duisburg-Essen, Essen, Germany Institute of Biostatistics and Analysis, Masaryk University, Brno, Czech Republic Institute of Endocrinology, Prague, Czech Republic Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal Institutes of Bioengineering and Nanotechnology, Singapore, Republic of Singapore Instituto de Salud Carlos III, Madrid, Spain International Institute of Anticancer Research, Kapandriti, Greece inventiv Health Clinical, Princeton, NJ, U.S.A. Isle of Man Anticancer Association, Douglas, Isle of Man, U.K. Israel Cancer Association, Givatayim, Israel Istanbul University, Istanbul, Turkey János Bolyai Research Scholarship, Hungarian Academy of Sciences, Budapest, Hungary Janssen Pharmaceutical K.K., Tokyo, Japan Japan Brain Foundation, Japan Japan Science and Technology Agency (JSTA), Kawaguchi, Japan Japan Society for the Promotion of Science, (JSPS), Tokyo, Japan Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan Japanese Society of Gastroenterology, Tokyo, Japan Japanese Society of Strategies for Cancer Research and Therapy, Japan Jen-Ai Hospital, Dali, Taichung, Taiwan, R.O.C. Jerry Zucker Fund for Brain Tumor Research, MUSC Foundation, Charleston, SC, U.S.A. John and Augusta Persson Foundation for Scientific Medical Research, Sweden Kanagawa Health Foundation, Kanagawa, Japan Kanagawa Prefectural Hospitals Cancer Fund, Japan Kanazawa Medical Association, Kanazawa, Japan Kanazawa Medical Research Foundation, Kanazawa, Japan Kansai Genshi-ryoku Kondankai, Osaka, Japan Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan, R.O.C. Karolinska Institutet, Solna, Sweden Karolinska University Hospital, Stockholm, Sweden Kathrine og Vigo Skovgaards Foundation, Denmark KfH Kidney Centre, Dritter Orden Clinic, Munich, Germany Kitasato University Hospital, Sagamihara, Japan KKR Sapporo Medical Center, Sapporo, Japan 7007

14 Klinikum Großhadern, Munich, Germany Kobe Tokushukai Hospital, Kobe, Japan Kochi University, Nankoku, Japan Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea Korean Healthcare Technology R&D, Korean Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Sejong, Republic of Korea Korean Radiation Oncology Group, Republic of Korea Kornerup Fund, Denmark KRIBB Research Initiative Program, Ministry of Science, ICT and Future Planning (MSIP), Republic of Korea KRP, KCCH Research Competence Promotion, Republic of Korea Krumme Foundation, Bristow, OK, U.S.A. K-STEMCELL Co., Ltd, Seoul, Republic of Korea Kuopio University Hospital, Kuopio, Finland Kyungpook National University Hospital, Daegu, Republic of Korea Kyushu University, Fukuoka, Japan La Ligue Contre le Cancer, Paris, France Laboratoire de Suivi Thérapeutique Pharmacologique, Hôpital Saint Antoine, Paris, France Laboratory of Division for Medical Research Engineering, Nagoya University Graduate School of Medicine, Nagoya, Japan Laboratory of Surgical Pathology, Shimane University Hospital, Shimane, Japan Laboratory of Veterinary Pathology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal Landspitali, University Hospital, Reykjavik, Iceland Latvian Science Council, Riga, Latvia Ligue Nationale Contre Le Cancer, Paris, France Linköping University and Region Östergötland, Linköping, Sweden LION Cancer Foundation, Umeå, Sweden Lund University Hospital, Lund, Sweden Lundgren Foundation, Sweden Lynde and Harry Bradley Foundation, Milwaukee, WI, U.S.A. Maastricht University, Maastricht, the Netherlands Malaysian Palm Oil Board (MPOB), Kuala Lumpur, Malaysia Masaryk University, Brno, Czech Republic Max-Planck Society for the Advancement of Science, Munich, Germany McElroy Trust Foundation, Waterloo, IA, U.S.A. medac GmbH, Wedel, Germany Medical Biomics Centre, St. George s University of London, London, U.K. Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea Medical Research Core Facilities Center, Office of Research and Development, China Medical University, Taichung, Taiwan, R.O.C. Medical School of São Paulo University, São Paulo, Brazil Medical University of Lublin, Lublin, Poland Medi-Kelsey Limited, Derbyshire, U.K. Medinet Co., Ltd., Yokohama, Japan Medistat GmbH, Kiel, Germany Ministry of Economics and Science of the Saarland, Germany Ministry of Economy, Trade and Industry, Tokyo, Japan Ministry of Education (MEST), Sejong, Republic of Korea Ministry of Education and Scientific Research, Bucharest, Romania Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan Ministry of Education, Science and Technology, Republic of Kosovo Ministry of Education, Sejong, Republic of Korea Ministry of Education, Youth and Sports, Prague, Czech Republic Ministry of Environment, Forest and Climate Change, Government of India, New Delhi, India Ministry of Food and Drug Safety, Cheongwon County, Republic of Korea Ministry of Health & Welfare, Sejong, Republic of Korea Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan, R.O.C. Ministry of Health of the Czech Republic, Prague, Czech Republic Ministry of Health, Labor and Welfare of Japan, Tokyo, Japan Ministry of Health, Prague, Czech Republic Ministry of Health, Social Services and Equality, Madrid, Spain Ministry of Science and Higher Education of Poland, Warsaw, Poland Ministry of Science and Technology (MOST), Taipei City, Taiwan, R.O.C. Ministry of Science, ICT & Future Planning, Gwacheon, Republic of Korea Ministry of Science, Technology and Higher Education (MCTES), Lisbon, Portugal 7008

15 Minnesota Supercomputing Institute, Minneapolis, MN, U.S.A. Mitsui Life Social Welfare Foundation, Tokyo, Japan Miyagi Cancer Center, Sendai, Japan Moffitt Cancer Center, Tampa, FL, U.S.A. MRC-Holland, Amsterdam, the Netherlands Multidisciplinary Education and Research Center for Regenerative Medicine (MERCREM), Ministry of Education, Culture, Sports Science, and Technology (MEXT), Tokyo, Japan Nagoya City University, Nagoya Japan Naito Foundation Subsidy for Dispatch of Young Researchers Abroad, Tokyo, Japan Nakayama Cancer Research Institute, Tokyo, Japan National Cancer Center Research and Development Fund, Tokyo, Japan National Cancer Center, Tokyo, Japan National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A. National Cancer Research Centre Giovanni Paolo II, Bari, Italy National Center for Advancing Translational Sciences, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A. National Center for Biological Sciences, Bengaluru, India National Center for Research Resources (NCRR), National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A. National Center on Minority Health and Health Disparities (NIMHD), Bethesda, MD, U.S.A. National Health and Medical Research Council (NHMRC), Canberra, Australia National Institute of Minority Health and Health Disparities (NIMHD), NIH, Bethesda, MD, U.S.A. National Institutes of Health (NIH), Department of Health and Human Services, Bethesda, MD, U.S.A. National Natural Science Foundation of China, P.R. China National Nuclear R&D Program, Ministry of Science, ICT and Future Planning, Gwacheon, Republic of Korea National R&D Program for Cancer Control, Ministry of Health & Welfare, Sejong, Republic of Korea National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea National Resource Centre for Sarcomas in Norway, Oslo, Norway National Science Centre of Poland, Krakow, Poland National Science Council of Taiwan, Taipei, Taiwan, R.O.C. National Translational Medicine and Clinical Trial Resource Center, National Research Program for Biopharmaceuticals, National Science Council of Taiwan, Taipei, Taiwan, R.O.C. National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C. Natural Sciences and Engineering Research Council (NSERC), Ottawa, ON, Canada Netherlands Cancer Institute, Amsterdam, the Netherlands Netherlands Cancer Registry (NCR), Utrecht, the Netherlands Nevada Cancer Institute, Las Vegas, NV, U.S.A. New Brunswick Health Research Foundation (NBHRF), Fredericton, NB, Canada New Brunswick Innovation Foundation (NBIF), Fredericton, NB, Canada New Energy and Industrial Technology Development Organization (NEDO), Kawasaki City, Kanagawa, Japan Nilsson-Ehle Foundation, Royal Physiographic Society in Lund, Lund, Sweden North-Easthern Society of Gynecological Oncology (NOGGO), Berlin, Germany Northern-Norwegian Health Authority, Bodø, Norway Norwegian Cancer Society, Oslo, Norway Norwegian Radium Hospital, Oslo, Norway Novartis International AG, Basel, Switzerland Oesterreichische Nationalbank, Wien, Austria Office of Research and Development (ORD), Department of Veterans Affairs, Washington, DC, U.S.A. OncoSur Group, Spain Ono Cancer Research Fund, Japan Optics & Imaging Centre, University of KwaZulu-Natal, Durban, South Africa Örebro County Council, Sweden Organization for Life Science Advancement Programs and Translational Research Program, Japan Österreichischer Austauschdienst (OEAD), Vienna, Austria Otago Medical Research Foundation, Dunedin, New Zeland Otto Endowed Professorship, Waverly, IA, U.S.A. P.O.R Campania FESR, Italy Paavo and Eila Salonen Legacy, Finland Paavo Koistinen Foundation, Mikkeli, Sweden Pancreas Research Foundation, Japan Paracelsus Medical University, Salzburg, Austria Paulo Foundation, Espoo, Finland 7009

16 PerkinElmer, Waltham, MA, U.S.A. Pfizer Belgium, Puurs, Belgium Philips Research, Eindhoven, the Netherlands Picower Institute for Learning and Memory, M.I.T., Cambridge, MA, U.S.A. Pirkanmaa Hospital District, Tampere, Finland Pirkanmaa Regional Fund, Finland POLA network, France Practical Research for Innovative Cancer Control, Japan Agency For Medical Research and Development (AMED), Tokyo, Japan Priority Academic Program Development, Jiangsu Higher Education Institutions, P.R. China Professor John Naeslunds Stipendiefond, Sweden Programa Operacional Temático de Factores de Competitividade (POFC) - COMPETE, Portugal Project ODIN, European Union's Seventh Framework Programme, Brussels, Belgium Project Stealth, University of Minnesota, Minneapolis, MN, U.S.A. Pró-Reitoria de Pesquisa e Pós Graduação/Universidade Federal do Pará-Fundação de Amparo e Desenvolvimento da Pesquisa (PROPESP/UFPA-FADESP), Brazil Quadro de Referência de Estratégia Nacional (QREN), Lisbon, Portugal Queensland Head and Neck Cancer Centre, Australia Rachadapisaek Sompote Post-Doctoral Fund, Chulalongkorn University, Bangkok, Thailand Radiological Translational Research (RTR) Program, Seoul, Republic of Korea Radiotherapy Unit, IRCCS San Matteo Hospital Foundation, Pavia, Italy Radium Hospital Research Foundation, Oslo, Norway Randy Shaver Cancer Research & Community Fund, St. Louis Park, MN, U.S.A. Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand Rede de Pesquisa em Genômica Populacional Humana, Brazil Regional Zealand s Research Grant, New Zealand Research and Creative Activities Fund, University of Michigan-Flint, Flint, MI, U.S.A. Research Animal Resources, University of Minnesota, Minneapolis, MN, U.S.A. Research Council of Lithuania, Vilnius, Lithuania Research Department, Durban University of Technology, Durban, South Africa Research Foundation, Norwegian Radium Hospital, Oslo, Norway Research Fund of Dankook University, Yongin, Republic of Korea Research Fund of Istanbul University, Istanbul, Turkey Research Institute for Veterinary Science, Seoul National University, Seoul, Republic of Korea Research Program on Hepatitis, Japan Agency for Medical Research and Development, Tokyo, Japan Research Reactor Institute, Kyoto University, Osaka, Japan Research Support Center, Division of Clinical Science, Dokkyo Medical University, Tochigi, Japan Research Support Center, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan Reykjavik Private Clinic, Reykjavik, Iceland Richard and Ethel Herzfeld Foundation, Milwaukee, WI, U.S.A. Rigshospitalet Copenhagen University Hospital Research Grants, Copenhagen, Denmark RIKEN BioResource Center, Tsukuba, Japan Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, U.S.A. Roche Diagnostics GmbH, Penzberg, Germany Ronald Bittner Brain Tumor Research Fund, U.S.A. Royal Marsden/ICR NIHR Biomedical Research Centre, London, U.K. Royal Physiographic Society, Lund, Sweden Russian Foundation for Basic Research, Moscow, Russia Sagawa Foundation for Promotion of Cancer Research, Japan Samsung Biomedical Research Institute, Seoul, Republic of Korea Sanofi-Aventis, Paris, France Sapienza Ph.D. Program in Biotechnology in Clinical Medicine, University of Rome Sapienza, Rome, Italy Sawmill Owner Jeppe Juhl & Wife Ovita Juhl Memorial Scholarship, Copenhagen, Denmark Scare Crow, Inc., Tokyo, Japan School of Chemistry, University of Sydney, Sydney, NSW, Australia Scientific Research Projects Coordination Unit, Istanbul University, Istanbul, Turkey Seoul National University Bundang Hospital, Bundang, Republic of Korea Seoul National University Hospital (SNUH) Research Fund, Seoul, Republic of Korea Seppo Nieminen's Testament Fund, Finland Ser Cymru Welsh Life Science Network, Wales, U.K. 7010

17 Service d Oncologie Médicale, Hôpital Tenon, Paris, France Shinshu Medical Foundation, Matsumoto, Japan Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan, R.O.C. Sigrid Jusélius Foundation, Helsinki, Finland Medicinska Understödsföreningen Liv & Hälsa, Helsinki, Finland Simon Fougner Hartmanns Family Foundation, Denmark SIRIC of Marseille, Marseille, France Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany Soonchunhyang University Research Fund, Asan, Republic of Korea South-Eastern Norway Regional Health Authority, Hamar, Norway Southern and Eastern Norway Regional Health Authority (RHF), Hamar, Norway Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica), Madrid, Spain Spectrum Radiológiával az Egészségért Foundation, Budapest, Hungary St. Joseph Regional Health Center, Bryan, TX, U.S.A. Statistical Analysis Laboratory, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan, R.O.C. Sterix Ltd., Oxford, U.K. Stiftung zur Krebsbekämpfung, Zurich, Switzerland Stiftungsfonds BIOX, Stuttgart, Germany Stockholm Cancer Society, Stockholm, Sweden Stockholm City Council, Stockholm, Sweden Sudanese National Research Council, Khartoum, Sudan Suganthi Devadason Marine Research Institute, Thoothukudi, India Suharakinennzaidann Co., Ltd., Sapporo, Japan Summer Undergraduate Research Experience, Division of Natural and Social Sciences, Carthage College, Kenosha, WI, U.S.A. Supported Program for the Strategic Research Foundation at Private Universities, MEXT, Japan Surgery Clinic, Norwegian Radium Hospital, Oslo, Norway Susan G. Komen for the Cure Foundation, Alexandria, VA, U.S.A. Swedish Cancer Foundation, Stockholm, Sweden Swedish Dental Society, Sweden Swedish International Development Cooperation Agency (Sida), Stockholm, Sweden Swim Across America, Boston, MA, U.S.A. Szeged Foundation for Cancer Research (Szegedi Rákkutatásért Alapítvány), Szeged, Hungary Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C. Takeda Science Foundation, Japan Teaching and Research Institute, Barretos Cancer Hospital, Barretos, SP, Brazil Terry Fox Cancer Research Foundation, Taipei, Taiwan, R.O.C. Teva Pharmaceutical Industries LTD, Petah Tikva, Israel Thailand Research Fund, Bangkok, Thailand Thureus Foundation, Uppsala, Sweden TiHo Hannover, Hannover, Germany Tissue Bank, China Medical University, Taichung, Taiwan, R.O.C. Tokyo Cooperative Oncology Group, Tokyo, Japan Tokyo Metropolitan Cancer & Infectious Diseases Center, Komagome Hospital, Tokyo, Japan Toranomon Hospital, Tokyo, Japan Translational Research and Applied Medicine (TRAM), School of Medicine, Stanford University, Stanford, CA, U.S.A. Trion Pharma Inc., Munich, Germany Triumph Over Kid Cancer Foundation, Christi, TX, U.S.A. Tumor Cell Line Repository, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A. Turku University, Turku, Finland Undergraduate Research Opportunity Program, University of Michigan-Flint, Flint, MI, U.S.A. United States Department of Defense, The Pentagon, VA, U.S.A. University of Cologne, Cologne, Germany University of Dammam, Dammam, Saudi Arabia University of Otago, Dunedin, New Zeland University of Pécs, Pécs, Hungary University of Rochester, Rochester, NY, U.S.A. University of Siena, Siena, Italy University of Texas Health Science Center at San Antonio, San Antonio, TX, U.S.A. University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A. University of Tuebingen, Tuebingen, Germany University of Wisconsin-Milwaukee, Milwaukee, WI, U.S.A. Uppsala County Association Against Heart and Lung Diseases, Uppsala, Sweden 7011

18 Urologic Surgery, University of Siena, Siena, Italy Urology Unit, University of Siena, Siena, Italy US Army Medical Research and Materiel Command, Fort Detrick, MD, U.S.A. US Department of Agriculture, ARS, Northern Plains Area, Fort Collins, CO, U.S.A. Vanderbilt University Medical Center, Nashville, TN, U.S.A. Verein für Tumorforschung, Innsbruck, Austria W. L. Gore & Associates, Inc., Newark, DE, U.S.A. Welsh Life Science Fund, Wales, U.K. Werner und Klara Kreitz-Foundation, Kiel, Germany West German Breast Center, Germany Wetenschappelijk Fonds Willy Gepts, UZ Brussel, Brussels, Belgium Wetenschap pelijk Fonds Willy Gepts, Universitair Ziekenhuis Brussel, Brussels, Belgium Wilhelm-Sander-Foundation for Cancer Research, Munich, Germany Wilkes University, Wilkes-Barre, PA, U.S.A. Wissenschaftlicher Verein der Pathologie, Salzburg, Austria Women and Infants Hospital of Rhode Island, Providence, RI, U.S.A. World University Service (WUS), Austria, Graz, Austria Wroclaw Medical University, Wroclaw, Poland Yokohama Foundation for Advancement of Medical Science, Yokohama, Japan Yokohama Municipal Citizen's Hospital, Yokohama, Japan Zahnarztpraxis Weiß und Partner, Bremen, Germany Zentrum für Soziale Innovation (ZSI), Vienna, Austria 7012

19 Contents, Volume 35, 2015 Number 1 Reviews Management of Chronic Myelogenous Leukemia in Pregnancy. A. BHANDARI, K. ROLEN, B.K. SHAH (Lewiston, ID, USA)... Female Genital Tract Chronic Graft-versus-Host Disease: Review of the Literature. A. CIAVATTINI, N. CLEMENTE (Ancona, Italy)... Cytokine Networks in Animal Models of Colitis-associated Cancer. E. ANTONIOU, G.A. MARGONIS, A. ANGELOU, G.C. ZOGRAFOS, E. PIKOULIS (Athens, Greece) Experimental Studies Class II Transactivator Expression in Melanoma Cells Facilitates T-cell Engulfment. M.C. LLOYD, K. SZEKERES, J.S. BROWN, G. BLANCK (Tampa, FL; Chicago, IL, USA)... The Anti-hypertensive Drug Prazosin Induces Apoptosis in the Medullary Thyroid Carcinoma Cell Line TT. R. FUCHS, G. SCHWACH, A. STRACKE, N. MEIER-ALLARD, M. ABSENGER, E. INGOLIC, H.S. HAAS, R. PFRAGNER, A. SADJAK (Graz, Austria)... Curcumin and Epigallocatechin Gallate Inhibit the Cancer Stem Cell Phenotype via Down-regulation of STAT3 NFĸB Signaling. S.S. CHUNG, J.V. VADGAMA (Los Angeles, CA, USA)... Oncolytic Potential of a Novel KGFR Tyrosine Kinase Inhibitor Using a KGFR-selective Breast Cancer Xenograft Model. J.W. KESINGER, M. MEHTA, M.R. LERNER, D.J. BRACKETT, R.W. BRUEGGEMEIER, P.-K. LI, J.T. PENTO (Oklahoma City, OK; Columbus, OH, USA)... Targeting Chemokine Receptor CXCR7 Inhibits Glioma Cell Proliferation and Mobility. Y. LIU, E. CARSON-WALTER, K.A. WALTER (Rochester, NY, USA)... Enlargement and Multinucleation of U937 Leukemia and MCF7 Breast Carcinoma Cells by Antineoplastic Agents to Enhance Sensitivity to Low Frequency Ultrasound and to DNA-directed Anticancer Agents. M. TRENDOWSKI, V. WONG, G. YU, T.P. FONDY (Syracuse, NY, USA)... Dual Targeting NG2 and GD3A Using Mab-Zap Immunotoxin Results in Reduced Glioma Cell Viability In Vitro. S.C. HIGGINS, H.L. FILLMORE, K. ASHKAN, A.M. BUTT, G.J. PILKINGTON (Portsmouth; London, UK)... Differential Contribution of ROS to Resveratrol-induced Cell Death and Loss of Self-renewal Capacity of Ovarian Cancer Stem Cells. M. SEINO, M. OKADA, K. SHIBUYA, S. SEINO, S. SUZUKI, H. TAKEDA, T. OHTA, H. KURACHI, C. KITANAKA (Yamagata; Tokyo; Osaka, Japan)... Oil Palm Phenolics (OPP) Inhibit Pancreatic Cancer Cell Proliferation via Suppression of NF-κB Pathway. X. JI, A. USMAN, N.H. RAZALLI, R. SAMBANTHAMURTHI, S.V. GUPTA (Detroit, MI, USA; Selangor, Malaysia)... Pattern of IGF-1 Variants Expression in Human Cancer Cell Lines Using a Novel q-rt-pcr Approach. P.F. CHRISTOPOULOS, A. PHILIPPOU, M. KOUTSILIERIS (Athens, Greece)... Is Relative Quantification Dispensable for the Measurement of MicroRNAs as Serum Biomarkers in Germ Cell Tumors? M. SPIEKERMANN, K.-P. DIECKMANN, T. BALKS, J. BULLERDIEK, G. BELGE (Bremen; Hamburg; Rostock, Germany)

20 Diminished Expression of MiR-15a Is an Independent Prognostic Marker for Breast Cancer Cases. Y. SHINDEN, S. AKIYOSHI, H. UEO, S. NAMBARA,T. SAITO, H. KOMATSU, M. UEDA, H. HIRATA, S. SAKIMURA, R. UCHI, Y. TAKANO, T. IGUCHI, H. EGUCHI, K. SUGIMACHI, Y. KIJIMA, H. UEO, S. NATSUGOE, K. MIMORI (Beppu; Fukuoka; Kagoshima; Haya, Japan)... Combination Immunotherapy with 4-1BB Activation and PD-1 Blockade Enhances Antitumor Efficacy in a Mouse Model of Subcutaneous Tumor. Y. SHINDO, K. YOSHIMURA, A. KURAMASU, Y. WATANABE, HIDEAKI ITO, T. KONDO, A. OGA, HIROSHI ITO, S. YOSHINO, S. HAZAMA, K. TAMADA, H. YAGITA, M. OKA (Ube; Tokyo, Japan)... Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and Epithelial Growth Factor Receptor in Peripheral Nerve Sheath Tumors of Neurofibromatosis Type 1. R.E. FRIEDRICH, C. BEER, M. GLATZEL, C. HAGEL (Hamburg, Germany)... Verification of a Canine PSMA (FolH1) Antibody. S. WAGNER, D. MAIBAUM, A. PICH, I. NOLTE, H.M. ESCOBAR (Hannover; Rostock, Germany)... CD47 Activation-induced UHRF1 Over-expression is Associated with Silencing of Tumor Suppressor Gene p16 INK4A in Glioblastoma Cells. A. BOUKHARI, M. ALHOSIN, C. BRONNER, K. SAGINI, C. TRUCHOT, E. SICK, V.B. SCHINI-KERTH, P. ANDRÉ, Y. MÉLY, M. MOUSLI, J.-P. GIES (Illkirch, France)... Human Adipose Tissue-derived Mesenchymal Stem Cells Inhibit Melanoma Growth Ιn Vitro and In Vivo. J.- O. AHN, Y.-R. COH, H.-W. LEE, I.-S. SHIN, S.-K. KANG, H.-Y. YOUN (Seoul, Republic of Korea)... Influence of p53 Status on the Effects of Boron Neutron Capture Therapy in Glioblastoma. K. SEKI, Y. KINASHI, S. TAKAHASHI (Osaka, Japan)... In Vitro Anticancer Activity of PI3K Alpha Selective Inhibitor BYL719 in Head and Neck Cancer. B. KEAM, S. KIM, Y.-O. AHN, T.M. KIM, S.-H. LEE, D.-W. KIM, D.S. HEO (Seoul, Republic of Korea)... KML001 Enhances Anticancer Activity of Gemcitabine Against Pancreatic Cancer Cells. M.H. YANG, K.T. LEE, S. YANG, J.K. LEE, K.H. LEE, J.C. RHEE (Seoul, Republic of Korea)... Cytotoxic Effect of S-Petasin and Iso-S-Petasin on the Proliferation of Human Prostate Cancer Cells. Z.-H. WANG, H.-W. HSU, J.-C. CHOU, C.-H. YU,D.-T. BAU, G.-J. WANG, C.-Y. HUANG, P.S. WANG, S.-W. WANG (Taichung; Taipei, Taiwan, ROC)... Dendrofalconerol A Suppresses Migrating Cancer Cells via EMT and Integrin Proteins. P. PENGPAENG, B. SRITULARAK, P. CHANVORACHOTE (Bangkok, Thailand)... Comparative Effects Between Fucoxanthinol and its Precursor Fucoxanthin on Viability and Apoptosis of Breast Cancer Cell Lines MCF-7 and MDA-MB-231. A. RWIGEMERA, J. MAMELONA, L.J. MARTIN (Moncton, NB, Canada)... Active Estrogen Synthesis and its Function in Prostate Cancer- derived Stromal Cells. K. MACHIOKA, A. MIZOKAMI, Y. YAMAGUCHI, K. IZUMI, S. HAYASHI, M. NAMIKI (Ishikawa; Saitama; Sendai, Japan)... Discovery of PAT-1102, a Novel, Potent and Orally Active Histone Deacetylase Inhibitor with Antitumor Activity in Cancer Mouse Models. J. HIRIYAN, P. SHIVARUDRAIAH, G. GAVARA, P. ANNAMALAI, S. NATESAN, G. SAMBASIVAM, S.K. SUKUMARAN (Bangalore; Chennai; Hosur, India)... Cancer Stem Cell Marker in Circulating Tumor Cells: Expression of CD44 Variant Exon 9 Is Strongly Correlated to Treatment Refractoriness, Recurrence and Prognosis of Human Colorectal Cancer. S. KATOH, T. GOI, T. NARUSE, Y. UEDA, H. KUREBAYASHI, T. NAKAZAWA, Y. KIMURA, Y. HIRONO, A. YAMAGUCHI (Fukui, Japan)

21 Epidermal Growth Factor-induced Cell Death and Radiosensitization in Epidermal Growth Factor Receptoroverexpressing Cancer Cell Lines. K. KIM, H.-G. WU, S.-R. JEON (Seoul, Republic of Korea)... Determination of Gene Expression and Serum Levels of MnSOD and GPX1 in Colorectal Cancer. I. NALKIRAN, S. TURAN, S. ARIKAN, Ö. TIMIRCI KAHRAMAN, L. ACAR, I. YAYLIM, A. ERGEN (Rize; Istanbul, Turkey)... FOXD1 Expression Is Associated with Poor Prognosis in Non-small Cell Lung Cancer. S. NAKAYAMA, K. SOEJIMA, H. YASUDA, S. YODA, R. SATOMI, S. IKEMURA, H. TERAI, T. SATO, N. YAMAGUCHI, J. HAMAMOTO, D. ARAI, K. ISHIOKA, K. OHGINO, K. NAOKI, T. BETSUYAKU (Tokyo, Japan; New York, NY, USA)... Akt1 rs Is Related to Survival in Head and Neck Squamous Cell Cancer Treated with Radiotherapy. F. PASQUALETTI, G. BOCCI, V. MEY, V. MENGHINI, S. MONTRONE, P. COCUZZA, P. FERRAZZA, V. SECCIA, D. DELISHAJ, C. ORLANDINI, M.G. FABRINI, R. DANESI (Pisa, Italy)... Resveratrol at Anti-angiogenesis/Anticancer Concentrations Suppresses Protein Kinase G Signaling and Decreases IAPs Expression in HUVECs. J.C. WONG, R.R. FISCUS (Las Vegas; Henderson, NV, USA)... Anticancer Effects of Brominated Indole Alkaloid Eudistomin H from Marine Ascidian Eudistoma viride Against Cervical Cancer Cells (HeLa). R.P. RAJESH, M. ANNAPPAN (Bangalore; Tuticorin, India) Clinical Studies Urological Procedures in Patients with Peritoneal Carcinomatosis of Colorectal Cancer Treated with HIPEC: Morbidity and Survival Analysis. H.J. BRAAM, T.R. VAN OUDHEUSDEN, I.H.J.T. DE HINGH, S.W. NIENHUIJS, D. BOERMA, M.J. WIEZER, B. VAN RAMSHORST (Nieuwegein; Eindhoven, Netherlands)... Prognostic Significance of Microscopic Tumor Burden in Sentinel Lymph Node in Patients with Cutaneous Melanoma. C. KIM, S. ECONOMOU, T.T. AMATRUDA, J.C. MARTIN, A.Z. DUDEK (Minneapolis; Edina; Fridley, MN; Chicago, IL, USA)... Presence of CD3- Positive T- Cells in Oral Premalignant Leukoplakia Indicates Prevention of Cancer Transformation. J. ÖHMAN, R. MOWJOOD, L. LARSSON, A. KOVACS, B. MAGNUSSON, G. KJELLER, M, JONTELL, B. HASSEUS (Gothenburg, Sweden)... CT-Guided Brachytherapy as Salvage Therapy for Intrahepatic Recurrence of HCC After Surgical Resection. D. SCHNAPAUFF, F. COLLETTINI, K. HARTWIG, G. WIENERS, S. CHOPRA, B. HAMM, B. GEBAUER (Berlin, Germany)... Single Hepatocellular Carcinoma Smaller than 2 cm: Are Ethanol Injection and Radiofrequency Ablation Equally Effective? M. POMPILI, N. DE MATTHAEIS, A. SAVIANO, I. DE SIO, G. FRANCICA, F. BRUNELLO, A. CANTAMESSA, A. GIORGIO, U. SCOGNAMIGLIO, F. FORNARI, F. GIANGREGORIO, F. PISCAGLIA, S. GUALANDI, E. CATURELLI, P. ROSELLI, L. RICCARDI, G.L. RAPACCINI (Rome; Naples; Castel Volturno; Turin; Piacenza; Bologna; Viterbo, Italy)... Radiosurgery with 20 Gy Provides Better Local Contol of 1-3 Brain Metastases from Breast Cancer than with Lower Doses. D. RADES, S. HUTTENLOCHER, V. RUDAT, D. HORNUNG, O. BLANCK, P.C. PHUONG, M.T. KHOA, S.E. SCHILD, D. FISCHER (Lübeck; Hamburg; Güstrow, Germany; Al Khobar, Saudi Arabia; Hanoi, Vietnam; Scottsdale, AZ, USA)... Pre-treatment Neutrophil to Lymphocyte Ratio Is a Predictor of Prognosis in Endometrial Cancer. T. HARUMA, K. NAKAMURA, T. NISHIDA, C. OGAWA, T. KUSUMOTO, N. SEKI, Y. HIRAMATSU (Okayama, Japan)

22 Immunohistochemical, Cytogenetic, and Molecular Cytogenetic Characterization of Both Components of a Dedifferentiated Liposarcoma: Implications for Histogenesis. J. NISHIO, H. IWASAKI, K. NABESHIMA, M. NAITO (Fukuoka, Japan)... Paucity of Tumor-infiltrating Lymphocytes Is an Unfavorable Prognosticator and Predicts Lymph Node Metastases in Cutaneous Melanoma Patients. P. DONIZY, M. KACZOROWSKI, A. HALON, M. LESKIEWICZ, C. KOZYRA, R. MATKOWSKI (Wroclaw, Poland)... Usefulness of Duloxetine for Paclitaxel-Induced Peripheral Neuropathy Treatment in Gynecological Cancer Patients. A. OTAKE, K. YOSHINO,Y. UEDA, K. SAWADA, S. MABUCHI, T. KIMURA, E. KOBAYASHI, A. ISOBE, T. EGAWA- TAKATA, S. MATSUZAKI, M. FUJITA, T. KIMURA (Osaka, Japan)... Impact of Adjuvant Pelvic Radiotherapy in Stage I Uterine Sarcoma. W.J. MAGNUSON, D.G. PETEREIT, B.M. ANDERSON, H.M. GEYE, K.A. BRADLEY (Madison, WI; Rapid City, SD, USA)... Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan. G. HIRANO, A. MAKIYAMA, C. MAKIYAMA, T. ESAKI, H. ODA, K. UCHINO, M. KOMODA, R. TANAKA, Y. MATSUSHITA, K. MITSUGI, Y. SHIBATA, H. KUMAGAI, S. ARITA, H. ARIYAMA, H. KUSABA, K. AKASHI, E. BABA (Kitakyushu; Fukuoka; Miyazaki, Japan)... Differential Impact of Fosaprepitant on Infusion Site Adverse Events Between Cisplatin- and Anthracyclinebased Chemotherapy Regimens. T. FUJII, N. NISHIMURA, K.Y. URAYAMA, H. KANAI, H. ISHIMARU, J. KAWANO, O. TAKAHASHI, H. YAMAUCHI, T. YAMAUCHI (Tokyo, Japan)... Predicting Survival of Patients with Metastatic Epidural Spinal Cord Compression from Cancer of the Headand-Neck. D. RADES, S.E. SCHILD, J.H. KARSTENS, S.G. HAKIM (Lübeck; Hannover, Germany; Scottsdale, AZ, USA)... Comparative Analysis of Tumor Angiogenesis and Clinical Features of 55 Cases of Pleomorphic Carcinoma and Adenocarcinoma of the Lung. Y. TSUBATA, A. SUTANI, T. OKIMOTO, I. MURAKAMI, R. USUDA, T. OKUMICHI, S.-I. KAKEGAWA, K.-I. TOGASHI, S. KOSAKA, Y. YAMASHITA, K. KISHIMOTO, T. KURAKI, T. ISOBE (Izumo, Shimane; Hiroshima; Yokohama, Kanagawa; Shibukawa, Gunma; Nagaoka, Niigata, Japan)... Multiparametric Pelvic MRI Accuracy in Diagnosing Clinically Significant Prostate Cancer in the Reevaluation of Biopsy Microfocal Tumor. P. PEPE, G. DIBENEDETTO, A. GARUFI, G. PRIOLO, M. PENNISI (Catania, Italy)... Clinical Significance of Adjuvant Surgery Following Chemotherapy for Patients with Initially Unresectable Stage IV Gastric Cancer. S. ITO, E. OKI, Y. NAKASHIMA, K. ANDO, Y. HIYOSHI, K. OHGAKI, H. SAEKI, M. MORITA, Y. SAKAGUCHI, Y. MAEHARA (Fukuoka, Japan)... Cardiac Tamponade Due to Bleeding as a Potential Lethal Complication After Surgery for Esophageal Cancer. S. ITO, M. MORITA, S. NANBARA, Y. NAKAJI, K. ANDO, Y. HIYOSHI, T. OKAMOTO, H. SAEKI, E. OKI, H. KAWANAKA, Y. TANOUE, Y. MAEHARA (Fukuoka, Japan)... Expression of Hepatocyte Growth Factor in Prostate Cancer May Indicate a Biochemical Recurrence After Radical Prostatectomy. S. NISHIDA, Y. HIROHASHI, T. TORIGOE, M. NOJIMA, R. INOUE, H. KITAMURA, T. TANAKA, H. ASANUMA, N. SATO, N. MASUMORI (Sapporo; Tokyo, Japan)... Benefit of Neoadjuvant Chemotherapy for Siewert Type II Esophagogastric Junction Adenocarcinoma. K. HOSODA, K. YAMASHITA, N. KATADA, H. MORIYA, H. MIENO, S. SAKURAMOTO, S. KIKUCH, M. WATANABE (Sagamihara, Kanagawa; Hidaka, Saitama, Japan)

23 Surgical Treatment of Metastatic Femoral Fractures: Achieving an Improved Quality of Life for Cancer Patients. M. MORISHIGE, K. MURAMATSU, Y. TOMINAGA, T. HASHIMOTO, T. TAGUCHI (Ube, Yamaguchi, Japan)... Survival in Patients with Clear Cell Renal Cell Carcinoma Is Predicted by HIF-1α Expression. D. MINARDI, G. LUCARINI, M. SANTONI, R. MAZZUCCHELLI, L. BURATTINI, A. CONTI, E. PRINCIPI, M. BIANCONI, M. SCARTOZZI, G. MILANESE, R. DI PRIMIO, R. MONTIRONI, S. CASCINU, G. MUZZONIGRO (Ancona, Italy)... Deregulation of Glyceraldehyde-3-Phosphate Dehydrogenase Expression During Tumor Progression of Human Cutaneous Melanoma. D. RAMOS, A. PELLÍN-CARCELÉN, J. AGUSTÍ, A. MURGUI, E. JORDÁ, A. PELLÍN, C. MONTEAGUDO (Valencia, Spain)... Impact of Lower Mediastinal Lymphadenectomy for the Treatment of Esophagogastric Junction Carcinoma. K. HOSODA, K. YAMASHITA, N. KATADA, H. MORIYA, H. MIENO, S. SAKURAMOTO, S. KIKUCHI, M. WATANABE (Kanagawa, Japan)... Impact of Clinical Pharmacy Services in a Hematology/Oncology Inpatient Setting. A. DELPEUCH, D. LEVEQUE, B. GOURIEUX, R. HERBRECHT (Strasbourg, France)... Azacitidine in the Front-line Treatment of Therapy-related Myeloid Neoplasms: A Multicenter Case Series. C. MINOIA, N. SGHERZA, G. LOSETO, G. GRECO, C. BUQUICCHIO, F. MERCHIONNE, C. TOLDO, I. GALISE, A. MELPIGNANO, G. TARANTINI, V. PAVONE, A. GUARINI ( Bari; Lecce; Barletta; Brindisi; Trento, Italy)... Phase I Study of S-1 plus Fractional Cisplatin as Adjuvant Chemotherapy for Advanced Gastric Cancer in an Outpatient Setting (KOGC-03). T. TAKAHASHI, Y. SAIKAWA, K. FUKUDA, R. NAKAMURA, N. WADA, H. KAWAKUBO, H. TAKEUCHI, H. TAKAISHI, Y. KITAGAWA (Tokyo, Japan)... Systemic Treatment Options for Epithelioid Haemangioendothelioma: The Royal Marsden Hospital Experience. N. YOUSAF, M. MARUZZO, I. JUDSON, O. AL- MUDERIS, C. FISHER, C. BENSON (London, UK)... Sunitinib-induced Thyrotoxicosis A not so Rare Entity. M. JAZVIĆ, M. PRPIĆ, T. JUKIĆ, J. MURGIĆ, B. JAKŠIĆ, D. KUST, A. PRGOMET, A. BOLANČA, Z. KUSIĆ (Zagreb, Croatia)... Neutrophil-rich Gastric Carcinoma in the Integrated Cancer Registry of Eastern Sicily, Italy. A. IENI, G. BRANCA, A. PARISI, F. FEDELE, E. IRATO, A. VENUTI, R.A. CARUSO (Messina, Italy)... Salvage Method for Unplanned Excision of Soft Tissue Sarcoma: Longterm Results of Second-look Surgery Following Radio-hyperthermo-chemotherapy. K. HAYASHI, S. YAMADA, H. INATANI, H. OKAMOTO, A. TAKEUCHI, H. NISHIDA, N. YAMAMOTO, H. TSUCHIYA, T. OTSUKA (Nagoya; Kanazawa, Japan)... Perioperative Serum Albumin Correlates with Postoperative Pancreatic Fistula After Pancreatico - duodenectomy. Y. FUJIWARA, H. SHIBA, Y. SHIRAI, R. IWASE, K. HARUKI, K. FURUKAWA, Y. FUTAGAWA, T. MISAWA, K. YANAGA (Tokyo, Japan)... Factors Predicting Recurrence in Patients with Siewert Type II Carcinoma Treated with Curative Resection. M. FUKUCHI, E. MOCHIKI, O. SUZUKI, T. ISHIGURO, J. SOBAJIMA, H. ONOZAWA, H. IMAIZUMI, K. SHIBATA, K. SAITO, H. NAITOH, Y. KUMAGAI, K. ISHIBASHI, H. ISHIDA (Saitama; Gunma, Japan)... Assessment of Surgical Treatment and Postoperative Nutrition in Gastric Cancer Patients Older than 80 Years. T. NAKANOKO, Y. KAKEJI, K. ANDO, Y. NAKASHIMA, K. OHGAKI, Y. KIMURA, H. SAEKI, E. OKI, M. MORITA, Y. MAEHARA (Fukuoka, Japan)

24 Lapatinib-plus-Pegylated Liposomal Doxorubicin in Advanced HER2-positive Breast Cancer Following Trastuzumab: A Phase II Trial. M. PIRCHER, B. MLINERITSCH, M.A. FRIDRIK, C. DITTRICH, A. LANG, E. PETRU, A. WELTERMANN, J. THALER, C. HUFNAGL, S.P. GAMPENRIEDER, G. RINNERTHALER, S. RESSLER, H. ULMER, R. GREIL (Salzburg; Linz; Vienna; Rankweil; Graz; Grieskirchen; Innsbruck, Austria)... MicroRNA Expressions in HPV- induced Cervical Dysplasia and Cancer. K. GOCZE, K. GOMBOS, K. KOVACS, K. JUHASZ, P. GOCZE, I. KISS (Pecs, Hungary)... Inhibition of Placental Growth Factor in Renal Cell Carcinoma. H. BESSHO, B. WONG, D. HUANG, E.Y. SIEW, D. HUANG., J. TAN., C.K. ONG, S.Y. TAN, K. MATSUMOTO, M. IWAMURA, B.T TEH (Singapore, Singapore; Kanagawa, Japan; Grand Rapids, MI, USA)... Non-pegylated Liposomal Doxorubicin plus Ifosfamide in Metastatic Soft Tissue Sarcoma: Results from a Phase-II Trial. R. DE SANCTIS, A. BERTUZZI, U. BASSO, A. COMANDONE, S. MARCHETTI, A. MARRARI, P. COLOMBO, R.F. LUTMAN, L. GIORDANO, A. SANTORO (Milan; Padova; Turin, Italy; Dublin, Ireland)... Transarterial Chemoembolization with Miriplatin plus Epirubicin in Patients with Hepatocellular Carcinoma. A. TAWADA, T. CHIBA, Y. OOKA, N. KANOGAWA, T. SAITO, T. MOTOYAMA, S. OGASAWARA, E. SUZUKI, F. KANAI, M. YOSHIKAWA, O. YOKOSUKA (Chiba, Japan)... Prognostic Markers for Patient Outcome Following Vaccination with Multiple MHC Class I/II-restricted WT1 Peptide-pulsed Dendritic Cells Plus Chemotherapy for Pancreatic Cancer. K. TAKAKURA, S. KOIDO, S. KAN, K. YOSHIDA, M. MORI, Y. HIRANO, Z. ITO, H. KOBAYASHI, S. TAKAMI, Y. MATSUMOTO, M. KAJIHARA, T. MISAWA, M. OKAMOTO, H. SUGIYAMA, S. HOMMA, T. OHKUSA, H. TAJIRI (Tokyo; Osaka, Japan)... Primary Gastric Small Cell Carcinoma: A Series of Seven Cases. T. TOYOKAWA, H. TANAKA, K. MUGURUMA, T. TAMURA, K. SAKURAI, N. KUBO, M. OHIRA, K. HIRAKAWA (Osaka, Japan)... Histological Grade ( HG) in Invasive Ductal Carcinomas of the Breast of Less than 1 cm: Clinical and Biological Associations During Progression from HG1 to HG3. Á. RUIBAL, P. AGUIAR, M.C. DEL RIO, J.I. ARIAS, P. MENÉNDEZ-RODRÍGUEZ, F. GUDE, M. HERRANZ (Santiago de Compostela; Madrid; Ferrol; Oviedo, Spain)... Cancer of Unknown Primary During Pregnancy: An Exceptionally Rare Coexistence. N. PAVLIDIS, F. PECCATORI, F. LOFTS, A.F. GRECO (Ioannina, Greece; Milan, Italy; London, UK; Nashville, TN, USA)... MRI Evaluation of Residual Breast Cancer After Neoadjuvant Chemotherapy: Influence of Patient, Tumor and Chemotherapy Characteristics on the Correlation with Pathological Response. C. DIGUISTO, L. OULDAMER, F. ARBION, A. VILDÉ, G. BODY (Tours, France)... Book Reviews... Announcements

25 Number 2 Reviews Curcumin and Cancer Stem Cells: Curcumin Ηas Asymmetrical Effects on Cancer and Normal Stem Cells. P.P. SORDILLO, L. HELSON (Quakertown, PA, USA)... Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy. P. LEE, B. MURPHY, R. MILLER, V. MENON, N.L. BANIK, P. GIGLIO, S.M. LINDHORST, A.K. VARMA, W.A. VANDERGRIFT III, S.J. PATEL, A. DAS (Charleston, SC; Columbus, OH, USA)... Targeting the Peritoneum with Novel Drug Delivery Systems in Peritoneal Carcinomatosis: A Review of the Literature. T.R. VAN OUDHEUSDEN, H. GRULL, P.Y.W. DANKER, I.H.J.T. DE HINGH (Eindhoven, the Netherlands)... Mode of Action of Anticancer Peptides (ACPs) from Amphibian Origin. C. OELKRUG, M. HARTKE, A. SCHUBERT (Leipzig, Germany)... Potential Anticancer Properties and Mechanisms of Action of Curcumin. N.G. VALLIANOU, A. EVANGELOPOULOS, N. SCHIZAS, C. KAZAZIS (Athens; Samos, Greece) Experimental Studies In Vitro Evaluation of 3-Arylcoumarin Derivatives in A549 Cell Line. M.A. MUSA, M.Y. JOSEPH, L.M. LATINWO, V. BADISA, J.S. COOPERWOOD (Tallahassee, FL, USA)... Complementarity of Variable-magnification and Spectral-separation Fluorescence Imaging Systems for Noninvasive Detection of Metastasis and Intravital Detection of Single Cancer Cells in Mouse Models. Y. ZHANG, Y. HIROSHIMA, H. MA, N. ZHANG, M. ZHAO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama, Japan)... GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray. J.W. RIESS, R. WEST, M. DEAN, A.C. KLIMOWICZ, J.W. NEAL, C. HOANG, H.A. WAKELEE (Sacramento; Stanford, CA, USA; Alberta, Canada)... Expression of xct as a Predictor of Disease Recurrence in Patients with Colorectal Cancer. K. SUGANO, K. MAEDA, H. OHTANI, H. NAGAHARA, M. SHIBUTANI, K. HIRAKAWA (Osaka, Japan)... Detection of Circulating Tumor Cells in High-risk Endometrial Cancer. G. BOGANI, M.C. LIU, S.C. DOWDY, W.A. CLIBY, S.E. KERR, K.R. KALLI, B.R. KIPP, K.C. HALLING, M.B. CAMPION, A. MARIANI (Rochester, MN, USA)... Involvement of mtor Signaling Pathways in Regulating Growth and Dissemination of Metastatic Brain Tumors via EMT. A. KWASNICKI, D. JEEVAN, A. BRAUN, R. MURALI, M. JHANWAR- UNIYAL (Valhalla, NY, USA)... Patient-derived Orthotopic Xenograft (PDOX) Nude Mouse Model of Soft-tissue Sarcoma More Closely Mimics the Patient Behavior in Contrast to the Subcutaneous Ectopic Model. Y. HIROSHIMA, Y. ZHANG, N. ZHANG, F. UEHARA, A. MAAWY, T. MURAKAMI, S. MII, M. YAMAMOTO, S. MIWA, S. YANO, M. MOMIYAMA, R. MORI, R. MATSUYAMA, T. CHISHIMA, K. TANAKA, Y. ICHIKAWA, M. BOUVET, I. ENDO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama, Japan)... Tumor Progression Is Associated with Increasing CD11b+ Cells and CCL2 in Lewis Rat Sarcoma. R. MISHRA, J. KOVALSKA, J. JANDA, L. VANNUCCI, R. RAJMON, V. HORAK (Libechov; Prague, Czech Republic)

26 Treatment of Transmissible Venereal Tumors in Dogs with Intratumoral Interleukin-2 (IL-2). A Pilot Study. W. DEN OTTER, M. HACK, J.J.L. JACOBS, J.F.V. TAN, L. ROZENDAAL, R.J.A. VAN MOORSELAAR (Amsterdam; Curaçao; Gouda, the Netherlands)... MicroRNA Profiles to Predict Postoperative Prognosis in Patients with Small Cell Carcinoma of the Esophagus. T. OKUMURA, Y. SHIMADA, T. OMURA, K. HIRANO, T. NAGATA, K. TSUKADA (Toyama; Kyoto, Japan)... Cantharidin Impairs Cell Migration and Invasion of A375.S2 Human Melanoma Cells by Suppressing MMP- 2 and -9 Through PI3K/NF-ĸB Signaling Pathways. B.-C. JI, Y.-P. HSIAO, C. H. TSAI, S.-J. CHANG, S.- C. HSU, H.-C. LIU, Y.-P. HUANG, J.-C. LIEN, J.-G. CHUNG (Changhua; Taichung, Taiwan, ROC)... Renal Fibrogenesis and Platinum Compounds in a Rat Model: A Novel Pt (II) Complex vs. Cisplatin. C. FENOGLIO, F. ALBICINI, S.A. DE PASCALI, G. MILANESI, M. FUMAGALLI, D. MIGONI, F.P. FANIZZI, G. BERNOCCHI (Pavia; Lecce, Italy)... Multi-Responsive Polymer Micelles as Ellipticine Delivery Carriers for Cancer Therapy. M. STUDENOVSKÝ, O. SEDLÁČEK, M. HRUBÝ, J. PÁNEK, K. ULBRICH (Prague, Czech Republic)... Differential Expression of E-Cadherin in Primary Breast Cancer and Corresponding Lymph Node Metastases. V. FULGA, L. RUDICO, A.R. BALICA, A.M. CIMPEAN, L. SAPTEFRATI, M.-M. MARGAN, M. RAICA (Chisinau, Republic of Moldova; Timisoara, Romania)... Resveratrol Induces Apoptosis and Alters Gene Expression in Human Fibrosarcoma Cells. K. HARATI, P. SLODNIK, A.M. CHROMIK, O. GOERTZ, T. HIRSCH, N. KAPALSCHINSKI, L. KLEIN-HITPASS, J. KOLBENSCHLAG, W. UHL, M. LEHNHARDT, A. DAIGELER (Bochum; Essen, Germany)... Comparative Effects of 4-Phenyl-3-Butenoic Acid and Vorinostat on Cell Growth and Signaling. T.J. BURNS, A. ALI, D.F. MATESIC (Atlanta, GA, USA)... Prolyl Isomerase PIN1 Negatively Regulates SGK1 Stability to Mediate Tamoxifen Resistance in Breast Cancer Cells. A. JO, H.J. YUN, J.Y. KIM, S.-C. LIM, H.J. CHOI, B.S. KANG, B.-Y. CHOI, H.S. CHOI (Gwangju; Daegu; Cheongju, Republic of Korea)... Cantharidin Induces DNA Damage and Inhibits DNA Repair-associated Protein Expressions in TSGH8301 Human Bladder Cancer Cell. J.-H. KUO, T.-Y. SHIH, J.-P. LIN, K.-C. LAI, M.-L. LIN, M.-D. YANG, J.- G. CHUNG (Taichung; Yunlin, Taiwan, ROC)... Vitamin D Effect on Growth and Vitamin D Metabolizing Enzymes in Triple-negative Breast Cancer. S.E. RICHARDS, K.A. WEIERSTAHL, J.L. KELTS (Flint, MI, USA)... Synthesis and Structure Activity Relationship Studies of Furan-ring Fused Chalcones as Antiproliferative Agents. Y. SAITO, M. KISHIMOTO, Y. YOSHIZAWA, S. KAWAII (Hatoyama, Saitama; Akita, Japan)... The Role of KISS1/KISS1R System in Tumor Growth and Invasion of Differentiated Thyroid Cancer. C. SAVVIDIS, E. PAPAOICONOMOU, C. PETRAKI, P. MSAOUEL, M. KOUTSILIERIS (Athens, Greece; Bronx, NY, USA)... Langmuir-Blodgett (LB)-based Nanobiocrystallography at the Frontiers of Cancer Proteomics. E. PECHKOVA, N.L. BRAGAZZI, S. FIORDORO, C. NICOLINI (Bergamo; Genova, Italy; Grenoble, France)... In Vitro Efficacy of Cinnarizine Against Lymphoma and Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, Y. KIM, S. BLAUM-FEDER, T. ENDO, I.G.H. SCHMIDT-WOLF (Bonn, Germany; Sapporo, Japan)... Attenuated Salmonella enterica Typhimurium Reduces Tumor Burden in an Autochthonous Breast Cancer Model. J. DREES, M. MERTENSOTTO, G. LIU, J. PANYAM, A. LEONARD, L. AUGUSTIN, J. SCHOTTEL, D. SALTZMAN (Minneapolis, MN, USA)

27 Human Papillomavirus and Breast Cancer: No Evidence of Association in a Spanish Set of Cases. M. VERNET- TOMAS, M. MENA, L. ALEMANY, I. BRAVO, S. DE SANJOSÉ, P. NICOLAU, A. BERGUEIRO, J.M. COROMINAS, S. SERRANO, R. CARRERAS, B. LLOVERAS (Barcelona; L Hospitalet de Llobregat, Spain)... Which Sequence Best Protects the Heart Against Trastuzumab and Anthracycline Toxicity? An Electron Microscopy Study in Rats. N. KERTMEN, S. AKSOY, A. UNER, M. SARGON, O. OZKAYAR, O. KESKIN, T. BABACAN, F. SARICI, M.A. SENDUR, Z. ARIK, S. AKIN, K. ALTUNDAG (Ankara, Turkey)... Clinical Studies Macrophage-Colony Stimulating Factor (CSF1) Predicts Breast Cancer Progression and Mortality. E. RICHARDSEN, R. DALE UGLEHUS, S.H. JOHNSEN, L.-T. BUSUND (Tromsø, Norway)... Rare Case of a Primary Intracranial Chondrosarcoma. E. SMOLLE, M. MOKRY, J. HAYBAECK (Graz, Austria)... Proteomic Identification of Autoantibodies in Sera from Patients with Ovarian Cancer as Possible Diagnostic Biomarkers. K. YONEYAMA, S. KOJIMA, Y. KODANI, N. YAMAGUCHI, A. IGARASHI, K. KUROSE, R. KAWASE, T. TAKESHITA, S. HATTORI, K. NAGATA (Tokyo; Saitama, Japan)... Chylothorax After Esophagectomy Cured by Intranodal Lymphangiography: A Case Report. M. YAMAMOTO, H. MIYATA, M. YAMASAKI, N. MAEDA, Y. MIYAZAKI, T. TAKAHASHI, Y. KUROKAWA, K. NAKAJIMA, S. TAKIGUCHI, M. MORI, Y. DOKI (Osaka, Japan)... Survival Outcome of Borrmann Type IV Gastric Cancer Potentially Improved by Multimodality Treatment. K. YAMASHITA, K. HOSODA, N. KATADA, H. MORIYA, H. MIENO, K. HIGUCHI, T. SASAKI, C. KATADA, S. SAKURAMOTO, S. TANABE, W. KOIZUMI, S. KIKUCHI, M. WATANABE (Sagamihara, Kanagawa; Hidaka, Saitama, Japan)... Neoadjuvant Docetaxel/Cyclophosphamide in Triple-negative Breast Cancer: Predictive Value of Class III-Β Tubulin and Non-basal Subtype. K. SHIMADA, T. ISHIKAWA, K. KITA, K. NARUI, S. SUGAE, D. SHIMIZU, M. TANABE, T. SASAKI, T. CHISHIMA, Y. ICHIKAWA, I. ENDO (Yokohama, Japan)... Age Influences the Clinical Significance of Atypical Glandular Cells on Cytology. K.C. ASCIUTTO, E. HENIC, O. FORSLUND, K. BJELKENKRANTZ, C. BORGFELDT (Lund, Sweden)... VEGFR3 and CD31 as Prognostic Factors in Renal Cell Cancer. J. VIRMAN, P. BONO, T. LUUKKAALA, K. SUNELA, P. KUJALA, P.-L. KELLOKUMPU-LEHTINEN (Tampere; Helsinki, Finland)... β-catenin Helices in the Cytoplasm of Sessile Serrated Adenoma/Polyps and Conventional Colorectal Adenomas. C.A. RUBIO, A. KAUFELDT, R. KOHA, M. USHOIDA, J. LINDAHL, L.L. KIS (Stockholm, Sweden)... Radiobiological Treatment Planning Evaluation of Inverse Planning Simulated Annealing for Cervical Cancer High-dose-rate Brachytherapy. T. PALMQVIST, L. DOS S. MATIAS, A.B.L. MARTHINSEN, M. SUNDSET, A.D. WANDERÅS, S. DANIELSEN, I. TOMA-DASU (Stockholm, Sweden; Maputo, Mozambique; Trondheim, Norway)... The Relation of Hopelessness/Helplessness versus Beck Depression Inventory (BDI) in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case-control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland)... Low PHLDA3 Expression in Oesophageal Squamous Cell Carcinomas Is Associated with Poor Prognosis. H. MUROI, M. NAKAJIMA, H. SATOMURA, M. TAKAHASHI, S. YAMAGUCHI, K. SASAKI, T. YOKOBORI, T. MIYAZAKI, H. KUWANO, H. KATO (Tochigi; Gunma, Japan)... Assessment of Grading in Newly-diagnosed Glioma Using 18 F-Fluorothymidine PET/CT. E. FERDOVÁ, J. FERDA, J. BAXA, R. TUPÝ, J. MRAČEK, O. TOPOLČAN, O. HES (Plzeň, Czech Republic)

28 Inter- and Intra-observer Variability in Biopsy of Bone and Soft Tissue Sarcomas. H.M.L. MÜHLHOFER, U. LENZE, F. LENZE, I.-C. RONDAK, J. SCHAUWECKER, H. RECHL, R. VON EISENHART-ROTHE, F. POHLIG (Munich, Germany)... FDG PET/CT and MR Imaging of CD34-Negative Soft-tissue Solitary Fibrous Tumor with NAB2-STAT6 Fusion Gene. J. NISHIO, H. IWASAKI, M. AOKI, K. NABESHIMA, M. NAITO (Fukuoka, Japan)... Claudin-5 Is Associated with Elevated TATI and CA125 Levels in Mucinous Ovarian Borderline Tumors. R. NISSI, A. TALVENSAARI- MATTILA, P. KUVAJA, P. PÄÄKKÖ, Y. SOINI, M. SANTALA (Oulu; Kuopio, Finland)... Feasibility Study of Alternate-day S-1 as Adjuvant Chemotherapy for Head and Neck Cancer. Y. MORO, Y. KOGASHIWA, D. SATO, Y. MATSUMOTO, T. NAKAMURA, K. YAMAUCHI, H. SAKURAI, N. KOHNO (Tokyo; Hidaka, Saitama, Japan)... Prognostic Factors in Cancer Patients with Symptomatic Pituitary Metastasis: A Clinical Case Study. C.- Y. LIN, W.-K. HUANG, F.-T. CHUNG, H.-K. CHANG (Taoyuan, Taiwan, ROC)... Left Ventricular Systolic Dysfunction in Metastatic Breast Cancer Patients: A Polish Multicenter Registry. S. SZMIT, J. STREB, W. STARZEC, D. ZUZIAK, M. KWIATKOWSKI, B. CZARTORYSKA- ARŁUKOWICZ, D. IŻYCKI, A. ŚMIAŁOWSKA- JANISZEWSKA, J. HANSLIK, A. BRYJAK, M. TALERCZYK, J.M. ZAUCHA (Otwock; Cracow; Bydgoszcz; Bielsko-Biała; Białystok; Poznań; Łódź; Racibórz; Szczecin; Gdynia, Poland)... Preoperative Serum Methylation Signature as Prognostic Tool After Curative Hepatectomy in Patients with Hepatocellular Carcinoma. S. KANEKIYO, N. IIZUKA, R. TSUNEDOMI, Y. TOKUMITSU, N. HASHIMOTO, Y. TOKUHISA, Y. MAEDA, M. IIDA, K. SAKAMOTO, T. TAMESA, Y. FUJITA, S. YOSHINO, S. HAZAMA, Y. HAMAMOTO, M. OKA (Ube, Yamaguchi, Japan)... Correlation Between 18 F-FDG-uptake and In Vitro Chemosensitivity of Cisplatin in Head and Neck Cancer. H. SUZUKI, M. NISHIO, N. HANAI, H. HIRAKAWA, T. TAMAKI, Y. HASEGAWA (Nagoya, Japan)... Improving the Prediction of Pathologic Outcomes in Patients Undergoing Radical Prostatectomy: The Value of Prostate Cancer Antigen 3 (PCA3), Prostate Health Index (Phi) and Sarcosine. M. FERRO, G. LUCARELLI, D. BRUZZESE, S. PERDONÀ, C. MAZZARELLA, G. PERRUOLO, A. MARINO, V. COSIMATO, E. GIORGIO, V. TAGLIAMONTE, D. BOTTERO, O. DE COBELLI, D. TERRACCIANO (Milan; Bari; Naples, Italy)... Prognostic Impact of Central Nervous System Metastases After Acquired Resistance to EGFR-TKI: Poorer Prognosis Associated with T790M-negative Status and Leptomeningeal Metastases. A. HATA, N. KATAKAMI, H. YOSHIOKA, J. TAKESHITA, K. TANAKA, K. MASAGO, S. FUJITA, R. KAJI, Y. IMAI, K. MONDEN, T. MATSUMOTO, K. NAGATA, K. OTSUKA, R. TACHIKAWA, K. TOMII, K. KUNIMASA, M. IWASAKU, A. NISHIYAMA, T. ISHIDA, Y. NISHIMURA (Kobe; Kurashiki, Japan)... Surgical Option for Intestinal Gastrointestinal Stromal Tumors Perioperative and Oncological Outcomes of Laparoscopic Surgery. C.-H. LIAO, C.-N YEH, S.-Y. WANG, C.-Y. FU, C.-Y. TSAI, Y.-Y. LIU, C.-T. CHENG, T.-S. YEH (Taoyuan, Taiwan, ROC)... Lymphatic and Blood Vessels in Male Breast Cancer. J. NIEMIEC, B. SAS-KORCZYNSKA, A. HARAZIN-LECHOWSKA, D. MARTYNOW, A. ADAMCZYK (Krakow, Poland)... Immunohistochemical Expression of Sex Steroid Hormone Receptors, Cell Cycle Regulators and Angiogenesis Factors in Intraductal Papillary Mucinous Neoplasms: An Explorative Study. D. GEORGIADOU, T.N. SERGENTANIS, S. SAKELLARIOU, G.M. FILIPPAKIS, F. ZAGOURI, T. PSALTOPOULOU, A.C. LAZARIS, E. PATSOURIS, A. GOUNARIS, G.C. ZOGRAFOS (Athens, Greece)

29 Predictive Factors for Response to Abiraterone in Metastatic Castration Refractory Prostate Cancer. M. AFSHAR, F. AL-ALLOOSH, S. PIRRIE, C. ROWAN, N.D. JAMES, E. PORFIRI (Birmigham; Warwick, UK)... Difference in Benefit of Chemotherapy Between Small Cell Lung Cancer Patients with Interstitial Pneumonia and Patients with Non-small Cell Lung Cancer. K. KASHIWABARA, H. SEMBA, S. FUJII, S. TSUMURA, R. AOKI (Kumamoto, Japan)... Clinicopathological Characteristics of Multiple Primary Cancers in Hepatobiliary and Pancreas Malignancies. A. NANASHIMA, H. KONDO, M. NAKASHIMA, T. ABO, J. ARAI, M. ISHII, S. HIDAKA, M. KUNIZAKI, K. TO, H. TAKESHITA, N. YAMASAKI, T. TSUCHIYA, T. NAGAYASU (Nagasaki, Japan)... Angiogenic Markers in Plasma Cell Myeloma Patients Treated with Novel Agents. M. MEDINGER, J. HALTER, D. HEIM, A. BUSER, S. GERULL, M. STERN, J. PASSWEG (Basel, Switzerland)... Alteration of mirna Expression Correlates with Lifestyle, Social and Environmental Determinants in Esophageal Carcinoma. É. STÁNITZ, K. JUHÁSZ, K. GOMBOS, K. GŐCZE, C. TÓTH, I. KISS (Szombathely; Pécs, Hungary)... Correlation Between CA125 Levels After Sixth Cycle of Chemotherapy and Clinical Outcome in Advanced Ovarian Carcinoma. A. GADDUCCI, A. MENICHETTI, I. GUIGGI, M. NOTARNICOLA, S. COSIO (Pisa, Italy)... Predictive Biomarkers to Chemotherapy in Patients with Advanced Melanoma Receiving the Combination of Cisplatin - Vinblastine -Temozolomide (PVT) as First-line Treatment: A Study of the Hellenic Cooperative Oncology Group (HECOG). H. LINARDOU, G. PENTHEROUDAKIS, I. VARTHALITIS, H. GOGAS, D. PECTASIDES, T. MAKATSORIS, G. FOUNTZILAS, D. BAFALOUKOS (Athens; Ioannina; Hania; Patras; Thessaloniki, Greece)... Cyclin I mrna Expression Correlates with Kinase Insert Domain Receptor Expression in Human Epithelial Ovarian Cancer. M. CYBULSKI, W. JELENIEWICZ, A. NOWAKOWSKI, A. STENZEL-BEMBENEK, R. TARKOWSKI, J. KOTARSKI, A. STEPULAK (Lublin; Warszawa, Poland)... Second Primary Lung Cancers Among Breast Cancer Patients Treated with Anti-estrogens Have a Longer Cancer-specific Survival. L.-H. HSU, A.-C. FENG, S.-H. KAO, C.-C. LIU, S.Y.C. TSAI, L.-S. SHIH, N.- M. CHU (Taipei, Taiwan, ROC)... Levels of Vascular Endothelial Growth Factor in Serum and Pleural Fluid Are Independent Predictors of Survival in Advanced Non-small Cell Lung Cancer: Results of a Prospective Study. I. GKIOZOS, S. TSAGOULI, A. CHARPIDOU, D. GRAPSA, E. KAINIS, C. GRATZIOU, K. SYRIGOS (Athens, Greece)... Abstracts of the Christie International Student Cancer Conference 2014 (Manchester, UK)... PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON VITAMIN D AND ANALOGS IN CANCER PREVENTION AND THERAPY, 2-3 May, 2014, Krefeld, Germany... What Do We Learn from the Genome-wide Perspective on Vitamin D 3 (Review)? C. CARLBERG (Kuopio, Finland) Hydroxyvitamin D and Breast Cancer, Colorectal Cancer, and Colorectal Adenomas: Case Control versus Nested Case Control Studies (Review). W.B. GRANT (San Francisco, CA, USA)... Vitamin D in Preventive Medicine (Review). S. PILZ, M. GAKSCH, B. Ó HARTAIGH, A. TOMASCHITZ, W. MÄRZ (Graz; Bad Aussee, Austria; Amsterdam, the Netherlands; New York, NY; New Haven, CT, USA; Mannheim, Germany)... Vitamin D Levels and Dietary Intake Among Patients with Benign Soft Tissue Tumors and Sarcomas. A. JUZENIENE, A.C. POROJNICU, Z. BATURAITE, Z. LAGUNOVA, L. AKSNES, Ø.S. BRULAND, J. MOAN (Oslo; Bergen, Norway)

30 Vitamin D Status and Cancer Prevalence of Hemodialysis Patients in Germany. P. MARQUARDT, R. KRAUSE, M. SCHALLER, D. BACH, G. VON GERSDORFF (Cologne; Berlin; Neu-Isenburg, Germany)... Combined Treatment of Breast Cancer Cell Lines with Vitamin D and COX-2 Inhibitors. M. THILL, K. REICHERT, A. WOESTE, S. POLACK, D. FISCHER, F. HOELLEN, A. RODY, M. FRIEDRICH, F. KÖSTER (Frankfurt; Lübeck; Krefeld, Germany)... Vitamin D Inhibits Ovarian Cancer Cell Line Proliferation in Combination with Celecoxib and Suppresses Cyclooxygenase-2 Expression. M. THILL, A. WOESTE, K. REICHERT, D. FISCHER, A. RODY, M. FRIEDRICH, F. KÖSTER (Frankfurt; Lübeck; Krefeld, Germany)... Development of Efficient Chemical Syntheses of Vitamin D Degradation Products. L. KATTNER, D. BERNARDI, E. RAUCH (Saarbrücken, Germany)... Effect of Serum Cotinine on Vitamin D Serum Concentrations Among American Females with Different Ethnic Backgrounds. K.R. MANAVI, B.P. ALSTON-MILLS, M.P. THOMPSON, J.C. ALLEN (Raleigh, NC; East Lansing, MI, USA)... Errata... Book Reviews... Announcements Number 3 Reviews Topics in Chemotherapy, Molecular-targeted Therapy, and Immunotherapy for Newly-diagnosed Glioblastoma Multiforme. N. OKONOGI, K. SHIRAI, T. OIKE, K. MURATA, S.-E. NODA, Y. SUZUKI, T. NAKANO (Maebashi; Fukushima, Japan)... Diagnostic Potential of Ancillary Molecular Testing in Differentiation of Benign and Malignant Thyroid Nodules. P. BHATIA, A. DENIWAR, P. FRIEDLANDER, R. ASLAM, E. KANDIL (New Orleans, LA, USA) Experimental Studies Co-targeting ER and HER Family Receptors Induces Apoptosis in HER2-normal or Overexpressing Breast Cancer Models. A.K. CHAKRABORTY, R. MEHRA, M.P. DIGIOVANNA (New Haven, CT, USA)... Transduction of a Novel HLA-DRB1*04:05-restricted, WT1-specific TCR Gene into Human CD4+ T Cells Confers Killing Activity Αgainst Human Leukemia Cells. A. KATSUHARA, F. FUJIKI, N. AOYAMA, S. TANII, S. MORIMOTO, Y. OKA, A. TSUBOI, H. NAKAJIMA, K. KONDO, N. TATSUMI, J. NAKATA, Y. NAKAE, S. TAKASHIMA, S. NISHIDA, N. HOSEN, S. SOGO, Y. OJI, H. SUGIYAMA (Osaka; Tokushima, Japan)... The Effect of Silibinin in Enhancing Toxicity of Temozolomide and Etoposide in p53 and PTEN-mutated Resistant Glioma Cell Lines. R. ELHAG, E.A. MAZZIO, K.F.A. SOLIMAN (Tallahassee, FL, USA)... MicroRNA Expression in Differentially Metastasizing Tumors of the Head and Neck: Adenoid Cystic Versus Squamous Cell Carcinoma. J.A. VEIT, K. SCHECKENBACH, P.J. SCHULER, S. LABAN, S.P. WIGGENHAUSER, J. THIERAUF, J.P. KLUSSMANN, T.K. HOFFMANN (Ulm; Düsseldorf; Giessen, Germany)

31 Chondroitin Sulfate Proteoglycan-4 Does Not Protect Melanoma Cells During Inhibition of PI3K and mtor Pathways. S. JAVAID, K. TERAI, A.Z. DUDEK (Minneapolis, MN; Chicago, IL, USA)... Remodeling of Tannic Acid Crosslinked Collagen Type I Induces Apoptosis in ER+ Breast Cancer Cells. T.A. NGOBILI, H. SHAH, J.P. PARK, K.W. KWIST, B. INSKEEP, K.J.L. BURG, B.W. BOOTH (Clemson, SC; Manhattan, KS, USA)... Ectopic Expression of Protein Kinase C-β Sensitizes Head and Neck Squamous Cell Carcinoma to Diterpene Esters. R.A. ADAMS, M.M.A. D SOUZA, C.J. PIERCE, N. KORICA, B. WALLWORK, P.G. PARSONS, B. PANIZZA, G.M. BOYLE (Brisbane, Queensland, Australia)... Prognostic Impact of Blood Biomarkers TS and DPD in Neoadjuvant-treated Esophageal Cancer Patients. P.P. GRIMMINGER, M.K.H. MAUS, J. BERGENTHAL, C. WANDHÖFER, U.K. FETZNER, T. HERBOLD, E. BOLLSCHWEILER, A.H. HÖLSCHER, J. BRABENDER (Cologne, Germany)... The Protective Effect of Pyrimidine Nucleosides on Human HaCaT Keratinocytes Treated with 5-FU. J. HARTINGER, P. VESELÝ, I. NETÍKOVÁ, E. MATOUŠKOVÁ, L. PETRUŽELKA (Prague; Brno, Czech Republic)... Effect of Anaesthetic Technique on Immune Cell Infiltration in Breast Cancer: A Follow-up Pilot Analysis of a Prospective, Randomised, Investigator-masked Study. F. DESMOND, J. MCCORMACK, N. MULLIGAN, M. STOKES, D.J. BUGGY (Dublin, Ireland; Cleveland, OH, USA)... Expression of Sonic Hedgehog (SHH) in Human Lung Cancer and the Impact of YangZheng XiaoJi on SHH-mediated Biological Function of Lung Cancer Cells and Tumor Growth. W.G. JIANG, L. YE, F. RUGE, P.-H. SUN, A.J. SANDERS, K. JI, J. LANE, L. ZHANG, L. SATHERLEY, H.P. WEEKS, X. ZHI, Y. GAO, C. WEI, Y. WU, M.D. MASON (Cardiff, UK; Beijing; Shijiazhuang, PR China)... A Metastatic Hepatoma Model of Rats Using the MAT-B-III Cell Line: Basic Characteristics and Potential as a Tool for Interventional Oncology Experiments. J.W. CHOI, H.-C. KIM, S.Y. BAEK, Y.J. RYU, J.W. CHUNG (Seoul, Republic of Korea)... DNA Damage in Dihydroartemisinin-resistant Molt-4 Cells. J. PARK, H.C. LAI, T. SASAKI, N.P. SINGH (Seattle, WA, USA)... Interrogation of MicroRNAs Involved in Gastric Cancer Using 5p-Arm and 3p-Arm Annotated MicroRNAs. W.-T. KUO, M.-R. HO, C.-W. WU, W.-L. FANG, K.-H. HUANG, W.-C. LIN (Taipei, Taiwan, ROC)... Detection of Peritoneal Dissemination with Near-infrared Fluorescence Laparoscopic Imaging Using a Liposomal Formulation of a Synthesized Indocyanine Green Liposomal Derivative. I. HOSHINO, T. MARUYAMA, H. FUJITO, Y. TAMURA, A. SUGANAMI, H. HAYASHI, T. TOYOTA, Y. AKUTSU, K. MURAKAMI, Y. ISOZAKI, N. AKANUMA, N. TAKESHITA, T. TOYOZUMI, A. KOMATSU, H. MATSUBARA (Chiba, Japan)... HVEM Expression Contributes to Tumor Progression and Prognosis in Human Colorectal Cancer. T. INOUE, M. SHO, S. YASUDA, S. NISHIWADA, S. NAKAMURA, T. UEDA, N. NISHIGORI, K. KAWASAKI, S. OBARA, T. NAKAMOTO, F. KOYAMA, H. FUJII, Y. NAKAJIMA (Kashihara, Nara, Japan)... Flunarizine Exhibits In Vitro Efficacy Against Lymphoma and Multiple Myeloma Cells. L.C. SCHMEEL, F.C. SCHMEEL, Y. KIM, S. BLAUM-FEDER, T. ENDO, I.G.H. SCHMIDT-WOLF (Bonn, Germany; Sapporo, Japan)... PCK3145 Inhibits Proliferation and Induces Apoptosis in Breast and Colon Cancer Cells. A. KOSTOPOULOS, E. PAPAGEORGIOU, M. KOUTSILIERIS, G. SIVOLAPENKO (Patras; Athens, Greece)

32 A Long Noncoding RNA, lncrna-atb, Is Involved in the Progression and Prognosis of Colorectal Cancer. T. IGUCHI, R. UCHI, S. NAMBARA, T. SAITO, H. KOMATSU, H. HIRATA, M. UEDA, S. SAKIMURA, Y. TAKANO, J. KURASHIGE, Y. SHINDEN, H. EGUCHI, K. SUGIMACHI, Y. MAEHARA, K. MIMORI (Beppu; Fukuoka, Japan)... Small Molecules Alter VEGFR and PTEN Expression in HPV-positive and -negative SCC: New Hope for Targeted-therapy. C. ADERHOLD, A. FABER, C. UMBREIT, A. CHAKRABORTY, A. BOCKMAYER, R. BIRK, J.U. SOMMER, K. HÖRMANN, J.D. SCHULTZ (Mannheim, Germany)... mir-200a, mir-200b and mir-429 Are Onco-miRs that Target the PTEN Gene in Endometrioid Endometrial Carcinoma. K. YONEYAMA, O. ISHIBASHI, R. KAWASE, K. KUROSE, T. TAKESHITA (Tokyo; Sakai, Japan)... Aberrant Methylation of GCNT2 Is Tightly Related to Lymph Node Metastasis of Primary CRC. K. NAKAMURA, K. YAMASHITA, H. SAWAKI, M. WARAYA, H. KATOH, N. NAKAYAMA, H. KAWAMATA, H. NISHIMIYA, A. EMA, H. NARIMATSU, M. WATANABE (Kanagawa; Ibaraki, Japan)... TSU-68 Ameliorates Hepatocellular Carcinoma Growth by Inhibiting Microenvironmental Platelet-derived Growth Factor Signaling. Y. HARA, T. YAMASHITA, N. OISHI, K. NIO, T. HAYASHI, Y. NOMURA, M. YOSHIDA, T. HAYASHI, T. HASHIBA, Y. ASAHINA, M. KONDO, H. OKADA, H. SUNAGOZAKA, M. HONDA, S. KANEKO (Ishikawa, Japan)... β-catenin Helices in the Cytoplasm of Sporadic and FAP Duodenal Adenomas. C.A. RUBIO, A. KAUFELDT, R. KOHAN, M. USHOIDA, E. EZELIUS, S. BJÖRK, J. LINDAHL (Stockholm, Sweden)... Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts. M. NUKATSUKA, F. NAKAGAWA, H. SAITO, M. SAKATA, J. UCHIDA, T. TAKECHI (Tokushima, Japan)... MicroRNA-503 Promotes Tumor Progression and Acts as a Novel Biomarker for Prognosis in Oesophageal Cancer. S. IDE, Y. TOIYAMA, T. SHIMURA, M. KAWAMURA, H. YASUDA, S. SAIGUSA, M. OHI, K. TANAKA, Y. MOHRI, M. KUSUNOKI (Tsu, Japan)... Antiproliferative Activities of Fagara xanthoxyloides and Pseudocedrela kotschyi Against Prostate Cancer Cell Lines. O.O. KASSIM, R.L. COPELAND, H.M. KENGUELE, S. NEKHAI, K.A. AKO-NAI, Y.M. KANAAN (Washington, DC, USA; Ile-Ife, Nigeria)... Phosphatidylserine-specific Phospholipase A1 (PS-PLA 1 ) Expression in Colorectal Cancer Correlates with Tumor Invasion and Hematogenous Metastasis. Y. IIDA, E. SUNAMI, H. YAMASHITA, M. HIYOSHI, S. ISHIHARA, H. YAMAGUCHI, A. INOUE, K. MAKIDE, N.H. TSUNO, J. AOKI, J. KITAYAMA, T. WATANABE (Tokyo; Miyagi, Japan)... Effects on DNA Repair in Human Lymphocytes Exposed to the Food Dye Tartrazine Yellow. B.M. SOARES, T.M.T. ARAÚJO, J.A.B. RAMOS, L.C. PINTO, B.M. KHAYAT, M.D.O. BAHIA, R.C. MONTENEGRO, R.M.R. BURBANO, A.S. KHAYAT (Belém, Brazil)... Sulfobetaine (Dimethylsulfoniopropionate) and Glycine Betaine Show Incompatible Involvement in Crucial Ehrlich Ascites Carcinoma in Mice. K. NAKAJIMA, Y. NAKAJIMA, S. TSUJIWAKI (Hyogo; Okayama, Japan)... Chemotherapy-induced Changes and Immunosenescence of CD8+ T-Cells in Patients with Breast Cancer. O.O. ONYEMA, L. DECOSTER, R. NJEMINI, L. N. FORTI, I. BAUTMANS, M. DE WAELE, T. METS (Brussels, Belgium)... Anticancer Effect of a Novel Palladium Saccharinate Complex of Terpyridine by Inducing Apoptosis on Ehrlich Ascites Carcinoma ( EAC) in Balb- C Mice. E.I. IKITIMUR- ARMUTAK, K. SONMEZ, K. AKGUN-DAR, G. SENNAZLI, A. KAPUCU, F. YIGIT, V.T. YILMAZ, E. ULUKAYA (Istanbul; Bursa, Turkey)

33 Supernatants of Tumours Treated with Chemotherapy Can Alter Tumour Growth and Development In Vivo. W.M. LIU, K.A. SCOTT, A.G. DALGLEISH (London, UK)... Elimination of Ras Suppressor-1 from Hepatocellular Carcinoma Cells Hinders their In Vitro Metastatic Properties. V. GKRETSI, D.P. BOGDANOS (Larissa, Greece; London, UK)... Expression of Immunohistochemical Markers of Progression in Pre-cancerous and Cancerous Human Colon: Correlation with Serum Vitamin D Levels. A. JUNIKU- SHKOLOLLI, S. MANXHUKA- KERLIU, H. AHMETAJ, V. KHARE, S. ZEKAJ (Prishtina, Republic of Kosovo; Vienna, Austria)... APOBEC3B: A Potential Factor Suppressing Growth of Human Hepatocellular Carcinoma Cells. P.-F. WU, Y.-S. CHEN, T.-Y. KUO, H.-H. LIN, C.-W. LIU, L.-C. CHANG (Kaohsiung, Taiwan, ROC)... Predominance of Th17 Over Regulatory T-Cells in Pleural Effusions of Patients with Lung Cancer Implicates A Proinflammatory Profile. H. PRADO- GARCIA, S. ROMERO- GARCIA, U. RUMBO- NAVA, J.S. LOPEZ-GONZALEZ (Mexico City, Mexico)... AKT/mTOR Down-regulation by CX-4945, a CK2 Inhibitor, Promotes Apoptosis in Chemorefractory Nonsmall Cell Lung Cancer Cells. K.S. SO, J.K. RHO, Y.J. CHOI, S.Y. KIM, C.M. CHOI, Y.J. CHUN, J.C. LEE (Seoul, Republic of Korea)... In Vitro Exposure of NK-92 Cells to Serum from Patients with Non-small Cell Lung Cancer Impairs Their Cytotoxicity. D. TSARTSALIS, D. GRAPSA, M. SKOPELITI, E. DRAGIOTI, A. CHARPIDOU, E. POLITI, O. TSITSILONIS, K. SYRIGOS (Athens, Greece) Clinical Studies Vitamin D Receptor Genetic Polymorphisms Are Associated with PSA Level, Gleason Score and Prostate Cancer Risk in African-American Men. E.Y. JINGWI, M. ABBAS, L. RICKS-SANTI, A. WINCHESTER, D. BEYENE, A. DAY, T.J. NAAB, O.O. KASSIM, G.M. DUNSTON, R.L. COPELAND JR, Y.M. KANAAN (Washington, DC; Hampton, VA; Baltimore, MD, USA)... The Concurrent Use of Aromatase Inhibitors and Radiotherapy Induces Echocardiographic Changes in Patients with Breast Cancer. T. SKYTTÄ, S. TUOHINEN, V. VIRTANEN, P. RAATIKAINEN, P.- L. KELLOKUMPU-LEHTINEN (Tampere, Finland)... Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer. J.R. HECHT, T.R. REID, C.R. GARRETT, J.T. BECK, S.J. DAVIDSON, M.J. MACKENZIE, U. BRANDT, S. RIZVI, S. SHARMA (Santa Monica; La Jolla; Northridge, CA; Houston, TX; Fayetteville, AR; East Hanover, NJ; Salt Lake City, UT, USA; London, ON, Canada; Basel, Switzerland)... Matched-pair Analysis of Dendritic Cell Versus Targeted- therapy in Patients with Metastatic Renal Cell Carcinoma. A. ISAAK, S. HAUSER, S. ROGENHOFER, I.G.H. SCHMIDT-WOLF (Bonn, Germany)... Hybrid-including Endoscopic versus Open Hepatic Resection for Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: A Propensity Case-matched Analysis. T. BEPPU, H. HAYASHI, H. OKABE, K. IMAI, H. NITTA, T. MASUDA, D. HASHIMOTO, A. CHIKAMOTO, T. ISHIKO, K. KIKUCHI, H. BABA (Kumamoto, Japan)... Surgery at Primary Versus Relapsed Epithelial Ovarian Cancer: A Study on Aspects of Anaesthesiological Management. A. FELDHEISER, A. BAR YOSEF, E.-I. BRAICU, T. BONOMO, L. KAUFNER, C. SPIES, J. SEHOULI, C. FOTOPOULOU, K. PIETZNER (Berlin, Germany; Milan, Italy; London, UK)

34 Efficacy of Tegafur-Uracil in Advanced Urothelial Cancer Patients after the Treatment Failure of Platinumbased Chemotherapy. A. MAOLAKE, K. IZUMI, R. TAKAHASHI, S. ITAI, K. MACHIOKA, H. YAEGASHI, T. NOHARA, Y. KITAGAWA, Y. KADONO, H. KONAKA, A. MIZOKAMI, M. NAMIKI (Ishikawa, Japan)... A Case of Endobronchial NUT Midline Carcinoma with Intraluminal Growth. S. WATANABE, S. HIRANO, S. MINE, A. YOSHIDA, T. MOTOI, S. ISHII, G. NAKA, Y. TAKEDA, T. IGARI, H. SUGIYAMA, N. KOBAYASHI (Tokyo, Japan)... Pancreatoduodenectomy En Bloc with Portal and Superior Mesenteric Artery Resection A Case Report and Literature Review. V. BRASOVEANU, C. ANGHEL, I. BARBU, M. PAUTOV, M.I. IONESCU, M. MOTTHOR, I. BALESCU, S. DIMA, N. BACALBASA (Bucharest, Romania)... Long-term Platinum Retention After Platinum-based Chemotherapy in Testicular Cancer Survivors: A 20- Year Follow-up Study. L.V. HJELLE, P.O.M. GUNDERSEN, J. OLDENBURG, M. BRYDØY, T. TANDSTAD, T. WILSGAARD, S.D. FOSSÅ, R.M. BREMNES, H.S. HAUGNES (Tromsø; Trondheim; Bergen; Oslo, Norway)... Emotional Personality/Proximity Versus Emotional Authenticity in Patient Physician Communication in Healthy Study Participants, and in Patients with Benign Breast Disease, and Breast Cancer: A Prospective Case Control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland)... The Impact of Thyroid Nodule Size on the Risk of Malignancy in Follicular Neoplasms. Y. IBRAHIM, S.E.H. MOHAMED, A. DENIWAR, Z.H. AL-QURAYSHI, A.N. KHAN, K. MOROZ, P. FRIEDLANDER, E. KANDIL (New Orleans, LA, USA)... Aberrant P53 Expression Lacks Prognostic or Predictive Significance in Colorectal Cancer: Results from the VICTOR Trial. M.J. MCGREGOR, W. FADHIL, R. WHARTON, Y. YANAGISAWA, M. PRESZ, A. PRITCHARD, C. WOMACK, S. DUTTON, R.S. KERR, D.J. KERR, E.C. JOHNSTONE, M. ILYAS (Oxford; Nottingham; Macclesfield, Cheshire, UK)... Antiviral Therapy and Long-term Outcome for Hepatitis B Virus-related Hepatocellular Carcinoma after Curative Liver Resection in a Japanese Cohort. K. SAKAMOTO, T. BEPPU, H. HAYASHI, S. NAKAGAWA, H. OKABE, H. NITTA, K. IMAI, D. HASHIMOTO, A. CHIKAMOTO, T. ISIKO, K. KIKUCHI, H. BABA (Kumamoto, Japan)... EBV, HSV, CMV and HPV in Laryngeal and Oropharyngeal Carcinoma in Polish Patients. D. POLZ- GRUSZKA, A. STEC, J. DWORZAŃSKI, M. POLZ-DACEWICZ (Lublin, Poland)... The Alternatively Spliced Actinin-4 Variant as a Prognostic Marker for Metastasis in Small-cell Lung Cancer. N. OKAMOTO, H. SUZUKI, K. KAWAHARA, K. HONDA, N. MIURA, T. HIRASHIMA, M. TAMIYA, N. MORISHITA, T. SHIROYAMA, A. TANAKA, E. TANI, M. HAMAGUCHI, M. KITANI, T. YAMADA, I. KAWASE (Osaka; Tokyo, Japan)... Validity of Sentinel Lymph Node Biopsy by ICG Fluorescence for Early Head and Neck Cancer. T. NAKAMURA, Y. KOGASHIWA, H. NAGAFUJI, K. YAMAUCHI, N. KOHNO (Tokyo, Japan)... Operation for Preservation of Lung Parenchyma in Central Lung Cancer In Vivo and Ex Situ Reimplantation Techniques. C. EMMANOUILIDES, S. TRYFON, S. BAKA, H. TITOPOULOS, A. DAGER, D. FILIPPOU (Thessaloniki, Greece)... Circulating Hepatocyte Growth Factor is Correlated with Resistance to Cetuximab in Metastatic Colorectal Cancer. K. YONESAKA, T. SATOH, S. UEDA, T. YOSHIDA, M. TAKEDA, T. SHIMIZU, I. OKAMOTO, K. NISHIO, T. TAMURA, K. NAKAGAWA (Osaka; Fukuoka, Japan)

35 Surgical Loupes at 5.0 Magnification and the VIO Soft-coagulation System Can Prevent Postoperative Pancreatic Fistula in Duct-to-Mucosa Pancreaticojejunostomy. Y.-I. YAMASHITA, Y. YOSHIDA, T. KURIHARA, E. TSUJITA, K. TAKEISHI, T. ISHIDA, T. IKEDA, Y. FURUKAWA, K. SHIRABE, Y. MAEHARA (Fukuoka; Hiroshima, Japan)... Vinorelbine and Cisplatin in Patients with Advanced Non-small Cell Lung Cancer with Interstitial Pneumonia. N. WATANABE, S. NIHO, K. KIRITA, S. UMEMURA, S. MATSUMOTO, K. YOH, H. OHMATSU, K. GOTO (Kashiwa, Japan)... Circulating Pigment Epithelium-derived Factor (PEDF) is Associated with Pathological Grade of Prostate Cancer. H. IDE, S.-I. YAMAGISHI, Y. LU, K. SAKAMAKI, A. NAKAJIMA, A. HORIUCHI, K. KITAMURA, S.-I. HISASUE, S. MUTO, R. YAMAGUCHI, S. HORIE (Tokyo; Kurume; Yokohama, Japan)... Primary Malignant Melanoma of the Breast: Case Report and Review of the Literature. D. DRUEPPEL, B. SCHULTHEIS, W. SOLASS, H. ERGONENC, C.B. TEMPFER (Herne; Bochum, Germany)... Cyclin A Correlates with YB1, Progression and Resistance to Chemotherapy in Human Epithelial Ovarian Cancer. M. CYBULSKI, B. JAROSZ, A. NOWAKOWSKI, W. JELENIEWICZ, E. KUTARSKA, W. BEDNAREK, A. STEPULAK (Lublin; Warsaw, Poland)... Clinical Outcomes of Patients with Localized and Locally Advanced Prostate Cancer Undergoing High-doserate Brachytherapy with External-beam Radiotherapy at our Institute. T. MAKINO, A. MIZOKAMI, M. NAMIKI (Kanazawa, Ishikawa, Japan)... Impact of Radical Surgery on Outcome in Locally Advanced Breast Cancer Patients Without Metastasis at the Time of Diagnosis. M. NIKPAYAM, C. UZAN, S. RIVERA, S. DELALOGE, L. CAHEN-DOIDY, S. GIACCHETTI, M. ESPIÉ, D. GROHEUX (Villejuif; Paris, France)... Prognostic Factor of Severe Complications in Patients with Hypopharyngeal Cancer with Primary Concurrent Chemoradiotherapy. L.- Y. CHEN, C.- C. HUANG, Y.- A. TSOU, D.- T. BAU, M- H. TSAI (Taichung, Taiwan, ROC)... The Effect of Re-operation on Survival in Patients with Recurrent Glioblastoma. E. FRANCESCHI, M. BARTOLOTTI, A. TOSONI, S. BARTOLINI, C. STURIALE, A. FIORAVANTI, E. POZZATI, R. GALZIO, A. TALACCHI, L. VOLPIN, L. MORANDI, D. DANIELI, M. ERMANI, A.A. BRANDES (Bologna; L'Aquila; Verona; Vicenza; Padova, Italy)... Significance of Histopathological Evaluation of Pancreatic Fibrosis to Predict Postoperative Course After Pancreatic Surgery. K. TANAKA, H. TOMITA, S. OSADA, H. WATANABE, H. IMAI, Y. SASAKI, S. GOSHIMA, H. KONDO, M. KANEMATSU, A. HARA, K. YOSHIDA (Gifu, Japan)... Proton Beam Therapy Combined with Concurrent Chemotherapy for Esophageal Cancer. H. ISHIKAWA, T. HASHIMOTO, T. MORIWAKI, I. HYODO, K. HISAKURA, H. TERASHIMA, N. OHKOHCHI, T. OHNO, H. MAKISHIMA, M. MIZUMOTO, K. OHNISHI, T. OKUMURA, H. SAKURAI (Ibaraki, Japan)... Role of p53 Codon72 SNP in Breast Cancer Risk and Anthracycline Resistance. A. ARFAOUI, H. DOUIK, G. KABLOUTI, A. BEN CHAABEN, N. HANDIRI, Z. ZID, N. OUNI, F. ZOUIOUCH, F. AYARI, T. MAMOUGHLI, J. BOUASSIDA, H. ABAZZA, L. HARZALLAH, F. GUEMIRA (Tunis, Tunisia)... The Impact of Radiotherapy on Symptoms, Anxiety and QoL in Patients with Cancer. P. GOGOU, E. TSILIKA, E. PARPA, I. KOUVARIS, D. DAMIGOS, M. BALAFOUTA, V. MAUREAS, K. MYSTAKIDOU (Ioannina; Athens, Greece)... Treatment of Multiple Unresectable Basal Cell Carcinomas from Gorlin-Goltz Syndrome: A Case Report. F.O. OJEVWE, C.D. OJEVWE, J.P. ZACNY, A.Z. DUDEK, A. LIN, P. KOHLITZ (Syracuse, NY; Chicago, IL, USA)

36 Role of Salvage Stereotactic Body Radiation Therapy in Post-surgical Loco-regional Recurrence in a Selected Population of Non-small Cell Lung Cancer Patients. L. AGOLLI, M. VALERIANI, A. CARNEVALE, T. FALCO, S. BRACCI, V. DE SANCTIS, G. MINNITI, R. MAURIZI ENRICI, M.F. OSTI (Rome, Italy)... Associations Between Driver Gene Mutations and Cytotoxic Chemosensitivity in Patients with Non-small Cell Lung Cancer. Y. MORODOMI, T. OKAMOTO, M. KOHNO, M. KATSURA, K. TAKADA, Y. SUZUKI, T. FUJISHITA, H. KITAHARA, S. SHIMAMATSU, T. YOSHIDA, T. TAGAWA, S. OKANO, Y. MAEHARA (Fukuoka, Japan)... Lack of Difference in Acute Nephrotoxicity of Intravenous Bisphosphonates Zoledronic Acid and Ibandronate in Women with Breast Cancer and Bone Metastases. D.W. LUEDDERS, J. STEINHOFF, M. THILL, A. RODY, M.K. BOHLMANN (Oldenburg; Luebeck; Frankfurt, Germany)... Biomarkers of Apoptosis and Necrosis in Patients with Hepatocellular Carcinoma Treated with Sorafenib. C. GODIN, C. LOUANDRE, S. BODEAU, M. DIOUF, Z. SAIDAK, M.-A. CONTE, B. CHAUFFERT, J.- C. BARBARE, N. BARGET, J.-C. TRINCHET, N. GANNE, A. GALMICHE (Amiens; Bondy; Bobigny; Paris, France)... Risk of Second Primary Cancer in Patients with B-cell Non-Hodgkin Lymphoma Receiving Rituximabcontaining Chemotherapy: A Nationwide Population-based Study. S.-F. CHO, W.-H. WU, Y.-H. YANG, C.-S. CHANG (Kaohsiung, Taiwan, ROC)... Safety and Efficacy of Adjuvant Therapy with Oxaliplatin, Leucovorin and 5-Fluorouracil After Mesorectal Excision with Lateral Pelvic Lymph Node Dissection for Stage III Lower Rectal Cancer. S. IWASA, H. SOUDA, K. YAMAZAKI, D. TAKAHARI, Y. MIYAMOTO, Y. TAKII, S. IKEDA, T. HAMAGUCHI, Y. KANEMITSU, Y. SHIMADA (Tokyo; Chiba; Shizuoka; Aichi; Kumamoto; Niigata; Hiroshima, Japan)... Book Reviews... Announcements Number 4 Experimental Studies Characterization of the 12q Amplicons in Lipomatous Soft Tissue Tumors by Multiplex Ligation-dependent Probe Amplification-based Copy Number Analysis. D. CREYTENS, J. VAN GORP, E.-J. SPEEL, L. FERDINANDE (Ghent, Belgium; Utrecht; Maastricht, The Netherlands)... The Expression of Toll- like Receptors 2, 4, 5, 7 and 9 in Merkel Cell Carcinoma. L. JOUHI, V. KOLJONEN, T. BÖHLING, C. HAGLUND, J. HAGSTRÖM (Helsinki, Finland)... Synergistic Growth Inhibition of PC3 Prostate Cancer Cells with Lowdose Combinations of Simvastatin and Alendronate. M. ROGERS, S. KALRA, J. MOUKHARSKAYA, K. CHAKRABORTY, M. NIYAZI, K. KRISHNAN, J. LIGHTNER, M. BRANNON, W.L. STONE, V.E. PALAU (Johnson City, TN; Burlington, VT, USA; Munich, Germany)... Clinical Significance of Kallikrein-related Peptidase-4 in Oral Cancer. P. PAPAGERAKIS, G. PANNONE, L. ZHENG, M. ATHANASSIOU-PAPAEFTHYMIOU, Y. YAMAKOSHI, H.S. MCGUFF, O. SHKEIR, K. GHIRTIS, S. PAPAGERAKIS (Ann Arbor, MI; San Antonio, TX, USA; Foggia, Italy)... Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells. T. GERHARDT, R. JONES, J. PARK, R. LU, H.W. CHAN, Q. FANG, N. SINGH, H. LAI (Seattle, WA, USA)

37 Non-small Cell Lung Cancer Detection Using MicroRNA Expression Profiling of Bronchoalveolar Lavage Fluid and Sputum. J.O. KIM, S. GAZALA, R. RAZZAK, L. GUO, S. GHOSH, W.H. ROA, E.L.R. BÉDARD (Edmonton, Alberta; Winnipeg, Manitoba, Canada)... Proliferating Fibroblasts and HeLa Cells Co-cultured In Vitro Reciprocally Influence Growth Patterns, Protein Expression, Chromatin Features and Cell Survival. J.G. DELINASIOS, F. ANGELI, G. KOUMAKIS, S. KUMAR, W.-H. KANG, G. SICA, F. IACOPINO, G. LAMA, S. LAMPRECHT, I. SIGAL-BATIKOFF, G.T. TSANGARIS, C.D. FARFARELOS, M.C. FARFARELOS, E. VAIRAKTARIS, S. VASSILIOU, G.J. DELINASIOS (Kapandriti; Athens; Piraeus, Greece; Manchester, UK; Rome, Italy; Beersheba, Israel)... Comparative Characterization of Stem Cell Marker Expression, Metabolic Activity and Resistance to Doxorubicin in Adherent and Spheroid Cells Derived from the Canine Prostate Adenocarcinoma Cell Line CT1258. W. LIU, M. MOULAY, S. WILLENBROCK, C. ROOLF, C. JUNGHANSS, A. NGENAZAHAYO, I. NOLTE, H.M. ESCOBAR (Hannover; Rostock, Germany)... Quantitative Structure Activity Relationship and Molecular Docking of Artemisinin Derivatives to Vascular Endothelial Growth Factor Receptor 1. M.E.M. SAEED, O. KADIOGLU, E.-J. SEO, H.J. GRETEN, R. BRENK, T. EFFERTH (Mainz; Heidelberg, Germany; Porto, Portugal)... Formamidinodoxorubicins Are more Potent than Doxorubicin as Apoptosis Inducers in Human Breast Cancer Cells. A. MARCZAK, M. DENEL- BOBROWSKA, M. ŁUKAWSKA, I. OSZCZAPOWICZ (Lodz; Warsaw, Poland)... Resistance to Gemcitabine in the Pancreatic Cancer Cell Line KLM1-R Reversed by Metformin Action. B. BARON, Y. WANG, S.-I. MAEHARA, Y. MAEHARA, Y. KURAMITSU, K. NAKAMURA (Ube; Shunanshi; Fukuoka, Japan; Msida, Malta)... Targeting mtor and AREG with Everolimus, Sunitinib and Sorafenib in HPV-positive and -negative SCC. C. ADERHOLD, A. FABER, C. UMBREIT, R. BIRK, C. WEISS, J.U. SOMMER, K. HÖRMANN, J.D. SCHULTZ (Mannheim, Germany)... Carbonyl Levels and Survival Rates in Oral Cancer Cells Exposed to Cigarette Smoke. E. KRAYZLER, R.M. NAGLER (Haifa, Israel)... Sorafenib Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells Through Suppression of Matrix Metalloproteinase Expression. T.-Y. HA, S. HWANG, K.-M. MOON, Y.-J. WON, G.-W. SONG, N. KIM, E. TAK, B.-Y. RYOO, H.-N. HONG (Seoul; Yangsan, Republic of Korea)... The Therapeutic Effect of Photon Irradiation on Viable Glioblastoma Cells Is Reinforced by Hyperbaric Oxygen. H. BÜHLER, G.L. STROHM, P. NGUEMGO-KOUAM, H. LAMM, K. FAKHRIAN, I.A. ADAMIETZ (Herne; Hannover, Germany)... Synergistic Effect of Sorafenib and Vitamin K on Suppression of Hepatocellular Carcinoma Cell Migration and Metastasis. T.-Y. HA, S. HWANG, H.-N. HONG, Y.-I. CHOI, S.-Y. YOON, Y.-J. WON, G.-W. SONG, N. KIM, E. TAK, B.-Y. RYOO (Seoul; Busan; Gyeongi-do, Republic of Korea)... The Novel CA IX Inhibition Antibody chkm4927 Shows Anti-tumor Efficacy In Vivo. A. YAMAGUCHI, K. USAMI, M. SHIMABE, K. HASEGAWA, M. ASADA, K. MOTOKI, T. TAHARA, K. MASUDA (Tokyo, Japan)... Afatinib is Especially Effective Against Non-small Cell Lung Cancer Carrying an EGFR Exon 19 Deletion. E. BANNO, Y. TOGASHI, Y. KOBAYASHI, H. HAYASHI, T. MITSUDOMI, K. NISHIO (Osaka, Japan)

38 Population Stratification Effect on Cancer Susceptibility in an Admixed Population from Brazilian Amazon. P.C. VIEIRA, R.M.R. BURBANO, D.C.R.O. FERNANDES, R.C. MONTENEGRO, S.E.B. DOS SANTOS, V.A. SORTICA, P.P. ASSUMPÇÃO, Â.K.C. RIBEIRO- DOS- SANTOS, A.A. CARVALHO, N.P.C. DOS SANTOS (Belém, Pará, Brazil)... Dual Expression of shakt1 and Pdcd4 Suppresses Lung Tumorigenesis in K-ras LA1 Mice. S.-H. HONG, J.- H. LEE, H.-L. JIANG, J.-E. KIM, A.Y. LEE, S. KIM, C.-S. CHO, M.-H. CHO (Seoul; Suwon; Pyeongchang-gun, Republic of Korea; Nanjing, PR China)... Gene Expression Analysis for Evaluation of Potential Biomarkers in Hepatocellular Carcinoma. H. HASS, J. JOBST, M. SCHEURLEN, U. VOGEL, O. NEHLS (Scheidegg; Reutlingen; Wuerzburg; Tuebingen; Stuttgart, Germany)... Search for New Genetic Biomarkers in Poorly Differentiated and Anaplastic Thyroid Carcinomas Using Next Generation Sequencing. V. SYKOROVA, S. DVORAKOVA, J. VCELAK, E. VACLAVIKOVA, T. HALKOVA, D. KODETOVA, P. LASTUVKA, J. BETKA, P. VLCEK, M. REBOUN, R. KATRA, B. BENDLOVA (Prague, Czech Republic)... The Role of MicroRNAs in Thyroid Carcinomas. S. FORTE, C. LA ROSA, V. PECCE, F. ROSIGNOLO, L. MEMEO (Viagrande; Rome, Italy)... Effect of Perioperative Treatment with a Hypoxia-inducible Factor-1-alpha Inhibitor in an Orthotopic Surgical Mouse Model of Thyroid Cancer. W. CHA, D.-W. KIM, S.D. KIM, E.-H. JEON, W.-J. JEONG, S.-H. AHN (Busan; Seongnam; Seoul, Republic of Korea)... Dysregulation of MicroRNAs in Angioimmunoblastic T-Cell Lymphoma. K. REDDEMANN, D. GOLA, A. SCHILLERT, J. KNIEF, C. KUEMPERS, J. RIBBAT-IDEL, S. BER, J. SCHEMME, V. BERNARD, N. GEBAUER, A.C. FELLER, C. THORNS (Luebeck, Germany)... Structural Changes in Albumin Are a Possible Mechanism for Fluctuation of Cefazorin and Ibuprofen Plasma Protein Binding in Rats with Carcinogen-induced Osteosarcoma. Y. ITAKURA, S. TAGA, C. IWATA, H. TERAMACHI, K.-I. MIYAMOTO, H. TSUCHIYA, T. WADA, R. MATSUSHITA (Aichi; Kanazawa; Gifu, Japan)... The Relationship of CD133, Histone Deacetylase 1 and Thrombospondin-1 in Gastric Cancer. S. ETO, K. YOSHIKAWA, M. SHIMADA, J. HIGASHIJIMA, T. TOKUNAGA, T. NAKAO, M. NISHI, C. TAKASU, H. SATO, N. KURITA (Tokushima, Japan)... Gallic Acid Induces DNA Damage and Inhibits DNA Repair-associated Protein Expression in Human Oral Cancer SCC-4 Cells. S.-W. WENG, S.-C. HSU, H.-C. LIU, B.-C. JI, J.-C. LIEN, F.-S. YU, K.-C. LIU, K.-C. LAI, J.-P. LIN, J.-G. CHUNG (Taichung; Changhua; Tainan, Taiwan, ROC)... Novel In Vitro Platform to Investigate Myotube Atrophy. C. OELKRUG, K. HORN, G.R. MAKERT, A. SCHUBERT (Leipzig, Germany)... Aberrant Glycosylation of α v β 3 Integrin is Associated with Melanoma Progression. E. POCHEĆ, M. BUBKA, M. RYDLEWSKA, M. JANIK, M. POKRYWKA, A. LITYŃSKA (Krakow, Poland)... Substituted Steroidal Compounds Containing Amino and Amido Groups Reverse Multidrug Resistance of Mouse T-Lymphoma and Two Human Prostate Cancer Cell Lines In Vitro. Á. CSONKA, S. HAMDOUN, G. SPENGLER, A. MARTINS, I. VINCZE, T. EFFERTH, J. MOLNÁR (Szeged, Hungary; Lisbon, Portugal; Mainz, Germany)... Clinical and Prognostic Significance of Survivin, AKT and VEGF in Primary Mucosal Oral Melanoma. O. SIMONETTI, G. LUCARINI, C. RUBINI, R. LAZZARINI, R. DI PRIMIO, A. OFFIDANI (Ancona, Italy)

39 Clinical studies Synchronous Quadruple Primary Neoplasms: Glioblastoma, Neuroendocrine Tumor, Schwannoma and Sessile Serrated Adenoma in a Patient with History of Prostate Cancer. S. GRACE, R. MUZAFFAR, J. VEERAPONG, S. ALKAADE, N. PODDAR, N. PHILLIPS, M. GUZMAN, J. BATANIAN, C. VOGLER, J.-P. LAI (Saint Louis, MO, USA)... Extraskeletal Osteosarcoma in Norway, Between 1975 and 2009, and a Brief Review of the Literature. K. BERNER, B. BJERKEHAGEN, Ø.S. BRULAND, A. BERNER (Oslo, Norway)... Early Effects of Adjuvant Breast Cancer Radiotherapy on Right Ventricular Systolic and Diastolic Function. S.S. TUOHINEN, T. SKYTTÄ, V. VIRTANEN, T. LUUKKAALA, P.-L. KELLOKUMPU-LEHTINEN, P. RAATIKAINEN (Tampere; Jyväskylä, Finland)... Volumetric-modulated Arc Therapy with Vaginal Cuff Simultaneous Integrated Boost as an Alternative to Brachytherapy in Adjuvant Irradiation for Endometrial Cancer: A Prospective Study. F. ALONGI, R. MAZZOLA, F. RICCHETTI, S. FERSINO, N. GIAJ LEVRA, A. FIORENTINO, S. NACCARATO, G. SICIGNANO, G. DI PAOLA, R. RUGGIERI, S. GORI, M. CECCARONI (Verona; Palermo, Italy)... Scoring System Based on Tumor Markers and Child-Pugh Classification for HCC Patients who Underwent Liver Resection. S. NAKAGAWA, H. HAYASHI, H. NITTA, H. OKABE, K. SAKAMOTO, T. HIGASHI, H. KUROKI, K. IMAI, D. HASHIMOTO, Y. SAKAMOTO, A. CHIKAMOTO, T. BEPPU, H. BABA (Kumamoto, Japan)... Long-term Control in a Patient with Refractory Multiple Myeloma by Oral Cyclophosphamide and Dexamethasone. N. STEINER, D. NACHBAUR, P. KÖNIG, W. WILLENBACHER, E. GUNSILIUS (Innsbruck, Austria)... Multiple Visceral Resection for Giant Non-Secretory Adrenocortical Carcinoma in an Elderly Patient: A Case Report. N. BACALBASA, D. TERZEA, V. JIANU, M. MARCU, C. STOICA, I. BALESCU (Bucharest, Romania)... Post-void Residual Urinary Volume Is an Independent Predictor of Biopsy Results in Men at Risk for Prostate Cancer. L. CORMIO, G. LUCARELLI, G.S. NETTI, G. STALLONE, O. SELVAGGIO, F. TROIANO, G. DI FINO, F. SANGUEDOLCE, P. BUFO, G. GRANDALIANO, G. CARRIERI (Foggia, Italy)... Epirubicin plus Paclitaxel Regimen as Second-line Treatment of Patients with Small-cell Lung Cancer. G. PASELLO, P. CARLI, F. CANOVA, L. BONANNO, V. POLO, G. ZAGO, L. URSO, P. CONTE, A. FAVARETTO (Padova; Treviso, Italy)... Impact of Age on Early Surgical Outcomes of Laparoscopy-assisted Gastrectomy with Suprapancreatic Nodal Dissection for Clinical Stage I Gastric Cancer. T. KOSUGA, D. ICHIKAWA, K. OKAMOTO, S. KOMATSU, H. KONISHI, H. TAKESHITA, A. SHIOZAKI, H. FUJIWARA, R. MORIMURA, H. IKOMA, Y. MURAYAMA, Y. KURIU, M. NAKANISHI, C. SAKAKURA, E. OTSUJI (Kyoto, Japan)... Nephroprotective Effects of Hydration with Magnesium in Patients with Cervical Cancer Receiving Cisplatin. Y. YAMAMOTO, K. WATANABE, I. TSUKIYAMA, H. MATSUSHITA, H. YABUSHITA, K. MATSUURA, A. WAKATSUKI (Aichi, Japan)... VEGF in Patients with Advanced Hepatocellular Carcinoma Receiving Intra- arterial Chemotherapy. D. MATSUI, H. NAGAI, T. MUKOZU, Y. OGINO, Y. SUMINO (Tokyo, Japan)... Association of Liver Steatosis with Colorectal Cancer and Adenoma in Patients with Metabolic Syndrome. E. FIORI, A. LAMAZZA, E. DE MASI, A. SCHILLACI, D. CROCETTI, A. ANTONIOZZI, A.V. STERPETTI, G. DE TOMA (Rome, Italy)

40 Agreement Between Hopelessness/Helplessness and Montgomery-Asberg Depression Rating Scale in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case-Control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland)... Preoperative Systemic and Intraperitoneal Chemotherapy Consisting of S-1, Cisplatin and Docetaxel in Patients with Marginally Resectable Gastric Cancer. Y. KUROKAWA, T. HAMAKAWA, Y. MIYAZAKI, T. TAKAHASHI, M. YAMASAKI, H. MIYATA, K. NAKAJIMA, S. TAKIGUCHI, M. MORI, Y. DOKI (Osaka, Japan)... Prognostic Factors and Survival in Patients Treated Surgically for Primary and Recurrent Uterine Leiomyosarcoma: A Single Center Experience. N. BACALBASA, I. BALESCU, S. DIMA, V. BRASOVEANU, I. POPESCU (Bucharest, Romania)... High Interleukin-6 mrna Expression Is a Predictor of Relapse in Colon Cancer. J. OLSEN, L.T. KIRKEBY, J. OLSEN, S. EIHOLM, P. JESS, I. GÖGENUR, J.T. TROELSEN (Roskilde; Copenhagen, Denmark)... The Role of 18 F-FDG Accumulation and Arterial Enhancement as Biomarkers in the Assessment of Typing, Grading and Staging of Hepatocellular Carcinoma Using 18 F-FDG-PET/CT with Integrated Dual-phase CT Angiography. J. FERDA, E. FERDOVÁ, J. BAXA, B. KREUZBERG, O. DAUM, V. TŘEŠKA, T. SKALICKÝ (Pilsen, Czech Republic)... Efficacy of 18-FDG PET-CT Dual-phase Scanning for Detection of Lymph Node Metastasis in Gynecological Cancer. Y. NOGAMI, K. BANNO, H. IRIE, M. IIDA, Y. MASUGI, K. MURAKAMI, D. AOKI (Tokyo, Japan)... Bevacizumab and Postoperative Wound Complications in Patients with Liver Metastases of Colorectal Cancer. H. UTSUMI, Y. HONMA, K. NAGASHIMA, S. IWASA, A. TAKASHIMA, K. KATO, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA, Y. KISHI, S. NARA, M. ESAKI, K. SHIMADA (Tokyo; Chiba, Japan)... Gastric Cancer Patients with End-stage Renal Disease Who Underwent Radical Gastrectomy. Y.-Y. LIU, C.- Y. TSAI, C.-N. YEH, K.-C. CHIANG, S.-Y. WANG, C.-T. CHENG, C.-H. LIAO, J.-T. HSU, T.-S. YEH, Y.-Y. JAN, M.-F. CHEN (Taipei, Taiwan, ROC)... Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. H. NAGAI, T. MUKOZU, Y. OGINO, D. MATSUI, T. MATSUI, N. WAKUI, K. MOMIYAMA, Y. IGARASHI, Y. SUMINO, K. HIGAI (Tokyo; Funabashi, Japan)... Human Leukocyte Antigen (HLA)-E and HLA-F Expression in Gastric Cancer. S. ISHIGAMI, T. ARIGAMI, H. OKUMURA, Y. UCHIKADO, Y. KITA, H. KURAHARA, K. MAEMURA, Y. KIJIMA, Y. ISHIHARA, K. SASAKI, Y. UENOSONO, S. NATSUGOE (Kagoshima, Japan)... Clinical Significance of CD155 Expression in Human Pancreatic Cancer. S. NISHIWADA, M. SHO, S. YASUDA, K. SHIMADA, I. YAMATO, T. AKAHORI, S. KINOSHITA, M. NAGAI, N. KONISHI, Y. NAKAJIMA (Kashihara, Japan)... Hyperthermia Combined with Chemotherapy for Patients with Residual or Recurrent Oesophageal Cancer After Definitive Chemoradiotherapy. S. NISHIMURA, H. SAEKI, T. NAKANOKO, Y. KASAGI, Y. TSUDA, Y. ZAITSU, K. ANDO, Y. NAKASHIMA, Y. IMAMURA, K. OHGAKI, E. OKI, S. OHGA, K. NAKAMURA, M. MORITA, Y. MAEHARA (Fukuoka, Japan)... Histopathologic Features Predictive of Aggressiveness of Post-transplant Cutaneous Squamous-cell Carcinomas. J. KANITAKIS, G. KARAYANNOPOULOU, A. ROUX, S. EUVRARD (Lyon, France; Thessaloniki, Greece)

41 Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient. U. GIGER-PABST, W. SOLASS, B. BUERKLE, M.-A. REYMOND, C.B. TEMPFER (Bochum; Hannover, Germany)... Initial Incomplete Surgery Modifies Prognosis in Advanced Ovarian Cancer Regardless of Subsequent Management. N. BACALBASA, I. BALESCU, S. DIMA, V. HERLEA, L. DAVID, V. BRASOVEANU, I. POPESCU (Bucharest, Romania)... Expression of Phosphorylated Akt, mtor and MAPK in Type I Endometrial Carcinoma: Clinical Significance. H.P. KOUREA, M. NIKOLAOU, V. TZELEPI, G. ADONAKIS, D. KARDAMAKIS, V. TSAPANOS, C.D. SCOPA, C. KALOFONOS, G. DECAVALAS (Patras, Greece)... Risk of Anemia Attributable to Everolimus in Patients with Cancer: A Meta-analysis of Randomized Controlled Trials. R. SHAMEEM, M.S. HAMID, S. WU (Philadelphia, PA; Detroit, MI; Stony Brook; Northport, NY, USA)... Necessity for Resection of Gastric Gastrointestinal Stromal Tumors 20 mm. T. KOGA, Y. HIRAYAMA, S. YOSHIYA, K. TAKETANI, T. NAKANOKO, R. YOSHIDA, R. MINAGAWA, M. KAI, K. KAJIYAMA, K. AKAHOSHI, Y. MAEHARA (Fukuoka, Japan)... BRAF V600E Mutation in Colorectal Cancer Is Associated with Right-sided Tumours and Iron Deficiency Anaemia. M. SIDERIS, K. ADAMS, J. MOORHEAD, S. DIAZ- CANO, I. BJARNASON, S. PAPAGRIGORIADIS (London, UK)... Diffusion-weighted Imaging Using 3.0 T MRI as a Possible Biomarker of Renal Tumors. H. MIRKA, E. KORCAKOVA, J. KASTNER, M. HORA, O. HES, P. HOSEK, J. FERDA (Pilsen, Czech Republic)... Post-chemotherapeutic CEA and CA19-9 Are Prognostic Factors in Patients with Colorectal Liver Metastases Treated with Hepatic Resection After Oxaliplatin-based Chemotherapy. Y. SAKAMOTO, Y. MIYAMOTO, T. BEPPU, H. NITTA, K. IMAI, H. HAYASHI, Y. BABA, N. YOSHIDA, A. CHIKAMOTO, H. BABA (Kumamoto, Japan)... Clinical Decision-making in Atypical and Suspicious Categories in Fine-needle Aspiration Cytology of the Breast. M. GIPPONI, P. FREGATTI, A. GARLASCHI, M. CALABRESE, P. BACCINI, M. GALLO, F. MURELLI, C. MARGARINO, C. BOBBIO, D. FRIEDMAN (Genoa, Italy)... Analysis of the Risk Factors for Febrile Neutropenia in Patients with Bone and Soft Tissue Sarcoma. T. AOYAGI, T. MORII, T. TAJIMA, A. YOSHIYAMA, S. ICHIMURA (Mitaka, Tokyo, Japan)... Critical Evaluation of a Prospective Study of Concurrent Chemoradiotherapy with S-1 for Early Glottic Carcinoma. K. KIMURA, Y. ITOH, T. OKADA, R. NAKAHARA, M. KAWAMURA, S. KUBOTA, J. ITOH, M. HIRAMATSU, Y. FUJIMOTO, T. SHIBATA, S. NAGANAWA (Aichi, Japan)... Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study. S.E. LUTRINO, F. BERGAMO, M. SCHIRRIPA, G. ROSATI, A. AVALLONE, R. GIAMPIERI, S. CORDIO, M. BERRETTA, F.R. LLIMPE, F.E. PISA, S. LONARDI, F. LOUPAKIS, G. FASOLA, G. APRILE (Udine; Padova; Pisa; Potenza; Napoli; Ancona; Catania; Aviano; Bologna, Italy)... Impact of Postoperative Complications on Survival and Recurrence in Pancreatic Cancer. T. AOYAMA, M. M. URAKAWA, Y. KATAYAMA, K. YAMAOKU, A. KANAZAWA, A. HIGUCHI, M. SHIOZAWA, M. MORIMOTO, T. YOSHIKAWA, N. YAMAMOTO, Y. RINO, M. MASUDA, S. MORINAGA (Yokohama, Japan)

42 Src Kinase-associated Phosphoprotein2 Expression Is Associated with Poor Prognosis in Non-small Cell Lung Cancer. S. KURANAMI, T. YOKOBORI, A. MOGI, B. ALTAN, T. YAJIMA, R. ONOZATO, Y. AZUMA, M. IIJIMA, T. KOSAKA, H. KUWANO (Maebashi, Japan)... Pathological Patterns of Prostate Biopsy in Men with Fluctuations of Prostate Cancer Gene 3 Score: A Preliminary Report. S. DE LUCA, R. PASSERA, S. CAPPIA, E. BOLLITO, D.F. RANDONE, F. PORPIGLIA (Orbassano; Torino, Italy)... mir-7 Expression in Serous Ovarian Carcinomas. A. SWIERCZ, M. CHECHLINSKA, J. KUPRYJANCZYK, A. DANSONKA-MIESZKOWSKA, A. REMBISZEWSKA, K. GORYCA, M. KULINCZAK, M. ZAJDEL, M. SROMEK, J.K. SIWICKI (Warsaw, Poland)... Radiation-induced Second Malignancies. S. MAHMOOD, K. VU, P. TAI, K. JOSEPH, R. KOUL, A. DUBEY, E. YU (Regina, SK; Edmonton, AB; Winnipeg, MB; London, ON, Canada)... Assessment of Circulating Serum DNA Integrity in Colorectal Cancer Patients. E.E. YÖRÜKER, E. ÖZGÜR, M. KESKIN, N. DALAY, S. HOLDENRIEDER, U. GEZER (Istanbul, Turkey; Bonn, Germany)... Correlation of HER2 Expression with Clinicopathological Characteristics and Prognosis in Resectable Gastric Cancer. H. OTSU, E. OKI, A. IKAWA-YOSHIDA, H. KAWANO, K. ANDO, S. IDA, Y. KIMURA, S. AISHIMA, H. SAEKI, M. MORITA, S. KOHNOE, Y. ODA, Y. MAEHARA (Fukuoka; Shizuoka, Japan)... High Expression of Phospho-H2AX Predicts a Poor Prognosis in Colorectal Cancer. Y.-C. LEE, T.C. YIN, Y.-T. CHEN, C.-Y. CHAI, J.Y. WANG, M.-C. LIU, Y.-C. LIN, J.Y. KAN (Kaohsiung, Taiwan, ROC)... MicroRNA Profile in Site-specific Head and Neck Squamous Cell Cancer. D. KALFERT, M. PESTA, V. KULDA, O. TOPOLCAN, A. RYSKA, P. CELAKOVSKY, J. LACO, M. LUDVIKOVA (Hradec Kralove; Pilsen, Czech Republic)... The Clinical Significance of Activated p-akt Expression in Peripheral T-cell Lymphoma. J.Y. HONG, M.E. HONG, M.K. CHOI, W. CHANG, I.-G. DO, J.-S. JO, S.-H. JUNG, S. PARK, S.J. KIM, Y.H. KO, W.S. KIM (Seoul; Gyeonggi-do, Republic of Korea; Durham, NC, USA)... Long-term Outcome of Living-donor Liver Transplantation for Combined Hepatocellular-cholangiocarcinoma. S. ITOH, T. IKEGAMI, T. YOSHIZUMI, H. WANG, K. TAKEISHI, N. HARIMOTO, Y.-I. YAMASHITA, H. KAWANAKA, S. AISHIMA, K. SHIRABE, Y. MAEHARA (Fukuoka; Saga, Japan)... Errata... Retraction Number 5 Reviews Recent Developments in Radiosensitization. J. LINAM, L.-X. YANG (San Francisco, CA, USA)... Radiation-associated Cardiac Injury. R. ELDABAJE, D.L. LE, W. HUANG, L.-X. YANG (San Francisco, CA; Providence, RI, USA)... Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review. C. BLOMBERG, J. NILSSON, G. HOLGERSSON, P. EDLUND, M. BERGQVIST, L. ADWALL, S. EKMAN, D. BRATTSTRÖM, S. BERGSTRÖM (Gävle; Uppsala; Umeå, Sweden)

43 Targeted Therapy for NSCLC A Double-edged Sword? W.C.M. DEMPKE (Munich, Germany)... The Role of Human Papilloma Virus in Urological Malignancies. I. HEIDEGGER, W. BORENA, R. PICHLER (Innsbruck, Austria) Experimental Studies Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic mirnas. B.H HAUG, Ø.H. HALD, P. UTNES, S.A. ROTH, C. LØKKE, T. FLÆGSTAD, C. EINVIK (Tromsø, Norway)... Fast, Stable Induction of P-Glycoprotein-mediated Drug Resistance in BT-474 Breast Cancer Cells by Stable Transfection of ABCB1 Gene. Y. TANG, Y. WANG, S. DEOSARKAR, F. SOROUSH, M.F. KIANI, B. WANG (Philadelphia; Wynnewood; Chester, PA, USA)... Early Reporting of Apoptosis by Real-time Imaging of Cancer Cells Labeled with Green Fluorescent Protein in the Nucleus and Red Fluorescent Protein in the Cytoplasm. M. YANG, P. JIANG, R.M. HOFFMAN (San Diego, CA, USA; Beijing, PR China)... Imaging the Interaction of Pancreatic Cancer and Stellate Cells in the Tumor Microenvironment during Metastasis. A. SUETSUGU, C.S. SNYDER, H. MORIWAKI, S. SAJI, M. BOUVET, R.M. HOFFMAN (San Diego, CA, USA; Gifu, Japan)... The Use of Living Cancer Cells Expressing Green Fluorescent Protein in the Nucleus and Red Fluorescence Protein in the Cytoplasm for Real-time Confocal Imaging of Chromosome and Cytoplasmic Dynamics During Mitosis. A. SUETSUGU, P. JIANG, M. YANG, N. YAMAMOTO, H. MORIWAKI, S. SAJI, R.M. HOFFMAN (San Diego, CA, USA; Gifu; Kanazawa, Japan; Beijing, PR China)... Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors. A.B. BOHN, A.S. BREMS-ESKILDSEN, B.K. MØLLER, M.R. HORSMAN (Aarhus, Denmark)... Analyzing the Association of Polymorphisms in the CRYBB2 Gene with Prostate Cancer Risk in African Americans. M.U. FARUQUE, R. PAUL, L. RICKS- SANTI, E.Y. JINGWI, C.A. AHAGHOTU, G.M. DUNSTON (Washington, DC; Hampton, VA, USA)... Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy. L.V. KLOTZ, D.-A. CLEVERT, S. SCHECKINGER, S. STRIETH, M.E. EICHHORN (Munich; Mainz; Heidelberg, Germany)... High-dose Ionizing Radiation Regulates Gene Expression Changes in the MCF7 Breast Cancer Cell Line. V. BRAVATÀ, L. MINAFRA, G. RUSSO, G.I. FORTE, F.P. CAMMARATA, M. RIPAMONTI, C. CASARINO, G. AUGELLO, F. COSTANTINI, G. BARBIERI, C. MESSA, M.C. GILARDI (Cefalù; Palermo; Milan; Monza, Italy)... Differential Gene Expression of the Proto-oncogene VAV3 and the Transcript Variant VAV3.1 in Oral Squamous Cell Carcinoma. T. TRENKLE, S.G. HAKIM, H.-C. JACOBSEN, P. SIEG (Lübeck, Germany)... A Comparative Analysis of Breast and Ovarian Cancer- related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer. Y. AMEMIYA, S. BACOPULOS, M. AL- SHAWARBY, D. AL- TAMIMI, W. NASER, A. AHMED, M. KHALIFA, E. SLODKOWSKA, A. SETH (Toronto, ON, Canada; Dammam, Kingdom of Saudi Arabia)... Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer. G.O. CHONG, H.-S. JEON, H.S. HAN, J.W. SON, Y.H. LEE, D.G. HONG, Y.S. LEE, Y.L. CHO (Daegu; Daejeon, Republic of Korea)

44 Down-regulation of Immune-related Genes by PSCA in Gallbladder Cancer Cells Implanted into Mice. N. SAEKI, H. ONO, H. SAKAMOTO, T. YOSHIDA (Tokyo, Japan)... Reduced UDP-glucose Levels Are Associated with P-glycoprotein Over-expression in L1210 Cells and Limit Glucosylceramide Synthase Activity. K. TURÁKOVÁ, L. PAVLÍKOVÁ, L. MESSINGEROVÁ, B. LAKATOŠ, A. BREIER, Z. SULOVÁ (Bratislava, Slovak Republic)... Epithelial-mesenchymal Transition (EMT) Markers in Human Pituitary Adenomas Indicate a Clinical Course. W. JIA, J. ZHU, T.A. MARTIN, A. JIANG, A.J. SANDERS, W.G. JIANG (Beijing; Shandong; YanTai, PR China; Cardiff, UK)... Kaempferol Is an Anti-Inflammatory Compound with Activity towards NF-κB Pathway Proteins. O. KADIOGLU, J. NASS, M.E.M. SAEED, B. SCHULER, T. EFFERTH (Mainz; Freiburg, Germany)... Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer. T.H. ECKE, C. ARNDT, C. STEPHAN, S. HALLMANN, O. LUX, T. OTTO, J. RUTTLOFF, H. GERULLIS (Bad Saarow; Neuss; Berlin; Oldenburg, Germany)... Cytotoxicity of Endogenous Lipids N-acyl Dopamines and their Possible Metabolic Derivatives for Human Cancer Cell Lines of Different Histological Origin. M.G. AKIMOV, N.M. GRETSKAYA, G.N. ZINCHENKO, V.V. BEZUGLOV (Moscow, Russia)... Pentraxin-3 Silencing Suppresses Gastric Cancer-related Inflammation by Inhibiting Chemotactic Migration of Macrophages. B. CHOI, E.-J. LEE, Y.S. PARK, S.-M. KIM, E.-Y. KIM, Y. SONG, S.-W. KANG, M.- H. RHU, E.-J. CHANG (Seoul, Republic of Korea)... Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response. T. OHASHI, T. YOSHIMASU, S. OURA, Y. KOKAWA, M. KAWAGO, Y. HIRAI, M. MIYASAKA, Y. AOISHI, M. KIYOI, H. NISHIGUCHI, M. HONDA, Y. OKAMURA (Wakayama, Japan)... Enhanced Antiproliferative and Pro-apoptotic Activities of a Novel Curcumin-related Compound in Jurkat Leukemia T-Cells. K. GOLDHAHN, M. HINTERSTEININGER, G. STEINER, T. ERKER, B. KLOESCH (Vienna, Austria)... Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. J. LOHR, A. MOCK, P. BECKHOVE, C. HEROLD-MENDE (Heidelberg, Germany)... Demethoxycurcumin-induced DNA Damage Decreases DNA Repair-associated Protein Expression Levels in NCI-H460 Human Lung Cancer Cells. Y.-C. KO, J.-C. LIEN, H.-C. LIU, S.-C. HSU, H.-Y. LIN, F.-S. CHUEH, B.-C. JI, M.-D. YANG, W.-H. HSU, J.-G. CHUNG (Taichung; Changhua, Taiwan, ROC)... Combining CAL-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPKinduced ER Stress. G.B. PARK, D.Y. HUR, D. KIM (Busan, Republic of Korea)... Analyses of EGF A61G Gene Variation and Serum EGF Level on Gastric Cancer Susceptibility and Clinicopathological Parameters. C. CACINA, S. ARIKAN, Y. DÜZKÖYLÜ, M.B. DOĞAN, E. OKAY, S. TURAN, İ. YAYLIM, T. İSBİR (Istanbul; Kocaeli, Turkey)... Identification, Molecular Characterization and Alternative Splicing of Three Novel Members of the Canine Kallikrein (Klk)-related Peptidase Family. K. ANGELOPOULOU, G.S. KARAGIANNIS (Thessaloniki, Greece; Toronto, Canada)... Significant Association of Cyclo-oxygenase 2 Genotypes with Upper Tract Urothelial Cancer. W.-S. CHANG, C.-H. LIAO, C.-M HSU, C.-Y. HUANG, H.-Y. FANG, P.-Y. KAO, C.-W. TSAI, H.-C. WU, P.-S. HU, T.- C. WANG, Y.-R. SYU, H.-A. SHUI, D.-T. BAU (Taichung; Taipei; Changhua, Taiwan, ROC)

45 Gemcitabine Induces Radiosensitization Through Inhibition of RAD51-dependent Repair for DNA Double-strand Breaks. S. KOBASHIGAWA, K. MORIKAWA, H. MORI, G. KASHINO (Oita; Fukuoka, Japan)... Azaspirene Analogs Inhibit the Growth of Human Uterine Carcinosarcoma In Vitro and In Vivo. M. EMOTO, K. YANO, B. CHOIJAMTS, S. SAKAI, S. HIRASAWA, S. WAKAMORI, M. AIZAWA, K. NABESHIMA, K. TACHIBANA, N. KANOMATA (Fukuoka; Tokyo; Kawasaki, Japan)... Expression of mirnas as Important Element of Melanoma Cell Plasticity in Response to Microenvironmental Stimuli. M. WOZNIAK, M. SZTILLER-SIKORSKA, M. CZYZ (Lodz, Poland)... Sensitivity of Neoplastic Cells to Senescence Unveiled Under Standard Cell Culture Conditions. J. ZIEBA, M. KSIAZKIEWCZ, K. JANIK, M. BANASZCZYK, J. PECIAK, S. PIASKOWSKI, M. LIPINSKI, M. OLCZAK, E. STOCZYNSKA-FIDELUS, P. RIESKE (Lodz, Poland)... Expression of Formyl-peptide Receptors in Human Lung Carcinoma. F. CATTANEO, G. GUERRA, M. PARISI, A. LUCARIELLO, A. DE LUCA, N. DE ROSA, G. MAZZARELLA, A. BIANCO, R. AMMENDOLA (Naples; Campobasso, Italy)... Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. S. KANG, Y.S. CHAE, S.J. LEE, B.W. KANG, J.G. KIM, W.W. KIM, J.H. JUNG, H.Y. PARK, J.-H. JEONG, J.Y. JEONG, J.-Y PARK (Daegu, Republic of Korea)... Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models. L. ARZUMAN, P. BEALE, J.Q. YU, F. HUQ (Lidcombe; Concord, Australia)... Down-regulation of Phospholipase D Stimulates Death of Lung Cancer Cells Involving Up-regulation of the Long ncrna ANRIL. Y.-H. KANG, D. KIM, E.-J. JIN (Iksan, Republic of Korea)... Evaluation of Stem Cell Marker Expression in Canine B-Cell Lymphoma Cell Lines, B-Cell Lymphomagenerated Spheres and Primary Samples. W. LIU, F. SELÇUK, B.C. RÜTGEN, M. MOULAY, S. WILLENBROCK, S.E. HAMMER, K.A. STERENCZAK, C. JUNGHANSS, M. HEWICKER- TRAUTWEIN, I. NOLTE, H.M. ESCOBAR (Hannover; Rostock, Germany; Vienna, Austria)... Amifostine Increases FAS and Caspase-3 Expression in Colonic Tissue of Irradiated Mice. C.T.F. OSHIMA, D.A. RIBEIRO, T.S. GOMES, P.C. ADIOS, M.I. EGAMI, H.R.C. SEGRETO (São Paulo, SP, Brazil)... Circulating Tumour Cells in Patients with Malignant Lung Tumors Undergoing Radio-frequency Ablation. D. CHUDASAMA, A. RICE, V. ANIKIN, G. SOPPA, P. DALAL (Harefield, Middlesex, UK)... Lupalbigenin from Derris scandens Sensitizes Detachment-induced Cell Death in Human Lung Cancer Cells. A. AUSAWASAMRIT, N. ITTHIWARAPORNKUL, C. CHAOTHAM, S. SUKRONG, P. CHANVORACHOTE (Bangkok, Thailand)... Effect of New Oxicam Derivatives on Efflux Pumps Overexpressed in Resistant a Human Colorectal Adenocarcinoma Cell Line. K. ŚRODA-POMIANEK, O. WESOŁOWSKA, B. SZCZĘŚNIAK-SIĘGA, B. PUŁA, P. DZIĘGIEL, J. MANIEWSKA, W. MALINKA, A. PALKO-ŁABUZ, K. MICHALAK (Wroclaw, Poland) Clinical Studies Analytical Anisotropic Algorithm Versus Pencil Beam Convolution for Treatment Planning of Breast Cancer: Implications for Target Coverage and Radiation Burden of Normal Tissue. A.M. FLEJMER, F. DOHLMAR, M. NILSSON, M. STENMARKER, A. DASU (Linköping; Jönköping, Sweden)

46 Serum Angiopoietin-like Protein 2 Improves Preoperative Detection of Lymph Node Metastasis in Colorectal Cancer. Y. TOIYAMA, Y. INOUE, T. SHIMURA, H. FUJIKAWA, S. SAIGUSA, J. HIRO, M. KOBAYASHI, M. OHI, T. ARAKI, K. TANAKA, Y. MOHRI, M. KUSUNOKI (Mie, Japan)... Radiation-induced Chondrosarcoma of the Bladder. Case Report and Review of Literature. N. SULE, B. XU, D. EL ZEIN, K. SZIGETI, S. GEORGE, J.M. KANE, R. CHENEY (Buffalo, NY, USA)... Absolute Lymphocyte Count with Extreme Hyperleukocytosis Does Not Have a Prognostic Impact in Chronic Lymphocytic Leukemia. L. SHVIDEL, O. BAIREY, T. TADMOR, A. BRAESTER, R. RUCHLEMER, R. FINEMAN, E. JOFFE, A. BERREBI, A. POLLIACK (Rehovot; Petah-Tikva; Haifa; Naharyia; Jerusalem, Israel)... Recurrence 11 Years After Complete Response to Gemcitabine, 5-Fluorouracil, and Cisplatin Chemotherapy Followed by Radiotherapy in a Patient with Advanced Pancreatic Cancer: a Case Report. T. UCHIHARA, Y.- I. YAMASHITA, W. HUALIN, K. TAKEISHI, S. ITOH, N. HARIMOTO, T. YOSHIZUMI, S. AISHIMA, K. SHIRABE, H. BABA, Y. MAEHARA (Fukuoka; Kumamoto; Saga, Japan)... A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients. S. VASILYEV, E. SMIRNOVA, D. POPOV, A. SEMENOV, C. EKLUND, P. HENDOLIN, L. PALOHEIMO, K. SYRJÄNEN (St. Petersburg, Russia; Helsinki, Finland; Barretos, SP, Brazil)... Development and Validation of a Nomogram to Estimate the Risk of Prostate Cancer in Brazil. T.B. SILVA, C.Z. OLIVEIRA, E.F. FARIA, E.C. MAUAD, K.J. SYRJÄNEN, A.L. CARVALHO (Barretos, SP, Brazil; Helsinki, Finland)... Impact of Surgical Case Volume on the Accuracy of Preoperative Staging and Compliance with the Guidelines for the Management of Endometrial Cancer. M. KOSKAS, L. OULDAMER, N. BOURDEL, T. GAUTHIER, J.-L. BRUN, C. HUCHON (Paris; Tours; Clermont Ferrand; Limoges; Bordeaux; Poissy, France)... Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer. A. RABINOVICH, L. BERNARD, T.M. NIAZI, A.V. RAMANAKUMAR, W.H. GOTLIEB, S. LAU, B. BAHORIC (Montreal, Quebec, Canada)... Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen. E. TABOURET, G. REYES-BOTERO, C. DEHAIS, M. DAROS, M. BARRIE, M. MATTA, G. PETRIRENA, D. AUTRAN, A. DURAN, C. BEQUET, J.-Y. DELATTRE, O. CHINOT (Marseille; Paris, France)... Construction of a Model for Predicting Creatinine Clearance in Japanese Patients Treated with Cisplatin Therapy. A. YAJIMA, Y. UESAWA, C. OGAWA, M. YATABE, N. KONDO, S. SAITO, Y. SUZUKI, K. ATSUDA, H. KAGAYA (Tokyo; Chiba; Kanagawa, Japan)... Positive Interplay Between CD3 + T-lymphocytes and Concurrent COX-2/EGFR Expression in Canine Malignant Mammary Tumors. M.I. CARVALHO, I. PIRES, J. PRADA, A.F. FERREIRA, F.L. QUEIROGA (Vila Real; Porto, Portugal; Sousa, PB, Brazil)... Significance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma. T. OCHIAI, H. ISHII, Y. YAMAMOTO, R. MORIMURA, H. IKOMA, E. OTSUJI (Kyoto, Japan)... Impact of Nagasaki Atomic Bomb Exposure on Myelodysplastic Syndrome Patients Who Are Treated with Azacitidine. T. JO, K. HORIO, K. SHIGEMATSU (Nagasaki, Japan)... Nuclear Survivin Expression in Small Cell Lung Cancer. Y. YANO, T. OTSUKA, H. HIRANO, T. UENAMI, A. SATOMI, M. KUROYAMA, M. NIINAKA, T. YONEDA, H. KIMURA, M. MORI, T. YAMAGUCHI, S. YOKOTA (Toyonaka; Suita, Japan)

47 Interleukin-32 Expression and Treg Infiltration in Esophageal Squamous Cell Carcinoma. B. NABEKI, S. ISHIGAMI, Y. UCHIKADO, K. SASAKI, Y. KITA, H. OKUMURA, T. ARIGAMI, Y. KIJIMA, H. KURAHARA, K. MAEMURA, S. NATSUGOE (Kagoshima, Japan)... The Prognostic Role of Claudins -1 and -4 in Oral Squamous Cell Carcinoma. J.C. DE VICENTE, Á. FERNÁNDEZ-VALLE, B. VIVANCO-ALLENDE, T.R. SANTAMARTA, P. LEQUERICA-FERNÁNDEZ, G. HERNÁNDEZ-VALLEJO, E. ALLONCA-CAMPA (Oviedo; Madrid, Spain)... Profile of Serum Factors and Disseminated Tumor Cells Before and After Radiofrequency Ablation Compared to Resection of Colorectal Liver Metastases-A Pilot Study. S. HINZ, J. TEPEL, C. RÖDER, H. KALTHOFF, T. BECKER (Kiel; Osnabrück, Germany)... Additional Surgery After Non-curative Resection of ESD for Early Gastric Cancer. T. KATSUBE, M. MURAYAMA, K. YAMAGUCH, A. USUDA, A. SHIMAZAKI, S. ASAKA, S. KONNNO, A. MIYAKI, T. USUI, H. YOKOMIZO, S. SHIOZAWA, K. YOSHIMATSU, T. SHIMAKAWA, Y. NARITAKA (Tokyo, Japan)... Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus. S. TAMURA, A. TAKENO, H. TANIGUCHI, Y. KATSURA, Y. OHMURA, Y. KAGAWA, H. SAKISAKA, Y. TAKEDA, T. KATO (Hyogo, Japan)... Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer. S. KAZAMA, J. KITAYAMA, M. HIYOSHI, Y. TAKETOMI, M. MURAKAMI, T. NISHIKAWA, T. TANAKA, J. TANAKA, T. KIYOMATSU, K. KAWAI, K. HATA, H. YAMAGUCHI, H. NOZAWA, S. ISHIHARA, E. SUNAMI, T. WATANABE (Tokyo, Japan)... Simultaneous Integrated Boost (SIB): RapidArc and Tomotherapy Plan Comparison for Unilateral and Bilateral Neck Irradiation. C. STROMBERGER, W. WLODARCZYK, S. MARNITZ, B. JAMIL, V. BUDACH, J.-D. RAGUSE, A. BOETTCHER, H. BADAKHSHI (Berlin; Frankfurt, Germany) F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies. V. CAMUS, A. EDET-SANSON, M. BUBENHEIM, A. HITZEL, S. BECKER, M. DAVID, A. STAMATOULLAS, P. LENAIN, F. JARDIN, N. CONTENTIN, M.L. FONTOURA, N. CARDINAEL, S. VAUDAUX, S. DUBOIS, H. TILLY, P. VERA, S. LEPRÊTRE (Rouen; Toulouse, France)... Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer. E.M. AZZATO, C. DESHPANDE, V. AIKAWA, C. AGGARWAL, E. ALLEY, B. JACOBS, J. MORRISSETTE, R. DABER (Philadelphia, PA, USA)... Radiation Therapy for Choroid Plexus Carcinoma Patients with Li-Fraumeni Syndrome: Advantageous or Detrimental? M. BAHAR, U. KORDES, T. TEKAUTZ, J. WOLFF (Cleveland, OH, USA; Hamburg, Germany)... Thymidine Kinase Levels Correlate with Prognosis in Aggressive Lymphoma and Can Discriminate Patients with a Clinical Suspicion of Indolent to Aggressive Transformation. M.E. GATT, N. GOLDSCHMIDT, I. KALICHMAN, M. FRIEDMAN, A.C. ARRONSON, V. BARAK (Jerusalem, Israel)... Does the Diagnosis Center Influence the Prognosis of Ovarian Cancer Patients Submitted to Neoadjuvant Chemotherapy? G. VIZZIELLI, F. FANFANI, V. CHIANTERA, L. TORTORELLA, A. LUCIDI, M. PETRILLO, B. COSTANTINI, G. SCAMBIA, A. FAGOTTI (Rome; Campobasso; Terni, Italy)... Endoscopic Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma. K. DOI, T. BEPPU, T. ISHIKO, A. CHIKAMOTO, H. HAYASHI, K. IMAI, H. NITTA, Y. BABA, T. MASUDA, K. OKABE, M. KURAMOTO, K. KUDO, K. OGATA, T. OHCHI, H. TAKAMORI, K. KIKUCHI, H. BABA (Kumamoto; Miyazaki, Japan)

48 Single-phase Whole-body 64-MDCT Split-bolus Protocol for Pediatric Oncology: Diagnostic Efficacy and Dose Radiation. M. SCIALPI, R. SCHIAVONE, A. D ANDREA, I. PALUMBO, M. MAGLI, S. GRAVANTE, G. FALCONE, C. DE FILIPPI, L. MANGANARO, B. PALUMBO (Perugia; Florence; Parma; Caserta; Rome, Italy)... Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono- Institutional Phase II Study. F. TRAMACERE, S. ARCANGELI, A. PIGNATELLI, R. CASTAGNA, M. PORTALURI (Brindisi; Rome; Pisa, Italy)... Radiosurgery or Fractionated Stereotactic Radiotherapy plus Wholebrain Radioherapy in Brain Oligometastases: A Long-term Analysis. M. BALDUCCI, R. AUTORINO, S. CHIESA, G. MATTIUCCI, A. POMPUCCI, L. AZARIO, G.R. D AGOSTINO, M. FERRO, A. FIORENTINO, S. FERSINO, C. MAZZARELLA, C. COLOSIMO, V. FRASCINO, C. ANILE, V. VALENTINI (Rome, Italy)... Predictors of Intrahepatic Multiple Recurrences After Curative Hepatectomy for Hepatocellular Carcinoma. K. TAKEISHI, T. MAEDA, E. TSUJITA, Y. -I. YAMASHITA, N. HARADA, S. ITOH, N. HARIMOTO, T. IKEGAMI, T. YOSHIZUMI, K. SHIRABE, Y. MAEHARA (Fukuoka; Hiroshima, Japan)... No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. A. MIYAZAKI, H. MIYAKE, K.- I. HARADA, M. FUJISAWA (Kobe, Japan)... The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. A. BOURDOUMIS, M. CHRISOFOS, T. STASINOU, P. CHRISTOPOULOS, P. MOURMOURIS, A. KOSTAKOPOULOS, C. DELIVELIOTIS (Torquay; Exeter; Manchester, UK; Athens, Greece)... Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. J.Y. HONG, J.-Y. SEO, S.-H. KIM, H.A. JUNG, S. PARK, K. KIM, C.W. JUNG, J.S. KIM, J.S. PARK, H.-J. KIM, J.H. JANG (Seoul; Incheon; Suwon, Republic of Korea)... Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary. O. JAMY, G. YAGHMOUR, F. HARE, M.G. MARTIN (Memphis, TN, USA)... Reduced Dose of Abiraterone Acetate with Concomitant Low- dose Prednisone in the Treatment of 85 Yearold Patients with Advanced Castrate-resistant Prostate Cancer. R. PETRIOLI, E. FRANCINI, A.I. FIASCHI, L. LAERA, S.T. MIANO, G. DE RUBERTIS, G. ROVIELLO (Siena; Rome, Italy)... A New Strategy for Metachronous Primary Lung Cancer: Stereotactic Body Radiation Therapy with Concurrent Chemotherapy. J. TAKESHITA, K. MASAGO, R. KATO, K. OTSUKA, C. OKUDA, A. HATA, R. KAJI, S. FUJITA, K. TAKAYAMA, M. KOKUBO, N. KATAKAMI (Kobe, Japan)... Errata... Book Reviews Number 6 Reviews Emergency Fertility Preservation for Female Patients with Cancer: Clinical Perspectives. M. SALAMA, P. MALLMANN (Cologne, Germany)... Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer. C. DAMASKOS, T. KARATZAS, L. NIKOLIDAKIS, I.D. KOSTAKIS, S. KARAMAROUDIS, G. BOUTSIKOS, Z. DAMASKOU, A. KOSTAKIS, G. KOURAKLIS (Athens, Greece)

49 Anticancer Effects of Sandalwood (Santalum album). S. SANTHA, C. DWIVEDI (Brookings, SD, USA)... The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Ş. COMŞA, A.M. CÎMPEAN, M. RAICA (Timişoara, Romania) Experimental Studies Whole-genome Linkage Analysis and Sequence Analysis of Candidate Loci in Familial Breast Cancer. R. MARIKKANNU, C. ARAVIDIS, J. RANTALA, S. PICELLI, T. ADAMOVIC, M. KEIHAS, T. LIU, V. KONTHAM, D. NILSSON, A. LINDBLOM (Stockholm; Uppsala, Sweden)... Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms. C.-C. YEH, Y. FAN, L. JIANG, Y.-L. YANG, B. HE, L. YOU, M. MANN (San Francisco, CA, USA)... Expression and Tissue Distribution of MicroRNA-21 in Malignant and Benign Breast Tissues. K.A. HUG, L. ANTHONY, D. ELDEIRY, J. BENSON, E. WHEELER, S. MOUSA, B. SHI (Albany; Troy, NY, USA)... Reduced Expression of RECK Protein May Help Differentiate Cutaneous Malignant Melanoma from Melanocytic Nevus. L. ZHANG, Q. XIE, S.- J. SHAN, M.K. TABOR, J.M. JUNKINS- HOPKINS (Nanchang; Tianjin, PR China; New York, NY, USA)... Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein. G. YIN, D. TANG, J. DAI, M. LIU, M. WU, Y. SUN, Z. YANG, R.M. HOFFMAN, L. LI, S. ZHANG, X. GUO (Nanjing, Jiangsu, PR China; San Diego, CA, USA)... MicroRNA-145 Promotes the Phenotype of Human Glioblastoma Cells Selected for Invasion. S. KOO, G. MARTIN, L.G. TOUSSAINT (Bryan, TX, USA)... Inflammation-Related Tumor Progression in Murine Fibrosarcoma Exhibited Over-expression of Sexdetermining Region Y-box 2 (Sox2) Compared to Parental Regressor Cells. Y. KURAMITSU, I. TANAKA, Y. WANG, F. OKADA, K. TOKUDA, T. KITAGAWA, J. AKADA, K. NAKAMURA (Ube; Shunan, Yamaguchi; Yonago, Japan)... Gene Expression Profiling of MCF10A Breast Epithelial Cells Exposed to IOERT. L. MINAFRA, V. BRAVATÀ, G. RUSSO, G.I. FORTE, F.P. CAMMARATA, M. RIPAMONTI, G. CANDIANO, M. CERVELLO, A. GIALLONGO, G. PERCONTI, C. MESSA, M.C. GILARDI (Cefalù; Palermo; Milan; Monza, Italy)... Induction of G 1 Arrest by SB Involves Cyclin D3 Downregulation and Suppression of CDK2 (Thr160) Phosphorylation. A.E. GODA, R.L. ERIKSON, J.-S. AHN, B.-Y. KIM (Cheongwon, Republic of Korea; Cambridge, MA, USA; Tanta, Egypt)... Reversal of ABCB1-related Multidrug Resistance of Colonic Adenocarcinoma Cells by Phenothiazines. D. TAKÁCS, Á. CSONKA, Á. HORVÁTH, T. WINDT, M. GAJDÁCS, Z. RIEDL, G. HAJÓS, L. AMARAL, J. MOLNÁR, G. SPENGLER (Budapest; Szeged, Hungary; Lisbon, Portugal)... Differential Gene Regulation in Fibroblasts in Co-culture with Keratinocytes and Head and Neck SCC Cells. M. HAKELIUS, D. SAIEPOUR, H. GÖRANSSON, K. RUBIN, B. GERDIN, D. NOWINSKI (Uppsala, Sweden)... ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. J. LI, S.S. BHARADWAJ, G. GUZMAN, R. VISHNUBHOTLA, S.C. GLOVER (Gainesville, FL; Chicago, IL, USA)

50 Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model. J. MACKIEWICZ, U. KAZIMIERCZAK, M. KOTLARSKI, E. DONDAJEWSKA, A. KOZŁOWSKA, E. KWIATKOWSKA, A. NOWICKA-KOTLARSKA, H. DAMS-KOZŁOWSKA, P.J. WYSOCKI, A. MACKIEWICZ (Poznan, Poland)... Microarray Analysis Reveals Distinct Gene Set Profiles for Gastric and Intestinal Gastrointestinal Stromal Tumors. R. HARA, H. KIKUCHI, T. SETOGUCHI, S. MIYAZAKI, M. YAMAMOTO, Y. HIRAMATSU, K. KAMIYA, M. OHTA, S. BABA, H. KONNO (Hamamatsu, Japan)... MCP1-Induced Epithelial Mesenchymal Transition in Head and Neck Cancer by AKT Activation. C.-C. LEE, H.-C. HO, Y.-C. SU, M.-S. LEE, S.-K. HUNG, C.-H. LIN (Chiayi; Hualian, Taiwan, ROC)... Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML RARA. M. TAKENOKUCHI, K. MIYAMOTO, K. SAIGO, T. TANIGUCHI (Hyogo, Japan)... Correlation of HIWI and HILI Expression with Cancer Stem Cell Markers in Colorectal Cancer. M. LITWIN, J. DUBIS, K. ARCZYŃSKA, A. PIOTROWSKA, A. FRYDLEWICZ, M. KARCZEWSKI, P. DZIĘGIEL, W. WITKIEWICZ (Wroclaw, Poland)... Differential Genomic Damage in Different Tumor Lines Induced by Prodigiosin. J.C. LAPENDA LINS, M.E.B. DE MELO, S.C. DO NASCIMENTO, M.L. ADAM (Recife; Pernambuco, Brazil)... Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma. D.H. LIM, W.S. KIM, S.J. KIM, H.Y. YOO, Y.H. KO (Cheonan; Seoul, Republic of Korea)... Characterization of Cells Cultured from Chylous Effusion from a Patient with Sporadic Lymphangioleiomyomatosis. I. GRZEGOREK, E. ZUBA-SURMA, M. CHABOWSKI, D. JANCZAK, A. SZUBA, P. DZIEGIEL (Wroclaw; Krakow, Poland)... Immunohistochemical Evaluation of Pulmonary Lymphangioleiomyomatosis. I. GRZEGOREK, D. LENZE, M. CHABOWSKI, D. JANCZAK, M. SZOLKOWSKA, R. LANGFORT, A. SZUBA, P. DZIEGIEL (Wroclaw, Poland; Berlin, Germany)... Characterization of α-, β- and p120-catenin Expression in Feline Mammary Tissues and their Relation with E- and P-Cadherin. A.C. FIGUEIRA, C. GOMES, H. VILHENA, S. MIRANDA, J. CARVALHEIRA, A.J.F. DE MATOS, P. DIAS-PEREIRA, F. GÄRTNER (Coimbra; Porto; Águeda; Vila Real; Vairão, Portugal)... Biochemical Action of New Complexes of Ruthenium with Quinolones as Potential Antitumor Agents. M.I. GRUIA, V. NEGOITA, M. VASILESCU, M. PANAIT, I. GRUIA, B.S. VELESCU, V. UIVAROSI (Bucharest, Romania)... Circulating Cytokine Levels in Patients with Prostate Cancer: Effects of Neoadjuvant Hormonal Therapy and External-beam Radiotherapy. N. TANJI, T. KIKUGAWA, T. OCHI, S. TAGUCHI, H. SATO, T. SATO, T. SUGAHARA, H. HAMADA, S. ASAI, A. MATSUMOTO (Ehime, Japan) Clinical Studies Effective Treatment of Transmissible Venereal Tumors in Dogs with Vincristine and IL2. W. DEN OTTER, M. HACK, J.J.L. JACOBS, J.F.V. TAN, L. ROZENDAAL, R.J.A. VAN MOORSELAAR (Amsterdam; Gouda, the Netherlands; Rondeklip, Curacao)... Cyclin E Expression Correlates with Cancer-specific Survival in Endometrial Endometrioid Adenocarcinoma. S. SANTALA, A. TALVENSAARI-MATTILA, Y. SOINI, M. SANTALA (Oulu; Kuopio, Finland)

51 Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mtor Signaling in PEComa: A Case Report. F. WEEBER, M.J. KOUDIJS, M. HOOGSTRAAT, N.J.M. BESSELINK, S. VAN LIESHOUT, I.J. NIJMAN, E. CUPPEN, G.J. OFFERHAUS, E.E. VOEST (Amsterdam; Utrecht, the Netherlands)... Atypical Paracaval Recurrence of Uterine Endometrial Stromal Sarcoma: A Case Report. N. BACALBAȘA, I. BALESCU (Bucharest, Romania)... Liver Transplantation Followed by Pulmonary Resection Complicated with End-Stage Liver Cirrhosis: A Case Report. D. TANIGUCHI, N. HARIMOTO, K. TAKEISHI, S. ITOH, Y. YAMASHITA, T. IKEGAMI, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MORODOMI, T. TAGAWA, T. OKAMOTO, Y. MAEHARA (Fukuoka, Japan)... Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma. K. UEDA, S. SUEKANE, K. NISHIHARA, N. OGASAWARA, H. KUROSE, S. HAYASHI, K. CHIKUI, S. SUYAMA, M. NAKIRI, M. MATSUO, T. IGAWA (Fukuoka, Japan)... AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer. M.Z. MUALLEM, K. GASIMLI, R. RICHTER, J. ALMUHEIMID, S. NASSER, E.I. BRAICU, J. SEHOULI (Berlin, Germany)... A Cohort Study Evaluating the Role of Surgery for Lung Metastases from Colorectal Cancer. F. SOCOLA, D.M. NGUYEN, R.E. OCHOA, C.M. ROCHA LIMA, P.J. HOSEIN (Little Rock, AR; Miami, FL; Lexington, KY, USA)... Second Primary Malignancies in Mantle Cell Lymphoma: A U.S. Population-based Study. B.K. SHAH, A. KHANAL (Lewiston, ID; Chicago, IL, USA)... Adjuvant Chemoradiation in Pancreatic Cancer: Α Pooled Analysis in Elderly ( 75 years) Patients. G.-C. MATTIUCCI, M. FALCONI, R.G.P.M. VAN STIPHOUT, S. ALFIERI, F.A. CALVO, J.M. HERMAN, B.W. MAIDMENT III, R.C. MILLER, W.F. REGINE, M. RENI, N. SHARMA, S. PARTELLI, D. GENOVESI, M. BALDUCCI, F. DEODATO, V. VALENTINI, A.G. MORGANTI (Rome; Verona; Milan; Ancona; Chieti; Campobasso, Italy; Maastricht, the Netherlands; Madrid, Spain; Baltimore, MD; Charlottesville, VA; Rochester, MN,USA)... Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer. K. SONODA, H. YAHATA, A. ICHINOE, K. OKUGAWA, E. KANEKI, Y. KAWANO, H. KENJO, T. OHGAMI, H. YAGI, S. OHGA, K. ASAI, K. NAKAMURA, H. HONDA, K. KATO (Fukuoka, Japan)... Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. I. KOCAKOVA, B. MELICHAR, I. KOCAK, Z. BORTLICEK, T. BÜCHLER, L. DUSEK, L. PETRUZELKA, M. KOHOUTEK, J. PRAUSOVÁ, J. FINEK, B. MOHELNIKOVA-DUCHONOVA, R. VYZULA (Brno; Olomouc; Prague; Zlin; Plzen, Czech Republic)... Preoperative Leucocytosis, Thrombocytosis and Anemia as Potential Prognostic Factors in Non-metastatic Renal Cell Carcinoma. G.C. HUTTERER, D. KRIEGER, E. MRSIC, K. POHLMANN, A. BEZAN, T. STOJAKOVIC, K. PUMMER, R. ZIGEUNER, M. PICHLER (Graz, Austria; Houston, TX, USA)... Non-menopausal Status, High Nuclear Grade, Tumor Size >30 mm and Positive Resection Margins Are Predictors of Residual Tumor After Lumpectomy for Ductal Carcinoma In Situ of the Breast. M. JOSTE, V. MENDES, S. TIXIER, C. PALPACUER, B. LAVIOLLE, J. LEVEQUE, L. OULDAMER (Rennes; Tours; Angers, France)... Role of Pelvic and Para-aortic Lymph Node Metastases in Optimally Cytoreduced Advanced Ovarian Cancer. C. BACHMANN, R. BACHMANN, S.Y. BRUCKER, A. STAEBLER, F. FEND, D. WALLWIENER, E.- M. GRISCHKE (Tübingen, Germany)

52 Serrated Adenoma of the Gallbladder: A Case Report. C.A. RUBIO (Stockholm, Sweden)... Sentinel Node Navigation Surgery for Lower Rectal Cancer. H. KAWAHARA, K. WATANABE, H. ENOMOTO, M. TOMODA, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan)... Prognostic Value of Total Lesion Glycolysis Measured by 18 F-FDG-PET/CT in Patients with Colorectal Cancer. S. OGAWA, M. ITABASHI, C. KONDO, M. MOMOSE, S. SAKAI, S. KAMEOKA (Tokyo, Japan)... Telomere Length Abnormalities and Telomerase RNA Component Expression in Gastroenteropancreatic Neuroendocrine Tumors. H.S. KIM, H.S. LEE, K.H. NAM, J. CHOI, W.H. KIM (Seoul; Gyeonggi-do; Busan, Republic of Korea)... Preoperative Prediction of Peritoneal Metastasis in Gastric Cancer as an Indicator for Neoadjuvant Treatment. M. OHI, K. MORI, Y. TOIYAMA, Y. MOHRI, M. OKIGAMI, H. YASUDA, S. SAIGUSA, K. TANAKA, Y. INOUE, M. KUSUNOKI (Mie, Japan)... The Role of Quaternary Cytoreduction in Recurrent Epithelial Ovarian Cancer: A Single-center Experience. N. BACALBAȘA, I. BALESCU, S. DIMA, V. BRASOVEANU, I. POPESCU (Bucharest, Romania)... Local Therapy Improvement of Outcome in a Patient with Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Case Report. M. SHIMOKAWA, S. ITOH, T. IKEGAMI, K. TAKEISHI, N. HARIMOTO, Y.- I. YAMASHITA, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MAEHARA (Fukuoka, Japan)... Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. J.Y. KIM, H.M. RYOO, S.H. BAE, B.W. KANG, Y.S. CHAE, S. YOON, J.H. BAEK, M.K KIM, K.H. LEE, S.A. LEE, H.S. SONG, J.G. KIM (Daegu; Ulsan, Republic of Korea)... Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics. R. KUCERA, O. TOPOLCAN, I. TRESKOVA, J. KINKOROVA, J. WINDRICHOVA, R. FUCHSOVA, S. SVOBODOVA, V. TRESKA, V. BABUSKA, J. NOVAK, J. SMEJKAL (Prague, Czech Republic)... Hopelessness/Helplessness in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland)... The Impact of Perioperative Allogeneic Blood Transfusion on Survival in Elderly Patients with Colorectal Cancer. M. KANEKO, S. SASAKI, K. ISHIMARU, E. TERAI, H. NAKAYAMA, T. WATANABE (Tokyo, Japan)... Cerebral Relapsing Meningioma: A Surgical Series with Lack of Reliability of Standard Parameters Establishing Prognosis. F. FOREST, V. YVOREL, F. VASSAL, B. TROMBERT, J.-M. DUMOLLARD, C. NUTI, M. PÉOC'H (Saint Étienne, France)... Short-term Survival of Patients with Lung Metastases from Colorectal and Non-colorectal Cancer Who Underwent Pulmonary Metastasectomy. F. LUMACHI, F. MAZZA, A. DEL CONTE, G. LO RE, M. ERMANI, G.B. CHIARA, S.M.M. BASSO (Padova; Pordenone, Italy)... PSA Isoforms Velocities for Early Diagnosis of Prostate Cancer. I. HEIDEGGER, H. KLOCKER, R. PICHLER, W. HORNINGER, J. BEKTIC (Innsbruck, Austria)... Impact of Stereotactic Radiosurgery Dose on Control of Cerebral Metastases from Renal Cell Carcinoma. D. RADES, S. HUTTENLOCHER, N. GEBAUER, D. HORNUNG, N.T. TRANG, M.T. KHOA, S.E. SCHILD (Lübeck; Hamburg, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA)

53 Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer. A. SHIDA, N. FUTAWATARI, T. FUKUYAMA, Y. ICHIKI, Y. TAKAHASHI, Y. NISHI, N. KOBAYASHI, H. YAMAZAKI, M. WATANABE (Kitamoto, Saitama; Kitakyushu, Fukuoka; Sagamihara, Kanagawa, Japan)... Significance of Lymphatic Invasion Combined with Size of Primary Tumor for Predicting Sentinel Lymph Node Metastasis in Patients with Breast Cancer. T. FUJII, R. YAJIMA, H. TATSUKI, T. SUTO, H. MORITA, S. TSUTSUMI, H. KUWANO (Maebashi, Gunma, Japan)... New Approach to Complete Video-assisted Thoracoscopic Lobectomy in T2 and T3 Non-Small Cell Lung Cancer. M. KATO, H. ONISHI, K. FURUGAKI, S. YUNOTANI, K. MATSUMOTO, N. TSURUTA, K. NAKAMURA, M. KATANO (Karatsu, Saga; Fukuoka, Japan)... Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma Prognostic Effect of the AJCC Tumor- Node-Metastasis Clinical Staging System. S. OHGA, K. NAKAMURA, Y. SHIOYAMA, T. SASAKI, T. YAMAGUCHI, T. YOSHITAKE, K. TERASHIMA, K. ASAI, K. MATSUMOTO, H. HONDA (Fukuoka; Saga, Japan)... ABSTRACTS OF THE INTERNATIONAL SYMPOSIUM BIOLOGIC EFFECTS OF LIGHT June, 2015 Schlossberg Hotel, Homburg/Saar, Germany... ABSTRACTS OF THE 25th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) June, 2015, Rome, Italy... Errata Number 7 Experimental Studies Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties. R. HUANG, J. WANG, Y. ZHONG, Y. LIU, T. STOKKE, C.G. TROPE, J.M. NESLAND, Z. SUO (Oslo, Norway; Zhengzhou; Beijing, PR China)... Real-time Non-invasive Spectral Imaging of Orthotopic Red Fluorescent Protein-expressing Lung Tumor Growth in Nude Mice. Y. ZHANG, N. ZHANG, M. ZHAO, R.M. HOFFMAN (San Diego, CA, USA)... Systematic Review of Candidate Single-nucleotide Polymorphisms as Biomarkers for Responsiveness to Neoadjuvant Chemoradiation for Rectal Cancer. E.D. MARING, P.S. TAWADROS, C.J. STEER, J.T. LEE (Minneapolis, MN, USA)... Expression of Stem Cell-associated Marker HES77 in Rectal Neuroendocrine Tumors. J. JERNMAN, J. HAGSTRÖM, H. MÄENPÄÄ, M.J. VÄLIMÄKI, H. HAAPASALO, O. NILSSON, C. FERMÉR, C. HAGLUND, J. AROLA (Helsinki; Tampere, Finland; Gothenburg, Sweden)... Molecular Mechanism(s) Involved in 25-Hydroxyvitamin D s Antiproliferative Effects in CYP27B1- transfected LNCaP Cells. M. BANKS, M.F. HOLICK (Boston, MA, USA)... Analysis of the Antitumor Activity of Clotrimazole on A375 Human Melanoma Cells. B. ADINOLFI, S. CARPI, A. ROMANINI, E. DA POZZO, M. CASTAGNA, B. COSTA, C. MARTINI, S.-P. OLESEN, N. SCHMITT, M.C. BRESCHI, P. NIERI, S. FOGLI (Pisa; Florence, Italy; Copenhagen, Denmark)... CD114 Expression Mediates Melanoma Tumor Cell Growth and Treatment Resistance. L. ZHANG, S. AGARWAL, J.M. SHOHET, P.E. ZAGE (Houston, TX, USA)

54 PDGFR-α and CD117 Expression Pattern in Esophageal Carcinomas. M.A. GOSCINSKI, S.G. LARSEN, K.-E. GIERCKSKY, J.M. NESLAND, Z. SUO (Oslo, Norway)... MMP9, Cyclin D1 and β-catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. C. UMBREIT, P. ERBEN, A. FABER, R.-D. HOFHEINZ, C. ADERHOLD, C. WEISS, K. HOERMANN, A. WENZEL, J.D. SCHULTZ (Mannheim, Germany)... SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients. D. WINCHESTER, L. RICKS-SANTI, T. MASON, M. ABBAS, R.L. COPELAND JR, D. BEYENE, E.Y. JINGWI, G.M. DUNSTON, Y.M. KANAAN (Baltimore, MD; Hampton, VA; Washington, DC, USA)... Establishment and Characterization of Two Novel Human Pancreatic Carcinoma Cell Lines. K. HIRANO, T. OKUMURA, Y. SHIMADA, T. WATANABE, T. YAMAGUCHI, T. NAGATA, K. TSUKADA (Toyama, Japan)... Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib. Y.W. YI, J.- S. PARK, S.-J. KWAK, Y.-S. SEONG (Washington, DC, USA; Cheonan, Chungnam, Republic of Korea)... High-fat Diet Enhances and Plasminogen Activator Inhibitor-1 Deficiency Attenuates Bone Loss in Mice with Lewis Lung Carcinoma. L. YAN, F.H. NIELSEN, S. SUNDARAM, J. CAO (Grand Forks, ND, USA)... Design, Synthesis and Biological Evaluation of Novel HIF1α Inhibitors. G.N. MASOUD, J. WANG, J. CHEN, D. MILLER, W. LI (Memphis; Knoxville, TN, USA)... High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Upregulated in Gemcitabine-resistant Pancreatic Cancer Cells. Y. KURAMITSU, Y. WANG, T. KITAGAWA, K. TOKUDA, J. AKADA, M. TOKUNAGA, K. NAKAMURA (Ube; Shunan, Yamaguchi, Japan)... Curcumin Triggers DNA Damage and Inhibits Expression of DNA Repair Proteins in Human Lung Cancer Cells. C.-Y. TING, H.-E. WANG, C.-C. YU, H.-C. LIU, Y.-C. LIU, I-T. CHIANG (Taipei; Kaohsiung; Taichung; Yilan, Taiwan, ROC)... Protective Effect of Leuprorelin on Radiation-induced Intestinal Toxicity. M. MANGONI, M. SOTTILI, C. GERINI, R. FUCCI, A. PINI, L. CALOSI, P. BONOMO, B. DETTI, D. GRETO, I. MEATTINI, G. SIMONTACCHI, M. LOI, D. SCARTONI, I. FURFARO, S. PALLOTTA, L. LIVI (Florence, Italy)... Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). T. OTSUKA, M. MORI, Y. YANO, J. UCHIDA, K. NISHINO, R. KAJI, A. HATA, Y. HATTORI, Y. URATA, T. KANEDA, M. TACHIHARA, F. IMAMURA, N. KATAKAMI, S. NEGORO, S. MORITA, S. YOKOTA (Toyonaka; Suita; Osaka; Kobe; Akashi; Kyoto, Japan)... Contribution of Genotype of DNA Double-strand Break Repair Gene XRCC3, Gender, and Smoking Behavior to Lung Cancer Risk in Taiwan. H.-J. CHEN, W.-S. CHANG, T.-C. HSIA, C.-E. MIAO, W.-C. CHEN, S.-J. LIANG, A.-C. CHEN, J.-G. CHANG, C.-W. TSAI, C.-M. HSU, C.-H. TSAI, D-T. BAU (Taichung, Taiwan, ROC)... Sulforaphene Synergistically Sensitizes Cisplatin via Enhanced Mitochondrial Dysfunction and PI3K/PTEN Modulation in Ovarian Cancer Cells. R. BISWAS, J.-C. AHN, J.-S. KIM (Cheonan, Republic of Korea)... Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia- Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance. B. LEE, H.J. LEE, H.-Y. CHO, D.H. SUH, K. KIM, J.H. NO, H. KIM, Y.-B. KIM (Gyeonggi-do; Seoul-si, Republic of Korea)... Stimulation by Monocyte Chemoattractant Protein-1 Modulates the Ex-vivo Colony Formation by Head and Neck Squamous Cell Carcinoma Cells. G. WICHMANN, C. KÖRNER, A. BOEHM, C. MOZET, A. DIETZ (Leipzig, Germany)

55 Altered Expression of Yes-associated Protein and β-catenin in Non-neoplastic and Neoplastic Gastric Surface Epithelia. S.-H. KIM, O.-J. LEE, J.-L. KWON, J.M. KIM, H.-J. SUL, K.S. SONG, K.-H. KIM (Seoul; Cheongju; Daejeon, Republic of Korea)... Distribution and Effects of CDKN2 p C>G and 580 C>T, and MDM2 SNP309 T>G Polymorphisms in Patients with Primary Brain Tumors. A. KAFADAR, Ö. KÜÇÜKHÜSEYIN, S. TURAN, E.N. YENILMEZ, S. TUNOGLU, U. ZEYBEK, M.Y. KAYNAR, R. KEMERDERE, I. YAYLIM (Istanbul, Turkey)... Phthalocyanine-mediated Photodynamic Treatment of Tumoural and Non-tumoural cell lines. B. MANISOVA, S. BINDER, L. MALINA, J. JIRAVOVA, K. LANGOVA, H. KOLAROVA (Olomouc, Czech Republic)... Expression of the Epithelial Cell Adhesion Molecule and Cytokeratin 8 in Head and Neck Squamous Cell Cancer: A Comparative Study. M. ANDRATSCHKE, H. HAGEDORN, A. NERLICH (Dachau; Luebeck; Munich, Germany)... Expression of EMT Markers SLUG and TWIST in Breast Cancer. J. GRZEGRZOLKA, M. BIALA, P. WOJTYRA, C. KOBIERZYCKI, M. OLBROMSKI, A. GOMULKIEWICZ, A. PIOTROWSKA, J. RYS, M. PODHORSKAOKOLOW, P. DZIEGIEL (Wroclaw; Krakow, Poland)... Clinical Studies microrna Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR. C.-W. CHANG, H.-C. WU, M.B. TERRY, R.M. SANTELLA (New York, NY, USA)... Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome. M. SANDELIN, A. BERGLUND, M. SUNDSTRÖM, P. MICKE, S. EKMAN, M. BERGQVIST, S. BERGSTRÖM, H. KOYI, E. BRANDÉN, C. JANSON, J. BOTLING (Uppsala; Gävle, Sweden)... Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study. M. TAMIYA, S. TOKUNAGA, H. OKADA, H. SUZUKI, S. SASADA, N. OKAMOTO, N. MORISHITA, T. SHIROYAMA, T. OTSUKA, N. MIYAMOTO, K. TAIRA, H. DAGA, K. TAKEDA, T. HIRASHIMA (Habikino; Osaka; Tokyo, Japan)... Several Site-specific Cancers are Increased in the Volcanic Area in Sicily. M. RUSSO, P. MALANDRINO, W.P. ADDARIO, G. DARDANONI, P. VIGNERI, G. PELLEGRITI, S. SQUATRITO, R. VIGNERI (Catania; Palermo, Italy)... Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. T. YOSHINO, K. YAMAZAKI, M. GOTOH, F. NASROULAH, L. GAO, N. YOSHIZUKA, A. OHTSU (Kashiwa; Shizuoka; Takatsuki, Osaka; Kobe, Japan; Bridgewater, NJ, USA)... Trichloroethylene Is Associated with Kidney Cancer Mortality: A Population-based Analysis. S. ALANEE, J. CLEMONS, W. ZAHND, D. SADOWSKI, D. DYNDA (Springfield, IL, USA)... Incidence Changes of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma and Effects on Survival in the Netherlands Cancer Institute, R. HENNEMAN, H.S. VAN MONSJOU, C.V.M. VERHAGEN, M.- L.F. VAN VELTHUYSEN, N.T. TER HAAR, E.M. OSSE, M.I. LOPEZ- YURDA, A.J.M. BALM, M.W.M. VAN DEN BREKEL (Amsterdam; Leiden; Nijmegen, the Netherlands)... Prognostic Significance of VEGFC and VEGFR1 mrna Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. H. LINARDOU, K.T. KALOGERAS, R. KRONENWETT, Z. ALEXOPOULOU, R.M. WIRTZ, F. ZAGOURI, C.D. SCOPA, H. GOGAS, K. PETRAKI, C. CHRISTODOULOU, K. PAVLAKIS, A.K. KOUTRAS, E. SAMANTAS, H. PATSEA, D. PECTASIDES, D. BAFALOUKOS, G. FOUNTZILAS (Piraeus; Thessaloniki; Athens; Patras, Greece; Cologne; Dusseldorf, Germany)

56 Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report. T. AKAMINE, K. ANDO, E. OKI, H. SAEKI, Y. NAKASHIMA, Y. IMAMURA, K. OHGAKI, Y. MAEHARA (Fukuoka, Japan)... Death Receptor Expression on Blasts in AML Is Associated with Unfavorable Prognosis. J.U. SCHMOHL, T. NUEBLING, J. WILD, J. JUNG, T. KROELL, L. KANZ, H.R. SALIH, H. SCHMETZER (Tuebingen; Munich, Germany)... Obesity and Lymphovascular Invasion in Women with Uterine Endometrioid Carcinoma. M. KAMAL, C. BURMEISTER, Z. ZHANG, A. MUNKARAH, M.A. ELSHAIKH (Detroit, MI, USA)... Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer. K. SUGITA, K. KAWAKAMI, T. YOKOKAWA, Y. MAE, W. TOYA, A. HAGINO, K. SUZUKI, M. SUENAGA, N. MIZUNUMA, T. YAMAGUCHI, T. HAMA (Tokyo, Japan)... Prognostic Role of Nodal Status and Clinically Asymptomatic Valvular Insufficiency in Patients with HER2- positive Breast Cancer Treated with Chemotherapy, Radiotherapy and Trastuzumab in an Adjuvant Setting. A. GRELA- WOJEWODA, J. NIEMIEC, B. SAS- KORCZYŃSKA, I. CEDRYCH, M. DOMAGAŁA- HADUCH, A. ADAMCZYK, A. AMBICKA, J. KOŁACZ, J. JAKUBOWICZ (Krakow, Poland)... Case Mix Difference Can Affect Evaluation of Outcome of Treatment for Colorectal Cancer. D. LJUNGMAN, K. KODEDA, K. DERWINGER (Gothenburg, Sweden)... Splenectomy Followed by Hepatectomy for Hepatocellular Carcinoma with Hypersplenism and Portal Hypertension Caused by Macroglobulinemia. Q. HU, K. TAKEISHI, Y.-I. YAMASHITA, T. IKEDA, H. WANG, S. ITOH, N. HARIMOTO, T. IKEGAMI, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MAEHARA (Fukuoka, Japan)... Treatment Planning Comparison for Carbon Ion Radiotherapy, Proton Therapy and Intensity-modulated Radiotherapy for Spinal Sarcoma. K. MATSUMOTO, K. NAKAMURA, Y. SHIOYAMA, T. SASAKI, S. OHGA, T. YAMAGUCHI, T. YOSHITAKE, K. ASAI, G. KAKIUCHI, H. HONDA (Fukuoka; Tosu, Japan)... The Role of Adjuvant Chemotherapy for Patients with Stage IB Gastric Cancer. T. TOYOKAWA, M. OHIRA, K. SAKURAI, N. KUBO, H. TANAKA, K. MUGURUMA, K. HIRAKAWA (Osaka, Japan)... Results of Primary Cytoreductive Surgery in Advanced-stage Epithelial Ovarian Cancer: A Single-center Experience. N. BACALBASA, S. DIMA, I. BALESCU, L. DAVID, V. BRASOVEANU, I. POPESCU (Bucharest, Romania)... Predicting Survival After Irradiation of Metastases from Pancreatic Cancer. L. BOLM, S. JANSSEN, L. KÄSMANN, U. WELLNER, T. BARTSCHT, S.E. SCHILD, D. RADES (Lübeck; Hannover, Germany; Scottsdale, AZ, USA)... Neoadjuvant Chemoradiotherapy with Volumetric-modulated Arc Therapy for Medium-distal Oesophageal and Gastro-oesophageal Junction Carcinoma. A. TOZZI, C. IFTODE, L. COZZI, A.M. ASCOLESE, S. BATTISTA, R. CAVINA, E. CLERICI, T. COMITO, G.R. D AGOSTINO, F. DE ROSE, C. FRANZESE, I. GARASSINO, U. FUMAGALLI ROMARIO, P. NAVARRIA, R. ROSATI, P. SPAGGIARI, S. TOMATIS, M. SCORSETTI (Milan, Italy)... Epidermal Growth Factor Receptor Expression May Correlate with Survival Through Clinical and Radiological Features of Aggressiveness in Glioblastoma Treated with Radiochemotherapy. P. TINI, A. CERASE, G. CEVENINI, S.F. CARBONE, C. MIRACCO, L. PIRTOLI (Siena, Italy)... Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer A Single-center Experience. N. BACALBASA, I. BALESCU, S. DIMA, V. BRASOVEANU, I. POPESCU (Bucharest, Romania)

57 Second Primary Malignancy in Anal Carcinoma A US Population-based Study. B.K. SHAH, N. BUDHATHOKI (Lewiston, ID, USA)... Characteristics and Treatment Strategies for Small Bowel Adenocarcinoma in Advanced- stage Cases. T. NAKANOKO, T. KOGA, K. TAKETANI, Y. HIRAYAMA, S. YOSHIYA, R. MINAGAWA, M. KAI, K. KAJIYAMA,Y. MAEHARA (Fukuoka, Japan)... Maspin, a Marker of Serrated Colorectal Polyps. C.A. RUBIO, A. KAUFELDT, J. BJÖRK, E. JARAMILLO (Stockholm, Sweden)... Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer. S. ALANEE, A. MOORE, M. NUTT, B. HOLLAND, D. DYNDA, A. EL-ZAWAHRY, K.T. MCVARY (Springfield, IL, USA)... Prophylactic Radiotherapy to Intervention Sites in Malignant Pleural Mesothelioma Single-institution Experience and Literature Review. S. JANSSEN, B. SCHÖNHOFER, D. RADES (Hannover; Lübeck, Germany)... Exclusive Radiotherapy for Early-stage Glottic Cancer: A Single-institution Retrospective Analysis with a Focus on Voice Quality. I. POTENZA, P. FRANCO, F. MORETTO, S. BADELLINO, V. BALCET, G. ROSSI, V. LANDOLFO, G. RIVA, G. PECORARI, R. RAGONA, M. RAMPINO, U. RICARDI (Turin, Italy)... Adjuvant Chemotherapy in Locally Advanced Cervical Cancer After Treatment with Concomitant Chemoradiotherapy Room for Improvement? T. BORASKA JELAVIĆ, B. PETRIĆ MIŠE, A. STRIKIC, M. BAN, E. VRDOLJAK (Split, Croatia)... Outcomes After Laparoscopic Hepatectomy in the Semi-prone Position for Hepatocellular Carcinoma Located in Segment 6, 7, or 8. N. HARIMOTO, T. IKEDA, K. TAKEISHI, S. ITOH, Y.- I. YAMASHITA, T. IKEGAMI, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MAEHARA (Fukuoka, Japan)... Stereotactic Body Radiation Therapy for Liver Lesions. A Single-institution Experience. D. CAIVANO, S. BRACCI, I. RUSSO, A. MONTALTO, V. ARMOSINI, V. DE SANCTIS, M. VALERIANI, G. MINNITI, R.M. ENRICI, M. FALCHETTO OSTI (Rome, Italy)... Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function. G. GIRELLI, P. FRANCO, P. SCIACERO, D. CANTE, V. CASANOVA BORCA, M. PASQUINO, S. ANNOSCIA, S. TOFANI, M.R. LA PORTA, U. RICARDI (Ivrea; Turin, Italy)... Reliability of Endocervical Curettage in the Diagnosis of High-grade Cervical Neoplasia and Cervical Cancer in Selected Patients. C. AKLADIOS, L. LECOINTRE, E. BAULON, V. THOMA, G. AVEROUS, M. FENDER, F. LEFEBVRE, J.-J. BALDAUF (Strasbourg; Graffenstaden, France)... Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting. H. TSUBAMOTO, T. SONODA, S. IKUTA, S. TANI, K. INOUE, N. YAMANAKA (Nishinomiya; Kobe, Japan)... Utility of Human Papillomavirus Genotyping for Triage of Patients with Atypical Squamous Cells of Undetermined Significance by Cervical Cytology. B. LEE, D.H. SUH, K. KIM, J.H. NO, Y.-B. KIM (Seongnam; Seoul, Republic of Korea)... Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report. K. FURUKAWA, T. UWAGAWA, T. SAKAMOTO, H. SHIBA, J. TSUTSUMI, K. YANAGA (Tokyo; Saitama, Japan)... Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations. Y.-H. LIANG, Y.-L. LIN, J.-Y. LIAU, J.-H. TSAI, J.-T. LIANG, B.-R. LIN, J.-S. HUNG, L.-H. TSENG, L.-I. LIN, Y.-L. CHANG, A.-L. CHENG, K.-H. YEH (Hsinchu; Taipei, Taiwan, ROC)

58 Estimation of the Six-month Survival Probability After Radiosurgery for Brain Metastases from Kidney Cancer. S. JANSSEN, M. DAHLKE, N. THUY TRANG, M. TRONG KHOA, D. RADES (Lübeck; Hannover, Germany; Hanoi, Vietnam)... Value of the Nottingham Histological Grading Parameters and Nottingham Prognostic Index in Canine Mammary Carcinoma. M. SANTOS, C. CORREIA-GOMES, R. MARCOS, A. SANTOS, A. DE MATOS, C. LOPES, P. DIAS-PEREIRA (Porto; Lisbon, Portugal; Inverness, UK)... Factors Predictive of Re-excision Αfter Oncoplastic Breast-conserving Surgery. M.-I. AMABILE, C. MAZOUNI, C. GUIMOND, B. SARFATI, N. LEYMARIE, A.-S. CLOUTIER, E. BENTIVEGNA, J.-R. GARBAY, F. KOLB, F. RIMAREIX (Villejuif, France)... Effect of Celecoxib on Survival of Mobile Tongue Cancer. D.Y. LEE, J.H. LIM, Y.J. KIM, S.D. KIM, S.- W. PARK, S.K. KWON, J.H. HAH, T.-K. KWON, K.H. KIM, Y.H. KIM, M.-W. SUNG (Seoul, Republic of Korea; Ras Al Khaimah, United Arab Emirates)... Effect of Race and Insurance on the Outcome of Stage I Non-small Cell Lung Cancer. T. BISWAS, P. WALKER, T. PODDER, J.T. EFIRD (Cleveland, OH; Greenville, NC, USA)... Association of Basal and Calcium-stimulated Calcitonin Levels with Pathological Findings After Total Thyroidectomy. G. PAPADAKIS, I. KERAMIDAS, E. TRIANTAFILLOU, F. KANOUTA, T. PAPPA, V. KALTZIDOU, A. TERTIPI, L. IORDANIDOU, E. TRIVIZAKI, G. VECCHINI, V. VILLIOTOU, A. PAPPAS (Piraeus, Greece)... Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Nonsquamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multiinstitutional Study. Y. ENOMOTO, H. KENMOTSU, N. WATANABE, T. BABA, H. MURAKAMI, K. YOH, T. OGURA, T. TAKAHASHI, K. GOTO, T. KATO (Yokohama, Kanagawa; Sunto-gun; Hamamatsu, Shizuoka; Kashiwa, Chiba, Japan) In-Pentetreotide SPECT/CT in Pulmonary Carcinoid. A. CHIARAVALLOTI, A. SPANU, R. DANIELI, F. DORE, B. PIRAS, A. FALCHI, M. TAVOLOZZA, G. MADEDDU, O. SCHILLACI (Rome; Sassari; Trieste; Pozzilli, Italy)... Plasma Tumor M2- Pyruvate Kinase Levels in Different Cancer Types. A. MUÑOZ- COLMENERO, A. FERNÁNDEZ-SUÁREZ, D. FATELA-CANTILLO, E. OCAÑA-PÉREZ, J.L. DOMÍNGUEZ-JIMÉNEZ, J.M. DÍAZ-IGLESIAS (Jaén, Spain)... Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma. D. SIKIC, S. WACH, H. TAUBERT, M. RICHTERSTETTER, F. KUNATH, P.J. GOEBELL, S. SCHICK, P. OLBERT, J. HUBER, B. WULLICH, B. KECK (Erlangen; Marburg; Dresden, Germany)... ABSTRACTS OF THE CHINA UNITED KINGDOM CANCER (CUKC) CONFERENCE 2015, 17th and 18th July, 2015, Cardiff, Wales, UK... Errata... Retraction... Book Reviews

59 Number 8 Proceedings of the 18th Annual Meeting of the Society of Biotherapeutic Approaches, 13 December 2014, Takamatsu, Japan. Special Issue Edited by M. Kuroki and G.-I. Soma Preface Reviews Functional Alteration of Tumor-infiltrating Myeloid Cells in RNA Adjuvant Therapy. T. SEYA, H. SHIME, M. MATSUMOTO (Sapporo, Japan)... Methods to Prevent or Treat Refractory Diseases by Focusing on Intestinal Microbes Using LPS and Macrophages. G.-I. SOMA, H. INAGAWA (Kagawa; Niigata, Japan)... Transcriptional Regulation of the p16 Tumor Suppressor Gene. Y. KOTAKE, M. NAEMURA, C. MURASAKI, Y. INOUE, H. OKAMOTO (Fukuoka, Japan) Experimental Studies Analysis of Wnt and β-catenin Expression in Advanced Colorectal Cancer. N. YOSHIDA, T. KINUGASA, K. OHSHIMA, K. YUGE, T. OHCHI, S. FUJINO, S. SHIRAIWA, M. KATAGIRI, Y. AKAGI (Fukuoka, Japan)... Development of a Sortase A-mediated Peptide-labeled Liposome Applicable to Drug-delivery Systems. A. TABATA, Y. OHKUBO, N. ANYOJI, K. HOJO, T. TOMOYASU, Y. TATEMATSU, K. OHKURA, H. NAGAMUNE (Tokushima; Kobe; Suzuka, Mie, Japan)... Marked Reduction in FoxO1 Protein by its Enhanced Proteasomal Degradation in Zfat-deficient Peripheral T- Cells. Y. IWAIHARA, S. ISHIKURA, K. DOI, T. TSUNODA, T. FUJIMOTO, T. OKAMURA, S. SHIRASAWA (Fukuoka; Tokyo, Japan)... Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation. D. OTSUBO, K. YAMASHITA, M. FUJITA, M. NISHI, Y. KIMURA, H. HASEGAWA, S. SUZUKI, Y. KAKEJI (Kobe; Osaka, Japan)... Validity of HB- EGF as Target for Human Neuroblastoma Therapy. S.O. NAM, F. YOTSUMOTO, K. MIYATA, R. SOUZAKI, T. TAGUCHI, M. KUROKI, S. MIYAMOTO (Fukuoka, Japan)... Establishment of a Macrophage-activating Factor Assay System Using the Human Monocytic Cell Line THP-1. T. INOUE, M. ISHIKAWA, Y. SUMIYA, H. KOHDA, T. INUI, D. KUCHIIKE, K. KUBO, Y. UTO, T. NISHIKATA (Kobe; Tokushima; Osaka, Japan)... Macrophage Activation Mechanisms in Human Monocytic Cell Line-derived Macrophages. Y. SUMIYA, M. ISHIKAWA, T. INOUE, T. INUI, D. KUCHIIKE, K. KUBO, Y. UTO, T. NISHIKATA (Kobe; Tokushima; Osaka, Japan)... Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRASmediated Signaling Molecules. T. TSUNODA, S. ISHIKURA, K. DOI, Y. IWAIHARA, H. HIDESIMA, H. LUO, Y. HIROSE, S. SHIRASAWA (Fukuoka, Japan)... Innate Immunity Activated by Oral Administration of LPSp Is Phylogenetically Preserved and Developed in Broiler Chickens. T. KOMORI, K. SAITO, N. SAWA, Y. SHIBASAKI, C. KOHCHI, G.-I. SOMA, H. INAGAWA (Osaka; Tokushima; Kanagawa; Kagawa, Japan)

60 Effects of the Subaleurone Layer of Rice on Macrophage Activation and Protection of Pollen Allergy in a Murine Model. Y. TAMURA, H. INAGAWA, Y. NAKATA, C. KOHCHI, G.-I. SOMA (Kagawa; Niigata, Japan)... Molecular Response of Human Monocytes Following Interaction with Colon Cancer Cells by Pre-treatment with Low-dose Lipopolysaccharide. T. HONDA, H. INAGAWA (Kanagawa, Japan)... Aloe vera Extract Suppresses Proliferation of Neuroblastoma Cells In Vitro. A. YONEHARA, Y. TANAKA, K. KULKEAW, T. ERA, Y. NAKANISHI, D. SUGIYAMA (Fukuoka; Kumamoto, Japan)... Degalactosylated/Desialylated Bovine Colostrum Induces Macrophage Phagocytic Activity Independently of Inflammatory Cytokine Production. Y. UTO, T. KAWAI, T. SASAKI, K. HAMADA, H. YAMADA, D. KUCHIIKE, K. KUBO, T. INUI, M. METTE, K. TOKUNAGA, A. HAYAKAWA, A. GO, T. OOSAKI (Tokushima; Osaka; Kobe; Tokyo; Tottori, Japan)... Apoptosis-inducing Factor, Mitochondrion-associated 2, Regulates Klf1 in a Mouse Erythroleukemia Cell Line. N. KOJIMA, Y. TANAKA, K. KULKEAW, Y. NAKANISHI, S. SHIRASAWA, D. SUGIYAMA (Fukuoka, Japan)... Immunopotentiator from Pantoea agglomerans Prevents Atopic Dermatitis Induced by Dermatophagoides farinae Extract in NC/Nga Mouse. K. WAKAME, K.-I. KOMATSU, H. INAGAWA, T. NISHIZAWA (Hokkaido; Kagawa, Japan)... Oral Administration of Lipopolysaccharide of Acetic Acid Bacteria Protects Pollen Allergy in a Murine Model. S. AMANO, H. INAGAWA, Y. NAKATA, M. OHMORI, C. KOHCHI, G.-I. SOMA (Kagawa; Aichi; Niigata, Japan)... Cytolytic Activity and Molecular Feature of Cardiotoxin and Cardiotoxin-like Basic Protein: The Electrostatic Potential Field Is an Important Factor for Cell Lytic Activity. Y. KAWAGUCHI, Y. TATEMATSU, A. TABATA, H. NAGAMUNE, K. OHKURA (Chiba; Mie; Tokushima, Japan)... Clinical Studies The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial. D. MIYAHARA, T. UEDA, T. KATSUDA, M. MAEHARA, S. FUKAGAWA, K. MIYATA, S.O. NAM, H. KONDO, S. MIYAMOTO (Fukuoka; Kitakyushu, Japan)... Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin. M. MAEHARA, T. UEDA, D. MIYAHARA, Y. TAKAHASHI, K. MIYATA, S.O. NAM, T. KATSUDA, H. KONDO, S. MIYAMOTO (Fukuoka; Kitakyushu, Japan)... Improvement of Impaired Immunological Status of Patients with Various Types of Advanced Cancers by Autologous Immune Cell Therapy. T. KAMIGAKI, H. IBE, S. OKADA, E. MATSUDA, M. TANAKA, E. OGUMA, Y. KINOSHITA, S. OGASAWARA, A. ONO, K. MAKITA, K. NAITOH, S. GOTO (Tokyo, Japan)... Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports. T. INUI, K. KUBO, D. KUCHIIKE, Y. UTO, T. NISHIKATA, N. SAKAMOTO, M. METTE (Tokushima; Osaka; Kobe, Japan)... A Clinical Investigation of Oral Sarcomas at Multi-institutions Over the Past 30 Years. T. SUMIDA, N. OTAWA, Y. KAMATA, T. YAMADA, K. UCHIDA, H. NAKANO, H. HAMAKAWA, T. YAMAMOTO, Y. UEYAMA, Y. MORI (Fukuoka; Kochi; Yamaguchi; Ehime, Japan)

61 Number 9 Reviews Novel Molecular Targets for the Therapy of Urothelial Cancer. B.R.P. JANA, Y. ZHOU (Galveston, TX, USA)... The Role of Methylation in Breast Cancer Susceptibility and Treatment. M.-C. POULIOT, Y. LABRIE, C. DIORIO, F. DUROCHER (Quebec, Canada)... Second-line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives. P. CHROM, R. STEC, C. SZCZYLIK (Warsaw, Poland)... Nitric Oxide and Aggressive Behavior of Lung Cancer Cells. S. LUANPITPONG, P. CHANVORACHOTE (Bangkok, Thailand) Experimental Studies Memory Antitumor T-Cells Resist Inhibition by Immune Suppressor Cells. Y. GAO, P. WHITAKER- DOWLING, I. BERGMAN (Pittsburgh, PA, USA)... Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. R. KIM, T. YAMAUCHI, K. HUSAIN, S. SEBTI, M. MALAFA (Tampa, FL, USA; Tokyo, Japan)... Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts. M. NUKATSUKA, F. NAKAGAWA, T. TAKECHI (Tokushima, Japan)... Suppressor microrna-145 Is Epigenetically Regulated by Promoter Hypermethylation in Esophageal Squamous Cell Carcinoma. K. HARADA, Y. BABA, T. ISHIMOTO, K. KOSUMI, R. TOKUNAGA, D. IZUMI, M. OHUCHI, K. NAKAMURA, Y. KIYOZUMI, J. KURASHIGE, S. IWAGAMI, Y. MIYAMOTO, Y. SAKAMOTO, N. YOSHIDA, E. OKI, M. WATANABE, H. BABA (Kumamoto; Higashi-ku, Fukuoka; Koto-ku, Tokyo, Japan)... WNT16-expressing Acute Lymphoblastic Leukemia Cells are Sensitive to Autophagy Inhibitors after ER Stress Induction. M. VERRAS, I. PAPANDREOU, N.C. DENKO (Rio, Greece; Columbus, OH, USA)... Angiopoietin-like Protein 2 as a Predictor of Early Recurrence in Patients After Curative Surgery for Gastric Cancer. T. SHIMURA, Y. TOIYAMA, K. TANAKA, S. SAIGUSA, T. KITAJIMA, S. KONDO, M. OKIGAMI, H. YASUDA, M. OHI, T. ARAKI, Y. INOUE, K. UCHIDA, Y. MOHRI, M. KUSUNOKI (Tsu, Mie, Japan)... Surgically-Induced Multi-organ Metastasis in an Orthotopic Syngeneic Imageable Model of 4T1 Murine Breast Cancer. Y. ZHANG, N. ZHANG, R.M. HOFFMAN, M. ZHAO (San Diego, CA, USA)... A Color-coded Imageable Syngeneic Mouse Model of Stromal-cell Recruitment by Metastatic Lymphoma. T. MATSUMOTO, A. SUETSUGU, Y. SHIBATA, N. NAKAMURA, H. AOKI, T. KUNISADA, H. TSURUMI, M. SHIMIZU, R.M. HOFFMAN (Gifu, Japan; San Diego, CA, USA)... Comparison of GFP-Expressing Imageable Mouse Models of Human Esophageal Squamous Cell Carcinoma Established in Various Anatomical Sites. T. HU, H. QI, P. LI, G. ZHAO, Y. MA, Q. HAO, C. GAO, Y. ZHANG, C. WANG, M. YANG, R.M. HOFFMAN, P. CHEN, Z. DONG (Zhengzhou; Beijing, P.R. China; San Diego, CA, USA)

62 Uterine Leiomyosarcoma Tumorigenesis in Lmp2-deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1. T. HAYASHI, A. HORIUCHI, K. SANO, N. YAEGASHI, I. KONISHI (Matsumoto, Nagano; Sendai, Miyagi; Kyoto; Tokyo, Japan)... Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats. K. HOTTA, J. UEYAMA, Y. TATSUMI, I. TSUKIYAMA, Y. SUGIURA, H. SAITO, K. MATSUURA, T. HASEGAWA (Nagakute; Nagoya, Aichi, Japan)... Contribution of X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 3 (XRCC3) Genotype to Leiomyoma Risk. W.-S. CHANG, C.-W. TSAI, J.-Y. WANG, T.-H. YING, T.-S. HSIAO, C.- L. CHUANG, T.-C. YUEH, C.-H. LIAO, C.-M. HSU, S.-P. LIU, C.-L. GONG, C.-H. TSAI, D.-T. BAU (Taichung, Taiwan, ROC)... 3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer. C. MAYR, A. WAGNER, A. STOECKLINGER, M. JAKAB, R. ILLIG, F. BERR, M. PICHLER, P. DI FAZIO, M. OCKER, D. NEUREITER, T. KIESSLICH (Salzburg; Graz, Austria; Marburg, Germany)... The Use of Styrene Maleic Acid Nanomicelles Encapsulating the Synthetic Cannabinoid Analog WIN55,212-2 for the Treatment of Cancer. S. XIAN, N.N. PARAYATH, H. NEHOFF, N.M. GILES, K. GREISH (Dunedin, New Zealand)... Vessel and Mast Cell Densities in Sporadic and Syndrome-associated Peripheral Nerve Sheath Tumors. R.E. FRIEDRICH, U. NABER, M. GLATZEL, C. HAGEL (Hamburg, Germany)... Apoptotic Effects of Novel Dithiocarbamate Analogs of Emetine in Prostate Cancer Cell Lines. Z.D. BAMJI, K.N. WASHINGTON, E. AKINBOYE, O. BAKARE, Y.M. KANAAN, R.L. COPELAND JR (Washington, DC, USA)... HPV-related Oropharyngeal Squamous Cell Carcinoma: p16ink4a Immunohistochemistry or HPV Genotyping? M. ORSARIA, S. MARZINOTTO, L. DE MARCHI, V. GIACOMARRA, S. BORIA, C. RUBINI, A.P. LONDERO, C. DI LORETO, L. MARIUZZI (Udine; Tolmezzo; Ancona; Monfalcone, Italy)... Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis. A.-R. CHOI, M.-J. JUNG, J.-H. KIM, S. YOON (Gyeonggi-do, Republic of Korea)... Pro-apoptotic and Growth-inhibitory Effect of IFN-β-Overexpressing Canine Adipose Tissue-derived Mesenchymal Stem Cells Against Melanoma Cells. S.-M. HAN, C.-W. PARK, J.-O. AHN, S.-C. PARK, W.-S. JUNG, K.-W. SEO, J.-C. RA, S.-K. KANG, H.-W. LEE, H.-Y. YOUN (Seoul; Daejeon, Republic of Korea)... Advanced Chemoembolization by Anti-angiogenic Calcium-Phosphate Ceramic Microspheres Targeting the Vascular Heterogeneity of Cancer Xenografts. M. EMOTO, H. YOSHIHISA, K. YANO, B. CHOIJAMTS, H. TSUGU, K. TACHIBANA, M. AIZAWA (Sawara-ku; Jonan-ku, Fukuoka; Tama-ku, Kawasaki, Japan)... Chemoprevention of Azoxymethane-induced Colonic Carcinogenesis in Balb/c mice Using a Modified Pectin Alginate Probiotic. F. ODUN-AYO, J. MELLEM, T. NAICKER, L. REDDY (KwaZulu-Natal; Cape Town, South Africa)... Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium- 188 Against Cancer Cells. W.-C. HSU, C.-N. CHENG, T.-W. LEE, J.-J. HWANG (Taipei; Taoyuan, Taiwan, ROC)... Angiotensin II Increases Cancer Stem Cell-like Phenotype in Lung Cancer Cells. S. TAWINWUNG, C. NINSONTIA, P. CHANVORACHOTE (Bangkok, Thailand)

63 Role of Hyaluronan and Glucose on 4-Methylumbelliferone-inhibited Cell Proliferation in Breast Carcinoma Cells. R. WANG, W. ZHOU, J. WANG, Y. LIU, Y. CHEN, S. JIANG, X. LUO, D.G. STUPACK, N. LUO (Tianjin, PR China; La Jolla, CA, USA)... Q192R and L55M Polymorphisms of Paraoxonase 1 Gene in Chronic Myelogenous Leukemia and Chronic Lymphocytic Leukemia. A.G. TOMATIR, S. PEHLIVAN, H. HAYDAROĞLU SAHIN, S. OGUZKAN BALCI, S. BUDEYRI, M. PEHLIVAN (Denizli; Istanbul; Gaziantep, Turkey) Clinical Studies Predicting Outcome in Colonoscopic High-risk Surveillance. A.M. FORSBERG, E. HAGEL, E. JARAMILLO, C.A. RUBIO, E. BJÖRCK, A. LINDBLOM (Stockholm, Sweden)... A Case of Focal Small-cell Neuroendocrine Carcinoma in the Vicinity of the Extrahepatic Bile Duct, Adjacent to an Extensive Biliary Intraepithelial Neoplasm: A Diagnostic Challenge with Major Clinical Implications. B. AIGNER, P. KORNPRAT, H. SCHÖLLNAST, A.-K. KASPAREK, H.-J. MISCHINGER, J. HAYBAECK (Graz, Austria)... Prognostic Impact of ALDH1 Expression in Transitional Cell Carcinoma of the Renal Pelvis. J. LIU, J. JIN, Y. YANG, W. HAN, W. YU, C. SHEN, N. ZHANG, P. DU, Q. ZHAO, S. WANG, X. TANG (Beijing, PR China)... Sporadic Burkitt Lymphoma Mimicking Osteomyelitis of the Mandible Revealing Clinically Unsuspected HIV Infection. S. SIVOLELLA, G. RIZZO, M. VALENTE, F. LUMACHI (Padova, Italy)... Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna. R.K. DANDAMUDI, S. ASLAM, N. WALJI, A. EL-MODIR, I. FERNANDO (Birmingham, UK)... Radiation Therapy for Para-Aortic Lymph Node Metastasis from Uterine Cervical Cancer. M. HATA, E. MIYAGI, I. KOIKE, R. NUMAZAKI, M. ASAI- SATO, T. KASUYA, H. KAIZU, Y. MUKAI, F. HIRAHARA, T. INOUE (Yokohama, Kanagawa, Japan)... PHI in the Early Detection of Prostate Cancer. R. FUCHSOVA, O. TOPOLCAN, J. WINDRICHOVA, M. HORA, O. DOLEJSOVA, L. PECEN, P. KASIK, J. NOVAK, M. CASOVA, J. SMEJKAL (Pilsen, Czech Republic)... Comparison of Neoadjuvant Chemotherapy to Surgery Followed by Adjuvant Chemotherapy in Japanese Patients with Peritoneal Lavage Cytology Positive for Gastric Carcinoma. M. YAMAMOTO, H. KAWANO, S. YAMAGUCHI, A. EGASHIRA, K. MINAMI, K. TAGUCHI, Y. IKEDA, M. MORITA, Y. TOH, T. OKAMURA (Minami-ku, Fukuoka, Japan)... Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery. S. MORINAGA, M. MURAKAWA, Y. KATAYAMA, K. YAMAOKU, T. AOYAMA, A. KANAZAWA, A. HIGUCHI, M. SHIOZAWA, S. KOBAYASHI, M. UENO, M. MORIMOTO (Asahiku, Yokohama, Japan)... Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression. J. BOSCH-BARRERA, F. HOLGUIN, X. BALDÓ, M. RUBIO, R. PORTA, R. FUENTES, C. TEIXIDÓ, J.L. RAMIREZ, N. FERRAN, F. SEBASTIÁN, R. ROSELL (Girona; Barcelona; Badalona, Spain)... Palliative Pelvic Exenteration for Pelvic Recurrence Invading the Sciatic Foramen with Chronic Cutaneous Perineal Fistula after Radical Surgery for Cervical Cancer: A Case Report. N. BACALBASA, I. BALESCU (Bucharest, Romania)

64 5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Doseescalation Method. Y. YOSHIDA, K. OGURA, A. HIRATSUKA, N. AISU, T. YAMADA, D. KOJIMA, S. TANIMURA, K. OGATA, S. HARA, A. MOGI, Y. TAKAMATSU, K. TAMURA, H. MISHIMA, Y. YAMASHITA (Fukuoka; Tokyo; Nagakute, Japan)... Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with Locally Advanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy. M. OHIRA, N. KUBO, Y. YAMASHITA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, K. HIRAKAWA (Osaka, Japan)... Glasgow Prognostic Score as a Prognostic Clinical Marker in T4 Esophageal Squamous Cell Carcinoma. M. OHIRA, N. KUBO, G. MASUDA, Y. YAMASHITA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, K. HIRAKAWA (Osaka, Japan)... Stereotactic Body Radiotherapy Results for Pulmonary Oligometastases: A Two-Institution Collaborative Investigation. Y. NIIBE, H. YAMASHITA, K. SEKIGUCHI, W. TAKAHASHI, K. SHIRAISHI, K. OKUMA, A. TERAHARA, J. KAWAMORI, K. NAKAGAWA (Tokyo, Japan)... Impact of Interstitial Changes on Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Cancer. T. YOSHITAKE, Y. SHIOYAMA, K. ASAI, K. NAKAMURA, T. SASAKI, S. OHGA, T. KAMITANI, T. YAMAGUCHI, K. OHSHIMA, K. MATSUMOTO, S. KAWANAMI, H. HONDA (Fukuoka; Tosu-shi, Saga, Japan)... TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis. N. NOEL, J. COUTEAU, G. MAILLET, F. GOBET, F. D ALOISIO, C. MINIER, C. PFISTER (Rouen; Le Havre, France)... Impact of Itraconazole After First-line Chemotherapy on Survival of Patients with Metastatic Biliary Tract Cancer. H. TSUBAMOTO, T. SONODA, S. IKUTA, S. TANI, K. INOUE, N. YAMANAKA (Nishinomiya, Hyogo; Kobe, Japan)... Two Phenotypes of Traditional Serrated Adenomas Nationwide Survey in Iceland. C.A. RUBIO, J.G. JÓNASSON (Stockholm, Sweden; Reykjavik, Iceland)... Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals. I.J. CHRISTENSEN, N. BRÜNNER, B. DOWELL, G. DAVIS, H.J. NIELSEN, G. NEWSTEAD, D. KING (Copenhagen; Frederiksberg; Hvidovre, Denmark; Chicago, IL, USA; Randswick; Kogarah, NSW, Australia)... Strategies for Preventing Pseudomyxoma Peritonei After Resection of a Mucinous Neoplasm of the Appendix. C. HONORÉ, F. CARUSO, P. DARTIGUES, L. BENHAIM, M. CHIRICA, D. GOÉRÉ, D. ELIAS (Villejuif, France)... Facial Basal Cell Carcinomas in Elderly Frail Patients Treated with Low Total-dose Radiotherapy. E.G. RUSSI, A. PELISSERO, A. MELANO, C. FILLINI, R. VIGNA-TAGLIANTI, L. GIANELLO, F. LUCIO, N. SETTINERI, A. SANTACATERINA, A. PONTORIERO, G. IATÌ, S. PERGOLIZZI (Cuneo; Messina, Italy)... Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. J. KERSCHBAUMER, F.A. SCHMIDT, A.E. GRAMS, M. NOWOSIELSKI, D. PINGGERA, K.R. BRAWANSKI, O. PETR, C. THOMÉ, J. TUETTENBERG, M. SEIZ, C.F. FREYSCHLAG (Innsbruck, Austria; Idar-Oberstein; Mannheim, Germany)

65 Preoperative Change in Peripheral Blood Monocyte Count May Predict Long-term Outcomes After Pancreaticoduodenectomy for Bile Duct Cancer. K. HARUKI, H. SHIBA, T. HORIUCHI, Y. SHIRAI, R. IWASE, Y. FUJIWARA, K. FURUKAWA, T. MISAWA, K. YANAGA (Tokyo, Japan)... Cardiac Surveillance Findings During Adjuvant and Palliative Trastuzumab Therapy in Patients with Breast Cancer. E. VALICSEK, R. KÓSZÓ, Á. DOBI, G. UHERCSÁK, Z. VARGA, A. VASS, É. JEBELOVSZKY, Z. KAHÁN (Szeged, Hungary)... Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotype to Gastric Cancer Risk in Taiwan. H.-X. JI, W.-S. CHANG, C.-W. TSAI, J.-Y. WANG, N.-K. HUANG, A.-S. LEE, M.-Y. SHEN, W.-Y. CHEN, Y.-C. CHIANG, T.-C. SHIH, C.-M. HSU, D.-T. BAU (Taichung; Taipei; New Taipei, Taiwan, ROC)... Relation of Vitamin E and Selenium Exposure to Prostate Cancer Risk by Smoking Status: A Review and Meta-Analysis. Y. KIM, J. WEI, J. CITRONBERG, T. HARTMAN, V. FEDIRKO, M. GOODMAN (Atlanta, GA; Baltimore, MD; Chapel Hill, NC; Seattle, WA, USA)... Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer. J.-M. CLASSE, O. GLEHEN, E. DECULLIER, J.M. BEREDER, S. MSIKA, G. LORIMIER, K. ABBOUD, P. MEEUS, G. FERRON, F. QUENET, F. MARCHAL, S. GOUY, C. POMEL, M. POCARD, F. GUYON, N. BAKRIN (Saint-Herblain; Villeurbanne; Pierre-Bénite; Lyon; Nice; Colombes; Angers; Saint-Priest-en-Jarez; Laennec; Toulouse; Montpellier; Vandoeuvre-lès-Nancy; Villejuif; Clermont-Ferrand; Paris; Bordeaux, France)... Pentafecta Outcomes of 230 Cases of Robotic-assisted Radical Prostatectomy with Bilateral Neurovascular Bundle Preservation. Y.-C. OU, C.-K. YANG, H.-M. KANG, K.-S. CHANG, J. WANG, S.-W. HUNG, M.-C. TUNG, A.K. TEWARI, V.R. PATEL (Taichung; Taipei, Taiwan, ROC; New York, NY; Orlando, FL, USA)... Comparative Study Βetween Total Laparoscopic and Total Robotic Radical Hysterectomy for Cervical Carcinoma: Clinical Study. J.Y. KIM, Y.H. LEE, G.O. CHONG, Y.S. LEE, Y.L. CHO, D.G. HONG (Daegu, Republic of Korea)... Laparoscopic Total Gastrectomy for RGC: Four Case Reports. S. KOREHISA, K. OHGAKI, T. YUKAYA, Y. ZAITU, Y. TSUDA, Y. KASAGI, K. ANDO, Y. NAKASHIMA, Y. IMAMURA, H. SAEKI, E. OKI, Y. MAEHARA (Fukuoka, Japan)... Combination of Juvenile Papillomatosis, Juvenile Fibroadenoma and Intraductal Carcinoma of the Breast in a 15-Year-old Girl. T. SEDLOEV, A. BASSAROVA, K. ANGELOV, M. VASILEVA, Y. ASENOV (Sofia, Bulgaria; Oslo, Norway)... Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study. Y. KITAGAWA, S. URATA, A. MIZOKAMI, K. NAKASHIMA, K. KOSHIDA, T. NAKASHIMA, K. MIYAZAKI, M. NAMIKI (Kanazawa, Ishikawa, Japan)... Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer. M. SHIBUTANI, K. MAEDA, H. NAGAHARA, H. OHTANI, K. SAKURAI, S. YAMAZOE, K. KIMURA, T. TOYOKAWA, R. AMANO, N. KUBO, H. TANAKA, K. MUGURUMA, M. OHIRA, K. HIRAKAWA (Osaka, Japan)... Survival Advantage Associated with Metformin Usage in Hepatocellular Carcinoma Patients Receiving Radiotherapy: A Propensity Score Matching Analysis. W.I. JANG, M.-S. KIM, J.S. LIM, H.J. YOO, Y.S. SEO, C.J. HAN, S.C. PARK, C.S. KAY, M. KIM, H.S. JANG, D.S. LEE, A.R. CHANG, H.J. PARK (Seoul, Republic of Korea)

66 Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance. H. SHOJI, Y. YAMADA, N. OKITA, A. TAKASHIMA, Y. HONMA, S. IWASA, K. KATO, T. HAMAGUCHI, Y. SHIMADA (Tokyo, Japan)... Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond Preliminary Results. T. TŐKÉS, G. SZENTMÁRTONI, L. TORGYÍK, K. SOMLAI, J. KULKA, Z. LENGYEL, T. GYÖRKE, M. DANK (Budapest, Hungary)... Large Colorectal Carcinoma Is Predictive of Recurrence After Adjuvant Chemotherapy Using Oxaliplatin. H. NOZAWA, T. NISHIKAWA, T. TANAKA, J. TANAKA, T. KIYOMATSU, K. KAWAI, K. HATA, S. KAZAMA, H. YAMAGUCHI, S. ISHIHARA, E. SUNAMI, J. KITAYAMA, T. WATANABE (Tokyo, Japan)... Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. K. FURUKAWA, H. SHIBA, Y. SHIRAI, T. HORIUCHI, R. IWASE, K. HARUKI, Y. FUJIWARA, T. MISAWA, K. YANAGA (Tokyo, Japan)... T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. L.L. MICHEL, J.L. BERMEJO, A. GONDOS, F. MARMÉ, A. SCHNEEWEISS (Heidelberg, Germany)... Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer. P. HABBEL, A. KURRECK, C.-O. SCHULZ, A.C. REGIERER, D. KAUL, C.W. SCHOLZ, C. NEUMANN, K. POSSINGER, J. EUCKER (Berlin, Germany)... Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer. N. BACALBASA, I. BALESCU, S. DIMA, V. BRASOVEANU, I. POPESCU (Bucharest, Romania)... Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11). H.J. PARK, A.R. CHANG, Y. SEO, C.K. CHO, W.-I. JANG, M.S. KIM, C. CHOI (Seoul; Busan, Republic of Korea)... Pathological Characteristics of Both Tumors in Bifocal and Bicentric Breast Cancer. R. MOSBAH, R. ROUZIER, J.-M. GUINEBRETIÈRE, M.-C. FALCOU, D. STEVENS, D. HÉQUET (St Cloud; Montignyle-Bretonneux; Paris, France)... The Role of PET [ 18 F]FDOPA in Evaluating Low-grade Glioma. V. VILLANI, C.M. CARAPELLA, A. CHIARAVALLOTI, I. TERRENATO, F. PILUDU, A. VIDIRI, O. SCHILLACI, R. FLORIS, S. MARZI, A. FABI, A. PACE (Rome; Pozzilli, Italy)... Impact of Hepatitis B Virus on Clinicopathological Features and Outcomes After Resection for Pancreatic Adenocarcinoma. T. DUMITRASCU, P. PINEAU, S. DIMA, C. STROESCU, V. BRASOVEANU, V. HERLEA, M. IONESCU, I. POPESCU (Bucharest, Romania; Paris, France)... Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study. M. NINKOVIC, M. FIEGL, M. MIAN, P. MONDELLO, F. KOCHER, C. WALDTHALER, I. VERDORFER, M. STEURER, G. GASTL, A. PIRCHER (Innsbruck, Austria; Bolzano; Messina, Italy)... 5-Azacytidine in the Treatment of Intermediate-2 and High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia. A Five-year Experience with 44 Consecutive Patients. P. DIAMANTOPOULOS, K. ZERVAKIS, V. PAPADOPOULOU, T. ILIAKIS, F. KALALA, N. GIANNAKOPOULOU, N. ROUGALA, A. GALANOPOULOS, P. BAKARAKOS, E. VARIAMI, A. DIMITRAKOPOULOU, N.- A. VINIOU (Athens, Greece)

67 Number 10 Reviews Chronic Lymphocytic Leukemia: Current Concepts. E.-M. YU, A. KITTAI, I.A. TABBARA (Washington, DC, USA)... Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy. H. YAMAZAKI, S. NAKAMURA, G. SUZUKI, K. YOSHIDA, Y. YOSHIOKA, M. KOIZUMI, K. OGAWA (Kyoto; Takatsuki City; Suita, Japan)... Predictive and Prognostic Value of the Tau Protein in Breast Cancer. C. BONNEAU, Z.A. GURARD- LEVIN, F. ANDRE, L. PUSZTAI, R. ROUZIER (Versailles; Paris, France; New Haven, CT, USA)... Primary Thyroid Sarcoma: A Systematic Review. A. SUROV, S. GOTTSCHLING, A. WIENKE, H. JONAS MEYER, R.P. SPIELMANN, H. DRALLE (Halle-Wittenberg; Leipzig, Germany) Experimental Studies Effects of Single and Fractionated Irradiation on Natural Killer Cell Populations: Radiobiological Characteristics of Viability and Cytotoxicity In Vitro. T. HIETANEN, M. PITKÄNEN, M. KAPANEN, P.-L. KELLOKUMPU-LEHTINEN (Tampere, Finland)... Imaging and Antitumoral Effect of a Cyclo-oxygenase 2-specific Replicative Adenovirus for Small Metastatic Gastric Cancer Lesions. T. KOSAKA, J. DAVYDOVA, H.A. ONO, H. AKIYAMA, S.-I. HIRAI, S. OHNO, F. TAKESHITA, K. AOKI, T. OCHIYA, M. YAMAMOTO, C. KUNISAKI, I. ENDO (Yokohama; Tokyo, Japan; Minneapolis, MN, USA)... Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives. D.M. FERGUSON, B.A. JACOBSON, J. JAY-DIXON, M.R. PATEL, R.A. KRATZKE, A. RAZA (Minneapolis, MN, USA)... Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. A. LIVUN, K.J. NEWBERRY, T. MANSHOURI, R. KUSEC, S. VERSTOVSEK (Zagreb, Croatia; Houston, TX, USA)... Imaging the Different Mechanisms of Prostate Cancer Cell-killing by Tumor-targeting Salmonella typhimurium A1-R. A. UCHUGONOVA, Y. ZHANG, R. SALZ, F. LIU, A. SUETSUGU, L. ZHANG, K. KOENIG, R.M. HOFFMAN, M. ZHAO (San Diego, CA, USA; Saarbruecken, Germany)... Hyaluronic Acid Inhibitor 4-Methylumbelliferone Activates the Intrinsic Apoptosis Pathway in K562 Chronic Myelogenous Leukemia Cells. H. BAN, O. UCHAKINA, R.J. MCKALLIP (Macon, GA, USA)... Reversal of c-met-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-met Inhibitor TAS E. KUNII, H. OZASA, T. OGURI, K. MAENO, S. FUKUDA, T. UEMURA, O. TAKAKUWA, H. OHKUBO, M. TAKEMURA, A. NIIMI (Nagoya; Kyoto, Japan)... The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. C. STENGEL, S.P. NEWMAN, M.P. LEESE, M.P. THOMAS, B.V.L. POTTER, M.J. REED, A. PUROHIT, P.A. FOSTER (London; Oxford; Bath; Birmingham, UK)... Lysophosphatidic Acid Stimulates Urokinase Receptor (upar/cd87) in Ovarian Epithelial Cancer Cells. J. LIZALEK, T. MCKENNA, K. HUEGEL, S. MARSH, A. CAROLAN, A. KOBLISKA, E. HEYING, N. GARDNER, G. MILLER, A. KOTECKI, M. HENNINGSEN, A. LUNDT, J. FARLEY, S.M. ELLERBROEK (Waverly, IA, USA)

68 The New Semisynthetic Cardenolide Analog 3β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines. E. NOLTE, A. SOBEL, S. WACH, H. HERTLEIN, N. EBERT, F. MÜLLER-URI, R. SLANY, H. TAUBERT, B. WULLICH, W. KREIS (Erlangen, Germany)... Gelsolin Is Associated with Longer Metastasis-free Survival and Reduced Cell Migration in Estrogen Receptorpositive Breast Cancer. A.-M. STOCK, F. KLEE, K. EDLUND, M. GRINBERG, S. HAMMAD, R. MARCHAN, C. CADENAS, B. NIGGEMANN, K.S. ZÄNKER, J. RAHNENFÜHRER, M. SCHMIDT, J. G. HENGSTLER, F. ENTSCHLADEN (Witten; Dortmund; Mainz, Germany; Qena, Egypt)... Glucan Supplementation Has Strong Anti-melanoma Effects: Role of NK Cells. V. VETVICKA, J. VETVICKOVA (Louisville, KY, USA)... The Effects of Curcumin-based Compounds on Proliferation and Cell Death in Cervical Cancer Cells. X. ZHANG, R. WANG, G. CHEN, L. DEJEAN, Q.-H. CHEN (Fresno, CA, USA)... Quantitative Structure Cytotoxicity Relationship of 3-Styryl-2H-chromenes. Y. UESAWA, H. SAKAGAMI, M. ISHIHARA, H. KAGAYA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, H. YAHAGI, K. TAKAO, Y. SUGITA (Kiyose; Sakado; Kanagawa, Japan)... Zinc Induces Apoptosis of Human Melanoma Cells, Increasing Reactive Oxygen Species, p53 and FAS Ligand. M. PROVINCIALI, E. PIERPAOLI, B. BARTOZZI, G. BERNARDINI (Ancona, Italy)... GADD34 Facilitates Cell Death Resulting from Proteasome Inhibition. L. LIU, S. ITO, N. NISHIO, Y. SUN, N. CHEN, Y. TANAKA, K.-I. ISOBE (Nagoya, Japan)... Tryptase-positive and CD117 Positive Mast Cells Correlate with Survival in Patients with Liver Metastasis. S.E. GIUŞCĂ, I.D. CĂRUNTU, A.M. CÎMPEAN, R.E. AVADANEI, A.R. BALICA, A.A. JITARIU, M. RAICA (Iaşi; Timişoara, Romania)... Lectin Histochemistry Shows WGA, PHA-L and HPA Binding Increases During Progression of Human Colorectal Cancer. P. HÄGERBÄUMER, M. VIETH, M. ANDERS, U. SCHUMACHER ( Hamburg; Bayreuth, Germany)... Quantitative Structure Cytotoxicity Relationship of Oleoylamides. H. SAKAGAMI, Y. UESAWA, M. ISHIHARA, H. KAGAYA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, K. TAKAO, Y. SUGITA (Sakado; Kiyose; Kanagawa, Japan)... Survivin Down-regulation by α-santalol Is Not Mediated Through PI3K AKT Pathway in Human Breast Cancer Cells. A. BOMMAREDDY, K. CRISAMORE, S. FILLMAN, S. BROZENA, J. STEIGERWALT, T. LANDIS, A.L. VANWERT, C. DWIVEDI (Wilkes-Barre, PA; Brookings, SD, USA)... CHM-1 Suppresses Formation of Cell Surface-associated GRP78 p85α Complexes, Inhibiting PI3K AKT Signaling and Inducing Apoptosis of Human Nasopharyngeal Carcinoma Cells. M.-L. LIN, S.-S. CHEN, S.-H. NG (Taichung, Taiwan, ROC)... Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. T. TAMURA, M. OHIRA, H. TANAKA, K. MUGURUMA, T. TOYOKAWA, N. KUBO, K. SAKURAI, R. AMANO, K. KIMURA, M. SHIBUTANI, K. MAEDA, K. HIRAKAWA (Osaka, Japan)... Long Noncoding RNA ANRIL Regulates Proliferation of Non-Small Cell Lung Cancer and Cervical Cancer Cells. M. NAEMURA, C. MURASAKI, Y. INOUE, H. OKAMOTO, Y. KOTAKE (Fukuoka, Japan)... Human Mesenchymal Stem Cells Protect Dorsal Root Ganglia from the Neurotoxic Effect of Cisplatin. A. SCUTERI, M. RAVASI, M. MONFRINI, A. MILANO, G. D AMICO, M. MILOSO, G. TREDICI (Monza; Milan, Italy)

69 Individual and Combined Effects of CTLA4-CD28 Variants and Oxidant-Antioxidant Status on the Development of Colorectal Cancer. O. KUCUKHUSEYIN, S. TURAN, K. YANAR, S. ARIKAN, Y. DUZKOYLU, S. AYDIN, U. CAKATAY, B. MEZANI, A.A. FAROOQI, G.A. ISITMANGIL, B. KIRAN, C. CACINA, E.N. YENILMEZ, A. ERGEN, U. ZEYBEK, I. YAYLIM (Istanbul; Kastamonu, Turkey; Lahore, Pakistan)... Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus. M. PAP, J. BÁTOR, J. SZEBERÉNYI (Pécs, Hungary)... Synthetic Bichalcone TSWU-BR23 Induces Apoptosis of Human Colon Cancer HT-29 Cells by p53- Mediated Mitochondrial Oligomerization of BAX/BAK and Lipid Raft Localization of CD95/FADD. M.-L. LIN, S.-S. CHEN, T.-S. WU (Taichung; Tainan, Taiwan, ROC)... Tumor Necrosis Factor-α Genotypes Are Associated with Hepatocellular Carcinoma Risk in Taiwanese Males, Smokers and Alcohol Drinkers. M.-D. YANG, C.-M. HSU, W.-S. CHANG, T.-C. YUEH, Y.-L. LAI, C.- L. CHUANG, S.- C. WANG, L.- B. JENG, H.- X. JI, C.- L. HSIAO, C.- N. WU, C.- W. TSAI, J.- G. CHUNG, D.-T. BAU (Taichung, Taiwan, ROC)... Preliminary Study: Prominent mirnas of Breast Malignant Tissues Compared to Normal Tissues in Turkish Patients with Breast Cancer. T. OZTURK, O. KUCUKHUSEYIN, A.P. ERONAT, M.B. TUZUNER, A. DAGLAR-ADAY, N. SAYGILI, H.I. KISAKESEN, F. SEYHAN, M. VELIDEDEOĞLU, Z. CALAY, Ş. İLVAN, H. YILMAZ-AYDOĞAN, O. OZTURK, T. İSBIR (Istanbul, Turkey)... Non-covalent Nanocomplexes of Folic Acid and Reducible Polyethylenimine for Survivin sirna Delivery. B. ZHENG, S. YANG, M. WANG, X. YANG, L. TENG, J. XIE, L. TENG, R.J. LEE (Changchun, PR China; Columbus, OH, USA)... Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer. Y. TOLKACH, A. MERSEBURGER, T. HERRMANN, M. KUCZYK, J. SERTH, F. IMKAMP (Hannover, Germany) Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells. S.H. KIM, J.G. KANG, C.S. KIM, S.-H. IHM, M.G. CHOI, H.J. YOO, S.J. LEE (Chuncheon, Republic of Korea) Clinical Studies Impaired Immune Function in Patients Undergoing Surgery for Bone Cancer. J.F. VELÁSQUEZ, M.F. RAMÍREZ, D. AI, V. LEWIS, J.P. CATA (Houston; Temple, TX; Boston, MA, USA)... PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. C. WEBRE, N. SHONKA, L. SMITH, D. LIU, J. DE GROOT (Bryan; Houston, TX; Omaha, NE, USA)... Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. N. IRIYAMA, Y. HATTA, S. KOBAYASHI, Y. UCHINO, K. MIURA, D. KURITA, H. KODAIRA, H. TAKAHASHI, Y. IIZUKA, M. INOUE, M. TAKEI (Tokyo, Japan)... Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer. P. KERN, G. VON MINCKWITZ, C. PUETTER, S. PAVLIDOU, A. FLACH, R. KIMMIG, M. REZAI (Essen; Neu-Isenburg; Düsseldorf, Germany)... Preoperative Chemotherapy Can Change the Surgical Procedure for Hepatectomy in Patients with Liver Metastasis of Colorectal Cancer. Y. SASAKI, S. OSADA, S. MATSUI, H. IMAI, T. TANAHASHI, Y. TANAKA, N. MATSUHASHI, N. OKUMURA, K. YAMAGUCHI, K. YOSHIDA (Gifu, Japan)

70 Effect of Increased Radiotoxicity on Survival of Patients with Non-Small Cell Lung Cancer Treated with Curatively Intended Radiotherapy. G. HOLGERSSON, S. BERGSTRÖM, P. LIV, J. NILSSON, P. EDLUND, C. BLOMBERG, J. NYMAN, S. FRIESLAND, S. EKMAN, T. ASKLUND, R. HENRIKSSON, M. BERGQVIST (Gävle; Gothenburg; Stockholm; Uppsala; Umeå, Sweden)... Survival After Distant Metastasis in Head and Neck Cancer. S. WIEGAND, A. ZIMMERMANN, T. WILHELM, J.A. WERNER (Marburg, Germany)... Impact of Pelvic and Para-aortic Lymphadenectomy in Advanced Ovarian Cancer After Neoadjuvant Chemotherapy. L. SCHWARTZ, S. SCHROT-SANYAN, C. BRIGAND, J.-J. BALDAUF, A. WATTIEZ, C. AKLADIOS (Strasbourg, France)... Early and Severe Radiation Toxicity Associated with Concurrent Sirolimus in an Organ Transplant Recipient with Head and Neck Cutaneous Squamous Cell Carcinoma: A Case Report. B.V. MANYAM, T.I. NWIZU, M.L. RAHE, B.A. HARR, S.A. KOYFMAN (Cleveland, OH, USA)... Α New Predictive Tool for Optimization of the Treatment of Brain Metastases from Colorectal Cancer After Stereotactic Radiosurgery. D. RADES, M. DAHLKE, N. GEBAUER, T. BARTSCHT, D. HORNUNG, N.T. TRANG, P.C. PHUONG, M.T. KHOA, J. GLIEMROTH (Lübeck; Hamburg, Germany; Hanoi, Vietnam)... The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. V. BARAK, A. MEIROVITZ, V. LEIBOVICI, J. RACHMUT, T. PERETZ, R. ELIASHAR, M. GROSS (Jerusalem, Israel)... Effects of Pre-surgical Vitamin D Supplementation and Ketogenic Diet in a Patient with Recurrent Breast Cancer. J.J.V. BRANCA, S. PACINI, M. RUGGIERO (Florence, Italy)... Decreased Expression of PDHE1α Predicts Worse Clinical Outcome in Esophageal Squamous Cell Carcinoma. Y. ZHONG, R. HUANG, X. LI, R. XU, F. ZHOU, J. WANG, H. FAN, M. GOSCINSKI, M. ZHANG, J.-G. WEN, J. M. NESLAND, Z. SUO (Zhengzhou; Anyang, PR China; Oslo, Norway)... Partial Cystectomy with Distal Ureteral Resection and Re-implantation for Locally Invasive Cervical Cancer. N. BACALBASA, I. BALESCU, D. TOMESCU (Bucharest, Romania)... Use of Inflated Foley Catheters to Prevent Early Empty Pelvis Complications Following Pelvic Exenteration. N. BACALBASA, D. TOMESCU, I. BALESCU (Bucharest, Romania)... Endometrial Carcinoma Associated with Ovarian Granulosa Cell Tumors A Case Report. N. BACALBASA, C. STOICA, I. POPA, G. MIREA, I. BALESCU (Bucharest, Romania)... Sunitinib Malate plus Lomustine for Patients with Temozolomide refractory Recurrent Anaplastic or Lowgrade Glioma. J. DUERINCK, S. DU FOUR, W. SANDER, A.- M. VAN BINST, H. EVERAERT, A. MICHOTTE, P. HAU, B. NEYNS (Brussels, Belgium; Regensburg, Germany)... Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life. H. ISHIKAWA, H. KATOH, T. KAMINUMA, H. KAWAMURA, K. ITO, H. MATSUI, J. HIRATO, N. SHIMIZU, Y. TAKEZAWA, H. TSUJI, K. SUZUKI, T. OHNO, T. NAKANO (Ibaraki; Gunma; Chiba, Japan)... Survival and Toxicity Following Chemoradiation for Carcinoma of the Cervix Impact of Multiple-phase Treatment and Shielding. S. YAHYA, L. BHATT, M. KING, S. PIRRIE, R. WYATT, M.S. ANWAR, A. EL-MODIR, I. FERNANDO (Birmingham; Manchester; Wolverhampton, UK)... Prevalence and Prognostic Value of Lymph Node Dissection in Treating Adrenocortical Carcinoma: A National Experience. S. ALANEE, D. DYNDA, B. HOLLAND (Springfield, IL, USA)

71 Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas. R. FRAKULLI, F. SALVI, D. BALESTRINI, A. PARISI, M. PALOMBARINI, S. CAMMELLI, M. ROCCA, M. SALONE, A. LONGHI, S. FERRARI, A.G. MORGANTI, G. FREZZA (Bologna, Italy)... Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients. B. MAYER, S. SANDER, S. PASCHKE, D. HENNE-BRUNS, K.-H. LINK, M. KORNMANN (Ulm; Wiesbaden, Germany)... Lymphatic Vascularization in Prostate Adenocarcinoma: Correlation with Tumor Grade, Androgen Withdrawal and Prognosis. M.R. AMBROSIO, B.J. ROCCA, A. BARONE, A. GINORI, F. CRIVELLI, L. PIRTOLI, M.T. DEL VECCHIO (Siena; Saronno, Italy)... Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. M.J. BOERS- SONDEREN, I.M.E. DESAR, J.J. FÜTTERER, S.F. MULDER, L.-F. DE GEUS-OEI, P.F. MULDERS, W.T.A. VAN DER GRAAF, W.J.G. OYEN, C.M.L. VAN HERPEN (Nijmegen, the Netherlands)... Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection. E.A. KASTELIJN, S.Y. EL SHAROUNI, F.N. HOFMAN, B.P. VAN PUTTE, E.M. MONNINKHOF, M. VAN VULPEN, F.M.N.H. SCHRAMEL (Nieuwegein; Utrecht, the Netherlands)... What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer? R. S. DAVIES, C. SMITH, M.R. BUTTON, J. TANGUAY, J. BARBER, N. PALANIAPPAN, J. STAFFURTH, J.F. LESTER (Cardiff, Wales, UK)... Comparing Endurance and Resistance Training with Standard Care during Chemotherapy for Patients with Primary Breast Cancer. T. SCHMIDT, B. WEISSER, J. DÜRKOP, W. JONAT, M. VAN MACKELENBERGH, C. RÖCKEN, C. MUNDHENKE (Kiel, Germany)... Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. K.-M. CHO, Y.J. KIM, S.H. KIM, J.W. KIM, J.-O. LEE, J.H. HAN, K.-W. LEE, J.H. KIM, C.-Y. KIM, S.-M. BANG, I.-A. KIM, J.S. KIM, J.-S. LEE (Seongnam; Seoul, Republic of Korea)... Preoperative Lower Body Mass Index Correlates with Poorer Prognosis in Patients Undergoing Curative Laparoscopic Surgery for Colorectal Cancer. R. URATANI, Y. TOIYAMA, T. SHIMURA, K. MORI, H. FUJIKAWA, J. HIRO, M. OHI, Y. INOUE, K. TANAKA, T. ARAKI, Y. MOHRI, M. KUSUNOKI (Mie, Japan)... Hematogenous Splenic Metastases as an Independent Negative Prognosis Factor at the Moment of Primary Cytoreduction in Advanced Stage Epithelial Ovarian Cancer A Single Center Experience. N. BACALBASA, I. BALESCU, S. DIMA, V. BRASOVEANU, I. POPESCU (Bucharest, Romania)... Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites. J. TRAPÉ, G. GURT, J. FRANQUESA, J. MONTESINOS, A. ARNAU, M. SALA, F. SANT, E. CASADO, J.M. ORDEIG, C. BERGOS, F. VIDA, P. SORT, Á. ISAVA, M. GONZÁLEZ, R. MOLINA (Manresa; Vic; Barcelona, Spain)... Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma. I. TRÁVNÍČEK, J. BRANŽOVSKÝ, K. KALUSOVÁ, O. HES, L. HOLUBEC, K.B. PELE, T. ÜRGE, M. HORA (Pilsen, Czech Republic)... Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia. M. POGORZALA, M. KUBICKA, B. RAFINSK, M. WYSOCKI, J. STYCZYNSKI (Bydgoszcz, Poland)... Relative Uptake Factor of Invasive Ductal Breast Cancer in Breast-specific Gamma Imaging as a Surrogate Parameter for Sub-typing. T. MEISSNITZER, M.W. MEISSNITZER, A. SEYMER, K. HERGAN, D. NEUREITER (Salzburg, Austria)

72 Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy. M. THALGOTT, B. RACK, T. HORN, M.M. HECK, M. EIBER, H. KÜBLER, M. RETZ, J.E. GSCHWEND, U. ANDERGASSEN, R. NAWROTH (Munich, Germany)... Nutritional Supplement Based on Zinc, Prebiotics, Probiotics and Vitamins to Prevent Radiation-related Gastrointestinal Disorders. D. SCARTONI, I. DESIDERI, I. GIACOMELLI, V. DI CATALDO, L. DI BRINA, A. MANCUSO, I. FURFARO, P. BONOMO, G. SIMONTACCHI, L. LIVI (Florence, Italy)... Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up. L. AGOLLI, M. VALERIANI, S. BRACCI, L. NICOSIA, V. DE SANCTIS, R.M. ENRICI, M.F. OSTI (Rome, Italy)... Defining the Optimal Dose of Stereotactic Radiosurgery for Treating Cerebral Metastases in Elderly Patients. D. RADES, M. DAHLKE, L. DZIGGEL, S. JANSSEN, A. BAJROVIC, N.T. TRANG, M.T. KHOA, S.E. SCHILD (Lübeck; Hannover; Hamburg, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA)... Errata... Book Reviews Number 11 Reviews Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy. M. KOCH, A.J. FREUNDL, A. AGAIMY, F. KIESEWETTER, J. KÜNZEL, I. CICHA, C. ALEXIOU (Erlangen; Mainz, Germany)... Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. M. STOTZ, A. GERGER, J. HAYBAECK, T. KIESSLICH, M.D. BULLOCK, M. PICHLER (Graz; Salzburg, Austria; Houston, TX, USA)... Immunotherapies for NSCLC: Are We Cutting the Gordian Helix? W.C.M. DEMPKE, L. SELLMANN, K. FENCHEL, K. EDVARDSEN (Munich; Mönchengladbach; Hamburg, Germany; Cambridge, UK)... Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST? I. HOMPLAND, Ø.S. BRULAND (Oslo, Norway)... Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. G.V. SHERBET (Huntington Beach, CA, USA; Newcastle, UK)... Natural Products That Target Cancer Stem Cells. J. MOSELHY, S. SRINIVASAN, M.K. ANKEM, C. DAMODARAN (Louisville, KY, USA)... Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding the Anticancer Effect of Metformin and Its Clinical Implications. M. CAZZANIGA, B. BONANNI (Milan, Italy)... Brain Metastases in NSCLC Are TKIs Changing the Treatment Strategy? W.C.M. DEMPKE, K. EDVARDSEN, S. LU, N. REINMUTH, M. RECK, A. INOUE (Cambridge, UK; Munich; Grosshansdorf, Germany; Shanghai, PR China; Sendai, Japan)

73 Primary Breast Cancer with Synchronous Metastatic Disease Indications for Local Radiotherapy to the Breast and Chest Wall. S. JANSSEN, D. RADES (Hannover; Lübeck, Germany) Experimental Studies Electrochemotherapy Evidence for Cell-type Selectivity In Vitro. F. LANDSTRÖM, M. IVARSSON, A. KOSKELA VON SYDOW, A. MAGNUSON, M. VON BECKERATH, C. MÖLLER (Örebro, Sweden)... Recruitment of Cancer-Associated Fibroblasts and Blood Vessels by Orthotopic Liver Tumors Imaged in Red Fluorescent Protein ( RFP) Transgenic Nude Mice. A. SUETSUGU, Y. HIROSHIMA, T. MATSUMOTO, K. HASAGAWA, M. NAKAMURA, M. SHIMIZU, S. SAJI, H. MORIWAKI, M. BOUVET, R.M. HOFFMAN (Gifu, Japan; San Diego, CA, USA)... Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. K.A. SCOTT, J.L. DENNIS, A.G. DALGLEISH, W.M. LIU (London, UK)... Up-regulation of Toll-like Receptor 9 in Osteosarcoma. Y. JING, H. LIANG, Y. ZHANG, J. CLEVELAND, J. YAN, D. ZHANG (Harbin, PR China; Houston, TX, USA)... Breast Cancer Cell Lines Exhibit Differential Sensitivities to Microtubule-targeting Drugs Independent of Doubling Time. A.L. RISINGER, N.F. DYBDAL-HARGREAVES, S.L. MOOBERRY (San Antonio, TX, USA)... A Theoretical Model for the Hormetic Dose-response Curve for Anticancer Agents. T. YOSHIMASU, T. OHASHI, S. OURA, Y. KOKAWA, M. KAWAGO, Y. HIRAI, M. MIYASAKA, H. NISHIGUCHI, S. KAWASHIMA, Y. YATA, M. HONDA, T. FUJIMOTO, Y. OKAMURA (Wakayama, Japan)... Microcystin LR Shows Cytotoxic Activity Against Pancreatic Cancer Cells Expressing the Membrane OATP1B1 and OATP1B3 Transporters. V. KOUNNIS, G. CHONDROGIANNIS, M.D. MANTZARIS, A.G. TZAKOS, D. FOKAS, N.A. PAPANIKOLAOU, V. GALANI, I. SAINIS, E. BRIASOULIS (Oxford, UK; Ioannina; Thessaloniki, Greece)... Expression of Estrogen Receptors in OSCC in Relation to Histopathological Grade. C. DOLL, R. ARSENIC, H. LAGE, K. JÖHRENS, S. HARTWIG, K. NELSON, J.D. RAGUSE (Berlin; Freiburg, Germany)... The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis. A. GÖKE, R. GÖKE, A. OFNER, A. HERBST, B. LANKAT- BUTTGEREIT (Marburg; Munich, Germany)... Oxidative Stress Activates Membrane Ion Channels in Human Biliary Epithelial Cancer Cells (Mz-Cha-1). T. SCHLENKER, L. SCHWAKE, A. VOSS, W. STREMMEL, C. ELSING (Heidelberg; Dorsten, Germany)... Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism. M.A. LEA, M. ALTAYYAR, C. DESBORDES (Newark; Brooklyn, NY, USA)... HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. R. WATROWSKI, D. CACSIRE CASTILLO-TONG, A. WOLF, E. SCHUSTER, M.B. FISCHER, P. SPEISER, R. ZEILLINGER (Freiburg, Germany; Vienna, Austria)... Core Needle Biopsy Wash Optimization: Enabling Specimen Integrity for both Cytological and Histological Evaluation. W.D. MOJICA, N.K. FRISCH, J.K. PATERSON (Buffalo, NY, USA)... Fluorinated β-diketo Phosphorus Ylides Are Novel Inhibitors of the ABCB1 Efflux Pump of Cancer Cells. G. SPENGLER, I. OCSOVSZKI, Á. SZABÓ TÖNKI, R. SAIJO, G. WATANABE, M. KAWASE, J. MOLNÁR (Szeged, Hungary; Ehime, Japan)

74 In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, S. BLAUM-FEDER, I.G.H. SCHMIDT-WOLF (Bonn, Germany)... Intercellular HOCl-mediated Apoptosis Induction in Malignant Cells: Interplay Between NOX1-Dependent Superoxide Anion Generation and DUOX-related HOCl-generating Peroxidase Activity. S.J. POTTGIESSER, S. HEINZELMANN, G. BAUER (Freiburg, Germany)... Evaluation of 111 In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis. T.R. VAN MOURIK, T. LÄPPCHEN, R. ROSSIN, J.R. VAN BEIJNUM, J.R. MACDONALD, K.H. MAYO, A.W. GRIFFIOEN, K. NICOLAY, H. GRÜLL (Eindhoven; Amsterdam, the Netherlands; Excelsior; Minneapolis, MN, USA)... Site-specific Effects of DUOX1-Related Peroxidase on Intercellular Apoptosis Signaling. S. HEINZELMANN, G. BAUER (Freiburg, Germany)... Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts. A.M. BASCHNAGEL, S. GALOFORO, B.J. THIBODEAU, S. AHMED, S. NIRMAL, J. AKERVALL, G.D. WILSON (Madison, WI; Royal Oak, MI, USA)... Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion. M.H. PHAM, L. DELESTRE, A. DEWITTE, N. WATTEZ, F. LEPRETRE, A. LANSIAUX (Lille; Paris, France)... Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties. T. YAMANE, K. ASANOMA, H. KOBAYASHI, G. LIU, H. YAGI, T. OHGAMI, A. ICHINOE, K. SONODA, N. WAKE, K. KATO (Fukuoka; Kagoshima, Japan)... Antitumor Activity of 3-Indolylmethanamines 31B and PS M.L. GUTHRIE, P.S. SIDHU, E.K. HILL, T.C. HORAN, P. NANDHIKONDA, K.A. TESKE, N.Y. YUAN, M. SIDORKO, R. RODALI, J.M. COOK, L. HAN, N.R. SILVAGGI, D.D. BIKLE, R.G. MOORE, R.K. SINGH, L.A. ARNOLD (Providence, RI; Milwaukee, WI; San Francisco, CA, USA)... Plasminogen Activation System in Rectal Adenocarcinoma. E. RAZIK, C. KOBIERZYCKI, J. GRZEGRZOLKA, M. PODHORSKA-OKOLOW, M. DRAG-ZALESINSKA, M. ZABEL, P. DZIEGIEL (Wroclaw; Poznan, Poland)... Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas. A. JANKOWSKA-KONSUR, C. KOBIERZYCKI, A. REICH, J. GRZEGRZOLKA, J. MAJ, P. DZIEGIEL (Wroclaw, Poland)... Combination of Genistein and Cisplatin with Two Designed Monofunctional Platinum Agents in Human Ovarian Tumour Models. L. ARZUMAN, P. BEALE, N. PROSCHOGO, J.Q. YU, F. HUQ (Lidcombe; Concord; Sydney, NSW, Australia)... Effects of Vitamin K 3 and K 5 on Daunorubicin-resistant Human T Lymphoblastoid Leukemia Cells. E. NAKAOKA, S. TANAKA, K. ONDA, K. SUGIYAMA, T. HIRANO (Hachioji, Japan)... Increased Expression of MuRF1 Is Associated with Radiation-induced Laryngeal Muscle Atrophy. X. HAN, L. PIRES, J.D. BROWNE, C.A. SULLIVAN, W. ZHAO, X. FENG (Winston-Salem, NC, USA; Tangshan, HeBei, PR China)... Investigation of Interleukin-1β Polymorphisms in Prostate Cancer. F. YENCILEK, A. YILDIRIM, S.G. YILMAZ, E.M. ALTINKILIC, A.B. DALAN, Y. BASTUG, T. ISBIR (Istanbul, Turkey)... Active Hexose-correlated Compound Down-regulates Heat Shock Factor 1, a Transcription Factor for HSP27, in Gemcitabine-resistant Human Pancreatic Cancer Cells. M. TOKUNAGA, B. BARON, T. KITAGAWA, K. TOKUDA, Y. KURAMITSU (Ube, Yamaguchi, Japan)

75 Cell Membrane Perforation with Photosensitizer and a Brush-shaped Soft-polymer Sheet Using a Malignant Glioma Cell Line. T. TACHIBANA, Y. SUZUKI, K. FUJIOKA, K. IKEDA, Y. INOUE, Y. TADA, T.K. SAITO, Y. MANOME (Tokyo; Iwate; Yurihonjo City, Akita, Japan)... Bis(phenylidenebenzeneamine)-1-disulfide Derivatives Induce Autophagy in Melanoma Cells Through a Mitochondria-mediated Pathway. W.-P. HU, C.-C. HSU, Y.-C. WANG, G.C. SENADI, K.-K. KUO, J.-F. JEN, J.-J. WANG (Kaohsiung; Taichung, Taiwan, ROC) Clinical Studies Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study. L. FAUSKE, H. BONDEVIK, Ø.S. BRULAND, G. OZAKINCI (Oslo, Norway; Fife, Scotland, UK)... Dosimetric and Radiobiological Evaluation of Hybrid Inverse Planning and Optimization for Cervical Cancer Brachytherapy. L.D.S. MATIAS, T. PALMQVIST, J. WOLKE, J. NILSSON, C. BESKOW, A.M. MAPHOSSA, I. TOMA-DASU (Stockholm, Sweden; Maputo, Mozambique)... Incisional Recurrences After Endometrial Cancer Surgery. G. BOGANI, S.C. DOWDY, W.A. CLIBY, B.S. GOSTOUT, S. KUMAR, F. GHEZZI, F. MULTINU, A. MARIANI (Rochester, MN, USA; Varese, Italy)... Laparoendoscopic Single-site Surgery (LESS) for Prophylactic Salpingo-oophorectomy Improves Cosmetic Satisfaction Compared to Standard Laparoscopy. G. MIAILHE, S. DAUCHY, E. BENTIVEGNA, S. GOUY, C. CHARLES, S. DELALOGE, P. MORICE, C. UZAN (Villejuif; Boulogne, France)... Tumor Budding, EMT and Cancer Stem Cells in T1-2/N0 Oral Squamous Cell Carcinomas. C.G. ATTRAMADAL, S. KUMAR, M.E. BOYSEN, H.P. DHAKAL, J.M. NESLAND, M. BRYNE (Oslo, Norway)... Electrochemotherapy of a Multirecurrent Dermatofibrosarcoma Protuberans of the Orbital Margin: A Case Report. A. BONADIES, F. ELIA, F.M. SOLIVETTI, A. VIDIRI, L. MUSCARDIN, S. BUCHER (Rome, Italy)... Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations. E. KLIESER, R. ILLIG, S. STÄTTNER, F. PRIMAVESI, T. JÄGER, S. SWIERCZYNSKI, T. KIESSLICH, R. KEMMERLING, C. BOLLMANN, P. DI FAZIO, D. NEUREITER (Salzburg, Austria; Trier; Marburg, Germany)... Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml. M. SHIOTA, A. TAKEUCHI, M. SUGIMOTO, T. DEJIMA, E. KASHIWAGI, K. KIYOSHIMA, J. INOKUCHI, K. TATSUGAMI, A. YOKOMIZO (Fukuoka, Japan)... Long-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer. K.-H. HARALDSDÓTTIR, C. INGVAR, U. STENRAM, K.-G. TRANBERG (Lund, Sweden)... Gene Expression of Col11A1 Is a Marker Not Only for Pancreas Carcinoma But Also for Adenocarcinoma of the Papilla of Vater, Discriminating Between Carcinoma and Chronic Pancreatitis. R. KLEINERT, K. PRENZEL, N. STOECKLEIN, H. ALAKUS, E. BOLLSCHWEILER, A. HÖLSCHER, U. WARNECKE- EBERZ (Cologne; Düsseldorf, Germany)... Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus. M. KLAIRMONT, K. KOPKASH, J. FAVUZZA, M. HILL, R. RAO, B. MAHON, C.W. SEDER (Chicago, IL, USA)... Tumor-like Chronic Pancreatitis Is Often Autoimmune Pancreatitis. S. RÄTY, J. SAND, I. NORDBACK, I. RINTA- KIIKKA, K. VASAMA, J. HAGSTRÖM, S. NORDLING, J. SIRÉN, T. KIVILUOTO, C. HAGLUND (Tampere; Helsinki, Finland)

76 Translocation (1;5) in a Glomus Tumor. J. NISHIO, K. NABESHIMA, S. MORI, M. NAITO (Fukuoka, Japan)... Extraskeletal Myxoid Chondrosarcoma Presenting as a Plantar Fibroma: Case Report and Review of the Literature. M.G. LOCKYER, D.G. ROSEN (Houston, TX, USA)... Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients. M. YAMADA, H. IIHARA, H. FUJII, M. ISHIHARA, N. MATSUHASHI, T. TAKAHASHI, K. YOSHIDA, Y. ITOH (Gifu, Japan)... Risk Factors for Recurrence After Curative Conversion Surgery for Unresectable Gastric Cancer. M. FUKUCHI, T. ISHIGURO, K. OGATA, A. KIMURA, Y. KUMAGAI, K. ISHIBASHI, H. ISHIDA, H. KUWANO, E. MOCHIKI (Kawagoe; Maebashi, Japan)... Metastatic Spinal Cord Compression: A Survival Score Particularly Developed for Elderly Prostate Cancer Patients. D. RADES, A.J. CONDE-MORENO, J. CACICEDO, B. SEGEDIN, T. VENINGA, S.E. SCHILD (Lübeck, Germany; Castellón; Vizcaya, Spain; Ljubljana, Slovenia; Tilburg, the Netherlands; Scottsdale, AZ, USA)... Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. H. MATSUMOTO, H. OKUMURA, H. MURAKAMI, H. KUBOTA, M. HIGASHIDA, A. TSURUTA, K. TOHYAMA, T. HIRAI (Kurashiki City, Okayama, Japan)... Visualization of the Stomach s Arterial Networks During Esophageal Surgery Using the HyperEye Medical System. H. KITAGAWA, T. NAMIKAWA, M. MUNEKAGE, T. AKIMORI, M. KOBAYASHI, K. HANAZAKI (Nankoku; Sukumo, Kochi, Japan)... Number of Lymph Node Metastases May Indicate the Regimen for Adjuvant Chemotherapy in Patients with Stage III Colorectal Cancer. K. ANDO, E. OKI, H. SAEKI, Y. KASAGI, Y. TSUDA, Y. ZAITSU, Y. NAKASHIMA, Y. IMAMURA, K. OHGAKI, Y. MAEHARA (Fukuoka, Japan)... Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study. J. NOUJAIM, K. THWAY, R.L. JONES, A. MIAH, K. KHABRA, R. LANGER, B. KASPER, I. JUDSON, C. BENSON, A. KOLLÀR (London, UK; Bern, Switzerland; Mannheim, Germany)... A Tool to Estimate Survival of Elderly Patients Presenting with Metastatic Epidural Spinal Cord Compression (MESCC) from Cancer of Unknown Primary. D. RADES, A.J. CONDE-MORENO, R. GARCIA, T. VENINGA, S.E. SCHILD (Lübeck, Germany; Castellón, Spain; Tilburg, the Netherlands; Scottsdale, AZ, USA)... Methylation-associated Silencing of microrna-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. M. ANDERSEN, D. TRAPANI, J. RAVN, J.B. SØRENSEN, C. BØGELUND ANDERSEN, M. GRAUSLUND, E. SANTONI-RUGIU (Copenhagen, Denmark)... Postoperative External Irradiation of Patients with Primary Biliary Tract Cancer: A Multicenter Retrospective Study. K. HAYASHI, F. ISOHASHI, K. OGAWA, H. OIKAWA, H. ONISHI, Y. ITO, M. TAKEMOTO, K. KARASAWA, M. IMAI, Y. KOSAKA, H. YAMAZAKI, Y. YOSHIOKA, K. NEMOTO, Y. NISHIMURA and THE JAPANESE RADIATION ONCOLOGY STUDY GROUP (JROSG) (Osaka; Iwate; Yamanashi; Tokyo; Okayama; Shizuoka; Hyogo; Kyoto; Yamagata, Japan)... Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach. L. AGOLLI, M. VALERIANI, L. NICOSIA, S. BRACCI, V. DE SANCTIS, G. MINNITI, R.M. ENRICI, M.F. OSTI (Rome, Italy)... Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes. P. FRANCO, I. POTENZA, M. SCHENA, G. RIVA, G. PECORARI, P. GARZINO DEMO, M. FASOLIS, F. MORETTO, M. GARZARO, J. DI MUZIO, M. MELANO, M. AIROLDI, R. RAGONA, M. RAMPINO, U. RICARDI (Turin, Italy)

77 Platinum Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC. L. MICHELSEN, J.B. SØRENSEN (Copenhagen, Denmark)... Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease. D. FUJIMOTO, R. SHIMIZU, R. KATO, Y. SATO, M. KOGO, J. ITO, S. TERAOKA, T. OTOSHI, K. NAGATA, A. NAKAGAWA, K. OTSUKA, N. KATAKAMI, K. TOMII (Kobe, Japan)... MR Spectroscopic Profile of an Angiocentric Glioma. M.T. WHITEHEAD, G. VEZINA (Washington, DC, USA)... Development and Validation of a Novel Plasma Protein Signature for Breast Cancer Diagnosis by Using Multiple Reaction Monitoring-based Mass Spectrometry. H.-B. LEE, U.-B. KANG, H.-G. MOON, J. LEE, K.-M. LEE, M. YI, Y.S. PARK, J.W. LEE, J.-H. YU, S.H. CHOI, S.H. CHO, C. LEE, W. HAN, D.-Y. NOH (Seoul; Gyeonggi-do, Republic of Korea)... Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma. G.S. MAIER, K. HORAS, A.A. KURTH, D. LAZOVIC, J.B. SEEGER, U. MAUS (Oldenburg; Ratingen; Giessen, Germany; Sydney, NSW, Australia)... Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine. E. WIEDOWER, O. JAMY, M.G. MARTIN (Memphis, TN, USA)... Expression of p16/ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA. C. SOLARES, J. VELASCO, E. ÁLVAREZ-RUIZ, L. GONZÁLEZ-FERNÁNDEZ, A. ENCINAS, A. ASTUDILLO, J. SCHNEIDER (Avilés; Oviedo; Madrid, Spain)... Contribution of Interleukin-4 Genotypes to Lung Cancer Risk in Taiwan. W.-S. CHANG, S.-C. WANG, C.- L. CHUANG, H.-X. JI, C.-L. HSIAO, C.-M. HSU, C.-W. TSAI, S.-P. LIU, P.-C. HSU, Y.-L. LO, D.- T. BAU (Taichung; Taoyuan; Taipei, Taiwan, ROC)... Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma. I. KRAJSOVÁ, P. ARENBERGER, R. LAKOMÝ, E. KUBALA, I. BŘEZINOVÁ, A. POPRACH, M. ŠŤASTNÝ, J. MUŽÍK, B. MELICHAR (Prague; Brno; Hradec Králové; Ostrava; Olomouc, Czech Republic)... Dietetic and Psychological Mindfulness Workshops for the Management of Cachectic Cancer Patients. A Randomized Study. C. FOCAN, G. HOUBIERS, L. GILLES, T. VAN STEELAND, N. GEORGES, A. MANIGLIA, J.-P. LOBELLE, V. BARO, M.-P. GRAAS (Liège, Belgium)... Ureteral Metastasis: Uncommon Manifestation in Prostate Cancer. D. SCHALLIER, B. RAPPE, M. CARPRIEAUX, F. VANDENBROUCKE (Brussels; Aalst, Belgium)... Surgical Management of Duodenal Gastrointestinal Stromal Tumors: A Case Report. K. MRAK, B. LIEGL- ATZWANGER, J. HAYBAECK, W. PETRITSCH, H.-J. MISCHINGER, P. KORNPRAT (Graz, Austria)... Unresectable Middle Mediastinal Biphasic Pulmonary Blastoma. K. GALLO, A. BRICKMAN, W.H. WARREN, P. GATTUSO, C.W. SEDER (Chicago, IL, USA)... PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. P. LOHNEIS, S. DARB-ESFAHANI, M. DIETEL, I. BRAICU, J. SEHOULI, R. ARSENIC (Berlin, Germany)... Clinical Significance of Multinodularity in Patients with Papillary Thyroid Carcinoma. D. KUST, N. MATEŠA, Z. KUSIĆ (Zagreb, Croatia)

78 Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses. L. MANGANARO, E. ANASTASI, M.G. PORPORA, V. VINCI, M. SALDARI, S. BERNARDO, L. BALLESIO, P. SOLLAZZO, I. PECORELLA, N. RECCHIA, F. STRACCI, P.B. PANICI, A. ANGELONI, C. CATALANO, M. SCIALPI (Rome; Perugia, Italy)... Errata Number 12 Reviews Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J. PINILLA- IBARZ, K. SWEET, J. EMOLE, M. FRADLEY (Tampa, FL, USA)... Increased Production of Lysozyme Associated with Bacterial Proliferation in Barrett s Esophagitis, Chronic Gastritis, Gluten-induced Atrophic Duodenitis (Celiac Disease), Lymphocytic Colitis, Collagenous Colitis, Ulcerative Colitis and Crohn s Colitis. C.A. RUBIO (Stockholm, Sweden)... Curcumin for the Treatment of Glioblastoma. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown PA, USA)... Extracellular Vesicles as Biomarkers and Therapeutic Targets in Breast Cancer. L. SADOVSKA, J. EGLĪTIS, A. LINĒ (Riga, Latvia)... Innovative Therapeutic Strategies in the Treatment of Meningioma. G. CARUSO, S.K. ELBABAA, P. GONZALEZ-LOPEZ, V. BARRESI, M. PASSALACQUA, M. CAFFO (Messina, Italy; Saint Louis, MO, USA; Alicante, Spain) Experimental Studies Expression of PAX2 and PTEN Correlates to Therapy Response in Endometrial Hyperplasia. A. ØRBO, M. ARNES, L. MYRENG LYSÅ, B. STRAUME (Tromsø, Norway)... Enhanced Systemic Bioavailability of Curcumin Through Transmucosal Administration of a Novel Microgranular Formulation. B. LATIMER, O. EKSHYYAN, N. NATHAN, T. MOORE- MEDLIN, X. RONG, X. MA, A. KHANDELWAL, H.T. CHRISTY, F. ABREO, G. MCCLURE, J.A. VANCHIERE, G. CALDITO, T. DUGAS, K. MCMARTIN, T. LIAN, V. MEHTA, C.-A.O. NATHAN (Shreveport; Baton Rouge, LA, USA)... Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine. T. YEROKUN, L.L. WINFIELD (Atlanta, GA, USA)... Novel Nanoscale Delivery Particles Encapsulated with Anticancer Drugs, All-trans Retinoic Acid or Curcumin, Enhance Apoptosis in Lymphoma Cells Predominantly Expressing CD20 Antigen. R.G. STAUFFER, M. MOHAMMAD, A.T.K. SINGH (Kenosha, WI, USA)... Establishment of a Novel In Vitro Model for Predicting Incidence and Severity of Microtubule-targeting Agent-induced Peripheral Neuropathy. Y. SAWAGUCHI, S. UENO, Y. NISHIYΑMA, R. YAMAZAKI, T. MATSUZAKI (Tokyo, Japan)... Evidence of 18 F-FCH Uptake in Human T98G Glioblastoma Cells. F.E. BURONI, F. PASI, M.G. PERSICO, L. LODOLA, C. APRILE, R. NANO (Pavia, Italy)

79 Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors. C. HOLZMANN, D.N. MARKOWSKI, I. VON LEFFERN, T. LÖNING, J. BULLERDIEK (Rostock; Bremen; Hamburg, Germany)... Comparison of Methods to Identify Lymphatic and Blood Vessel Invasion and their Prognostic Value in Patients with Primary Operable Colorectal Cancer. H.C. VAN WYK, A.K. FOULIS, C.S. ROXBURGH, C. ORANGE, P.G. HORGAN, D.C. MCMILLAN (Glasgow, UK)... Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy. S. RAATIKAINEN, S. AAALTOMAA, V. KÄRJÄ, Y. SOINI (Kuopio, Finland)... Ferredoxin Reductase Is Useful for Predicting the Effect of Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma. H. OKUMURA, Y. UCHIKADO, I. OMOTO, M. MOTOMURA, Y. KITA, K. SASAKI, M. NODA, T. ARIGAMI, Y. UENOSONO, K. BABA, S. MORI, Y. KIJIMA, A. NAKAJO, H. KURAHARA, K. MAEMURA, M. SAKODA, T. OWAKI, S. ISHIGAMI, S. NATSUGOE (Kagoshima, Japan)... Down-regulation of HDGF Inhibits the Growth of Hepatocellular Carcinoma Cells In Vitro and In Vivo. H. ENOMOTO, H. NAKAMURA, W. LIU, Y. IWATA, H. NISHIKAWA, R. TAKATA, K. YOH, K. HASEGAWA, A. ISHII, T. TAKASHIMA, Y. SAKAI, N. AIZAWA, N. IKEDA, H. IIJIMA, S. NISHIGUCHI (Nishinomiya, Hyogo; Osaka, Japan; Guangdong, PR China)... A Biomimicking Tumor Tissue Model Using Hepatocellular Carcinoma Cell Sheet in a Collagen Sandwich System. Y. IWASE, M. NAKAYAMA, M. YAMATO, T. OKANO (Tokyo, Japan)... Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma. M.- W. POON, J.T.F. ZHUANG, S.T.S. WONG, S. SUN, X.- Q. ZHANG, G.K.K. LEUNG (Hong Kong, ROC)... Comparative Chemosensitivity of VX2 and HCC Cell Lines to Drugs Used in TACE. F. PASCALE, L. BEDOUET, M. BAYLATRY, J. NAMUR, A. LAURENT (Jouy-en-Josas; Paris, France)... Molecular Docking Analysis of Steroid-based Copper Transporter 1 Inhibitors. O. KADIOGLU, J. SERLY, E.-J. SEO, I. VINCZE, C. SOMLAI, M.E.M. SAEED, J. MOLNÁR, T. EFFERTH (Mainz, Germany; Szeged, Hungary)... Vascular Innervation in Benign Neurofibromas of Patients with Neurofibromatosis Type 1. R.E. FRIEDRICH, C.-A. BEHRENDT, M. GLATZEL, C. HAGEL (Hamburg, Germany)... Cytological and Immunocytological Monitoring of Oropharyngeal Dysplasia and Squamous Cell Carcinomas. M. ANDRATSCHKE, S. SCHMITZ, H. HAGEDORN, A. NERLICH (Munich; Lübeck, Germany)... Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane. O. FERICIAN, A.M. CIMPEAN, S. AVRAM, M. RAICA (Timisoara, Romania)... Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells. S.H. KIM, J.G. KANG, C.S. KIM, S.- H. IHM, M.G. CHOI, H.J. YOO, S.J. LEE (Chuncheon, Republic of Korea)... Tumour Progression and Spontaneous Regression in the Lewis Rat Sarcoma Model. J. KOVALSKÁ, R. MISHRA, L. JEBAVÝ, P. MAKOVICKÝ, J. JANDA, D. PLÁNSKÁ, M. ČERVINKOVÁ, V. HORÁK (Liběchov; Prague, Czech Republic)... Pattern of Melanotransferrin Expression in Human Colorectal Tissues: An Immunohistochemical Study on Potential Clinical Application. K. DUŚ-SZACHNIEWICZ, P. OSTASIEWICZ, M. WOŹNIAK, P. KOŁODZIEJ, J.R. WIŚNIEWSKI, P. ZIÓŁKOWSKI (Wrocław, Poland; Martinsried, Germany)

80 Phosphatidylinositol Derivatives Induce Gastric Cancer Cell Apoptosis by Accumulating AIF and AMID in the Nucleus. M. OHYAMA, A. TSUCHIYA, Y. KAKU, T. KANNO, T. SHIMIZU, A. TANAKA, T. NISHIZAKI (Nishinomiya; Kobe, Japan)... Bioluminescence Imaging of Adoptively Transferred Lymphocytes During Allogeneic Tumor Rejection. J. JURŠĖNAITĖ, I. GIRKONTAITĖ, M. MAURICAS, R. EIDUKEVIČIUS, A. ŠIAURYS, D. CHARACIEJUS (Vilnius, Lithuania)... Microarray Analysis of Gene Expression at the Tumor Front of Colon Cancer. T. KOBAYASHI, T. MASAKI, E. NOZAKI, M. SUGIYAMA, F. NAGASHIMA, J. FURUSE, H. ONISHI, T. WATANABE, Y. OHKURA (Tokyo, Japan)... Potentiation of Acute Promyelocytic Leukemia Cell Differentiation and Prevention of Leukemia Development in Mice by Oleanolic Acid. R.D.S. RAWENDRA, P.-Y. LIN, C.-D. CHANG, J.-L. HSU, T.-C. HUANG, W.- L. SHIH (Pingtung, Taiwan, ROC)... Clinical Significance of Expression of Nephroblastoma Overexpressed (NOV) in Patients with Colorectal Cancer. M. UEDA, T. IGUCHI, H. KOMATSU, S. KIDOGAMI, Q. HU, K. SATO, Y. OGAWA, S. NAMBARA, T. SAITO, S. SAKIMURA, H. HIRATA, R. UCHI, Y. SHINDEN, H. EGUCHI, S. ITO, T. MASUDA, H. YAMAMOTO, Y. DOKI, M. MORI, K. MIMORI (Beppu; Suita, Japan)... CD133 Expression in Lymph Node Metastases Is Associated with Tumor Aggressiveness During Lymph Node Metastasis in Colorectal Cancer. S. KAZAMA, J. KISHIKAWA, K. YASUDA, K. OTANI, T. NISHIKAWA, T. TANAKA, J. TANAKA, T. KIYOMATSU, K. KAWAI, K. HATA, H. NOZAWA, H. YAMAGUCHI, S. ISHIHARA, E. SUNAMI, T. WATANABE (Tokyo, Japan)... GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells. H. SAKAKI, M. OKADA, K. KURAMOTO, H. TAKEDA, H. WATARAI, S. SUZUKI, S. SEINO, M. SEINO, T. OHTA, S. NAGASE, H. KURACHI, C. KITANAKA (Yamagata; Osaka, Japan)... Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome in Acute Leukemia. M.-Y. YANG, P.-M. LIN, H.-H. HSIAO, J.-F. HSU, H.Y-H. LIN, C.-M HSU, I.-Y. CHEN, S.-W. SU, Y.-C. LIU, S.-F. LIN (Tao-Yuan; Kaohsiung, Taiwan, ROC)... 2-Deoxy-D-glucose Sensitizes Cancer Cells to Barasertib and Everolimus by ROS-independent Mechanism(s). Z. ZHELEV, D. IVANOVA, I. AOKI, T. SAGA, R. BAKALOVA (Stara Zagora; Sofia, Bulgaria; Chiba, Japan)... Molecular Pathogenesis of Human Papillomavirus Type 16 in Tonsillar Squamous Cell Carcinoma. S. HASSANI, A. CASTILLO, J.- I. OHORI, M. HIGASHI, Y. KURONO, S. AKIBA, C. KORIYAMA (Kagoshima, Japan; Cali, Colombia)... Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. V. PERRIER-TRUDOVA, B.W. HUIMIN, S. KONGPETCH, D. HUANG, P. ONG, A. LE FORMAL, S.L. POON, E.Y. SIEW, S.S. MYINT, S. GAD, B. GARDIE, S. COUVÉ, Y.M. FOONG, Y. CHOUDHURY, J. POH, C.K. ONG, C.K. TOH, A. OOI, S. RICHARD, M.- H. TAN, B.T. TEH (Villejuif; Nantes; Paris, France; Singapore, Republic of Singapore; Arizona, AZ, USA)... Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model. K. SCHMIDT, C. MOSER, C. HELLERBRAND, D. ZIEKER, C. WAGNER, J. REDEKOPF, H.J. SCHLITT, E.K. GEISSLER, S.A. LANG (Regensburg; Tuebingen, Germany)... HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. R. WATROWSKI, D.C. CASTILLO- TONG, A. WOLF, E. SCHUSTER, M.B. FISCHER, P. SPEISER, R. ZEILLINGER (Freiburg, Germany; Vienna, Austria)

81 Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines. K. MIZUTANI, M. TOMODA, Y. OHNO, H. HAYASHI, Y. FUJITA, K. KAWAKAMI, K. KAMEYAMA, T. KATO, T. SUGIYAMA, Y. ITOH, M. ITO, T. DEGUCHI (Gifu; Tokyo, Japan)... Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line. K. HAGIWARA, T. TOKUNAGA, H. IIDA, H. NAGAI (Nagoya, Japan)... Amentoflavone Induces Anti-angiogenic and Anti-metastatic Effects Through Suppression of NF-ĸB Activation in MCF-7 cells. J.-H. CHEN, W.-L. CHEN, Y.-C. LIU (Taipei; Yilan, Taiwan, ROC)... ABSTRACTS OF THE INTERNATIONAL CONFERENCE ON ADVANCES IN HEMATOLOGY AND ONCOLOGY, August, 2015 (Coeur d Alene, ID, USA)... Clinical Studies Multicenter Phase II Study of Nedaplatin and Irinotecan for Patients with Squamous Cell Carcinoma of the Lung: Thoracic Oncology Research Group K. YAMADA, H. SAITO, T. KONDO, S. MURAKAMI, N. MASUDA, M. YAMAMOTO, S. IGAWA, K. KATONO, Y. TAKIGUCHI, S. IWASAWA, R. KURIMOTO, H. OKAMOTO, T. SHIMOKAWA, Y. HOSOMI, Y. TAKAGI, K. KISHI, M. OHBA, F. OSHITA, K. WATANABE (Yokohama; Sagamihara; Chiba; Yokohama; Tokyo; Matsuda-machi; Kanagawa, Japan)... Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. S. BOUSSIOS, A. ATTYGALLE, S. HAZELL, M. MOSCHETTA, J. MCLACHLAN, A. OKINES, S. BANERJEE (London, UK)... Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study. C.B. TEMPFER, G.A. REZNICZEK, P. ENDE, W. SOLASS, M.-A. REYMOND (Bochum; Hannover, Germany)... High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma. Z.G. ZIMLING, E. SANTONI-RUGIU, C. BECH, J.B. SØRENSEN (Copenhagen, Denmark)... A Multidisciplinary Approach for Advanced Gastric Cancer with Paraaortic Lymph Node Metastasis. Y. FUJIWARA, T. OMORI, K. DEMURA, H. MIYATA, K. SUGIMURA, M. OHUE, S. KOBAYASHI, H. TAKAHASHI, Y. DOKI, M. YANO (Osaka, Japan)... Adequate Margins to Prevent Local Re-recurrence of Rectal Cancer: Viewpoint of Pathological Findings. K. KOMORI, K. KIMURA, T. KINOSHITA, S. ITO, T. ABE, Y. SENDA, K. MISAWA, Y. ITO, N. UEMURA, S. NATSUME, J. KAWAKAMI, Y. IWATA, M. TSUTSUYAMA, I. SHIGEYOSHI, T. AKAZAWA, D. HAYASHI, Y. SHIMIZU (Nagoya, Aichi, Japan)... Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β. V. BARAK, V. LEIBOVICI, T. PERETZ, I. KALICHMAN, M. LOTEM, S. MERIMS (Jerusalem, Israel)... Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer. S.A. THOMAS, N. TOMEH, S. THEARD (Suwanee, GA, USA)... Predictors of Gastric Neoplasia in Cases Negative for Helicobacter pylori Antibody and with Normal Pepsinogen. H. KISHIKAWA, K. KIMURA, A. ITO, K. ARAHATA, S. TAKARABE, S. KAIDA, J. MIYAUCHI, S. MIURA, J. NISHIDA (Chiba; Saitama, Japan)... Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts. L. ALBERTS, S.Y. EL SHAROUNI, F.N. HOFMAN, B.P. VAN PUTTE, E. TROMP, M. VAN VULPEN, E.A. KASTELIJN, F.M.N.H. SCHRAMEL (Nieuwegein; Utrecht, the Netherlands)

82 D-dimer Level Changes During Systemic Chemotherapy Can Predict Prognosis of High-grade Musculoskeletal Sarcoma Patients. T. MORII, T. TAJIMA, T. AOYAGI, S. ICHIMURA (Tokyo, Japan)... Detection of Bone Metastases Using 11 C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence. C. SPICK, S.H. POLANEC, M. MITTERHAUSER, W. WADSAK, P. ANNER, B. REITERITS, A.R. HAUG, M. HACKER, M. BEHESHTI, G. KARANIKAS (Vienna; Linz, Austria)... Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. L. DZIGGEL, M. DAHLKE, S. JANSSEN, D. HORNUNG, O. BLANCK, M.T. KHOA, S.E. SCHILD, D. RADES (Lübeck; Hannover; Hamburg; Güstrow, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA)... Cancer Incidence in Patients with Atypical Endometrial Hyperplasia Managed by Primary Hysterectomy or Fertility-sparing Treatment. C. GONTHIER, B. PIEL, C. TOUBOUL, F. WALKER, A. CORTEZ, D. LUTON, E. DARAÏ, M. KOSKAS (Paris, France)... Radiosurgery Using Tomotherapy for Patients with Brain Oligo-metastasis: A Retrospective Analysis on Feasibility and Tolerance. A. BRUNI, S. GAITO, A. CIARMATORI, B. LANFRANCHI, E. MAZZEO, N. MAFFEI, P. GIACOBAZZI, E. TURCO, G. GUIDI, F. BERTONI (Modena, Italy)... Ipsilateral Sphenoid Wing Dysplasia, Orbital Plexiform Neurofibroma and Fronto-Parietal Dermal Cylindroma in a Patient with Segmental Neurofibromatosis. R.E. FRIEDRICH, C. HAGEL, V.-F. MAUTNER (Hamburg, Germany)... Loss of ARID1A, ARID1B, and ARID2 Expression During Progression of Gastric Cancer. T. ASO, H. UOZAKI, S. MORITA, A. KUMAGAI, M. WATANABE (Tokyo, Japan)... Retrograde Jejunojejunal Intussusception After Gastrectomy: Report of Four Cases. S. YOSHIYA, T. NAKANOKO, T. KOGA, S. INOKUCHI, K. HIROSE, Y. HIRAYAMA, K. TAKETANI, R. YOSHIDA, R. MINAGAWA, M. KAI, K. KAJIYAMA, Y. MAEHARA (Iizuka; Higashiku, Fukuoka, Japan)... Comparison of Failure Patterns Between Conventional and Intensity-modulated Radiotherapy for Stage III and IV Head and Neck Squamous Cell Carcinoma. J.H. SONG, B.-K. JEONG, H.-S. CHOI, H. JEONG, M.H. KANG, J.H. KANG, J.P. KIM, J.J. PARK, S.H. WOO, H.S. JANG, B.O. CHOI, K.M. KANG (Jinju; Seoul, Republic of Korea)... Correlation Between Different ADC Fractions, Cell Count, Ki-67, Total Nucleic Areas and Average Nucleic Areas in Meningothelial Meningiomas. A. SUROV, H. CAYSA, A. WIENKE, R.P. SPIELMANN, E. FIEDLER (Halle, Germany)... Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer. F. RECCHIA, G. CANDELORO, M. ROSSELLI, M. BRATTA, V. PASTA, V. D ORAZI, L.A. FUMAGALLI, S. REA (Avezzano; Frascati; Rome; Aquila; Lecco, Italy)... Hepatic Resection for Hepatocellular Carcinoma in the Elderly: Selecting Hepatectomy Procedures Based on Patient Age. S. SATO, K. TANAKA, K. NOJIRI, T. KUMAMOTO, R. MORI, K. TANIGUCHI, R. MATSUYAMA, K. TAKEDA, M. UEDA, H. AKIYAMA, M. TAGURI, I. ENDO (Yokohama, Kanagawa; Ichihara, Chiba, Japan)... Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma. M. KOMATSU, Y. ARAI, K. YABUKI, D. SANO, O. SHIONO, Y. SAKUMA, G. NISHIMURA, M. TAKAHASHI, T. TAGUCHI, N. ORIDATE (Yokohama, Japan) Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study. R. CHEKEROV, G. KALTENECKER, D. REICHERT, T. GÖHLER, P. KLARE, G. OSKAY- 7076

83 ÖZCELIK, U. SAUER, A. WISCHNIK, U. VEHLING-KAISER, M. BECKER, U. HUTZSCHENREUTER, A. AMMON, E. HEIDRICH-LORSBACH, J. SEHOULI (Berlin; Karlsruhe; Westerstede; Dresden; Nordhorn; Augsburg; Landshut; Minden; Göttingen; Giessen, Germany)... The Role of Re-resection for Breast Cancer Liver Metastases-a Single Center Experience. N. BACALBASA, I. BALESCU, S. DIMA, I. POPESCU (Bucharest, Romania)... The Role of Percutaneous Biopsy and Prognostic Factors of Malignancy in Solitary Breast Papilloma: A Retrospective Multicenter Study of 259 Cases. M. LAVAL, R. DELANGLE, A. NDOYE, E. SYLVESTRE, B. LAVIOLLE, V. LAVOUE, J. LEVÊQUE (Rennes; Tours; Poitiers, France)... Undetermined Margins After Colonoscopic Polypectomy for Malignant Polyps: The Need for Radical Resection. E.-J. JUNG, C.-G. RYU, J.H. PAIK, D.-Y. HWANG (Seoul, Republic of Korea)... Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma. L. DECOSTER, I.V. BROEK, B. NEYNS, F. MAJOIS, J.F. BAURAIN, S. ROTTEY, A. RORIVE, E. ANCKAERT, J. DE MEY, S. DE BRAKELEER, J. DE GRÈVE (Brussels; Sint Niklaas; Haine Saint Paul; Gent; Liège, Belgium)... Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. M.J. ABRAMS, K.E. HUBER, J.P.S. KNISELY, B.W. CHANG, S.M. RUSSO, M.W. SAIF (Boston, MA; New York, NY; Torrance, CA; Cleveland, OH, USA)... One-stage Procedure for Concomitant Abdominal Aortic Aneurysm and Gastric Cancer. T. MATSUMOTO, D. MATSUDA, K. HONMA, Y. AOYAGI, J. OKADOME, K. MORISAKI, S. TANAKA, H. SAEKI, E. OKI, Y. MAEHARA (Fukuoka, Japan)... Long-term Survivors After Liver Resection for Breast Cancer Liver Metastases. N. BACALBASA, I. BALESCU, S. DIMA, I. POPESCU (Bucharest, Romania)... Long-term Survivors After Liver Resection for Ovarian Cancer Liver Metastases. N. BACALBASA, I. BALESCU, S. DIMA, I. POPESCU (Bucharest, Romania)... Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer. M. SHIOTA, A. TAKEUCHI, M. SUGIMOTO, E. KASHIWAGI, T. DEJIMA, K. KIYOSHIMA, J. INOKUCHI, K. TATSUGAMI, A. YOKOMIZO (Fukuoka, Japan)... Biochemical Effects of Levothyroxine Withdrawal in Patients with Differentiated Thyroid Cancer. G. PAPADAKIS, S. KALAITZIDOU, E. TRIANTAFILLOU, A. DROSOU, K. KAKAVA, N. DOGKAS, T. PAPPA, V. KALTZIDOU, A. TERTIPI, V. VILLIOTOU, A. PAPPAS (Athens, Greece)... Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study. L. MANSO, A.G. PALOMO, R.P. CARRIÓN, J. CASSINELLO, I.G. SANCHO, I.C. LÓPEZ-MUÑIZ, C. OLIER, A. FERNÁNDEZ- ARAMBURO, C. LLORCA, X. GONZÁLEZ, R. LLORENTE, D. TORREGROSA, I. ÁLVAREZ, E. GÁLVE, C. BUENO, I. GARAU, M.J. GARCÍA, S. GONZÁLEZ-SANTIAGO, A.I. BALLESTEROS, E. BLANCO, A. GALÁN, S. GONZÁLEZ, A. PERELLÓ, H. CORTÉS-FUNES, C. GRÁVALOS (Madrid; León; Guadalajara; Segovia; Toledo; Alicante; Valencia; Huesca; Palma de Mallorca; Ciudad Real; Cáceres; Badajoz; Barcelona, Spain)... Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer? F. FANFANI, A. FAGOTTI, A. ERCOLI, V. GALLOTTA, V. CHIANTERA, S. RESTAINO, G. MONTEROSSI, G. SCAMBIA (Rome; Terni; Padua; Campobasso; Trieste, Italy)... Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion. S. WATANABE, A. INOUE, T. NUKIWA, K. KOBAYASHI (Niigata; Sendai; Tokyo; Hidaka City, Saitama, Japan)

84 Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma. K. SHIRABE, K. SUGIMACHI, N. HARADA, H. KAYASHIMA, T. MAEDA, E. TSUJITA, R. MINAGAWA, K. KAJIYAMA, S. YOSHIYA, Y. MAEHARA (Fukuoka; Kitakyushu; Hiroshima; Iizuka, Japan)... Investigation of Potentially Deleterious Alleles for Response to Cancer Treatment with 5-Fluorouracil. G.C. CAVALCANTE, N.D.S.D.C. FREITAS, A.M. RIBEIRO-DOS-SANTOS, D.C. DE CARVALHO, E.M. DA SILVA, P.P. DE ASSUMPÇÃO, Â. RIBEIRO- DOS- SANTOS, S. SANTOS, N.P.C. DOS SANTOS (Belém, PA, Brazil)... Diagnostic Value of Circulating CXC Chemokines in Non- small Cell Lung Cancer. A. SPAKS, I. JAUNALKSNE, I. SPAKA, D. CHUDASAMA, A. PIRTNIEKS, D. KRIEVINS (Middlesex; Cardiff, UK; Riga, Latvia)... Prognostic Value of FDG-PET/CT Total Lesion Glycolysis for Patients with Resectable Distal Bile Duct Adenocarcinoma. E.J. LEE, S.-H. CHANG, T.Y. LEE, S.Y. YOON, Y.K. CHEON, C.S. SHIM, Y. SO, H.W. CHUNG (Seoul, Republic of Korea)... Errata... Index

85 Subject Index (Figures refer to page numbers) 1, 25-hydroxyvitamin D, 25-dihydroxyvitamin D, parathyroid hormone, daily vitamin D intake, benign soft tissue tumor, sarcoma, , vitamin D insuffiency, genome-wide research, vitamin D receptor, 25(OH)2D3, ChIP-seq, review, In-pentetreotide, pulmonary carcinoid, NET, somatostatin receptors, scintigraphy, SPECT, q amplicon, lipoma, well-differentiated liposarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, multiplex ligation-dependent probe amplification, MAT-B-III, animal model, metastasis, liver, transarterial embolization, AAG, anaplastic thyroid carcinoma, herbimycin A, HSP90, β-catenin, AKT, FRO cells, Re-DXR-IL-C225, immunoliposomes, cytotoxicity, theranostic vehicle, F-fluorodeoxyglucose, hepatocellular carcinoma, positron emission tomography, PET/CT, FDG-PET/CT, radical surgery, breast cancer, N3, supraclavicular, neoadjuvant chemotherapy, F-FDG PET/CT, total lesion glycolysis, TLG, colorectal cancer, prognostic value, F-FDG-PET/CT, febrile neutropenia, invasive aspergillosis, haematological malignancies, F-FDG-PET/CT, head and neck cancer, overall survival, SUVmax, inhibition index cisplatin, F-fluorocholine, glioma, T98G human cells, 18 F-fluorodeoxyglucose, radiation injury, F-fluorodeoxyglucose, glioma, T98G human cells, 18 F-fluorocholine, radiation injury, , cannabinoids, WIN55, breast, cancer, micelle(s), nanoparticle(s), nano-micelle, (OH)2D3, vitamin D insufficiency, genome-wide research, vitamin D receptor, 1, ChIP-seq, review, (OH)D, vitamin D, preventive medicine, cancer, epidemiology, review, dihydroxyvitamin D, 25-hydroxyvitamin D, 1, parathyroid hormone, daily vitamin D intake, benign soft tissue tumor, sarcoma, hydroxyvitamin D, 1, 25-dihydroxyvitamin D, parathyroid hormone, daily vitamin D intake, benign soft tissue tumor, sarcoma, hydroxyvitamin D, breast cancer, triple-negative breast cancer, vitamin D, CYP24A1, CYP27B1, vitamin D receptor, deoxy-D-glucose, anticancer drugs, reactive oxygen species, apoptosis, synergism, deoxyglucose, bladder cancer cells, glycolysis, growth, PFKFB3 inhibitor, butyrate, dichloroacetate, phenformin, proPSA, PSA, PHI, prostate cancer, biopsy, arylcoumarin derivatives, cytotoxic effect, cell cycle phase, mitochondrial transmembrane potential, reactive oxygen species production, 653 3D conformal radiotherapy, hypofractionated, prostate cancer, toxicity, dimensional floating culture, KRAS, colorectal cancer, drug screening, hydroxypyridine, ovarian cancer, imidazole, DNA fragmentation, drug resistance, drug combination, indolylmethanamine, ovarian cancer, leukemia, p-arm, MicroRNA, 5p-arm, bioinformatics, gastric cancer, phosphoinositide-dependent protein kinase 1, serous carcinoma of the ovary, immunohistochemistry, intracellular signaling, styryl-2H-chromenes, QSAR analysis, cytotoxicity, tumor selectivity, anti-hiv activity, β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin, AMANTADIG, cardenolide analog, human leukemia cells, human urological cancer cells, porcine cerebral cortex Na + /K + -ATPase, BB, cancer immunotherapy, PD-1, immune checkpoint, methylumbelliferone, hyaluronan, glucose, proliferation, breast carcinoma cell, methylumbelliferone, K562 cells, apoptosis, ROS, BCL2 family, mitochondria, BP1, boron neutron capture therapy, neutron, p53, apoptosis, BP1, olaparib, BEZ235, BRCA1, breast cancer, azacytidine, myelodysplastic syndrome, acute myeloid leukemia, fluorouracil, chemotherapy toxicity, deleterious alleles, DPYD, OPRT, TYMS, TP53, fluorouracil, dihydropyrimidine dehydrogenase, DPD, DPYD deficiency, cancer, capecitabine, fluorouracil, nasopharyngeal carcinoma, chemoradiotherapy, docetaxel, cisplatin, FU resistance, TAS-102, irinotecan hydrochloride, colorectal cancer, gastric cancer, FU resistance, TAS-102, oxaliplatin, colorectal cancer, gastric cancer, FU, adjuvant chemotherapy, colon cancer, elderly patients, FU, hand-foot syndrome, cytidine, uridine, thymidine, deoxycytidine, keratinocytes, FU, MDSC, lung metastasis, tumor immunity, primary resection, FU-based chemotherapy, concentration of 5-FU, My5- FU immunoassay, FOLFIRI, FOLFOX, p-arm, MicroRNA, 3p-arm, bioinformatics, gastric cancer,

86 5-year survival, prostate, prostate cancer, neuroendocrine prostate cancer, androgen deprivation therapy, incidence, mortality, aminoacridine derivatives, non-small cell lung cancer, human topoisomerase II, 5211 A375 cells, clotrimazole, melanoma, apoptosis, cell cycle, hexokinase, 3781 ABC method, gastric cancer, pepsinogen, Helicobacter pylori, screening, 6765 ABCB1 transporter, steroids, multidrug resistance, mouse T- lymphoma, PC-3 prostate cancer cell line, 2105 ABCB1, multidrug resistance, phosphorus ylide, trifluoroacetyl, P-glycoprotein, mouse T-lymphoma, 5915 Abdominal aortic aneurysm, gastric cancer, one-stage procedure, endovascular abdominal aortic aneurysm repair, 6909 Abiraterone acetate, prostate cancer, ureteral metastasis, 6317 Abiraterone, castrate-resistant, elderly, prostate cancer, PSA, 3097 Abiraterone, metastatic prostate cancer, CRPC, predictive algorithm, 1057 Abiraterone, metastatic, castrate-resistant, prostate cancer, predictors response, drug sequencing, 5615 Ablative, circulating tumor cells, radiofrequency ablation, ScreenCell, 2823 Acelate, bone metastases, PET, prostate cancer, 6787 Acetic acid bacteria, lipopolysaccharide, oral administration of LPS, anti-allergy, macrophages, 4507 Acetylasation, HDAC, histone, inhibitors, epigenetics, pancreatic cancer, review, 3129 Acneiform rash, minocycline, skin care, panitumumab, colorectal cancer, tumor response, time to treatment failure, 6175 Acquired resistance, central nervous system, epidermal growth factor receptor-tyrosine kinase inhibitor, T790M, leptomeningeal metastases, brain metastases, 1025 Actin assembly, SKAP2, lung cancer, Src, 2411 Actinin-4, small-cell lung cancer, transbronchial biopsy, biomarker, prognosis, 1663 Activated macrophages, dimethylsulfoniopropionate, betaine, Ehrlich ascites carcinoma, methylation reaction, 1475 Acute exacerbation, bevacizumab, interstitial lung disease, non-small cell lung cancer, 4259 Acute exacerbation, cisplatin, interstitial pneumonia, nonsmall cell lung cancer, vinorelbine, 1697 Acute lymphoblastic leukemia, ex vivo drug resistance, individualized tumor response testing, children, relapse, minimal residual disease, 5667 Acute lymphoblastic leukemia, unfolded protein response, tumor hypoxia, WNT growth factors, ER-associated degradation, 4625 Acute lymphoid leukemia, circadian clock genes, acute myeloid leukemia, 6615 Acute myeloid leukemia, 5-azacytidine, myelodysplastic syndrome, 5141 Acute myeloid leukemia, circadian clock genes, acute lymphoid leukemia, 6615 Acute myeloid leukemia, induction, cladribine, idarubicin, 6287 Acute myeloid leukemia, TNFR1, TRAILR, FAS, death receptors, 4043 Acute promyelocytic leukemia, all-trans retinoic acid, differentiation, oleanolic acid, WEHI-3, 6583 ADC, meningioma, tumor cellularity, Ki-67, nucleic area, 6841 Adducin 3, co-expression, cytoskeletal protein, cancer stem cell marker, CD133, neurospheres, temozolomide-resistant subclone, glioblastoma, NANOG, 6487 Adenocarcinoma in situ, cervical cancer, atypical glandular cells, Pap smear, clinical population study, 913 Adenocarcinoma, squamous cell carcinoma, esophagus, PDGFR-α, CD117, immunohistochemistry, 3793 Adenocarcinoma, yes-associated protein, β-catenin, carcinogenesis, signet-ring cell carcinoma, gastric neoplasia, 3925 Adenoid cystic carcinoma, microrna, head and neck squamous cell carcinoma, HPV, 1271 Adenoma, gallbladder, serrated, case report, 3485 Adenoma carcinoma sequence, colon cancer, glycosylation, lectins, malignant progression, metastasis, 5333 Adenoma carcinoma sequence, melanotransferrin, colorectal carcinoma, poorly differentiated adenocarcinoma, pathogenesis, tumorigenesis, 6551 Adenomas, duodenum adenomas, β-catenin, cytoplasmic helices, 1433 Adherence, adverse effects, BCR-ABL1, chronic myeloid leukemia, medication, therapy management, review, 6355 Adhesion, hepatocellular carcinoma, Ras suppressor-1, invasion, 1509 Adipose tissue-derived mesenchymal stem cells (AT-MSCs), melanoma, growth inhibition, cytotherapy, 159 Adjuvant chemotherapy, cervical cancer, concomitant chemoradiotherapy, ifosfamide, cisplatin, 4161 Adjuvant chemotherapy, colon cancer, elderly patients, 5- FU, 5587 Adjuvant chemotherapy, colorectal cancer, numbers of metastatic lymph nodes, 6207 Adjuvant chemotherapy, colorectal cancer, oxaliplatin, recurrence, tumor size, 5073 Adjuvant chemotherapy, gastric cancer, outpatient setting, S- 1, cisplatin, 467 Adjuvant chemotherapy, gastric cancer, stage IB, 4091 Adjuvant chemotherapy, prognostic/predictive factors, qrt- PCR, anti-vegf therapy, angiogenesis, 4023 Adjuvant chemotherapy, thyroid cancer, HIF1α inhibitor, orthotopic mouse model, molecular targeted therapy, echinomycin,

87 Adjuvant ovarian suppression, immunotherapy, premenopausal, breast cancer, 6847 Adjuvant ovarian suppresion, immunotherapy, premenopausal, breast cancer, 6847 Adjuvant surgery, gastric cancer, non-curative clinical factor, peritoneal dissemination, 401 Adjuvant therapy, chemotherapy, pancreatic neoplasms, 6901 Adjuvant therapy, lateral pelvic lymph node dissection, mesorectal excision, oxaliplatin, rectal cancer, 1815 Adjuvant, pancreatic cancer, aged, pooled analysis, radiotherapy, chemotherapy, multicenter study, 3441 Adoptive transfer, murine tumor model, T lymphocytes, bioluminescence imaging, 6573 Adrenocortical carcinoma, lymph node dissection, prognosis, prevalence, 5575 Adrenocortical carcinoma, retroperitoneal giant tumor, nonsecretory tumor, multi-visceral resection, 2169 Adriamycin, induction chemotherapy, metastatic esophageal cancer, cisplatin, fluorouracil, combination chemotherapy, 2975 Advanced colorectal cancer, bevacizumab, older patients, Italian study, 2391 Advanced gastric cancer, second-line, chemotherapy, molecular targeted therapy, review, 4575 Advanced glycation end-products (AGEs), CTLA4, CD28, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), protein carbonyl (PCO), superoxide dismutase, copper, zinc, 5391 Advanced HCC, VEGF, intra-arterial chemotherapy, liver cirrhosis, 2205 Advanced ovarian cancer, biopsy, neoadjuvant chemotherapy, interval debulking surgery, IDs, incomplete cytoreduction, 2315 Advanced ovarian cancer, node ratio, lymphadenectomy, prognosis, residual tumor, node metastases, 3479 Advanced oxidation protein products (AOPP), CTLA4, CD28, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), protein carbonyl (PCO), superoxide dismutase, advanced glycation end-products (AGEs), copper, zinc, 5391 Advanced stage, hypofractionated radiotherapy, non-small cell lung cancer, unresectable, image-guidance, 5693 Advanced-stage endometrial cancer, extended-field externalbeam radiotherapy, intensity-modulated radiotherapy, 2893 Advanced-stage epithelial ovarian cancer, parenchymatous metastasis, peritoneal, splenic metastasis, overall survival, 5649 Advanced-stage ovarian cancer, recurrence, cytoreductive surgery, pancreatic resection, 4125 Adverse effects, adherence, BCR-ABL1, chronic myeloid leukemia, medication, therapy management, review, 6355 Adverse effects, ovarian cancer, quality of life, antineoplastic agents, intraperitoneal chemotherapy, peritoneal carcinomatosis, octogenarian, high pressure, 2309 Adverse events, regorafenib, metastatic colorectal cancer, chemotherapy, 371 Aerosol delivery, lung cancer, gene therapy, sorbitol diacrylate, PDCD4, shakt1, 2015 Aerosol, peritoneal metastasis, ovarian cancer, cisplatin, doxorubicin, intraperitoneal chemotherapy, pressure, quality of life, 6723 Afatinib, non-small cell lung cancer, epidermal growth factor receptor gene mutation, exon 19 deletion, exon 21 L858R, 2005 African American, prostate cancer, Gleason, BPH, SPINK1, SNPs, 3811 African Americans, prostate cancer, single nucleotide polymorphism, CRYBB2, genetic association, 2565 African-American, SNP, prostate cancer, vitamin D receptor, clinical phenotype, 1549 AFX diagnosis, atypical fibroxanthoma, AFX tumor markers, immunohistochemistry, AFX therapy, review, 5717 AFX therapy, atypical fibroxanthoma, AFX diagnosis, AFX tumor markers, immunohistochemistry, review, 5717 AFX tumor markers, atypical fibroxanthoma, AFX diagnosis, immunohistochemistry, AFX therapy, review, 5717 Aged, pancreatic cancer, adjuvant, pooled analysis, radiotherapy, chemotherapy, multicenter study, 3441 AGO-score, secondary cytoredustive surgery, ovarian cancer, 3423 AHCC, HSF1, HMGB1, HSP27, pancreatic cancer, gemcitabine, 6063 AIF, phosphatidylinositol derivative, enantiomer, caspaseindependent apoptosis, AMID, 6563 AJCC TNM clinical staging system, primary ocular adnexal MALT lymphoma, radiotherapy, 3591 AKT inhibitor, gemcitabine, pancreatic cancer, 4599 AKT, anaplastic thyroid carcinoma, 17-AAG, herbimycin A, HSP90, β-catenin, FRO cells, 5453 AKT, anaplastic thyroid carcinoma, apigenin, TRAIL, Bcl2, 6529 AKT, head neck, radiotherapy, chemotherapy, 269 AKT, MCP1, epithelial mesenchymal transition, head and neck cancer, 3299 Akt, oesophageal cancer, PHLDA3, prognostic factor, 949 AKT, renal cell carcinoma, docetaxel, cabazitaxel, p- glycoprotein, Caki-1, KMRC-1, OS-RC-2, 6671 AKT, survivin, VEGF, microvessel density, oral melanoma, prognostic factor, 2113 AKT/mTOR, CK2, chemorefractory, lung cancer, 1537 Albumin, lymphocyte, gastric cancer, peritoneal metastasis,

88 Albumin, plasma protein binding, oxidation, cancer, osteosarcoma, rat, 2063 Alcohol consumption, gastric cancer, genotype, polymorphism, smoking, XPD, 4975 Alcohol drinking, genotype, hepatocellular carcinoma, polymorphism, smoking, TNFα, 5417 ALDH1, renal transitional cell carcinoma, survival, cancer stem cell, 4829 Alendronate, synergy, simvastatin, prostate cancer, 1851 ALK inhibitor, non-small cell lung cancer, ALK translocation, KRAS, STK11, ATM, crizotinib resistance, genomics, next-generation sequencing, case report, 3007 ALK translocation, non-small cell lung cancer, ALK inhibitor, KRAS, STK11, ATM, crizotinib resistance, genomics, next-generation sequencing, case report, 3007 ALK-EML4 translocation, pulmonary blastoma, neoadjuvant treatment, EGFR mutation, PD-L1 expression, chemo - radiotherapy, pembrolizumab, 4871 All-trans retinoic acid, acute promyelocytic leukemia, differentiation, oleanolic acid, WEHI-3, 6583 All-trans retinoic acid, nanodisks, lymphoma, curcumin, apoptosis, 6425 Aloe vera, neuroblastoma, proliferation, 4477 Alpha-fetoprotein (AFP), hepatocellular carcinoma (HCC), Lens culinaris agglutinin-reactive fraction of AFP (AFP- L3), des-γ-carboxyprothrombin (DCP), tumor marker, 2157 Alpha-fetoprotein, hepatocellular carcinoma, biomarkers, gene expression analysis, osteopontin, glypican 3, 2021 Altered lengthening of telomeres, telomere shortening, TERC, telomerase, in situ, hybridization, DAXX, ATRX, immunohistochemistry, 3501 Alternative splicing, kallikrein-related peptidases, gene expression, Canis familiaris, mammary cancer, 2715 AMANTADIG, 3β-[2-(1-Amantadine)-1-on-ethylamine]- digitoxigenin, cardenolide analog, human leukemia cells, human urological cancer cells, porcine cerebral cortex Na + /K + -ATPase, 5271 Ambulatory surgery, laparoendoscopic single-site surgery, prophylactic bilateral salpingo-oophorectomy, BRCA mutation, cosmetic satisfaction, 6105 Amelanotic, breast cancer, melanoma, malignant, melanotic, 1709 Amentoflavone, anti-angiogenesis, anti-metastasis, NF-ĸB, 6685 AMID, phosphatidylinositol derivative, enantiomer, caspaseindependent apoptosis, AIF, 6563 Amifostine, radiation, mouse, apoptosis, 2817 Amphiregulin, hepatocyte growth factor, transforming growth factor-α, epidermal growth factor receptor, cetuximab, colorectal cancer, 1683 Anaesthetic technique, breast cancer immune cell infiltration, randomised grial, 1311 Anal cancer, second primary malignancy, SEER, latency, 4131 Analytical anisotropic algorithm, breast radiotherapy, dose calculation algorithm, pencil beam convolution, planning guidelines, 2841 Anaplastic lymphoma kinase, non-small cell lung cancer, epidermal growth factor receptor, chemosensitivity, 1791 Anaplastic oligoastrocytoma, anaplastic oligodendroglial tumor, anaplastic oligodendroglioma, chemotherapy, PCV, 5467 Anaplastic oligodendroglial tumor, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, chemotherapy, PCV, 5467 Anaplastic oligodendroglioma, anaplastic oligodendroglial tumor, anaplastic oligoastrocytoma, chemotherapy, PCV, 5467 Anaplastic thyroid carcinoma, 17-AAG, herbimycin A, HSP90, β-catenin, AKT, FRO cells, 5453 Anaplastic thyroid carcinoma, apigenin, TRAIL, AKT, Bcl2, 6529 Anaplastic thyroid carcinoma, poorly differentiated thyroid carcinoma, genetics, next-generation sequencing, 2029 Ancestry, XRCC1, MTHFR, EGFR, cancer, population stratification, 2009 Anchorage-independent growth, biliary tract cancer, EZH2, PRC2, DZNep, cancer stem cells, 4697 Anchorage-independent growth, mirna, melanospheres, melanoma, 2747 Androgen deprivation therapy, prostate, prostate cancer, neuroendocrine prostate cancer, incidence, 5-year survival, mortality, 4145 Androgen deprivation treatment (ADT), castration-resistant prostate cancer (CRPC), PCA 3, prognostic factor, docetaxel, 3075 Androgen receptor, breast tumors, histological grading, SUV, estrogen receptor, progesterone receptor, Ki67, BCL2, p53, 569 Androgen-deprivation therapy, metastatic prostate cancer, obesity, prostate-specific antigen, testosterone, 6925 Anemia, leucocytosis, prognosis, renal cell carcinoma, thrombocytosis, 3463 ANG2, small molecule FGFR1 inhibitor, NVP-BGJ398, caspases, PDCD4, 5873 Anginex, tumor angiogenesis, galectin-1, cancer, indium- 111, 5945 Angiocentric, glioma, MRI, spectroscopy, 6267 Angiogenesis molecules, sex steroid receptors, cell cycle regulators, IPMN, image analysis, 1049 Angiogenesis, anti-angiogenic therapy, ZD6474, contrast enhanced ultrasound, vessel density, tumor microcirculation, imaging, 2571 Angiogenesis, Artemisia annua, artemisinin, cancer, molecu - lar docking, quantitative structure-activity relationship calcula tions, QSAR, vascular endothelial growth factor receptor,

89 Angiogenesis, bortezomib, immunomodulatory drugs, plasma cell myeloma, vascular endothelial growth factor, 1085 Angiogenesis, CD155, prognostic factor, pancreatic cancer, tumor immunity, 2287 Angiogenesis, cyclin I, CCNI, kinase insert domain receptor, KDR, ovarian cancer, chemotherapy, 1115 Angiogenesis, FGFR, gastric cancer, 6655 Angiogenesis, hepatoma-derived growth factor, hepatocellular carcinoma, targeted therapy, xenograft model, VEGF, 6475 Angiogenesis, immunotherapy, invasion, metastasis, signalling systems, thalidomide analogues, review, 5767 Angiogenesis, MCF-7, breast cancer, lymphangiogenesis, mesenchymal stem cells, review, 3147 Angiogenesis, non-small cell lung cancer, pleural fluid, serum, VEGF, 1129 Angiogenesis, pleomorphic carcinoma, immun - ohistochemistry, vascular endothelial growth factor, hypoxia-inducible factor-1α, 389 Angiogenesis, prognostic/predictive factors, qrt-pcr, adjuvant chemotherapy, anti-vegf therapy, 4023 Angiogenesis, resveratrol, protein kinase G (PKG), HUVECs, Inhibitor of Apoptosis Proteins (IAPs), 273 Angiogenesis, sandalwood, santalol, cancer, apoptosis, cell cycle, carcinogenesis, review, 3137 Angioimmunoblastic T-cell lymphoma, lymphadenitis with T-zone hyperplasia, microrna, 2055 Angiopoietin-like protein 2, ANGPTL2, immunohistochemistry, gastric cancer, 4633 Angiotensin II, lung cancer, cancer stem cells, spheroid, 4789 ANGPTL2, angiopoietin-like protein 2, immunohistochemistry, gastric cancer, 4633 ANGPTL2, C-reactive protein, CEA, lymph node metastasis, colorectal cancer, 2849 Animal experiment, drug delivery systems, intraperitoneal chemotherapy, peritoneal carcinomatosis, review, 627 Animal model, MAT-B-III, metastasis, liver, transarterial embolization, 1333 Animal models, cytokines, colitis-associated cancer, carcinogenesis, review, 19 Anoikis, lung cancer, pro-survival pathway, lupalbigenin, Derris scandens, 2827 ANRIL, cell cycle, CDK inhibitor, p16, transcription, polycomb, MLL, review, 4395 ANRIL, long noncoding RNA, p15, p16, cell cycle, 5377 ANRIL, PLD inhibitor, LncRNA, H460 cells, lung cancer, 2795 Anthra cycline resistance, breast cancer risk, p53 codon72 polymorphism, 1763 Anthracycline, fosaprepitant, cisplatin, infusion site adverse events, 379 Anthracyclines, chemotherapy, left ventricular systolic dysfunction, metastatic breast cancer, risk factors, 989 Anthracyline, trastuzumab, sequence, cardiotoxicity, 857 Anti-allergy, lipopolysaccharide, acetic acid bacteria, oral administration of LPS, macrophages, 4507 Anti-allergy, lipopolysaccharide, rice retaining subaleurone layer, innate immunity, macrophage, 4465 Anti-angiogenesis, amentoflavone, anti-metastasis, NF-ĸB, 6685 Anti-angiogenesis, SN-38, cetuximab, irinotecan, antiinvasion, colon cancer, 5983 Anti-angiogenic therapy, chemoembolization, vascular heterogeneity, ceramics, microsphere, drug delivery system (DDS), TNP-470, uterine sarcoma, carcinosarcoma, 4757 Antiangiogenic therapy, placental growth factor (PlGF), renal cell carcinoma, sunitinib resistance, 531 Anti-angiogenic therapy, uterine carcinosarcoma, azaspirene, 2739 Anti-angiogenic therapy, ZD6474, contrast enhanced ultrasound, vessel density, tumor microcirculation, angiogenesis, imaging, 2571 Anti-angiogenic, HIF1Α, CAIX, VEGF, MCF-7 cells, MDA- MB-231 cells, xenografts, microtubule disruptor, 5249 Anti-apoptosis, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deep-sequencing, cancer stem cells, CSCs, cancer cell proliferation, stemness, western blotting, RT-PCR, immunocytochemistry, 3743 Antibodies, glucan, melanoma, NK cells, immunity, cancer, 5287 Antibody cross-reactivity, prostate cancer, PSMA, molecular marker, diagnosis, dog, 145 Antibody, CAIX, carbonic anhydrase, antibody-dependent cellular cytotoxicity, kidney cancer, 1997 Antibody-dependent cellular cytotoxicity, CAIX, carbonic anhydrase, antibody, kidney cancer, 1997 Anticancer agent, oncology, clinical pharmacy services, drug-related problem, inpatient setting, 457 Anticancer drug combinations, lung cancer, drug resistance, c-met inhibitor, TAS-115, 5241 Anticancer drugs, 2-deoxy-D-glucose, reactive oxygen species, apoptosis, synergism, 6623 Anticancer peptides, temporin, cytotoxicity, cancer, review, 635 Anticancer treatment, oxidative stress, ruthenium complexes, 3371 Anti-HIV activity, 3-styryl-2H-chromenes, QSAR analysis, cytotoxicity, tumor selectivity, 5299 Anti-HIV activity, oleoylamides, QSAR analysis, cytotoxicity, tumor selectivity, 5341 Anti-invasion, SN-38, cetuximab, irinotecan, antiangiogenesis, colon cancer,

90 Anti-MCP1, MCP1, HNSCC, FLAVINO assay, ex-vivo chemoresponse, 3917 Anti-metastasis, amentoflavone, anti-angiogenesis, NF-ĸB, 6685 Antineoplastic agents, ovarian cancer, quality of life, adverse effects, intraperitoneal chemotherapy, peritoneal carcinomatosis, octogenarian, high pressure, 2309 Antioxidants, MnSOD, GPX1, oxidative stress, colorectal cancer, 255 Antiproliferative action, prostate cancer, Fagara xanthoxyloides, Pseudocedrela kotschyi, 1453 Anti-proliferative activity, curcumin-based compounds, cytotoxicity, apoptosis, cancer, 5293 Antiproliferative activity, furochalcones, HL60 cells, structure and activity relationship, 811 Anti-proliferative, petasin, apoptosis, prostate cancer, 191 Antitumor immunotherapy, tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), dendritic cells (DCs), Poly(I:C), Toll-like receptor 3, TICAM-1, review, 4383 Anti-VEGF therapy, prognostic/predictive factors, qrt-pcr, adjuvant chemotherapy, angiogenesis, 4023 Antiviral therapy, hepatitis B virus, hepatocellular carcinoma, nucleotide/nucleoside analog, propensity scorematching, 1647 Anxiety, radiotherapy, quality of life, 1771 Apigenin, anaplastic thyroid carcinoma, TRAIL, AKT, Bcl2, 6529 Apolipoprotein B mrna editing enzyme, hepatocellular carcinoma (HCC), catalytic polypeptide-like 3B (APOBEC3B), vascular invasion, Hep 3B, 1521 Apoptosis, 4-methylumbelliferone, K562 cells, ROS, BCL2 family, mitochondria, 5231 Apoptosis, amifostine, radiation, mouse, 2817 Apoptosis, anticancer drugs, 2-deoxy-D-glucose, reactive oxygen species, synergism, 6623 Apoptosis, ascidian, Eudistoma viride, cytotoxicity, HeLa, DNA fragmentation, flow cytometry, 283 Apoptosis, AZD5363, salinomycin, cancer, 4741 Apoptosis, BAX/BAK, bichalcone analog, CD95, FADD, human colon carcinoma HT-29 cells, 5407 Apoptosis, boron neutron capture therapy, neutron, p53, 53BP1, 169 Apoptosis, breast cancer, estrogen receptor (ER), HER2, EGFR, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, proliferation, 1243 Apoptosis, breast cancer, tannic acid, tissue engineering, 1285 Apoptosis, CHM-1, GRP78, nasopharyngeal carcinoma, p85α, 5359 Apoptosis, clotrimazole, melanoma, A375 cells, cell cycle, hexokinase, 3781 Apoptosis, curcumin, HP102, Jurkat T-cells, IL2, proliferation, 2675 Apoptosis, curcumin-based compounds, cytotoxicity, antiproliferative activity, cancer, 5293 Apoptosis, cytotoxicity, formamidine anthracy clines, necrosis, 1935 Apoptosis, EGF, EGFR-overexpressing cancer cell line, PI3K/AKT/mTOR signaling pathway, radiosensitization, 245 Apoptosis, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, nonspecific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Apoptosis, GFP, histone H2B, fusion gene, RFP, imaging, paclitaxel, vinblastine, nuclear fragmentation, DNA fragmentation, real-time, imaging, 2539 Apoptosis, HOCl, superoxide anion, NOX1, DUOX, hydroxyl radical, 5927 Apoptosis, mantle cell lymphoma, bendamustine, BCR signaling, BTK inhibitor, 6679 Apoptosis, medullary thyroid carcinoma, cell culture, α1- adrenergic receptors, quinazolines, prazosin, 31 Apoptosis, melanoma, mesenchymal stem cells, interferon β, cell cycle, 4749 Apoptosis, melanoma, zinc, reactive oxygen species, FAS ligand, p53, 5309 Apoptosis, nanodisks, lymphoma, curcumin, all-trans retinoic acid, 6425 Apoptosis, nitric oxide, lung cancer, metastasis, migration, cancer stem cells, review, 4585 Apoptosis, NOX1, DUOX1, HOCl, matrix metallo - proteinase, 5955 Apoptosis, pancreatic cancer, NF-ĸB, oil palm phenolics, 97 Apoptosis, Pd(II) complex, EAC, in vivo, tumor, PCNA, 1491 Apoptosis, petasin, anti-proliferative, prostate cancer, 191 Apoptosis, phenothiazines, multidrug resistance, MDR, P- glycoprotein (ABCB1), rhodamine 123, colon adenocarcinoma, doxorubicin, verapamil, 3245 Apoptosis, prostate cancer, dithiocarbamate analogs, emetine gene regulation, chemotherapeutic agents, 4723 Apoptosis, Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, cell line, PC-3, LNCaP, DU- 145, necrosis, cell burst, 5225 Apoptosis, sandalwood, santalol, cancer, cell cycle, carcinogenesis, angiogenesis, review, 3137 Apoptosis, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, necrosis, gene expression, FACS, proliferation, chemotherapy, 767 Apoptosis, sulforaphene, cisplatin, PI3K, PTEN, synergy, 3901 Apoptosis, vitamin K 3, vitamin K 5, human T-lymphoblastoid leukemia, daunorubicin resistance, P-glycoprotein,

91 Apoptosis-inducing factor, erythropoiesis, mitochondrionassociated 2 (Aifm2), murine erythroleukemia cells, 4491 Apparent diffusion coefficient, pancreatic fibrosis, pancreatic stellate cells, pancreas texture, 1749 Apparent diffusion coefficient, renal tumor, magnetic resonance imaging, diffusion weighted MRI, biomarker, 2351 Aprepitant, gynecological cancer, NK1 receptor, CINV, 4525 Aquaporin 3, early breast cancer, polymorphism, prognosis, 2775 AREG, tyrosin-kinase-inhibitor, mtor, head and neck squamous cell carcinoma, everolimus, sorafenib, sunitinib, 1951 Aromatase inhinitors, breast cancer, radiotherapy, cardiotoxicity, 1559 Array, head and neck cancer, keratinocytes, differential gene regulation, 3253 Artemisia annua, angiogenesis, artemisinin, cancer, molecu - lar docking, quantitative structure-activity relationship calcula tions, QSAR, vascular endothelial growth factor receptor, 1929 Artemisinin, angiogenesis, Artemisia annua, cancer, molecu - lar docking, quantitative structure-activity relationship calcula tions, QSAR, vascular endothelial growth factor receptor, 1929 Artemisinin, sodium ascorbate, vitamin D 3, Trolox, dexamethasone, hydrogen peroxide, Molt-4 cells, 1867 Artemisinin-tagged holotransferrin, dihydroartemisinin, dihydroartemisinin-resistant Molt-4 cells, DNA damage, comet assay, 1339 Ascidian, Eudistoma viride, cytotoxicity, HeLa, apoptosis, DNA fragmentation, flow cytometry, 283 Ascitic fluid, CA125, CYFRA 21-1, differential diagnosis, malignant effusion, 5655 Assay development, vitamin D metabolites, stereoselective synthesis, 1205 Astragalus membranaceus, Curcuma wenyujin, ovarian cancer, red fluorescent protein, orthotopic, nude mice, tumor progression, metastasis, 3193 Astrocytoma, CD47, NF-ĸB, UHRF1, 149 ATM, non-small cell lung cancer, ALK translocation, ALK inhibitor, KRAS, STK11, crizotinib resistance, genomics, next-generation sequencing, case report, 3007 Atomic bomb, high-dose radiation exposure, myelodysplastic syndrome, azacitidine, hypomethylating agents, 2929 Atopic dermatitis, lipopolysaccharide, Pantoea agglomerans, dermatophagoides farinae body extract, NC/Nga mice, 4499 AT-rich interactive domain-containing protein, gastric cancer, chromatin remodeling factor, immunohistochemistry, carcinogenesis, 6819 Atrophy, electrical current exclusion, ECE, curcumin, BCAA, C2C12, cachexia, 2085 ATRX, telomere shortening, altered lengthening of telomeres, TERC, telomerase, in situ, hybridization, DAXX, immunohistochemistry, 3501 Atypical endometrial hyperplasia, fertility-sparing management, progression risk, endometrial cancer, 6799 Atypical fibroxanthoma, AFX diagnosis, AFX tumor markers, immunohistochemistry, AFX therapy, review, 5717 Atypical glandular cells, cervical cancer, Pap smear, adenocarcinoma in situ, clinical population study, 913 Authenticity, patient physician communication, emotional, personality, proximity, breast cancer, 1627 Autoantibody, diagnosis, biomarker, ovarian cancer slot-blot, 881 Autochthonous model, salmonella, cancer therapy, breast cancer, BALB-neuT, genetically-engineered, mouse model, immunotherapy, myeloid-derived suppressor cells, 843 Autoimmune pancreatitis, chronic pancreatitis, IgG4, 6163 Autophagy, bis(phenylidenebenzeneamine)-1-disulfide, melanoma, mitochondria, 6075 Autophagy, GADD34, proteasome inhibition, cell death, eif2α, 5317 Autotransplantation, emergency fertility preservation, cancer, cryopreservation, in vitro maturation, oncofertility, review, 3117 Autotransplantation, non-small-cell lung cancer, reimplantation, bench surgery, in vivo, ex situ, 1675 Azacitidine, atomic bomb, high-dose radiation exposure, myelodysplastic syndrome, hypomethylating agents, 2929 Azacitidine, therapy-related myeloid neosplasm, outcome, safety, 461 Azaspirene, uterine carcinosarcoma, anti-angiogenic therapy, 2739 AZD5363, salinomycin, apoptosis, cancer, 4741 Azoxymethane, colonic cancer, modified citrus pectin, probiotic, galectin-3, immunohistochemistry, 4765 Balb-c mice, breast cancer, syngeneic, orthotopic, tumor resection, metastasis, RFP, imaging, 4641 BALB-neuT, salmonella, cancer therapy, breast cancer, autochthonous model, genetically-engineered, mouse model, immunotherapy, myeloid-derived suppressor cells, 843 Basal cell carcinoma, hypofractionated radiotherapy, skin cancer, frail patients, 4949 Basic fibroblastic growth factor, epidermal growth factor receptor, vascular endothelial growth factor, neurofibromatosis type 1, vessel density, malignant peripheral nerve sheath tumor, 137 BAX/BAK, apoptosis, bichalcone analog, CD95, FADD, human colon carcinoma HT-29 cells, 5407 BCAA, electrical current exclusion, ECE, curcumin, C2C12, atrophy, cachexia, 2085 BCL2 family, 4-methylumbelliferone, K562 cells, apoptosis, ROS, mitochondria,

92 Bcl2, anaplastic thyroid carcinoma, apigenin, TRAIL, AKT, 6529 BCL2, breast tumors, histological grading, SUV, estrogen receptor, progesterone receptor, Ki67, p53, androgen receptor, 569 BCL2, mir-7, ovarian cancer, TP53 status, tumour grade, EGFR, 2423 BCR signaling, mantle cell lymphoma, bendamustine, BTK inhibitor, apoptosis, 6679 BCR-ABL1, adherence, adverse effects, chronic myeloid leukemia, medication, therapy management, review, 6355 BDI, hopelessness, helplessness, depression, breast disease, 941 Bench surgery, non-small-cell lung cancer, reimplantation, autotransplantation, in vivo, ex situ, 1675 Bendamustine, mantle cell lymphoma, BCR signaling, BTK inhibitor, apoptosis, 6679 Bendamustine, rituximab, chronic lymphocytic leukemia (CLL), chemotherapy, immunotherapy, 5129 Benign soft tissue tumor, 25-hydroxyvitamin D, 1, 25- dihydroxyvitamin D, parathyroid hormone, daily vitamin D intake, sarcoma, 1171 Benzimidazole, cyclooxygenase-2, sulfasalazine, celecoxib, combination therapy, synergistic effects, brain cancer, glioma, LN18, 6419 Benzimidazoles, hypoxia, HIF-1α inhibitors, breast cancer, 3849 Beta-catenin, thymoma, immunohistochemistry, notch, sonic hedgehog, 669 Betaine, dimethylsulfoniopropionate, Ehrlich ascites carcinoma, methylation reaction, activated macrophages, 1475 Bevacizumab, breast cancer, epidermal growth factor receptor (HER2)-negative, metastatic disease, predictive factors, 6941 Bevacizumab, FOLFIRI, XELIRI, colorectal cancer, 3455 Bevacizumab, interstitial lung disease, non-small cell lung cancer, acute exacerbation, 4259 Bevacizumab, lung cancer, non-small cell lung cancer, platinum-based chemotherapy, overall survival, progression-free survival, pemetrexed, maintenance treatment, 6255 Bevacizumab, older patients, italian study, advanced colorectal cancer, 2391 Bevacizumab, postoperative wound complications, liver metastases of colorectal cancer, 2255 BEZ235, olaparib, 53BP1, BRCA1, breast cancer, 3829 Bias, selection, hospital structure, outcome, survival, 4073 Bichalcone analog, apoptosis, BAX/BAK, CD95, FADD, human colon carcinoma HT-29 cells, 5407 Bile duct cancer, monocyte, immune supression, systemic inflammatory response, 4961 Biliary duct cancer, neoadjuvant chemotherapy, case report, 4203 Biliary excretion, regorafenib, disposition, multidrug resistance-associated protein, organic anion-transporting polypeptide, hepatic uptake, protein-binding, 4681 Biliary intraepithelial neoplasia, neuroendocrine carcinoma, extrahepatic bile duct, chemotherapy, 4821 Biliary tract cancer, EZH2, PRC2, DZNep, anchorageindependent growth, cancer stem cells, 4697 Biliary tract cancer, postoperative radiotherapy, 6231 Biliary tract cancer, second-line chemotherapy, itraconazole, 4923 Bioavailability, curcumin, microgranules, head and neck squamous cell carcinoma, 6411 Bioavailability, curcumin; anti-cancer properties; autophagy, transcription factors, review, 645 Biochemical alterations, differentiated thyroid carcinoma, thyroxine withdrawal, hypothyroidism, 6933 Biochemical recurrence, laparoscopy, pentafecta, prostate cancer, radical prostatectomy, robotics, 5007 Bioinformatics, microrna, 5p-arm, 3p-arm, gastric cancer, 1345 Biological markers, thyroid nodules, thyroid neoplasms, mutations, cytodiagnosis, 1237 Bioluminescence imaging, murine tumor model, T lymphocytes, adoptive transfer, 6573 Biomarker, autoantibody, diagnosis, ovarian cancer slot-blot, 881 Biomarker, endogenous control, germ cell tumors, microrna, real time PCR, testicular cancer, 117 Biomarker, ferredoxin reductase, esophageal squamous cell carcinoma, chemoradiation therapy, 6471 Biomarker, malignant pleural mesothelioma, mir-126, EGFL7, DNA-methylation, prognosis, 6223 Biomarker, microrna, mononuclear cells, 3969 Biomarker, mir-503, oesophageal cancer, prognosis, 1447 Biomarker, peripheral blood, prospective, TS, DPD, survival, esophageal cancer, neoadjuvant, 1297 Biomarker, PVT, temozolomide, cisplatin, first-line chemotherapy, BRAF, MGMT, ERCC1, 1105 Biomarker, rectal cancer, single nucleotide polymorphism, neoadjuvant chemoradiation, review, 3761 Biomarker, renal tumor, magnetic resonance imaging, diffusion weighted MRI, apparent diffusion coefficient, 2351 Biomarker, small-cell lung cancer, actinin-4, transbronchial biopsy, prognosis, 1663 Biomarkers, breast cancer, extracellular vesicles, exosomes, microvesicles, liquid biopsy, review, 6379 Biomarkers, circulating tumor cells, CTCs, molecular marker, prostate cancer, 5679 Biomarkers, colorectal cancer, early detection, bowel endoscopy, screening,

93 Biomarkers, colorectal cancer, P53, immunohistochemistry, prognosis, 1641 Biomarkers, DNA methylation, breast cancer, CpG islands, treatment, review, 4569 Biomarkers, hepatocellular carcinoma, gene expression analysis, alpha-fetoprotein, osteopontin, glypican 3, 2021 Biomarkers, malignant melanoma, phase II study, sunitinib, PlGF, 6893 Biomarkers, malignant mesothelioma, chemotherapy, vinorelbine, 6731 Biomarkers, melanoma, treatment response, prognosis, 6755 Biomarkers, metastatic renal carcinoma, targeted-therapy, prediction, immunohistochemistry, 5661 Biomimick, in vitro tumor tissue model, cancer cell sheet, cytotoxicity, 6481 Biomolecular markers, premalignant leukoplakia, oral cancer, immunosurveillance, 311 Biopsy, advanced ovarian cancer, neoadjuvant chemotherapy, interval debulking surgery, IDs, incomplete cytoreduction, 2315 Biopsy, colposcopy, genotyping, human papillomavirus, triage, 4197 Biopsy, open biopsy, core needle biopsy, sarcoma, 961 Biopsy, predictive value, prostate neoplasms, model, nomogram, screening programs, 2881 Biopsy, prostate-specific antigen, prostate cancer, prostate volume, residual urinary volume, 2175 Biopsy, PSA, 2proPSA, PHI, prostate cancer, 4855 Biparameric MRI (Bp-MRI), magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), tumor markers, CA125, HE4, ovarian tumors characterization, pelvic mass, 6341 Bis(phenylidenebenzeneamine)-1-disulfide, melanoma, autophagy, mitochondria, 6075 Bladder cancer cells, glycolysis, growth, PFKFB3 inhibitor, butyrate, 2-deoxyglucose, dichloroacetate, phenformin, 5889 Bladder cancer, HPV, prostate cancer, renal cell carcinoma, testicular cancer, penile cancer, review, 2513 Bladder cancer, TP53, FGFR3, urine sediment, mutation phenotype, 4915 Bladder chondrosarcoma, postradiation sarcoma, 2857 Block copolymers, cancer treatment, experimental chemotherapy, ellipticine, micelles, 753 Blood transfusion, colorectal cancer, TRIM, immunosenescence, 3553 Blood vessel invasion, colorectal cancer, lymphatic invasion, prognosis, 6457 Blood vessels, male breast cancer, lymphatic vessels, podoplanin, CD34, 1041 Blood vessels, nerve fibre density, vessel density, lymphatic vessels, NF1, neurofibroma, neurofibromatosis, vessel innervation, 6509 Blood vessels, tumor microenvironment, cancer-associated fibroblasts, liver metastasis, RFP, fluorescence; colorcoded imaging, 5821 Blood vessels, vessel density, lymphatic vessels, NF1, NF2, schwannomatosis, schwannoma, neurofibromatosis, mast cell, MPNST, 4713 Blood brain barrier, glioblastoma, curcumin, lomustine, cancer stem cells, ceramide, combination chemotherapy, lipophilic agent, review, 6373 BMI, trastuzumab, cardiac dysfunction, risk factor, hypertension, radiotherapy, 4967 Body mass index, colorectal cancer, laparoscopic surgery, prognosis, recurrence, 5639 Body mass index, uterine cancer, EC, obesity, lymphovascular invasion, grade, 4053 Bone and soft tissue sarcoma, febrile neutropenia, chemotherapy, 2375 Bone cancer, osteosarcoma, qualitative, cancer survivors, disability, post-traumatic growth, 6081 Bone cancer, surgery, immune function, inflammatory response, 5461 Bone cancer, vitamin D deficiency, vitamin D, bone metastases, bone tumor, 6281 Bone marrow stroma, myelofibrosis, lenalidomide, gene expression, SOCS3, 5219 Bone metastases, PET, acelate, prostate cancer, 6787 Bone metastases, vitamin D deficiency, vitamin D, bone tumor, bone cancer, 6281 Bone metastasis, cross-linked N-Telopeptides of type I collagen, NTx, lung cancer, 3987 Bone metastasis, head and neck cancer, distant metastasis, lung metastasis, survival, 5499 Bone tumor, vitamin D deficiency, vitamin D, bone metastases, bone cancer, 6281 Bone, high-fat diet, PAI1, metastasis, mice, 3839 Boron neutron capture therapy, neutron, p53, 53BP1, apoptosis, 169 Bortezomib, angiogenesis, immunomodulatory drugs, plasma cell myeloma, vascular endothelial growth factor, 1085 Bortezomib, HLRCC, fumarate hydratase gene, PRCC2, Warburg effect, 6639 Bowel endoscopy, colorectal cancer, early detection, screening, biomarkers, 4935 BPH, African American, prostate cancer, Gleason, SPINK1, SNPs, 3811 Brachytherapy, cervical cancer, radiotherapy, shielding, toxicity, 5567 Brachytherapy, hepatocellular carcinoma, recurrence, local ablation, 319 Brachytherapy, IPSA, radiobiological evaluation, 935 BRAF V600E, colorectal cancer, KRAS, molecular biomarkers, iron-deficiency anaemia,

94 BRAF, biomarker, PVT, temozolomide, cisplatin, first-line chemotherapy, MGMT, ERCC1, 1105 Brain cancer, cyclooxygenase-2, sulfasalazine, celecoxib, benzimidazole, combination therapy, synergistic effects, glioma, LN18, 6419 Brain metastases, central nervous system, epidermal growth factor receptor-tyrosine kinase inhibitor, acquired resistance, T790M, leptomeningeal metastases, 1025 Brain metastases, EMT, mtor, mtorc1, mtorc2, 689 Brain metastases, NSCLC, tyrosine kinase inhibitors, review, 5797 Brain metastasis, breast cancer, radiosurgery, radiation dose, local control, distant brain control, overall survival, 333 Brain metastasis, kidney cancer, radiosurgery, survival, estimation, 4215 Brain metastasis, stereotactic radiosurgery, tomotherapy, 6805 Brain oligometastases, fractionation, stereotactic radiotherapy, whole brain radiotherapy, RPA, 3055 Brain tumor, endothelial cells, culture, vasculature, HUVEC, 2681 Brain tumor, p16, MDM2, polymorphism, glioma, meningioma, 3933 Brain tumors, tumor grading, proliferation activity, PET/CT, fluorothymidine, 955 BRCA mutation, laparoendoscopic single-site surgery, prophylactic bilateral salpingo-oophorectomy, cosmetic satisfaction, ambulatory surgery, 6105 BRCA1, olaparib, BEZ235, 53BP1, breast cancer, 3829 Breast cancer immune cell infiltration, anaesthetic technique, randomised grial, 1311 Breast cancer liver metastases, liver resection, long term survival, 6913 Breast cancer liver metastases, re-resection, survival, 6877 Breast cancer risk, p53 codon72 polymorphism, anthra - cycline resistance, 1763 Breast cancer, adjuvant ovarian suppresion, immunotherapy, premenopausal, 6847 Breast cancer, adjuvant ovarian suppression, immunotherapy, premenopausal, 6847 Breast cancer, apoptosis, tannic acid, tissue engineering, 1285 Breast cancer, Balb-c mice, syngeneic, orthotopic, tumor resection, metastasis, RFP, imaging, 4641 Breast cancer, bevacizumab, epidermal growth factor receptor (HER2)-negative, metastatic disease, predictive factors, 6941 Breast cancer, brain metastasis, radiosurgery, radiation dose, local control, distant brain control, overall survival, 333 Breast cancer, case-control study, colorectal adenoma, colorectal cancer, nested case-control study, vitamin D, 1153 Breast cancer, CD28, CD57, cellular senescence, immunosenescence, chemotherapy, 1481 Breast cancer, cerebral metastases, stereotactic radiosurgery, freedom from new cerebral metastases, prognostic tool, 6793 Breast cancer, chemotherapy, physical activity, exercise, 5623 Breast cancer, cytology, breast imaging, 2369 Breast cancer, DNA methylation, CpG islands, biomarkers, treatment, review, 4569 Breast cancer, ductal carcinoma in situ, conservative treatment, residual tumor, 3471 Breast cancer, estrogen receptor (ER), HER2, EGFR, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, proliferation, apoptosis, 1243 Breast cancer, estrogen, incidence, lung cancer, survival, 1121 Breast cancer, extracellular vesicles, exosomes, microvesicles, biomarkers, liquid biopsy, review, 6379 Breast cancer, gelsolin, prognosis, migration, cytoskeleton, estrogen receptor-positive, 5277 Breast cancer, GFP xenograft assay, metastasis, 47 Breast cancer, HER2, ERBB2, codon 655, Ile655Val, polymorphism, 5901 Breast cancer, HER2, ERBB2, codon 655, Ile655Val, polymorphism, 6667 Breast cancer, human papillomavirus, polymerase chain reaction, 851 Breast cancer, hypoxia, benzimidazoles, HIF-1α inhibitors, 3849 Breast cancer, laser thermotherapy, minimally invasive treatment, thermal treatment, therapy, tumor immunology, 6147 Breast cancer, lymphatic invasion, tumor size, lymph node metastasis, sentinel node, 3581 Breast cancer, mammoplasty, mastectomy, neoadjuvant chemotherapy, oncoplastic breast-conserving surgery, 4229 Breast cancer, MCF-7, angiogenesis, lymphangiogenesis, mesenchymal stem cells, review, 3147 Breast cancer, MDR, HER2, P-glycoprotein, transfection, BT-474, 2531 Breast cancer, melanoma, malignant, melanotic, amelanotic, 1709 Breast cancer, metastases, CSF1, CSF1R, tumor-infiltrating macrophages, T-lymphocytes, epithelial tumor cells, tumor stromal cells, 865 Breast cancer, microtubule-associated protein, tau protein, taxanes, chemotherapy sensitivity, cancer treatment, review, 5179 Breast cancer, mir-15a, prognosis, 123 Breast cancer, mir-21, chromogenic in situ hybridization 3175 Breast cancer, mirna21, mirna155, let7a, mirna19a, mirna17-5p, paraffin-embedded tissue, 5425 Breast cancer, molecular subtypes, invasive carcinoma NST type, metastasis,

95 Breast cancer, MRI, neoadjuvant chemotherapy, correlation, pathological response, 581 Breast cancer, multifocality, multicentricity, 5111 Breast cancer, neoadjuvant chemotherapy, docetaxel, cyclophosphamide, predictive factor, triple-negative, 907 Breast cancer, nephrotoxicity, ibandronate, zoledronic acid, metastases, 1797 Breast cancer, olaparib, BEZ235, 53BP1, BRCA1, 3829 Breast cancer, ovarian cancer, mutations, Canadian patients, Saudi Arabian patients, comparative study, next generation sequencing, 2601 Breast cancer, papilloma of the breast, percutaneous biopsy, surgical biopsy, 6881 Breast cancer, patient physician communication, emotional, personality, proximity, authenticity, 1627 Breast cancer, PCK3145, PSP94, colon cancer, prostate cancer, ERK, laminin receptor, 1377 Breast cancer, PIN1, SGK1, ubiquitination, RAF1, tamoxifen resistance, 785 Breast cancer, primary systemic therapy, FDG-PET/CT, Ki- 67, response evaluation, 5063 Breast cancer, proteomics, multiple reaction monitoring, diagnosis, plasma, 6271 Breast cancer, radical surgery, N3, supraclavicular, 18FDG- PET/CT, neoadjuvant chemotherapy, 1729 Breast cancer, radiotherapy, cardiotoxicity, aromatase inhinitors, 1559 Breast cancer, radiotherapy, right ventricle, TAPSE, 2141 Breast cancer, salmonella, cancer therapy, BALB-neuT, autochthonous model, genetically-engineered, mouse model, immunotherapy, myeloid-derived suppressor cells, 843 Breast cancer, SLUG, TWIST, EMT, epithelial-mesenchymal transition, 3961 Breast cancer, triple-negative breast cancer, vitamin D, 25- hydroxyvitamin D, CYP24A1, CYP27B1, vitamin D receptor, 805 Breast cancer, valvular regurgitation, left ventricular ejection fraction, HER2-positive, trastuzumab, 4063 Breast cancer, vitamin D, celecoxib, cyclooxygenase-2, 1189 Breast cancer, vitamin D 3, ketogenic diet, 5525 Breast carcinoma cell, 4-methylumbelliferone, hyaluronan, glucose, proliferation, 4799 Breast carcinoma, chemotherapy, cytochalasin B, leukemia, cytoskeletal-directed agents, nucleic acid-directed agents, cell enlargement, 65 Breast disease, hopelessness, helplessness, suicidal ideation, 3543 Breast disease, hopelessness, helplessness, BDI, depression, 941 Breast disease, hopelessness, helplessness, MADRS, depression, 2215 Breast imaging, breast cancer, cytology, 2369 Breast radiotherapy, dose calculation algorithm, analytical anisotropic algorithm, pencil beam convolution, planning guidelines, 2841 Breast tumors, histological grading, SUV, estrogen receptor, progesterone receptor, Ki67, BCL2, p53, androgen receptor, 569 Breast, cannabinoids, WIN55, 212-2, cancer, micelle(s), nanoparticle(s), nano-micelle, 4707 Breast-specific gamma imaging, relative uptake factor, invasive ductal breast cancer (IDC) sub-types, correlation of relative uptake factor and IDC sub-types, 5671 Breslow score, melanoma, interleukin, sentinel node, 3537 Broiler, lipopolysaccharide, oral administration of LPS, priming, cytokine, 4459 Bronchoalveolar lavage, non-small cell lung cancer, micro RNA profiling, sputum, cancer detection, 1873 BT-474, MDR, HER2, P-glycoprotein, transfection, breast cancer, 2531 BTK inhibitor, mantle cell lymphoma, bendamustine, BCR signaling, apoptosis, 6679 Burkitt lymphoma, non-hodgkin lymphoma, HIV infection, mandible, osteomyelitis, FDG-PET, EBV, Epstein-Barr, 4837 Butyrate, bladder cancer cells, glycolysis, growth, PFKFB3 inhibitor, 2-deoxyglucose, dichloroacetate, phenformin, 5889 BYL719, head and neck squamous cell carcinoma, PIK3CA, dacomitinib, 175 C2C12, electrical current exclusion, ECE, curcumin, BCAA, atrophy, cachexia, 2085 C57/BL6-GFP mice, RFP, malignant lymphoma, liver metastasis, imaging, 4647 CA 125, TATI, claudin, ovarian mucinous borderline tumor, 973 CA125, ascitic fluid, CYFRA 21-1, differential diagnosis, malignant effusion, 5655 CA125, magnetic resonance imaging (MRI), diffusionweighted imaging (DWI), biparameric MRI (Bp-MRI), tumor markers, HE4, ovarian tumors characterization, pelvic mass, 6341 CA125, ovarian carcinoma, chemotherapy, progression-free survival, overall survival, 1099 Cabazitaxel, renal cell carcinoma, docetaxel, p-glycoprotein, AKT, Caki-1, KMRC-1, OS-RC-2, 6671 Cachexia, dietetics, mindfulness, 6311 Cachexia, electrical current exclusion, ECE, curcumin, BCAA, C2C12, atrophy, 2085 Cadherin, side-effect, des-γ-carboxyprothrombin, cell migration, metastasis, hepatocellular carcinoma, 1985 Cadherins, feline, mammary tumours, catenins, 3361 CAIX, carbonic anhydrase, antibody, antibody-dependent cellular cytotoxicity, kidney cancer,

96 CAIX, HIF1Α, VEGF, MCF-7 cells, MDA-MB-231 cells, xenografts, microtubule disruptor, anti-angiogenic, 5249 Caki-1, renal cell carcinoma, docetaxel, cabazitaxel, p- glycoprotein, AKT, KMRC-1, OS-RC-2, 6671 CAL-101, Celecoxib, ER stress, EBV-transformed B cells, 2699 Calcitonin, medullary thyroid carcinoma, C-cell hyperplasia, RET, calcium stimulation test, papillary thyroid carcinoma, 4251 Calcium stimulation test, calcitonin, medullary thyroid carcinoma, C-cell hyperplasia, RET, papillary thyroid carcinoma, 4251 Calponin 1 (CNN1), F-actin, cell motility, cell invasion, 5993 Canadian patients, breast cancer, ovarian cancer, mutations, Saudi Arabian patients, comparative study, next generation sequencing, 2601 Cancer biomarker, gastroenterology, colon cancer, cytokines, interleukin-6, IL6, 2235 Cancer cell line, senescence, oncogene-induced senescence, primary cell culture, senescence-associated heterochromatin foci, senescence-associated β- galactosidase, 2759 Cancer cell lines, IGF-1 isoforms, IGF-1 classes, IGF-1Ea, IGF-1Eb, Ec peptide, 107 Cancer cell proliferation, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deep-sequencing, cancer stem cells, CSCs, anti-apoptosis, stemness, western blotting, RT-PCR, immunocytochemistry, 3743 Cancer cell sheet, in vitro tumor tissue model, cytotoxicity, biomimick, 6481 Cancer cells, GFP, histone-h2b, fusion, nuclear labeling, RFP, retrovirus, cytoplasmic labeling, mitosis, chromosomes, 2553 Cancer detection, non-small cell lung cancer, micro RNA profiling, sputum, bronchoalveolar lavage, 1873 Cancer epidemiology, cancer incidence, Volcanic environment, volcanic carcinogens, Mt. Etna pollution, 3995 Cancer epigenetics, esophageal squamous cell carcinoma, microrna, DNA methylation, 4617 Cancer immunotherapy, 4-1BB, PD-1, immune checkpoint, 129 Cancer incidence, volcanic environment, volcanic carcinogens, cancer epidemiology, Mt. Etna pollution, 3995 Cancer initiating c ells, chemoprevention, ovarian cancer, oxidative stress, 85 Cancer of the papilla of Vater, pancreatic cancer, chronic pancreatitis, Col11A1, mrna quantification, diagnostic marker, 6153 Cancer of unknown primary, elderly, MESCC, radiation therapy, survival tool, 6219 Cancer of unknown primary, pregnancy, treatment, prognosis, placental in-vasion, review, 575 Cancer Registry Study, gastric adenocarcinoma, tumorinfiltrating neutrophils, Messina province, 487 Cancer risk, gastric cancer, epidermal growth factor, serum level, progression, 2709 Cancer stem cell marker, co-expression, cytoskeletal protein, adducin 3, CD133, neurospheres, temozolomide-resistant subclone, glioblastoma, NANOG, 6487 Cancer stem cell marker, prostate cancer, canine cancer stem cells, spheroid cell clusters, 1917 Cancer stem cell, ALDH1, renal transitional cell carcinoma, survival, 4829 Cancer stem cell, hepatocyte growth factor, prostate cancer, prostatectomy, recurrence, 413 Cancer stem cells, biliary tract cancer, EZH2, PRC2, DZNep, anchorage-independent growth, 4697 Cancer stem cells, curcumin, EGCG, STAT3, NFĸB, CD44, 39 Cancer stem cells, curcumin, interleukin-6, interleukin-8, interleukin-1, CXCR1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 Cancer stem cells, dietary agents, mechanism of action, signal transduction pathways, review, 5773 Cancer stem cells, glioblastoma, curcumin, lomustine, ceramide, blood brain barrier, combination chemotherapy, lipophilic agent, review, 6373 Cancer stem cells, HIWI, HILI, colorectal cancer, gene expression, 3317 Cancer stem cells, lung cancer, angiotensin II, spheroid, 4789 Cancer stem cells, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deep-sequencing, CSCs, cancer cell proliferation, antiapoptosis, stemness, western blotting, RT-PCR, immunocytochemistry, 3743 Cancer stem cells, nitric oxide, lung cancer, metastasis, apoptosis, migration, review, 4585 Cancer survivors, bone cancer, osteosarcoma, qualitative, disability, post-traumatic growth, 6081 Cancer therapy, cinnarizine, multiple myeloma, lymphoma, WNT, 835 Cancer therapy, flunarizine, multiple myeloma, lymphoma, WNT, pathway, 1369 Cancer therapy, salmonella, breast cancer, BALB-neuT, autochthonous model, genetically-engineered, mouse model, immunotherapy, myeloid-derived suppressor cells, 843 Cancer treatment, experimental chemotherapy, ellipticine, block copolymers, micelles, 753 Cancer treatment, JMJD3, UTX, epigenetic, histone modification, xenograft analysis,

97 Cancer treatment, microtubule-associated protein, tau protein, taxanes, chemotherapy sensitivity, breast cancer, review, 5179 Cancer treatment, organic anion-transporting polypeptides, OATPs. microcystin-lr, pancreatic cancer, drug development, targeted-therapy, 5857 Cancer type, tumor M2-pyruvate kinase, tumor size, nodal metastases, distant metastases, tumor stage, 4271 Cancer vaccine, docetaxel, immunotherapy, murine model, prostate cancer, 3275 Cancer, anginex, tumor angiogenesis, galectin-1, indium- 111, 5945 Cancer, angiogenesis, Artemisia annua, artemisinin, molecu - lar docking, quantitative structure-activity relationship calcula tions, QSAR, vascular endothelial growth factor receptor, 1929 Cancer, anticancer peptides, temporin, cytotoxicity, review, 635 Cancer, AZD5363, salinomycin, apoptosis, 4741 Cancer, cannabinoids, WIN55, 212-2, breast, micelle(s), nanoparticle(s), nano-micelle, 4707 Cancer, casein kinase II (CK2), in silico systematic mutagenesis, KINARI mutagen web-server, LB-based nanocrystallo graphy, proteomics, ribonuclease A (RNase A), 827 Cancer, curcumin-based compounds, cytotoxicity, antiproliferative activity, apoptosis, 5293 Cancer, dihydropyrimidine dehydrogenase, DPD, 5- fluorouracil, DPYD deficiency, capecitabine, 4881 Cancer, drug resistance, copper transporter, molecular docking, 6505 Cancer, emergency fertility preservation, cryopreservation, autotransplantation, in vitro maturation, oncofertility, review, 3117 Cancer, glucan, melanoma, NK cells, immunity, antibodies, 5287 Cancer, immunotherapy, colostrum, macrophage-activating factor (MAF), chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), 4543 Cancer, N-acyl dopamine, metabolites, vanilloids, cytotoxicity, 2657 Cancer, plasma protein binding, albumin, oxidation, osteosarcoma, rat, 2063 Cancer, polyethylenimine, sirna, folate receptor, drug delivery, nanoparticle, 5433 Cancer, sandalwood, santalol, apoptosis, cell cycle, carcinogenesis, angiogenesis, review, 3137 Cancer, vitamin D, chronic kidney disease, CKD, dialysis, ESRD, renal replacement therapy (RRT), epidemiology, CKD-MBD, mineral and bone disease, 1181 Cancer, vitamin D, preventive medicine, epidemiology, 25(OH)D, review, 1161 Cancer, XRCC1, MTHFR, EGFR, population stratifica tion, ancestry, 2009 Cancer/testis antigen, kita-kyushu lung cancer antigen-1, KK-LC-1, gastric cancer, 3575 Cancer-associated fibroblasts, tumor microenvironment, blood vessels, liver metastasis, RFP, fluorescence, colorcoded imaging, 5821 Cancer-specific survival, urothelial carcinoma, upper urinary tract, gender; age at diagnosis, 4277 Canine cancer stem cells, prostate cancer, spheroid cell clusters, cancer stem cell marker, 1917 Canine mammary tumors, CD3, COX-2, EGFR, 2915 Canine mammary tumors, Nottingham histological grade, prognosis, survival, 4219 Canine model, lymphoma, stem cell marker, spheres, dog, 2805 Canis familiaris, kallikrein-related peptidases, gene expression, alternative splicing, mammary cancer, 2715 Cannabidiol, heat shock proteins, tetrahydrocannabinol, glioma, reactive oxygen species, 5827 Cannabinoids, WIN55, 212-2, breast, cancer, micelle(s), nanoparticle(s), nano-micelle, 4707 Cantharidin, DNA damage, Comet assay, DNA repair, TSGH8301 human bladder cancer cells, 795 Cantharidin, human melanoma cancer A375.S2 cells, PI3K/NF-ĸB signaling pathways, invasion, migration, 729 Capecitabine, dihydropyrimidine dehydrogenase, DPD, 5- fluorouracil, DPYD deficiency, cancer, 4881 Carbon ion radiotherapy, proton therapy, patch-field technique, intensity-modulated radiotherapy, spinal sarcoma, 4083 Carbonic anhydrase, CAIX, antibody, antibody-dependent cellular cytotoxicity, kidney cancer, 1997 Carbon-ion therapy, prostate cancer, toxicity, quality of life, hypofractionation, 5559 Carbonyls, oral cancer, cell death, cigarette smoke, 1961 Carboplatin, uterine carcinosarcoma, chemotherapy, ifosfamide, mesna, 4841 Carcinogenesis, cytokines, colitis-associated cancer, animal models, review, 19 Carcinogenesis, gastric cancer, chromatin remodeling factor, immunohistochemistry, AT-rich interactive domaincontaining protein, 6819 Carcinogenesis, sandalwood, santalol, cancer, apoptosis, cell cycle, angiogenesis, review, 3137 Carcinogenesis, yes-associated protein, β-catenin, adenocarcinoma, signet-ring cell carcinoma, gastric neoplasia, 3925 Carcinoid, rectum, neuroendocrine tumor, HES77, metastasis, prognosis, 3767 Carcinosarcoma, chemoembolization, vascular heterogeneity, anti-angiogenic therapy, ceramics, microsphere, drug delivery system (DDS), TNP-470, uterine sarcoma,

98 Cardenolide analog, 3β-[2-(1-amantadine)-1-on-ethylamine]- digitoxigenin, AMANTADIG, human leukemia cells, human urological cancer cells, porcine cerebral cortex Na + /K + -ATPase, 5271 Cardiac dysfunction, trastuzumab, risk factor, hypertension, BMI, radiotherapy, 4967 Cardiac injury, chest radiotherapy, radiation, review, 2487 Cardiac tamponade, esophageal cancer, postoperative complication, 407 Cardiotoxicity, breast cancer, radiotherapy, aromatase inhinitors, 1559 Cardiotoxicity, trastuzumab, anthracyline, sequence, 857 Cardiotoxin, cytotoxicity, electrostatic potential, 4513 Carmine labeling, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, coculture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Case report, biliary duct cancer, neoadjuvant chemotherapy, 4203 Case report, endometrial stromal sarcoma, paracaval recurrence, complete resection, 3405 Case report, esophageal cancer, chylothorax, lymphangiography, 891 Case report, gallbladder, adenoma, serrated, 3485 Case report, GIST, regorafenib monotherapy, liver failure, 4037 Case report, hepatocellular carcinoma, living donor liver transplantation, microsatellite analysis, 3525 Case report, intraductal carcinoma of the breast, juvenile papillomathosis, juvenile fibroadenoma, 5027 Case report, non-small cell lung cancer, ALK translocation, ALK inhibitor, KRAS, STK11, ATM, crizotinib resistance, genomics, next-generation sequencing, 3007 Case report, pancreatic cancer, complete response, recurrence, 2867 Case report, PEC, PEComa, PEC tumor, mesenchymal neoplasm, everolimus, mtor inhibition, targeted therapy, 3399 Case report, relapsed/refractory multiple myeloma, cyclophosphamide, dexamethasone, treatment options, old drugs, 2165 Case-control study, breast cancer, colorectal adenoma, colorectal cancer, nested case-control study, vitamin D, 1153 Casein kinase II (CK2), cancer, in silico systematic mutagenesis, KINARI mutagen web-server, LB-based nanocrystallo graphy, proteomics, ribonuclease A (RNase A), 827 Caspase-independent apoptosis, phosphatidylinositol derivative, enantiomer, AIF, AMID, 6563 Caspases, small molecule FGFR1 inhibitor, NVP-BGJ398, PDCD4, ANG2, 5873 Castrate-resistant, abiraterone, elderly, prostate cancer, PSA, 3097 Castrate-resistant, metastatic, prostate cancer, abiraterone, predictors response, drug sequencing, 5615 Castration-resistant prostate cancer (CRPC), PCA 3, androgen deprivation treatment (ADT), prognostic factor, docetaxel, 3075 Castration-resistant prostate cancer, estrogen, testosterone, prostate cancer-derived stromal cell, chimeric coculture, 221 Catalytic polypeptide-like 3B (APOBEC3B), hepatocellular carcinoma (HCC), apolipoprotein B mrna editing enzyme, vascular invasion, Hep 3B, 1521 Catenins, feline, mammary tumours, cadherins, 3361 C-cell hyperplasia, calcitonin, medullary thyroid carcinoma, RET, calcium stimulation test, papillary thyroid carcinoma, 4251 CCL2, lewis rat sarcoma, CD11b+ cells, neutrophils, tumor immunology, 703 CCNI, cyclin I, kinase insert domain receptor, KDR, ovarian cancer, chemotherapy, angiogenesis, 1115 CD114, G-CSF, melanoma, nifurtimox, 3787 CD117, squamous cell carcinoma, adenocarcinoma, esophagus, PDGFR-α, immunohistochemistry, 3793 CD11b+ cells, lewis rat sarcoma, neutrophils, CCL2, tumor immunology, 703 CD133, co-expression, cytoskeletal protein, adducin 3, cancer stem cell marker, neurospheres, temozolomideresistant subclone, glioblastoma, NANOG, 6487 CD133, colorectal cancer, lymph node metastasis, immunohistochemistry, 6599 CD133, gastric cancer, histone deacetylase, HDAC, thrombospondin-1, THBS1, 2071 CD155, prognostic factor, pancreatic cancer, tumor immunity, angiogenesis, 2287 CD28, CD57, cellular senescence, immunosenescence, breast cancer, chemotherapy, 1481 CD28, CTLA4, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), protein carbonyl (PCO), superoxide dismutase, advanced glycation end-products (AGEs), copper, zinc, 5391 CD3, canine mammary tumors, COX-2, EGFR, 2915 CD-31, renal cell cancer (RCC), vascular endothelial growth factor receptor (VEGFR), prognostic factor, 921 CD34, male breast cancer, lymphatic vessels, podoplanin, blood vessels, 1041 CD34, solitary fibrous tumor, thigh, PET/CT, MRI, STAT6, NAB2-STAT6, 967 CD4+CD25+CD127 low/ regulatory T-cells, CD4+RORγt + Th17 cells, pleural effusion, lung cancer,

99 CD4+RORγt + Th17 cells, CD4+CD25+CD127 low/ regulatory T-cells, pleural effusion, lung cancer, 1529 CD44 variant exon 9, colorectal cancer, circulating tumor cells, 239 CD44, curcumin, EGCG, STAT3, NFĸB, cancer stem cells, 39 CD44v6, xct, CRC, immunohistochemistry, colorectal cancer, recurrence, 677 CD47, astrocytoma, NF-ĸB, UHRF1, 149 CD57, CD28, cellular senescence, immunosenescence, breast cancer, chemotherapy, 1481 CD95, apoptosis, BAX/BAK, bichalcone analog, FADD, human colon carcinoma HT-29 cells, 5407 CDK inhibitor, cell cycle, p16, transcription, polycomb, MLL, ANRIL, review, 4395 CDK4, dedifferentiated liposarcoma, well-differentiated liposarcoma, ring chromosome, MDM2, 345 CDKs, cyclin E, cyclins, endometrial adenocarcinoma, prognosis, 3393 CEA, ANGPTL2, C-reactive protein, lymph node metastasis, colorectal cancer, 2849 Celecoxib, CAL-101, ER stress, EBV-transformed B cells, 2699 Celecoxib, cyclooxygenase-2, sulfasalazine, benzimidazole, combination therapy, synergistic effects, brain cancer, glioma, LN18, 6419 Celecoxib, glioblastoma, dual anti-angiogenic chemotherapy, temozolomide, 4955 Celecoxib, tongue cancer, chemotherapy, survival, 4235 Celecoxib, vitamin D, cyclooxygenase-2, breast cancer, 1189 Celecoxib, vitamin D, cyclooxygenase-2, ovarian cancer, 1197 Cell affinity, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, nonspecific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Cell burst, Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, cell line, PC-3, LNCaP, DU- 145, apoptosis, necrosis, 5225 Cell culture, medullary thyroid carcinoma, α1-adrenergic receptors, quinazolines, prazosin, apoptosis, 31 Cell cycle phase, 3-arylcoumarin derivatives, cytotoxic effect, mitochondrial transmembrane potential, reactive oxygen species production, 653 Cell cycle regulators, sex steroid receptors, angiogenesis molecules, IPMN, image analysis, 1049 Cell cycle, CDK inhibitor, p16, transcription, polycomb, MLL, ANRIL, review, 4395 Cell cycle, clotrimazole, melanoma, A375 cells, apoptosis, hexokinase, 3781 Cell cycle, long noncoding RNA, ANRIL, p15, p16, 5377 Cell cycle, melanoma, mesenchymal stem cells, interferon β, apoptosis, 4749 Cell cycle, sandalwood, santalol, cancer, apoptosis, carcinogenesis, angiogenesis, review, 3137 Cell death, GADD34, proteasome inhibition, eif2α, autophagy, 5317 Cell death, oral cancer, carbonyls, cigarette smoke, 1961 Cell enlargement, chemotherapy, cytochalasin B, leukemia, breast carcinoma, cytoskeletal-directed agents, nucleic acid-directed agents, 65 Cell invasion, calponin 1 (CNN1), F-actin, cell motility, 5993 Cell line characterization, pancreatic carcinoma, chemotherapy, 3821 Cell line, prostate neoplasms, gene expression, surgical pathology, radical prostatectomy, 5443 Cell line, Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, PC-3, LNCaP, DU-145, apoptosis, necrosis, cell burst, 5225 Cell lines, oral squamous cell carcinoma (OSCC), Kallikrein-related-peptidase-4 (KLK4), clinical outcome, invasion, metastasis, 1861 Cell migration, cadherin, side-effect, des-γcarboxyprothrombin, metastasis, hepatocellular carcinoma, 1985 Cell motility, calponin 1 (CNN1), F-actin, cell invasion, 5993 Cell motility, lymphangioleiomyomatosis, LAM cells, mtor, rapamycin, metastasis, 3341 Cell stamper, nanoprinting perforator, malignant glioma, 6069 Cell-cell interactions, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Cell-free DNA, HCC, methylation, epigenetic, quantitative MSP, 997 Cellular damage, photosensitizer, phthalocyanine, photodynamic treatment, oxidative stress, phototoxicity, tumour cells, 3943 Cellular immunotherapy, non-small cell lung cancer, NK cells, NK-92, 1543 Cellular migration, sonic hedgehog (SHH), lung cancer, tumor model, YangZheng XiaoJi, invasion, cyclopamine, Smo, Gli, 1321 Cellular senescence, CD28, CD57, immunosenescence, breast cancer, chemotherapy, 1481 Central nervous system, epidermal growth factor receptortyrosine kinase inhibitor, acquired resistance, T790M, leptomeningeal metastases, brain metastases,

100 Ceramics, chemoembolization, vascular heterogeneity, anti-angiogenic therapy, microsphere, drug delivery system (DDS), TNP-470, uterine sarcoma, carcinosarcoma, 4757 Ceramide induced cell death, L1210 cells, P-glycoprotein, glucosylceramide synthase, UDP-glucose, 2627 Ceramide, glioblastoma, curcumin, lomustine, cancer stem cells, blood brain barrier, combination chemotherapy, lipophilic agent, review, 6373 Cerebral metastases, breast cancer, stereotactic radiosurgery, freedom from new cerebral metastases, prognostic tool, 6793 Cerebral metastases, elderly patients, stereotactic radiosurgery, optimal dose, treatment results, 5701 Cerebral metastases, renal cell carcinoma, stereotactic radiosurgery, local control, freedom from new cerebral metastases, survival, 3571 Cerebral oligo-metastases, colorectal cancer, stereotactic radiosurgery, survival, predictive tool, treatment optimization, 5515 Cervical cancer, adjuvant chemotherapy, concomitant chemoradiotherapy, ifosfamide, cisplatin, 4161 Cervical cancer, atypical glandular cells, Pap smear, adenocarcinoma in situ, clinical population study, 913 Cervical cancer, brachytherapy, radiotherapy, shielding, toxicity, 5567 Cervical cancer, cervical intraepithelial neoplasia, microrna expression, single and multiple HPV infection, 523 Cervical cancer, CIN, colposcopy, endocervical curettage, 4183 Cervical cancer, cisplatin, hydration, magnesium, nephrotoxicity, 2199 Cervical cancer, concurrent chemoradiation, survival, 3447 Cervical cancer, laparoscopy, robotic, radical hysterectomy, quality of life, 5015 Cervical cancer, para-aortic lymph node metastasis, radiation therapy, squamous cell carcinoma, uterine cervix, 4849 Cervical cancer, pelvic recurrence, pelvic exenteration, palliation, 4877 Cervical cancer, recurrent, oligometastasis, stereotactic body radiotherapy, CyberKnife, radiosurgery, 5103 Cervical intraepithelial neoplasia, cervical cancer, microrna expression, single and multiple HPV infection, 523 Cetuximab, epidermal growth factor receptor, KRAS, metastatic colorectal cancer, 4207 Cetuximab, hepatocyte growth factor, amphiregulin, transforming growth factor-α, epidermal growth factor receptor, colorectal cancer, 1683 Cetuximab, SN-38, irinotecan, anti-angiogenesis, antiinvasion, colon cancer, 5983 CFP nude mouse, pancreatic cancer, dual color cells, GFP, RFP, stellate cells, interaction, color-coded fluorescence imaging, 2545 Chemoembolization, vascular heterogeneity, anti-angiogenic therapy, ceramics, microsphere, drug delivery system (DDS), TNP-470, uterine sarcoma, carcinosarcoma, 4757 Chemoimmunotherapy, cytokine, dendritic cell, MHC class II, pancreatic cancer, vaccine, WT1, 555 Chemokines, CXC, NSCLC biomarkers, lung cancer, 6979 Chemokines, gene-expression profiling, colon cancer, tumor front, epithelial mesenchymal transition, microarray, 6577 Chemoprevention, cancer initiating c ells, ovarian cancer, oxidative stress, 85 Chemoradiation therapy, ferredoxin reductase, esophageal squamous cell carcinoma, biomarker, 6471 Chemoradiation, esophageal cancer, myelosuppression, 4889 Chemoradiotherapy, hypopharyngeal cancer, hyoid bone, larynx preservation, complication, 1735 Chemoradiotherapy, nasopharyngeal carcinoma, docetaxel, cisplatin, 5-fluorouracil, 6861 Chemo radiotherapy, pulmonary blastoma, neoadjuvant treatment, EGFR mutation, PD-L1 expression, ALK- EML4 translocation, pembrolizumab, 4871 Chemorefractory, CK2, AKT/mTOR, lung cancer, 1537 Chemosensitivity, non-small cell lung cancer, anaplastic lymphoma kinase, epidermal growth factor receptor, 1791 Chemosensitivity, VX2, HepG2, chemotherapy, TACE, HCC, 6497 Chemotherapeutic agents, prostate cancer, apoptosis, dithiocarbamate analogs, emetine gene regulation, 4723 Chemotherapy sensitivity, microtubule-associated protein, tau protein, taxanes, cancer treatment, breast cancer, review, 5179 Chemotherapy toxicity, deleterious alleles, 5-fluorouracil, DPYD, OPRT, TYMS, TP53, 6971 Chemotherapy, adjuvant therapy, pancreatic neoplasms, 6901 Chemotherapy, advanced gastric cancer, second-line, molecular targeted therapy, review, 4575 Chemotherapy, AKT, head neck, radiotherapy, 269 Chemotherapy, anaplastic oligodendroglial tumor, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, PCV, 5467 Chemotherapy, anthracyclines, left ventricular systolic dysfunction, metastatic breast cancer, risk factors, 989 Chemotherapy, bendamustine, rituximab, chronic lymphocytic leukemia (CLL), immunotherapy, 5129 Chemotherapy, biomarkers, malignant mesothelioma, vinorelbine, 6731 Chemotherapy, breast cancer, physical activity, exercise, 5623 Chemotherapy, CD28, CD57, cellular senescence, immunosenescence, breast cancer, 1481 Chemotherapy, colorectal cancer, colorectal liver metastasis, hepatectomy, 2359 Chemotherapy, colorectal cancer, surgery, prognostic factors,

101 Chemotherapy, cyclin A, YB-1, ovarian cancer, progression, 1715 Chemotherapy, cyclin I, CCNI, kinase insert domain receptor, KDR, ovarian cancer, angiogenesis, 1115 Chemotherapy, cytochalasin B, leukemia, breast carcinoma, cytoskeletal-directed agents, nucleic acid-directed agents, cell enlargement, 65 Chemotherapy, D-dimer, high-grade sarcoma, 6781 Chemotherapy, docetaxel, oxaliplatin, gastric cancer, 3531 Chemotherapy, epithelioid haemangioendothelioma, EHE, survival, observation, surgery, sarcoma, 473 Chemotherapy, febrile neutropenia, bone and soft tissue sarcoma, 2375 Chemotherapy, gastric cancer, FGFR2 amplification, prognosis, 5055 Chemotherapy, glioblastoma multiforme (GBM), moleculartargeted therapy, immunotherapy, review, 1229 Chemotherapy, HER2-positive metastatic breast cancer, T- DM1, 5085 Chemotherapy, histoculture drug response assay, paclitaxel, predictive factor, non-small cell lung cancer, class III betatubulin, 2669 Chemotherapy, hormesis, lung cancer, 5851 Chemotherapy, metastatic breast cancer, platinum, etoposide, ifosfamide, 5091 Chemotherapy, neuroendocrine carcinoma, extrahepatic bile duct, biliary intraepithelial neoplasia, 4821 Chemotherapy, ovarian carcinoma, CA125, progression-free survival, overall survival, 1099 Chemotherapy, pancreatic cancer, adjuvant, aged, pooled analysis, radiotherapy, multicenter study, 3441 Chemotherapy, pancreatic carcinoma, cell line characterization, 3821 Chemotherapy, pleomorphic rhabdomyosarcoma, multicenter study, prognosis, 6213 Chemotherapy, regorafenib, metastatic colorectal cancer, adverse events, 371 Chemothe rapy, small cell carcinoma, epirubicin, paclitaxel, recurrence, 2183 Chemotherapy, small cell carcinoma, stomach, paclitaxel, 563 Chemotherapy, soft tissue sarcoma, hyperthermotherapy, unplanned excision, surgery, 493 Chemotherapy, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, gene expression, FACS, proliferation, 767 Chemotherapy, tongue cancer, celecoxib, survival, 4235 Chemotherapy, tumour-supernatants, murine model, GM- CSF, 1499 Chemotherapy, type IV gastric cancer, survival, 897 Chemotherapy, urothelial carcinoma, tegafur-uracil, 1603 Chemotherapy, uterine carcinosarcoma, carboplatin, ifosfamide, mesna, 4841 Chemotherapy, VX2, HepG2, chemosensitivity, TACE, HCC, 6497 Chemotherapy-related exacerbation, interstitial lung disease, small cell lung cancer, usual interstitial pneumonia, 6261 Chest radiotherapy, cardiac injury, radiation, review, 2487 Chick embryo chorioallantoic membrane, endostatin, renal cell carcinoma, 6521 Children, ex vivo drug resistance, individualized tumor response testing, acute lymphoblastic leukemia, relapse, minimal residual disease, 5667 Chimeric coculture, castration-resistant prostate cancer, estrogen, testosterone, prostate cancer-derived stromal cell, 221 ChIP-seq, vitamin D insufficiency, genome-wide research, vitamin D receptor, 1, 25(OH)2D3, review, 1143 CHM-1, apoptosis, GRP78, nasopharyngeal carcinoma, p85α, 5359 Cholangiocarcinoma, distal bile duct, positron-emission tomography, total lesion glycolysis, prognosis, 6985 Cholangiocytes, oxidative stress, ion transport, hydrogen peroxide, 5881 Chondroitin sulfate proteoglycan-4, PI3K, mtor, melanoma, 1279 Chondrosarcoma, intracranial tumour, prognosis, 875 Choroid plexus carcinoma, Li-Fraumeni syndrome, TP53 mutation, radiation, 3013 Chromatin remodeling factor, gastric cancer, immunohistochemistry, carcinogenesis, AT-rich interactive domain-containing protein, 6819 Chromosomes, cancer cells, GFP, histone-h2b, fusion, nuclear labeling, RFP, retrovirus, cytoplasmic labeling, mitosis, 2553 Chronic fatigue syndrome (CFS), immunotherapy, colostrum, macrophage-activating factor (MAF), cancer, myalgic encephalomyelitis (ME), 4543 Chronic GVHD, graft-versus-host disease, genital GVHD, review, 13 Chronic hepatitis C, hepatectomy, hepatocellular carcinoma, interferon, sustained virological response, 6963 Chronic inflammation, lysozyme, esophagus, stomach, duodenum, colon, review, 6365 Chronic kidney disease, vitamin D, CKD, dialysis, ESRD, renal replacement therapy (RRT), cancer, epidemiology, CKD-MBD, mineral and bone disease, 1181 Chronic lymphocytic leukemia (CLL), bendamustine, rituximab, chemotherapy, immunotherapy, 5129 Chronic lymphocytic leukemia (CLL), paraoxonase-1 (PON1), Q192R polymorphism, L55M polymorphism, chronic myeloid leukemia (CML), PCR-RFLP, 4807 Chronic lymphocytic leukemia, hyperleukocytosis, prognosis, survival, 2861 Chronic lymphocytic leukemia, small-cell lymphoma, ibrutinib, idelalisib, rituximab, ofatumumab, review,

102 Chronic myeloid leukemia, adherence, adverse effects, BCR- ABL1, medication, therapy management, review, 6355 Chronic myeloid leukemia, red blood cell distribution width, prognosis, 5473 Chronic myeloid leukemia (CML), paraoxonase-1 (PON1), Q192R polymorphism, L55M polymorphism, chronic lymphocytic leukemia (CLL), PCR-RFLP, 4807 Chronic pancreatitis, autoimmune pancreatitis, IgG4, 6163 Chronic pancreatitis, pancreatic cancer, cancer of the papilla of Vater, Col11A1, mrna quantification, diagnostic marker, 6153 Chylothorax, esophageal cancer, lymphangiography, case report, 891 Cigarette smoke, oral cancer, carbonyls, cell death, 1961 CIITA, HLA class II, T-cell, melanoma, immune response, Jurkat-C, 25 CIN, cervical cancer, colposcopy, endocervical curettage, 4183 Cinnarizine, multiple myeloma, lymphoma, cancer therapy, WNT, 835 CINV, gynecological cancer, NK1 receptor, aprepitant, 4525 CIPN, neuropathy, duloxetine, paclitaxel, gynecologic cancer, 359 Circadian clock genes, acute myeloid leukemia, acute lymphoid leukemia, 6615 Circulating cell-free DNA, colorectal cancer, DNA integrity, circulating nucleosomes, 2435 Circulating nucleosomes, colorectal cancer, circulating cellfree DNA, DNA integrity, 2435 Circulating tumor cells, biomarkers, CTCs, molecular marker, prostate cancer, 5679 Circulating tumor cells, colorectal cancer, CD44 variant exon 9, 239 Circulating tumor cells, endometrial cancer, hematogenous dissemination, prognosis, recurrence, 683 Circulating tumor cells, radiofrequency ablation, ScreenCell, ablative, 2823 Circumferential resection margin, local recurrence of rectal cancer, 6747 Cisplatin, Pt(O, O -acac)(γ-acac)(dms), renal fibrogenesis, epithelial-mesenchymal transition, 739 Cisplatin, acute exacerbation, interstitial pneumonia, nonsmall cell lung cancer, vinorelbine, 1697 Cisplatin, biomarker, PVT, temozolomide, first-line chemotherapy, BRAF, MGMT, ERCC1, 1105 Cisplatin, cervical cancer, adjuvant chemotherapy, concomitant chemoradiotherapy, ifosfamide, 4161 Cisplatin, cervical cancer, hydration, magnesium, nephrotoxicity, 2199 Cisplatin, DRG, MSC, peripheral neuropathy, neurite elongation, NOGO, MAG, 5383 Cisplatin, fosaprepitant, anthracycline, infusion site adverse events, 379 Cisplatin, gastric cancer, adjuvant chemotherapy, outpatient setting, S-1, 467 Cisplatin, gastric cancer, intraperitoneal chemotherapy, S-1, docetaxel, DCS, 2223 Cisplatin, head and neck cancer, serum albumin, creatinine clearance, renal function, 2909 Cisplatin, induction chemotherapy, metastatic esophageal cancer, adriamycin, fluorouracil, combination chemotherapy, 2975 Cisplatin, nasopharyngeal carcinoma, chemoradiotherapy, docetaxel, 5-fluorouracil, 6861 Cisplatin, ovarian cancer, drug resistance, monofunctional platinum, combination chemotherapy, phytochemical, 2783 Cisplatin, peritoneal metastasis, ovarian cancer, doxorubicin, intraperitoneal chemotherapy, pressure, aerosol, quality of life, 6723 Cisplatin, platinum retention, testicular cancer, follow-up, 1619 Cisplatin, sulforaphene, PI3K, PTEN, synergy, apoptosis, 3901 CK2, AKT/mTOR, chemorefractory, lung cancer, 1537 CK8, head and neck cancer, squamous cell carcinoma, cytokeratin 8, EpCAM, 3953 CKD, vitamin D, chronic kidney disease, dialysis, ESRD, renal replacement therapy (RRT), cancer, epidemiology, CKD-MBD, mineral and bone disease, 1181 CKD-MBD, vitamin D, chronic kidney disease, CKD, dialysis, ESRD, renal replacement therapy (RRT), cancer, epidemiology, mineral and bone disease, 1181 Cladribine, acute myeloid leukemia, induction, idarubicin, 6287 Class III beta-tubulin, histoculture drug response assay, paclitaxel, predictive factor, non-small cell lung cancer, chemotherapy, 2669 Claudin 1, claudin 4, oral squamous cell carcinoma, prognosis, immunohistochemistry, 2949 Claudin 4, claudin 1, oral squamous cell carcinoma, prognosis, immunohistochemistry, 2949 Claudin, TATI, CA 125, ovarian mucinous borderline tumor, 973 Clear cell renal cell carcinoma, hypoxia inducible factor, tumor stage, tumor grade, overall survival, 433 Clinical oncology, positron emission tomography, diagnostic imaging, lym ph atic metastasis, gynecology, 2247 Clinical outcome, glascow prognostic score, pancreatic cancer, gemcitabine monotherapy, curative surgery, 4865 Clinical outcome, non-small cell lung cancer, stage I-II, surgery, stereotactic body radiotherapy, 5607 Clinical outcome, NSCLC, molecular biology, immunotherapies, review, 5745 Clinical outcome, oral squamous cell carcinoma (OSCC), cell lines, Kallikrein-related-peptidase-4 (KLK4), invasion, metastasis,

103 Clinical pharmacy services, oncology, anticancer agent, drug-related problem, inpatient setting, 457 Clinical phenotype, SNP, prostate cancer, vitamin D receptor, African-American, 1549 Clinical population study, cervical cancer, atypical glandular cells, Pap smear, adenocarcinoma in situ, 913 Clinical sign, thyroid sarcoma, thyroid imaging, review, 5185 Clinical trials, epigenetics, glioblastoma, histone deacetylase inhibitor, preclinical trials, review, 615 Clinical trials, NSCLC, novel therapies, tyrosine kinase inhibitors, monoclonal antibodies, review, 2503 Clinical utility, head and neck cancer, tumor markers, 5519 Clinicopathological factors, type I endometrial carcinoma, p-mapk, p-akt, p-mtor, prognosis, 2321 Clonogenicity, glioblastoma, hyperbaric oxygen, HBO, motility, time-lapse videography, 1977 Clotrimazole, melanoma, A375 cells, apoptosis, cell cycle, hexokinase, 3781 C-MET inhibitor, lung cancer, drug resistance, TAS-115, anticancer drug combinations, 5241 C-MET, MET, HGF, crizotinib, head and neck cancer, radiation, 5973 CML, treatment, pregnancy, TKIs, review, 1 CMV, oral squamous cell carcinoma, OSCC, larynx, oropha - rynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, human papilloma virus, HPV, cytomegalovirus, 1657 Co-culture, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Co-culture, monocyte, colon cancer cell, low-dose lipopolysaccharide, RelB, STAT3, 4471 Codon 655, HER2, ERBB2, breast cancer, Ile655Val, polymorphism, 5901 Codon 655, HER2, ERBB2, breast cancer, Ile655Val, polymorphism, 6667 Co-expression, cytoskeletal protein, adducin 3, cancer stem cell marker, CD133, neurospheres, temozolomide-resistant subclone, glioblastoma, NANOG, 6487 Col11A1, pancreatic cancer, cancer of the papilla of Vater, chronic pancreatitis, mrna quantification, diagnostic marker, 6153 Colitis-associated cancer, cytokines, animal models, carcinogenesis, review, 19 Colon adenocarcinoma, phenothiazines, multidrug resistance, MDR, P-glycoprotein (ABCB1), rhodamine 123, apoptosis, doxorubicin, verapamil, 3245 Colon cancer cell, monocyte, co-culture, low-dose lipopolysaccharide, RelB, STAT3, 4471 Colon cancer, adenoma carcinoma sequence, glycosylation, lectins, malignant progression, metastasis, 5333 Colon cancer, adjuvant chemotherapy, elderly patients, 5-FU, 5587 Colon cancer, gastroenterology, cytokines, interleukin-6, IL6, cancer biomarker, 2235 Colon cancer, gene-expression profiling, tumor front, chemokines, epithelial mesenchymal transition, microarray, 6577 Colon cancer, PCK3145, PSP94, breast cancer, prostate cancer, ERK, laminin receptor, 1377 Colon cancer, SN-38, cetuximab, irinotecan, antiangiogenesis, anti-invasion, 5983 Colon polyp, colorectal neoplasm, endoscopic mucosal resection, polypectomy, 6887 Colon, lysozyme, chronic inflammation, esophagus, stomach, duodenum, review, 6365 Colon, maspin, serrated polyps, rectum, conventional adenomas, 4139 Colon, serrated polyps, rectum, conventional adenomas, β- catenin, 929 Colonic cancer, azoxymethane, modified citrus pectin, probiotic, galectin-3, immunohistochemistry, 4765 Colonoscopy, colorectal cancer, family history, surveillance, risk stratification, 4813 Color-coded fluorescence imaging, pancreatic cancer, dual color cells, GFP, RFP, stellate cells, interaction, CFP nude mouse, 2545 Colorectal adenoma, breast cancer, case-control study, colorectal cancer, nested case-control study, vitamin D, 1153 Colorectal adenomas, traditional serrated adenomas, incidence rate, invasive carcinoma, nationwide survey, Iceland, 4929 Colorectal cancer, acneiform rash, minocycline, skin care, panitumumab, tumor response, time to treatment failure, 6175 Colorectal cancer, ANGPTL2, C-reactive protein, CEA, lymph node metastasis, 2849 Colorectal cancer, bevacizumab, FOLFIRI, XELIRI, 3455 Colorectal cancer, blood transfusion, TRIM, immunosenescence, 3553 Colorectal cancer, BRAF V600E, KRAS, molecular biomarkers, iron-deficiency anaemia, 2345 Colorectal cancer, breast cancer, case-control study, colorectal adenoma, nested case-control study, vitamin D, 1153 Colorectal cancer, CD133, lymph node metastasis, immunohistochemistry, 6599 Colorectal cancer, CD44 variant exon 9, circulating tumor cells,

104 Colorectal cancer, circulating cell-free DNA, DNA integrity, circulating nucleosomes, 2435 Colorectal cancer, colorectal liver metastasis, hepate ctomy, chemotherapy, 2359 Colorectal cancer, colorectal polyps, metabolic syndrome, obesity, 2211 Colorectal cancer, early detection, bowel endoscopy, screening, biomarkers, 4935 Colorectal cancer, family history, colonoscopy, surveillance, risk stratification, 4813 Colorectal cancer, fluorouracil, hyperammonemia, fluorocitrate, 6761 Colorectal cancer, GCNT2, glycogene, epigenetics, lymph node metastasis, 1411 Colorectal cancer, hepatocyte growth factor, amphiregulin, transforming growth factor-α, epidermal growth factor receptor, cetuximab, 1683 Colorectal cancer, HIWI, HILI, cancer stem cells, gene expression, 3317 Colorectal cancer, HVEM, prognosis, surgery, tumor immunity, 1361 Colorectal cancer, immunohistochemistry, phosphati - dylserine-specific phospholipase A1, tumor invasion, metastasis, 1459 Colorectal cancer, KRAS, 3-dimensional floating culture, drug screening, 4451 Colorectal cancer, laparoscopic surgery, body mass index, prognosis, recurrence, 5639 Colorectal cancer, liver metastases, hepatectomy, vascular invasion, vascular attachment, 5485 Colorectal cancer, long noncoding RNA, TGF-β, progression, prognosis, 1385 Colorectal cancer, lung metastases, pulmonary metastasectomy, prognostic factors, 3563 Colorectal cancer, lymphatic invasion, blood vessel invasion, prognosis, 6457 Colorectal cancer, MnSOD, GPX1, oxidative stress, antioxidants, 255 Colorectal cancer, NOV, invasion, 6591 Colorectal cancer, numbers of metastatic lymph nodes, adjuvant chemotherapy, 6207 Colorectal cancer, oxaliplatin, adjuvant chemotherapy, recurrence, tumor size, 5073 Colorectal cancer, P53, immunohistochemistry, prognosis, biomarkers, 1641 Colorectal cancer, phospho-h2ax, immunohisto che mistry, prognosis, 2447 Colorectal cancer, phospholipase A2, immuno histochemistry, lymph node metastasis, 2983 Colorectal cancer, probiotic, prostate cancer, endometrial cancer, 5687 Colorectal cancer, ROCK I, MET, immunohistochemistry, tissue microarray, five-year survival, 3267 Colorectal cancer, screening, fecal occult blood (FOB), quaiac-based FOB test, fecal immunochemical test (FIT), performance, R.O.C. analysis, 2873 Colorectal cancer, stereotactic radiosurgery, cerebral oligometastases, survival, predictive tool, treatment optimization, 5515 Colorectal cancer, surgery, chemotherapy, prognostic factors, 3431 Colorectal cancer, TAS-102, 5-FU resistance, irinotecan hydrochloride, gastric cancer, 1437 Colorectal cancer, TAS-102, oxaliplatin, gastric cancer, 5-FU resistance, 4605 Colorectal cancer, total lesion glycolysis, TLG, 18 F-FDG PET/CT, prognostic value, 3495 Colorectal cancer, unresectable, prognosis, neutrophil to lymphocyte ratio, C-reactive protein, Glasgow prognostic score, 5037 Colorectal cancer, Wnt, β-catenin, 4401 Colorectal cancer, xct, CD44v6, CRC, immunohistochemistry, recurrence, 677 Colorectal carcinoma, melanotransferrin, poorly differentiated adenocarcinoma, pathogenesis, adenoma carcinoma sequence, tumorigenesis, 6551 Colorectal liver metastases, radiofrequency ablation, liver resection, disseminated tumor cells, HGF, IL-6, HSP-70, 2961 Colorectal liver metastasis, colorectal cancer, hepate ctomy, chemotherapy, 2359 Colorectal neoplasm, colon polyp, endoscopic mucosal resection, polypectomy, 6887 Colorectal neoplasms, peritoneal neoplasms, urinary tract, intraperitoneal chemotherapy, hyperthermia, postoperative complications, prognosis, 295 Colorectal polyps, colorectal cancer, metabolic syndrome, obesity, 2211 Colostrum, immunotherapy, macrophage-activating factor (MAF), cancer, chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), 4543 Colposcopy, biopsy, genotyping, human papillomavirus, triage, 4197 Colposcopy, CIN, cervical cancer, endocervical curettage, 4183 Combination chemotherapy, cisplatin, ovarian cancer, drug resistance, monofunctional platinum, phytochemical, 2783 Combination chemotherapy, glioblastoma, curcumin, lomustine, cancer stem cells, ceramide, blood brain barrier, lipophilic agent, review, 6373 Combination chemotherapy, induction chemotherapy, metastatic esophageal cancer, adriamycin, cisplatin, fluorouracil, 2975 Combination therapy, cyclooxygenase-2, sulfasalazine, celecoxib, benzimidazole, synergistic effects, brain cancer, glioma, LN18,

105 Combination therapy, hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, epirubicin, 549 Combination therapy, hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, epirubicin, 549 Combined androgen blockade therapy, prostate adenocarcinoma, lymphatic vessel density, 5595 Combined hepatocellular-cholangiocarcinoma, hepato cellular carcinoma, living-donor liver transplantation, 2475 Combretastatin, monocytes, neutrophils, tumors, 2559 Comet assay, cantharidin, DNA damage, DNA repair, TSGH8301 human bladder cancer cells, 795 Comet assay, demethoxycurcumin (DMC); DNA damage, DAPI staining, human lung cancer NCI-H460 cells, 2691 Comet assay, dihydroartemisinin, dihydroartemisininresistant Molt-4 cells, artemisinin-tagged holotransferrin, DNA damage, 1339 Comet assay, gallic acid (GA), DNA damage, DNA repair, human oral cancer SCC-4 cells, 2077 Comparative study, breast cancer, ovarian cancer, mutations, Canadian patients, Saudi Arabian patients, next generation sequencing, 2601 Complete cytoreduction, epithelial ovarian cancer, multivisceral resection, overall survival, 4099 Complete resection, endometrial stromal sarcoma, paracaval recurrence, case report, 3405 Complete resection, uterine leiomyosarcomas, recurrence, 2229 Complete response, pancreatic cancer, recurrence, case report, 2867 Complication, hypopharyngeal cancer, hyoid bone, chemoradiotherapy, larynx preservation, 1735 Complication, intussusception, invagination, small bowel obstruction, gastrectomy, 6829 concentration of 5-FU, 5-FU-based chemotherapy, My5- FU immunoassay, FOLFIRI, FOLFOX, 6193 Concomitant chemo-radiation, induction chemotherapy, head and neck cancer, treatment breaks, intensity-modulated radiotherapy, 6247 Concomitant chemoradiotherapy, cervical cancer, adjuvant chemotherapy, ifosfamide, cisplatin, 4161 Concurrent chemoradiation, cervical cancer, survival, 3447 Concur rent chemoradiotherapy, head and neck cancer, S-1, early glottic cancer, phase I/II study, prospective study, recom mend dose, radiosentitizer, 2385 Concurrent chemoradiotherapy, proton beam therapy, esophageal cancer, survival, late toxicity, 1757 Conditionally replicative adenovirus, gastric cancer, peritoneal dissemination, luminescent imaging, 5201 Conservative treatment, breast cancer, ductal carcinoma in situ, residual tumor, 3471 Contrast enhanced ultrasound, anti-angiogenic therapy, ZD6474, vessel density, tumor microcirculation, angiogenesis, imaging, 2571 Conventional adenomas, maspin, serrated polyps, colon, rectum, 4139 Conventional adenomas, serrated polyps, colon, rectum, β-catenin, 929 Conversion surgery, unresectable gastric cancer, recurrence, 6183 Copper transporter, cancer, drug resistance, molecular docking, 6505 Copper, CTLA4, CD28, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), protein carbonyl (PCO), superoxide dismutase, advanced glycation end-products (AGEs), zinc, 5391 Core needle biopsy, biopsy, open biopsy, sarcoma, 961 Core needle biopsy, core needle wash, PBS, microfluidics, cytology, 5905 Core needle wash, core needle biopsy, PBS, microfluidics, cytology, 5905 Correlation of relative uptake factor and IDC sub-types, breast-specific gamma imaging, relative uptake factor, invasive ductal breast cancer (IDC) sub-types, 5671 Correlation, MRI, breast cancer, neoadjuvant chemotherapy, pathological response, 581 Cosmetic satisfaction, laparoendoscopic single-site surgery, prophylactic bilateral salpingo-oophorectomy, BRCA mutation, ambulatory surgery, 6105 COX-2, canine mammary tumors, CD3, EGFR, 2915 COX2, genotype, polymorphism, Taiwan, upper tract urothelial cancer, 2725 CpG islands, DNA methylation, breast cancer, biomarkers, treatment, review, 4569 CRC, xct, CD44v6, immunohistochemistry, colorectal cancer, recurrence, 677 C-reactive protein, ANGPTL2, CEA, lymph node metastasis, colorectal cancer, 2849 C-reactive protein, colorectal cancer, unresectable, prognosis, neutrophil to lymphocyte ratio, Glasgow prognostic score, 5037 Creatinine clearance, head and neck cancer, serum albumin, renal function, cisplatin, 2909 Crizotinib resistance, non-small cell lung cancer, ALK translocation, ALK inhibitor, KRAS, STK11, ATM, genomics, next-generation sequencing, case report, 3007 Crizotinib, MET, c-met, HGF, head and neck cancer, radiation, 5973 CRM197, neuroblastoma, HB-EGF, 4431 Cross-linked N-Telopeptides of type I collagen, NTx, bone metastasis, lung cancer, 3987 CRPC, abiraterone, metastatic prostate cancer, predictive algorithm, 1057 CRYBB2, prostate cancer, African Americans, single nucleotide polymorphism, genetic association,

106 Cryopreservation, emergency fertility preservation, cancer, autotransplantation, in vitro maturation, oncofertility, review, 3117 CSC, oral squamous cell carcinoma, tumor budding, EMT, prognosis, 6111 CSCs, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deepsequencing, cancer stem cells, cancer cell proliferation, anti-apoptosis, stemness, western blotting, RT-PCR, immunocytochemistry, 3743 CSF1, breast cancer, metastases, CSF1R, tumor-infiltrating macrophages, T-lymphocytes, epithelial tumor cells, tumor stromal cells, 865 CSF1R, breast cancer, metastases, CSF1, tumor-infiltrating macrophages, T-lymphocytes, epithelial tumor cells, tumor stromal cells, 865 CTCs, biomarkers, circulating tumor cells, molecular marker, prostate cancer, 5679 CTLA4, CD28, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), protein carbonyl (PCO), superoxide dismutase, advanced glycation end-products (AGEs), copper, zinc, 5391 Culture, endothelial cells, brain tumor, vasculature, HUVEC, 2681 Curative surgery, glascow prognostic score, clinical outcome, pancreatic cancer, gemcitabine monotherapy, 4865 Curative surgery, small bowel adenocarcinoma, definitive chemotherapy, recurrent tumor resection, distant metastasis, unresectable case, 4135 Curcuma wenyujin, astragalus membranaceus, ovarian cancer, red fluorescent protein, orthotopic, nude mice, tumor progression, metastasis, 3193 Curcumin, bioavailability, microgranules, head and neck squamous cell carcinoma, 6411 Curcumin, cancer stem cells, interleukin-6, interleukin-8, interleukin-1, CXCR1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 Curcumin, EGCG, STAT3, NFĸB, CD44, cancer stem cells, 39 Curcumin, electrical current exclusion, ECE, BCAA, C2C12, atrophy, cachexia, 2085 Curcumin, glioblastoma, lomustine, cancer stem cells, ceramide, blood brain barrier, combination chemotherapy, lipophilic agent, review, 6373 Curcumin, HP102, Jurkat T-cells, IL2, proliferation, apoptosis, 2675 Curcumin, human lung cancer, DNA damage, DNA repair, 3867 Curcumin, nanodisks, lymphoma, all-trans retinoic acid, apoptosis, 6425 Curcumin; anti-cancer properties; autophagy, transcription factors, bioavailability, review, 645 Curcumin-based compounds, cytotoxicity, anti-proliferative activity, apoptosis, cancer, 5293 Cure, GIST, imatinib, surgery, discontinuation of treatment, treatment algorithm, review, 5759 Cutaneous squamous cell carcinoma of the head and neck, radiation toxicity, organ transplant recipient, sirolimus, 5511 CXC, chemokines, NSCLC biomarkers, lung cancer, 6979 CXCL12, CXCR7, glioma, proliferation, mobility, 53 CXCR1, curcumin, cancer stem cells, interleukin-6, interleukin-8, interleukin-1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 CXCR2, curcumin, cancer stem cells, interleukin-6, interleukin-8, interleukin-1, CXCR1, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 CXCR7, CXCL12, glioma, proliferation, mobility, 53 CyberKnife, cervical cancer, recurrent, oligometastasis, stereotactic body radiotherapy, radiosurgery, 5103 Cyclin A, YB-1, ovarian cancer, chemotherapy, progression, 1715 Cyclin D1, gefitinib, lapatinib, MMP9, β-catenin, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 Cyclin D3, SB265610, G1 arrest, phospho(thr160)-cdk2, p21, p38mapk, 3235 Cyclin E, cyclins, CDKs, endometrial adenocarcinoma, prognosis, 3393 Cyclin I, CCNI, kinase insert domain receptor, KDR, ovarian cancer, chemotherapy, angiogenesis, 1115 Cyclins, cyclin E, CDKs, endometrial adenocarcinoma, prognosis, 3393 Cyclooxygenase 2 (COX2), multidrug resistance (MDR), P- glycoprotein, non-steroidal anti-inflammatory drugs (NSAIDs), 2835 Cyclooxygenase-2, sulfasalazine, celecoxib, benzimidazole, combination therapy, synergistic effects, brain cancer, glioma, LN18, 6419 Cyclooxygenase-2, vitamin D, celecoxib, breast cancer, 1189 Cyclooxygenase-2, vitamin D, celecoxib, ovarian cancer, 1197 Cyclopamine, sonic hedgehog (SHH), lung cancer, tumor model, YangZheng XiaoJi, cellular migration, invasion, Smo, Gli, 1321 Cyclophosphamide, breast cancer, neoadjuvant chemotherapy, docetaxel, predictive factor, triple-negative, 907 Cyclophosphamide, memory T-cells, immunotherapy, vesicular stomatitis virus, 4593 Cyclophosphamide, relapsed/refractory multiple myeloma, dexamethasone, treatment options, old drugs, case report, 2165 CYFRA 21-1, ascitic fluid, CA125, differential diagnosis, malignant effusion,

107 CYP24A1, breast cancer, triple-negative breast cancer, vitamin D, 25-hydroxyvitamin D, CYP27B1, vitamin D receptor, 805 CYP27B1, breast cancer, triple-negative breast cancer, vitamin D, 25-hydroxyvitamin D, CYP24A1, vitamin D receptor, 805 CYP27B1, vitamin D, LNCaP, 3773 Cytidine, hand-foot syndrome, uridine, thymidine, deoxycytidine, 5-FU, keratinocytes, 1303 Cytochalasin B, chemotherapy, leukemia, breast carcinoma, cytoskeletal-directed agents, nucleic acid-directed agents, cell enlargement, 65 Cytodiagnosis, thyroid nodules, thyroid neoplasms, biological markers, mutations, 1237 Cytogenetics, glomus tumor, t(1;5), NOTCH2, MIR143, 6167 Cytokeratin 8, head and neck cancer, squamous cell carcinoma, CK8, EpCAM, 3953 Cytokine, chemoimmunotherapy, dendritic cell, MHC class II, pancreatic cancer, vaccine, WT1, 555 Cytokine, lipopolysaccharide, broiler, oral administration of LPS, priming, 4459 Cytokines, colitis-associated cancer, animal models, carcinogenesis, review, 19 Cytokines, gastroenterology, colon cancer, interleukin-6, IL6, cancer biomarker, 2235 Cytokines, prostate cancer, radiotherapy, hormonal therapy, 3379 Cytology, breast cancer, breast imaging, 2369 Cytology, core needle biopsy, core needle wash, PBS, microfluidics, 5905 Cytology, immunocytology, pre-malignant lesions, SCCHN, oropharynx, 6517 Cytomegalovirus, oral squamous cell carcinoma, OSCC, larynx, oropha rynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, human papilloma virus, HPV, CMV, 1657 Cytoplasmic helices, duodenum adenomas, adenomas, β- catenin, 1433 Cytoplasmic labeling, cancer cells, GFP, histone-h2b, fusion, nuclear labeling, RFP, retrovirus, mitosis, chromosomes, 2553 Cytoreduction, ovarian cancer, interval debulking surgery, prognosis, 3027 Cytoreductive surgery, advanced-stage ovarian cancer, recurrence, pancreatic resection, 4125 Cytoreductive surgery, ovarian cancer, relapse, postoperative morbidity, haemodynamic management, transfusion, 1591 Cytoskeletal protein, co-expression, adducin 3, cancer stem cell marker, CD133, neurospheres, temozolomide-resistant subclone, glioblastoma, NANOG, 6487 Cytoskeletal-directed agents, chemotherapy, cytochalasin B, leukemia, breast carcinoma, nucleic acid-directed agents, cell enlargement, 65 Cytoskeleton, gelsolin, breast cancer, prognosis, migration, estrogen receptor-positive, 5277 Cytotherapy, adipose tissue-derived mesenchymal stem cells (AT-MSCs), melanoma, growth inhibition, 159 Cytotoxic effect, 3-arylcoumarin derivatives, cell cycle phase, mitochondrial transmembrane potential, reactive oxygen species production, 653 Cytotoxicity, 3-styryl-2H-chromenes, QSAR analysis, tumor selectivity, anti-hiv activity, 5299 Cytotoxicity, anticancer peptides, temporin, cancer, review, 635 Cytotoxicity, apoptosis, formamidine anthracy clines, necrosis, 1935 Cytotoxicity, ascidian, Eudistoma viride, HeLa, apoptosis, DNA fragmentation, flow cytometry, 283 Cytotoxicity, curcumin-based compounds, anti-proliferative activity, apoptosis, cancer, 5293 Cytotoxicity, electrostatic potential, cardiotoxin, 4513 Cytotoxicity, food dye, tartrazine, genotoxicity, DNA repair, 1465 Cytotoxicity, immunoliposomes, 188 Re-DXR-IL-C225, theranostic vehicle, 4777 Cytotoxicity, in vitro tumor tissue model, cancer cell sheet, biomimick, 6481 Cytotoxicity, N-acyl dopamine, metabolites, vanilloids, cancer, 2657 Cytotoxicity, natural killer cells, natural killer cell subsets, irradiation, viability, radiobiological models, enrichment methods, 5193 Cytotoxicity, oleoylamides, QSAR analysis, tumor selectivity, anti-hiv activity, 5341 Dacomitinib, head and neck squamous cell carcinoma, PIK3CA, BYL719, 175 Daily vitamin D intake, 25-hydroxyvitamin D, 1, 25- dihydroxyvitamin D, parathyroid hormone, benign soft tissue tumor, sarcoma, 1171 DAPI staining, demethoxycurcumin (DMC); DNA damage, comet assay, human lung cancer NCI-H460 cells, 2691 Daunorubicin resistance, vitamin K 3, vitamin K 5, human T-lymphoblastoid leukemia, P-glycoprotein, apoptosis, 6041 DAXX, telomere shortening, altered lengthening of telomeres, TERC, telomerase, in situ, hybridization, ATRX, immunohistochemistry, 3501 DCS regimen, siewert type II adenocarcinoma, neoadjuvant chemotherapy, 419 DCS, gastric cancer, intraperitoneal chemotherapy, S-1, cisplatin, docetaxel, 2223 D-dimer, high-grade sarcoma, chemotherapy, 6781 Death receptors, acute myeloid leukemia, TNFR1, TRAILR, FAS, 4043 Decitabine, myelodysplastic syndrome, SRSF2, U2AF1, ZRSR2,

108 Dedifferentiated liposarcoma, lipoma, well-differentiated liposarcoma, pleomorphic liposarcoma, multiplex ligationdependent probe amplification, 12q amplicon, 1835 Dedifferentiated liposarcoma, well-differentiated liposarcoma, ring chromosome, MDM2, CDK4, 345 Definitive chemora dio therapy, esophageal cancer, hyperthermia, long-term survival, 2299 Definitive chemotherapy, small bowel adenocarcinoma, curative surgery, recurrent tumor resection, distant metastasis, unresectable case, 4135 Degalactosylated/desialylated bovine colostrum, GcMAF, macrophage phagocytic activity, mouse peritoneal macrophage, mouse intestinal macrophage, 4485 Deleterious alleles, chemotherapy toxicity, 5-fluorouracil, DPYD, OPRT, TYMS, TP53, 6971 Demethoxycurcumin (DMC); DNA damage, comet assay, DAPI staining, human lung cancer NCI-H460 cells, 2691 Dendritic cell vaccine, immune cell therapy, regulatory T cell, effector cell therapy, 4533 Dendritic cell, cytokine, chemoimmunotherapy, MHC class II, pancreatic cancer, vaccine, WT1, 555 Dendritic cells (DCs), tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), Poly(I:C), Toll-like receptor 3, TICAM-1, antitumor immunotherapy, review, 4383 Dendritic cells, immunotherapy, metastases, renal cell carcinoma, sequential therapy, targeted-therapy, 1575 Dendrobium falconeri, dendrofalconerol A, EMT, integrin, suppression, migration, lung cancer, 201 Dendrofalconerol A, dendrobium falconeri, EMT, integrin, suppression, migration, lung cancer, 201 Deoxycytidine, hand-foot syndrome, cytidine, uridine, thymidine, 5-FU, keratinocytes, 1303 Depression, hopelessness, helplessness, BDI, breast disease, 941 Depression, hopelessness, helplessness, MADRS, breast disease, 2215 Dermal cylindroma, neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, mosaicism, rare tumor, 6813 Dermatofibrosarcoma protuberans, ocular area, electrochemotherapy, quality of life, 6121 Dermatophagoides farinae body extract, lipopolysaccharide, Pantoea agglomerans, atopic dermatitis, NC/Nga mice, 4499 Derris scandens, lung cancer, anoikis, pro-survival pathway, lupalbigenin, 2827 Desmoplasia, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, nonspecific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Des-γ-carboxyprothrombin (DCP), hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), tumor marker, 2157 Des-γ-carboxyprothrombin, cadherin, side-effect, cell migration, metastasis, hepatocellular carcinoma, 1985 Dexamethasone, artemisinin, sodium ascorbate, vitamin D 3, Trolox, hydrogen peroxide, Molt-4 cells, 1867 Dexamethasone, relapsed/refractory multiple myeloma, cyclophosphamide, treatment options, old drugs, case report, 2165 Diagnosis, autoantibody, biomarker, ovarian cancer slot-blot, 881 Diagnosis, breast cancer, proteomics, multiple reaction monitoring, plasma, 6271 Diagnosis, prostate cancer, PSMA, antibody cross-reactivity, molecular marker, dog, 145 Diagnostic assay, HPV infection, squamous cell oropharyngeal tumors, p16 immunohistochemistry, HPV PCR assay, 4733 Diagnostic biomarkers, thyroid carcinomas review, 2037 Diagnostic imaging, positron emission tomography, lym ph - atic metastasis, gynecology, clinical oncology, 2247 Diagnostic marker, pancreatic cancer, cancer of the papilla of Vater, chronic pancreatitis, Col11A1, mrna quantification, 6153 Dialysis, vitamin D, chronic kidney disease, CKD, ESRD, renal replacement therapy (RRT), cancer, epidemiology, CKD-MBD, mineral and bone disease, 1181 Dichloroacetate, bladder cancer cells, glycolysis, growth, PFKFB3 inhibitor, butyrate, 2-deoxyglucose, phenformin, 5889 Dietary agents, cancer stem cells, mechanism of action, signal transduction pathways, review, 5773 Dietetics, cachexia, mindfulness, 6311 Differential diagnosis, ascitic fluid, CA125, CYFRA 21-1, malignant effusion, 5655 Differential gene regulation, head and neck cancer, keratinocytes, array, 3253 Differentiated thyroid cancer, KISS1, KISS1R, Kisspeptin, local metastasis, tumor growth, invasion, 819 Differentiated thyroid carcinoma, thyroxine withdrawal, hypothyroidism, biochemical alterations, 6933 Differentiation, acute promyelocytic leukemia, all-trans retinoic acid, oleanolic acid, WEHI-3, 6583 Diffuse large B-cell lymphoma, primary CNS lymphoma, gene expression, microarray, 3333 Diffusion weighted MRI, renal tumor, magnetic resonance imaging, apparent diffusion coefficient, biomarker, 2351 Diffusion-weighted imaging (DWI), magnetic resonance imaging (MRI), biparameric MRI (Bp-MRI), tumor markers, CA125, HE4, ovarian tumors characterization, pelvic mass,

109 Dihydroartemisinin, dihydroartemisinin-resistant Molt-4 cells, artemisinin-tagged holotransferrin, DNA damage, comet assay, 1339 Dihydroartemisinin-resistant Molt-4 cells, dihydroartemisinin, artemisinin-tagged holotransferrin, DNA damage, comet assay, 1339 Dihydrofolate reductase (DHFR), fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 - M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E- cadherin, lipids, 1881 Dihydropyrimidine dehydrogenase, DPD, 5-fluorouracil, DPYD deficiency, cancer, capecitabine, 4881 Dimethylsulfoniopropionate, betaine, Ehrlich ascites carcinoma, methylation reaction, activated macrophages, 1475 Disability, bone cancer, osteosarcoma, qualitative, cancer survivors, post-traumatic growth, 6081 Discontinuation of treatment, GIST, imatinib, surgery, cure, treatment algorithm, review, 5759 Disease prevention, macrophages, intestinal microbiota, oral administration of LPS, review, 4391 Disposition, regorafenib, multidrug resistance-associated protein, organic anion-transporting polypeptide, hepatic uptake, biliary excretion, protein-binding, 4681 Disseminated tumor cells, radiofrequency ablation, liver resection, colorectal liver metastases, HGF, IL-6, HSP-70, 2961 Dissemination, staging laparoscopy, near-infrared fluorescence imaging, indocyanin green, liposome, 1353 Distal bile duct, cholangiocarcinoma, positron-emission tomography, total lesion glycolysis, prognosis, 6985 Distal ureterectomy, locally invasive cervical cancer, ureteral reimplantation, 5539 Distant brain control, breast cancer, brain metastasis, radiosurgery, radiation dose, local control, overall survival, 333 Distant metastases, tumor M2-pyruvate kinase, cancer type, tumor size, nodal metastases, tumor stage, 4271 Distant metastasis, head and neck cancer, lung metastasis, bone metastasis, survival, 5499 Distant metastasis, small bowel adenocarcinoma, curative surgery, definitive chemotherapy, recurrent tumor resection, unresectable case, 4135 Diterpene, protein kinase C, HNSCC, TPA, PEP005, 1291 Dithiocarbamate analogs, prostate cancer, apoptosis, emetine gene regulation, chemotherapeutic agents, 4723 DNA damage response-related proteins, ovarian cancer, immunohistochemistry, prognosis, 3909 DNA damage, cantharidin, Comet assay, DNA repair, TSGH8301 human bladder cancer cells, 795 DNA damage, curcumin, human lung cancer, DNA repair, 3867 DNA damage, dihydroartemisinin, dihydroartemisininresistant Molt-4 cells, artemisinin-tagged holotransferrin, comet assay, 1339 DNA damage, gallic acid (GA), Comet assay, DNA repair, human oral cancer SCC-4 cells, 2077 DNA fragmentation, ascidian, Eudistoma viride, cytotoxicity, HeLa, apoptosis, flow cytometry, 283 DNA fragmentation, GFP, histone H2B, fusion gene, RFP, imaging, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, real-time, imaging, 2539 DNA fragmentation, ovarian cancer, 3-hydroxypyridine, imidazole, drug resistance, drug combination, 6027 DNA integrity, colorectal cancer, circulating cell-free DNA, circulating nucleosomes, 2435 DNA methylation, breast cancer, CpG islands, biomarkers, treatment, review, 4569 DNA methylation, cancer epigenetics, esophageal squamous cell carcinoma, microrna, 4617 DNA repair, cantharidin, DNA damage, Comet assay, TSGH8301 human bladder cancer cells, 795 DNA repair, curcumin, human lung cancer, DNA damage, 3867 DNA repair, food dye, tartrazine, cytotoxicity, genotoxicity, 1465 DNA repair, gallic acid (GA), DNA damage, Comet assay, human oral cancer SCC-4 cells, 2077 DNA-methylation, malignant pleural mesothelioma, mir- 126, EGFL7, prognosis, biomarker, 6223 Docetaxel, breast cancer, neoadjuvant chemotherapy, cyclophosphamide, predictive factor, triple-negative, 907 Docetaxel, cancer vaccine, immunotherapy, murine model, prostate cancer, 3275 Docetaxel, castration-resistant prostate cancer (CRPC), PCA 3, androgen deprivation treatment (ADT), prognostic factor, 3075 Docetaxel, gastric cancer, intraperitoneal chemotherapy, S-1, cisplatin, DCS, 2223 Docetaxel, microtubule, microtubule destabilizer, eribulin, paclitaxel, vinorelbine, ixabepilone, 5845 Docetaxel, nasopharyngeal carcinoma, chemoradiotherapy, cisplatin, 5-fluorouracil, 6861 Docetaxel, oxaliplatin, chemotherapy, gastric cancer, 3531 Docetaxel, renal cell carcinoma, cabazitaxel, p-glycoprotein, AKT, Caki-1, KMRC-1, OS-RC-2, 6671 Dog, lymphoma, stem cell marker, spheres, canine model, 2805 Dog, prostate cancer, PSMA, antibody cross-reactivity, molecular marker, diagnosis, 145 Dogs, transmissible venereal tumors, TVT, Interleukin-2, IL- 2,

110 Dogs, transmissible venereal tumors, TVT, interleukin-2, IL2, vincristine, 3385 Dose calculation algorithm, breast radiotherapy, analytical anisotropic algorithm, pencil beam convolution, planning guidelines, 2841 Dose determination, EGFR monoclonal antibody, mtor inhibitor, targeted-therapy, 1567 Dosimetric comparison, head and neck cancer, unilateral neck, volumetric arc techniques, helical IMRT, 2991 Doxorubicin, peritoneal metastasis, ovarian cancer, cisplatin, intraperitoneal chemotherapy, pressure, aerosol, quality of life, 6723 Doxorubicin, phenothiazines, multidrug resistance, MDR, P-glycoprotein (ABCB1), rhodamine 123, colon adenocarcinoma, apoptosis, verapamil, 3245 Doxorubicin, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, HT1080, taurolidine, apoptosis, necrosis, gene expression, FACS, proliferation, chemotherapy, 767 DPD, dihydropyrimidine dehydrogenase, 5-fluorouracil, DPYD deficiency, cancer, capecitabine, 4881 DPD, peripheral blood, biomarker, prospective, TS, survival, esophageal cancer, neoadjuvant, 1297 DPYD deficiency, dihydropyrimidine dehydrogenase, DPD, 5-fluorouracil, cancer, capecitabine, 4881 DPYD, chemotherapy toxicity, deleterious alleles, 5- fluorouracil, OPRT, TYMS, TP53, 6971 DRG, MSC, cisplatin, peripheral neuropathy, neurite elongation, NOGO, MAG, 5383 Drug combination, ovarian cancer, 3-hydroxypyridine, imidazole, DNA fragmentation, drug resistance, 6027 Drug delivery system (DDS), chemoembolization, vascular heterogeneity, anti-angiogenic therapy, ceramics, microsphere, TNP-470, uterine sarcoma, carcinosarcoma, 4757 Drug delivery systems, intraperitoneal chemotherapy, peritoneal carcinomatosis, animal experiment, review, 627 Drug delivery, polyethylenimine, sirna, folate receptor, cancer, nanoparticle, 5433 Drug development, organic anion-transporting polypeptides, OATPs. microcystin-lr, pancreatic cancer, cancer treatment, targeted-therapy, 5857 Drug resistance, cancer, copper transporter, molecular docking, 6505 Drug resistance, cisplatin, ovarian cancer, monofunctional platinum, combination chemotherapy, phytochemical, 2783 Drug resistance, lung cancer, c-met inhibitor, TAS-115, anticancer drug combinations, 5241 Drug resistance, ovarian cancer, 3-hydroxypyridine, imidazole, DNA fragmentation, drug combination, 6027 Drug screening, KRAS, colorectal cancer, 3-dimensional floating culture, 4451 Drug sequencing, metastatic, castrate-resistant, prostate cancer, abiraterone, predictors response, 5615 Drug-delivery system, liposome, sortase A, 4409 Drug-induced interstitial lung disease, small cell lung cancer, non-small cell lung cancer, idiopathic interstitial pneumonia, number of regimens, 1065 Drug-related problem, oncology, anticancer agent, clinical pharmacy services, inpatient setting, 457 DU-145, salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, cell line, PC-3, LNCaP, apoptosis, necrosis, cell burst, 5225 Dual anti-angiogenic chemotherapy, glioblastoma, temozolomide, celecoxib, 4955 Dual color cells, pancreatic cancer, GFP, RFP, stellate cells, interaction, CFP nude mouse, color-coded fluorescence imaging, 2545 Ductal carcinoma in situ, breast cancer, conservative treatment, residual tumor, 3471 Duloxetine, CIPN, neuropathy, paclitaxel, gynecologic cancer, 359 Duodenum adenomas, adenomas, β-catenin, cytoplasmic helices, 1433 Duodenum, gastrointestinal stromal tumor, surgical treatment, 6321 Duodenum, lysozyme, chronic inflammation, esophagus, stomach, colon, review, 6365 DUOX, apoptosis, HOCl, superoxide anion, NOX1, hydroxyl radical, 5927 DUOX1, NOX1, HOCl, apoptosis, matrix metallo proteinase, 5955 Duration of first-line treatment, renal cell carcinoma, molecular targeted therapy, prognostic factor, 3415 DZNep, biliary tract cancer, EZH2, PRC2, anchorageindependent growth, cancer stem cells, 4697 EAC, Pd(II) complex, in vivo, tumor, PCNA, apoptosis, 1491 Early breast cancer, aquaporin 3, polymorphism, prognosis, 2775 Early detection, colorectal cancer, bowel endoscopy, screening, biomarkers, 4935 Early diagnosis, prostate cancer, PSAV, fpsa,v, propsa,v, 3567 Early gastric cancer, non-curative resection, ESD, 2969 Early glottic cancer, head and neck cancer, S-1, concur rent chemoradiotherapy, phase I/II study, prospective study, recom mend dose, radiosentitizer, 2385 EBV, Burkitt lymphoma, non-hodgkin lymphoma, HIV infection, mandible, osteomyelitis, FDG-PET, Epstein- Barr, 4837 EBV, oral squamous cell carcinoma, OSCC, larynx, oropha - rynx, Epstein-Barr virus, human herpes virus-1, HHV-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 EBV-transformed B cells, CAL-101, Celecoxib, ER stress, 2699 Ec peptide, IGF-1 isoforms, cancer cell lines, IGF-1 classes, IGF-1Ea, IGF-1Eb,

111 EC, uterine cancer, obesity, lymphovascular invasion, grade, body mass index, 4053 E-cadherin, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, dihydrofolate reductase (DHFR), lipids, 1881 E-cadherin, lymphangioleiomyomatosis, β-catenin, podoplanin, EGFR, 3353 E-cadherin, pituitary adenoma, EMT, N-cadherin, SLUG, SNA1, TWIST, 2635 ECE, electrical current exclusion, curcumin, BCAA, C2C12, atrophy, cachexia, 2085 Echinomycin, thyroid cancer, HIF1α inhibitor, orthotopic mouse model, molecular targeted therapy, adjuvant chemotherapy, 2049 Effector cell therapy, immune cell therapy, regulatory T cell, dendritic cell vaccine, 4533 EGCG, curcumin, STAT3, NFĸB, CD44, cancer stem cells, 39 EGF, EGFR-overexpressing cancer cell line, apoptosis, PI3K/AKT/mTOR signaling pathway, radiosensitization, 245 EGFL7, malignant pleural mesothelioma, mir-126, DNAmethylation, prognosis, biomarker, 6223 EGFR monoclonal antibody, dose determination, mtor inhibitor, targeted-therapy, 1567 EGFR mutation, gefitinib, non-small cell lung cancer, exon 19 deletion, L858R, 6957 EGFR mutation, pulmonary blastoma, neoadjuvant treatment, PD-L1 expression, ALK-EML4 translocation, chemo radiotherapy, pembrolizumab, 4871 EGFR, breast cancer, estrogen receptor (ER), HER2, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, proliferation, apoptosis, 1243 EGFR, canine mammary tumors, CD3, COX-2, 2915 EGFR, glioblastoma, peritumoral edema, radiotherapy, response assessment, 4117 EGFR, lymphangioleiomyomatosis, β-catenin, E-cadherin, podoplanin, 3353 EGFR, mir-7, ovarian cancer, TP53 status, tumour grade, BCL2, 2423 EGFR, non-small cell lung cancer, mutation, outcome, population, prevalence, 3979 EGFR, XRCC1, MTHFR, cancer, population stratifica tion, ancestry, 2009 EGFR-overexpressing cancer cell line, EGF, apoptosis, PI3K/AKT/mTOR signaling pathway, radiosensitization, 245 EGFR-TKI, gefitinib, erlotinib, non-small-cell lung cancer, minor EGFR mutation, 3885 EHE, epithelioid haemangioendothelioma, survival, observation, chemotherapy, surgery, sarcoma, 473 Ehrlich ascites carcinoma, dimethylsulfoniopropionate, betaine, methylation reaction, activated macrophages, 1475 EIF2α, GADD34, proteasome inhibition, cell death, autophagy, 5317 Elderly patients, adjuvant chemotherapy, colon cancer, 5-FU, 5587 Elderly patients, cerebral metastases, stereotactic radiosurgery, optimal dose, treatment results, 5701 Elderly patients, endoscopic radiofrequency ablation, hepatocellular carcinoma, 3033 Elderly patients, gastrectomy, nutrition, 511 Elderly patients, gastric cancer, laparoscopic surgery, gastrectomy, laparoscopy-assisted gastrectomy, 2191 Elderly patients, prostate cancer, metastatic epidural spinal cord compression, irradiation, overall survival, 6189 Elderly, abiraterone, castrate-resistant, prostate cancer, PSA, 3097 Elderly, cancer of unknown primary, MESCC, radiation therapy, survival tool, 6219 Elderly, HCC, hepatectomy, 6855 Elderly, treosulfan, ovarian cancer, non-interventional study, 6869 Electrical current exclusion, ECE, curcumin, BCAA, C2C12, atrophy, cachexia, 2085 Electrocautery, nuclear protein in testis, NUT midline carcinoma, Ewing sarcoma, endobronchial tumour, 1607 Electrochemotherapy, dermatofibrosarcoma protuberans, ocular area, quality of life, 6121 Electrostatic potential, cytotoxicity, cardiotoxin, 4513 Ellipticine, cancer treatment, experimental chemotherapy, block copolymers, micelles, 753 Emergency fertility preservation, cancer, cryopreservation, autotransplantation, in vitro maturation, oncofertility, review, 3117 Emetine gene regulation, prostate cancer, apoptosis, dithiocarbamate analogs, chemotherapeutic agents, 4723 Emotional, patient physician communication, personality, proximity, authenticity, breast cancer, 1627 Empty pelvis syndrome, pelvic exenteration, enteroperineal fistula, 5543 EMT, Dendrobium falconeri, dendrofalconerol A, integrin, suppression, migration, lung cancer, 201 EMT, mtor, mtorc1, mtorc2, brain metastases, 689 EMT, oral squamous cell carcinoma, tumor budding, CSC, prognosis, 6111 EMT, pituitary adenoma, N-cadherin, E-cadherin, SLUG, SNA1, TWIST, 2635 EMT, SLUG, TWIST, breast cancer, epithelial-mesenchymal transition, 3961 Enantiomer, phosphatidylinositol derivative, caspaseindependent apoptosis, AIF, AMID,

112 Endobronchial tumour, nuclear protein in testis, NUT midline carcinoma, Ewing sarcoma, electrocautery, 1607 Endocervical curettage, CIN, cervical cancer, colposcopy, 4183 Endogenous control, biomarker, germ cell tumors, microrna, real time PCR, testicular cancer, 117 Endometrial adenocarcinoma, cyclin E, cyclins, CDKs, prognosis, 3393 Endometrial cancer, circulating tumor cells, hematogenous dissemination, prognosis, recurrence, 683 Endometrial cancer, fertility-sparing management, atypical endometrial hyperplasia, progression risk, 6799 Endometrial cancer, incisional recurrence, laparoscopy, open surgery, port site metastases, 6097 Endometrial cancer, neutrophil to lymphocyte ratio, prognosis, 337 Endometrial cancer, patient volume, guidelines, preoperative staging, lymphadenectomy, 2887 Endometrial cancer, probiotic, prostate cancer, colorectal cancer, 5687 Endometrial cancer, VMAT, SIB, gynecological cancer, 2149 Endometrial carcinoma, granulosa cell tumor of the ovary, total hysterectomy with bilateral adnexectomy, 5547 Endometrial hyperplasia, progestin therapy, PAX2, PTEN, therapy response, 6401 Endometrial stromal sarcoma, paracaval recurrence, complete resection, case report, 3405 Endometrioid endometrial cancer, microrna, PTEN, 1401 Endoplasmic reticulum stress, pancreatic neuroendocrine tumor, grading, 6127 Endoscopic biliary drainage, pancreatic cancer, pancreaticoduodenectomy, 5079 Endoscopic hepatectomy, hepatocellular carcinoma, Milan criteria, open hepatectomy, propensity case-matched analysis, 1583 Endoscopic mucosal resection, colon polyp, colorectal neoplasm, polypectomy, 6887 Endoscopic radiofrequency ablation, elderly patients, hepatocellular carcinoma, 3033 Endostatin, renal cell carcinoma, chick embryo chorioallantoic membrane, 6521 Endothelial cells, culture, brain tumor, vasculature, HUVEC, 2681 Endovascular abdominal aortic aneurysm repair, gastric cancer, abdominal aortic aneurysm, one-stage procedure, 6909 Enrichment methods, natural killer cells, natural killer cell subsets, irradiation, viability, cytotoxicity, radiobiological models, 5193 Enteroperineal fistula, pelvic exenteration, empty pelvis syndrome, 5543 Environmental factors, esophageal carcinoma, lifestyle factors, microrna, socioeconomic factors, 1091 EpCAM, head and neck cancer, squamous cell carcinoma, cytokeratin 8, CK8, 3953 Epidemiology, vitamin D, chronic kidney disease, CKD, dialysis, ESRD, renal replacement therapy (RRT), cancer, CKD-MBD, mineral and bone disease, 1181 Epidemiology, vitamin D, preventive medicine, cancer, 25(OH)D, review, 1161 Epidermal growth factor receptor (HER2)-negative, bevacizumab, breast cancer, metastatic disease, predictive factors, 6941 Epidermal growth factor receptor gene mutation, non-small cell lung cancer, exon 19 deletion, exon 21 L858R, afatinib, 2005 Epidermal growth factor receptor, cetuximab, KRAS, metastatic colorectal cancer, 4207 Epidermal growth factor receptor, hepatocyte growth factor, amphiregulin, transforming growth factor-α, cetuximab, colorectal cancer, 1683 Epidermal growth factor receptor, non-small cell lung cancer, anaplastic lymphoma kinase, chemosensitivity, 1791 Epidermal growth factor receptor, vascular endothelial growth factor, basic fibroblastic growth factor, neurofibromatosis type 1, vessel density, malignant peripheral nerve sheath tumor, 137 Epidermal growth factor receptor-tyrosine kinase inhibitor, central nervous system, acquired resistance, T790M, leptomeningeal metastases, brain metastases, 1025 Epidermal growth factor, gastric cancer, serum level, cancer risk, progression, 2709 Epigenetic, HCC, cell-free DNA, methylation, quantitative MSP, 997 Epigenetic, JMJD3, UTX, histone modification, xenograft analysis, cancer treatment, 6611 Epigenetics, clinical trials, glioblastoma, histone deacetylase inhibitor, preclinical trials, review, 615 Epigenetics, GCNT2, glycogene, colorectal cancer, lymph node metastasis, 1411 Epigenetics, HDAC, histone, inhibitors, acetylasation, pancreatic cancer, review, 3129 Epirubicin, hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, combination therapy, 549 Epirubicin, hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, combination therapy, 549 Epirubicin, small cell carcinoma, paclitaxel, chemothe rapy, recurrence, 2183 Epithelial growth factor receptor (EGFR), gefitinib, lapatinib, MMP9, cyclin D1, β-catenin, head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 Epithelial ovarian cancer, complete cytoreduction, multivisceral resection, overall survival,

113 Epithelial ovarian cancer, recurrence, microrna, 2611 Epithelial ovarian cancer, recurrence, quaternary cytoreduction, prolonged survival, 3519 Epithelial tumor cells, breast cancer, metastases, CSF1, CSF1R, tumor-infiltrating macrophages, T-lymphocytes, tumor stromal cells, 865 Epithelial-mesenchymal transition (EMT), gefitinib, lapatinib, MMP9, cyclin D1, β-catenin, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 Epithelial-mesenchymal transition, cisplatin, (Pt(O, O - acac)(γ-acac)(dms)), renal fibrogenesis, 739 Epithelial mesenchymal transition, gene-expression profiling, colon cancer, tumor front, chemokines, microarray, 6577 Epithelial mesenchymal transition, MCP1, AKT, head and neck cancer, 3299 Epithelial-mesenchymal transition, SLUG, TWIST, EMT, breast cancer, 3961 Epithelial mesenchymal transition, sorafenib, hepatocellular carcinoma, matrix metalloproteinase, 1967 Epithelioid haemangioendothelioma, EHE, survival, observation, chemotherapy, surgery, sarcoma, 473 Epstein-Barr, Burkitt lymphoma, non-hodgkin lymphoma, HIV infection, mandible, osteomyelitis, FDG-PET, EBV, 4837 Epstein-Barr virus, oral squamous cell carcinoma, OSCC, larynx, oropha rynx, EBV, human herpes virus-1, HHV-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 ER stress, CAL-101, Celecoxib, EBV-transformed B cells, 2699 ER stress, proteasome inhibitor, ubiquitin-proteasome system, PML RARA, 3307 ER-associated degradation, unfolded protein response, tumor hypoxia, acute lymphoblastic leukemia, WNT growth factors, 4625 ERBB2, HER2, breast cancer, codon 655, Ile655Val, polymorphism, 5901 ERBB2, HER2, breast cancer, codon 655, Ile655Val, polymorphism, 6667 ERCC1, biomarker, PVT, temozolomide, cisplatin, first-line chemotherapy, BRAF, MGMT, 1105 Erectile dysfunction, hypofractionation, simultaneous integrated boost, prostate cancer, IMRT, IGRT, 4177 Eribulin, microtubule, microtubule destabilizer, paclitaxel, docetaxel, vinorelbine, ixabepilone, 5845 ERK, PCK3145, PSP94, breast cancer, colon cancer, prostate cancer, laminin receptor, 1377 Erlotinib, EGFR-TKI, gefitinib, non-small-cell lung cancer, minor EGFR mutation, 3885 Erythropoiesis, apoptosis-inducing factor, mitochondrionassociated 2 (Aifm2), murine erythroleukemia cells, 4491 ESD, non-curative resection, early gastric cancer, 2969 Esophageal cancer, cardiac tamponade, postoperative complication, 407 Esophageal cancer, chylothorax, lymphangiography, case report, 891 Esophageal cancer, hyperthermia, definitive chemora dio - therapy, long-term survival, 2299 Esophageal cancer, mouse models, orthotopic, experimental metastasis, GFP imaging, 4655 Esophageal cancer, myelosuppression, chemoradiation, 4889 Esophageal cancer, peripheral blood, biomarker, prospective, TS, DPD, survival, neoadjuvant, 1297 Esophageal cancer, proton beam therapy, concurrent chemoradiotherapy, survival, late toxicity, 1757 Esophageal cancer, small cell carcinoma, mirna, prognostic marker, surgery, 719 Esophageal carcinoma, environmental factors, lifestyle factors, microrna, socioeconomic factors, 1091 Esophageal carcinoma, IL32, regulatory T-cell, immunsuppressive, survival, 2941 Esophageal squamous cell carcinoma, cancer epigenetics, microrna, DNA methylation, 4617 Esophageal squamous cell carcinoma, ferredoxin reductase, chemoradiation therapy, biomarker, 6471 Esophageal squamous cell carcinoma, PDHE1α, immunohistochemistry, Warburg effect, overall survival, 5533 Esophagitis, NSCLC, radiotherapy, toxicity, survival, 5491 Esophagogastric junction carcinoma, Siewert type II, recurrence, 505 Esophagogastric junction, lymph node excision, neoplasms, surgery, prognosis, 445 Esophagus, lysozyme, chronic inflammation, stomach, duodenum, colon, review, 6365 Esophagus, squamous cell carcinoma, adenocarcinoma, PDGFR-α, CD117, immunohistochemistry, 3793 ESRD, gastric cancer, gastrectomy, 2263 ESRD, vitamin D, chronic kidney disease, CKD, dialysis, renal replacement therapy (RRT), cancer, epidemiology, CKD-MBD, mineral and bone disease, 1181 Estimation, kidney cancer, radiosurgery, brain metastasis, survival, 4215 Estrogen receptor (ER), breast cancer, HER2, EGFR, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, proliferation, apoptosis, 1243 Estrogen receptor, breast tumors, histological grading, SUV, progesterone receptor, Ki67, BCL2, p53, androgen receptor, 569 Estrogen receptor, oral squamous cell carcinoma, head and neck cancer, histopathologic grade, immunohistochemistry, 5867 Estrogen receptor-positive, gelsolin, breast cancer, prognosis, migration, cytoskeleton,

114 Estrogen, breast cancer, incidence, lung cancer, survival, 1121 Estrogen, castration-resistant prostate cancer, testosterone, prostate cancer-derived stromal cell, chimeric coculture, 221 Ethnicity, serum cotinine, serum vitamin D, smoking, lung cancer, 1211 Etoposide, metastatic breast cancer, chemotherapy, platinum, ifosfamide, 5091 Eudistoma viride, ascidian, cytotoxicity, HeLa, apoptosis, DNA fragmentation, flow cytometry, 283 Everolimus, mtor inhibitor-associated anemia, mtor inhibitor, 2333 Everolimus, PEC, PEComa, PEC tumor, mesenchymal neoplasm, mtor inhibition, targeted therapy, case report, 3399 Everolimus, tyrosine kinase inhibitor, PTEN, VEGFR, head and neck squamous cell carcinoma, sorafenib, sunitinib, 1389 Everolimus, tyrosin-kinase-inhibitor, mtor, AREG, head and neck squamous cell carcinoma, sorafenib, sunitinib, 1951 Ewing sarcoma, nuclear protein in testis, NUT midline carcinoma, endobronchial tumour, electrocautery, 1607 Ex situ, non-small-cell lung cancer, reimplantation, bench surgery, autotransplantation, in vivo, 1675 Ex vivo chemoresponse, MCP1, anti-mcp1, HNSCC, FLAVINO assay, 3917 Ex vivo drug resistance, individualized tumor response testing, acute lymphoblastic leukemia, children, relapse, minimal residual disease, 5667 Exercise, breast cancer, chemotherapy, physical activity, 5623 Exon 19 deletion, gefitinib, EGFR mutation, non-small cell lung cancer, L858R, 6957 Exon 19 deletion, non-small cell lung cancer, epidermal growth factor receptor gene mutation, exon 21 L858R, afatinib, 2005 Exon 21 L858R, non-small cell lung cancer, epidermal growth factor receptor gene mutation, exon 19 deletion, afatinib, 2005 Exosome, neuroblastoma, microrna, mirna, 2521 Exosomes, breast cancer, extracellular vesicles, microvesicles, biomarkers, liquid biopsy, review, 6379 Expected survival, pancreatic cancer, metastasis, irradiation, predictive factors, 4105 Experimental chemotherapy, cancer treatment, ellipticine, block copolymers, micelles, 753 Experimental metastasis, esophageal cancer, mouse models, orthotopic, GFP imaging, 4655 Extended lymphadenectomy, gastric cancer, para-aortic lymph node metastasis, induction chemotherapy, 6739 Extended-field external-beam radiotherapy, advanced-stage endometrial cancer, intensity-modulated radiotherapy, 2893 Extracellular vesicles, breast cancer, exosomes, microvesicles, biomarkers, liquid biopsy, review, 6379 Extrahepatic bile duct, neuroendocrine carcinoma, biliary intraepithelial neoplasia, chemotherapy, 4821 Extraskeletal myxoid chondrosarcoma, plantar fibroma, 6171 Extraskeletal, osteosarcoma, immunohistochemistry, therapy, treatment outcome, 2129 EZH2, biliary tract cancer, PRC2, DZNep, anchorageindependent growth, cancer stem cells, 4697 FACS, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, gene expression, proliferation, chemotherapy, 767 F-actin, calponin 1 (CNN1), cell motility, cell invasion, 5993 FADD, apoptosis, BAX/BAK, bichalcone analog, CD95, human colon carcinoma HT-29 cells, 5407 Fagara xanthoxyloides, antiproliferative action, prostate cancer, Pseudocedrela kotschyi, 1453 FAK pathway, curcumin, cancer stem cells, interleukin-6, interleukin-8, interleukin-1, CXCR1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, review, 599 Familial breast cancer, microsatellite markers, linkage analysis, next generation sequencing, sequencing analysis, 3155 Family history, colorectal cancer, colonoscopy, surveillance, risk stratification, 4813 FANCD2, human papillomavirus, tonsillar carcinoma, tonsillitis, p16 INK4A, 6633 FAS ligand, melanoma, zinc, apoptosis, reactive oxygen species, p53, 5309 FAS, acute myeloid leukemia, TNFR1, TRAILR, death receptors, 4043 FDG-PET, Burkitt lymphoma, non-hodgkin lymphoma, HIV infection, mandible, osteomyelitis, EBV, Epstein-Barr, 4837 FDG-PET/CT, breast cancer, primary systemic therapy, Ki- 67, response evaluation, 5063 Feasibility, glioma, PCV, tolerance, 2901 Febrile neutropenia, 18 F-FDG-PET/CT, invasive aspergillosis, haematological malignancies, 2999 Febrile neutropenia, bone and soft tissue sarcoma, chemotherapy, 2375 Fecal immunochemical test (FIT), colorectal cancer, screening, fecal occult blood (FOB), quaiac-based FOB test, performance, R.O.C. analysis, 2873 Fecal occult blood (FOB), colorectal cancer, screening, quaiac-based FOB test, fecal immunochemical test (FIT), performance, R.O.C. analysis, 2873 Feline, mammary tumours, cadherins, catenins, 3361 Femur, metastasis, intramedullary nailing, polymethyl - methacrylate, physical status, prognosis,

115 Ferredoxin reductase, esophageal squamous cell carcinoma, chemoradiation therapy, biomarker, 6471 Fertility-sparing management, atypical endometrial hyperplasia, progression risk, endometrial cancer, 6799 FGFR, angiogenesis, gastric cancer, 6655 FGFR2 amplification, gastric cancer, chemotherapy, prognosis, 5055 FGFR3, TP53, urine sediment, mutation phenotype, bladder cancer, 4915 Fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Fibrosarcoma, soft tissue sarcoma, resveratrol, phytotherapy, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, gene expression, FACS, proliferation, chemotherapy, 767 First-line chemotherapy, biomarker, PVT, temozolomide, cisplatin, BRAF, MGMT, ERCC1, 1105 First-line, tyrosine kinase inhibitor, metastatic renal cell carcinoma, second-line, objective response, progressionfree survival, 3067 Five-year survival, colorectal cancer, ROCK I, MET, immunohistochemistry, tissue microarray, 3267 FLAVINO assay, MCP1, anti-mcp1, HNSCC, ex-vivo chemoresponse, 3917 Flow cytometry, ascidian, Eudistoma viride, cytotoxicity, HeLa, apoptosis, DNA fragmentation, 283 Flunarizine, multiple myeloma, lymphoma, cancer therapy, WNT, pathway, 1369 Fluorescence; color-coded imaging, tumor microenvironment, cancer-associated fibroblasts, blood vessels, liver metastasis, RFP, 5821 Fluorocitrate, fluorouracil, hyperammonemia, colorectal cancer, 6761 Fluorothymidine, brain tumors, tumor grading, proliferation activity, PET/CT, 955 Fluorouracil, hyperammonemia, colorectal cancer, fluorocitrate, 6761 Fluorouracil, induction chemotherapy, metastatic esophageal cancer, adriamycin, cisplatin, combination chemotherapy, 2975 Folate receptor, polyethylenimine, sirna, drug delivery, cancer, nanoparticle, 5433 FOLFIRI, concentration of 5-FU, 5-FU-based chemotherapy, My5-FU immunoassay, FOLFOX, 6193 FOLFIRI, bevacizumab, XELIRI, colorectal cancer, 3455 FOLFIRI, ramucirumab, metastatic colorectal carcinoma, Japanese patients, pharmacokinetics, 4003 FOLFOX, concentration of 5-FU, 5-FU-based chemotherapy, My5-FU immunoassay, FOLFIRI, 6193 Follicular lesion of undetermined significance, nodule size, follicular neoplasms, thyroid malignancy, thyroid cancer, 1635 Follicular neoplasms, nodule size, follicular lesion of undetermined significance, thyroid malignancy, thyroid cancer, 1635 Follow-up, platinum retention, testicular cancer, cisplatin, 1619 Food dye, tartrazine, cytotoxicity, genotoxicity, DNA repair, 1465 Formamidine anthracy clines, apoptosis, cytotoxicity, necrosis, 1935 Formyl-peptide receptors, lung cancer, gene expression, 2769 Fosaprepitant, anthracycline, cisplatin, infusion site adverse events, 379 FOXD1, non-small cell lung cancer, microarray, pathway signature, PTEN, 261 FoxO1, Zfat, proteasomal degradation, IL-7Rα, T-cell homeostasis, 4417 FPSA,V, prostate cancer, PSAV, propsa,v, early diagnosis, 3567 Fractionation, brain oligometastases, stereotactic radiotherapy, whole brain radiotherapy, RPA, 3055 Frail patients, basal cell carcinoma, hypofractionated radiotherapy, skin cancer, 4949 Freedom from new cerebral metastases, cerebral metastases, breast cancer, stereotactic radiosurgery, prognostic tool, 6793 Freedom from new cerebral metastases, renal cell carcinoma, cerebral metastases, stereotactic radiosurgery, local control, survival, 3571 FRO cells, anaplastic thyroid carcinoma, 17-AAG, herbimycin A, HSP90, β-catenin, AKT, 5453 Fucoxanthin, fucoxanthinol, MCF-7, MDA-MB-231, NF-ĸB, SOX9, 207 Fucoxanthinol, fucoxanthin, MCF-7, MDA-MB-231, NF-ĸB, SOX9, 207 Fulvestrant (Faslodex), breast cancer, estrogen receptor (ER), HER2, EGFR, tamoxifen, trastuzumab (Herceptin), GW2974, proliferation, apoptosis, 1243 Fumarate hydratase gene, HLRCC, PRCC2, Warburg effect, bortezomib, 6639 Furochalcones, antiproliferative activity, HL60 cells, structure and activity relationship, 811 Fusion gene, GFP, histone H2B, RFP, imaging, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, imaging, 2539 Fusion, cancer cells, GFP, histone-h2b, nuclear labeling, RFP, retrovirus, cytoplasmic labeling, mitosis, chromosomes,

116 G1 arrest, SB265610, cyclin D3, phospho(thr160)-cdk2, p21, p38mapk, 3235 G 2 -M phase, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 GADD34, proteasome inhibition, cell death, eif2α, autophagy, 5317 Galectin-1, anginex, tumor angiogenesis, cancer, indium- 111, 5945 Galectin-3, azoxymethane, colonic cancer, modified citrus pectin, probiotic, immunohistochemistry, 4765 Gallbladder cancer, prostate stem cell antigen, GPIanchored protein, intracellular signaling, tumor suppressor, 2619 Gallbladder, adenoma, serrated, case report, 3485 Gallic acid (GA), DNA damage, Comet assay, DNA repair, human oral cancer SCC-4 cells, 2077 Gap junction, PBA, vorinostat, p38 MAPK, JNK, 775 GAPDH, immunohistochemistry, mrna expression, melanoma, prognosis, 439 Gastrectomy, elderly patients, nutrition, 511 Gastrectomy, gastric cancer, ESRD, 2263 Gastrectomy, gastric cancer, laparoscopic surgery, elderly patients, laparoscopy-assisted gastrectomy, 2191 Gastrectomy, intussusception, invagination, small bowel obstruction, complication, 6829 Gastric adenocarcinoma, tumor-infiltrating neutrophils, Cancer Registry Study, Messina province, 487 Gastric cancer, abdominal aortic aneurysm, one-stage procedure, endovascular abdominal aortic aneurysm repair, 6909 Gastric cancer, adjuvant chemotherapy, outpatient setting, S-1, cisplatin, 467 Gastric cancer, adjuvant chemotherapy, stage IB, 4091 Gastric cancer, adjuvant surgery, non-curative clinical factor, peritoneal dissemination, 401 Gastric cancer, albumin, lymphocyte, peritoneal metastasis, 3511 Gastric cancer, alcohol consumption, genotype, polymorphism, smoking, XPD, 4975 Gastric cancer, angiopoietin-like protein 2, ANGPTL2, immuno-histochemistry, 4633 Gastric cancer, chromatin remodeling factor, immunohistochemistry, carcinogenesis, AT-rich interactive domain-containing protein, 6819 Gastric cancer, docetaxel, oxaliplatin, chemotherapy, 3531 Gastric cancer, epidermal growth factor, serum level, cancer risk, progression, 2709 Gastric cancer, ESRD, gastrectomy, 2263 Gastric cancer, FGFR, angiogenesis, 6655 Gastric cancer, FGFR2 amplification, chemotherapy, prognosis, 5055 Gastric cancer, HER2, prognosis, tumor grade, 2441 Gastric cancer, histone deacetylase, HDAC, CD133, thrombospondin-1, THBS1, 2071 Gastric cancer, HLA-E, HLA-F, immuno suppression, postoperative outcome, 2279 Gastric cancer, intraperitoneal chemotherapy, S-1, cisplatin, docetaxel, DCS, 2223 Gastric cancer, kita-kyushu lung cancer antigen-1, KK-LC-1, cancer/testis antigen, 3575 Gastric cancer, laparoscopic surgery, gastrectomy, elderly patients, laparoscopy-assisted gastrectomy, 2191 Gastric cancer, MicroRNA, 5p-arm, 3p-arm, bioinformatics, 1345 Gastric cancer, para-aortic lymph node metastasis, induction chemotherapy, extended lymphadenectomy, 6739 Gastric cancer, pepsinogen, Helicobacter pylori, screening, ABC method, 6765 Gastric cancer, peritoneal dissemination, conditionally replicative adenovirus, luminescent imaging, 5201 Gastric cancer, programmed cell death-1 (PD1), programmed death-1 ligand-1 (PDL1), 5369 Gastric cancer, PTX3, inflammation, macrophage, 2663 Gastric cancer, TAS-102, 5-FU resistance, irinotecan hydrochloride, colorectal cancer, 1437 Gastric cancer, TAS-102, oxaliplatin, colorectal cancer, 5-FU resistance, 4605 Gastric carcinoma, peritoneal washing, neoadjuvant chemotherapy, 4859 Gastric gastrointestinal stromal tumor, tumor size, post - operative sequelae, 2341 Gastric neoplasia, yes-associated protein, β-catenin, carcinogenesis, adenocarcinoma, signet-ring cell carcinoma, 3925 Gastric tube, indocyanine green fluorescence, line-marking method, HyperEye medical system, 6201 Gastroenterology, colon cancer, cytokines, interleukin-6, IL6, cancer biomarker, 2235 Gastrointestinal stromal tumor, duodenum, surgical treatment, 6321 Gastrointestinal stromal tumor, laparoscopic surgery, intestinal GIST, overall survival, recurrence-free survival, small bowel GIST, 1033 Gastrointestinal stromal tumor, microarray, stomach, intestine, SLIT2, 3289 GcMAF, degalactosylated/desialylated bovine colostrum, macrophage phagocytic activity, mouse peritoneal macrophage, mouse intestinal macrophage, 4485 GCNT2, glycogene, epigenetics, colorectal cancer, lymph node metastasis, 1411 G-CSF, CD114, melanoma, nifurtimox,

117 GD3A, NG2 proteoglycan, immunoablation, saporin, glioma, 77 Gefitinib, EGFR mutation, non-small cell lung cancer, exon 19 deletion, L858R, 6957 Gefitinib, EGFR-TKI, erlotinib, non-small-cell lung cancer, minor EGFR mutation, 3885 Gefitinib, lapatinib, MMP9, cyclin D1, β-catenin, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 Gelsolin, breast cancer, prognosis, migration, cytoskeleton, estrogen receptor-positive, 5277 Gemcitabine monotherapy, glascow prognostic score, clinical outcome, pancreatic cancer, curative surgery, 4865 Gemcitabine, AKT inhibitor, pancreatic cancer, 4599 Gemcitabine, HSF1, HMGB1, HSP27, AHCC, pancreatic cancer, 6063 Gemcitabine, KML001, pancreatic cancer, 183 Gemcitabine, radiosensitization, homologous recombination, RAD51, 2731 Gemcitabine-resistant, HMGB1, MAPKAPK2, pancreatic cancer, HSP27, 3861 Gender, genotype, lung cancer, polymorphism, smoking, Taiwan, XRCC3, 3893 Gender; age at diagnosis, urothelial carcinoma, upper urinary tract, cancer-specific survival, 4277 Gene expression analysis, hepatocellular carcinoma, biomarkers, alpha-fetoprotein, osteopontin, glypican 3, 2021 Gene expression, diffuse large B-cell lymphoma, primary CNS lymphoma, microarray, 3333 Gene expression, formyl-peptide receptors, lung cancer, 2769 Gene expression, HIWI, HILI, colorectal cancer, cancer stem cells, 3317 Gene expression, kallikrein-related peptidases, alternative splicing, Canis familiaris, mammary cancer, 2715 Gene expression, myelofibrosis, lenalidomide, bone marrow stroma, SOCS3, 5219 Gene expression, prostate neoplasms, cell line, surgical pathology, radical prostatectomy, 5443 Gene expression, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, FACS, proliferation, chemotherapy, 767 Gene therapy, lung cancer, aerosol delivery, sorbitol diacrylate, PDCD4, shakt1, 2015 Gene-expression profiling, colon cancer, tumor front, chemokines, epithelial mesenchymal transition, microarray, 6577 Gene-expression profiling, intraoperative electron radiation therapy, IOERT, ionizing radiation, IR, MCF10A cells, microarray, 3223 Genetic association, prostate cancer, African Americans, single nucleotide polymorphism, CRYBB2, 2565 Genetically-engineered, salmonella, cancer therapy, breast cancer, BALB-neuT, autochthonous model, mouse model, immunotherapy, myeloid-derived suppressor cells, 843 Genetics, anaplastic thyroid carcinoma, poorly differentiated thyroid carcinoma, next-generation sequencing, 2029 Genistein, sarcoma, programmed cell death, hormonal therapy, isoflavones, 3167 Genital GVHD, graft-versus-host disease, chronic GVHD, review, 13 Genome-wide research, vitamin D insufficiency, vitamin D receptor, 1, 25(OH)2D3, ChIP-seq, review, 1143 Genomics, non-small cell lung cancer, ALK translocation, ALK inhibitor, KRAS, STK11, ATM, crizotinib resistance, next-generation sequencing, case report, 3007 Genotoxicity, food dye, tartrazine, cytotoxicity, DNA repair, 1465 Genotoxicity, prodigiosin, micronucleus, tumor cells, 3325 Genotype, alcohol consumption, gastric cancer, polymorphism, smoking, XPD, 4975 Genotype, alcohol drinking, hepatocellular carcinoma, polymorphism, smoking, TNFα, 5417 Genotype, COX2, polymorphism, Taiwan, upper tract urothelial cancer, 2725 Genotype, gender, lung cancer, polymorphism, smoking, Taiwan, XRCC3, 3893 Genotype, interleukin-4, lung, polymorphism, Taiwan, 6297 Genotype, leiomyoma, polymorphism, Taiwan, XRCC3, 4691 Genotyping, biopsy, colposcopy, human papillomavirus, triage, 4197 Germ cell tumors, biomarker, endogenous control, microrna, real time PCR, testicular cancer, 117 GFP imaging, esophageal cancer, mouse models, orthotopic, experimental metastasis, 4655 GFP xenograft assay, breast cancer, metastasis, 47 GFP, cancer cells, histone-h2b, fusion, nuclear labeling, RFP, retrovirus, cytoplasmic labeling, mitosis, chromosomes, 2553 GFP, histone H2B, fusion gene, RFP, imaging, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, imaging, 2539 GFP, pancreatic cancer, dual color cells, RFP, stellate cells, interaction, CFP nude mouse, color-coded fluorescence imaging, 2545 GFP, RFP, nude mice, human tumors, metastasis, imaging, noninvasive, variable magnification, subcellular in vivo imaging, spectral separation, tunable filter, 661 GFP, Salmonella typhimurium A1-R, tumor targeting, RFP, prostate cancer, cell line, PC-3, LNCaP, DU-145, apoptosis, necrosis, cell burst, 5225 GIST, imatinib, surgery, discontinuation of treatment, cure, treatment algorithm, review,

118 GIST, regorafenib monotherapy, liver failure, case report, 4037 Glascow prognostic score, clinical outcome, pancreatic cancer, gemcitabine monotherapy, curative surgery, 4865 Glasgow prognostic score, colorectal cancer, unresectable, prognosis, neutrophil to lymphocyte ratio, C-reactive protein, 5037 Glasgow Prognostic Score, T4 esophageal cancer, Prognostic Nutritional Index, 4897 Gleason score 7, prostate cancer, repeat biopsy, percentage free PSA, PSA velocity, population screening, 5031 Gleason score, PCA3, phi, sarcosine, tumor volume, tumor stage, 1017 Gleason score, prostate cancer, PEDF, 1703 Gleason score, prostate cancer, prostate-specific antigen, testosterone, 6137 Gleason, African American, prostate cancer, BPH, SPINK1, SNPs, 3811 Gli, sonic hedgehog (SHH), lung cancer, tumor model, YangZheng XiaoJi, cellular migration, invasion, cyclopamine, Smo, 1321 Glioblastoma multiforme (GBM), chemotherapy, moleculartargeted therapy, immunotherapy, review, 1229 Glioblastoma multiforme, synchronous, multiple primary malignant neoplasms, glioblastoma, neuroendocrine tumor, sessile serrated adenoma/polyp, schwannoma, 2121 Glioblastoma, clinical trials, epigenetics, histone deacetylase inhibitor, preclinical trials, review, 615 Glioblastoma, co-expression, cytoskeletal protein, adducin 3, cancer stem cell marker, CD133, neurospheres, temozolomide-resistant subclone, NANOG, 6487 Glioblastoma, curcumin, lomustine, cancer stem cells, ceramide, blood brain barrier, combination chemotherapy, lipophilic agent, review, 6373 Glioblastoma, dual anti-angiogenic chemotherapy, temozolomide, celecoxib, 4955 Glioblastoma, EGFR, peritumoral edema, radiotherapy, response assessment, 4117 Glioblastoma, hyperbaric oxygen, HBO, clonogenicity, motility, time-lapse videography, 1977 Glioblastoma, milk thistle, silibinin, temozolomide, natural compounds, 1263 Glioblastoma, mirna-145, srgap, SLIT-ROBO, 3209 Glioblastoma, surgery, radiotherapy, temozolomide, second surgery, 1743 Glioblastoma, synchronous, multiple primary malignant neoplasms, glioblastoma multiforme, neuroendocrine tumor, sessile serrated adenoma/polyp, schwannoma, 2121 Glioma, angiocentric, MRI, spectroscopy, 6267 Glioma, brain tumor, p16, MDM2, polymorphism, meningioma, 3933 Glioma, CXCR7, CXCL12, proliferation, mobility, 53 Glioma, cyclooxygenase-2, sulfasalazine, celecoxib, benzimidazole, combination therapy, synergistic effects, brain cancer, LN18, 6419 Glioma, heat shock proteins, cannabidiol, tetrahydrocannabinol, reactive oxygen species, 5827 Glioma, NG2 proteoglycan, GD3A, immunoablation, saporin, 77 Glioma, PCV, tolerance, feasibility, 2901 Glioma, sunitinib, lomustine, recurrent disease, 5551 Glioma, T98G human cells, 18 F-fluorodeoxyglucose, 18 F- fluorocholine, radiation injury, 6439 Glomus tumor, cytogenetics, t(1;5), NOTCH2, MIR143, 6167 Glottic cancer, radiotherapy, voice quality, 4155 Glucan, melanoma, NK cells, immunity, antibodies, cancer, 5287 Glucose, 4-methylumbelliferone, hyaluronan, proliferation, breast carcinoma cell, 4799 Glucosylceramide synthase, L1210 cells, P-glycoprotein, UDP-glucose, ceramide induced cell death, 2627 Glycogene, GCNT2, epigenetics, colorectal cancer, lymph node metastasis, 1411 Glycolysis, bladder cancer cells, growth, PFKFB3 inhibitor, butyrate, 2-deoxyglucose, dichloroacetate, phenformin, 5889 Glycosylation, adenoma carcinoma sequence, colon cancer, lectins, malignant progression, metastasis, 5333 Glycosylation, α v β 3 integrin, melanoma, migration, vitronectin, 2093 Glypican 3, hepatocellular carcinoma, biomarkers, gene expression analysis, alpha-fetoprotein, osteopontin, 2021 GM-CSF, tumour-supernatants, chemotherapy, murine model, 1499 GPI-anchored protein, prostate stem cell antigen, intracellular signaling, gallbladder cancer, tumor suppressor, 2619 GPX1, MnSOD, oxidative stress, colorectal cancer, antioxidants, 255 Grade, uterine cancer, EC, obesity, lymphovascular invasion, body mass index, 4053 Grading, pancreatic neuroendocrine tumor, endoplasmic reticulum stress, 6127 Graft-versus-host disease, chronic GVHD, genital GVHD, review, 13 Granulosa cell tumor of the ovary, endometrial carcinoma, total hysterectomy with bilateral adnexectomy, 5547 Growth inhibition, adipose tissue-derived mesenchymal stem cells (AT-MSCs), melanoma, cytotherapy, 159 Growth, bladder cancer cells, glycolysis, PFKFB3 inhibitor, butyrate, 2-deoxyglucose, dichloroacetate, phenformin, 5889 GRP78, apoptosis, CHM-1, nasopharyngeal carcinoma, p85α, 5359 Guidelines, endometrial cancer, patient volume, preoperative staging, lymphadenectomy,

119 GW2974, breast cancer, estrogen receptor (ER), HER2, EGFR, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), proliferation, apoptosis, 1243 Gynecologic cancer, CIPN, neuropathy, duloxetine, paclitaxel, 359 Gynecological cancer, endometrial cancer, VMAT, SIB, 2149 Gynecological cancer, NK1 receptor, aprepitant, CINV, 4525 Gynecology, positron emission tomography, diagnostic imaging, lym ph atic metastasis, clinical oncology, 2247 H460 cells, PLD inhibitor, LncRNA, ANRIL, lung cancer, 2795 Haematological malignancies, 18 F-FDG-PET/CT, febrile neutropenia, invasive aspergillosis, 2999 Haemodynamic management, ovarian cancer, relapse, postoperative morbidity, transfusion, cytoreductive surgery, 1591 Hand-foot syndrome, cytidine, uridine, thymidine, deoxycytidine, 5-FU, keratinocytes, 1303 Hashimoto s thyroiditis, thyroid cancer, papillary carcinoma, multinodular thyroid, nodular goitre, intraglandular dissemination, 6335 HB-EGF, neuroblastoma, CRM197, 4431 HBO, glioblastoma, hyperbaric oxygen, clonogenicity, motility, time-lapse videography, 1977 HCC, cell-free DNA, methylation, epigenetic, quantitative MSP, 997 HCC, elderly, hepatectomy, 6855 HCC, sorafenib, hepatic arterial infusion chemotherapy, liver cirrhosis, 2269 HCC, VX2, HepG2, chemosensitivity, chemotherapy, TACE, 6497 HDAC inhibitor, histone deacetylation, PAT-1102, vorinostat, 229 HDAC, gastric cancer, histone deacetylase, CD133, thrombospondin-1, THBS1, 2071 HDAC, histone, inhibitors, acetylasation, epigenetics, pancreatic cancer, review, 3129 HE4, magnetic resonance imaging (MRI), diffusionweighted imaging (DWI), biparameric MRI (Bp-MRI), tumor markers, CA125, ovarian tumors characterization, pelvic mass, 6341 Head and neck cancer, distant metastasis, lung metastasis, bone metastasis, survival, 5499 Head and neck cancer, induction chemotherapy, concomitant chemo-radiation, treatment breaks, intensity-modulated radiotherapy, 6247 Head and neck cancer, keratinocytes, differential gene regulation, array, 3253 Head and neck cancer, MCP1, epithelial mesenchymal transition, AKT, 3299 Head and neck cancer, MET, c-met, HGF, crizotinib, radiation, 5973 Head and neck cancer, oral squamous cell carcinoma, estrogen receptor, histopathologic grade, immunohistochemistry, 5867 Head and neck cancer, overall survival, 18 F-FDG-PET/CT, SUVmax, inhibition index cisplatin, 1009 Head and neck cancer, radiotherapy, intensity-modulated radiotherapy, patterns of failure, 6833 Head and neck cancer, S-1, early glottic cancer, concur rent chemoradiotherapy, phase I/II study, prospective study, recom mend dose, radiosentitizer, 2385 Head and neck cancer, serum albumin, creatinine clearance, renal function, cisplatin, 2909 Head and neck cancer, squamous cell carcinoma, cytokeratin 8, CK8, EpCAM, 3953 Head and neck cancer, tumor markers, clinical utility, 5519 Head and neck cancer, unilateral neck, volumetric arc techniques, helical IMRT, dosimetric comparison, 2991 Head and neck squamous cancer cells (HNSCC), gefitinib, lapatinib, MMP9, cyclin D1, β-catenin, epithelial growth factor receptor (EGFR), epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 Head and neck squamous cell carcinoma, curcumin, bioavailability, microgranules, 6411 Head and neck squamous cell carcinoma, HNSCC, oropharynx, human papillomavirus, HPV incidence, survival, 4015 Head and neck squamous cell carcinoma, microrna, adenoid cystic carcinoma, HPV, 1271 Head and neck squamous cell carcinoma, microrna, let-7a, mir-21, mir-200c, mir-34a, mir-375, oropharyngeal, laryngeal, hypopharyngeal cancer, 2455 Head and neck squamous cell carcinoma, PIK3CA, BYL719, dacomitinib, 175 Head and neck squamous cell carcinoma, tyrosine kinase inhibitor, PTEN, VEGFR, everolimus, sorafenib, sunitinib, 1389 Head and neck squamous cell carcinoma, tyrosin-kinaseinhibitor, mtor, AREG, everolimus, sorafenib, sunitinib, 1951 Head neck, AKT, radiotherapy, chemotherapy, 269 Head-and-neck cancer, metastatic epidural spinal cord compression, irradiation, survival, predictive instrument, 385 Heat shock proteins, cannabidiol, tetrahydrocannabinol, glioma, reactive oxygen species, 5827 Hedgehog pathway, curcumin, cancer stem cells, interleukin- 6, interleukin-8, interleukin-1, CXCR1, CXCR2, Wnt pathway, Notch pathway, FAK pathway, review, 599 Hedgehog, pancreatic cancer, second-line chemotherapy, itraconazole, 4191 HeLa, ascidian, Eudistoma viride, cytotoxicity, apoptosis, DNA fragmentation, flow cytometry,

120 HeLa, fibroblasts, stromal fibroblasts, proliferating fibroblasts, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Helical computed tomography (CT), pediatric tumors, multidetector-row CT (MDCT), radiation dose, split-bolus technique, 3041 Helical IMRT, head and neck cancer, unilateral neck, volumetric arc techniques, dosimetric comparison, 2991 Helicobacter pylori, gastric cancer, pepsinogen, screening, ABC method, 6765 Helper peptide, Wilms tumor gene (WT1), HLA- DRB1*04:05, HLA class II, TCR gene therapy, 1251 Helplessness, hopelessness, BDI, depression, breast disease, 941 Helplessness, hopelessness, MADRS, depression, breast disease, 2215 Helplessness, hopelessness, suicidal ideation, breast disease, 3543 Hematogenous dissemination, circulating tumor cells, endometrial cancer, prognosis, recurrence, 683 Hep 3B, hepatocellular carcinoma (HCC), apolipoprotein B mrna editing enzyme, catalytic polypeptide-like 3B (APOBEC3B), vascular invasion, 1521 Hepatectomy, chronic hepatitis C, hepatocellular carcinoma, interferon, sustained virological response, 6963 Hepate ctomy, colorectal cancer, colorectal liver metastasis, chemotherapy, 2359 Hepatectomy, colorectal cancer, liver metastases, vascular invasion, vascular attachment, 5485 Hepatectomy, HCC, elderly, 6855 Hepatectomy, hepatocellular carcinoma, multiple recurrences, 3061 Hepatic arterial infusion chemotherapy, HCC, sorafenib, liver cirrhosis, 2269 Hepatic resection, ovarian cancer liver metastases, long-term survival, 6919 Hepatic uptake, regorafenib, disposition, multidrug resistance-associated protein, organic anion-transporting polypeptide, biliary excretion, protein-binding, 4681 Hepatitis B virus, hepatocellular carcinoma, antiviral therapy, nucleotide/nucleoside analog, propensity scorematching, 1647 Hepatitis B virus, pancreatic adenocarcinoma, pancreatectomy, 5123 Hepatobiliary and pancreas, multiple primary cancers, risk factors, surgery, prognosis, 1073 Hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP- L3), des-γ-carboxyprothrombin (DCP), tumor marker, 2157 Hepatocellular carcinoma (HCC), apolipoprotein B mrna editing enzyme, catalytic polypeptide-like 3B (APOBEC3B), vascular invasion, Hep 3B, 1521 Hepatocellular carcinoma, 18 F-fluorodeoxyglucose, positron emission tomography, PET/CT, 2241 Hepatocellular carcinoma, alcohol drinking, genotype, polymorphism, smoking, TNFα, 5417 Hepatocellular carcinoma, biomarkers, gene expression analysis, alpha-fetoprotein, osteopontin, glypican 3, 2021 Hepatocellular carcinoma, cadherin, side-effect, des-γcarboxyprothrombin, cell migration, metastasis, 1985 Hepatocellular carcinoma, chronic hepatitis C, hepatectomy, interferon, sustained virological response, 6963 Hepato cellular carcinoma, combined hepatocellularcholangiocarcinoma, living-donor liver transplantation, 2475 Hepatocellular carcinoma, endoscopic hepatectomy, Milan criteria, open hepatectomy, propensity case-matched analysis, 1583 Hepatocellular carcinoma, endoscopic radiofrequency ablation, elderly patients, 3033 Hepatocellular carcinoma, hepatitis B virus, antiviral therapy, nucleotide/nucleoside analog, propensity scorematching, 1647 Hepatocellular carcinoma, hepatoma-derived growth factor, targeted therapy, xenograft model, VEGF, angiogenesis, 6475 Hepatocellular carcinoma, laparoscopic hepatectomy, semiprone position, 4167 Hepatocellular carcinoma, liver cirrhosis, percutaneous ethanol injection, radiofrequency ablation, overall survival, tumor recurrence, 325 Hepatocellular carcinoma, living donor liver transplantation, microsatellite analysis, case report, 3525 Hepatocellular carcinoma, metformin, radiotherapy, survival, 5047 Hepatocellular carcinoma, molecular-targeted therapy, sorafenib, tyrosine kinase inhibitor, review, 5737 Hepatocellular carcinoma, multiple recurrences, hepatectomy, 3061 Hepatocellular carcinoma, platelet-derived growth factors, TSU-68, 1423 Hepatocellular carcinoma, Ras suppressor-1, invasion, adhesion, 1509 Hepatocellular carcinoma, recurrence, local ablation, brachytherapy, 319 Hepatocellular carcinoma, sorafenib, matrix metalloproteinase, epithelial mesenchymal transition, 1967 Hepatocellular carcinoma, sorafenib, programmed cell death, M30, M65, 1803 Hepatocellular carcinoma, splenectomy, hypersplenism, primary macroglobulinemia,

121 Hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, epirubicin, combination therapy, 549 Hepatocellular carcinoma, transcatheter arterial chemoembolization, miriplatin, epirubicin, combination therapy, 549 Hepatocellular carcinoma, UICC, stage, surgery, 2921 Hepatocyte growth factor, amphiregulin, transforming growth factor-α, epidermal growth factor receptor, cetuximab, colorectal cancer, 1683 Hepatocyte growth factor, cancer stem cell, prostate cancer, prostatectomy, recurrence, 413 Hepatoma-derived growth factor, hepatocellular carcinoma, targeted therapy, xenograft model, VEGF, angiogenesis, 6475 HepG2, VX2, chemosensitivity, chemotherapy, TACE, HCC, 6497 HER2, breast cancer, estrogen receptor (ER), EGFR, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, proliferation, apoptosis, 1243 HER2, ERBB2, breast cancer, codon 655, Ile655Val, polymorphism, 5901 HER2, ERBB2, breast cancer, codon 655, Ile655Val, polymorphism, 6667 HER2, gastric cancer, prognosis, tumor grade, 2441 HER2, MDR, P-glycoprotein, transfection, breast cancer, BT-474, 2531 HER2-positive metastatic breast cancer, T-DM1, chemotherapy, 5085 HER2-positive, breast cancer, valvular regurgitation, left ventricular ejection fraction, trastuzumab, 4063 Her2-positive, metastatic breast cancer, lapatinib, pegylated liposomal doxorubicin, 517 Herbimycin A, anaplastic thyroid carcinoma, 17-AAG, HSP90, β-catenin, AKT, FRO cells, 5453 HES77, rectum, neuroendocrine tumor, carcinoid, metastasis, prognosis, 3767 Hexokinase, clotrimazole, melanoma, A375 cells, apoptosis, cell cycle, 3781 HGF, MET, c-met, crizotinib, head and neck cancer, radiation, 5973 HGF, radiofrequency ablation, liver resection, colorectal liver metastases, disseminated tumor cells, IL-6, HSP-70, 2961 HHV-1, oral squamous cell carcinoma, OSCC, larynx, oropha - rynx, Epstein-Barr virus, EBV, human herpes virus-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 HIF1α inhibitor, thyroid cancer, orthotopic mouse model, molecular targeted therapy, echinomycin, adjuvant chemotherapy, 2049 HIF-1α inhibitors, hypoxia, benzimidazoles, breast cancer, 3849 HIF1Α, CAIX, VEGF, MCF-7 cells, MDA-MB-231 cells, xenografts, microtubule disruptor, anti-angiogenic, 5249 High pressure, ovarian cancer, quality of life, antineoplastic agents, adverse effects, intraperitoneal chemotherapy, peritoneal carcinomatosis, octogenarian, 2309 High tumor take rates, lung cancer, surgical orthotopic implantation, nude mice, noninvasive imaging, spectral separation, 3755 High-dose radiation exposure, atomic bomb, myelodysplastic syndrome, azacitidine, hypomethylating agents, 2929 High-dose-rate brachytherapy, prostate cancer, 1723 High-dose-rate brachytherapy, prostate cancer, radiotherapy, hypofractionation, stereotactic radiotherapy, particle therapy, review, 5167 High-fat diet, PAI1, bone, metastasis, mice, 3839 High-grade prostate intraepithelial neoplasia, prostate cancer, prostate cancer gene 3, prostate-specific antigen, prostatitis, 2417 High-grade sarcoma, D-dimer, chemotherapy, 6781 HILI, HIWI, colorectal cancer, cancer stem cells, gene expression, 3317 HIPEC, Pseudomyxoma peritonei, mucinous neoplasm, mucocele, perforated appendix, peritoneal carcinomatosis, 4943 HIPO, pulsed brachytherapy, optimization, radiobiology, treatment planning, 6091 Histoculture drug response assay, paclitaxel, predictive factor, non-small cell lung cancer, chemotherapy, class III beta-tubulin, 2669 Histological grading, breast tumors, SUV, estrogen receptor, progesterone receptor, Ki67, BCL2, p53, androgen receptor, 569 Histology, soft-tissue sarcoma, patient-derived orthotopic xenograft (PDOX), subcutaneous model, nude mouse, spindle cells, 697 Histone deacetylase inhibitor, clinical trials, epigenetics, glioblastoma, preclinical trials, review, 615 Histone deacetylase, gastric cancer, HDAC, CD133, thrombospondin-1, THBS1, 2071 Histone deacetylation, HDAC inhibitor, PAT-1102, vorinostat, 229 Histone H2B, GFP, fusion gene, RFP, imaging, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, imaging, 2539 Histone modification, JMJD3, UTX, epigenetic, xenograft analysis, cancer treatment, 6611 Histone, HDAC, inhibitors, acetylasation, epigenetics, pancreatic cancer, review, 3129 Histone-H2B, cancer cells, GFP, fusion, nuclear labeling, RFP, retrovirus, cytoplasmic labeling, mitosis, chromosomes, 2553 Histopathologic grade, oral squamous cell carcinoma, head and neck cancer, estrogen receptor, immunohistochemistry,

122 HIV infection, Burkitt lymphoma, non-hodgkin lymphoma, mandible, osteomyelitis, FDG-PET, EBV, Epstein-Barr, 4837 HIWI, HILI, colorectal cancer, cancer stem cells, gene expression, 3317 HL60 cells, furochalcones, antiproliferative activity, structure and activity relationship, 811 HLA class II, T-cell, CIITA, melanoma, immune response, Jurkat-C, 25 HLA class II, Wilms tumor gene (WT1), HLA- DRB1*04:05, helper peptide, TCR gene therapy, 1251 HLA-DRB1*04:05, Wilms tumor gene (WT1), HLA class II, helper peptide, TCR gene therapy, 1251 HLA-E, gastric cancer, HLA-F, immuno suppression, postoperative outcome, 2279 HLA-F, gastric cancer, HLA-E, immuno suppression, postoperative outcome, 2279 HLRCC, fumarate hydratase gene, PRCC2, Warburg effect, bortezomib, 6639 HMGB1, HSF1, HSP27, AHCC, pancreatic cancer, gemcitabine, 6063 HMGB1, MAPKAPK2, gemcitabine-resistant, pancreatic cancer, HSP27, 3861 HNSCC, head and neck squamous cell carcinoma, oropharynx, human papillomavirus, HPV incidence, survival, 4015 HNSCC, MCP1, anti-mcp1, FLAVINO assay, ex-vivo chemoresponse, 3917 HNSCC, protein kinase C, TPA, PEP005, diterpene, 1291 HOCl, apoptosis, superoxide anion, NOX1, DUOX, hydroxyl radical, 5927 HOCl, NOX1, DUOX1, apoptosis, matrix metallo proteinase, 5955 Homologous recombination, radiosensitization, gemcitabine, RAD51, 2731 Hopelessness, helplessness, BDI, depression, breast disease, 941 Hopelessness, helplessness, MADRS, depression, breast disease, 2215 Hopelessness, helplessness, suicidal ideation, breast disease, 3543 Hormesis, lung cancer, chemotherapy, 5851 Hormonal therapy, cytokines, prostate cancer, radiotherapy, 3379 Hormonal therapy, genistein, sarcoma, programmed cell death, isoflavones, 3167 Hospital structure, selection, bias, outcome, survival, 4073 HP102, curcumin, Jurkat T-cells, IL2, proliferation, apoptosis, 2675 HPV incidence, head and neck squamous cell carcinoma, HNSCC, oropharynx, human papillomavirus, survival, 4015 HPV infection, squamous cell oropharyngeal tumors, p16 immunohistochemistry, HPV PCR assay, diagnostic assay, 4733 HPV PCR assay, HPV infection, squamous cell oropharyngeal tumors, p16 immunohistochemistry, diagnostic assay, 4733 HPV, microrna, adenoid cystic carcinoma, head and neck squamous cell carcinoma, 1271 HPV, oral squamous cell carcinoma, OSCC, larynx, oropha - rynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, human papilloma virus, cytomegalovirus, CMV, 1657 HPV, prostate cancer, renal cell carcinoma, bladder cancer, testicular cancer, penile cancer, review, 2513 HSF1, HMGB1, HSP27, AHCC, pancreatic cancer, gemcitabine, 6063 HSF1, SOX2, HSPB1, tumor progression, 3217 HSP27, HMGB1, MAPKAPK2, gemcitabine-resistant, pancreatic cancer, 3861 HSP27, HSF1, HMGB1, AHCC, pancreatic cancer, gemcitabine, 6063 HSP27, metformin, pancreatic cancer, 1941 HSP-70, radiofrequency ablation, liver resection, colorectal liver metastases, disseminated tumor cells, HGF, IL-6, 2961 HSP90, anaplastic thyroid carcinoma, 17-AAG, herbimycin A, β-catenin, AKT, FRO cells, 5453 HSPB1, SOX2, HSF1, tumor progression, 3217 HT1080, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, taurolidine, apoptosis, necrosis, gene expression, FACS, proliferation, chemotherapy, 767 Human colon carcinoma HT-29 cells, apoptosis, BAX/BAK, bichalcone analog, CD95, FADD, 5407 Human herpes virus-1, oral squamous cell carcinoma, OSCC, larynx, oropha rynx, Epstein-Barr virus, EBV, HHV-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 Human leukemia cells, 3β-[2-(1-amantadine)-1-onethylamine]-digitoxigenin, AMANTADIG, cardenolide analog, human urological cancer cells, porcine cerebral cortex Na + /K + -ATPase, 5271 Human lung cancer NCI-H460 cells, demethoxycurcumin (DMC); DNA damage, comet assay, DAPI staining, 2691 Human lung cancer, curcumin, DNA damage, DNA repair, 3867 Human melanoma cancer A375.S2 cells, cantharidin, PI3K/NF-ĸB signaling pathways, invasion, migration, 729 Human oral cancer SCC-4 cells, gallic acid (GA), DNA damage, Comet assay, DNA repair, 2077 Human papilloma virus, oral squamous cell carcinoma, OSCC, larynx, oropha rynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, HPV, cytomegalovirus, CMV,

123 Human papillomavirus (HPV), gefitinib, lapatinib, MMP9, cyclin D1, β-catenin, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), mesenchymalepithelial transition (MET), 3801 Human papillomavirus, biopsy, colposcopy, genotyping, triage, 4197 Human papillomavirus, breast cancer, polymerase chain reaction, 851 Human papillomavirus, head and neck squamous cell carcinoma, HNSCC, oropharynx, HPV incidence, survival, 4015 Human papillomavirus, tonsillar carcinoma, tonsillitis, p16 INK4A, FANCD2, 6633 Human T-lymphoblastoid leukemia, vitamin K 3, vitamin K 5, daunorubicin resistance, P-glycoprotein, apoptosis, 6041 Human topoisomerase II, non-small cell lung cancer, 9- aminoacridine derivatives, 5211 Human tumors, GFP, RFP, nude mice, metastasis, imaging, noninvasive, variable magnification, subcellular in vivo imaging, spectral separation, tunable filter, 661 Human urological cancer cells, 3β-[2-(1-amantadine)-1-onethylamine]-digitoxigenin, AMANTADIG, cardenolide analog, human leukemia cells, porcine cerebral cortex Na + /K + -ATPase, 5271 Human, meningioma, recurrent brain tumor, meningeal neoplasm, WHO classification, 3559 HUVEC, endothelial cells, culture, brain tumor, vasculature, 2681 HUVECs, resveratrol, protein kinase G (PKG), angiogenesis, Inhibitor of Apoptosis Proteins (IAPs), 273 HVEM, colorectal cancer, prognosis, surgery, tumor immunity, 1361 Hyaluronan, 4-methylumbelliferone, glucose, proliferation, breast carcinoma cell, 4799 Hybridization, telomere shortening, altered lengthening of telomeres, TERC, telomerase, in situ, DAXX, ATRX, immunohistochemistry, 3501 Hydration, cervical cancer, cisplatin, magnesium, nephrotoxicity, 2199 Hydrogen peroxide, artemisinin, sodium ascorbate, vitamin D 3, Trolox, dexamethasone, Molt-4 cells, 1867 Hydrogen peroxide, oxidative stress, cholangiocytes, ion transport, 5881 Hydroxyl radical, apoptosis, HOCl, superoxide anion, NOX1, DUOX, 5927 Hyoid bone, hypopharyngeal cancer, chemoradiotherapy, larynx preservation, complication, 1735 Hyperammonemia, fluorouracil, colorectal cancer, fluorocitrate, 6761 Hyperbaric oxygen, glioblastoma, HBO, clonogenicity, motility, time-lapse videography, 1977 HyperEye medical system, indocyanine green fluorescence, gastric tube, line-marking method, 6201 Hyperleukocytosis, chronic lymphocytic leukemia, prognosis, survival, 2861 Hypersplenism, splenectomy, hepatocellular carcinoma, primary macroglobulinemia, 4077 Hypertension, trastuzumab, cardiac dysfunction, risk factor, BMI, radiotherapy, 4967 Hyperthermia, colorectal neoplasms, peritoneal neoplasms, urinary tract, intraperitoneal chemotherapy, postoperative complications, prognosis, 295 Hyperthermia, esophageal cancer, definitive chemora dio - therapy, long-term survival, 2299 Hyperthermic intra-peritoneal chemotherapy, ovarian cancer relapse, secondary surgery, 4997 Hyperthermotherapy, soft tissue sarcoma, unplanned excision, chemotherapy, surgery, 493 Hypofractionated radiotherapy, basal cell carcinoma, skin cancer, frail patients, 4949 Hypofractionated radiotherapy, non-small cell lung cancer, advanced stage, unresectable, image-guidance, 5693 Hypofractionated, 3D conformal radiotherapy, prostate cancer, toxicity, 3049 Hypofractionation, carbon-ion therapy, prostate cancer, toxicity, quality of life, 5559 Hypofractionation, prostate cancer, radiotherapy, high-doserate brachytherapy, stereotactic radiotherapy, particle therapy, review, 5167 Hypofractionation, simultaneous integrated boost, prostate cancer, IMRT, IGRT, erectile dysfunction, 4177 Hypomethylating agents, atomic bomb, high-dose radiation exposure, myelodysplastic syndrome, azacitidine, 2929 Hypopharyngeal cancer, hyoid bone, chemoradiotherapy, larynx preservation, complication, 1735 Hypopharyngeal cancer, microrna, let-7a, mir-21, mir- 200c, mir-34a, mir-375, head and neck squamous cell carcinoma, oropharyngeal, laryngeal, 2455 Hypopharyngeal cancer, oral cancer, oropharyngeal cancer, radioisotope, ICG fluorescence, 1669 hypothyroidism, differentiated thyroid carcinoma, thyroxine withdrawal, biochemical alterations, 6933 Hypothyroidism, regorafenib, thyroid-stimulating hormone, metastatic colorectal cancer, 4059 Hypothyroidism, renal cell carcinoma, sunitinib, thyrotoxicosis, levothyroxine substitution therapy, thiamazole antithyroid therapy, 481 Hypoxia inducible factor, clear cell renal cell carcinoma, tumor stage, tumor grade, overall survival, 433 Hypoxia, benzimidazoles, HIF-1α inhibitors, breast cancer, 3849 Hypoxia, radiosensitivity, radiosensitizers, topoisomerase, radiotherapy, reactive oxygen species, review,

124 Hypoxia-inducible factor-1α, pleomorphic carcinoma, angiogenesis, immun ohistochemistry, vascular endothelial growth factor, 389 Ibandronate, nephrotoxicity, zoledronic acid, breast cancer, metastases, 1797 Ibrutinib, chronic lymphocytic leukemia, small-cell lymphoma, idelalisib, rituximab, ofatumumab, review, 5149 Iceland, colorectal adenomas, traditional serrated adenomas, incidence rate, invasive carcinoma, nationwide survey, 4929 ICG fluorescence, oral cancer, hypopharyngeal cancer, oropharyngeal cancer, radioisotope, 1669 Idarubicin, acute myeloid leukemia, induction, cladribine, 6287 Idelalisib, chronic lymphocytic leukemia, small-cell lymphoma, ibrutinib, rituximab, ofatumumab, review, 5149 Idiopathic interstitial pneumonia, small cell lung cancer, non-small cell lung cancer, drug-induced interstitial lung disease, number of regimens, 1065 IDs, advanced ovarian cancer, biopsy, neoadjuvant chemotherapy, interval debulking surgery, incomplete cytoreduction, 2315 IFN-γ, LMP2, IRF1, uterine leiomyosarcoma, smooth muscle cell, 4665 Ifosfamide, cervical cancer, adjuvant chemotherapy, concomitant chemoradiotherapy, cisplatin, 4161 Ifosfamide, metastatic breast cancer, chemotherapy, platinum, etoposide, 5091 Ifosfamide, uterine carcinosarcoma, chemotherapy, carboplatin, mesna, 4841 IGF-1 classes, IGF-1 isoforms, cancer cell lines, IGF-1Ea, IGF-1Eb, Ec peptide, 107 IGF-1 isoforms, cancer cell lines, IGF-1 classes, IGF-1Ea, IGF-1Eb, Ec peptide, 107 IGF-1Ea, IGF-1 isoforms, cancer cell lines, IGF-1 classes, IGF-1Eb, Ec peptide, 107 IGF-1Eb, IGF-1 isoforms, cancer cell lines, IGF-1 classes, IGF-1Ea, Ec peptide, 107 IgG4, autoimmune pancreatitis, chronic pancreatitis, 6163 IGRT, hypofractionation, simultaneous integrated boost, prostate cancer, IMRT, erectile dysfunction, 4177 IL2, curcumin, HP102, Jurkat T-cells, proliferation, apoptosis, 2675 IL-2, transmissible venereal tumors, TVT, dogs, interleukin- 2, 713 IL2, transmissible venereal tumors, TVT, dogs, interleukin-2, vincristine, 3385 IL32, esophageal carcinoma, regulatory T-cell, immunsuppressive, survival, 2941 IL6, gastroenterology, colon cancer, cytokines, interleukin-6, cancer biomarker, 2235 IL-6, radiofrequency ablation, liver resection, colorectal liver metastases, disseminated tumor cells, HGF, HSP-70, 2961 IL-7Rα, Zfat, FoxO1, proteasomal degradation, T-cell homeostasis, 4417 Ile655Val, HER2, ERBB2, breast cancer, codon 655, polymorphism, 5901 Ile655Val, HER2, ERBB2, breast cancer, codon 655, polymorphism, 6667 Image analysis, sex steroid receptors, angiogenesis molecules, cell cycle regulators, IPMN, 1049 Image-guidance, hypofractionated radiotherapy, non-small cell lung cancer, advanced stage, unresectable, 5693 Imaging, anti-angiogenic therapy, ZD6474, contrast enhanced ultrasound, vessel density, tumor microcirculation, angiogenesis, 2571 Imaging, breast cancer, Balb-c mice, syngeneic, orthotopic, tumor resection, metastasis, RFP, 4641 Imaging, GFP, histone H2B, fusion gene, RFP, imaging, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, 2539 Imaging, GFP, histone H2B, fusion gene, RFP, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, imaging, 2539 Imaging, GFP, RFP, nude mice, human tumors, metastasis, noninvasive, variable magnification, subcellular in vivo imaging, spectral separation, tunable filter, 661 Imaging, RFP, C57/BL6-GFP mice, malignant lymphoma, liver metastasis, 4647 Imatinib, GIST, surgery, discontinuation of treatment, cure, treatment algorithm, review, 5759 Imidazole, ovarian cancer, 3-hydroxypyridine, DNA fragmentation, drug resistance, drug combination, 6027 Immune cell therapy, regulatory T cell, effector cell therapy, dendritic cell vaccine, 4533 Immune checkpoint, cancer immunotherapy, 4-1BB, PD-1, 129 Immune function, bone cancer, surgery, inflammatory response, 5461 Immune response, HLA class II, T-cell, CIITA, melanoma, Jurkat-C, 25 Immune supression, bile duct cancer, monocyte, systemic inflammatory response, 4961 Immunity, glucan, melanoma, NK cells, antibodies, cancer, 5287 Immunoablation, NG2 proteoglycan, GD3A, saporin, glioma, 77 Immunocytochemistry, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deep-sequencing, cancer stem cells, CSCs, cancer cell proliferation, anti-apoptosis, stemness, western blotting, RT-PCR, 3743 Immunocytology, cytology, pre-malignant lesions, SCCHN, oropharynx, 6517 Immunohistochemical stain, melanoma, nevus, reversioninducing cysteine-rich protein with Kazal motifs, RECK,

125 Immunohistochemistry, 3-phosphoinositide-dependent protein kinase 1, serous carcinoma of the ovary, intracellular signaling, 6329 Immuno-histochemistry, angiopoietin-like protein 2, ANGPTL2, gastric cancer, 4633 Immunohistochemistry, atypical fibroxanthoma, AFX diagnosis, AFX tumor markers, AFX therapy, review, 5717 Immunohistochemistry, azoxymethane, colonic cancer, modified citrus pectin, probiotic, galectin-3, 4765 Immunohistochemistry, CD133, colorectal cancer, lymph node metastasis, 6599 Immunohistochemistry, claudin 1, claudin 4, oral squamous cell carcinoma, prognosis, 2949 Immunohistochemistry, colorectal cancer, P53, prognosis, biomarkers, 1641 Immunohistochemistry, colorectal cancer, phosphati - dylserine-specific phospholipase A1, tumor invasion, metastasis, 1459 Immunohisto che mistry, colorectal cancer, phospho-h2ax, prognosis, 2447 Immunohistochemistry, colorectal cancer, ROCK I, MET, tissue microarray, five-year survival, 3267 Immunohistochemistry, DNA damage response-related proteins, ovarian cancer, prognosis, 3909 Immunohistochemistry, extraskeletal, osteosarcoma, therapy, treatment outcome, 2129 Immunohistochemistry, GAPDH, mrna expression, melanoma, prognosis, 439 Immunohistochemistry, gastric cancer, chromatin remodeling factor, carcinogenesis, AT-rich interactive domaincontaining protein, 6819 Immunohistochemistry, metastatic renal carcinoma, targetedtherapy, prediction, biomarkers, 5661 Immunohistochemistry, oral squamous cell carcinoma, head and neck cancer, estrogen receptor, histopathologic grade, 5867 Immunohistochemistry, PDHE1α, esophageal squamous cell carcinoma, Warburg effect, overall survival, 5533 Immuno histochemistry, phospholipase A2, colorectal cancer, lymph node metastasis, 2983 Immun ohistochemistry, pleomorphic carcinoma, angiogenesis, vascular endothelial growth factor, hypoxiainducible factor-1α, 389 Immunohistochemistry, small cell lung cancer, survivin, nucleus, labeling index, 2935 Immunohistochemistry, squamous cell carcinoma, adenocarcinoma, esophagus, PDGFR-α, CD117, 3793 Immunohistochemistry, telomere shortening, altered lengthening of telomeres, TERC, telomerase, in situ, hybridization, DAXX, ATRX, 3501 Immunohistochemistry, thymoma, notch, sonic Hedgehog, beta-catenin, 669 Immunohistochemistry, xct, CD44v6, CRC, colorectal cancer, recurrence, 677 Immunoliposomes, 188 Re-DXR-IL-C225, cytotoxicity, theranostic vehicle, 4777 Immunomodulatory drugs, angiogenesis, bortezomib, plasma cell myeloma, vascular endothelial growth factor, 1085 Immunosenescence, blood transfusion, colorectal cancer, TRIM, 3553 Immunosenescence, CD28, CD57, cellular senescence, breast cancer, chemotherapy, 1481 Immuno suppression, gastric cancer, HLA-E, HLA-F, postoperative outcome, 2279 Immunosuppression, squamous cell carcinoma, skin, tumour aggressiveness, organ transplantation, pathology, 2305 Immunosurveillance, premalignant leukoplakia, oral cancer, biomolecular markers, 311 Immunotherapies, NSCLC, molecular biology, clinical outcome, review, 5745 Immunotherapy, adjuvant ovarian suppression, premenopausal, breast cancer, 6847 Immunotherapy, adjuvant ovarian suppression, premenopausal, breast cancer, 6847 Immunotherapy, angiogenesis, invasion, metastasis, signalling systems, thalidomide analogues, review, 5767 Immunotherapy, bendamustine, rituximab, chronic lymphocytic leukemia (CLL), chemotherapy, 5129 Immunotherapy, cancer vaccine, docetaxel, murine model, prostate cancer, 3275 Immunotherapy, colostrum, macrophage-activating factor (MAF), cancer, chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), 4543 Immunotherapy, dendritic cells, metastases, renal cell carcinoma, sequential therapy, targeted-therapy, 1575 Immunotherapy, glioblastoma multiforme (GBM), chemotherapy, molecular-targeted therapy, review, 1229 Immunotherapy, macrophage-activating factor, phagocytic activity, U937 cell line, THP-1 cell line, 4439 Immunotherapy, macrophage-activating factor, phagocytic activity, U937 cell line, THP-1 cell line, 4445 Immunotherapy, memory T-cells, vesicular stomatitis virus, cyclophosphamide, 4593 Immunotherapy, salmonella, cancer therapy, breast cancer, BALB-neuT, autochthonous model, geneticallyengineered, mouse model, myeloid-derived suppressor cells, 843 Immunsuppressive, IL32, esophageal carcinoma, regulatory T-cell, survival, 2941 IMRT, hypofractionation, simultaneous integrated boost, prostate cancer, IGRT, erectile dysfunction, 4177 In silico systematic mutagenesis, cancer, casein kinase II (CK2), KINARI mutagen web-server, LB-based nanocrystallo graphy, proteomics, ribonuclease A (RNase A),

126 In situ, telomere shortening, altered lengthening of telomeres, TERC, telomerase, hybridization, DAXX, ATRX, immunohistochemistry, 3501 In vitro maturation, emergency fertility preservation, cancer, cryopreservation, autotransplantation, oncofertility, review, 3117 In vitro model, peripheral neuropathy, microtubule-targeting agents, neurite-distupting effects, PC-12 cells, SH-SY5Y cells, 6431 In vitro tumor tissue model, cancer cell sheet, cytotoxicity, biomimick, 6481 In vivo, non-small-cell lung cancer, reimplantation, bench surgery, autotransplantation, ex situ, 1675 In vivo, Pd(II) complex, EAC, tumor, PCNA, apoptosis, 1491 Incidence rate, colorectal adenomas, traditional serrated adenomas, invasive carcinoma, nationwide survey, Iceland, 4929 Incidence, breast cancer, estrogen, lung cancer, survival, 1121 Incidence, kidney cancer, trichloroethylene, mortality, 4009 Incidence, prostate, prostate cancer, neuroendocrine prostate cancer, androgen deprivation therapy, 5-year survival, mortality, 4145 Incisional recurrence, endometrial cancer, laparoscopy, open surgery, port site metastases, 6097 Incomplete cytoreduction, advanced ovarian cancer, biopsy, neoadjuvant chemotherapy, interval debulking surgery, IDs, 2315 Indium-111, anginex, tumor angiogenesis, galectin-1, cancer, 5945 Individualized treatment, synchronous primary malignant neoplasms, multiple primary malignant neoplasms, 6159 Individualized tumor response testing, ex vivo drug resistance, acute lymphoblastic leukemia, children, relapse, minimal residual disease, 5667 Indocyanin green, staging laparoscopy, near-infrared fluorescence imaging, liposome, dissemination, 1353 Indocyanine green fluorescence, gastric tube, line-marking method, HyperEye medical system, 6201 Induction chemotherapy, gastric cancer, para-aortic lymph node metastasis, extended lymphadenectomy, 6739 Induction chemotherapy, head and neck cancer, concomitant chemo-radiation, treatment breaks, intensity-modulated radiotherapy, 6247 Induction chemotherapy, metastatic esophageal cancer, adriamycin, cisplatin, fluorouracil, combination chemotherapy, 2975 Induction, acute myeloid leukemia, cladribine, idarubicin, 6287 Inflammation, gastric cancer, PTX3, macrophage, 2663 Inflammation, leukemia, molecular docking, NF-κB pathway, 2645 Inflammatory response, bone cancer, surgery, immune function, 5461 Infusion site adverse events, fosaprepitant, anthracycline, cisplatin, 379 Inhibition index cisplatin, head and neck cancer, overall survival, 18 F-FDG-PET/CT, SUVmax, 1009 Inhibitor of Apoptosis Proteins (IAPs), resveratrol, protein kinase G (PKG), angiogenesis, HUVECs, 273 Inhibitors, HDAC, histone, acetylasation, epigenetics, pancreatic cancer, review, 3129 Innate immunity, lipopolysaccharide, rice retaining subaleurone layer, macrophage, anti-allergy, 4465 Innate immunity, osteosarcoma, MG-63 cells, toll-like receptor, TLR9, 5839 Inoperable, non-small cell lung cancer, stage I, metachronous, platinum doublets, 3103 Inpatient setting, oncology, anticancer agent, clinical pharmacy services, drug-related problem, 457 Insurance, lung cancer, race, survival, 4243 Integrin, Dendrobium falconeri, dendrofalconerol A, EMT, suppression, migration, lung cancer, 201 Intensity-modulated radiotherapy, advanced-stage endometrial cancer, extended-field external-beam radiotherapy, 2893 Intensity-modulated radiotherapy, carbon ion radiotherapy, proton therapy, patch-field technique, spinal sarcoma, 4083 Intensity-modulated radiotherapy, head and neck cancer, radiotherapy, patterns of failure, 6833 Intensity-modulated radiotherapy, induction chemotherapy, head and neck cancer, concomitant chemo-radiation, treatment breaks, 6247 Interaction, pancreatic cancer, dual color cells, GFP, RFP, stellate cells, CFP nude mouse, color-coded fluorescence imaging, 2545 Interferon β, melanoma, mesenchymal stem cells, apoptosis, cell cycle, 4749 Interferon, chronic hepatitis C, hepatectomy, hepatocellular carcinoma, sustained virological response, 6963 Interleukin, melanoma, sentinel node, Breslow score, 3537 Interleukin-1, curcumin, cancer stem cells, interleukin-6, interleukin-8, CXCR1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 Interleukin-1β, prostate cancer, polymorphism, 6057 Interleukin-2, transmissible venereal tumors, TVT, dogs, IL- 2, 713 Interleukin-2, transmissible venereal tumors, TVT, dogs, IL2, vincristine, 3385 Interleukin-4, genotype, lung, polymorphism, Taiwan, 6297 Interleukin-6, curcumin, cancer stem cells, interleukin-8, interleukin-1, CXCR1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 Interleukin-6, gastroenterology, colon cancer, cytokines, IL6, cancer biomarker,

127 Interleukin-8, curcumin, cancer stem cells, interleukin-6, interleukin-1, CXCR1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 Interstitial changes, radiation pneumonitis, stereotactic radiation therapy, 4909 Interstitial lung disease, bevacizumab, non-small cell lung cancer, acute exacerbation, 4259 Interstitial lung disease, chemotherapy-related exacerbation, small cell lung cancer, usual interstitial pneumonia, 6261 Interstitial pneumonia, acute exacerbation, cisplatin, nonsmall cell lung cancer, vinorelbine, 1697 Interval debulking surgery, advanced ovarian cancer, biopsy, neoadjuvant chemotherapy, IDs, incomplete cytoreduction, 2315 Interval debulking surgery, ovarian cancer, cytoreduction, prognosis, 3027 Intervention-site metastases, malignant mesothelioma, prophylactic radiotherapy, procedure-tract metastases, 4151 Intestinal GIST, laparoscopic surgery, gastrointestinal stromal tumor, overall survival, recurrence-free survival, small bowel GIST, 1033 Intestinal injury, leuprorelin, radiotherapy, radioprotection, 3875 Intestinal microbiota, macrophages, oral administration of LPS, disease prevention, review, 4391 Intestine, gastrointestinal stromal tumor, microarray, stomach, SLIT2, 3289 Intra-arterial chemotherapy, VEGF, advanced HCC, liver cirrhosis, 2205 Intracellular signaling, 3-phosphoinositide-dependent protein kinase 1, serous carcinoma of the ovary, immunohistochemistry, 6329 Intracellular signaling, prostate stem cell antigen, GPIanchored protein, gallbladder cancer, tumor suppressor, 2619 Intracerebrospinal fluid chemotherapy, leptomeningeal metastasis, thiotepa, methotrexate, 5631 Intracranial calcifications, nevoid basal cell carcinomas, odontogenic keratocysts, palmar and plantar pits, 1777 Intracranial tumour, chondrosarcoma, prognosis, 875 Intraductal carcinoma of the breast, juvenile papillomathosis, juvenile fibroadenoma, case report, 5027 Intraglandular dissemination, thyroid cancer, papillary carcinoma, multinodular thyroid, nodular goitre, Hashimoto s thyroiditis, 6335 Intramedullary nailing, femur, metastasis, polymethyl - methacrylate, physical status, prognosis, 427 Intraoperative electron radiation therapy, IOERT, ionizing radiation, IR, MCF7 breast cancer cells, microarray, 2577 Intraoperative electron radiation therapy, IOERT, ionizing radiation, IR, MCF10A cells, microarray, gene-expression profiling, 3223 Intraperitoneal chemotherapy, colorectal neoplasms, peritoneal neoplasms, urinary tract, hyperthermia, postoperative complications, prognosis, 295 Intraperitoneal chemotherapy, drug delivery systems, peritoneal carcinomatosis, animal experiment, review, 627 Intraperitoneal chemotherapy, gastric cancer, S-1, cisplatin, docetaxel, DCS, 2223 Intraperitoneal chemotherapy, ovarian cancer, quality of life, antineoplastic agents, adverse effects, peritoneal carcinomatosis, octogenarian, high pressure, 2309 Intraperitoneal chemotherapy, peritoneal metastasis, ovarian cancer, cisplatin, doxorubicin, pressure, aerosol, quality of life, 6723 Intussusception, invagination, small bowel obstruction, gastrectomy, complication, 6829 Invagination, intussusception, small bowel obstruction, gastrectomy, complication, 6829 Invasion, angiogenesis, immunotherapy, metastasis, signalling systems, thalidomide analogues, review, 5767 Invasion, cantharidin, human melanoma cancer A375.S2 cells, PI3K/NF-ĸB signaling pathways, migration, 729 Invasion, hepatocellular carcinoma, Ras suppressor-1, adhesion, 1509 Invasion, KISS1, KISS1R, Kisspeptin, local metastasis, tumor growth, differentiated thyroid cancer, 819 Invasion, NOV, colorectal cancer, 6591 Invasion, oral squamous cell carcinoma (OSCC), cell lines, Kallikrein-related-peptidase-4 (KLK4), clinical outcome, metastasis, 1861 Invasion, sonic hedgehog (SHH), lung cancer, tumor model, YangZheng XiaoJi, cellular migration, cyclopamine, Smo, Gli, 1321 Invasive aspergillosis, 18 F-FDG-PET/CT, febrile neutropenia, haematological malignancies, 2999 Invasive carcinoma NST type, molecular subtypes, breast cancer, metastasis, 759 Invasive carcinoma, colorectal adenomas, traditional serrated adenomas, incidence rate, nationwide survey, Iceland, 4929 Invasive ductal breast cancer (IDC) sub-types, breast-specific gamma imaging, relative uptake factor, correlation of relative uptake factor and IDC sub-types, 5671 IOERT, intraoperative electron radiation therapy, ionizing radiation, IR, MCF7 breast cancer cells, microarray, 2577 IOERT, intraoperative electron radiation therapy, ionizing radiation, IR, MCF10A cells, microarray, gene-expression profiling, 3223 Ion transport, oxidative stress, cholangiocytes, hydrogen peroxide, 5881 Ionizing radiation, intraoperative electron radiation therapy, IOERT, IR, MCF7 breast cancer cells, microarray, 2577 Ionizing radiation, intraoperative electron radiation therapy, IOERT, IR, MCF10A cells, microarray, gene-expression profiling,

128 Ipilimumab, melanoma, survival, safety, 6303 IPMN, sex steroid receptors, angiogenesis molecules, cell cycle regulators, image analysis, 1049 IPSA, brachytherapy, radiobiological evaluation, 935 IR, intraoperative electron radiation therapy, IOERT, ionizing radiation, MCF7 breast cancer cells, microarray, 2577 IR, intraoperative electron radiation therapy, IOERT, ionizing radiation, MCF10A cells, microarray, gene-expression profiling, 3223 IRF1, LMP2, IFN-γ, uterine leiomyosarcoma, smooth muscle cell, 4665 Irinotecan hydrochloride, TAS-102, 5-FU resistance, colorectal cancer, gastric cancer, 1437 Irinotecan, nedaplatin, squamous cell carcinoma, lung cancer, 6705 Irinotecan, ovarian cancer, safety, phase I trial, pegylated liposomal doxorubicin, 4519 Irinotecan, SN-38, cetuximab, anti-angiogenesis, antiinvasion, colon cancer, 5983 Iron-deficiency anaemia, BRAF V600E, colorectal cancer, KRAS, molecular biomarkers, 2345 Irradiation, head-and-neck cancer, metastatic epidural spinal cord compression, survival, predictive instrument, 385 Irradiation, natural killer cells, natural killer cell subsets, viability, cytotoxicity, radiobiological models, enrichment methods, 5193 Irradiation, pancreatic cancer, metastasis, expected survival, predictive factors, 4105 Irradiation, prostate cancer, metastatic epidural spinal cord compression, elderly patients, overall survival, 6189 Isoflavones, genistein, sarcoma, programmed cell death, hormonal therapy, 3167 Italian study, bevacizumab, older patients, advanced colorectal cancer, 2391 Itraconazole, biliary tract cancer, second-line chemotherapy, 4923 Itraconazole, pancreatic cancer, second-line chemotherapy, Hedgehog, 4191 Ixabepilone, microtubule, microtubule destabilizer, eribulin, paclitaxel, docetaxel, vinorelbine, 5845 Japanese patients, ramucirumab, metastatic colorectal carcinoma, FOLFIRI, pharmacokinetics, 4003 JMJD3, UTX, epigenetic, histone modification, xenograft analysis, cancer treatment, 6611 JNK, PBA, vorinostat, p38 MAPK, gap junction, 775 Jurkat T-cells, curcumin, HP102, IL2, proliferation, apoptosis, 2675 Jurkat-C, HLA class II, T-cell, CIITA, melanoma, immune response, 25 Juvenile fibroadenoma, intraductal carcinoma of the breast, juvenile papillomathosis, case report, 5027 Juvenile papillomathosis, intraductal carcinoma of the breast, juvenile fibroadenoma, case report, 5027 K562 cells, 4-methylumbelliferone, apoptosis, ROS, BCL2 family, mitochondria, 5231 Kallikrein-related peptidases, gene expression, alternative splicing, Canis familiaris, mammary cancer, 2715 Kallikrein-related-peptidase-4 (KLK4), oral squamous cell carcinoma (OSCC), cell lines, clinical outcome, invasion, metastasis, 1861 KDR, cyclin I, CCNI, kinase insert domain receptor, ovarian cancer, chemotherapy, angiogenesis, 1115 Keratinocytes, hand-foot syndrome, cytidine, uridine, thymidine, deoxycytidine, 5-FU, 1303 Keratinocytes, head and neck cancer, differential gene regulation, array, 3253 Ketogenic diet, vitamin D 3, breast cancer, 5525 Ki-67, breast cancer, primary systemic therapy, FDG- PET/CT, response evaluation, 5063 Ki67, breast tumors, histological grading, SUV, estrogen receptor, progesterone receptor, BCL2, p53, androgen receptor, 569 Ki-67, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Ki-67, meningioma, ADC, tumor cellularity, nucleic area, 6841 Ki-67, proliferation marker, MCM-3, MCM-7, mycosis fungoides, primary cutaneous T-cell lymphoma, 6017 Ki67, vitamin D, β-catenin, PAK1, p53, malignant and benign colon tumors, 1513 Kidney cancer, CAIX, carbonic anhydrase, antibody, antibody-dependent cellular cytotoxicity, 1997 Kidney cancer, radiosurgery, brain metastasis, survival, estimation, 4215 Kidney cancer, trichloroethylene, mortality, incidence, 4009 KINARI mutagen web-server, cancer, casein kinase II (CK2), in silico systematic mutagenesis, LB-based nanocrystallo graphy, proteomics, ribonuclease A (RNase A), 827 Kinase insert domain receptor, cyclin I, CCNI, KDR, ovarian cancer, chemotherapy, angiogenesis, 1115 KISS1, KISS1R, Kisspeptin, local metastasis, tumor growth, invasion, differentiated thyroid cancer, 819 KISS1R, KISS1, Kisspeptin, local metastasis, tumor growth, invasion, differentiated thyroid cancer, 819 Kisspeptin, KISS1, KISS1R, local metastasis, tumor growth, invasion, differentiated thyroid cancer, 819 Kita-kyushu lung cancer antigen-1, KK-LC-1, cancer/testis antigen, gastric cancer, 3575 KK-LC-1, kita-kyushu lung cancer antigen-1, cancer/testis antigen, gastric cancer,

129 KML001, gemcitabine, pancreatic cancer, 183 KMRC-1, renal cell carcinoma, docetaxel, cabazitaxel, p- glycoprotein, AKT, Caki-1, OS-RC-2, 6671 KRAS, BRAF V600E, colorectal cancer, molecular biomarkers, iron-deficiency anaemia, 2345 KRAS, cetuximab, epidermal growth factor receptor, metastatic colorectal cancer, 4207 KRAS, colorectal cancer, 3-dimensional floating culture, drug screening, 4451 KRAS, non-small cell lung cancer, ALK translocation, ALK inhibitor, STK11, ATM, crizotinib resistance, genomics, next-generation sequencing, case report, 3007 L1210 cells, P-glycoprotein, glucosylceramide synthase, UDP-glucose, ceramide induced cell death, 2627 L55M polymorphism, paraoxonase-1 (PON1), Q192R polymorphism, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), PCR-RFLP, 4807 L858R, gefitinib, EGFR mutation, non-small cell lung cancer, exon 19 deletion, 6957 Labeling index, small cell lung cancer, survivin, nucleus, immunohistochemistry, 2935 LAM cells, lymphangioleiomyomatosis, mtor, rapamycin, cell motility, metastasis, 3341 Laminin receptor, PCK3145, PSP94, breast cancer, colon cancer, prostate cancer, ERK, 1377 Laparoendoscopic single-site surgery, prophylactic bilateral salpingo-oophorectomy, BRCA mutation, cosmetic satisfaction, ambulatory surgery, 6105 Laparoscopic hepatectomy, hepatocellular carcinoma, semiprone position, 4167 Laparoscopic surgery, colorectal cancer, body mass index, prognosis, recurrence, 5639 Laparoscopic surgery, gastric cancer, gastrectomy, elderly patients, laparoscopy-assisted gastrectomy, 2191 Laparoscopic surgery, gastrointestinal stromal tumor, intestinal GIST, overall survival, recurrence-free survival, small bowel GIST, 1033 Laparoscopic surgery, lower rectal cancer, lateral pelvic dissection, sentinel lymph node, 3489 Laparoscopic surgery, RGC, total gastrectomy, 5023 Laparoscopy, biochemical recurrence, pentafecta, prostate cancer, radical prostatectomy, robotics, 5007 Laparoscopy, cervical cancer, robotic, radical hysterectomy, quality of life, 5015 Laparoscopy, endometrial cancer, incisional recurrence, open surgery, port site metastases, 6097 Laparoscopy-assisted gastrectomy, gastric cancer, laparoscopic surgery, gastrectomy, elderly patients, 2191 Lapatinib, gefitinib, MMP9, cyclin D1, β-catenin, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 Lapatinib, metastatic breast cancer, Her2-positive, pegylated liposomal doxorubicin, 517 Laryngeal muscle, radiation, myosin, MuRF1, 6049 Laryngeal, microrna, let-7a, mir-21, mir-200c, mir-34a, mir-375, head and neck squamous cell carcinoma, oropharyngeal, hypopharyngeal cancer, 2455 Larynx preservation, hypopharyngeal cancer, hyoid bone, chemoradiotherapy, complication, 1735 Larynx, oral squamous cell carcinoma, OSCC, oropha rynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 Laser thermotherapy, breast cancer, minimally invasive treatment, thermal treatment, therapy, tumor immunology, 6147 Late toxicity, proton beam therapy, esophageal cancer, concurrent chemoradiotherapy, survival, 1757 Latency, anal cancer, second primary malignancy, SEER, 4131 Lateral pelvic dissection, lower rectal cancer, laparoscopic surgery, sentinel lymph node, 3489 Lateral pelvic lymph node dissection, adjuvant therapy, mesorectal excision, oxaliplatin, rectal cancer, 1815 LB-based nanocrystallo graphy, cancer, casein kinase II (CK2), in silico systematic mutagenesis, KINARI mutagen web-server, proteomics, ribonuclease A (RNase A), 827 Lectins, adenoma carcinoma sequence, colon cancer, glycosylation, malignant progression, metastasis, 5333 Left ventricular ejection fraction, breast cancer, valvular regurgitation, HER2-positive, trastuzumab, 4063 Left ventricular systolic dysfunction, anthracyclines, chemotherapy, metastatic breast cancer, risk factors, 989 Leiomyoma, genotype, polymorphism, Taiwan, XRCC3, 4691 Leiomyosarcoma, uterine smooth muscle tumors, STUMP, 6445 Lenalidomide, myelofibrosis, bone marrow stroma, gene expression, SOCS3, 5219 Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP), des-γ-carboxyprothrombin (DCP), tumor marker, 2157 Leptomeningeal metastases, central nervous system, epidermal growth factor receptor-tyrosine kinase inhibitor, acquired resistance, T790M, brain metastases, 1025 Leptomeningeal metastasis, intracerebrospinal fluid chemotherapy, thiotepa, methotrexate, 5631 Let7a, breast cancer, mirna21, mirna155, mirna19a, mirna17-5p, paraffin-embedded tissue, 5425 Let-7a, microrna, mir-21, mir-200c, mir-34a, mir-375, head and neck squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal cancer, 2455 Leucocytosis, anemia, prognosis, renal cell carcinoma, thrombocytosis,

130 Leukemia, 3-indolylmethanamine, ovarian cancer, 6001 Leukemia, chemotherapy, cytochalasin B, breast carcinoma, cytoskeletal-directed agents, nucleic acid-directed agents, cell enlargement, 65 Leukemia, inflammation, molecular docking, NF-κB pathway, 2645 Leuprorelin, intestinal injury, radiotherapy, radioprotection, 3875 Levothyroxine substitution therapy, renal cell carcinoma, sunitinib, thyrotoxicosis, hypothyroidism, thiamazole antithyroid therapy, 481 Lewis rat sarcoma, CD11b+ cells, neutrophils, CCL2, tumor immunology, 703 Lifestyle factors, environmental factors, esophageal carcinoma, microrna, socioeconomic factors, 1091 Li-Fraumeni syndrome, choroid plexus carcinoma, TP53 mutation, radiation, 3013 Line-marking method, indocyanine green fluorescence, gastric tube, HyperEye medical system, 6201 Linkage analysis, familial breast cancer, microsatellite markers, next generation sequencing, sequencing analysis, 3155 Lipid hydroperoxide (LHP) malon dialdehyde (MDA), CTLA4, CD28, polymorphism, advanced oxidation protein products (AOPP), protein carbonyl (PCO), superoxide dismutase, advanced glycation end-products (AGEs), copper, zinc, 5391 Lipids, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), 1881 Lipoma, well-differentiated liposarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, multiplex ligationdependent probe amplification, 12q amplicon, 1835 Lipophilic agent, glioblastoma, curcumin, lomustine, cancer stem cells, ceramide, blood brain barrier, combination chemotherapy, review, 6373 Lipopolysaccharide, acetic acid bacteria, oral administration of LPS, anti-allergy, macrophages, 4507 Lipopolysaccharide, broiler, oral administration of LPS, priming, cytokine, 4459 Lipopolysaccharide, Pantoea agglomerans, atopic dermatitis, dermatophagoides farinae body extract, NC/Nga mice, 4499 Lipopolysaccharide, rice retaining subaleurone layer, innate immunity, macrophage, anti-allergy, 4465 Liposome, drug-delivery system, sortase A, 4409 Liposome, staging laparoscopy, near-infrared fluorescence imaging, indocyanin green, dissemination, 1353 Liquid biopsy, breast cancer, extracellular vesicles, exosomes, microvesicles, biomarkers, review, 6379 Liver cirrhosis, HCC, sorafenib, hepatic arterial infusion chemotherapy, 2269 Liver cirrhosis, hepatocellular carcinoma, percutaneous ethanol injection, radiofrequency ablation, overall survival, tumor recurrence, 325 Liver cirrhosis, VEGF, advanced HCC, intra-arterial chemotherapy, 2205 Liver failure, GIST, regorafenib monotherapy, case report, 4037 Liver metastases of colorectal cancer, bevacizumab, postoperative wound complications, 2255 Liver metastases, colorectal cancer, hepatectomy, vascular invasion, vascular attachment, 5485 Liver metastases, stereotactic body radiation therapy, primary liver tumor, 4171 Liver metastasis, mast cells, prognosis, survival, 5325 Liver metastasis, RFP, C57/BL6-GFP mice, malignant lymphoma, imaging, 4647 Liver metastasis, tumor microenvironment, cancer-associated fibroblasts, blood vessels, RFP, fluorescence; color-coded imaging, 5821 Liver resection, breast cancer liver metastases, long term survival, 6913 Liver resection, radiofrequency ablation, colorectal liver metastases, disseminated tumor cells, HGF, IL-6, HSP-70, 2961 Liver, MAT-B-III, animal model, metastasis, transarterial embolization, 1333 Living donor liver transplantation, hepatocellular carcinoma, microsatellite analysis, case report, 3525 Living donor liver transplantation, lung cancer, pulmonary resection, 3411 Living-donor liver transplantation, combined hepatocellularcholangiocarcinoma, hepato cellular carcinoma, 2475 LMP2, IRF1, IFN-γ, uterine leiomyosarcoma, smooth muscle cell, 4665 LN18, cyclooxygenase-2, sulfasalazine, celecoxib, benzimidazole, combination therapy, synergistic effects, brain cancer, glioma, 6419 LNCaP, Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, cell line, PC-3, DU-145, apoptosis, necrosis, cell burst, 5225 LNCaP, vitamin D, CYP27B1, 3773 LncRNA, PLD inhibitor, ANRIL, H460 cells, lung cancer, 2795 Local ablation, hepatocellular carcinoma, recurrence, brachytherapy, 319 Local control, breast cancer, brain metastasis, radiosurgery, radiation dose, distant brain control, overall survival, 333 Local control, renal cell carcinoma, cerebral metastases, stereotactic radiosurgery, freedom from new cerebral metastases, survival,

131 Local control, salvage stereotactic radiotherapy, non-small cell lung cancer, post-surgical recurrence, 1783 Local metastasis, KISS1, KISS1R, Kisspeptin, tumor growth, invasion, differentiated thyroid cancer, 819 Local radiotherapy, metastatic breast cancer, review, 5807 Local recurrence of rectal cancer, circumferential resection margin, 6747 Locally invasive cervical cancer, distal ureterectomy, ureteral reimplantation, 5539 Lomustine, glioblastoma, curcumin, cancer stem cells, ceramide, blood brain barrier, combination chemotherapy, lipophilic agent, review, 6373 Lomustine, sunitinib, glioma, recurrent disease, 5551 Long noncoding RNA, ANRIL, p15, p16, cell cycle, 5377 Long noncoding RNA, TGF-β, colorectal cancer, progression, prognosis, 1385 Long term survival, breast cancer liver metastases, liver resection, 6913 Long-term survival, esophageal cancer, hyperthermia, definitive chemoradiotherapy, 2299 Long-term survival, ovarian cancer liver metastases, hepatic resection, 6919 Low-dose lipopolysaccharide, monocyte, colon cancer cell, co-culture, RelB, STAT3, 4471 Lower rectal cancer, lateral pelvic dissection, laparoscopic surgery, sentinel lymph node, 3489 Low-grade glioma, PET 18 F-FDOPA, prognostic factors, progressive disease, 5117 Low-grade squamous intraepithelial lesion, p16/ki-67, oncogenic HPV DNA, 6291 Luminescent imaging, gastric cancer, peritoneal dissemination, conditionally replicative adenovirus, 5201 Lung cancer, anoikis, pro-survival pathway, lupalbigenin, Derris scandens, 2827 Lung cancer, breast cancer, estrogen, incidence, survival, 1121 Lung cancer, cancer stem cells, angiotensin II, spheroid, 4789 Lung cancer, CD4+RORγt + Th17 cells, CD4+CD25+CD127 low/ regulatory T-cells, pleural effusion, 1529 Lung cancer, chemokines, CXC, NSCLC biomarkers, 6979 Lung cancer, CK2, AKT/mTOR, chemorefractory, 1537 Lung cancer, cross-linked N-Telopeptides of type I collagen, NTx, bone metastasis, 3987 Lung cancer, Dendrobium falconeri, dendrofalconerol A, EMT, integrin, suppression, migration, 201 Lung cancer, drug resistance, c-met inhibitor, TAS-115, anticancer drug combinations, 5241 Lung cancer, formyl-peptide receptors, gene expression, 2769 Lung cancer, gender, genotype, polymorphism, smoking, Taiwan, XRCC3, 3893 Lung cancer, gene therapy, aerosol delivery, sorbitol diacrylate, PDCD4, shakt1, 2015 Lung cancer, hormesis, chemotherapy, 5851 Lung cancer, living donor liver transplantation, pulmonary resection, 3411 Lung cancer, nedaplatin, irinotecan, squamous cell carcinoma, 6705 Lung cancer, nitric oxide, metastasis, apoptosis, migration, cancer stem cells, review, 4585 Lung cancer, non-small cell lung cancer, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, pemetrexed, maintenance treatment, 6255 Lung cancer, PLD inhibitor, LncRNA, ANRIL, H460 cells, 2795 Lung cancer, race, insurance, survival, 4243 Lung cancer, serum cotinine, serum vitamin D, smoking, ethnicity, 1211 Lung cancer, SKAP2, actin assembly, Src, 2411 Lung cancer, small cell ovarian carcinoma, 3091 Lung cancer, sonic hedgehog (SHH), tumor model, YangZheng XiaoJi, cellular migration, invasion, cyclopamine, Smo, Gli, 1321 Lung cancer, surgical orthotopic implantation, nude mice, high tumor take rates, noninvasive imaging, spectral separation, 3755 Lung metastases, colorectal cancer, pulmonary metastasectomy, prognostic factors, 3563 Lung metastases, SBRT, sarcoma, 5581 Lung metastases, stereotactic body radiotherapy, oligometastatic non-small lung cancer, 6239 Lung metastasis, head and neck cancer, distant metastasis, bone metastasis, survival, 5499 Lung metastasis, MDSC, 5-FU, tumor immunity, primary resection, 4423 Lung pathology, mediastinum, 6325 Lung, genotype, interleukin-4, polymorphism, Taiwan, 6297 Lupalbigenin, lung cancer, anoikis, pro-survival pathway, Derris scandens, 2827 Lymph node dissection, adrenocortical carcinoma, prognosis, prevalence, 5575 Lymph node excision, esophagogastric junction, neoplasms, surgery, prognosis, 445 Lymph node metastasis, ANGPTL2, C-reactive protein, CEA, colorectal cancer, 2849 Lymph node metastasis, CD133, colorectal cancer, immunohistochemistry, 6599 Lymph node metastasis, GCNT2, glycogene, epigenetics, colorectal cancer, 1411 Lymph node metastasis, lymphatic invasion, tumor size, breast cancer, sentinel node, 3581 Lymph node metastasis, phospholipase A2, colorectal cancer, immunohistochemistry,

132 Lymphadenectomy, advanced ovarian cancer, node ratio, prognosis, residual tumor, node metastases, 3479 Lymphadenectomy, endometrial cancer, patient volume, guidelines, preoperative staging, 2887 Lymphadenectomy, ovarian cancer, neoadjuvant chemotherapy, overall surivival, 5503 Lymphadenitis with T-zone hyperplasia, angioimmunoblastic T-cell lymphoma, microrna, 2055 Lymphangiogenesis, MCF-7, breast cancer, angiogenesis, mesenchymal stem cells, review, 3147 Lymphangiography, esophageal cancer, chylothorax, case report, 891 Lymphangioleiomyomatosis, LAM cells, mtor, rapamycin, cell motility, metastasis, 3341 Lymphangioleiomyomatosis, β-catenin, E-cadherin, podoplanin, EGFR, 3353 Lymphatic invasion, colorectal cancer, blood vessel invasion, prognosis, 6457 Lymphatic invasion, tumor size, breast cancer, lymph node metastasis, sentinel node, 3581 Lym ph atic metastasis, positron emission tomography, diagnostic imaging, gynecology, clinical oncology, 2247 Lymphatic vessel density, prostate adenocarcinoma, combined androgen blockade therapy, 5595 Lymphatic vessels, male breast cancer, podoplanin, blood vessels, CD34, 1041 Lymphatic vessels, nerve fibre density, vessel density, blood vessels, NF1, neurofibroma, neurofibromatosis, vessel innervation, 6509 Lymphatic vessels, vessel density, blood vessels, NF1, NF2, schwannomatosis, schwannoma, neurofibromatosis, mast cell, MPNST, 4713 Lymphocyte, albumin, gastric cancer, peritoneal metastasis, 3511 Lymphoma, cinnarizine, multiple myeloma, cancer therapy, WNT, 835 Lymphoma, flunarizine, multiple myeloma, cancer therapy, WNT, pathway, 1369 Lymphoma, naftifine, multiple myeloma, therapy, Wnt signaling, 5921 Lymphoma, nanodisks, curcumin, all-trans retinoic acid, apoptosis, 6425 Lymphoma, stem cell marker, spheres, dog, canine model, 2805 Lymphoma, thymidine kinase, prognosis, transformation, 3019 Lymphovascular invasion, uterine cancer, EC, obesity, grade, body mass index, 4053 Lysophosphatidic acid, upar, ovarian, upa, PI3K, 5263 Lysozyme, chronic inflammation, esophagus, stomach, duodenum, colon, review, 6365 M30, hepatocellular carcinoma, sorafenib, programmed cell death, M65, 1803 M65, hepatocellular carcinoma, sorafenib, programmed cell death, M30, 1803 Macrophage phagocytic activity, degalactosylated/desialylated bovine colostrum, GcMAF, mouse peritoneal macrophage, mouse intestinal macrophage, 4485 Macrophage, gastric cancer, PTX3, inflammation, 2663 Macrophage, lipopolysaccharide, rice retaining subaleurone layer, innate immunity, anti-allergy, 4465 Macrophage-activating factor (MAF), immunotherapy, colostrum, cancer, chronic fatigue syndrome (CFS), myalgic encephalomyelitis (ME), 4543 Macrophage-activating factor, immunotherapy, phagocytic activity, U937 cell line, THP-1 cell line, 4439 Macrophage-activating factor, immunotherapy, phagocytic activity, U937 cell line, THP-1 cell line, 4445 Macrophages, intestinal microbiota, oral administration of LPS, disease prevention, review, 4391 Macrophages, lipopolysaccharide, acetic acid bacteria, oral administration of LPS, anti-allergy, 4507 MADRS, hopelessness, helplessness, depression, breast disease, 2215 MAG, DRG, MSC, cisplatin, peripheral neuropathy, neurite elongation, NOGO, 5383 Magnesium, cervical cancer, cisplatin, hydration, nephrotoxicity, 2199 Magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), biparameric MRI (Bp-MRI), tumor markers, CA125, HE4, ovarian tumors characterization, pelvic mass, 6341 Magnetic resonance imaging, renal tumor, diffusion weighted MRI, apparent diffusion coefficient, biomarker, 2351 Maintenance treatment, lung cancer, non-small cell lung cancer, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, pemetrexed, 6255 Male breast cancer, lymphatic vessels, podoplanin, blood vessels, CD34, 1041 Malignant and benign colon tumors, vitamin D, β-catenin, PAK1, p53, Ki67, 1513 Malignant effusion, ascitic fluid, CA125, CYFRA 21-1, differential diagnosis, 5655 Malignant glioma, cell stamper, nanoprinting perforator, 6069 Malignant lymphoma, RFP, C57/BL6-GFP mice, liver metastasis, imaging, 4647 Malignant melanoma, phase II study, sunitinib, biomarkers, PlGF, 6893 Malignant melanoma, tumor-infiltrating lymphocytes, prognostic marker, prognosis, 351 Malignant mesothelioma, biomarkers, chemotherapy, vinorelbine,

133 Malignant mesothelioma, prophylactic radiotherapy, intervention-site metastases, procedure-tract metastases, 4151 Malignant mesothelioma, randomized trials, review, 2493 Malignant peripheral nerve sheath tumor, epidermal growth factor receptor, vascular endothelial growth factor, basic fibroblastic growth factor, neurofibromatosis type 1, vessel density, 137 Malignant pleural mesothelioma, mir-126, EGFL7, DNAmethylation, prognosis, biomarker, 6223 Malignant progression, adenoma carcinoma sequence, colon cancer, glycosylation, lectins, metastasis, 5333 Malignant, breast cancer, melanoma, melanotic, amelanotic, 1709 Mammary cancer, kallikrein-related peptidases, gene expression, alternative splicing, Canis familiaris, 2715 Mammary tumours, feline, cadherins, catenins, 3361 Mammoplasty, breast cancer, mastectomy, neoadjuvant chemotherapy, oncoplastic breast-conserving surgery, 4229 Mandible, Burkitt lymphoma, non-hodgkin lymphoma, HIV infection, osteomyelitis, FDG-PET, EBV, Epstein-Bar, 4837 Mantle cell lymphoma, bendamustine, BCR signaling, BTK inhibitor, apoptosis, 6679 Mantle cell lymphoma, SEER, second primary malignancies, 3437 MAPKAPK2, HMGB1, gemcitabine-resistant, pancreatic cancer, HSP27, 3861 Maspin, serrated polyps, colon, rectum, conventional adenomas, 4139 Mast cell, vessel density, blood vessels, lymphatic vessels, NF1, NF2, schwannomatosis, schwannoma, neurofibromatosis, MPNST, 4713 Mast cells, liver metastasis, prognosis, survival, 5325 Mastectomy, breast cancer, mammoplasty, neoadjuvant chemotherapy, oncoplastic breast-conserving surgery, 4229 Matrix metallo proteinase, NOX1, DUOX1, HOCl, apoptosis, 5955 Matrix metalloproteinase, sorafenib, hepatocellular carcinoma, epithelial mesenchymal transition, 1967 MCF10A cells, intraoperative electron radiation therapy, IOERT, ionizing radiation, IR, microarray, gene-expression profiling, 3223 MCF7 breast cancer cells, intraoperative electron radiation therapy, IOERT, ionizing radiation, IR, microarray, 2577 MCF-7 cells, HIF1Α, CAIX, VEGF, MDA-MB-231 cells, xenografts, microtubule disruptor, anti-angiogenic, 5249 MCF-7, breast cancer, angiogenesis, lymphangiogenesis, mesenchymal stem cells, review, 3147 MCF-7, fucoxanthin, fucoxanthinol, MDA-MB-231, NF-ĸB, SOX9, 207 MCM-3, proliferation marker, Ki-67, MCM-7, mycosis fungoides, primary cutaneous T-cell lymphoma, 6017 MCM-7, proliferation marker, Ki-67, MCM-3, mycosis fungoides, primary cutaneous T-cell lymphoma, 6017 MCP1, anti-mcp1, HNSCC, FLAVINO assay, ex-vivo chemoresponse, 3917 MCP1, epithelial mesenchymal transition, AKT, head and neck cancer, 3299 MCP1, spontaneous regression, progression, sarcoma, natural killer cells, platelets, 6539 MDA-MB-231 cells, HIF1Α, CAIX, VEGF, MCF-7 cells, xenografts, microtubule disruptor, anti-angiogenic, 5249 MDA-MB-231, fucoxanthin, fucoxanthinol, MCF-7, NF-ĸB, SOX9, 207 MDM2, brain tumor, p16, polymorphism, glioma, meningioma, 3933 MDM2, dedifferentiated liposarcoma, well-differentiated liposarcoma, ring chromosome, CDK4, 345 MDR, HER2, P-glycoprotein, transfection, breast cancer, BT-474, 2531 MDR, phenothiazines, multidrug resistance, P-glycoprotein (ABCB1), rhodamine 123, colon adenocarcinoma, apoptosis, doxorubicin, verapamil, 3245 MDSC, lung metastasis, 5-FU, tumor immunity, primary resection, 4423 Mechanism of action, dietary agents, cancer stem cells, signal transduction pathways, review, 5773 Mediastinum, lung pathology, 6325 Medication, adherence, adverse effects, BCR-ABL1, chronic myeloid leukemia, therapy management, review, 6355 Medullary thyroid carcinoma, calcitonin, C-cell hyperplasia, RET, calcium stimulation test, papillary thyroid carcinoma, 4251 Medullary thyroid carcinoma, cell culture, α1-adrenergic receptors, quinazolines, prazosin, apoptosis, 31 Melanoma, adipose tissue-derived mesenchymal stem cells (AT-MSCs), growth inhibition, cytotherapy, 159 Melanoma, biomarkers, treatment response, prognosis, 6755 Melanoma, bis(phenylidenebenzeneamine)-1-disulfide, autophagy, mitochondria, 6075 Melanoma, breast cancer, malignant, melanotic, amelanotic, 1709 Melanoma, CD114, G-CSF, nifurtimox, 3787 Melanoma, chondroitin sulfate proteoglycan-4, PI3K, mtor, 1279 Melanoma, clotrimazole, A375 cells, apoptosis, cell cycle, hexokinase, 3781 Melanoma, GAPDH, immunohistochemistry, mrna expression, prognosis, 439 Melanoma, glucan, NK cells, immunity, antibodies, cancer, 5287 Melanoma, HLA class II, T-cell, CIITA, immune response, Jurkat-C, 25 Melanoma, interleukin, sentinel node, Breslow score, 3537 Melanoma, ipilimumab, survival, safety,

134 Melanoma, mesenchymal stem cells, interferon β, apoptosis, cell cycle, 4749 Melanoma, mirna, melanospheres, anchorage-independent growth, 2747 Melanoma, nevus, reversion-inducing cysteine-rich protein with Kazal motifs, immunohistochemical stain, RECK, 3185 Melanoma, oncolytic viruses, Newcastle disease virus, virotherapy, 5401 Melanoma, sentinel lymph node, tumor burden, 301 Melanoma, zinc, apoptosis, reactive oxygen species, FAS ligand, p53, 5309 Melanoma, α v β 3 integrin, glycosylation, migration, vitronectin, 2093 Melanospheres, mirna, anchorage-independent growth, melanoma, 2747 Melanotic, breast cancer, melanoma, malignant, amelanotic, 1709 Melanotransferrin, colorectal carcinoma, poorly differentiated adenocarcinoma, pathogenesis, adenoma carcinoma sequence, tumorigenesis, 6551 Memory T-cells, immunotherapy, vesicular stomatitis virus, cyclophosphamide, 4593 Meningeal neoplasm, meningioma, recurrent brain tumor, human, WHO classification, 3559 Meningioma, ADC, tumor cellularity, Ki-67, nucleic area, 6841 Meningioma, brain tumor, p16, MDM2, polymorphism, glioma, 3933 Meningioma, nanomedicine, surgery, targeted therapies, treatment, review, 6391 Meningioma, recurrent brain tumor, meningeal neoplasm, human, WHO classification, 3559 Merkel cell carcinoma, prognosis, Merkel cell, polyoma virus infection, 1843 MESCC, cancer of unknown primary, elderly, radiation therapy, survival tool, 6219 Mesenchymal neoplasm, PEC, PEComa, PEC tumor, everolimus, mtor inhibition, targeted therapy, case report, 3399 Mesenchymal stem cells, MCF-7, breast cancer, angiogenesis, lymphangiogenesis, review, 3147 Mesenchymal stem cells, melanoma, interferon β, apoptosis, cell cycle, 4749 Mesenchymal-epithelial transition (MET), gefitinib, lapatinib, MMP9, cyclin D1, β-catenin, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), human papillomavirus (HPV), 3801 Mesna, uterine carcinosarcoma, chemotherapy, carboplatin, ifosfamide, 4841 Mesorectal excision, adjuvant therapy, lateral pelvic lymph node dissection, oxaliplatin, rectal cancer, 1815 Messina province, gastric adenocarcinoma, tumor-infiltrating neutrophils, Cancer Registry Study, 487 MET, c-met, HGF, crizotinib, head and neck cancer, radiation, 5973 MET, colorectal cancer, ROCK I, immunohistochemistry, tissue microarray, five-year survival, 3267 Metabolic reprogramming, mitochondria, metformin, review, 5789 Metabolic syndrome, colorectal cancer, colorectal polyps, obesity, 2211 Metabolites, N-acyl dopamine, vanilloids, cancer, cytotoxicity, 2657 Metachronous, non-small cell lung cancer, stage I, platinum doublets, inoperable, 3103 Metastases, breast cancer, CSF1, CSF1R, tumor-infiltrating macrophages, T-lymphocytes, epithelial tumor cells, tumor stromal cells, 865 Metastases, dendritic cells, immunotherapy, renal cell carcinoma, sequential therapy, targeted-therapy, 1575 Metastases, nephrotoxicity, ibandronate, zoledronic acid, breast cancer, 1797 Metastasis, MAT-B-III, animal model, liver, transarterial embolization, 1333 Metastasis, adenoma carcinoma sequence, colon cancer, glycosylation, lectins, malignant progression, 5333 Metastasis, angiogenesis, immunotherapy, invasion, signalling systems, thalidomide analogues, review, 5767 Metastasis, Astragalus membranaceus, Curcuma wenyujin, ovarian cancer, red fluorescent protein, orthotopic, nude mice, tumor progression, 3193 Metastasis, breast cancer, Balb-c mice, syngeneic, orthotopic, tumor resection, RFP, imaging, 4641 Metastasis, cadherin, side-effect, des-γ-carboxyprothrombin, cell migration, hepatocellular carcinoma, 1985 Metastasis, colorectal cancer, immunohistochemistry, phosphati dylserine-specific phospholipase A1, tumor invasion, 1459 Metastasis, femur, intramedullary nailing, polymethyl - methacrylate, physical status, prognosis, 427 Metastasis, GFP xenograft assay, breast cancer, 47 Metastasis, GFP, RFP, nude mice, human tumors, imaging, noninvasive, variable magnification, subcellular in vivo imaging, spectral separation, tunable filter, 661 Metastasis, high-fat diet, PAI1, bone, mice, 3839 Metastasis, lymphangioleiomyomatosis, LAM cells, mtor, rapamycin, cell motility, 3341 Metastasis, molecular subtypes, breast cancer, invasive carcinoma NST type, 759 Metastasis, nitric oxide, lung cancer, apoptosis, migration, cancer stem cells, review, 4585 Metastasis, oral squamous cell carcinoma (OSCC), cell lines, Kallikrein-related-peptidase-4 (KLK4), clinical outcome, invasion,

135 Metastasis, pancreatic cancer, irradiation, expected survival, predictive factors, 4105 Metastasis, rectum, neuroendocrine tumor, carcinoid, HES77, prognosis, 3767 Metastatic breast cancer, anthracyclines, chemotherapy, left ventricular systolic dysfunction, risk factors, 989 Metastatic breast cancer, chemotherapy, platinum, etoposide, ifosfamide, 5091 Metastatic breast cancer, Her2-positive, lapatinib, pegylated liposomal doxorubicin, 517 Metastatic breast cancer, local radiotherapy, review, 5807 Metastatic colorectal cancer, cetuximab, epidermal growth factor receptor, KRAS, 4207 Metastatic colorectal cancer, hypothyroidism, regorafenib, thyroid-stimulating hormone, 4059 Metastatic colorectal cancer, regorafenib, chemotherapy, adverse events, 371 Metastatic colorectal carcinoma, ramucirumab, Japanese patients, FOLFIRI, pharmacokinetics, 4003 Metastatic disease, bevacizumab, breast cancer, epidermal growth factor receptor (HER2)-negative, predictive factors, 6941 Metastatic epidural spinal cord compression, head-and-neck cancer, irradiation, survival, predictive instrument, 385 Metastatic epidural spinal cord compression, prostate cancer, elderly patients, irradiation, overall survival, 6189 Metastatic esophageal cancer, induction chemotherapy, adriamycin, cisplatin, fluorouracil, combination chemotherapy, 2975 Metastatic prostate cancer, abiraterone, CRPC, predictive algorithm, 1057 Metastatic prostate cancer, androgen-deprivation therapy, obesity, prostate-specific antigen, testosterone, 6925 Metastatic renal carcinoma, targeted-therapy, prediction, biomarkers, immunohistochemistry, 5661 Metastatic renal cell carcinoma, tyrosine kinase inhibitor, first-line, second-line, objective response, progression-free survival, 3067 Metastatic, castrate-resistant, prostate cancer, abiraterone, predictors response, drug sequencing, 5615 Metformin, hepatocellular carcinoma, radiotherapy, survival, 5047 Metformin, HSP27, pancreatic cancer, 1941 Metformin, metabolic reprogramming, mitochondria, review, 5789 Methotrexate, leptomeningeal metastasis, intracerebrospinal fluid chemotherapy, thiotepa, 5631 Methylation reaction, dimethylsulfoniopropionate, betaine, Ehrlich ascites carcinoma, activated macrophages, 1475 Methylation, HCC, cell-free DNA, epigenetic, quantitative MSP, 997 MG-63 cells, osteosarcoma, toll-like receptor, TLR9, innate immunity, 5839 MGMT, biomarker, PVT, temozolomide, cisplatin, first-line chemotherapy, BRAF, ERCC1, 1105 MHC class II, cytokine, chemoimmunotherapy, dendritic cell, pancreatic cancer, vaccine, WT1, 555 Mice, high-fat diet, PAI1, bone, metastasis, 3839 Micelle(s), cannabinoids, WIN55, 212-2, breast, cancer, nanoparticle(s), nano-micelle, 4707 Micelles, cancer treatment, experimental chemotherapy, ellipticine, block copolymers, 753 Micro RNA profiling, non-small cell lung cancer, sputum, bronchoalveolar lavage, cancer detection, 1873 Microarray, diffuse large B-cell lymphoma, primary CNS lymphoma, gene expression, 3333 Microarray, FOXD1, non-small cell lung cancer, pathway signature, PTEN, 261 Microarray, gastrointestinal stromal tumor, stomach, intestine, SLIT2, 3289 Microarray, gene-expression profiling, colon cancer, tumor front, chemokines, epithelial mesenchymal transition, 6577 Microarray, intraoperative electron radiation therapy, IOERT, ionizing radiation, IR, MCF7 breast cancer cells, 2577 Microarray, intraoperative electron radiation therapy, IOERT, ionizing radiation, IR, MCF10A cells, gene-expression profiling, 3223 Microfluidics, core needle biopsy, core needle wash, PBS, cytology, 5905 Microfocal prostate cancer, prostate cancer, multi-parametric MRI, 395 Microgranules, curcumin, bioavailability, head and neck squamous cell carcinoma, 6411 Micronucleus, prodigiosin, genotoxicity, tumor cells, 3325 MicroRNA expression, cervical intraepithelial neoplasia, cervical cancer, single and multiple HPV infection, 523 MicroRNA, 5p-arm, 3p-arm, bioinformatics, gastric cancer, 1345 MicroRNA, adenoid cystic carcinoma, head and neck squamous cell carcinoma, HPV, 1271 MicroRNA, angioimmunoblastic T-cell lymphoma, lymphadenitis with T-zone hyperplasia, 2055 MicroRNA, biomarker, endogenous control, germ cell tumors, real time PCR, testicular cancer, 117 MicroRNA, cancer epigenetics, esophageal squamous cell carcinoma, DNA methylation, 4617 MicroRNA, endometrioid endometrial cancer, PTEN, 1401 MicroRNA, environmental factors, esophageal carcinoma, lifestyle factors, socioeconomic factors, 1091 MicroRNA, epithelial ovarian cancer, recurrence, 2611 MicroRNA, exosome, neuroblastoma, mirna, 2521 MicroRNA, let-7a, mir-21, mir-200c, mir-34a, mir-375, head and neck squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal cancer, 2455 MicroRNA, mononuclear cells, biomarker,

136 Microsatellite analysis, hepatocellular carcinoma, living donor liver transplantation, case report, 3525 Microsatellite markers, familial breast cancer, linkage analysis, next generation sequencing, sequencing analysis, 3155 Microsphere, chemoembolization, vascular heterogeneity, anti-angiogenic therapy, ceramics, drug delivery system (DDS), TNP-470, uterine sarcoma, carcinosarcoma, 4757 Microtubule destabilizer, microtubule, eribulin, paclitaxel, docetaxel, vinorelbine, ixabepilone, 5845 Microtubule disruptor, HIF1Α, CAIX, VEGF, MCF-7 cells, MDA-MB-231 cells, xenografts, anti-angiogenic, 5249 Microtubule, microtubule destabilizer, eribulin, paclitaxel, docetaxel, vinorelbine, ixabepilone, 5845 Microtubule-associated protein, tau protein, taxanes, chemotherapy sensitivity, cancer treatment, breast cancer, review, 5179 Microtubule-targeting agents, peripheral neuropathy, neuritedistupting effects, in vitro model, PC-12 cells, SH-SY5Y cells, 6431 Microvesicles, breast cancer, extracellular vesicles, exosomes, biomarkers, liquid biopsy, review, 6379 Microvessel density, survivin, AKT, VEGF, oral melanoma, prognostic factor, 2113 Migration, cantharidin, human melanoma cancer A375.S2 cells, PI3K/NF-ĸB signaling pathways, invasion, 729 Migration, dendrobium falconeri, dendrofalconerol A, EMT, integrin, suppression, lung cancer, 201 Migration, gelsolin, breast cancer, prognosis, cytoskeleton, estrogen receptor-positive, 5277 Migration, nitric oxide, lung cancer, metastasis, apoptosis, cancer stem cells, review, 4585 Migration, α v β 3 integrin, glycosylation, melanoma, vitronectin, 2093 Milan criteria, endoscopic hepatectomy, hepatocellular carcinoma, open hepatectomy, propensity case-matched analysis, 1583 Milk thistle, glioblastoma, silibinin, temozolomide, natural compounds, 1263 Mindfulness, cachexia, dietetics, 6311 Mineral and bone disease, vitamin D, chronic kidney disease, CKD, dialysis, ESRD, renal replacement therapy (RRT), cancer, epidemiology, CKD-MBD, 1181 Minimal residual disease, ex vivo drug resistance, individualized tumor response testing, acute lymphoblastic leukemia, children, relapse, 5667 Minimally invasive treatment, breast cancer, laser thermotherapy, thermal treatment, therapy, tumor immunology, 6147 Minocycline, acneiform rash, skin care, panitumumab, colorectal cancer, tumor response, time to treatment failure, 6175 Minor EGFR mutation, EGFR-TKI, gefitinib, erlotinib, nonsmall-cell lung cancer, 3885 MiR-126, malignant pleural mesothelioma, EGFL7, DNAmethylation, prognosis, biomarker, 6223 MIR143, glomus tumor, cytogenetics, t(1;5), NOTCH2, 6167 MiR-15a, breast cancer, prognosis, 123 MiR-200c, microrna, let-7a, mir-21, mir-34a, mir-375, head and neck squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal cancer, 2455 MiR-21, breast cancer, chromogenic in situ hybridization 3175 MiR-21, microrna, let-7a, mir-200c, mir-34a, mir-375, head and neck squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal cancer, 2455 MiR-34a, microrna, let-7a, mir-21, mir-200c, mir-375, head and neck squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal cancer, 2455 MiR-375, microrna, let-7a, mir-21, mir-200c, mir-34a, head and neck squamous cell carcinoma, oropharyngeal, laryngeal, hypopharyngeal cancer, 2455 MiR-503, oesophageal cancer, prognosis, biomarker, 1447 MiR-7, ovarian cancer, TP53 status, tumour grade, EGFR, BCL2, 2423 Miriplatin, hepatocellular carcinoma, transcatheter arterial chemoembolization, epirubicin, combination therapy, 549 Miriplatin, hepatocellular carcinoma, transcatheter arterial chemoembolization, epirubicin, combination therapy, 549 MiRNA, esophageal cancer, small cell carcinoma, prognostic marker, surgery, 719 MiRNA, exosome, neuroblastoma, microrna, 2521 MiRNA, melanospheres, anchorage-independent growth, melanoma, 2747 MiRNA-145, glioblastoma, srgap, SLIT-ROBO, 3209 MiRNA155, breast cancer, mirna21, let7a, mirna19a, mirna17-5p, paraffin-embedded tissue, 5425 MiRNA17-5p, breast cancer, mirna21, mirna155, let7a, mirna19a, paraffin-embedded tissue, 5425 MiRNA19a, breast cancer, mirna21, mirna155, let7a, mirna17-5p, paraffin-embedded tissue, 5425 MiRNA21, breast cancer, mirna155, let7a, mirna19a, mirna17-5p, paraffin-embedded tissue, 5425 Mitochondria, 4-Methylumbelliferone, K562 cells, Apoptosis, ROS, BCL2 family, 5231 Mitochondria, bis(phenylidenebenzeneamine)-1-disulfide, melanoma, autophagy, 6075 Mitochondria, metabolic reprogramming, metformin, review, 5789 Mitochondrial DNA deficiency/ dysfunction, mitochondrion, transcriptome sequencing/rna deep-sequencing, cancer stem cells, CSCs, cancer cell proliferation, anti-apoptosis, stemness, western blotting, RT-PCR, immunocytochemistry,

137 Mitochondrial transmembrane potential, 3-arylcoumarin derivatives, cytotoxic effect, cell cycle phase, reactive oxygen species production, 653 Mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deep-sequencing, cancer stem cells, CSCs, cancer cell proliferation, anti-apoptosis, stemness, western blotting, RT-PCR, immunocytochemistry, 3743 Mitochondrion-associated 2 (Aifm2), erythropoiesis, apoptosis-inducing factor, murine erythroleukemia cells, 4491 Mitosis, cancer cells, GFP, histone-h2b, fusion, nuclear labeling, RFP, retrovirus, cytoplasmic labeling, chromosomes, 2553 MLL, cell cycle, CDK inhibitor, p16, transcription, polycomb, ANRIL, review, 4395 MMP9, gefitinib, lapatinib, cyclin D1, β-catenin, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 MnSOD, GPX1, oxidative stress, colorectal cancer, antioxidants, 255 Mobility, CXCR7, CXCL12, glioma, proliferation, 53 Model, biopsy, predictive value, prostate neoplasms, nomogram, screening programs, 2881 Modified citrus pectin, azoxymethane, colonic cancer, probiotic, galectin-3, immunohistochemistry, 4765 Molecular biology, NSCLC, immunotherapies, clinical outcome, review, 5745 Molecular biomarkers, BRAF V600E, colorectal cancer, KRAS, iron-deficiency anaemia, 2345 Molecu lar docking, angiogenesis, Artemisia annua, artemisinin, cancer, quantitative structure-activity relationship calcula tions, QSAR, vascular endothelial growth factor receptor, 1929 Molecular docking, cancer, drug resistance, copper transporter, 6505 Molecular docking, inflammation, leukemia, NF-κB pathway, 2645 Molecular marker, biomarkers, circulating tumor cells, CTCs, prostate cancer, 5679 Molecular marker, prostate cancer, PSMA, antibody crossreactivity, diagnosis, dog, 145 Molecular subtypes, breast cancer, invasive carcinoma NST type, metastasis, 759 Molecular targeted therapy, advanced gastric cancer, secondline, chemotherapy, review, 4575 Molecular targeted therapy, renal cell carcinoma, prognostic factor, duration of first-line treatment, 3415 Molecular targeted therapy, thyroid cancer, HIF1α inhibitor, orthotopic mouse model, echinomycin, adjuvant chemotherapy, 2049 Molecular-targeted therapy, glioblastoma multiforme (GBM), chemotherapy, immunotherapy, review, 1229 Molecular-targeted therapy, hepatocellular carcinoma, sorafenib, tyrosine kinase inhibitor, review, 5737 Molt-4 cells, artemisinin, sodium ascorbate, vitamin D 3, Trolox, dexamethasone, hydrogen peroxide, 1867 Monoclonal antibodies, NSCLC, novel therapies, tyrosine kinase inhibitors, clinical trials, review, 2503 Monocyte, bile duct cancer, immune supression, systemic inflammatory response, 4961 Monocyte, colon cancer cell, co-culture, low-dose lipopolysaccharide, RelB, STAT3, 4471 Monocytes, combretastatin, neutrophils, tumors, 2559 Monofunctional platinum, cisplatin, ovarian cancer, drug resistance, combination chemotherapy, phytochemical, 2783 Mononuclear cells, microrna, biomarker, 3969 Mortality, kidney cancer, trichloroethylene, incidence, 4009 Mortality, prostate, prostate cancer, neuroendocrine prostate cancer, androgen deprivation therapy, incidence, 5-year survival, 4145 Mosaicism, neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, dermal cylindroma, rare tumor, 6813 Motility, glioblastoma, hyperbaric oxygen, HBO, clonogenicity, time-lapse videography, 1977 Mouse intestinal macrophage, degalactosylated/desialylated bovine colostrum, GcMAF, macrophage phagocytic activity, mouse peritoneal macrophage, 4485 Mouse model, salmonella, cancer therapy, breast cancer, BALB-neuT, autochthonous model, geneticallyengineered, immunotherapy, myeloid-derived suppressor cells, 843 Mouse models, esophageal cancer, orthotopic, experimental metastasis, GFP imaging, 4655 Mouse peritoneal macrophage, degalactosylated/desialylated bovine colostrum, GcMAF, macrophage phagocytic activity, mouse intestinal macrophage, 4485 Mouse T-lymphoma, multidrug resistance, phosphorus ylide, trifluoroacetyl, ABCB1, P-glycoprotein, 5915 Mouse T-lymphoma, steroids, multidrug resistance, ABCB1 transporter, PC-3 prostate cancer cell line, 2105 Mouse, amifostine, radiation, apoptosis, 2817 MPNST, vessel density, blood vessels, lymphatic vessels, NF1, NF2, schwannomatosis, schwannoma, neurofibromatosis, mast cell, 4713 MRI, breast cancer, neoadjuvant chemotherapy, correlation, pathological response, 581 MRI, glioma, angiocentric, spectroscopy, 6267 MRI, solitary fibrous tumor, thigh, PET/CT, CD34, STAT6, NAB2-STAT6, 967 MRNA expression, GAPDH, immunohistochemistry, melanoma, prognosis,

138 MRNA quantification, pancreatic cancer, cancer of the papilla of Vater, chronic pancreatitis, Col11A1, diagnostic marker, 6153 MRNA, VAV3, VAV3.1, tumorigenesis, OSCC, 2593 MSC, DRG, cisplatin, peripheral neuropathy, neurite elongation, NOGO, MAG, 5383 Mt. Etna pollution, cancer incidence, volcanic environment, volcanic carcinogens, cancer epidemiology, 3995 MTHFR, XRCC1, EGFR, cancer, population stratifica tion, ancestry, 2009 MTOR inhibition, PEC, PEComa, PEC tumor, mesenchymal neoplasm, everolimus, targeted therapy, case report, 3399 MTOR inhibitor, dose determination, EGFR monoclonal antibody, targeted-therapy, 1567 MTOR inhibitor, mtor inhibitor-associated anemia, everolimus, 2333 MTOR inhibitor-associated anemia, mtor inhibitor, everolimus, 2333 MTOR, chondroitin sulfate proteoglycan-4, PI3K, melanoma, 1279 MTOR, EMT, mtorc1, mtorc2, brain metastases, 689 MTOR, lymphangioleiomyomatosis, LAM cells, rapamycin, cell motility, metastasis, 3341 MTOR, tyrosin-kinase-inhibitor, AREG, head and neck squamous cell carcinoma, everolimus, sorafenib, sunitinib, 1951 MTORC1, EMT, mtor, mtorc2, brain metastases, 689 MTORC2, EMT, mtor, mtorc1, brain metastases, 689 Mucinous neoplasm, Pseudomyxoma peritonei, mucocele, perforated appendix, peritoneal carcinomatosis, HIPEC, 4943 Mucocele, Pseudomyxoma peritonei, mucinous neoplasm, perforated appendix, peritoneal carcinomatosis, HIPEC, 4943 Multicenter study, pancreatic cancer, adjuvant, aged, pooled analysis, radiotherapy, chemotherapy, 3441 Multicenter study, pleomorphic rhabdomyosarcoma, chemotherapy, prognosis, 6213 Multicentricity, multifocality, breast cancer, 5111 Multidetector-row CT (MDCT), pediatric tumors, helical computed tomography (CT), radiation dose, split-bolus technique, 3041 Multidrug resistance (MDR), P-glycoprotein, non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase 2 (COX2), 2835 Multidrug resistance, phenothiazines, MDR, P-glycoprotein (ABCB1), rhodamine 123, colon adenocarcinoma, apoptosis, doxorubicin, verapamil, 3245 Multidrug resistance, phosphorus ylide, trifluoroacetyl, ABCB1, P-glycoprotein, mouse T-lymphoma, 5915 Multidrug resistance, steroids, ABCB1 transporter, mouse T-lymphoma, PC-3 prostate cancer cell line, 2105 Multidrug resistance-associated protein, regorafenib, disposition, organic anion-transporting polypeptide, hepatic uptake, biliary excretion, protein-binding, 4681 Multifocality, multicentricity, breast cancer, 5111 Multi-institution study, sarcoma, oral cavity, prognostic factors, 4549 Multinodular thyroid, thyroid cancer, papillary carcinoma, nodular goitre, Hashimoto s thyroiditis, intraglandular dissemination, 6335 Multi-nucleated cells, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, coculture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Multi-parametric MRI, prostate cancer, microfocal prostate cancer, 395 Multiple myeloma, cinnarizine, lymphoma, cancer therapy, WNT, 835 Multiple myeloma, flunarizine, lymphoma, cancer therapy, WNT, pathway, 1369 Multiple myeloma, naftifine, lymphoma, therapy, Wnt signaling, 5921 Multiple primary cancers, hepatobiliary and pancreas, risk factors, surgery, prognosis, 1073 Multiple primary malignant neoplasms, synchronous primary malignant neoplasms, individualized treatment, 6159 Multiple primary malignant neoplasms, synchronous, glioblastoma, glioblastoma multiforme, neuroendocrine tumor, sessile serrated adenoma/polyp, schwannoma, 2121 Multiple reaction monitoring, breast cancer, proteomics, diagnosis, plasma, 6271 Multiple recurrences, hepatocellular carcinoma, hepatectomy, 3061 Multiplex ligation-dependent probe amplification, lipoma, well-differentiated liposarcoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, 12q amplicon, 1835 Multivisceral resection, epithelial ovarian cancer, complete cytoreduction, overall survival, 4099 Multi-visceral resection, retroperitoneal giant tumor, adrenocortical carcinoma, non-secretory tumor, 2169 MuRF1, laryngeal muscle, radiation, myosin, 6049 Murine erythroleukemia cells, erythropoiesis, apoptosisinducing factor, mitochondrion-associated 2 (Aifm2), 4491 Murine model, cancer vaccine, docetaxel, immunotherapy, prostate cancer, 3275 Murine model, tumour-supernatants, chemotherapy, GM- CSF, 1499 Murine tumor model, T lymphocytes, adoptive transfer, bioluminescence imaging, 6573 Mutation phenotype, TP53, FGFR3, urine sediment, bladder cancer,

139 Mutation, non-small cell lung cancer, EGFR, outcome, population, prevalence, 3979 Mutations, breast cancer, ovarian cancer, Canadian patients, Saudi Arabian patients, comparative study, next generation sequencing, 2601 Mutations, thyroid nodules, thyroid neoplasms, biological markers, cytodiagnosis, 1237 My5-FU immunoassay, concentration of 5-FU, 5-FUbased chemotherapy, FOLFIRI, FOLFOX, 6193 Myalgic encephalomyelitis (ME), immunotherapy, colostrum, macrophage-activating factor (MAF), cancer, chronic fatigue syndrome (CFS), 4543 Mycosis fungoides, proliferation marker, Ki-67, MCM-3, MCM-7, primary cutaneous T-cell lymphoma, 6017 Myelodysplastic syndrome, 5-azacytidine, acute myeloid leukemia, 5141 Myelodysplastic syndrome, atomic bomb, high-dose radiation exposure, azacitidine, hypomethylating agents, 2929 Myelodysplastic syndrome, SRSF2, U2AF1, ZRSR2, decitabine, 3081 Myelofibrosis, lenalidomide, bone marrow stroma, gene expression, SOCS3, 5219 Myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM), dendritic cells (DCs), Poly(I:C), Toll-like receptor 3, TICAM-1, antitumor immunotherapy, review, 4383 Myeloid-derived suppressor cells, salmonella, cancer therapy, breast cancer, BALB-neuT, autochthonous model, genetically-engineered, mouse model, immunotherapy, 843 Myelosuppression, esophageal cancer, chemoradiation, 4889 Myosin, laryngeal muscle, radiation, MuRF1, 6049 N3, radical surgery, breast cancer, supraclavicular, 18FDG- PET/CT, neoadjuvant chemotherapy, 1729 NAB2-STAT6, solitary fibrous tumor, thigh, PET/CT, MRI, CD34, STAT6, 967 N-acyl dopamine, metabolites, vanilloids, cancer, cytotoxicity, 2657 Naftifine, multiple myeloma, lymphoma, therapy, Wnt signaling, 5921 Nanodisks, lymphoma, curcumin, all-trans retinoic acid, apoptosis, 6425 NANOG, co-expression, cytoskeletal protein, adducin 3, cancer stem cell marker, CD133, neurospheres, temozolomide-resistant subclone, glioblastoma, 6487 Nanomedicine, meningioma, surgery, targeted therapies, treatment, review, 6391 Nano-micelle, cannabinoids, WIN55, 212-2, breast, cancer, micelle(s), nanoparticle(s), 4707 Nanoparticle(s), cannabinoids, WIN55, 212-2, breast, cancer, micelle(s), nano-micelle, 4707 Nanoparticle, polyethylenimine, sirna, folate receptor, drug delivery, cancer, 5433 Nanoprinting perforator, cell stamper, malignant glioma, 6069 Nasopharyngeal carcinoma, apoptosis, CHM-1, GRP78, p85α, 5359 Nasopharyngeal carcinoma, chemoradiotherapy, docetaxel, cisplatin, 5-fluorouracil, 6861 Nationwide survey, colorectal adenomas, traditional serrated adenomas, incidence rate, invasive carcinoma, Iceland, 4929 Natural compounds, glioblastoma, milk thistle, silibinin, temozolomide, 1263 Natural killer cell subsets, natural killer cells, irradiation, viability, cytotoxicity, radiobiological models, enrichment methods, 5193 Natural killer cells, natural killer cell subsets, irradiation, viability, cytotoxicity, radiobiological models, enrichment methods, 5193 Natural killer cells, spontaneous regression, progression, sarcoma, platelets, MCP1, 6539 NC/Nga mice, lipopolysaccharide, Pantoea agglomerans, atopic dermatitis, dermatophagoides farinae body extract, 4499 N-cadherin, pituitary adenoma, EMT, E-cadherin, SLUG, SNA1, TWIST, 2635 Near-infrared fluorescence imaging, staging laparoscopy, indocyanin green, liposome, dissemination, 1353 Necrosis, apoptosis, cytotoxicity, formamidine anthracy - clines, 1935 Necrosis, Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, cell line, PC-3, LNCaP, DU- 145, apoptosis, cell burst, 5225 Necrosis, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, gene expression, FACS, proliferation, chemotherapy, 767 Nedaplatin, irinotecan, squamous cell carcinoma, lung cancer, 6705 Neoadjuvant chemoradiation, rectal cancer, single nucleotide polymorphism, biomarker, review, 3761 Neoadjuvant chemotherapy, advanced ovarian cancer, biopsy, interval debulking surgery, IDs, incomplete cytoreduction, 2315 Neoadjuvant chemotherapy, biliary duct cancer, case report, 4203 Neoadjuvant chemotherapy, breast cancer, docetaxel, cyclophosphamide, predictive factor, triple-negative, 907 Neoadjuvant chemotherapy, breast cancer, mammoplasty, mastectomy, oncoplastic breast-conserving surgery, 4229 Neoadjuvant chemotherapy, gastric carcinoma, peritoneal washing, 4859 Neoadjuvant chemotherapy, MRI, breast cancer, correlation, pathological response, 581 Neoadjuvant chemotherapy, ovarian cancer, overall surivival, lymphadenectomy,

140 Neoadjuvant chemotherapy, radical surgery, breast cancer, N3, supraclavicular, 18FDG-PET/CT, 1729 Neoadjuvant chemotherapy, siewert type II adenocarcinoma, DCS regimen, 419 Neoadjuvant chemotherapy, triple-negative breast cancer, pathological complete response, pcr, residual disease, prognostic impact, 5479 Neoadjuvant treatment, pulmonary blastoma, EGFR mutation, PD-L1 expression, ALK-EML4 translocation, chemo radiotherapy, pembrolizumab, 4871 Neoadjuvant, peripheral blood, biomarker, prospective, TS, DPD, survival, esophageal cancer, 1297 Neoajuvant radiochemotherapy, οesophageal cancer, RapidArc, 4109 Neoplasms, esophagogastric junction, lymph node excision, surgery, prognosis, 445 Nephrotoxicity, cervical cancer, cisplatin, hydration, magnesium, 2199 Nephrotoxicity, ibandronate, zoledronic acid, breast cancer, metastases, 1797 Nerve fibre density, vessel density, blood vessels, lymphatic vessels, NF1, neurofibroma, neurofibromatosis, vessel innervation, 6509 Nested case-control study, breast cancer, case-control study, colorectal adenoma, colorectal cancer, vitamin D, 1153 NET, 111 In-pentetreotide, pulmonary carcinoid, somatostatin receptors, scintigraphy, SPECT, 4265 Neurite elongation, DRG, MSC, cisplatin, peripheral neuropathy, NOGO, MAG, 5383 Neurite-distupting effects, peripheral neuropathy, microtubule-targeting agents, in vitro model, PC-12 cells, SH-SY5Y cells, 6431 Neuroblastoma, Aloe vera, proliferation, 4477 Neuroblastoma, exosome, microrna, mirna, 2521 Neuroblastoma, HB-EGF, CRM197, 4431 Neuroendocrine carcinoma, extrahepatic bile duct, biliary intraepithelial neoplasia, chemotherapy, 4821 Neuroendocrine prostate cancer, prostate, prostate cancer, androgen deprivation therapy, incidence, 5-year survival, mortality, 4145 Neuroendocrine tumor, rectum, carcinoid, HES77, metastasis, prognosis, 3767 Neuroendocrine tumor, synchronous, multiple primary malignant neoplasms, glioblastoma, glioblastoma multiforme, sessile serrated adenoma/polyp, schwannoma, 2121 Neurofibroma, nerve fibre density, vessel density, blood vessels, lymphatic vessels, NF1, neurofibromatosis, vessel innervation, 6509 Neurofibromatosis type 1, epidermal growth factor receptor, vascular endothelial growth factor, basic fibroblastic growth factor, vessel density, malignant peripheral nerve sheath tumor, 137 Neurofibromatosis, nerve fibre density, vessel density, blood vessels, lymphatic vessels, NF1, neurofibroma, vessel innervation, 6509 Neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, dermal cylindroma, mosaicism, rare tumor, 6813 Neurofibromatosis, vessel density, blood vessels, lymphatic vessels, NF1, NF2, schwannomatosis, schwannoma, mast cell, MPNST, 4713 Neuropathy, CIPN, duloxetine, paclitaxel, gynecologic cancer, 359 Neurospheres, co-expression, cytoskeletal protein, adducin 3, cancer stem cell marker, CD133, temozolomide-resistant subclone, glioblastoma, NANOG, 6487 Neutron, boron neutron capture therapy, p53, 53BP1, apoptosis, 169 Neutrophil to lymphocyte ratio, colorectal cancer, unresectable, prognosis, C-reactive protein, Glasgow prognostic score, 5037 Neutrophil to lymphocyte ratio, endometrial cancer, prognosis, 337 Neutrophils, combretastatin, monocytes, tumors, 2559 Neutrophils, lewis rat sarcoma, CD11b+ cells, CCL2, tumor immunology, 703 Nevoid basal cell carcinomas, odontogenic keratocysts, palmar and plantar pits, intracranial calcifications, 1777 Nevus, melanoma, reversion-inducing cysteine-rich protein with Kazal motifs, immunohistochemical stain, RECK, 3185 Newcastle disease virus, melanoma, oncolytic viruses, virotherapy, 5401 Next generation sequencing, breast cancer, ovarian cancer, mutations, Canadian patients, Saudi Arabian patients, comparative study, 2601 Next generation sequencing, familial breast cancer, microsatellite markers, linkage analysis, sequencing analysis, 3155 Next-generation sequencing, anaplastic thyroid carcinoma, poorly differentiated thyroid carcinoma, genetics, 2029 Next-generation sequencing, non-small cell lung cancer, ALK translocation, ALK inhibitor, KRAS, STK11, ATM, crizotinib resistance, genomics, case report, 3007 NF1, nerve fibre density, vessel density, blood vessels, lymphatic vessels, neurofibroma, neurofibromatosis, vessel innervation, 6509 NF1, neurofibromatosis, plexiform neurofibroma, sphenoid wing dysplasia, dermal cylindroma, mosaicism, rare tumor, 6813 NF1, vessel density, blood vessels, lymphatic vessels, NF2, schwannomatosis, schwannoma, neurofibromatosis, mast cell, MPNST, 4713 NF2, vessel density, blood vessels, lymphatic vessels, NF1, schwannomatosis, schwannoma, neurofibromatosis, mast cell, MPNST,

141 NF-ĸB, amentoflavone, anti-angiogenesis, anti-metastasis, 6685 NF-ĸB, astrocytoma, CD47, UHRF1, 149 NFĸB, curcumin, EGCG, STAT3, CD44, cancer stem cells, 39 NF-ĸB, fucoxanthin, fucoxanthinol, MCF-7, MDA-MB-231, SOX9, 207 NF-ĸB, pancreatic cancer, apoptosis, oil palm phenolics, 97 NF-κB pathway, inflammation, leukemia, molecular docking, 2645 NG2 proteoglycan, GD3A, immunoablation, saporin, glioma, 77 Nifurtimox, CD114, G-CSF, melanoma, 3787 Nitric oxide, lung cancer, metastasis, apoptosis, migration, cancer stem cells, review, 4585 NK cells, glucan, melanoma, immunity, antibodies, cancer, 5287 NK cells, non-small cell lung cancer, NK-92, cellular immunotherapy, 1543 NK1 receptor, gynecological cancer, aprepitant, CINV, 4525 NK-92, non-small cell lung cancer, NK cells, cellular immunotherapy, 1543 Nodal metastases, tumor M2-pyruvate kinase, cancer type, tumor size, distant metastases, tumor stage, 4271 Node metastases, advanced ovarian cancer, node ratio, lymphadenectomy, prognosis, residual tumor, 3479 Node ratio, advanced ovarian cancer, lymphadenectomy, prognosis, residual tumor, node metastases, 3479 Nodular goitre, thyroid cancer, papillary carcinoma, multinodular thyroid, Hashimoto s thyroiditis, intraglandular dissemination, 6335 Nodule size, follicular neoplasms, follicular lesion of undetermined significance, thyroid malignancy, thyroid cancer, 1635 NOGO, DRG, MSC, cisplatin, peripheral neuropathy, neurite elongation, MAG, 5383 Nomogram, biopsy, predictive value, prostate neoplasms, model, screening programs, 2881 Non-curative clinical factor, gastric cancer, adjuvant surgery, peritoneal dissemination, 401 Non-curative resection, ESD, early gastric cancer, 2969 Non-Hodgkin lymphoma, Burkitt lymphoma, HIV infection, mandible, osteomyelitis, FDG-PET, EBV, Epstein-Bar, 4837 Non-Hodgkin lymphoma, rituximab, second primary cancer, 1809 Non-interventional study, treosulfan, ovarian cancer, elderly, 6869 Noninvasive imaging, lung cancer, surgical orthotopic implantation, nude mice, high tumor take rates, spectral separation, 3755 Noninvasive, GFP, RFP, nude mice, human tumors, metastasis, imaging, variable magnification, subcellular in vivo imaging, spectral separation, tunable filter, 661 Non-pegylated liposomal doxorubicin, soft tissue sarcoma, Phase II, 543 Non-secretory tumor, retroperitoneal giant tumor, adrenocortical carcinoma, multi-visceral resection, 2169 Non-small cell lung cancer, acute exacerbation, cisplatin, interstitial pneumonia, vinorelbine, 1697 Non-small cell lung cancer, ALK translocation, ALK inhibitor, KRAS, STK11, ATM, crizotinib resistance, genomics, next-generation sequencing, case report, 3007 Non-small cell lung cancer, anaplastic lymphoma kinase, epidermal growth factor receptor, chemosensitivity, 1791 Non-small cell lung cancer, angiogenesis, pleural fluid, serum, VEGF, 1129 Non-small cell lung cancer, bevacizumab, interstitial lung disease, acute exacerbation, 4259 Non-small cell lung cancer, EGFR, mutation, outcome, population, prevalence, 3979 Non-small cell lung cancer, epidermal growth factor receptor gene mutation, exon 19 deletion, exon 21 L858R, afatinib, 2005 Non-small cell lung cancer, FOXD1, microarray, pathway signature, PTEN, 261 Non-small cell lung cancer, gefitinib, EGFR mutation, exon 19 deletion, L858R, 6957 Non-small cell lung cancer, histoculture drug response assay, paclitaxel, predictive factor, chemotherapy, class III betatubulin, 2669 Non-small cell lung cancer, human topoisomerase II, 9- aminoacridine derivatives, 5211 Non-small cell lung cancer, hypofractionated radiotherapy, advanced stage, unresectable, image-guidance, 5693 Non-small cell lung cancer, lung cancer, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, pemetrexed, maintenance treatment, 6255 Non-small cell lung cancer, micro RNA profiling, sputum, bronchoalveolar lavage, cancer detection, 1873 Non-small cell lung cancer, NK cells, NK-92, cellular immunotherapy, 1543 Non-small cell lung cancer, salvage stereotactic radiotherapy, post-surgical recurrence, local control, 1783 Non-small cell lung cancer, small cell lung cancer, idiopathic interstitial pneumonia, drug-induced interstitial lung disease, number of regimens, 1065 Non-small cell lung cancer, stage I, metachronous, platinum doublets, inoperable, 3103 Non-small cell lung cancer, stage I-II, clinical outcome, surgery, stereotactic body radiotherapy, 5607 Non-small cell lung cancer, VATS, T2 and T3, 3585 Non-small-cell lung cancer, EGFR-TKI, gefitinib, erlotinib, minor EGFR mutation, 3885 Non-small-cell lung cancer, reimplantation, bench surgery, autotransplantation, in vivo, ex situ,

142 Non-specific esterases (NSE), fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 - M phase, multi-nucleated cells, silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Non-steroidal anti-inflammatory drugs (NSAIDs), multidrug resistance (MDR), P-glycoprotein, cyclooxygenase 2 (COX2), 2835 Notch pathway, curcumin, cancer stem cells, interleukin-6, interleukin-8, interleukin-1, CXCR1, CXCR2, Wnt pathway, Hedgehog pathway, FAK pathway, review, 599 Notch, thymoma, immunohistochemistry, sonic Hedgehog, beta-catenin, 669 NOTCH2, glomus tumor, cytogenetics, t(1;5), MIR143, 6167 Nottingham histological grade, canine mammary tumors, prognosis, survival, 4219 NOV, colorectal cancer, invasion, 6591 Novel molecular targets, urothelial cancer, transitional cell carcinoma, targeted therapy, review, 4557 Novel therapies, NSCLC, tyrosine kinase inhibitors, monoclonal antibodies, clinical trials, review, 2503 NOX1, apoptosis, HOCl, superoxide anion, DUOX, hydroxyl radical, 5927 NOX1, DUOX1, HOCl, apoptosis, matrix metallo proteinase, 5955 NSCLC biomarkers, chemokines, CXC, lung cancer, 6979 NSCLC, brain metastases, tyrosine kinase inhibitors, review, 5797 NSCLC, molecular biology, immunotherapies, clinical outcome, review, 5745 NSCLC, novel therapies, tyrosine kinase inhibitors, monoclonal antibodies, clinical trials, review, 2503 NSCLC, radiotherapy, toxicity, esophagitis, survival, 5491 NTx, cross-linked N-Telopeptides of type I collagen, bone metastasis, lung cancer, 3987 Nuclear abnormalities, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, coculture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Nuclear fragmentation, GFP, histone H2B, fusion gene, RFP, imaging, paclitaxel, vinblastine, apoptosis, DNA fragmentation, real-time, imaging, 2539 Nuclear labeling, cancer cells, GFP, histone-h2b, fusion, RFP, retrovirus, cytoplasmic labeling, mitosis, chromosomes, 2553 Nuclear protein in testis, NUT midline carcinoma, Ewing sarcoma, endobronchial tumour, electrocautery, 1607 Nucleic acid-directed agents, chemotherapy, cytochalasin B, leukemia, breast carcinoma, cytoskeletal-directed agents, cell enlargement, 65 Nucleic area, meningioma, ADC, tumor cellularity, Ki-67, 6841 Nucleotide/nucleoside analog, hepatitis B virus, hepatocellular carcinoma, antiviral therapy, propensity score-matching, 1647 Nucleus, small cell lung cancer, survivin, labeling index, immunohistochemistry, 2935 Nude mice, Astragalus membranaceus, Curcuma wenyujin, ovarian cancer, red fluorescent protein, orthotopic, tumor progression, metastasis, 3193 Nude mice, GFP, RFP, human tumors, metastasis, imaging, noninvasive, variable magnification, subcellular in vivo imaging, spectral separation, tunable filter, 661 Nude mice, lung cancer, surgical orthotopic implantation, high tumor take rates, noninvasive imaging, spectral separation, 3755 Nude mouse, soft-tissue sarcoma, patient-derived orthotopic xenograft (PDOX), subcutaneous model, histology, spindle cells, 697 Number of regimens, small cell lung cancer, non-small cell lung cancer, idiopathic interstitial pneumonia, druginduced interstitial lung disease, 1065 Numbers of metastatic lymph nodes, colorectal cancer, adjuvant chemotherapy, 6207 NUT midline carcinoma, nuclear protein in testis, Ewing sarcoma, endobronchial tumour, electrocautery, 1607 Nutrition, gastrectomy, elderly patients, 511 NVP-BGJ398, small molecule FGFR1 inhibitor, caspases, PDCD4, ANG2, 5873 O -acac)(γ-acac)(dms)), cisplatin, (Pt(O, renal fibrogenesis, epithelial-mesenchymal transition, 739 OATPs. microcystin-lr, organic anion-transporting polypeptides, pancreatic cancer, drug development, cancer treatment, targeted-therapy, 5857 Obesity, androgen-deprivation therapy, metastatic prostate cancer, prostate-specific antigen, testosterone, 6925 Obesity, colorectal cancer, colorectal polyps, metabolic syndrome, 2211 Obesity, uterine cancer, EC, lymphovascular invasion, grade, body mass index, 4053 Objective response, tyrosine kinase inhibitor, metastatic renal cell carcinoma, first-line, second-line, progressionfree survival, 3067 Observation, epithelioid haemangioendothelioma, EHE, survival, chemotherapy, surgery, sarcoma, 473 Octogenarian, ovarian cancer, quality of life, antineoplastic agents, adverse effects, intraperitoneal chemotherapy, peritoneal carcinomatosis, high pressure, 2309 Ocular area, dermatofibrosarcoma protuberans, electrochemotherapy, quality of life,

143 Odontogenic keratocysts, nevoid basal cell carcinomas, palmar and plantar pits, intracranial calcifications, 1777 Oesophageal cancer, mir-503, prognosis, biomarker, 1447 Oesophageal cancer, PHLDA3, Akt, prognostic factor, 949 Ofatumumab, chronic lymphocytic leukemia, small-cell lymphoma, ibrutinib, idelalisib, rituximab, review, 5149 Oil palm phenolics, pancreatic cancer, NF-ĸB, apoptosis, 97 Olaparib, BEZ235, 53BP1, BRCA1, breast cancer, 3829 Old drugs, relapsed/refractory multiple myeloma, cyclophosphamide, dexamethasone, treatment options, case report, 2165 Older patients, bevacizumab, italian study, advanced colorectal cancer, 2391 Oleanolic acid, acute promyelocytic leukemia, all-trans retinoic acid, differentiation, WEHI-3, 6583 Oleoylamides, QSAR analysis, cytotoxicity, tumor selectivity, anti-hiv activity, 5341 Oligometastasis, cervical cancer, recurrent, stereotactic body radiotherapy, CyberKnife, radiosurgery, 5103 Oligometastatic non-small lung cancer, stereotactic body radiotherapy, lung metastases, 6239 Oligo-recurrence, pulmonary oligometastases, SBRT, syncoligometastases, 4903 Oncofertility, emergency fertility preservation, cancer, cryopreservation, autotransplantation, in vitro maturation, review, 3117 Oncogene-induced senescence, senescence, primary cell culture, cancer cell line, senescence-associated heterochromatin foci, senescence-associated β- galactosidase, 2759 Oncogenic HPV DNA, p16/ki-67, low-grade squamous intraepithelial lesion, 6291 Oncology, anticancer agent, clinical pharmacy services, drug-related problem, inpatient setting, 457 Oncolytic viruses, melanoma, Newcastle disease virus, virotherapy, 5401 Oncoplastic breast-conserving surgery, breast cancer, mammoplasty, mastectomy, neoadjuvant chemotherapy, 4229 One-stage procedure, gastric cancer, abdominal aortic aneurysm, endovascular abdominal aortic aneurysm repair, 6909 Open biopsy, biopsy, core needle biopsy, sarcoma, 961 Open hepatectomy, endoscopic hepatectomy, hepatocellular carcinoma, Milan criteria, propensity case-matched analysis, 1583 Open surgery, endometrial cancer, incisional recurrence, laparoscopy, port site metastases, 6097 OPRT, chemotherapy toxicity, deleterious alleles, 5-fluorouracil, DPYD, TYMS, TP53, 6971 Optimal dose, elderly patients, cerebral metastases, stereotactic radiosurgery, treatment results, 5701 Optimization, pulsed brachytherapy, radiobiology, treatment planning, HIPO, 6091 Oral administration of LPS, lipopolysaccharide, acetic acid bacteria, anti-allergy, macrophages, 4507 Oral administration of LPS, lipopolysaccharide, broiler, priming, cytokine, 4459 Oral administration of LPS, macrophages, intestinal microbiota, disease prevention, review, 4391 Oral cancer, carbonyls, cell death, cigarette smoke, 1961 Oral cancer, hypopharyngeal cancer, oropharyngeal cancer, radioisotope, ICG fluorescence, 1669 Oral cancer, premalignant leukoplakia, immunosurveillance, biomolecular markers, 311 Oral cavity, sarcoma, multi-institution study, prognostic factors, 4549 Oral melanoma, survivin, AKT, VEGF, microvessel density, prognostic factor, 2113 Oral squamous cell carcinoma (OSCC), cell lines, Kallikrein-related-peptidase-4 (KLK4), clinical outcome, invasion, metastasis, 1861 Oral squamous cell carcinoma, claudin 1, claudin 4, prognosis, immunohistochemistry, 2949 Oral squamous cell carcinoma, head and neck cancer, estrogen receptor, histopathologic grade, immunohistochemistry, 5867 Oral squamous cell carcinoma, OSCC, larynx, oropha rynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 Oral squamous cell carcinoma, tumor budding, EMT, CSC, prognosis, 6111 Oral therapy, retrospective study, S-1, toxic effects, 977 Organ transplant recipient, radiation toxicity, cutaneous squamous cell carcinoma of the head and neck, sirolimus, 5511 Organ transplantation, squamous cell carcinoma, skin, tumour aggressiveness, immunosuppression, pathology, 2305 Organic anion-transporting polypeptide, regorafenib, disposition, multidrug resistance-associated protein, hepatic uptake, biliary excretion, protein-binding, 4681 Organic anion-transporting polypeptides, OATPs. microcystin-lr, pancreatic cancer, drug development, cancer treatment, targeted-therapy, 5857 Oropharyngeal cancer, oral cancer, hypopharyngeal cancer, radioisotope, ICG fluorescence, 1669 Oropharyngeal, microrna, let-7a, mir-21, mir-200c, mir- 34a, mir-375, head and neck squamous cell carcinoma, laryngeal, hypopharyngeal cancer, 2455 Oropharynx, cytology, immunocytology, pre-malignant lesions, SCCHN, 6517 Oropharynx, head and neck squamous cell carcinoma, HNSCC, human papillomavirus, HPV incidence, survival,

144 Oropha rynx, oral squamous cell carcinoma, OSCC, larynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 Orthotopic mouse model, thyroid cancer, HIF1α inhibitor, molecular targeted therapy, echinomycin, adjuvant chemotherapy, 2049 Orthotopic, Astragalus membranaceus, Curcuma wenyujin, ovarian cancer, red fluorescent protein, nude mice, tumor progression, metastasis, 3193 Orthotopic, breast cancer, Balb-c mice, syngeneic, tumor resection, metastasis, RFP, imaging, 4641 Orthotopic, esophageal cancer, mouse models, experimental metastasis, GFP imaging, 4655 OSCC, oral squamous cell carcinoma, larynx, oropha rynx, Epstein-Barr virus, EBV, human herpes virus-1, HHV-1, human papilloma virus, HPV, cytomegalovirus, CMV, 1657 OSCC, VAV3, VAV3.1, tumorigenesis, mrna, 2593 OS-RC-2, renal cell carcinoma, docetaxel, cabazitaxel, p- glycoprotein, AKT, Caki-1, KMRC-1, 6671 Osteomyelitis, Burkitt lymphoma, non-hodgkin lymphoma, HIV infection, mandible, FDG-PET, EBV, Epstein-Barr, 4837 Osteopontin, hepatocellular carcinoma, biomarkers, gene expression analysis, alpha-fetoprotein, glypican 3, 2021 Osteosarcoma, bone cancer, qualitative, cancer survivors, disability, post-traumatic growth, 6081 Osteosarcoma, extraskeletal, immunohistochemistry, therapy, treatment outcome, 2129 Osteosarcoma, MG-63 cells, toll-like receptor, TLR9, innate immunity, 5839 Osteosarcoma, plasma protein binding, albumin, oxidation, cancer, rat, 2063 Outcome, non-small cell lung cancer, EGFR, mutation, population, prevalence, 3979 Outcome, selection, bias, hospital structure, survival, 4073 Outcome, therapy-related myeloid neosplasm, azacitidine, safety, 461 Outpatient setting, gastric cancer, adjuvant chemotherapy, S- 1, cisplatin, 467 Ovarian cancer liver metastases, long-term survival, hepatic resection, 6919 Ovarian cancer relapse, hyperthermic intra-peritoneal chemotherapy, secondary surgery, 4997 Ovarian cancer slot-blot, autoantibody, diagnosis, biomarker, 881 Ovarian cancer, 3-hydroxypyridine, imidazole, DNA fragmentation, drug resistance, drug combination, 6027 Ovarian cancer, 3-indolylmethanamine, leukemia, 6001 Ovarian cancer, AGO-score, secondary cytoredustive surgery, 3423 Ovarian cancer, Astragalus membranaceus, Curcuma wenyujin, red fluorescent protein, orthotopic, nude mice, tumor progression, metastasis, 3193 Ovarian cancer, breast cancer, mutations, Canadian patients, Saudi Arabian patients, comparative study, next generation sequencing, 2601 Ovarian cancer, cancer initiating c ells, chemoprevention, oxidative stress, 85 Ovarian cancer, cisplatin, drug resistance, monofunctional platinum, combination chemotherapy, phytochemical, 2783 Ovarian cancer, cyclin A, YB-1, chemotherapy, progression, 1715 Ovarian cancer, cyclin I, CCNI, kinase insert domain receptor, KDR, chemotherapy, angiogenesis, 1115 Ovarian cancer, DNA damage response-related proteins, immunohistochemistry, prognosis, 3909 Ovarian cancer, interval debulking surgery, cytoreduction, prognosis, 3027 Ovarian cancer, mir-7, TP53 status, tumour grade, EGFR, BCL2, 2423 Ovarian cancer, neoadjuvant chemotherapy, overall surivival, lymphadenectomy, 5503 Ovarian cancer, peritoneal metastasis, cisplatin, doxorubicin, intraperitoneal chemotherapy, pressure, aerosol, quality of life, 6723 Ovarian cancer, quality of life, antineoplastic agents, adverse effects, intraperitoneal chemotherapy, peritoneal carcinomatosis, octogenarian, high pressure, 2309 Ovarian cancer, relapse, postoperative morbidity, haemodynamic management, transfusion, cytoreductive surgery, 1591 Ovarian cancer, safety, phase I trial, pegylated liposomal doxorubicin, irinotecan, 4519 Ovarian cancer, treosulfan, elderly, non-interventional study, 6869 Ovarian cancer, vitamin D, celecoxib, cyclooxygenase-2, 1197 Ovarian carcinoma, CA125, chemotherapy, progression-free survival, overall survival, 1099 Ovarian germ cell, yolk sac tumor, postmenopausal, α- fetoprotein, 6713 Ovarian mucinous borderline tumor, TATI, CA 125, claudin, 973 Ovarian tumors characterization, magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), biparameric MRI (Bp-MRI), tumor markers, CA125, HE4, pelvic mass, 6341 Ovarian, lysophosphatidic acid, upar, upa, PI3K, 5263 Overall surivival, ovarian cancer, neoadjuvant chemotherapy, lymphadenectomy, 5503 Overall survival, advanced-stage epithelial ovarian cancer, parenchymatous metastasis, peritoneal, splenic metastasis,

145 Overall survival, breast cancer, brain metastasis, radiosurgery, radiation dose, local control, distant brain control, 333 Overall survival, epithelial ovarian cancer, complete cytoreduction, multivisceral resection, 4099 Overall survival, head and neck cancer, 18 F-FDG-PET/CT, SUVmax, inhibition index cisplatin, 1009 Overall survival, hepatocellular carcinoma, liver cirrhosis, percutaneous ethanol injection, radiofrequency ablation, tumor recurrence, 325 Overall survival, hypoxia inducible factor, clear cell renal cell carcinoma, tumor stage, tumor grade, 433 Overall survival, laparoscopic surgery, gastrointestinal stromal tumor, intestinal GIST, recurrence-free survival, small bowel GIST, 1033 Overall survival, lung cancer, non-small cell lung cancer, bevacizumab, platinum-based chemotherapy, progressionfree survival, pemetrexed, maintenance treatment, 6255 Overall survival, ovarian carcinoma, CA125, chemotherapy, progression-free survival, 1099 Overall survival, PDHE1α, esophageal squamous cell carcinoma, immunohistochemistry, Warburg effect, 5533 Overall survival, prostate cancer, metastatic epidural spinal cord compression, elderly patients, irradiation, 6189 Oxaliplatin, adjuvant therapy, lateral pelvic lymph node dissection, mesorectal excision, rectal cancer, 1815 Oxaliplatin, colorectal cancer, adjuvant chemotherapy, recurrence, tumor size, 5073 Oxaliplatin, docetaxel, chemotherapy, gastric cancer, 3531 Oxaliplatin, TAS-102, colorectal cancer, gastric cancer, 5-FU resistance, 4605 Oxidation, plasma protein binding, albumin, cancer, osteosarcoma, rat, 2063 Oxidative stress, anticancer treatment, ruthenium complexes, 3371 Oxidative stress, cancer initiating c ells, chemoprevention, ovarian cancer, 85 Oxidative stress, cholangiocytes, ion transport, hydrogen peroxide, 5881 Oxidative stress, MnSOD, GPX1, colorectal cancer, antioxidants, 255 Oxidative stress, photosensitizer, phthalocyanine, photodynamic treatment, cellular damage, phototoxicity, tumour cells, 3943 P15, long noncoding RNA, ANRIL, p16, cell cycle, 5377 P16 immunohistochemistry, HPV infection, squamous cell oropharyngeal tumors, HPV PCR assay, diagnostic assay, 4733 P16, brain tumor, MDM2, polymorphism, glioma, meningioma, 3933 P16, cell cycle, CDK inhibitor, transcription, polycomb, MLL, ANRIL, review, 4395 P16, long noncoding RNA, ANRIL, p15, cell cycle, 5377 P16/ki-67, oncogenic HPV DNA, low-grade squamous intraepithelial lesion, 6291 P16INK4A, human papillomavirus, tonsillar carcinoma, tonsillitis, FANCD2, 6633 P21, SB265610, G1 arrest, cyclin D3, phospho(thr160)- CDK2, p38mapk, 3235 P38 MAPK, PBA, vorinostat, JNK, gap junction, 775 P38MAPK, SB265610, G1 arrest, cyclin D3, phospho(thr160)-cdk2, p21, 3235 P53 codon72 polymorphism, breast cancer risk, anthra - cycline resistance, 1763 P53, boron neutron capture therapy, neutron, 53BP1, apoptosis, 169 P53, breast tumors, histological grading, SUV, estrogen receptor, progesterone receptor, Ki67, BCL2, androgen receptor, 569 P53, colorectal cancer, immunohistochemistry, prognosis, biomarkers, 1641 P53, melanoma, zinc, apoptosis, reactive oxygen species, FAS ligand, 5309 P53, vitamin D, β-catenin, PAK1, Ki67, malignant and benign colon tumors, 1513 P85α, apoptosis, CHM-1, GRP78, nasopharyngeal carcinoma, 5359 Paclitaxel, CIPN, neuropathy, duloxetine, gynecologic cancer, 359 Paclitaxel, GFP, histone H2B, fusion gene, RFP, imaging, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, imaging, 2539 Paclitaxel, histoculture drug response assay, predictive factor, non-small cell lung cancer, chemotherapy, class III betatubulin, 2669 Paclitaxel, microtubule, microtubule destabilizer, eribulin, docetaxel, vinorelbine, ixabepilone, 5845 Paclitaxel, small cell carcinoma, epirubicin, chemothe rapy, recurrence, 2183 Paclitaxel, small cell carcinoma, stomach, chemotherapy, 563 PAI1, high-fat diet, bone, metastasis, mice, 3839 PAI-1, plasminogen activation system, upa, upar, tpa, rectal adenocarcinoma, 6009 PAK1, vitamin D, β-catenin, p53, Ki67, malignant and benign colon tumors, 1513 P-AKT, peripheral T-cell lymphoma, PI3K/AKT pathway, 2465 P-Akt, type I endometrial carcinoma, p-mapk, p-mtor, clinicopathological factors, prognosis, 2321 Palliation, pelvic recurrence, cervical cancer, pelvic exenteration, 4877 Palmar and plantar pits, nevoid basal cell carcinomas, odontogenic keratocysts, intracranial calcifications, 1777 Pancreas texture, pancreatic fibrosis, pancreatic stellate cells, apparent diffusion coefficient,

146 Pancreatectomy, pancreatic adenocarcinoma, hepatitis B virus, 5123 Pancreatic adenocarcinoma, hepatitis B virus, pancreatectomy, 5123 Pancreatic cancer, adjuvant, aged, pooled analysis, radiotherapy, chemotherapy, multicenter study, 3441 Pancreatic cancer, AKT inhibitor, gemcitabine, 4599 Pancreatic cancer, cancer of the papilla of Vater, chronic pancreatitis, Col11A1, mrna quantification, diagnostic marker, 6153 Pancreatic cancer, CD155, prognostic factor, tumor immunity, angiogenesis, 2287 Pancreatic cancer, complete response, recurrence, case report, 2867 Pancreatic cancer, cytokine, chemoimmunotherapy, dendritic cell, MHC class II, vaccine, WT1, 555 Pancreatic cancer, dual color cells, GFP, RFP, stellate cells, interaction, CFP nude mouse, color-coded fluorescence imaging, 2545 Pancreatic cancer, glascow prognostic score, clinical outcome, gemcitabine monotherapy, curative surgery, 4865 Pancreatic cancer, HDAC, histone, inhibitors, acetylasation, epigenetics, review, 3129 Pancreatic cancer, HMGB1, MAPKAPK2, gemcitabineresistant, HSP27, 3861 Pancreatic cancer, HSF1, HMGB1, HSP27, AHCC, gemcitabine, 6063 Pancreatic cancer, HSP27, metformin, 1941 Pancreatic cancer, KML001, gemcitabine, 183 Pancreatic cancer, metastasis, irradiation, expected survival, predictive factors, 4105 Pancreatic cancer, NF-ĸB, apoptosis, oil palm phenolics, 97 Pancreatic cancer, organic anion-transporting polypeptides, OATPs, microcystin-lr, drug development, cancer treatment, targeted-therapy, 5857 Pancreatic cancer, pancreaticoduodenectomy, endoscopic biliary drainage, 5079 Pancreatic cancer, second-line chemotherapy, itraconazole, Hedgehog, 4191 Pancreatic cancer, surgical complication, survival, recurrence, 2401 Pancreatic cancer, vascular invasion, pancreatoduodenectomy, superior mesenteric artery resection, portal vein resection, re-implantation, 1613 Pancreatic carcinoma, cell line characterization, chemotherapy, 3821 Pancreatic fibrosis, pancreatic stellate cells, apparent diffusion coefficient, pancreas texture, 1749 Pancreatic neoplasms, chemotherapy, adjuvant therapy, 6901 Pancreatic neuroendocrine tumor, endoplasmic reticulum stress, grading, 6127 Pancreatic resection, advanced-stage ovarian cancer, recurrence, cytoreductive surgery, 4125 Pancreatic stellate cells, pancreatic fibrosis, apparent diffusion coefficient, pancreas texture, 1749 Pancreaticoduodenectomy, pancreatic cancer, endoscopic biliary drainage, 5079 Pancreaticoduodenectomy, postoperative pancreatic fistula, postoperative serum albumin, 499 Pancreaticojejunostomy, surgical loupes, soft coagulation, postoperative pancreatic fistula, 1691 Pancreato-duodenectomy, vascular invasion, pancreatic cancer, superior mesenteric artery resection, portal vein resection, re-implantation, 1613 Panitumumab, acneiform rash, minocycline, skin care, colorectal cancer, tumor response, time to treatment failure, 6175 Pantoea agglomerans, lipopolysaccharide, atopic dermatitis, dermatophagoides farinae body extract, NC/Nga mice, 4499 Pap smear, cervical cancer, atypical glandular cells, adenocarcinoma in situ, clinical population study, 913 Papillary carcinoma, thyroid cancer, multinodular thyroid, nodular goitre, Hashimoto s thyroiditis, intraglandular dissemination, 6335 Papillary thyroid carcinoma, calcitonin, medullary thyroid carcinoma, C-cell hyperplasia, RET, calcium stimulation test, 4251 Papilloma of the breast, percutaneous biopsy, surgical biopsy, breast cancer, 6881 Para-aortic lymph node metastasis, cervical cancer, radiation therapy, squamous cell carcinoma, uterine cervix, 4849 Para-aortic lymph node metastasis, gastric cancer, induction chemotherapy, extended lymphadenectomy, 6739 Paracaval recurrence, endometrial stromal sarcoma, complete resection, case report, 3405 Paraffin-embedded tissue, breast cancer, mirna21, mirna155, let7a, mirna19a, mirna17-5p, 5425 Paraoxonase-1 (PON1), Q192R polymorphism, L55M polymorphism, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), PCR-RFLP, 4807 Parathyroid hormone, 25-hydroxyvitamin D, 1, 25- dihydroxyvitamin D, daily vitamin D intake, benign soft tissue tumor, sarcoma, 1171 Parenchymatous metastasis, advanced-stage epithelial ovarian cancer, peritoneal, splenic metastasis, overall survival, 5649 Particle therapy, prostate cancer, radiotherapy, hypofractionation, high-dose-rate brachytherapy, stereotactic radiotherapy, review, 5167 PAT-1102, histone deacetylation, HDAC inhibitor, vorinostat, 229 Patch-field technique, carbon ion radiotherapy, proton therapy, intensity-modulated radiotherapy, spinal sarcoma,

147 Pathogenesis, melanotransferrin, colorectal carcinoma, poorly differentiated adenocarcinoma, adenoma carcinoma sequence, tumorigenesis, 6551 Pathological complete response, triple-negative breast cancer, neoadjuvant chemotherapy, pcr, residual disease, prognostic impact, 5479 Pathological response, MRI, breast cancer, neoadjuvant chemotherapy, correlation, 581 Pathology, squamous cell carcinoma, skin, tumour aggressiveness, organ transplantation, immunosuppression, 2305 Pathway signature, FOXD1, non-small cell lung cancer, microarray, PTEN, 261 Pathway, flunarizine, multiple myeloma, lymphoma, cancer therapy, WNT, 1369 Patient volume, endometrial cancer, guidelines, preoperative staging, lymphadenectomy, 2887 Patient-derived orthotopic xenograft (PDOX), soft-tissue sarcoma, subcutaneous model, nude mouse, histology, spindle cells, 697 Patient physician communication, emotional, personality, proximity, authenticity, breast cancer, 1627 Patterns of failure, head and neck cancer, radiotherapy, intensity-modulated radiotherapy, 6833 PAX2, endometrial hyperplasia, progestin therapy, PTEN, therapy response, 6401 PBA, vorinostat, p38 MAPK, JNK, gap junction, 775 PBS, core needle biopsy, core needle wash, microfluidics, cytology, 5905 PC-12 cells, peripheral neuropathy, microtubule-targeting agents, neurite-distupting effects, in vitro model, SH- SY5Y cells, 6431 PC-3 prostate cancer cell line, steroids, multidrug resistance, ABCB1 transporter, mouse T-lymphoma, 2105 PC-3, Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, cell line, LNCaP, DU-145, apoptosis, necrosis, cell burst, 5225 PCA 3, castration-resistant prostate cancer (CRPC), androgen deprivation treatment (ADT), prognostic factor, docetaxel, 3075 PCA3, phi, sarcosine, tumor volume, Gleason score, tumor stage, 1017 PCK3145, PSP94, breast cancer, colon cancer, prostate cancer, ERK, laminin receptor, 1377 PCNA, Pd(II) complex, EAC, in vivo, tumor, apoptosis, 1491 PCR, triple-negative breast cancer, neoadjuvant chemotherapy, pathological complete response, residual disease, prognostic impact, 5479 PCR-RFLP, paraoxonase-1 (PON1), Q192R polymorphism, L55M polymorphism, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), 4807 PCV, anaplastic oligodendroglial tumor, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, chemotherapy, 5467 PCV, glioma, tolerance, feasibility, 2901 Pd(II) complex, EAC, in vivo, tumor, PCNA, apoptosis, 1491 PD-1, cancer immunotherapy, 4-1BB, immune checkpoint, 129 PDCD4, lung cancer, gene therapy, aerosol delivery, sorbitol diacrylate, shakt1, 2015 PDCD4, small molecule FGFR1 inhibitor, NVP-BGJ398, caspases, ANG2, 5873 PDGFR-α, squamous cell carcinoma, adenocarcinoma, esophagus, CD117, immunohistochemistry, 3793 PDHE1α, esophageal squamous cell carcinoma, immunohistochemistry, Warburg effect, overall survival, 5533 PD-L1 expression, pulmonary blastoma, neoadjuvant treatment, EGFR mutation, ALK-EML4 translocation, chemo radiotherapy, pembrolizumab, 4871 PEC tumor, PEC, PEComa, mesenchymal neoplasm, everolimus, mtor inhibition, targeted therapy, case report, 3399 PEC, PEComa, PEC tumor, mesenchymal neoplasm, everolimus, mtor inhibition, targeted therapy, case report, 3399 PEComa, PEC, PEC tumor, mesenchymal neoplasm, everolimus, mtor inhibition, targeted therapy, case report, 3399 PEDF, prostate cancer, Gleason score, 1703 Pediatric tumors, helical computed tomography (CT), multidetector-row CT (MDCT), radiation dose, split-bolus technique, 3041 Pegylated liposomal doxorubicin, metastatic breast cancer, Her2-positive, lapatinib, 517 Pegylated liposomal doxorubicin, ovarian cancer, safety, phase I trial, irinotecan, 4519 Pelvic exenteration, empty pelvis syndrome, enteroperineal fistula, 5543 Pelvic exenteration, pelvic recurrence, cervical cancer, palliation, 4877 Pelvic mass, magnetic resonance imaging (MRI), diffusionweighted imaging (DWI), biparameric MRI (Bp-MRI), tumor markers, CA125, HE4, ovarian tumors characterization, 6341 Pelvic recurrence, cervical cancer, pelvic exenteration, palliation, 4877 Pembrolizumab, pulmonary blastoma, neoadjuvant treatment, EGFR mutation, PD-L1 expression, ALK- EML4 translocation, chemo radiotherapy, 4871 Pemetrexed, lung cancer, non-small cell lung cancer, bevacizumab, platinum-based chemotherapy, overall survival, progression-free survival, maintenance treatment,

148 Pencil beam convolution, breast radiotherapy, dose calculation algorithm, analytical anisotropic algorithm, planning guidelines, 2841 Penile cancer, HPV, prostate cancer, renal cell carcinoma, bladder cancer, testicular cancer, review, 2513 Pentafecta, biochemical recurrence, laparoscopy, prostate cancer, radical prostatectomy, robotics, 5007 PEP005, protein kinase C, HNSCC, TPA, diterpene, 1291 Pepsinogen, gastric cancer, Helicobacter pylori, screening, ABC method, 6765 Percentage free PSA, prostate cancer, repeat biopsy, PSA velocity, population screening, Gleason score 7, 5031 Percutaneous biopsy, papilloma of the breast, surgical biopsy, breast cancer, 6881 Percutaneous ethanol injection, hepatocellular carcinoma, liver cirrhosis, radiofrequency ablation, overall survival, tumor recurrence, 325 Perforated appendix, Pseudomyxoma peritonei, mucinous neoplasm, mucocele, peritoneal carcinomatosis, HIPEC, 4943 Performance, colorectal cancer, screening, fecal occult blood (FOB), quaiac-based FOB test, fecal immunochemical test (FIT), R.O.C. analysis, 2873 Peripheral blood, biomarker, prospective, TS, DPD, survival, esophageal cancer, neoadjuvant, 1297 Peripheral neuropathy, DRG, MSC, cisplatin, neurite elongation, NOGO, MAG, 5383 Peripheral neuropathy, microtubule-targeting agents, neuritedistupting effects, in vitro model, PC-12 cells, SH-SY5Y cells, 6431 Peripheral T-cell lymphoma, PI3K/AKT pathway, p-akt, 2465 Peritoneal carcinomatosis, drug delivery systems, intraperitoneal chemotherapy, animal experiment, review, 627 Peritoneal carcinomatosis, ovarian cancer, quality of life, antineoplastic agents, adverse effects, intraperitoneal chemotherapy, octogenarian, high pressure, 2309 Peritoneal carcinomatosis, Pseudomyxoma peritonei, mucinous neoplasm, mucocele, perforated appendix, HIPEC, 4943 Peritoneal dissemination, gastric cancer, adjuvant surgery, non-curative clinical factor, 401 Peritoneal dissemination, gastric cancer, conditionally replicative adenovirus, luminescent imaging, 5201 Peritoneal lesions, relapsed ovarian cancer, secondary cytoreduction, splenectomy, 5097 Peritoneal metastasis, albumin, lymphocyte, gastric cancer, 3511 Peritoneal metastasis, ovarian cancer, cisplatin, doxorubicin, intraperitoneal chemotherapy, pressure, aerosol, quality of life, 6723 Peritoneal neoplasms, colorectal neoplasms, urinary tract, intraperitoneal chemotherapy, hyperthermia, postoperative complications, prognosis, 295 Peritoneal washing, gastric carcinoma, neoadjuvant chemotherapy, 4859 Peritoneal, advanced-stage epithelial ovarian cancer, parenchymatous metastasis, splenic metastasis, overall survival, 5649 Peritumoral edema, glioblastoma, EGFR, radiotherapy, response assessment, 4117 Peroxiredoxin, prognosis, prostate cancer, radical prostatectomy, sulfiredoxin, 6465 Personality, patient physician communication, emotional, proximity, authenticity, breast cancer, 1627 PET 18 F-FDOPA, low-grade glioma, prognostic factors, progressive disease, 5117 PET, bone metastases, acelate, prostate cancer, 6787 PET/CT, brain tumors, tumor grading, proliferation activity, fluorothymidine, 955 PET/CT, hepatocellular carcinoma, 18 F-fluorodeoxyglucose, positron emission tomography, 2241 PET/CT, solitary fibrous tumor, thigh, MRI, CD34, STAT6, NAB2-STAT6, 967 Petasin, anti-proliferative, apoptosis, prostate cancer, 191 PFKFB3 inhibitor, bladder cancer cells, glycolysis, growth, butyrate, 2-deoxyglucose, dichloroacetate, phenformin, 5889 P-glycoprotein (ABCB1), phenothiazines, multidrug resistance, MDR, rhodamine 123, colon adenocarcinoma, apoptosis, doxorubicin, verapamil, 3245 P-glycoprotein, L1210 cells, glucosylceramide synthase, UDP-glucose, ceramide induced cell death, 2627 P-glycoprotein, MDR, HER2, transfection, breast cancer, BT-474, 2531 P-glycoprotein, multidrug resistance (MDR), non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase 2 (COX2), 2835 P-glycoprotein, multidrug resistance, phosphorus ylide, trifluoroacetyl, ABCB1, mouse T-lymphoma, 5915 P-glycoprotein, renal cell carcinoma, docetaxel, cabazitaxel, AKT, Caki-1, KMRC-1, OS-RC-2, 6671 P-glycoprotein, vitamin K 3, vitamin K 5, human T- lymphoblastoid leukemia, daunorubicin resistance, apoptosis, 6041 Phagocytic activity, immunotherapy, macrophage-activating factor, U937 cell line, THP-1 cell line, 4439 Phagocytic activity, immunotherapy, macrophage-activating factor, U937 cell line, THP-1 cell line, 4445 Pharmacokinetics, ramucirumab, metastatic colorectal carcinoma, Japanese patients, FOLFIRI, 4003 Phase I trial, ovarian cancer, safety, pegylated liposomal doxorubicin, irinotecan,

149 Phase I/II study, head and neck cancer, S-1, early glottic cancer, concur rent chemoradiotherapy, prospective study, recom mend dose, radiosentitizer, 2385 Phase II study, malignant melanoma, sunitinib, biomarkers, PlGF, 6893 Phase II, non-pegylated liposomal doxorubicin, soft tissue sarcoma, 543 Phenformin, bladder cancer cells, glycolysis, growth, PFKFB3 inhibitor, butyrate, 2-deoxyglucose, dichloroacetate, 5889 Phenothiazines, multidrug resistance, MDR, P-glycoprotein (ABCB1), rhodamine 123, colon adenocarcinoma, apoptosis, doxorubicin, verapamil, 3245 Phi, PCA3, sarcosine, tumor volume, Gleason score, tumor stage, 1017 PHI, PSA, 2proPSA, prostate cancer, biopsy, 4855 PHLDA3, oesophageal cancer, Akt, prognostic factor, 949 Phosphatidylinositol derivative, enantiomer, caspaseindependent apoptosis, AIF, AMID, 6563 Phosphati dylserine-specific phospholipase A1, colorectal cancer, immunohistochemistry, tumor invasion, metastasis, 1459 Phospho(Thr160)-CDK2, SB265610, G1 arrest, cyclin D3, p21, p38mapk, 3235 Phospho-H2AX, colorectal cancer, immunohisto che mistry, prognosis, 2447 Phospholipase A2, colorectal cancer, immuno histochemistry, lymph node metastasis, 2983 Phosphorus ylide, multidrug resistance, trifluoroacetyl, ABCB1, P-glycoprotein, mouse T-lymphoma, 5915 Photodynamic treatment, photosensitizer, Phthalocyanine, oxidative stress, cellular damage, phototoxicity, tumour cells, 3943 Photosensitizer, phthalocyanine, photodynamic treatment, oxidative stress, cellular damage, phototoxicity, tumour cells, 3943 Phototoxicity, photosensitizer, Phthalocyanine, photodynamic treatment, oxidative stress, cellular damage, tumour cells, 3943 Phthalocyanine, photosensitizer, photodynamic treatment, oxidative stress, cellular damage, phototoxicity, tumour cells, 3943 Physical activity, breast cancer, chemotherapy, exercise, 5623 Physical status, femur, metastasis, intramedullary nailing, polymethyl methacrylate, prognosis, 427 Phytochemical, cisplatin, ovarian cancer, drug resistance, monofunctional platinum, combination chemotherapy, 2783 Phytotherapy, soft tissue sarcoma, resveratrol, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, gene expression, FACS, proliferation, chemotherapy, 767 PI3K, chondroitin sulfate proteoglycan-4, mtor, melanoma, 1279 PI3K, lysophosphatidic acid, upar, ovarian, upa, 5263 PI3K, sulforaphene, cisplatin, PTEN, synergy, apoptosis, 3901 PI3K/AKT pathway, peripheral T-cell lymphoma, p-akt, 2465 PI3K/AKT/mTOR signaling pathway, EGF, EGFRoverexpressing cancer cell line, apoptosis, radiosensitization, 245 PI3K/NF-ĸB signaling pathways, cantharidin, human melanoma cancer A375.S2 cells, invasion, migration, 729 PIK3CA, head and neck squamous cell carcinoma, BYL719, dacomitinib, 175 PIN1, SGK1, ubiquitination, RAF1, tamoxifen resistance, breast cancer, 785 Pituitary adenoma, EMT, N-cadherin, E-cadherin, SLUG, SNA1, TWIST, 2635 Pituitary metastasis, prognosis, 983 Placental growth factor (PlGF), antiangiogenic therapy, renal cell carcinoma, sunitinib resistance, 531 Placental in-vasion, cancer of unknown primary, pregnancy, treatment, prognosis, review, 575 Planning guidelines, breast radiotherapy, dose calculation algorithm, analytical anisotropic algorithm, pencil beam convolution, 2841 Plantar fibroma, extraskeletal myxoid chondrosarcoma, 6171 Plasma cell myeloma, angiogenesis, bortezomib, immunomodulatory drugs, vascular endothelial growth factor, 1085 Plasma protein binding, albumin, oxidation, cancer, osteosarcoma, rat, 2063 Plasma, breast cancer, proteomics, multiple reaction monitoring, diagnosis, 6271 Plasminogen activation system, upa, upar, PAI-1, tpa, rectal adenocarcinoma, 6009 Platelet-derived growth factors, hepatocellular carcinoma, TSU-68, 1423 Platelets, spontaneous regression, progression, sarcoma, natural killer cells, MCP1, 6539 Platinum doublets, non-small cell lung cancer, stage I, metachronous, inoperable, 3103 Platinum retention, testicular cancer, cisplatin, follow-up, 1619 Platinum, metastatic breast cancer, chemotherapy, etoposide, ifosfamide, 5091 Platinum-based chemotherapy, lung cancer, non-small cell lung cancer, bevacizumab, overall survival, progressionfree survival, pemetrexed, maintenance treatment, 6255 PLD inhibitor, LncRNA, ANRIL, H460 cells, lung cancer, 2795 Pleomorphic carcinoma, angiogenesis, immuno - histochemistry, vascular endothelial growth factor, hypoxia-inducible factor-1α,

150 Pleomorphic liposarcoma, lipoma, well-differentiated liposarcoma, dedifferentiated liposarcoma, multiplex ligation-dependent probe amplification, 12q amplicon, 1835 Pleomorphic rhabdomyosarcoma, multicenter study, chemotherapy, prognosis, 6213 Pleural effusion, CD4+RORγt + Th17 cells, CD4+CD25+CD127 low/ regulatory T-cells, lung cancer, 1529 Pleural fluid, angiogenesis, non-small cell lung cancer, serum, VEGF, 1129 Plexiform neurofibroma, neurofibromatosis, NF1, sphenoid wing dysplasia, dermal cylindroma, mosaicism, rare tumor, 6813 PlGF, malignant melanoma, phase II study, sunitinib, biomarkers, 6893 P-MAPK, type I endometrial carcinoma, p-akt, p-mtor, clinicopathological factors, prognosis, 2321 PML RARA, proteasome inhibitor, ubiquitin-proteasome system, ER stress, 3307 P-mTOR, type I endometrial carcinoma, p-mapk, p-akt, clinicopathological factors, prognosis, 2321 Podoplanin, lymphangioleiomyomatosis, β-catenin, E- cadherin, EGFR, 3353 Podoplanin, male breast cancer, lymphatic vessels, blood vessels, CD34, 1041 Poly(I:C), tumor-associated macrophages (TAM), myeloidderived suppressor cells (MDSC), dendritic cells (DCs), Toll-like receptor 3, TICAM-1, antitumor immunotherapy, review, 4383 Polycomb, cell cycle, CDK inhibitor, p16, transcription, MLL, ANRIL, review, 4395 Polyethylenimine, sirna, folate receptor, drug delivery, cancer, nanoparticle, 5433 Polymerase chain reaction, breast cancer, human papillomavirus, 851 Polymethyl methacrylate, femur, metastasis, intramedullary nailing, physical status, prognosis, 427 Polymorphism, alcohol consumption, gastric cancer, genotype, smoking, XPD, 4975 Polymorphism, alcohol drinking, genotype, hepatocellular carcinoma, smoking, TNFα, 5417 Polymorphism, brain tumor, p16, MDM2, glioma, meningioma, 3933 Polymorphism, COX2, genotype, Taiwan, upper tract urothelial cancer, 2725 Polymorphism, CTLA4, CD28, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), protein carbonyl (PCO), superoxide dismutase, advanced glycation end-products (AGEs), copper, zinc, 5391 Polymorphism, early breast cancer, aquaporin 3, prognosis, 2775 Polymorphism, gender, genotype, lung cancer, smoking, Taiwan, XRCC3, 3893 Polymorphism, genotype, interleukin-4, lung, Taiwan, 6297 Polymorphism, genotype, leiomyoma, Taiwan, XRCC3, 4691 Polymorphism, HER2, ERBB2, breast cancer, codon 655, Ile655Val, 5901 Polymorphism, HER2, ERBB2, breast cancer, codon 655, Ile655Val, 6667 Polymorphism, prostate cancer, interleukin-1β, 6057 Polypectomy, colon polyp, colorectal neoplasm, endoscopic mucosal resection, 6887 Pooled analysis, pancreatic cancer, adjuvant, aged, radiotherapy, chemotherapy, multicenter study, 3441 Poorly differentiated adenocarcinoma, melanotransferrin, colorectal carcinoma, pathogenesis, adenoma carcinoma sequence, tumorigenesis, 6551 Poorly differentiated thyroid carcinoma, anaplastic thyroid carcinoma, genetics, next-generation sequencing, 2029 Population screening, prostate cancer, repeat biopsy, percentage free PSA, PSA velocity, Gleason score 7, 5031 Population stratifica tion, XRCC1, MTHFR, EGFR, cancer, ancestry, 2009 Population, non-small cell lung cancer, EGFR, mutation, outcome, prevalence, 3979 Porcine cerebral cortex Na + /K + -ATPase, 3β-[2-(1- amantadine)-1-on-ethylamine]-digitoxigenin, AMANTADIG, cardenolide analog, human leukemia cells, human urological cancer cells, 5271 Port site metastases, endometrial cancer, incisional recurrence, laparoscopy, open surgery, 6097 Portal vein resection, vascular invasion, pancreatic cancer, pancreato-duodenectomy, superior mesenteric artery resection, re-implantation, 1613 Positron emission tomography, diagnostic imaging, lym ph - atic metastasis, gynecology, clinical oncology, 2247 Positron emission tomography, hepatocellular carcinoma, 18 F-fluorodeoxyglucose, PET/CT, 2241 Positron-emission tomography, cholangiocarcinoma, distal bile duct, total lesion glycolysis, prognosis, 6985 Postmenopausal, yolk sac tumor, ovarian germ cell, α- fetoprotein, 6713 Postoperative complication, cardiac tamponade, esophageal cancer, 407 Postoperative complications, colorectal neoplasms, peritoneal neoplasms, urinary tract, intraperitoneal chemotherapy, hyperthermia, prognosis, 295 Postoperative morbidity, ovarian cancer, relapse, haemodynamic management, transfusion, cytoreductive surgery, 1591 Postoperative outcome, gastric cancer, HLA-E, HLA-F, immunosuppression, 2279 Postoperative pancreatic fistula, pancreaticoduodenectomy, postoperative serum albumin,

151 Postoperative pancreatic fistula, surgical loupes, soft coagulation, pancreaticojejunostomy, 1691 Postoperative radiotherapy, biliary tract cancer, 6231 Post operative sequelae, gastric gastrointestinal stromal tumor, tumor size, 2341 Postoperative serum albumin, postoperative pancreatic fistula, pancreaticoduodenectomy, 499 Postoperative wound complications, bevacizumab, liver metastases of colorectal cancer, 2255 Postradiation sarcoma, bladder chondrosarcoma, 2857 Post-surgical recurrence, salvage stereotactic radiotherapy, non-small cell lung cancer, local control, 1783 Post-traumatic growth, bone cancer, osteosarcoma, qualitative, cancer survivors, disability, 6081 Prazosin, medullary thyroid carcinoma, cell culture, α1- adrenergic receptors, quinazolines, apoptosis, 31 PRC2, biliary tract cancer, EZH2, DZNep, anchorageindependent growth, cancer stem cells, 4697 PRCC2, HLRCC, fumarate hydratase gene, Warburg effect, bortezomib, 6639 Preclinical trials, clinical trials, epigenetics, glioblastoma, histone deacetylase inhibitor, review, 615 Prediction, metastatic renal carcinoma, targeted-therapy, biomarkers, immunohistochemistry, 5661 Predictive algorithm, abiraterone, metastatic prostate cancer, CRPC, 1057 Predictive factor, breast cancer, neoadjuvant chemotherapy, docetaxel, cyclophosphamide, triple-negative, 907 Predictive factor, histoculture drug response assay, paclitaxel, non-small cell lung cancer, chemotherapy, class III beta-tubulin, 2669 Predictive factors, bevacizumab, breast cancer, epidermal growth factor receptor (HER2)-negative, metastatic disease, 6941 Predictive factors, pancreatic cancer, metastasis, irradiation, expected survival, 4105 Predictive instrument, head-and-neck cancer, metastatic epidural spinal cord compression, irradiation, survival, 385 Predictive tool, colorectal cancer, stereotactic radiosurgery, cerebral oligo-metastases, survival, treatment optimization, 5515 Predictive value, biopsy, prostate neoplasms, model, nomogram, screening programs, 2881 Predictors response, metastatic, castrate-resistant, prostate cancer, abiraterone, drug sequencing, 5615 Pregnancy, cancer of unknown primary, treatment, prognosis, placental in-vasion, review, 575 Pregnancy, CML, treatment, TKIs, review, 1 Pre-malignant lesions, cytology, immunocytology, SCCHN, oropharynx, 6517 Premalignant leukoplakia, oral cancer, immunosurveillance, biomolecular markers, 311 Premenopausal, adjuvant ovarian suppresion, immunotherapy, breast cancer, 6847 Premenopausal, adjuvant ovarian suppression, immunotherapy, breast cancer, 6847 Preoperative staging, endometrial cancer, patient volume, guidelines, lymphadenectomy, 2887 Pressure, peritoneal metastasis, ovarian cancer, cisplatin, doxorubicin, intraperitoneal chemotherapy, aerosol, quality of life, 6723 Prevalence, adrenocortical carcinoma, lymph node dissection, prognosis, 5575 Prevalence, non-small cell lung cancer, EGFR, mutation, outcome, population, 3979 Preventive medicine, vitamin D, cancer, epidemiology, 25(OH)D, review, 1161 Primary cell culture, senescence, oncogene-induced senescence, cancer cell line, senescence-associated heterochromatin foci, senescence-associated β- galactosidase, 2759 Primary CNS lymphoma, diffuse large B-cell lymphoma, gene expression, microarray, 3333 Primary cutaneous T-cell lymphoma, proliferation marker, Ki-67, MCM-3, MCM-7, mycosis fungoides, 6017 Primary liver tumor, stereotactic body radiation therapy, liver metastases, 4171 Primary macroglobulinemia, splenectomy, hepatocellular carcinoma, hypersplenism, 4077 Primary ocular adnexal MALT lymphoma, AJCC TNM clinical staging system, radiotherapy, 3591 Primary resection, MDSC, lung metastasis, 5-FU, tumor immunity, 4423 Primary systemic therapy, breast cancer, FDG-PET/CT, Ki- 67, response evaluation, 5063 Priming, lipopolysaccharide, broiler, oral administration of LPS, cytokine, 4459 Probiotic, azoxymethane, colonic cancer, modified citrus pectin, galectin-3, immunohistochemistry, 4765 Probiotic, prostate cancer, endometrial cancer, colorectal cancer, 5687 Procedure-tract metastases, malignant mesothelioma, prophylactic radiotherapy, intervention-site metastases, 4151 Prodigiosin, genotoxicity, micronucleus, tumor cells, 3325 Progesterone receptor, breast tumors, histological grading, SUV, estrogen receptor, Ki67, BCL2, p53, androgen receptor, 569 Progestin therapy, endometrial hyperplasia, PAX2, PTEN, therapy response, 6401 Prognosis, adrenocortical carcinoma, lymph node dissection, prevalence, 5575 Prognosis, advanced ovarian cancer, node ratio, lymphadenectomy, residual tumor, node metastases,

152 Prognosis, anemia, leucocytosis, renal cell carcinoma, thrombocytosis, 3463 Prognosis, cancer of unknown primary, pregnancy, treatment, placental in-vasion, review, 575 Prognosis, canine mammary tumors, Nottingham histological grade, survival, 4219 Prognosis, cholangiocarcinoma, distal bile duct, positronemission tomography, total lesion glycolysis, 6985 Prognosis, chondrosarcoma, intracranial tumour, 875 Prognosis, chronic lymphocytic leukemia, hyperleukocytosis, survival, 2861 Prognosis, circulating tumor cells, endometrial cancer, hematogenous dissemination, recurrence, 683 Prognosis, claudin 1, claudin 4, oral squamous cell carcinoma, immunohistochemistry, 2949 Prognosis, colorectal cancer, HVEM, surgery, tumor immunity, 1361 Prognosis, colorectal cancer, laparoscopic surgery, body mass index, recurrence, 5639 Prognosis, colorectal cancer, lymphatic invasion, blood vessel invasion, 6457 Prognosis, colorectal cancer, P53, immunohistochemistry, biomarkers, 1641 Prognosis, colorectal cancer, phospho-h2ax, immunohisto - chemistry, 2447 Prognosis, colorectal cancer, unresectable, neutrophil to lymphocyte ratio, C-reactive protein, Glasgow prognostic score, 5037 Prognosis, colorectal neoplasms, peritoneal neoplasms, urinary tract, intraperitoneal chemotherapy, hyperthermia, postoperative complications, 295 Prognosis, cyclin E, cyclins, CDKs, endometrial adenocarcinoma, 3393 Prognosis, DNA damage response-related proteins, ovarian cancer, immunohistochemistry, 3909 Prognosis, early breast cancer, aquaporin 3, polymorphism, 2775 Prognosis, endometrial cancer, neutrophil to lymphocyte ratio, 337 Prognosis, esophagogastric junction, lymph node excision, neoplasms, surgery, 445 Prognosis, femur, metastasis, intramedullary nailing, polymethyl methacrylate, physical status, 427 Prognosis, GAPDH, immunohistochemistry, mrna expression, melanoma, 439 Prognosis, gastric cancer, FGFR2 amplification, chemotherapy, 5055 Prognosis, gelsolin, breast cancer, migration, cytoskeleton, estrogen receptor-positive, 5277 Prognosis, HER2, gastric cancer, tumor grade, 2441 Prognosis, long noncoding RNA, TGF-β, colorectal cancer, progression, 1385 Prognosis, malignant pleural mesothelioma, mir-126, EGFL7, DNA-methylation, biomarker, 6223 Prognosis, mast cells, liver metastasis, survival, 5325 Prognosis, melanoma, biomarkers, treatment response, 6755 Prognosis, mir-15a, breast cancer, 123 Prognosis, mir-503, oesophageal cancer, biomarker, 1447 Prognosis, multiple primary cancers, hepatobiliary and pancreas, risk factors, surgery, 1073 Prognosis, oral squamous cell carcinoma, tumor budding, EMT, CSC, 6111 Prognosis, ovarian cancer, interval debulking surgery, cytoreduction, 3027 Prognosis, peroxiredoxin, prostate cancer, radical prostatectomy, sulfiredoxin, 6465 Prognosis, pituitary metastasis, 983 Prognosis, pleomorphic rhabdomyosarcoma, multicenter study, chemotherapy, 6213 Prognosis, rectum, neuroendocrine tumor, carcinoid, HES77, metastasis, 3767 Prognosis, red blood cell distribution width, chronic myeloid leukemia, 5473 Prognosis, small-cell lung cancer, actinin-4, transbronchial biopsy, biomarker, 1663 Prognosis, thymidine kinase, lymphoma, transformation, 3019 Prognosis, tumor-infiltrating lymphocytes, prognostic marker, malignant melanoma, 351 Prognosis, type I endometrial carcinoma, p-mapk, p-akt, p-mtor, clinicopathological factors, 2321 Prognostic factor, castration-resistant prostate cancer (CRPC), PCA 3, androgen deprivation treatment (ADT), docetaxel, 3075 Prognostic factor, CD155, pancreatic cancer, tumor immunity, angiogenesis, 2287 Prognostic factor, oesophageal cancer, PHLDA3, Akt, 949 Prognostic factor, renal cell cancer (RCC), vascular endothelial growth factor receptor (VEGFR), CD-31, 921 Prognostic factor, renal cell carcinoma, molecular targeted therapy, duration of first-line treatment, 3415 Prognostic factor, survivin, AKT, VEGF, microvessel density, oral melanoma, 2113 Prognostic factors, colorectal cancer, surgery, chemotherapy, 3431 Prognostic factors, low-grade glioma, PET 18 F-FDOPA, progressive disease, 5117 Prognostic factors, lung metastases, colorectal cancer, pulmonary metastasectomy, 3563 Prognostic factors, sarcoma, oral cavity, multi-institution study, 4549 Prognostic impact, triple-negative breast cancer, neoadjuvant chemotherapy, pathological complete response, pcr, residual disease, 5479 Prognostic marker, esophageal cancer, small cell carcinoma, mirna, surgery,

153 Prognostic marker, tumor-infiltrating lymphocytes, prognosis, malignant melanoma, 351 Prognostic Nutritional Index, T4 esophageal cancer, Glasgow Prognostic Score, 4897 Prognostic tool, cerebral metastases, breast cancer, stereotactic radiosurgery, freedom from new cerebral metastases, 6793 Prognostic value, total lesion glycolysis, TLG, 18 F-FDG PET/CT, colorectal cancer, 3495 Prognostic/predictive factors, qrt-pcr, adjuvant chemotherapy, anti-vegf therapy, angiogenesis, 4023 Programmed cell death, genistein, sarcoma, hormonal therapy, isoflavones, 3167 Programmed cell death, hepatocellular carcinoma, sorafenib, M30, M65, 1803 Programmed cell death-1 (PD1), programmed death-1 ligand-1 (PDL1), gastric cancer, 5369 Programmed death-1 ligand-1 (PDL1), programmed cell death-1 (PD1), gastric cancer, 5369 Progression risk, fertility-sparing management, atypical endometrial hyperplasia, endometrial cancer, 6799 Progression, cyclin A, YB-1, ovarian cancer, chemotherapy, 1715 Progression, gastric cancer, epidermal growth factor, serum level, cancer risk, 2709 Progression, long noncoding RNA, TGF-β, colorectal cancer, prognosis, 1385 Progression, spontaneous regression, sarcoma, natural killer cells, platelets, MCP1, 6539 Progression-free survival, lung cancer, non-small cell lung cancer, bevacizumab, platinum-based chemotherapy, overall survival, pemetrexed, maintenance treatment, 6255 Progression-free survival, ovarian carcinoma, CA125, chemotherapy, overall survival, 1099 Progression-free survival, tyrosine kinase inhibitor, metastatic renal cell carcinoma, first-line, second-line, objective response, 3067 Progressive disease, low-grade glioma, PET 18 F-FDOPA, prognostic factors, 5117 Progressive disease, vascular endothelial growth factor receptor inhibitor, renal cell carcinoma, treatment beyond progression, re-vascularization, tyrosine kinase inhibitor, 5601 Proliferating fibroblasts, fibroblasts, stromal fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Proliferation activity, brain tumors, tumor grading, PET/CT, fluorothymidine, 955 Proliferation marker, Ki-67, MCM-3, MCM-7, mycosis fungoides, primary cutaneous T-cell lymphoma, 6017 Proliferation, 4-methylumbelliferone, hyaluronan, glucose, breast carcinoma cell, 4799 Proliferation, breast cancer, estrogen receptor (ER), HER2, EGFR, tamoxifen, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, apoptosis, 1243 Proliferation, curcumin, HP102, Jurkat T-cells, IL2, apoptosis, 2675 Proliferation, CXCR7, CXCL12, glioma, mobility, 53 Proliferation, neuroblastoma, Aloe vera, 4477 Proliferation, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, gene expression, FACS, chemotherapy, 767 Prolonged survival, epithelial ovarian cancer, recurrence, quaternary cytoreduction, 3519 Propensity case-matched analysis, endoscopic hepatectomy, hepatocellular carcinoma, Milan criteria, open hepatectomy, 1583 Propensity score-matching, hepatitis B virus, hepatocellular carcinoma, antiviral therapy, nucleotide/nucleoside analog, 1647 Prophylactic bilateral salpingo-oophorectomy, laparoendoscopic single-site surgery, BRCA mutation, cosmetic satisfaction, ambulatory surgery, 6105 Prophylactic radiotherapy, malignant mesothelioma, intervention-site metastases, procedure-tract metastases, 4151 ProPSA,V, prostate cancer, PSAV, fpsa,v, early diagnosis, 3567 Prospective study, head and neck cancer, S-1, early glottic cancer, concur rent chemoradiotherapy, phase I/II study, recom mend dose, radiosentitizer, 2385 Prospective, peripheral blood, biomarker, TS, DPD, survival, esophageal cancer, neoadjuvant, 1297 Prostate adenocarcinoma, lymphatic vessel density, combined androgen blockade therapy, 5595 Prostate cancer gene 3, prostate cancer, prostate-specific antigen, prostatitis, high-grade prostate intraepithelial neoplasia, 2417 Prostate cancer risk, vitamin E, Selenium exposure, smoking status, 4983 Prostate cancer, 3D conformal radiotherapy, hypofractionated, toxicity, 3049 Prostate cancer, abiraterone, castrate-resistant, elderly, PSA, 3097 Prostate cancer, African American, Gleason, BPH, SPINK1, SNPs, 3811 Prostate cancer, African Americans, single nucleotide polymorphism, CRYBB2, genetic association, 2565 Prostate cancer, antiproliferative action, Fagara xanthoxyloides, Pseudocedrela kotschyi,

154 Prostate cancer, apoptosis, dithiocarbamate analogs, emetine gene regulation, chemotherapeutic agents, 4723 Prostate cancer, biochemical recurrence, laparoscopy, pentafecta, radical prostatectomy, robotics, 5007 Prostate cancer, biomarkers, circulating tumor cells, CTCs, molecular marker, 5679 Prostate cancer, bone metastases, PET, acelate, 6787 Prostate cancer, cancer stem cell, hepatocyte growth factor, prostatectomy, recurrence, 413 Prostate cancer, cancer vaccine, docetaxel, immunotherapy, murine model, 3275 Prostate cancer, canine cancer stem cells, spheroid cell clusters, cancer stem cell marker, 1917 Prostate cancer, carbon-ion therapy, toxicity, quality of life, hypofractionation, 5559 Prostate cancer, cytokines, radiotherapy, hormonal therapy, 3379 Prostate cancer, Gleason score, prostate-specific antigen, testosterone, 6137 Prostate cancer, high-dose-rate brachytherapy, 1723 Prostate cancer, HPV, renal cell carcinoma, bladder cancer, testicular cancer, penile cancer, review, 2513 Prostate cancer, hypofractionation, simultaneous integrated boost, IMRT, IGRT, erectile dysfunction, 4177 Prostate cancer, interleukin-1β, polymorphism, 6057 Prostate cancer, metastatic epidural spinal cord compression, elderly patients, irradiation, overall survival, 6189 Prostate cancer, metastatic, castrate-resistant, abiraterone, predictors response, drug sequencing, 5615 Prostate cancer, multi-parametric MRI, microfocal prostate cancer, 395 Prostate cancer, PCK3145, PSP94, breast cancer, colon cancer, ERK, laminin receptor, 1377 Prostate cancer, PEDF, Gleason score, 1703 Prostate cancer, peroxiredoxin, prognosis, radical prostatectomy, sulfiredoxin, 6465 Prostate cancer, petasin, anti-proliferative, apoptosis, 191 Prostate cancer, probiotic, endometrial cancer, colorectal cancer, 5687 Prostate cancer, prostate cancer gene 3, prostate-specific antigen, prostatitis, high-grade prostate intraepithelial neoplasia, 2417 Prostate cancer, prostate, neuroendocrine prostate cancer, androgen deprivation therapy, incidence, 5-year survival, mortality, 4145 Prostate cancer, prostate-specific antigen, biopsy, prostate volume, residual urinary volume, 2175 Prostate cancer, PSA, 2proPSA, PHI, biopsy, 4855 Prostate cancer, PSAV, fpsa,v, propsa,v, early diagnosis, 3567 Prostate cancer, PSMA, antibody cross-reactivity, molecular marker, diagnosis, dog, 145 Prostate cancer, radiotherapy, hypofractionation, high-doserate brachytherapy, stereotactic radiotherapy, particle therapy, review, 5167 Prostate cancer, repeat biopsy, percentage free PSA, PSA velocity, population screening, Gleason score 7, 5031 Prostate cancer, Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, cell line, PC-3, LNCaP, DU-145, apoptosis, necrosis, cell burst, 5225 Prostate cancer, SNP, vitamin D receptor, African-American, clinical phenotype, 1549 Prostate cancer, synergy, alendronate, simvastatin, 1851 Prostate cancer, ureteral metastasis, abiraterone acetate, 6317 Prostate cancer-derived stromal cell, castration-resistant prostate cancer, estrogen, testosterone, chimeric coculture, 221 Prostate neoplasms, biopsy, predictive value, model, nomogram, screening programs, 2881 Prostate neoplasms, gene expression, cell line, surgical pathology, radical prostatectomy, 5443 Prostate stem cell antigen, GPI-anchored protein, intracellular signaling, gallbladder cancer, tumor suppressor, 2619 Prostate volume, prostate-specific antigen, prostate cancer, biopsy, residual urinary volume, 2175 Prostate, prostate cancer, neuroendocrine prostate cancer, androgen deprivation therapy, incidence, 5-year survival, mortality, 4145 Prostatectomy, cancer stem cell, hepatocyte growth factor, prostate cancer, recurrence, 413 Prostate-specific antigen, androgen-deprivation therapy, metastatic prostate cancer, obesity, testosterone, 6925 Prostate-specific antigen, Gleason score, prostate cancer, testosterone, 6137 Prostate-specific antigen, prostate cancer, biopsy, prostate volume, residual urinary volume, 2175 Prostate-specific antigen, prostate cancer, prostate cancer gene 3, prostatitis, high-grade prostate intraepithelial neoplasia, 2417 Prostatitis, prostate cancer, prostate cancer gene 3, prostatespecific antigen, high-grade prostate intraepithelial neoplasia, 2417 Pro-survival pathway, lung cancer, anoikis, lupalbigenin, Derris scandens, 2827 Proteasomal degradation, Zfat, FoxO1, IL-7Rα, T-cell homeostasis, 4417 Proteasome inhibition, GADD34, cell death, eif2α, autophagy, 5317 Proteasome inhibitor, ubiquitin-proteasome system, PML RARA, ER stress, 3307 Protein carbonyl (PCO), CTLA4, CD28, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), superoxide dismutase, advanced glycation end-products (AGEs), copper, zinc,

155 Protein kinase C, HNSCC, TPA, PEP005, diterpene, 1291 Protein kinase G (PKG), resveratrol, angiogenesis, HUVECs, Inhibitor of Apoptosis Proteins (IAPs), 273 Protein-binding, regorafenib, disposition, multidrug resistance-associated protein, organic anion-transporting polypeptide, hepatic uptake, biliary excretion, 4681 Proteomics, breast cancer, multiple reaction monitoring, diagnosis, plasma, 6271 Proteomics, cancer, casein kinase II (CK2), in silico systematic mutagenesis, KINARI mutagen web-server, LB-based nanocrystallo graphy, ribonuclease A (RNase A), 827 Proton beam therapy, esophageal cancer, concurrent chemoradiotherapy, survival, late toxicity, 1757 Proton therapy, carbon ion radiotherapy, patch-field technique, intensity-modulated radiotherapy, spinal sarcoma, 4083 Proximity, patient physician communication, emotional, personality, authenticity, breast cancer, 1627 PSA velocity, prostate cancer, repeat biopsy, percentage free PSA, population screening, Gleason score 7, 5031 PSA, 2proPSA, PHI, prostate cancer, biopsy, 4855 PSA, abiraterone, castrate-resistant, elderly, prostate cancer, 3097 PSAV, prostate cancer, fpsa,v, propsa,v, early diagnosis, 3567 Pseudocedrela kotschyi, antiproliferative action, prostate cancer, Fagara xanthoxyloides, 1453 Pseudomyxoma peritonei, mucinous neoplasm, mucocele, perforated appendix, peritoneal carcinomatosis, HIPEC, 4943 PSMA, prostate cancer, antibody cross-reactivity, molecular marker, diagnosis, dog, 145 PSP94, PCK3145, breast cancer, colon cancer, prostate cancer, ERK, laminin receptor, 1377 PTEN, endometrial hyperplasia, progestin therapy, PAX2, therapy response, 6401 PTEN, endometrioid endometrial cancer, microrna, 1401 PTEN, FOXD1, non-small cell lung cancer, microarray, pathway signature, 261 PTEN, sulforaphene, cisplatin, PI3K, synergy, apoptosis, 3901 PTEN, tyrosine kinase inhibitor, VEGFR, head and neck squamous cell carcinoma, everolimus, sorafenib, sunitinib, 1389 (Pt(O, cisplatin, O -acac)(γ-acac)(dms), renal fibrogenesis, epithelial-mesenchymal transition, 739 PTX3, gastric cancer, inflammation, macrophage, 2663 Pulmonary blastoma, neoadjuvant treatment, EGFR mutation, PD-L1 expression, ALK-EML4 translocation, chemo radiotherapy, pembrolizumab, 4871 Pulmonary carcinoid, 111 In-pentetreotide, NET, somatostatin receptors, scintigraphy, SPECT, 4265 Pulmonary function, stage I and II non-small-cell lung cancer, stereotactic body radiation, surgery, 6773 Pulmonary metastasectomy, lung metastases, colorectal cancer, prognostic factors, 3563 Pulmonary oligometastases, SBRT, oligo-recurrence, syncoligometastases, 4903 Pulmonary resection, lung cancer, living donor liver transplantation, 3411 Pulsed brachytherapy, optimization, radiobiology, treatment planning, HIPO, 6091 PVT, biomarker, temozolomide, cisplatin, first-line chemotherapy, BRAF, MGMT, ERCC1, 1105 Q192R polymorphism, paraoxonase-1 (PON1), L55M polymorphism, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), PCR-RFLP, 4807 QRT-PCR, prognostic/predictive factors, adjuvant chemotherapy, anti-vegf therapy, angiogenesis, 4023 QSAR analysis, 3-styryl-2H-chromenes, cytotoxicity, tumor selectivity, anti-hiv activity, 5299 QSAR analysis, oleoylamides, cytotoxicity, tumor selectivity, anti-hiv activity, 5341 QSAR, angiogenesis, Artemisia annua, artemisinin, cancer, molecu lar docking, quantitative structure-activity relationship calcula tions, vascular endothelial growth factor receptor, 1929 Quaiac-based FOB test, colorectal cancer, screening, fecal occult blood (FOB), fecal immunochemical test (FIT), performance, R.O.C. analysis, 2873 Qualitative, bone cancer, osteosarcoma, cancer survivors, disability, post-traumatic growth, 6081 Quality of life, carbon-ion therapy, prostate cancer, toxicity, hypofractionation, 5559 Quality of life, cervical cancer, laparoscopy, robotic, radical hysterectomy, 5015 Quality of life, dermatofibrosarcoma protuberans, ocular area, electrochemotherapy, 6121 Quality of life, ovarian cancer, antineoplastic agents, adverse effects, intraperitoneal chemotherapy, peritoneal carcinomatosis, octogenarian, high pressure, 2309 Quality of life, peritoneal metastasis, ovarian cancer, cisplatin, doxorubicin, intraperitoneal chemotherapy, pressure, aerosol, 6723 Quality of life, radiotherapy, anxiety, 1771 Quantitative MSP, HCC, cell-free DNA, methylation, epigenetic, 997 Quantitative structure-activity relationship calcula tions, angiogenesis, Artemisia annua, artemisinin, cancer, molecu lar docking, QSAR, vascular endothelial growth factor receptor, 1929 Quaternary cytoreduction, epithelial ovarian cancer, recurrence, prolonged survival, 3519 Quaternary cytoreduction, recurrent ovarian cancer, tertiary cytoreduction,

156 Quinazolines, medullary thyroid carcinoma, cell culture, α1- adrenergic receptors, prazosin, apoptosis, 31 R.O.C. analysis, colorectal cancer, screening, fecal occult blood (FOB), quaiac-based FOB test, fecal immunochemical test (FIT), performance, 2873 Race, lung cancer, insurance, survival, 4243 RAD51, radiosensitization, gemcitabine, homologous recombination, 2731 Radiation dose, breast cancer, brain metastasis, radiosurgery, local control, distant brain control, overall survival, 333 Radiation dose, pediatric tumors, helical computed tomography (CT), multidetector-row CT (MDCT), splitbolus technique, 3041 Radiation injury, glioma, T98G human cells, 18 Ffluorodeoxyglucose, 18 F-fluorocholine, 6439 Radiation pneumonitis, stereotactic radiation therapy, interstitial changes, 4909 Radiation therapy, cancer of unknown primary, elderly, MESCC, survival tool, 6219 Radiation therapy, cervical cancer, para-aortic lymph node metastasis, squamous cell carcinoma, uterine cervix, 4849 Radiation toxicity, organ transplant recipient, cutaneous squamous cell carcinoma of the head and neck, sirolimus, 5511 Radiation, amifostine, mouse, apoptosis, 2817 Radiation, chest radiotherapy, cardiac injury, review, 2487 Radiation, laryngeal muscle, myosin, MuRF1, 6049 Radiation, Li-Fraumeni syndrome, choroid plexus carcinoma, TP53 mutation, 3013 Radiation, MET, c-met, HGF, crizotinib, head and neck cancer, 5973 Radiation-induced, second malignancies, re-irradiation, review, 2431 Radical hysterectomy, cervical cancer, laparoscopy, robotic, quality of life, 5015 Radical prostatectomy, biochemical recurrence, laparoscopy, pentafecta, prostate cancer, robotics, 5007 Radical prostatectomy, peroxiredoxin, prognosis, prostate cancer, sulfiredoxin, 6465 Radical prostatectomy, prostate neoplasms, gene expression, cell line, surgical pathology, 5443 Radical surgery, breast cancer, N3, supraclavicular, 18FDG- PET/CT, neoadjuvant chemotherapy, 1729 Radiobiological evaluation, brachytherapy, IPSA, 935 Radiobiological models, natural killer cells, natural killer cell subsets, irradiation, viability, cytotoxicity, enrichment methods, 5193 Radiobiology, pulsed brachytherapy, optimization, treatment planning, HIPO, 6091 Radiofrequency ablation, circulating tumor cells, ScreenCell, ablative, 2823 Radiofrequency ablation, hepatocellular carcinoma, liver cirrhosis, percutaneous ethanol injection, overall survival, tumor recurrence, 325 Radiofrequency ablation, liver resection, colorectal liver metastases, disseminated tumor cells, HGF, IL-6, HSP-70, 2961 Radioisotope, oral cancer, hypopharyngeal cancer, oropharyngeal cancer, ICG fluorescence, 1669 Radioprotection, leuprorelin, intestinal injury, radiotherapy, 3875 Radiosensitivity, radiosensitizers, topoisomerase, radiotherapy, reactive oxygen species, hypoxia, review, 2479 Radiosensitization, EGF, EGFR-overexpressing cancer cell line, apoptosis, PI3K/AKT/mTOR signaling pathway, 245 Radiosensitization, gemcitabine, homologous recombination, RAD51, 2731 Radiosensitizers, radiosensitivity, topoisomerase, radiotherapy, reactive oxygen species, hypoxia, review, 2479 Radiosentitizer, head and neck cancer, S-1, early glottic cancer, concur rent chemoradiotherapy, phase I/II study, prospective study, recom mend dose, 2385 Radiosurgery, breast cancer, brain metastasis, radiation dose, local control, distant brain control, overall survival, 333 Radiosurgery, cervical cancer, recurrent, oligometastasis, stereotactic body radiotherapy, CyberKnife, 5103 Radiosurgery, kidney cancer, brain metastasis, survival, estimation, 4215 Radiotherapy, AKT, head neck, chemotherapy, 269 Radiotherapy, anxiety, quality of life, 1771 Radiotherapy, brachytherapy, cervical cancer, shielding, toxicity, 5567 Radiotherapy, breast cancer, cardiotoxicity, aromatase inhinitors, 1559 Radiotherapy, breast cancer, right ventricle, TAPSE, 2141 Radiotherapy, cytokines, prostate cancer, hormonal therapy, 3379 Radiotherapy, glioblastoma, EGFR, peritumoral edema, response assessment, 4117 Radiotherapy, glioblastoma, surgery, temozolomide, second surgery, 1743 Radiotherapy, glottic cancer, voice quality, 4155 Radiotherapy, head and neck cancer, intensity-modulated radiotherapy, patterns of failure, 6833 Radiotherapy, hepatocellular carcinoma, metformin, survival, 5047 Radiotherapy, leuprorelin, intestinal injury, radioprotection, 3875 Radiotherapy, NSCLC, toxicity, esophagitis, survival, 5491 Radiotherapy, pancreatic cancer, adjuvant, aged, pooled analysis, chemotherapy, multicenter study, 3441 Radiotherapy, primary ocular adnexal MALT lymphoma, AJCC TNM clinical staging system,

157 Radiotherapy, prostate cancer, hypofractionation, high-doserate brachytherapy, stereotactic radiotherapy, particle therapy, review, 5167 Radiotherapy, radiosensitivity, radiosensitizers, topoisomerase, reactive oxygen species, hypoxia, review, 2479 Radiotherapy, trastuzumab, cardiac dysfunction, risk factor, hypertension, BMI, 4967 Radiotherapy, uterine, sarcoma, 365 RAF1, PIN1, SGK1, ubiquitination, tamoxifen resistance, breast cancer, 785 Ramucirumab, metastatic colorectal carcinoma, Japanese patients, FOLFIRI, pharmacokinetics, 4003 Randomised grial, anaesthetic technique, breast cancer immune cell infiltration, 1311 Randomized trials, malignant mesothelioma, review, 2493 Rapamycin, lymphangioleiomyomatosis, LAM cells, mtor, cell motility, metastasis, 3341 RapidArc, οesophageal cancer, neoajuvant radiochemotherapy, 4109 Rare tumor, neurofibromatosis, NF1, plexiform neurofibroma, sphenoid wing dysplasia, dermal cylindroma, mosaicism, 6813 Ras suppressor-1, hepatocellular carcinoma, invasion, adhesion, 1509 Rat, plasma protein binding, albumin, oxidation, cancer, osteosarcoma, 2063 Reactive oxygen species production, 3-Arylcoumarin derivatives, cytotoxic effect, cell cycle phase, mitochondrial transmembrane potential, 653 Reactive oxygen species, anticancer drugs, 2-deoxy-Dglucose, apoptosis, synergism, 6623 Reactive oxygen species, heat shock proteins, cannabidiol, tetrahydrocannabinol, glioma, 5827 Reactive oxygen species, melanoma, zinc, apoptosis, FAS ligand, p53, 5309 Reactive oxygen species, radiosensitivity, radiosensitizers, topoisomerase, radiotherapy, hypoxia, review, 2479 Real time PCR, biomarker, endogenous control, germ cell tumors, microrna, testicular cancer, 117 Real-time, GFP, histone H2B, fusion gene, RFP, imaging, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, imaging, 2539 RECK, melanoma, nevus, reversion-inducing cysteine-rich protein with Kazal motifs, immunohistochemical stain, 3185 Recom mend dose, head and neck cancer, S-1, early glottic cancer, concur rent chemoradiotherapy, phase I/II study, prospective study, radiosentitizer, 2385 Rectal adenocarcinoma, plasminogen activation system, upa, upar, PAI-1, tpa, 6009 Rectal cancer, adjuvant therapy, lateral pelvic lymph node dissection, mesorectal excision, oxaliplatin, 1815 Rectal cancer, single nucleotide polymorphism, neoadjuvant chemoradiation, biomarker, review, 3761 Rectum, maspin, serrated polyps, colon, conventional adenomas, 4139 Rectum, neuroendocrine tumor, carcinoid, HES77, metastasis, prognosis, 3767 Rectum, serrated polyps, colon, conventional adenomas, β-catenin, 929 Recurrence, advanced-stage ovarian cancer, cytoreductive surgery, pancreatic resection, 4125 Recurrence, cancer stem cell, hepatocyte growth factor, prostate cancer, prostatectomy, 413 Recurrence, circulating tumor cells, endometrial cancer, hematogenous dissemination, prognosis, 683 Recurrence, colorectal cancer, laparoscopic surgery, body mass index, prognosis, 5639 Recurrence, colorectal cancer, oxaliplatin, adjuvant chemotherapy, tumor size, 5073 Recurrence, epithelial ovarian cancer, microrna, 2611 Recurrence, epithelial ovarian cancer, quaternary cytoreduction, prolonged survival, 3519 Recurrence, esophagogastric junction carcinoma, Siewert type II, 505 Recurrence, hepatocellular carcinoma, local ablation, brachytherapy, 319 Recurrence, pancreatic cancer, complete response, case report, 2867 Recurrence, pancreatic cancer, surgical complication, survival, 2401 Recurrence, small cell carcinoma, epirubicin, paclitaxel, chemotherapy, 2183 Recurrence, unresectable gastric cancer, conversion surgery, 6183 Recurrence, uterine leiomyosarcomas, complete resection, 2229 Recurrence, xct, CD44v6, CRC, immunohistochemistry, colorectal cancer, 677 Recurrence-free survival, laparoscopic surgery, gastrointestinal stromal tumor, intestinal GIST, overall survival, small bowel GIST, 1033 Recurrent brain tumor, meningioma, meningeal neoplasm, human, WHO classification, 3559 Recurrent disease, sunitinib, lomustine, glioma, 5551 Recurrent ovarian cancer, tertiary cytoreduction, quaternary cytoreduction, 6951 Recurrent tumor resection, small bowel adenocarcinoma, curative surgery, definitive chemotherapy, distant metastasis, unresectable case, 4135 Recurrent, cervical cancer, oligometastasis, stereotactic body radiotherapy, CyberKnife, radiosurgery, 5103 Red blood cell distribution width, chronic myeloid leukemia, prognosis,

158 Red fluorescent protein, Astragalus membranaceus, Curcuma wenyujin, ovarian cancer, orthotopic, nude mice, tumor progression, metastasis, 3193 Regorafenib monotherapy, GIST, liver failure, case report, 4037 Regorafenib, disposition, multidrug resistance-associated protein, organic anion-transporting polypeptide, hepatic uptake, biliary excretion, protein-binding, 4681 Regorafenib, hypothyroidism, thyroid-stimulating hormone, metastatic colorectal cancer, 4059 Regorafenib, metastatic colorectal cancer, chemotherapy, adverse events, 371 Regulatory T cell, immune cell therapy, effector cell therapy, dendritic cell vaccine, 4533 Regulatory T-cell, IL32, esophageal carcinoma, immunsuppressive, survival, 2941 Reimplantation, non-small-cell lung cancer, bench surgery, autotransplantation, in vivo, ex situ, 1675 Re-implantation, vascular invasion, pancreatic cancer, pancreato-duodenectomy, superior mesenteric artery resection, portal vein resection, 1613 Re-irradiation, radiation-induced, second malignancies, review, 2431 Relapse, ex vivo drug resistance, individualized tumor response testing, acute lymphoblastic leukemia, children, minimal residual disease, 5667 Relapse, ovarian cancer, postoperative morbidity, haemodynamic management, transfusion, cytoreductive surgery, 1591 Relapsed ovarian cancer, secondary cytoreduction, splenectomy, peritoneal lesions, 5097 Relapsed/refractory multiple myeloma, cyclophosphamide, dexamethasone, treatment options, old drugs, case report, 2165 Relative uptake factor, breast-specific gamma imaging, invasive ductal breast cancer (IDC) sub-types, correlation of relative uptake factor and IDC sub-types, 5671 RelB, monocyte, colon cancer cell, co-culture, low-dose lipopolysaccharide, STAT3, 4471 Renal cell cancer (RCC), vascular endothelial growth factor receptor (VEGFR), CD-31, prognostic factor, 921 Renal cell carcinoma, anemia, leucocytosis, prognosis, thrombocytosis, 3463 Renal cell carcinoma, cerebral metastases, stereotactic radiosurgery, local control, freedom from new cerebral metastases, survival, 3571 Renal cell carcinoma, dendritic cells, immunotherapy, metastases, sequential therapy, targeted-therapy, 1575 Renal cell carcinoma, docetaxel, cabazitaxel, p-glycoprotein, AKT, Caki-1, KMRC-1, OS-RC-2, 6671 Renal cell carcinoma, endostatin, chick embryo chorioallantoic membrane, 6521 Renal cell carcinoma, HPV, prostate cancer, bladder cancer, testicular cancer, penile cancer, review, 2513 Renal cell carcinoma, molecular targeted therapy, prognostic factor, duration of first-line treatment, 3415 Renal cell carcinoma, placental growth factor (PlGF), antiangiogenic therapy, sunitinib resistance, 531 Renal cell carcinoma, sunitinib, thyrotoxicosis, hypothyroidism, levothyroxine substitution therapy, thiamazole antithyroid therapy, 481 Renal cell carcinoma, vascular endothelial growth factor receptor inhibitor, progressive disease, treatment beyond progression, re-vascularization, tyrosine kinase inhibitor, 5601 Renal fibrogenesis, cisplatin, (Pt(O, O -acac)(γacac)(dms)), epithelial-mesenchymal transition, 739 Renal function, head and neck cancer, serum albumin, creatinine clearance, cisplatin, 2909 Renal replacement therapy (RRT), vitamin D, chronic kidney disease, CKD, dialysis, ESRD, cancer, epidemiology, CKD-MBD, mineral and bone disease, 1181 Renal transitional cell carcinoma, ALDH1, survival, cancer stem cell, 4829 Renal tumor, magnetic resonance imaging, diffusion weighted MRI, apparent diffusion coefficient, biomarker, 2351 Repeat biopsy, prostate cancer, percentage free PSA, PSA velocity, population screening, Gleason score 7, 5031 Re-resection, breast cancer liver metastases, survival, 6877 Residual disease, triple-negative breast cancer, neoadjuvant chemotherapy, pathological complete response, pcr, prognostic impact, 5479 Residual tumor, advanced ovarian cancer, node ratio, lymphadenectomy, prognosis, node metastases, 3479 Residual tumor, breast cancer, ductal carcinoma in situ, conservative treatment, 3471 Residual urinary volume, prostate-specific antigen, prostate cancer, biopsy, prostate volume, 2175 Response assessment, glioblastoma, EGFR, peritumoral edema, radiotherapy, 4117 Response evaluation, breast cancer, primary systemic therapy, FDG-PET/CT, Ki-67, 5063 Resveratrol, protein kinase G (PKG), angiogenesis, HUVECs, Inhibitor of Apoptosis Proteins (IAPs), 273 Resveratrol, soft tissue sarcoma, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, gene expression, FACS, proliferation, chemotherapy, 767 RET, calcitonin, medullary thyroid carcinoma, C-cell hyperplasia, calcium stimulation test, papillary thyroid carcinoma, 4251 Retroperitoneal giant tumor, adrenocortical carcinoma, nonsecretory tumor, multi-visceral resection, 2169 Retrospective study, S-1, toxic effects, oral therapy,

159 Retrovirus, cancer cells, GFP, histone-h2b, fusion, nuclear labeling, RFP, cytoplasmic labeling, mitosis, chromosomes, 2553 Re-vascularization, vascular endothelial growth factor receptor inhibitor, progressive disease, renal cell carcinoma, treatment beyond progression, tyrosine kinase inhibitor, 5601 Reversion-inducing cysteine-rich protein with Kazal motifs, melanoma, nevus, immunohistochemical stain, RECK, 3185 Review, adherence, adverse effects, BCR-ABL1, chronic myeloid leukemia, medication, therapy management, 6355 Review, advanced gastric cancer, second-line, chemotherapy, molecular targeted therapy, 4575 Review, angiogenesis, immunotherapy, invasion, metastasis, signalling systems, thalidomide analogues, 5767 Review, anticancer peptides, temporin, cytotoxicity, cancer, 635 Review, atypical fibroxanthoma, AFX diagnosis, AFX tumor markers, immunohistochemistry, AFX therapy, 5717 Review, breast cancer, extracellular vesicles, exosomes, microvesicles, biomarkers, liquid biopsy, 6379 Review, cancer of unknown primary, pregnancy, treatment, prognosis, placental in-vasion, 575 Review, cell cycle, CDK inhibitor, p16, transcription, polycomb, MLL, ANRIL, 4395 Review, chest radiotherapy, cardiac injury, radiation, 2487 Review, chronic lymphocytic leukemia, small-cell lymphoma, ibrutinib, idelalisib, rituximab, ofatumumab, 5149 Review, clinical trials, epigenetics, glioblastoma, histone deacetylase inhibitor, preclinical trials, 615 Review, CML, treatment, pregnancy, TKIs, 1 Review, curcumin, cancer stem cells, interleukin-6, interleukin-8, interleukin-1, CXCR1, CXCR2, Wnt pathway, Notch pathway, Hedgehog pathway, FAK pathway, 599 Review, curcumin; anti-cancer properties; autophagy, transcription factors, bioavailability, 645 Review, cytokines, colitis-associated cancer, animal models, carcinogenesis, 19 Review, dietary agents, cancer stem cells, mechanism of action, signal transduction pathways, 5773 Review, DNA methylation, breast cancer, CpG islands, biomarkers, treatment, 4569 Review, drug delivery systems, intraperitoneal chemotherapy, peritoneal carcinomatosis, animal experiment, 627 Review, emergency fertility preservation, cancer, cryopreservation, autotransplantation, in vitro maturation, oncofertility, 3117 Review, GIST, imatinib, surgery, discontinuation of treatment, cure, treatment algorithm, 5759 Review, glioblastoma multiforme (GBM), chemotherapy, molecular-targeted therapy, immunotherapy, 1229 Review, glioblastoma, curcumin, lomustine, cancer stem cells, ceramide, blood brain barrier, combination chemotherapy, lipophilic agent, 6373 Review, graft-versus-host disease, chronic GVHD, genital GVHD, 13 Review, HDAC, histone, inhibitors, acetylasation, epigenetics, pancreatic cancer, 3129 Review, hepatocellular carcinoma, molecular-targeted therapy, sorafenib, tyrosine kinase inhibitor, 5737 Review, HPV, prostate cancer, renal cell carcinoma, bladder cancer, testicular cancer, penile cancer, 2513 Review, local radiotherapy, metastatic breast cancer, 5807 Review, lysozyme, chronic inflammation, esophagus, stomach, duodenum, colon, 6365 Review, macrophages, intestinal microbiota, oral administration of LPS, disease prevention, 4391 Review, malignant mesothelioma, randomized trials, 2493 Review, MCF-7, breast cancer, angiogenesis, lymphangiogenesis, mesenchymal stem cells, 3147 Review, meningioma, nanomedicine, surgery, targeted therapies, treatment, 6391 Review, metabolic reprogramming, mitochondria, metformin, 5789 Review, microtubule-associated protein, tau protein, taxanes, chemotherapy sensitivity, cancer treatment, breast cancer, 5179 Review, nitric oxide, lung cancer, metastasis, apoptosis, migration, cancer stem cells, 4585 Review, NSCLC, brain metastases, tyrosine kinase inhibitors, 5797 Review, NSCLC, molecular biology, immunotherapies, clinical outcome, 5745 Review, NSCLC, novel therapies, tyrosine kinase inhibitors, monoclonal antibodies, clinical trials, 2503 Review, prostate cancer, radiotherapy, hypofractionation, high-dose-rate brachytherapy, stereotactic radiotherapy, particle therapy, 5167 Review, radiation-induced, second malignancies, reirradiation, 2431 Review, radiosensitivity, radiosensitizers, topoisomerase, radiotherapy, reactive oxygen species, hypoxia, 2479 Review, rectal cancer, single nucleotide polymorphism, neoadjuvant chemoradiation, biomarker, 3761 Review, sandalwood, santalol, cancer, apoptosis, cell cycle, carcinogenesis, angiogenesis, 3137 Review, thyroid carcinomas; microrna; diagnostic biomarkers; risk assessment; prognosis prediction, 2037 Review, thyroid sarcoma, clinical sign, thyroid imaging, 5185 Review, tumor-associated macrophages (TAM), myeloidderived suppressor cells (MDSC), dendritic cells (DCs), Poly(I:C), Toll-like receptor 3, TICAM-1, antitumor immunotherapy,

160 Review, urothelial cancer, transitional cell carcinoma, novel molecular targets, targeted therapy, 4557 Review, vitamin D insufficiency, genome-wide research, vitamin D receptor, 1, 25(OH)2D3, ChIP-seq, 1143 Review, vitamin D, preventive medicine, cancer, epidemiology, 25(OH)D, 1161 RFP, breast cancer, Balb-c mice, syngeneic, orthotopic, tumor resection, metastasis, imaging, 4641 RFP, C57/BL6-GFP mice, malignant lymphoma, liver metastasis, imaging, 4647 RFP, cancer cells, GFP, histone-h2b, fusion, nuclear labeling, retrovirus, cytoplasmic labeling, mitosis, chromosomes, 2553 RFP, GFP, histone H2B, fusion gene, imaging, paclitaxel, vinblastine, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, imaging, 2539 RFP, GFP, nude mice, human tumors, metastasis, imaging, noninvasive, variable magnification, subcellular in vivo imaging, spectral separation, tunable filter, 661 RFP, pancreatic cancer, dual color cells, GFP, stellate cells, interaction, CFP nude mouse, color-coded fluorescence imaging, 2545 RFP, Salmonella typhimurium A1-R, tumor targeting, GFP, prostate cancer, cell line, PC-3, LNCaP, DU-145, apoptosis, necrosis, cell burst, 5225 RFP, tumor microenvironment, cancer-associated fibroblasts, blood vessels, liver metastasis, fluorescence, color-coded imaging, 5821 RGC, total gastrectomy, laparoscopic surgery, 5023 Rhodamine 123, phenothiazines, multidrug resistance, MDR, P-glycoprotein (ABCB1), colon adenocarcinoma, apoptosis, doxorubicin, verapamil, 3245 Ribonuclease A (RNase A), cancer, casein kinase II (CK2), in silico systematic mutagenesis, KINARI mutagen webserver, LB-based nanocrystallo graphy, proteomics, 827 Rice retaining subaleurone layer, lipopolysaccharide, innate immunity, macrophage, anti-allergy, 4465 Right ventricle, radiotherapy, breast cancer, TAPSE, 2141 Ring chromosome, dedifferentiated liposarcoma, welldifferentiated liposarcoma, MDM2, CDK4, 345 Risk factor, trastuzumab, cardiac dysfunction, hypertension, BMI, radiotherapy, 4967 Risk factors, anthracyclines, chemotherapy, left ventricular systolic dysfunction, metastatic breast cancer, 989 Risk factors, multiple primary cancers, hepatobiliary and pancreas, surgery, prognosis, 1073 Risk stratification, colorectal cancer, family history, colonoscopy, surveillance, 4813 Rituximab, bendamustine, chronic lymphocytic leukemia (CLL), chemotherapy, immunotherapy, 5129 Rituximab, chronic lymphocytic leukemia, small-cell lymphoma, ibrutinib, idelalisib, ofatumumab, review, 5149 Rituximab, non-hodgkin lymphoma, second primary cancer, 1809 Robotic, cervical cancer, laparoscopy, radical hysterectomy, quality of life, 5015 Robotics, biochemical recurrence, laparoscopy, pentafecta, prostate cancer, radical prostatectomy, 5007 ROCK I, colorectal cancer, MET, immunohistochemistry, tissue microarray, five-year survival, 3267 ROS, 4-methylumbelliferone, K562 cells, apoptosis, BCL2 family, mitochondria, 5231 RPA, brain oligometastases, fractionation, stereotactic radiotherapy, whole brain radiotherapy, 3055 RT-PCR, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deepsequencing, cancer stem cells, CSCs, cancer cell proliferation, anti-apoptosis, stemness, western blotting, immunocytochemistry, 3743 Ruthenium complexes, oxidative stress, anticancer treatment, 3371 S-1, gastric cancer, adjuvant chemotherapy, outpatient setting, cisplatin, 467 S-1, gastric cancer, intraperitoneal chemotherapy, cisplatin, docetaxel, DCS, 2223 S-1, head and neck cancer, early glottic cancer, concur rent chemoradiotherapy, phase I/II study, prospective study, recom mend dose, radiosentitizer, 2385 S-1, retrospective study, toxic effects, oral therapy, 977 Safety, melanoma, ipilimumab, survival, 6303 Safety, ovarian cancer, phase I trial, pegylated liposomal doxorubicin, irinotecan, 4519 Safety, therapy-related myeloid neosplasm, azacitidine, outcome, 461 Salinomycin, AZD5363, apoptosis, cancer, 4741 Salmonella typhimurium A1-R, tumor targeting, GFP, RFP, prostate cancer, cell line, PC-3, LNCaP, DU-145, apoptosis, necrosis, cell burst, 5225 Salmonella, cancer therapy, breast cancer, BALB-neuT, autochthonous model, genetically-engineered, mouse model, immunotherapy, myeloid-derived suppressor cells, 843 Salvage stereotactic radiotherapy, non-small cell lung cancer, post-surgical recurrence, local control, 1783 Sandalwood, santalol, cancer, apoptosis, cell cycle, carcinogenesis, angiogenesis, review, 3137 Santalol, sandalwood, cancer, apoptosis, cell cycle, carcinogenesis, angiogenesis, review, 3137 Saporin, NG2 proteoglycan, GD3A, immunoablation, glioma, 77 Sarcoma, 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D, parathyroid hormone, daily vitamin D intake, benign soft tissue tumor, 1171 Sarcoma, biopsy, open biopsy, core needle biopsy, 961 Sarcoma, epithelioid haemangioendothelioma, EHE, survival, observation, chemotherapy, surgery,

161 Sarcoma, genistein, programmed cell death, hormonal therapy, isoflavones, 3167 Sarcoma, oral cavity, multi-institution study, prognostic factors, 4549 Sarcoma, radiotherapy, uterine, 365 Sarcoma, SBRT, lung metastases, 5581 Sarcoma, spontaneous regression, progression, natural killer cells, platelets, MCP1, 6539 Sarcosine, PCA3, phi, tumor volume, Gleason score, tumor stage, 1017 Saudi Arabian patients, breast cancer, ovarian cancer, mutations, Canadian patients, comparative study, next generation sequencing, 2601 SB265610, G1 arrest, cyclin D3, phospho(thr160)-cdk2, p21, p38mapk, 3235 SBRT, pulmonary oligometastases, oligo-recurrence, syncoligometastases, 4903 SBRT, sarcoma, lung metastases, 5581 SCCHN, cytology, immunocytology, pre-malignant lesions, oropharynx, 6517 Schwannoma, synchronous, multiple primary malignant neoplasms, glioblastoma, glioblastoma multiforme, neuroendocrine tumor, sessile serrated adenoma/polyp, 2121 Schwannoma, vessel density, blood vessels, lymphatic vessels, NF1, NF2, schwannomatosis, neurofibromatosis, mast cell, MPNST, 4713 Schwannomatosis, vessel density, blood vessels, lymphatic vessels, NF1, NF2, schwannoma, neurofibromatosis, mast cell, MPNST, 4713 Scintigraphy, 111 In-pentetreotide, pulmonary carcinoid, NET, somatostatin receptors, SPECT, 4265 ScreenCell, circulating tumor cells, radiofrequency ablation, ablative, 2823 Screening programs, biopsy, predictive value, prostate neoplasms, model, nomogram, 2881 Screening, colorectal cancer, early detection, bowel endoscopy, biomarkers, 4935 Screening, colorectal cancer, fecal occult blood (FOB), quaiac-based FOB test, fecal immunochemical test (FIT), performance, R.O.C. analysis, 2873 Screening, gastric cancer, pepsinogen, Helicobacter pylori, ABC method, 6765 Second malignancies, radiation-induced, re-irradiation, review, 2431 Second primary cancer, non-hodgkin lymphoma, rituximab, 1809 Second primary malignancies, mantle cell lymphoma, SEER, 3437 Second primary malignancy, anal cancer, SEER, latency, 4131 Second surgery, glioblastoma, surgery, radiotherapy, temozolomide, 1743 Secondary cytoreduction, relapsed ovarian cancer, splenectomy, peritoneal lesions, 5097 Secondary cytoredustive surgery, AGO-score, ovarian cancer, 3423 Secondary surgery, ovarian cancer relapse, hyperthermic intra-peritoneal chemotherapy, 4997 Second-line chemotherapy, biliary tract cancer, itraconazole, 4923 Second-line chemotherapy, pancreatic cancer, itraconazole, Hedgehog, 4191 Second-line, advanced gastric cancer, chemotherapy, molecular targeted therapy, review, 4575 Second-line, tyrosine kinase inhibitor, metastatic renal cell carcinoma, first-line, objective response, progression-free survival, 3067 SEER, anal cancer, second primary malignancy, latency, 4131 SEER, mantle cell lymphoma, second primary malignancies, 3437 Selection, bias, hospital structure, outcome, survival, 4073 Selenium exposure, vitamin E, prostate cancer risk, smoking status, 4983 Semi-prone position, hepatocellular carcinoma, laparoscopic hepatectomy, 4167 Senescence, oncogene-induced senescence, primary cell culture, cancer cell line, senescence-associated heterochromatin foci, senescence-associated β- galactosidase, 2759 Senescence-associated heterochromatin foci, senescence, oncogene-induced senescence, primary cell culture, cancer cell line, senescence-associated β-galactosidase, 2759 Senescence-associated β-galactosidase, senescence, oncogene-induced senescence, primary cell culture, cancer cell line, senescence-associated heterochromatin foci, 2759 Sentinel lymph node, lower rectal cancer, lateral pelvic dissection, laparoscopic surgery, 3489 Sentinel lymph node, tumor burden, melanoma, 301 Sentinel node, lymphatic invasion, tumor size, breast cancer, lymph node metastasis, 3581 Sentinel node, melanoma, interleukin, Breslow score, 3537 Sequence, trastuzumab, anthracyline, cardiotoxicity, 857 Sequencing analysis, familial breast cancer, microsatellite markers, linkage analysis, next generation sequencing, 3155 Sequential therapy, dendritic cells, immunotherapy, metastases, renal cell carcinoma, targeted-therapy, 1575 Serous carcinoma of the ovary, 3-phosphoinositidedependent protein kinase 1, immunohistochemistry, intracellular signaling, 6329 Serrated polyps, colon, rectum, conventional adenomas, β- catenin, 929 Serrated polyps, maspin, colon, rectum, conventional adenomas,

162 Serrated, gallbladder, adenoma, case report, 3485 Serum albumin, head and neck cancer, creatinine clearance, renal function, cisplatin, 2909 Serum cotinine, serum vitamin D, smoking, lung cancer, ethnicity, 1211 Serum level, gastric cancer, epidermal growth factor, cancer risk, progression, 2709 Serum vitamin D, serum cotinine, smoking, lung cancer, ethnicity, 1211 Serum, angiogenesis, non-small cell lung cancer, pleural fluid, VEGF, 1129 Sessile serrated adenoma/polyp, synchronous, multiple primary malignant neoplasms, glioblastoma, glioblastoma multiforme, neuroendocrine tumor, schwannoma, 2121 Sex steroid receptors, angiogenesis molecules, cell cycle regulators, IPMN, image analysis, 1049 SGK1, PIN1, ubiquitination, RAF1, tamoxifen resistance, breast cancer, 785 ShAkt1, lung cancer, gene therapy, aerosol delivery, sorbitol diacrylate, PDCD4, 2015 Shielding, brachytherapy, cervical cancer, radiotherapy, toxicity, 5567 SH-SY5Y cells, peripheral neuropathy, microtubule-targeting agents, neurite-distupting effects, in vitro model, PC-12 cells, 6431 SIB, endometrial cancer, VMAT, gynecological cancer, 2149 Side-effect, cadherin, des-γ-carboxyprothrombin, cell migration, metastasis, hepatocellular carcinoma, 1985 Siewert type II adenocarcinoma, neoadjuvant chemotherapy, DCS regimen, 419 Siewert type II, esophagogastric junction carcinoma, recurrence, 505 Signal transduction pathways, dietary agents, cancer stem cells, mechanism of action, review, 5773 Signalling systems, angiogenesis, immunotherapy, invasion, metastasis, thalidomide analogues, review, 5767 Signet-ring cell carcinoma, yes-associated protein, β-catenin, carcinogenesis, adenocarcinoma, gastric neoplasia, 3925 Silibinin, glioblastoma, milk thistle, temozolomide, natural compounds, 1263 Silver staining, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), carmine labeling, Ki-67, E- cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Simultaneous integrated boost, hypofractionation, prostate cancer, IMRT, IGRT, erectile dysfunction, 4177 Simvastatin, synergy, alendronate, prostate cancer, 1851 Single and multiple HPV infection, cervical intraepithelial neoplasia, cervical cancer, microrna expression, 523 Single nucleotide polymorphism, prostate cancer, African Americans, CRYBB2, genetic association, 2565 Single nucleotide polymorphism, rectal cancer, neoadjuvant chemoradiation, biomarker, review, 3761 SiRNA, polyethylenimine, folate receptor, drug delivery, cancer, nanoparticle, 5433 Sirolimus, radiation toxicity, organ transplant recipient, cutaneous squamous cell carcinoma of the head and neck, 5511 SKAP2, lung cancer, actin assembly, Src, 2411 Skin cancer, basal cell carcinoma, hypofractionated radiotherapy, frail patients, 4949 Skin care, acneiform rash, minocycline, panitumumab, colorectal cancer, tumor response, time to treatment failure, 6175 Skin, squamous cell carcinoma, tumour aggressiveness, organ transplantation, immunosuppression, pathology, 2305 SLIT2, gastrointestinal stromal tumor, microarray, stomach, intestine, 3289 SLIT-ROBO, mirna-145, glioblastoma, srgap, 3209 SLUG, pituitary adenoma, EMT, N-cadherin, E-cadherin, SNA1, TWIST, 2635 SLUG, TWIST, EMT, breast cancer, epithelial-mesenchymal transition, 3961 Small bowel adenocarcinoma, curative surgery, definitive chemotherapy, recurrent tumor resection, distant metastasis, unresectable case, 4135 Small bowel GIST, laparoscopic surgery, gastrointestinal stromal tumor, intestinal GIST, overall survival, recurrence-free survival, 1033 Small bowel obstruction, intussusception, invagination, gastrectomy, complication, 6829 Small cell carcinoma, epirubicin, paclitaxel, chemothe rapy, recurrence, 2183 Small cell carcinoma, esophageal cancer, mirna, prognostic marker, surgery, 719 Small cell carcinoma, stomach, chemotherapy, paclitaxel, 563 Small cell lung cancer, chemotherapy-related exacerbation, interstitial lung disease, usual interstitial pneumonia, 6261 Small cell lung cancer, non-small cell lung cancer, idiopathic interstitial pneumonia, drug-induced interstitial lung disease, number of regimens, 1065 Small cell lung cancer, survivin, nucleus, labeling index, immunohistochemistry, 2935 Small cell ovarian carcinoma, lung cancer, 3091 Small molecule FGFR1 inhibitor, NVP-BGJ398, caspases, PDCD4, ANG2, 5873 Small-cell lung cancer, actinin-4, transbronchial biopsy, biomarker, prognosis, 1663 Small-cell lymphoma, chronic lymphocytic leukemia, ibrutinib, idelalisib, rituximab, ofatumumab, review, 5149 Smo, sonic Hedgehog (SHH), lung cancer, tumor model, YangZheng XiaoJi, cellular migration, invasion, cyclopamine, Gli,

163 Smoking status, vitamin E, Selenium exposure, prostate cancer risk, 4983 Smoking, alcohol consumption, gastric cancer, genotype, polymorphism, XPD, 4975 Smoking, alcohol drinking, genotype, hepatocellular carcinoma, polymorphism, TNFα, 5417 Smoking, gender, genotype, lung cancer, polymorphism, Taiwan, XRCC3, 3893 Smoking, serum cotinine, serum vitamin D, lung cancer, ethnicity, 1211 Smooth muscle cell, LMP2, IRF1, IFN-γ, uterine leiomyosarcoma, 4665 SN-38, cetuximab, irinotecan, anti-angiogenesis, antiinvasion, colon cancer, 5983 SNA1, pituitary adenoma, EMT, N-cadherin, E-cadherin, SLUG, TWIST, 2635 SNP, prostate cancer, vitamin D receptor, African-American, clinical phenotype, 1549 SNPs, African American, prostate cancer, Gleason, BPH, SPINK1, 3811 Socioeconomic factors, environmental factors, esophageal carcinoma, lifestyle factors, microrna, 1091 SOCS3, myelofibrosis, lenalidomide, bone marrow stroma, gene expression, 5219 Sodium ascorbate, artemisinin, vitamin D 3, Trolox, dexamethasone, hydrogen peroxide, Molt-4 cells, 1867 Soft coagulation, surgical loupes, pancreaticojejunostomy, postoperative pancreatic fistula, 1691 Soft tissue sarcoma, hyperthermotherapy, unplanned excision, chemotherapy, surgery, 493 Soft tissue sarcoma, non-pegylated liposomal doxorubicin, Phase II, 543 Soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, taurolidine, apoptosis, necrosis, gene expression, FACS, proliferation, chemotherapy, 767 Soft-tissue sarcoma, patient-derived orthotopic xenograft (PDOX), subcutaneous model, nude mouse, histology, spindle cells, 697 Solitary fibrous tumor, thigh, PET/CT, MRI, CD34, STAT6, NAB2-STAT6, 967 Somatostatin receptors, 111 In-pentetreotide, pulmonary carcinoid, NET, scintigraphy, SPECT, 4265 Sonic hedgehog (SHH), lung cancer, tumor model, YangZheng XiaoJi, cellular migration, invasion, cyclopamine, Smo, Gli, 1321 Sonic hedgehog, thymoma, immunohistochemistry, notch, beta-catenin, 669 Sorafenib, HCC, hepatic arterial infusion chemotherapy, liver cirrhosis, 2269 Sorafenib, hepatocellular carcinoma, matrix metalloproteinase, epithelial mesenchymal transition, 1967 Sorafenib, hepatocellular carcinoma, molecular-targeted therapy, tyrosine kinase inhibitor, review, 5737 Sorafenib, hepatocellular carcinoma, programmed cell death, M30, M65, 1803 Sorafenib, tyrosine kinase inhibitor, PTEN, VEGFR, head and neck squamous cell carcinoma, everolimus, sunitinib, 1389 Sorafenib, tyrosin-kinase-inhibitor, mtor, AREG, head and neck squamous cell carcinoma, everolimus, sunitinib, 1951 Sorbitol diacrylate, lung cancer, gene therapy, aerosol delivery, PDCD4, shakt1, 2015 Sortase A, drug-delivery system, liposome, 4409 SOX2, HSPB1, HSF1, tumor progression, 3217 SOX9, fucoxanthin, fucoxanthinol, MCF-7, MDA-MB-231, NF-ĸB, 207 SPECT, 111 In-pentetreotide, pulmonary carcinoid, NET, somatostatin receptors, scintigraphy, 4265 Spectral separation, GFP, RFP, nude mice, human tumors, metastasis, imaging, noninvasive, variable magnification, subcellular in vivo imaging, tunable filter, 661 Spectral separation, lung cancer, surgical orthotopic implantation, nude mice, high tumor take rates, noninvasive imaging, 3755 Spectroscopy, glioma, angiocentric, MRI, 6267 Sphenoid wing dysplasia, neurofibromatosis, NF1, plexiform neurofibroma, dermal cylindroma, mosaicism, rare tumor, 6813 Spheres, lymphoma, stem cell marker, dog, canine model, 2805 Spheroid cell clusters, prostate cancer, canine cancer stem cells, cancer stem cell marker, 1917 Spheroid, lung cancer, cancer stem cells, angiotensin II, 4789 Spinal sarcoma, carbon ion radiotherapy, proton therapy, patch-field technique, intensity-modulated radiotherapy, 4083 Spindle cells, soft-tissue sarcoma, patient-derived orthotopic xenograft (PDOX), subcutaneous model, nude mouse, histology, 697 SPINK1, African American, prostate cancer, Gleason, BPH, SNPs, 3811 Splenectomy, hepatocellular carcinoma, hypersplenism, primary macroglobulinemia, 4077 Splenectomy, relapsed ovarian cancer, secondary cytoreduction, peritoneal lesions, 5097 Splenic metastasis, advanced-stage epithelial ovarian cancer, parenchymatous metastasis, peritoneal, overall survival, 5649 Split-bolus technique, pediatric tumors, helical computed tomography (CT), multidetector-row CT (MDCT), radiation dose, 3041 Spontaneous regression, progression, sarcoma, natural killer cells, platelets, MCP1, 6539 Sputum, non-small cell lung cancer, micro RNA profiling, bronchoalveolar lavage, cancer detection,

164 Squamous cell carcinoma, adenocarcinoma, esophagus, PDGFR-α, CD117, immunohistochemistry, 3793 Squamous cell carcinoma, cervical cancer, para-aortic lymph node metastasis, radiation therapy, uterine cervix, 4849 Squamous cell carcinoma, head and neck cancer, cytokeratin 8, CK8, EpCAM, 3953 Squamous cell carcinoma, nedaplatin, irinotecan, lung cancer, 6705 Squamous cell carcinoma, skin, tumour aggressiveness, organ transplantation, immunosuppression, pathology, 2305 Squamous cell oropharyngeal tumors, HPV infection, p16 immunohistochemistry, HPV PCR assay, diagnostic assay, 4733 Src, SKAP2, lung cancer, actin assembly, 2411 SrGAP, mirna-145, glioblastoma, SLIT-ROBO, 3209 SRSF2, myelodysplastic syndrome, U2AF1, ZRSR2, decitabine, 3081 Stage I and II non-small-cell lung cancer, stereotactic body radiation, pulmonary function, surgery, 6773 Stage I, non-small cell lung cancer, metachronous, platinum doublets, inoperable, 3103 Stage IB, gastric cancer, adjuvant chemotherapy, 4091 Stage I-II, non-small cell lung cancer, clinical outcome, surgery, stereotactic body radiotherapy, 5607 Stage, hepatocellular carcinoma, UICC, surgery, 2921 Staging laparoscopy, near-infrared fluorescence imaging, indocyanin green, liposome, dissemination, 1353 STAT3, curcumin, EGCG, NFĸB, CD44, cancer stem cells, 39 STAT3, monocyte, colon cancer cell, co-culture, low-dose lipopolysaccharide, RelB, 4471 STAT6, solitary fibrous tumor, thigh, PET/CT, MRI, CD34, NAB2-STAT6, 967 Stellate cells, pancreatic cancer, dual color cells, GFP, RFP, interaction, CFP nude mouse, color-coded fluorescence imaging, 2545 Stem cell marker, lymphoma, spheres, dog, canine model, 2805 Stemness, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deepsequencing, cancer stem cells, CSCs, cancer cell proliferation, anti-apoptosis, western blotting, RT-PCR, immunocytochemistry, 3743 Stereoselective synthesis, vitamin D metabolites, assay development, 1205 Stereotactic body radiation therapy, liver metastases, primary liver tumor, 4171 Stereotactic body radiation, stage I and II non-small-cell lung cancer, pulmonary function, surgery, 6773 Stereotactic body radiotherapy, cervical cancer, recurrent, oligometastasis, CyberKnife, radiosurgery, 5103 Stereotactic body radiotherapy, non-small cell lung cancer, stage I-II, clinical outcome, surgery, 5607 Stereotactic body radiotherapy, oligometastatic non-small lung cancer, lung metastases, 6239 Stereotactic radiation therapy, radiation pneumonitis, interstitial changes, 4909 Stereotactic radiosurgery, cerebral metastases, breast cancer, freedom from new cerebral metastases, prognostic tool, 6793 Stereotactic radiosurgery, colorectal cancer, cerebral oligometastases, survival, predictive tool, treatment optimization, 5515 Stereotactic radiosurgery, elderly patients, cerebral metastases, optimal dose, treatment results, 5701 Stereotactic radiosurgery, renal cell carcinoma, cerebral metastases, local control, freedom from new cerebral metastases, survival, 3571 Stereotactic radiosurgery, tomotherapy, brain metastasis, 6805 Stereotactic radiotherapy, brain oligometastases, fractionation, whole brain radiotherapy, RPA, 3055 Stereotactic radiotherapy, prostate cancer, radiotherapy, hypofractionation, high-dose-rate brachytherapy, particle therapy, review, 5167 Steroids, multidrug resistance, ABCB1 transporter, mouse T- lymphoma, PC-3 prostate cancer cell line, 2105 STK11, non-small cell lung cancer, ALK translocation, ALK inhibitor, KRAS, ATM, crizotinib resistance, genomics, next-generation sequencing, case report, 3007 Stomach, gastrointestinal stromal tumor, microarray, intestine, SLIT2, 3289 Stomach, lysozyme, chronic inflammation, esophagus, duodenum, colon, review, 6365 Stomach, small cell carcinoma, chemotherapy, paclitaxel, 563 Stromal fibroblasts, fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, co-culture, tumour microenvironment, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, non-specific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids, 1881 Structure and activity relationship, furochalcones, antiproliferative activity, HL60 cells, 811 STUMP, uterine smooth muscle tumors, leiomyosarcoma, 6445 Subcellular in vivo imaging, GFP, RFP, nude mice, human tumors, metastasis, imaging, noninvasive, variable magnification, spectral separation, tunable filter, 661 Subcutaneous model, soft-tissue sarcoma, patient-derived orthotopic xenograft (PDOX), nude mouse, histology, spindle cells, 697 Suicidal ideation, hopelessness, helplessness, breast disease, 3543 Sulfasalazine, cyclooxygenase-2, celecoxib, benzimidazole, combination therapy, synergistic effects, brain cancer, glioma, LN18,

165 Sulfiredoxin, peroxiredoxin, prognosis, prostate cancer, radical prostatectomy, 6465 Sulforaphene, cisplatin, PI3K, PTEN, synergy, apoptosis, 3901 Sunitinib resistance, placental growth factor (PlGF), antiangiogenic therapy, renal cell carcinoma, 531 Sunitinib, lomustine, glioma, recurrent disease, 5551 Sunitinib, malignant melanoma, phase II study, biomarkers, PlGF, 6893 Sunitinib, renal cell carcinoma, thyrotoxicosis, hypothyroidism, levothyroxine substitution therapy, thiamazole antithyroid therapy, 481 Sunitinib, tyrosine kinase inhibitor, PTEN, VEGFR, head and neck squamous cell carcinoma, everolimus, sorafenib, 1389 Sunitinib, tyrosin-kinase-inhibitor, mtor, AREG, head and neck squamous cell carcinoma, everolimus, sorafenib, 1951 Superior mesenteric artery resection, vascular invasion, pancreatic cancer, pancreato-duodenectomy, portal vein resection, re-implantation, 1613 Superoxide anion, apoptosis, HOCl, NOX1, DUOX, hydroxyl radical, 5927 Superoxide dismutase, CTLA4, CD28, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), protein carbonyl (PCO), advanced glycation end-products (AGEs), copper, zinc, 5391 Suppression, Dendrobium falconeri, dendrofalconerol A, EMT, integrin, migration, lung cancer, 201 Supraclavicular, radical surgery, breast cancer, N3, 18FDG- PET/CT, neoadjuvant chemotherapy, 1729 Surgery, bone cancer, immune function, inflammatory response, 5461 Surgery, colorectal cancer, chemotherapy, prognostic factors, 3431 Surgery, colorectal cancer, HVEM, prognosis, tumor immunity, 1361 Surgery, epithelioid haemangioendothelioma, EHE, survival, observation, chemotherapy, sarcoma, 473 Surgery, esophageal cancer, small cell carcinoma, mirna, prognostic marker, 719 Surgery, esophagogastric junction, lymph node excision, neoplasms, prognosis, 445 Surgery, GIST, imatinib, discontinuation of treatment, cure, treatment algorithm, review, 5759 Surgery, glioblastoma, radiotherapy, temozolomide, second surgery, 1743 Surgery, hepatocellular carcinoma, UICC, stage, 2921 Surgery, meningioma, nanomedicine, targeted therapies, treatment, review, 6391 Surgery, multiple primary cancers, hepatobiliary and pancreas, risk factors, prognosis, 1073 Surgery, non-small cell lung cancer, stage I-II, clinical outcome, stereotactic body radiotherapy, 5607 Surgery, soft tissue sarcoma, hyperthermotherapy, unplanned excision, chemotherapy, 493 Surgery, stage I and II non-small-cell lung cancer, stereotactic body radiation, pulmonary function, 6773 Surgical biopsy, papilloma of the breast, percutaneous biopsy, breast cancer, 6881 Surgical complication, pancreatic cancer, survival, recurrence, 2401 Surgical loupes, soft coagulation, pancreaticojejunostomy, postoperative pancreatic fistula, 1691 Surgical orthotopic implantation, lung cancer, nude mice, high tumor take rates, noninvasive imaging, spectral separation, 3755 Surgical pathology, prostate neoplasms, gene expression, cell line, radical prostatectomy, 5443 Surgical treatment, gastrointestinal stromal tumor, duodenum, 6321 Surveillance, colorectal cancer, family history, colonoscopy, risk stratification, 4813 Survival tool, cancer of unknown primary, elderly, MESCC, radiation therapy, 6219 Survival, ALDH1, renal transitional cell carcinoma, cancer stem cell, 4829 Survival, breast cancer liver metastases, re-resection, 6877 Survival, breast cancer, estrogen, incidence, lung cancer, 1121 Survival, canine mammary tumors, Nottingham histological grade, prognosis, 4219 Survival, cervical cancer, concurrent chemoradiation, 3447 Survival, chronic lymphocytic leukemia, hyperleukocytosis, prognosis, 2861 Survival, colorectal cancer, stereotactic radiosurgery, cerebral oligo-metastases, predictive tool, treatment optimization, 5515 Survival, epithelioid haemangioendothelioma, EHE, observation, chemotherapy, surgery, sarcoma, 473 Survival, head and neck cancer, distant metastasis, lung metastasis, bone metastasis, 5499 Survival, head and neck squamous cell carcinoma, HNSCC, oropharynx, human papillomavirus, HPV incidence, 4015 Survival, head-and-neck cancer, metastatic epidural spinal cord compression, irradiation, predictive instrument, 385 Survival, hepatocellular carcinoma, metformin, radiotherapy, 5047 Survival, IL32, esophageal carcinoma, regulatory T-cell, immunsuppressive, 2941 Survival, kidney cancer, radiosurgery, brain metastasis, estimation, 4215 Survival, lung cancer, race, insurance, 4243 Survival, mast cells, liver metastasis, prognosis, 5325 Survival, melanoma, ipilimumab, safety,

166 Survival, NSCLC, radiotherapy, toxicity, esophagitis, 5491 Survival, pancreatic cancer, surgical complication, recurrence, 2401 Survival, peripheral blood, biomarker, prospective, TS, DPD, esophageal cancer, neoadjuvant, 1297 Survival, proton beam therapy, esophageal cancer, concurrent chemoradiotherapy, late toxicity, 1757 Survival, renal cell carcinoma, cerebral metastases, stereotactic radiosurgery, local control, freedom from new cerebral metastases, 3571 Survival, selection, bias, hospital structure, outcome, 4073 Survival, tongue cancer, celecoxib, chemotherapy, 4235 Survival, type IV gastric cancer, chemotherapy, 897 Survivin, AKT, VEGF, microvessel density, oral melanoma, prognostic factor, 2113 Survivin, small cell lung cancer, nucleus, labeling index, immunohistochemistry, 2935 Sustained virological response, chronic hepatitis C, hepatectomy, hepatocellular carcinoma, interferon, 6963 SUV, breast tumors, histological grading, estrogen receptor, progesterone receptor, Ki67, BCL2, p53, androgen receptor, 569 SUVmax, head and neck cancer, overall survival, 18 F-FDG- PET/CT, inhibition index cisplatin, 1009 Synchronous primary malignant neoplasms, multiple primary malignant neoplasms, individualized treatment, 6159 Synchronous, multiple primary malignant neoplasms, glioblastoma, glioblastoma multiforme, neuroendocrine tumor, sessile serrated adenoma/polyp, schwannoma, 2121 Sync-oligometastases, pulmonary oligometastases, SBRT, oligo-recurrence, 4903 Synergism, anticancer drugs, 2-deoxy-D-glucose, reactive oxygen species, apoptosis, 6623 Synergistic effects, cyclooxygenase-2, sulfasalazine, celecoxib, benzimidazole, combination therapy, brain cancer, glioma, LN18, 6419 Synergy, alendronate, simvastatin, prostate cancer, 1851 Synergy, sulforaphene, cisplatin, PI3K, PTEN, apoptosis, 3901 Syngeneic, breast cancer, Balb-c mice, orthotopic, tumor resection, metastasis, RFP, imaging, 4641 Systemic inflammatory response, bile duct cancer, monocyte, immune supression, 4961 T lymphocytes, murine tumor model, adoptive transfer, bioluminescence imaging, 6573 T(1;5), glomus tumor, cytogenetics, NOTCH2, MIR143, 6167 T2 and T3, VATS, non-small cell lung cancer, 3585 T4 esophageal cancer, Glasgow Prognostic Score, Prognostic Nutritional Index, 4897 T790M, central nervous system, epidermal growth factor receptor-tyrosine kinase inhibitor, acquired resistance, leptomeningeal metastases, brain metastases, 1025 T98G human cells, glioma, 18 F-fluorodeoxyglucose, 18 F- fluorocholine, radiation injury, 6439 TACE, VX2, HepG2, chemosensitivity, chemotherapy, HCC, 6497 Taiwan, COX2, genotype, polymorphism, upper tract urothelial cancer, 2725 Taiwan, gender, genotype, lung cancer, polymorphism, smoking, XRCC3, 3893 Taiwan, genotype, interleukin-4, lung, polymorphism, 6297 Taiwan, genotype, leiomyoma, polymorphism, XRCC3, 4691 Tamoxifen resistance, PIN1, SGK1, ubiquitination, RAF1, breast cancer, 785 Tamoxifen, breast cancer, estrogen receptor (ER), HER2, EGFR, trastuzumab (Herceptin), fulvestrant (Faslodex), GW2974, proliferation, apoptosis, 1243 Tannic acid, apoptosis, breast cancer, tissue engineering, 1285 TAPSE, radiotherapy, breast cancer, right ventricle, 2141 Targeted therapies, meningioma, nanomedicine, surgery, treatment, review, 6391 Targeted therapy, hepatoma-derived growth factor, hepatocellular carcinoma, xenograft model, VEGF, angiogenesis, 6475 Targeted therapy, PEC, PEComa, PEC tumor, mesenchymal neoplasm, everolimus, mtor inhibition, case report, 3399 Targeted therapy, urothelial cancer, transitional cell carcinoma, novel molecular targets, review, 4557 Targeted-therapy, dendritic cells, immunotherapy, metastases, renal cell carcinoma, sequential therapy, 1575 Targeted-therapy, dose determination, EGFR monoclonal antibody, mtor inhibitor, 1567 Targeted-therapy, metastatic renal carcinoma, prediction, biomarkers, immunohistochemistry, 5661 Targeted-therapy, organic anion-transporting polypeptides, OATPs. microcystin-lr, pancreatic cancer, drug development, cancer treatment, 5857 Tartrazine, food dye, cytotoxicity, genotoxicity, DNA repair, 1465 TAS-102, 5-FU resistance, irinotecan hydrochloride, colorectal cancer, gastric cancer, 1437 TAS-102, oxaliplatin, colorectal cancer, gastric cancer, 5-FU resistance, 4605 TAS-115, lung cancer, drug resistance, c-met inhibitor, anticancer drug combinations, 5241 TATI, CA 125, claudin, ovarian mucinous borderline tumor, 973 Tau protein, microtubule-associated protein, taxanes, chemotherapy sensitivity, cancer treatment, breast cancer, review, 5179 Taurolidine, soft tissue sarcoma, resveratrol, phytotherapy, fibrosarcoma, doxorubicin, HT1080, apoptosis, necrosis, gene expression, FACS, proliferation, chemotherapy,

167 Taxanes, microtubule-associated protein, tau protein, chemotherapy sensitivity, cancer treatment, breast cancer, review, 5179 T-cell homeostasis, Zfat, FoxO1, proteasomal degradation, IL-7Rα, 4417 T-cell, HLA class II, CIITA, melanoma, immune response, Jurkat-C, 25 TCR gene therapy, Wilms tumor gene (WT1), HLA- DRB1*04:05, HLA class II, helper peptide, 1251 T-DM1, HER2-positive metastatic breast cancer, chemotherapy, 5085 Tegafur-uracil, urothelial carcinoma, chemotherapy, 1603 Telomerase, telomere shortening, altered lengthening of telomeres, TERC, in situ, hybridization, DAXX, ATRX, immunohistochemistry, 3501 Telomere shortening, altered lengthening of telomeres, TERC, telomerase, in situ, hybridization, DAXX, ATRX, immunohistochemistry, 3501 Temozolomide, biomarker, PVT, cisplatin, first-line chemotherapy, BRAF, MGMT, ERCC1, 1105 Temozolomide, glioblastoma, dual anti-angiogenic chemotherapy, celecoxib, 4955 Temozolomide, glioblastoma, milk thistle, silibinin, natural compounds, 1263 Temozolomide, glioblastoma, surgery, radiotherapy, second surgery, 1743 Temozolomide-resistant subclone, co-expression, cytoskeletal protein, adducin 3, cancer stem cell marker, CD133, neurospheres, glioblastoma, NANOG, 6487 Temporin, anticancer peptides, cytotoxicity, cancer, review, 635 TERC, telomere shortening, altered lengthening of telomeres, telomerase, in situ, hybridization, DAXX, ATRX, immunohistochemistry, 3501 Tertiary cytoreduction, recurrent ovarian cancer, quaternary cytoreduction, 6951 Testicular cancer, biomarker, endogenous control, germ cell tumors, microrna, real time PCR, 117 Testicular cancer, HPV, prostate cancer, renal cell carcinoma, bladder cancer, penile cancer, review, 2513 Testicular cancer, platinum retention, cisplatin, follow-up, 1619 Testosterone, androgen-deprivation therapy, metastatic prostate cancer, obesity, prostate-specific antigen, 6925 Testosterone, castration-resistant prostate cancer, estrogen, prostate cancer-derived stromal cell, chimeric coculture, 221 Testosterone, Gleason score, prostate cancer, prostatespecific antigen, 6137 Tetrahydrocannabinol, heat shock proteins, cannabidiol, glioma, reactive oxygen species, 5827 TGF-β, long noncoding RNA, colorectal cancer, progression, prognosis, 1385 Thalidomide analogues, angiogenesis, immunotherapy, invasion, metastasis, signalling systems, review, 5767 THBS1, gastric cancer, histone deacetylase, HDAC, CD133, thrombospondin-1, 2071 Theranostic vehicle, immunoliposomes, 188 Re-DXR-IL- C225, cytotoxicity, 4777 Therapy management, adherence, adverse effects, BCR- ABL1, chronic myeloid leukemia, medication, review, 6355 Therapy response, endometrial hyperplasia, progestin therapy, PAX2, PTEN, 6401 Therapy, breast cancer, laser thermotherapy, minimally invasive treatment, thermal treatment, tumor immunology, 6147 Therapy, extraskeletal, osteosarcoma, immunohistochemistry, treatment outcome, 2129 Therapy, naftifine, multiple myeloma, lymphoma, Wnt signaling, 5921 Therapy-related myeloid neosplasm, azacitidine, outcome, safety, 461 Thermal treatment, breast cancer, laser thermotherapy, minimally invasive treatment, therapy, tumor immunology, 6147 Thiamazole antithyroid therapy, renal cell carcinoma, sunitinib, thyrotoxicosis, hypothyroidism, levothyroxine substitution therapy, 481 Thigh, solitary fibrous tumor, PET/CT, MRI, CD34, STAT6, NAB2-STAT6, 967 Thiotepa, leptomeningeal metastasis, intracerebrospinal fluid chemotherapy, methotrexate, 5631 THP-1 cell line, immunotherapy, macrophage-activating factor, phagocytic activity, U937 cell line, 4439 THP-1 cell line, immunotherapy, macrophage-activating factor, phagocytic activity, U937 cell line, 4445 Thrombocytosis, anemia, leucocytosis, prognosis, renal cell carcinoma, 3463 Thrombospondin-1, gastric cancer, histone deacetylase, HDAC, CD133, THBS1, 2071 Thymidine kinase, prognosis, lymphoma, transformation, 3019 Thymidine, hand-foot syndrome, cytidine, uridine, deoxycytidine, 5-FU, keratinocytes, 1303 Thymoma, immunohistochemistry, notch, sonic hedgehog, beta-catenin, 669 Thyroid cancer, HIF1α inhibitor, orthotopic mouse model, molecular targeted therapy, echinomycin, adjuvant chemotherapy, 2049 Thyroid cancer, nodule size, follicular neoplasms, follicular lesion of undetermined significance, thyroid malignancy, 1635 Thyroid cancer, papillary carcinoma, multinodular thyroid, nodular goitre, Hashimoto s thyroiditis, intraglandular dissemination,

168 Thyroid carcinomas, microrna, diagnostic biomarkers, risk assessment, prognosis prediction, review, 2037 Thyroid imaging, thyroid sarcoma, clinical sign, review, 5185 Thyroid malignancy, nodule size, follicular neoplasms, follicular lesion of undetermined significance, thyroid cancer, 1635 Thyroid neoplasms, thyroid nodules, biological markers, mutations, cytodiagnosis, 1237 Thyroid nodules, thyroid neoplasms, biological markers, mutations, cytodiagnosis, 1237 Thyroid sarcoma, clinical sign, thyroid imaging, review, 5185 Thyroid-stimulating hormone, hypothyroidism, regorafenib, metastatic colorectal cancer, 4059a Thyrotoxicosis, renal cell carcinoma, sunitinib, hypothyroidism, levothyroxine substitution therapy, thiamazole antithyroid therapy, 481 Thyroxine withdrawal, differentiated thyroid carcinoma, hypothyroidism, biochemical alterations, 6933 TICAM-1, tumor-associated macrophages (TAM), myeloidderived suppressor cells (MDSC), dendritic cells (DCs), Poly(I:C), Toll-like receptor 3, antitumor immunotherapy, review, 4383 Time to treatment failure, acneiform rash, minocycline, skin care, panitumumab, colorectal cancer, tumor response, 6175 Time-lapse videography, glioblastoma, hyperbaric oxygen, HBO, clonogenicity, motility, 1977 Tissue engineering, apoptosis, breast cancer, tannic acid, 1285 Tissue microarray, colorectal cancer, ROCK I, MET, immunohistochemistry, five-year survival, 3267 TKIs, CML, treatment, pregnancy, review, 1 TLG, total lesion glycolysis, 18 F-FDG PET/CT, colorectal cancer, prognostic value, 3495 TLR9, osteosarcoma, MG-63 cells, toll-like receptor, innate immunity, 5839 T-lymphocytes, breast cancer, metastases, CSF1, CSF1R, tumor-infiltrating macrophages, epithelial tumor cells, tumor stromal cells, 865 TNFR1, acute myeloid leukemia, TRAILR, FAS, death receptors, 4043 TNFα, alcohol drinking, genotype, hepatocellular carcinoma, polymorphism, smoking, 5417 TNP-470, chemoembolization, vascular heterogeneity, antiangiogenic therapy, ceramics, microsphere, drug delivery system (DDS), uterine sarcoma, carcinosarcoma, 4757 Tolerance, glioma, PCV, feasibility, 2901 Toll-like receptor 3, tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), dendritic cells (DCs), Poly(I:C), TICAM-1, antitumor immunotherapy, review, 4383 Toll-like receptor, osteosarcoma, MG-63 cells, TLR9, innate immunity, 5839 Tomotherapy, stereotactic radiosurgery, brain metastasis, 6805 Tongue cancer, celecoxib, chemotherapy, survival, 4235 Tonsillar carcinoma, human papillomavirus, tonsillitis, p16 INK4A, FANCD2, 6633 Tonsillitis, human papillomavirus, tonsillar carcinoma, p16 INK4A, FANCD2, 6633 Topoisomerase, radiosensitivity, radiosensitizers, radiotherapy, reactive oxygen species, hypoxia, review, 2479 Total gastrectomy, RGC, laparoscopic surgery, 5023 Total hysterectomy with bilateral adnexectomy, endometrial carcinoma, granulosa cell tumor of the ovary, 5547 Total lesion glycolysis, cholangiocarcinoma, distal bile duct, positron-emission tomography, prognosis, 6985 Total lesion glycolysis, TLG, 18 F-FDG PET/CT, colorectal cancer, prognostic value, 3495 Toxic effects, retrospective study, S-1, oral therapy, 977 Toxicity, 3D conformal radiotherapy, hypofractionated, prostate cancer, 3049 Toxicity, brachytherapy, cervical cancer, radiotherapy, shielding, 5567 Toxicity, carbon-ion therapy, prostate cancer, quality of life, hypofractionation, 5559 Toxicity, NSCLC, radiotherapy, esophagitis, survival, 5491 TP53 mutation, Li-Fraumeni syndrome, choroid plexus carcinoma, radiation, 3013 TP53 status, mir-7, ovarian cancer, tumour grade, EGFR, BCL2, 2423 TP53, chemotherapy toxicity, deleterious alleles, 5- fluorouracil, DPYD, OPRT, TYMS, 6971 TP53, FGFR3, urine sediment, mutation phenotype, bladder cancer, 4915 TPA, plasminogen activation system, upa, upar, PAI-1, rectal adenocarcinoma, 6009 TPA, protein kinase C, HNSCC, PEP005, diterpene, 1291 Traditional serrated adenomas, colorectal adenomas, incidence rate, invasive carcinoma, nationwide survey, Iceland, 4929 TRAIL, anaplastic thyroid carcinoma, apigenin, AKT, Bcl2, 6529 TRAILR, acute myeloid leukemia, TNFR1, FAS, death receptors, 4043 Transarterial embolization, MAT-B-III, animal model, metastasis, liver, 1333 Transbronchial biopsy, small-cell lung cancer, actinin-4, biomarker, prognosis, 1663 Transcatheter arterial chemoembolization, hepatocellular carcinoma, miriplatin, epirubicin, combination therapy, 549 Transcatheter arterial chemoembolization, hepatocellular carcinoma, miriplatin, epirubicin, combination therapy,

169 Transcription factors, curcumin; anti-cancer properties; autophagy, bioavailability, review, 645 Transcription, cell cycle, CDK inhibitor, p16, polycomb, MLL, ANRIL, review, 4395 Transcriptome sequencing/rna deep-sequencing, mitochondrion, mitochondrial DNA deficiency/ dysfunction, cancer stem cells, CSCs, cancer cell proliferation, anti-apoptosis, stemness, western blotting, RT-PCR, immunocytochemistry, 3743 Transfection, MDR, HER2, P-glycoprotein, breast cancer, BT-474, 2531 Transformation, thymidine kinase, prognosis, lymphoma, 3019 Transforming growth factor-α, hepatocyte growth factor, amphiregulin, epidermal growth factor receptor, cetuximab, colorectal cancer, 1683 Transfusion, ovarian cancer, relapse, postoperative morbidity, haemodynamic management, cytoreductive surgery, 1591 Transitional cell carcinoma, urothelial cancer, novel molecular targets, targeted therapy, review, 4557 Transmissible venereal tumors, TVT, dogs, interleukin-2, IL-2, 713 Transmissible venereal tumors, TVT, dogs, interleukin-2, IL2, vincristine, 3385 Trastuzumab (Herceptin), breast cancer, estrogen receptor (ER), HER2, EGFR, tamoxifen, fulvestrant (Faslodex), GW2974, proliferation, apoptosis, 1243 Trastuzumab, anthracyline, sequence, cardiotoxicity, 857 Trastuzumab, breast cancer, valvular regurgitation, left ventricular ejection fraction, HER2-positive, 4063 Trastuzumab, cardiac dysfunction, risk factor, hypertension, BMI, radiotherapy, 4967 Treatment algorithm, GIST, imatinib, surgery, discontinuation of treatment, cure, review, 5759 Treatment beyond progression, vascular endothelial growth factor receptor inhibitor, progressive disease, renal cell carcinoma, re-vascularization, tyrosine kinase inhibitor, 5601 Treatment breaks, induction chemotherapy, head and neck cancer, concomitant chemo-radiation, intensity-modulated radiotherapy, 6247 Treatment optimization, colorectal cancer, stereotactic radiosurgery, cerebral oligo-metastases, survival, predictive tool, 5515 Treatment options, relapsed/refractory multiple myeloma, cyclophosphamide, dexamethasone, old drugs, case report, 2165 Treatment outcome, extraskeletal, osteosarcoma, immunohistochemistry, therapy, 2129 Treatment planning, pulsed brachytherapy, optimization, radiobiology, HIPO, 6091 Treatment response, melanoma, biomarkers, prognosis, 6755 Treatment results, elderly patients, cerebral metastases, stereotactic radiosurgery, optimal dose, 5701 Treatment, cancer of unknown primary, pregnancy, prognosis, placental in-vasion, review, 575 Treatment, CML, pregnancy, TKIs, review, 1 Treatment, DNA methylation, breast cancer, CpG islands, biomarkers, review, 4569 Treatment, meningioma, nanomedicine, surgery, targeted therapies, review, 6391 Treosulfan, ovarian cancer, elderly, non-interventional study, 6869 Triage, biopsy, colposcopy, genotyping, human papillomavirus, 4197 Trichloroethylene, kidney cancer, mortality, incidence, 4009 Trifluoroacetyl, multidrug resistance, phosphorus ylide, ABCB1, P-glycoprotein, mouse T-lymphoma, 5915 TRIM, blood transfusion, colorectal cancer, immunosenescence, 3553 Triple-negative breast cancer, breast cancer, vitamin D, 25- hydroxyvitamin D, CYP24A1, CYP27B1, vitamin D receptor, 805 Triple-negative breast cancer, neoadjuvant chemotherapy, pathological complete response, pcr, residual disease, prognostic impact, 5479 Triple-negative, breast cancer, neoadjuvant chemotherapy, docetaxel, cyclophosphamide, predictive factor, 907 Trolox, artemisinin, sodium ascorbate, vitamin D 3, dexamethasone, hydrogen peroxide, Molt-4 cells, 1867 TS, peripheral blood, biomarker, prospective, DPD, survival, esophageal cancer, neoadjuvant, 1297 TSGH8301 human bladder cancer cells, cantharidin, DNA damage, Comet assay, DNA repair, 795 TSU-68, hepatocellular carcinoma, platelet-derived growth factors, 1423 Tumor angiogenesis, anginex, galectin-1, cancer, indium- 111, 5945 Tumor budding, oral squamous cell carcinoma, EMT, CSC, prognosis, 6111 Tumor burden, sentinel lymph node, melanoma, 301 Tumor cells, prodigiosin, genotoxicity, micronucleus, 3325 Tumor cellularity, meningioma, ADC, Ki-67, nucleic area, 6841 Tumor front, gene-expression profiling, colon cancer, chemokines, epithelial mesenchymal transition, microarray, 6577 Tumor grade, HER2, gastric cancer, prognosis, 2441 Tumor grade, hypoxia inducible factor, clear cell renal cell carcinoma, tumor stage, overall survival, 433 Tumor grading, brain tumors, proliferation activity, PET/CT, fluorothymidine, 955 Tumor growth, KISS1, KISS1R, Kisspeptin, local metastasis, invasion, differentiated thyroid cancer, 819 Tumor hypoxia, unfolded protein response, acute lymphoblastic leukemia, WNT growth factors, ERassociated degradation,

170 Tumor immunity, CD155, prognostic factor, pancreatic cancer, angiogenesis, 2287 Tumor immunity, colorectal cancer, HVEM, prognosis, surgery, 1361 Tumor immunity, MDSC, lung metastasis, 5-FU, primary resection, 4423 Tumor immunology, breast cancer, laser thermotherapy, minimally invasive treatment, thermal treatment, therapy, 6147 Tumor immunology, lewis rat sarcoma, CD11b+ cells, neutrophils, CCL2, 703 Tumor invasion, colorectal cancer, immunohistochemistry, phosphati dylserine-specific phospholipase A1, metastasis, 1459 Tumor M2-pyruvate kinase, cancer type, tumor size, nodal metastases, distant metastases, tumor stage, 4271 Tumor marker, hepatocellular carcinoma (HCC), alphafetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), des-γ-carboxyprothrombin (DCP), 2157 Tumor marker, urinary bladder cancer, UBC Rapid Test, 2651 Tumor markers, head and neck cancer, clinical utility, 5519 Tumor markers, magnetic resonance imaging (MRI), diffusion-weighted imaging (DWI), biparameric MRI (Bp- MRI), CA125, HE4, ovarian tumors characterization, pelvic mass, 6341 Tumor microcirculation, anti-angiogenic therapy, ZD6474, contrast enhanced ultrasound, vessel density, angiogenesis, imaging, 2571 Tumor microenvironment, cancer-associated fibroblasts, blood vessels, liver metastasis, RFP, fluorescence, colorcoded imaging, 5821 Tumor model, sonic hedgehog (SHH), lung cancer, YangZheng XiaoJi, cellular migration, invasion, cyclopamine, Smo, Gli, 1321 Tumor progression, Astragalus membranaceus, Curcuma wenyujin, ovarian cancer, red fluorescent protein, orthotopic, nude mice, metastasis, 3193 Tumor progression, SOX2, HSPB1, HSF1, 3217 Tumor recurrence, hepatocellular carcinoma, liver cirrhosis, percutaneous ethanol injection, radiofrequency ablation, overall survival, 325 Tumor resection, breast cancer, Balb-c mice, syngeneic, orthotopic, metastasis, RFP, imaging, 4641 Tumor response, acneiform rash, minocycline, skin care, panitumumab, colorectal cancer, time to treatment failure, 6175 Tumor selectivity, 3-styryl-2H-chromenes, QSAR analysis, cytotoxicity, anti-hiv activity, 5299 Tumor selectivity, oleoylamides, QSAR analysis, cytotoxicity, anti-hiv activity, 5341 Tumor size, colorectal cancer, oxaliplatin, adjuvant chemotherapy, recurrence, 5073 Tumor size, gastric gastrointestinal stromal tumor, post - operative sequelae, 2341 Tumor size, lymphatic invasion, breast cancer, lymph node metastasis, sentinel node, 3581 Tumor size, tumor M2-pyruvate kinase, cancer type, nodal metastases, distant metastases, tumor stage, 4271 Tumor stage, hypoxia inducible factor, clear cell renal cell carcinoma, tumor grade, overall survival, 433 Tumor stage, PCA3, phi, sarcosine, tumor volume, Gleason score, 1017 Tumor stage, tumor M2-pyruvate kinase, cancer type, tumor size, nodal metastases, distant metastases, 4271 Tumor stromal cells, breast cancer, metastases, CSF1, CSF1R, tumor-infiltrating macrophages, T-lymphocytes, epithelial tumor cells, 865 Tumor suppressor, prostate stem cell antigen, GPI-anchored protein, intracellular signaling, gallbladder cancer, 2619 Tumor targeting, Salmonella typhimurium A1-R, GFP, RFP, prostate cancer, cell line, PC-3, LNCaP, DU-145, apoptosis, necrosis, cell burst, 5225 Tumor volume, PCA3, phi, sarcosine, Gleason score, tumor stage, 1017 Tumor, Pd(II) complex, EAC, in vivo, PCNA, apoptosis, 1491 Tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), dendritic cells (DCs), Poly(I:C), Toll-like receptor 3, TICAM-1, antitumor immunotherapy, review, 4383 Tumorigenesis, melanotransferrin, colorectal carcinoma, poorly differentiated adenocarcinoma, pathogenesis, adenoma carcinoma sequence, 6551 Tumorigenesis, VAV3, VAV3.1, mrna, OSCC, 2593 Tumor-infiltrating lymphocytes, prognostic marker, prognosis, malignant melanoma, 351 Tumor-infiltrating macrophages, breast cancer, metastases, CSF1, CSF1R, T-lymphocytes, epithelial tumor cells, tumor stromal cells, 865 Tumor-infiltrating neutrophils, gastric adenocarcinoma, Cancer Registry Study, Messina province, 487 Tumors, combretastatin, monocytes, neutrophils, 2559 Tumour aggressiveness, squamous cell carcinoma, skin, organ transplantation, immunosuppression, pathology, 2305 Tumour cells, photosensitizer, phthalocyanine, photodynamic treatment, oxidative stress, cellular damage, phototoxicity, 3943 Tumour grade, mir-7, ovarian cancer, TP53 status, EGFR, BCL2, 2423 Tumour microenvironment, fibroblasts, stromal fibroblasts, proliferating fibroblasts, HeLa, cell-cell interactions, coculture, cell affinity, desmoplasia, apoptosis, nuclear abnormalities, G 2 -M phase, multi-nucleated cells, nonspecific esterases (NSE), silver staining, carmine labeling, Ki-67, E-cadherin, dihydrofolate reductase (DHFR), lipids,

171 Tumour-supernatants, chemotherapy, murine model, GM- CSF, 1499 Tunable filter, GFP, RFP, nude mice, human tumors, metastasis, imaging, noninvasive, variable magnification, subcellular in vivo imaging, spectral separation, 661 TVT, transmissible venereal tumors, dogs, Interleukin-2, IL- 2, 713 TVT, transmissible venereal tumors, dogs, interleukin-2, IL2, vincristine, 3385 TWIST, pituitary adenoma, EMT, N-cadherin, E-cadherin, SLUG, SNA1, 2635 TWIST, SLUG, EMT, breast cancer, epithelial-mesenchymal transition, 3961 TYMS, chemotherapy toxicity, deleterious alleles, 5- fluorouracil, DPYD, OPRT, TP53, 6971 Type I endometrial carcinoma, p-mapk, p-akt, p-mtor, clinicopathological factors, prognosis, 2321 Type IV gastric cancer, survival, chemotherapy, 897 Tyrosine kinase inhibitor, hepatocellular carcinoma, molecular-targeted therapy, sorafenib, review, 5737 Tyrosine kinase inhibitor, metastatic renal cell carcinoma, first-line, second-line, objective response, progression-free survival, 3067 Tyrosine kinase inhibitor, PTEN, VEGFR, head and neck squamous cell carcinoma, everolimus, sorafenib, sunitinib, 1389 Tyrosine kinase inhibitor, vascular endothelial growth factor receptor inhibitor, progressive disease, renal cell carcinoma, treatment beyond progression, revascularization, 5601 Tyrosine kinase inhibitors, NSCLC, brain metastases, review, 5797 Tyrosine kinase inhibitors, NSCLC, novel therapies, monoclonal antibodies, clinical trials, review, 2503 Tyrosin-kinase-inhibitor, mtor, AREG, head and neck squamous cell carcinoma, everolimus, sorafenib, sunitinib, 1951 U2AF1, myelodysplastic syndrome, SRSF2, ZRSR2, decitabine, 3081 U937 cell line, immunotherapy, macrophage-activating factor, phagocytic activity, THP-1 cell line, 4439 U937 cell line, immunotherapy, macrophage-activating factor, phagocytic activity, THP-1 cell line, 4445 UBC Rapid Test, urinary bladder cancer, tumor marker, 2651 Ubiquitination, PIN1, SGK1, RAF1, tamoxifen resistance, breast cancer, 785 Ubiquitin-proteasome system, proteasome inhibitor, PML RARA, ER stress, 3307 UDP-glucose, L1210 cells, P-glycoprotein, glucosylceramide synthase, ceramide induced cell death, 2627 UHRF1, astrocytoma, CD47, NF-ĸB, 149 UICC, hepatocellular carcinoma, stage, surgery, 2921 Unfolded protein response, tumor hypoxia, acute lymphoblastic leukemia, WNT growth factors, ER-associated degradation, 4625 Unilateral neck, head and neck cancer, volumetric arc techniques, helical IMRT, dosimetric comparison, 2991 Unplanned excision, soft tissue sarcoma, hyperthermotherapy, chemotherapy, surgery, 493 Unresectable case, small bowel adenocarcinoma, curative surgery, definitive chemotherapy, recurrent tumor resection, distant metastasis, 4135 Unresectable gastric cancer, conversion surgery, recurrence, 6183 Unresectable, colorectal cancer, prognosis, neutrophil to lymphocyte ratio, C-reactive protein, Glasgow prognostic score, 5037 Unresectable, hypofractionated radiotherapy, non-small cell lung cancer, advanced stage, image-guidance, 5693 UPA, lysophosphatidic acid, upar, ovarian, PI3K, 5263 UPA, plasminogen activation system, upar, PAI-1, tpa, rectal adenocarcinoma, 6009 UPAR, lysophosphatidic acid, ovarian, upa, PI3K, 5263 UPAR, plasminogen activation system, upa, PAI-1, tpa, rectal adenocarcinoma, 6009 Upper tract urothelial cancer, COX2, genotype, polymorphism, Taiwan, 2725 Upper urinary tract, urothelial carcinoma, cancer-specific survival, gender; age at diagnosis, 4277 Ureteral metastasis, prostate cancer, abiraterone acetate, 6317 Ureteral reimplantation, locally invasive cervical cancer, distal ureterectomy, 5539 Uridine, hand-foot syndrome, cytidine, thymidine, deoxycytidine, 5-FU, keratinocytes, 1303 Urinary bladder cancer, UBC Rapid Test, tumor marker, 2651 Urinary tract, colorectal neoplasms, peritoneal neoplasms, intraperitoneal chemotherapy, hyperthermia, postoperative complications, prognosis, 295 Urine sediment, TP53, FGFR3, mutation phenotype, bladder cancer, 4915 Urothelial cancer, transitional cell carcinoma, novel molecular targets, targeted therapy, review, 4557 Urothelial carcinoma, tegafur-uracil, chemotherapy, 1603 Urothelial carcinoma, upper urinary tract, cancer-specific survival, gender; age at diagnosis, 4277 Usual interstitial pneumonia, chemotherapy-related exacerbation, interstitial lung disease, small cell lung cancer, 6261 Uterine cancer, EC, obesity, lymphovascular invasion, grade, body mass index, 4053 Uterine carcinosarcoma, azaspirene, anti-angiogenic therapy, 2739 Uterine carcinosarcoma, chemotherapy, carboplatin, ifosfamide, mesna,

172 Uterine cervix, cervical cancer, para-aortic lymph node metastasis, radiation therapy, squamous cell carcinoma, 4849 Uterine leiomyosarcoma, LMP2, IRF1, IFN-γ, smooth muscle cell, 4665 Uterine leiomyosarcomas, complete resection, recurrence, 2229 Uterine sarcoma, chemoembolization, vascular heterogeneity, anti-angiogenic therapy, ceramics, microsphere, drug delivery system (DDS), TNP-470, carcinosarcoma, 4757 Uterine smooth muscle tumors, STUMP, leiomyosarcoma, 6445 Uterine, radiotherapy, sarcoma, 365 UTX, JMJD3, epigenetic, histone modification, xenograft analysis, cancer treatment, 6611 Vaccine, cytokine, chemoimmunotherapy, dendritic cell, MHC class II, pancreatic cancer, WT1, 555 Valvular regurgitation, breast cancer, left ventricular ejection fraction, HER2-positive, trastuzumab, 4063 Vanilloids, N-acyl dopamine, metabolites, cancer, cytotoxicity, 2657 Variable magnification, GFP, RFP, nude mice, human tumors, metastasis, imaging, noninvasive, subcellular in vivo imaging, spectral separation, tunable filter, 661 Vascular attachment, colorectal cancer, liver metastases, hepatectomy, vascular invasion, 5485 Vascular endothelial growth factor receptor (VEGFR), renal cell cancer (RCC), CD-31, prognostic factor, 921 Vascular endothelial growth factor receptor inhibitor, progressive disease, renal cell carcinoma, treatment beyond progression, re-vascularization, tyrosine kinase inhibitor, 5601 Vascular endothelial growth factor receptor, angiogenesis, Artemisia annua, artemisinin, cancer, molecu lar docking, quantitative structure-activity relationship calcula tions, QSAR, 1929 Vascular endothelial growth factor, angiogenesis, bortezomib, immunomodulatory drugs, plasma cell myeloma, 1085 Vascular endothelial growth factor, epidermal growth factor receptor, basic fibroblastic growth factor, neurofibromatosis type 1, vessel density, malignant peripheral nerve sheath tumor, 137 Vascular endothelial growth factor, pleomorphic carcinoma, angiogenesis, immun ohistochemistry, hypoxia-inducible factor-1α, 389 Vascular heterogeneity, chemoembolization, antiangiogenic therapy, ceramics, microsphere, drug delivery system (DDS), TNP-470, uterine sarcoma, carcinosarcoma, 4757 Vascular invasion, colorectal cancer, liver metastases, hepatectomy, vascular attachment, 5485 Vascular invasion, hepatocellular carcinoma (HCC), apolipoprotein B mrna editing enzyme, catalytic polypeptide-like 3B (APOBEC3B), Hep 3B, 1521 Vascular invasion, pancreatic cancer, pancreatoduodenectomy, superior mesenteric artery resection, portal vein resection, re-implantation, 1613 Vasculature, endothelial cells, culture, brain tumor, HUVEC, 2681 VATS, T2 and T3, non-small cell lung cancer, 3585 VAV3, VAV3.1, tumorigenesis, mrna, OSCC, 2593 VAV3.1, VAV3, tumorigenesis, mrna, OSCC, 2593 VEGF, advanced HCC, intra-arterial chemotherapy, liver cirrhosis, 2205 VEGF, angiogenesis, non-small cell lung cancer, pleural fluid, serum, 1129 VEGF, hepatoma-derived growth factor, hepatocellular carcinoma, targeted therapy, xenograft model, angiogenesis, 6475 VEGF, HIF1Α, CAIX, MCF-7 cells, MDA-MB-231 cells, xenografts, microtubule disruptor, anti-angiogenic, 5249 VEGF, survivin, AKT, microvessel density, oral melanoma, prognostic factor, 2113 VEGFR, tyrosine kinase inhibitor, PTEN, head and neck squamous cell carcinoma, everolimus, sorafenib, sunitinib, 1389 Verapamil, phenothiazines, multidrug resistance, MDR, P-glycoprotein (ABCB1), rhodamine 123, colon adenocarcinoma, apoptosis, doxorubicin, 3245 Vesicular stomatitis virus, memory T-cells, immunotherapy, cyclophosphamide, 4593 Vessel density, anti-angiogenic therapy, ZD6474, contrast enhanced ultrasound, tumor microcirculation, angiogenesis, imaging, 2571 Vessel density, blood vessels, lymphatic vessels, NF1, NF2, schwannomatosis, schwannoma, neurofibromatosis, mast cell, MPNST, 4713 Vessel density, epidermal growth factor receptor, vascular endothelial growth factor, basic fibroblastic growth factor, neurofibromatosis type 1, malignant peripheral nerve sheath tumor, 137 Vessel density, nerve fibre density, blood vessels, lymphatic vessels, NF1, neurofibroma, neurofibromatosis, vessel innervation, 6509 Vessel innervation, nerve fibre density, vessel density, blood vessels, lymphatic vessels, NF1, neurofibroma, neurofibromatosis, 6509 Viability, natural killer cells, natural killer cell subsets, irradiation, cytotoxicity, radiobiological models, enrichment methods, 5193 Vinblastine, GFP, histone H2B, fusion gene, RFP, imaging, paclitaxel, nuclear fragmentation, apoptosis, DNA fragmentation, real-time, imaging,

173 Vincristine, transmissible venereal tumors, TVT, dogs, interleukin-2, IL2, 3385 Vinorelbine, acute exacerbation, cisplatin, interstitial pneumonia, non-small cell lung cancer, 1697 Vinorelbine, biomarkers, malignant mesothelioma, chemotherapy, 6731 Vinorelbine, microtubule, microtubule destabilizer, eribulin, paclitaxel, docetaxel, ixabepilone, 5845 Virotherapy, melanoma, oncolytic viruses, Newcastle disease virus, 5401 Vitamin D deficiency, vitamin D, bone metastases, bone tumor, bone cancer, 6281 Vitamin D insufficiency, genome-wide research, vitamin D receptor, 1, 25(OH)2D3, ChIP-seq, review, 1143 Vitamin D metabolites, assay development, stereoselective synthesis, 1205 Vitamin D receptor, breast cancer, triple-negative breast cancer, vitamin D, 25-hydroxyvitamin D, CYP24A1, CYP27B1, 805 Vitamin D receptor, SNP, prostate cancer, African-American, clinical phenotype, 1549 Vitamin D receptor, vitamin D insufficiency, genome-wide research, 1, 25(OH)2D3, ChIP-seq, review, 1143 Vitamin D, breast cancer, case-control study, colorectal adenoma, colorectal cancer, nested case-control study, 1153 Vitamin D, breast cancer, triple-negative breast cancer, 25- hydroxyvitamin D, CYP24A1, CYP27B1, vitamin D receptor, 805 Vitamin D, celecoxib, cyclooxygenase-2, breast cancer, 1189 Vitamin D, celecoxib, cyclooxygenase-2, ovarian cancer, 1197 Vitamin D, chronic kidney disease, CKD, dialysis, ESRD, renal replacement therapy (RRT), cancer, epidemiology, CKD-MBD, mineral and bone disease, 1181 Vitamin D, LNCaP, CYP27B1, 3773 Vitamin D, preventive medicine, cancer, epidemiology, 25(OH)D, review, 1161 Vitamin D, vitamin D deficiency, bone metastases, bone tumor, bone cancer, 6281 Vitamin D, β-catenin, PAK1, p53, Ki67, malignant and benign colon tumors, 1513 Vitamin D 3, artemisinin, sodium ascorbate, Trolox, dexamethasone, hydrogen peroxide, Molt-4 cells, 1867 Vitamin D 3, ketogenic diet, breast cancer, 5525 Vitamin E, Selenium exposure, prostate cancer risk, smoking status, 4983 Vitamin K 3, vitamin K 5, human T-lymphoblastoid leukemia, daunorubicin resistance, P-glycoprotein, apoptosis, 6041 Vitamin K 5, vitamin K 3, human T-lymphoblastoid leukemia, daunorubicin resistance, P-glycoprotein, apoptosis, 6041 Vitronectin, α v β 3 integrin, glycosylation, melanoma, migration, 2093 VMAT, endometrial cancer, SIB, gynecological cancer, 2149 Voice quality, glottic cancer, radiotherapy, 4155 Volcanic carcinogens, cancer incidence, volcanic environment, cancer epidemiology, Mt. Etna pollution, 3995 Volcanic environment, cancer incidence, volcanic varcinogens, vancer epidemiology, Mt. Etna pollution, 3995 Volumetric arc techniques, head and neck cancer, unilateral neck, helical IMRT, dosimetric comparison, 2991 Vorinostat, histone deacetylation, HDAC inhibitor, PAT- 1102, 229 Vorinostat, PBA, p38 MAPK, JNK, gap junction, 775 VX2, HepG2, chemosensitivity, chemotherapy, TACE, HCC, 6497 Warburg effect, HLRCC, fumarate hydratase gene, PRCC2, bortezomib, 6639 Warburg effect, PDHE1α, esophageal squamous cell carcinoma, immunohistochemistry, overall survival, 5533 WEHI-3, acute promyelocytic leukemia, all-trans retinoic acid, differentiation, oleanolic acid, 6583 Well-differentiated liposarcoma, dedifferentiated liposarcoma, ring chromosome, MDM2, CDK4, 345 Well-differentiated liposarcoma, lipoma, dedifferentiated liposarcoma, pleomorphic liposarcoma, multiplex ligationdependent probe amplification, 12q amplicon, 1835 Western blotting, mitochondrion, mitochondrial DNA deficiency/ dysfunction, transcriptome sequencing/rna deep-sequencing, cancer stem cells, CSCs, cancer cell proliferation, anti-apoptosis, stemness, RT-PCR, immunocytochemistry, 3743 WHO classification, meningioma, recurrent brain tumor, meningeal neoplasm, human, 3559 Whole brain radiotherapy, brain oligometastases, fractionation, stereotactic radiotherapy, RPA, 3055 Wilms tumor gene (WT1), HLA-DRB1*04:05, HLA class II, helper peptide, TCR gene therapy, 1251 WIN55, cannabinoids, 212-2, breast, cancer, micelle(s), nanoparticle(s), nano-micelle, 4707 WNT growth factors, unfolded protein response, tumor hypoxia, acute lymphoblastic leukemia, ER-associated degradation, 4625 Wnt pathway, curcumin, cancer stem cells, interleukin-6, interleukin-8, interleukin-1, CXCR1, CXCR2, Notch pathway, Hedgehog pathway, FAK pathway, review, 599 Wnt signaling, naftifine, multiple myeloma, lymphoma, therapy, 5921 WNT, cinnarizine, multiple myeloma, lymphoma, cancer therapy, 835 WNT, flunarizine, multiple myeloma, lymphoma, cancer therapy, pathway, 1369 Wnt, β-catenin, colorectal cancer, 4401 WT1, cytokine, chemoimmunotherapy, dendritic cell, MHC class II, pancreatic cancer, vaccine,

174 XCT, CD44v6, CRC, immunohistochemistry, colorectal cancer, recurrence, 677 XELIRI, bevacizumab, FOLFIRI, colorectal cancer, 3455 Xenograft analysis, JMJD3, UTX, epigenetic, histone modification, cancer treatment, 6611 Xenograft model, hepatoma-derived growth factor, hepatocellular carcinoma, targeted therapy, VEGF, angiogenesis, 6475 Xenografts, HIF1Α, CAIX, VEGF, MCF-7 cells, MDA- MB-231 cells, microtubule disruptor, anti-angiogenic, 5249 XPD, alcohol consumption, gastric cancer, genotype, polymorphism, smoking, 4975 XRCC1, MTHFR, EGFR, cancer, population stratifica tion, ancestry, 2009 XRCC3, gender, genotype, lung cancer, polymorphism, smoking, Taiwan, 3893 XRCC3, genotype, leiomyoma, polymorphism, Taiwan, 4691 YangZheng XiaoJi, sonic hedgehog (SHH), lung cancer, tumor model, cellular migration, invasion, cyclopamine, Smo, Gli, 1321 YB-1, cyclin A, ovarian cancer, chemotherapy, progression, 1715 Yes-associated protein, β-catenin, carcinogenesis, adenocarcinoma, signet-ring cell carcinoma, gastric neoplasia, 3925 Yolk sac tumor, ovarian germ cell, postmenopausal, α- fetoprotein, 6713 ZD6474, anti-angiogenic therapy, contrast enhanced ultrasound, veassel density, tumor microcirculation, angiogenesis, imaging, 2571 Zfat, FoxO1, proteasomal degradation, IL-7Rα, T-cell homeostasis, 4417 Zinc, CTLA4, CD28, polymorphism, lipid hydroperoxide (LHP) malon dialdehyde (MDA), advanced oxidation protein products (AOPP), protein carbonyl (PCO), superoxide dismutase, advanced glycation end-products (AGEs), copper, 5391 Zinc, melanoma, apoptosis, reactive oxygen species, FAS ligand, p53, 5309 Zoledronic acid, nephrotoxicity, ibandronate, breast cancer, metastases, 1797 ZRSR2, myelodysplastic syndrome, SRSF2, U2AF1, decitabine, 3081 Α1-adrenergic receptors, medullary thyroid carcinoma, cell culture, quinazolines, prazosin, apoptosis, 31 Α-fetoprotein, yolk sac tumor, ovarian germ cell, postmenopausal, 6713 A v β 3 integrin, glycosylation, melanoma, migration, vitronectin, 2093 Β-catenin, anaplastic thyroid carcinoma, 17-AAG, herbimycin A, HSP90, AKT, FRO cells, 5453 Β-catenin, duodenum adenomas, adenomas, cytoplasmic helices, 1433 Β-catenin, gefitinib, lapatinib, MMP9, cyclin D1, epithelial growth factor receptor (EGFR), head and neck squamous cancer cells (HNSCC), epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition (MET), human papillomavirus (HPV), 3801 Β-catenin, lymphangioleiomyomatosis, E-cadherin, podoplanin, EGFR, 3353 Β-catenin, serrated polyps, colon, rectum, conventional adenomas, 929 Β-catenin, vitamin D, PAK1, p53, Ki67, malignant and benign colon tumors, 1513 Β-catenin, Wnt, colorectal cancer, 4401 Β-catenin, yes-associated protein, carcinogenesis, adenocarcinoma, signet-ring cell carcinoma, gastric neoplasia, 3925 Οesophageal cancer, neoajuvant radiochemotherapy, RapidArc,

175 Authors Index (Figures refer to page numbers) Aaaltomaa S, 6465 Abazza H, 1763 Abbas M, 1549, 3811 Abboud K, 4997 Abe T, 6747 Abo T, 1073 Abrams MJ, 6901 Abreo F, 6411 Absenger M, 31 Acar L, 255 Adam ML, 3325 Adamczyk A, 1041, 4063 Adamietz IA, 1977 Adamovic T, 3155 Adams K, 2345 Adams RA, 1291 Addario WP, 3995 Aderhold C, 1389, 1951, 3801 Adinolfi B, 3781 Adios PC, 2817 Adonakis G, 2321 Adwall L, 2493 Afshar M, 1057 Agaimy A, 5717 Agarwal S, 3787 Aggarwal C, 3007 Agolli L, 1783, 5693, 6239 Aguiar P, 569 Agustí J, 439 Ahaghotu CA, 2565 Ahmed A, 2601 Ahmed S, 5973 Ahmetaj H, 1513 Ahn J-C, 3901 Ahn J-O, 159, 4749 Ahn J-S, 3235 Ahn S-H, 2049 Ahn Y-O, 175 Ai D, 5461 Aigner B, 4821 Aikawa V, 3007 Airoldi M, 6247 Aishima S, 2441, 2475, 2867 Aisu N, 4881 Aizawa M, 2739 Aizawa M, 4757 Aizawa N, 6475 Akada J, 3217, 3861 Akagi Y, 4403 Akahori T, 2287 Akahoshi K, 2341 Akamine T, 4037 Akanuma N, 1353 Akashi K, 371 Akazawa T, 6747 Akervall J, 5973 Akgun-Dar K, 1491 Akiba S, 6633 Akiba T, 3489 Akimori T, 6201 Akimov MG, 2657 Akin S, 857 Akinboye E, 4723 Akiyama H, 5201, 6855 Akiyoshi S, 123 Akladios C, 4183, 5503 Ako-Nai KA, 1453 Aksnes L, 1171 Aksoy S, 857 Akutsu Y, 1353 Alakus H, 6153 Al-Alloosh F, 1057 Alanee S, 4009, 4145, 5575 Alberts L, 6773 Albicini F, 739 Alemany L, 851 Alexiou C, 5717 Alexopoulou Z, 4023 Alfieri S, 3441 Alhosin M, 149 Ali A, 775 Alkaade S, 2121 Allen JC, 1211 Alley E, 3007 Allonca-Campa E, 2949 Al-Muderis O, 473 Almuheimid J, 3423 Alongi F, 2149 Al-Qurayshi ZH, 1635 Al-Shawarby M, 2601 Alston-Mills BP, 1211 Al-Tamimi D, 2601 Altan B, 2411 Altayyar M, 5889 Altinkilic EM, 6057 Altundag K, 857 Álvarez I, 6941 Álvarez-Ruiz E, 6291 Amabile M-I, 4229 Amano R, 5037, 5369 Amano S, 4509 Amaral L, 3245 Amatruda TT, 301 Ambicka A, 4063 Ambrosio MR, 5595 Amemiya Y, 2601 Ammendola R, 2769 Ammon A, 6869 Anastasi E, 6341 Anckaert E, 6893 Andergassen U, 5679 Anders M, 5333 Andersen M, 6223 Anderson BM, 365 Ando K, 401, 407, 511, 2299, 2441, 4037, 5023, 6207 Andratschke M, 3953, 6517 Andre F, 5179 André P, 149 Angeli F, 1881 Angeloni A, 6341 Angelopoulou K, 2715 Angelou A, 19 Angelov K, 5027 Anghel C, 1613 Anikin V, 2823 Anile C, 3055 Ankem MK, 5773 Annamalai P, 229 Annappan M, 283 Anner P, 6787 Annoscia S, 4177 Anthony L, 3175 Antoniou E, 19 Antoniozzi A, 2211 Anwar MS, 5567 Anyoji N, 4411 Aoishi Y, 2669 Aoki D, 2247 Aoki H, 4647 Aoki I, 6623 Aoki J, 1459 Aoki K, 5201 Aoki M, 967 Aoki R, 1065 Aoyagi T, 2375, 6781 Aoyagi Y, 6909 Aoyama N, 1251 Aoyama T, 2401, 4865 Aprile C, 6439 Aprile G, 2391 Arahata K, 6765 Arai D, 261 Arai J, 1073 Arai Y, 6861 Araki T, 2849, 4633, 5639 Araújo TMT, 1465 Aravidis C, 3155 Arbion F, 581 Arcangeli S, 3049 Arczyńska K, 3317 Arenberger P, 6303 Arfaoui A, 1763 Arias JI, 569 Arigami T, 2279, 2941, 6471 Arik Z, 857 Arikan S, 255, 2709, 5391 Arita S, 371 Ariyama H, 371 Armosini V, 4171 Arnau A, 5655 Arndt C, 2651 Arnes M, 6401 Arnold LA, 6001 Arola J, 3767 Arronson A C, 3019 Arsenic R, 5867, 6329 Arzuman L, 2783, 6027 Asada M, 1997 Asahina Y, 1423 Asai K, 3447, 3591, 4083, 4909 Asai S, 3379 Asai-Sato M, 4849 Asaka S, 2969 Asanoma K, 5993 Asanuma H, 413 Asciutto KC, 913 Ascolese AM, 4109 Asenov Y, 5027 Ashkan K, 77 Asklund T, 5491 Aslam R, 1237 Aslam S,

176 Aso T, 6819 Assumpção PP, 2009 Astudillo A, 6291 Athanassiou-Papaefthymiou M, 1861 Atsuda K, 2909 Attramadal CG, 6111 Attygalle A, 6713 Augello G, 2577 Augustin L, 843 Ausawasamrit A, 2827 Autorino R, 3055 Autran D, 2901 Avadanei RE, 5325 Avallone A, 2391 Averous G, 4183 Avram S, 6521 Ayari F, 1763 Aydin S, 5391 Azario L, 3055 Azuma Y, 2411 Azzato EM, 3007 Baba E, 371 Baba H, 1583, 1647, 2157, 2359, 2867, 3033, 4617 Baba K, 6471 Baba S, 3289 Baba T, 4259 Baba Y, 2359, 3033, 4617 Babacan T, 857 Babuska V, 3537 Bacalbasa N, 1613, 2169, 2229, 2315, 3405, 3519, 4099, 4125, 4877, 5097, 5539, 5543, 5547, 5649, 6877, 6913, 6919 Baccini P, 2369 Bach D, 1181 Bachmann C, 3479 Bachmann R, 3479 Bacopulos S, 2601 Badakhshi H, 2991 Badellino S, 4155 Badisa V, 653 Bae SH, 3531 Baek JH, 3531 Baek SY, 1333 Bafaloukos D, 1105, 4023 Bahar M, 3013 Bahia MDO, 1465 Bahoric B, 2893 Bairey O, 2861 Bajrovic A, 5701 Baka S, 1675 Bakalova R, 6623 Bakarakos P, 5141 Bakare O, 4723 Bakrin N, 4997 Balafouta M, 1771 Balcet V, 4155 Baldauf J-J, 4183, 5503 Baldó X, 4871 Balducci M, 3055, 3441 Balescu I, 1613, 2169, 2229, 2315, 3405, 3519, 4099, 4125, 4877, 5097, 5539, 5543, 5547, 5649, 6877, 6913, 6919 Balestrini D, 5581 Balica AR, 759, 5325 Balks T, 117 Ballesio L, 6341 Ballesteros AI, 6941 Balm AJM, 4015 Bamji ZD, 4723 Ban H, 5231 Ban M, 4161 Banaszczyk M, 2759 Banerjee S, 6713 Bang S-M, 5631 Banik NL, 615 Banks M, 3773 Banno E, 2005 Banno K, 2247 Bar Yosef A, 1591 Barak V, 3019, 5519, 6755 Barbare J-C, 1803 Barber J, 5615 Barbieri G, 2577 Barbu I, 1613 Barget N, 1803 Baro V, 6311 Baron B, 1941, 6063 Barone A, 5595 Barresi V, 6391 Barrie M, 2901 Bartolini S, 1743 Bartolotti M, 1743 Bartozzi B, 5309 Bartscht T, 4105, 5515 Baschnagel AM, 5973 Bassarova A, 5027 Basso SMM, 3563 Basso U, 543 Bastug Y, 6057 Batanian J, 2121 Bátor J, 5401 Battista S, 4109 Baturaite Z, 1171 Bau D-T, 191, 1735, 2725, 3893, 4691, 4975, 5417, 6297 Bauer G, 5927, 5955 Baulon E, 4183 Baurain JF, 6893 Bautmans I, 1481 Baxa J, 955, 2241 Baylatry M, 6497 Beale P, 2783, 6027 Bech C, 6731 Beck JT, 1567 Becker M, 6869 Becker S, 2999 Becker T, 2961 Beckhove P, 2681 Bédard ELR, 1873 Bednarek W, 1715 Bedouet L, 6497 Beer C, 137 Beheshti M, 6787 Behrendt C-A, 6509 Bektic J, 3567 Belge G, 117 Ben Chaaben A, 1763 Bendlova B, 2029 Benhaim L, 4943 Benson C, 473, 6213 Benson J, 3175 Bentivegna E, 4229, 6105 Beppu T, 1583, 1647, 2157, 2359, 3033 Bequet C, 2901 Ber S, 2055 Bereder JM, 4997 Bergamo F, 2391 Bergenthal J, 1297 Berglund A, 3979 Bergman I, 4593 Bergos C, 5655 Bergqvist M, 2493, 3979, 5491 Bergström S, 2493, 3979, 5491 Bergueiro A, 851 Bermejo JL, 5085 Bernard L, 2893 Bernard V, 2055 Bernardi D, 1205 Bernardini G, 5309 Bernardo S, 6341 Berner A, 2129 Berner K, 2129 Bernocchi G, 739 Berr F, 4697 Berrebi A, 2861 Berretta M, 2391 Bertoni F, 6805 Bertuzzi A, 543 Beskow C, 6091 Besselink NJM, 3399 Bessho H, 531 Betka J, 2029 Betsuyaku T, 261 Beyene D, 1549, 3811 Bezan A, 3463 Bezuglov VV, 2657 Bhandari A, 1 Bharadwaj SS, 3267 Bhatia P, 1237 Bhatt L, 5567 Biala M, 3961 Bianco A, 2769 Bianconi M, 433 Bikle DD, 6001 Binder S, 3943 Birk R, 1389, 1951 Biswas R, 3901 Biswas T, 4243 Bjarnason I, 2345 Bjelkenkrantz K, 913 Bjerkehagen B, 2129 Björck E, 4813 Björk J, 4139 Björk S, 1433 Blanck G, 25 Blanck O, 333, 6793 Blanco E, 6941 Blaum-Feder S, 835, 1369, 5921 Blomberg C, 2493, 5491 Bobbio C, 2369 Bocci G, 269 Bockmayer A, 1389 Bodeau S, 1803 Body G, 581 Boehm A, 3917 Boerma D, 295 Boers-Sonderen MJ, 5601 Boettcher A, 2991 Bogani G, 683, 6097 Bogdanos DP, 1509 Bøgelund Andersen C,

177 Böhling T, 1843 Bohlmann MK, 1797 Bohn AB, 2559 Bolanča A, 481 Bollito E, 2417 Bollmann C, 6127 Bollschweiler E, 1297, 6153 Bolm L, 4105 Bommareddy A, 5353 Bonadies A, 6121 Bonanni B, 5789 Bonanno L, 2183 Bondevik H, 6081 Bonneau C, 5179 Bono P, 921 Bonomo P, 3875, 5687 Bonomo T, 1591 Booth BW, 1285 Boraska Jelavić T, 4161 Borena W, 2513 Borgfeldt C, 913 Boria S, 4733 Bortlicek Z, 3455 Bosch-Barrera J, 4871 Botling J, 3979 Bottero D, 1017 Bouassida J, 1763 Boukhari A, 149 Bourdel N, 2887 Bourdoumis A, 3075 Boussios S, 6713 Boutsikos G, 3129 Bouvet M, 697, 2545, 5821 Boyle GM, 1291 Boysen ME, 6111 Braam HJ, 295 Brabender J, 1297 Bracci S, 1783, 4171, 5693, 6239 Brackett DJ, 47 Bradley KA, 365 Braester A, 2861 Bragazzi NL, 827 Braicu E-I, 1591, 3423, 6329 Branca G, 487 Branca JJV, 5525 Brandén E, 3979 Brandes AA, 1743 Brandt U, 1567 Brannon M, 1851 Branžovský J, 5661 Brasoveanu V, 1613, 2229, 2315, 3519, 4099, 4125, 5097, 5123, 5649 Bratta M, 6847 Brattström D, 2493 Braun A, 689 Bravatà V, 2577, 3223 Bravo I, 851 Brawanski KR, 4955 Breier A, 2627 Bremnes RM, 1619 Brems-Eskildsen AS, 2559 Brenk R, 1929 Breschi MC, 3781 Březinová I, 6303 Briasoulis E, 5857 Brickman A, 6325 Brigand C, 5503 Broek IV, 6893 Bronner C, 149 Brown JS, 25 Browne JD, 6049 Brozena S, 5353 Brucker SY, 3479 Brueggemeier RW, 47 Bruland ØS, 1171, 2129, 5759, 6081 Brun J-L, 2887 Brunello F, 325 Bruni A, 6805 Brünner N, 4935 Bruzzese D, 1017 Brydøy M, 1619 Bryjak A, 989 Bryne M, 6111 Bubenheim M, 2999 Bubka M, 2093 Bucher S, 6121 Büchler T, 3455 Budach V, 2991 Budeyri S, 4807 Budhathoki N, 4131 Bueno C, 6941 Buerkle B, 2309 Bufo P, 2175 Buggy DJ, 1311 Bühler H, 1977 Bullerdiek J, 117, 6445 Bullock MD, 5737 Buquicchio C, 461 Burattini L, 433 Burbano RMR, 1465, 2009 Burg KJL, 1285 Burmeister C, 4053 Burns TJ, 775 Buroni FE, 6439 Buser A, 1085 Busund L-T, 865 Butt AM, 77 Button MR, 5615 Cacicedo J, 6189 Cacina C, 2709, 5391 Cacsire Castillo-Tong D, 5901 Cadenas C, 5277 Caffo M, 6391 Cahen-Doidy L, 1729 Caivano D, 4171 Cakatay U, 5391 Calabrese M, 2369 Calay Z, 5425 Caldito G, 6411 Calosi L, 3875 Calvo FA, 3441 Cammarata FP, 2577, 3223 Cammelli S, 5581 Campion MB, 683 Camus V, 2999 Candeloro G, 6847 Candiano G, 3223 Canova F, 2183 Cantamessa A, 325 Cante D, 4177 Cao J, 3839 Cappia S, 2417 Carapella CM, 5117 Carbone SF, 4117 Cardinael N, 2999 Carlberg C, 1143 Carli P, 2183 Carnevale A, 1783 Carolan A, 5263 Carpi S, 3781 Carprieaux M, 6317 Carreras R, 851 Carrieri G, 2175 Carrión RP, 6941 Carson-Walter E, 53 Căruntu ID, 5325 Caruso F, 4943 Caruso G, 6391 Caruso RA, 487 Carvalheira J, 3361 Carvalho AA, 2009 Carvalho AL, 2881 Carvalho MI, 2915 Casado E, 5655 Casanova Borca V, 4177 Casarino C, 2577 Cascinu S, 433 Casova M, 4855 Cassinello J, 6941 Castagna M, 3781 Castagna R, 3049 Castillo A, 6633 Castillo-Tong DC, 6667 Cata JP, 5461 Catalano C, 6341 Cattaneo F, 2769 Caturelli E, 325 Cavalcante GC, 6971 Cavina R, 4109 Caysa H, 6841 Cazzaniga M, 5789 Ceccaroni M, 2149 Cedrych I, 4063 Celakovsky P, 2455 Cerase A, 4117 Cervello M, 3223 Červinková M, 6539 Cevenini G, 4117 Cha W, 2049 Chabowski M, 3341, 3353 Chae YS, 2775, 3531 Chai C-Y, 2447 Chakraborty A, 1389 Chakraborty AK, 1243 Chakraborty K, 1851 Chan HW, 1867 Chang AR, 5047, 5103 Chang BW, 6901 Chang C-D, 6583 Chang C-S, 1809 Chang C-W, 3969 Chang E-J, 2663 Chang H-K, 983 Chang J-G, 3893 Chang K-S, 5007 Chang L-C, 1521 Chang S-H, 6985 Chang S-J, 729 Chang W, 2465 Chang W-S, 2725, 3893, 4691, 4975, 5417, 6297 Chang Y-L, 4207 Chanvorachote P, 201, 2827, 4585, 4789 Chaotham C, 2827 Characiejus D,

178 Charles C, 6105 Charpidou A, 1129, 1543 Chauffert B, 1803 Chechlinska M, 2423 Chekerov R, 6869 Chen A-C, 3893 Chen G, 5293 Chen H-J, 3893 Chen I-Y, 6615 Chen J, 3849 Chen J-H, 6685 Chen L-Y, 1735 Chen M-F, 2263 Chen N, 5317 Chen P, 4655 Chen Q-H, 5293 Chen S-S, 5359, 5407 Chen W-C, 3893 Chen W-L, 6685 Chen W-Y, 4975 Chen Y, 4799 Chen Y-S, 1521 Chen Y-T, 2447 Cheney R, 2857 Cheng A-L, 4207 Cheng C-N, 4777 Cheng C-T, 1033, 2263 Cheon YK, 6985 Chiang I-T, 3867 Chiang K-C, 2263 Chiang Y-C, 4975 Chiantera V, 3027, 6951 Chiara GB, 3563 Chiaravalloti A, 4265, 5117 Chiba T, 549 Chiesa S, 3055 Chikamoto A, 1583, 1647, 2157, 2359, 3033 Chikui K, 3415 Chinot O, 2901 Chirica M, 4943 Chishima T, 697, 907 Cho CK, 5103 Cho C-S, 2015 Cho H-Y, 3909 Cho K-M, 5631 Cho M-H, 2015 Cho S-F, 1809 Cho SH, 6271 Cho YL, 2611, 5015 Choi A-R, 4741 Choi B, 2663 Choi BO, 6833 Choi B-Y, 785 Choi C, 5103 Choi CM, 1537 Choi HJ, 785 Choi H-S, 6833 Choi HS, 785 Choi J, 3501 Choi JW, 1333 Choi MG, 5453, 6529 Choi MK, 2465 Choi SH, 6271 Choi Y-I, 1985 Choi YJ, 1537 Choijamts B, 2739, 4757 Chondrogiannis G, 5857 Chong GO, 2611, 5015 Chopra S, 319 Chou J-C, 191 Choudhury Y, 6639 Chrisofos M, 3075 Christensen IJ, 4935 Christodoulou C, 4023 Christopoulos P, 3075 Christopoulos PF, 107 Christy HT, 6411 Chrom P, 4575 Chromik AM, 767 Chu N-M, 1121 Chuang C-L, 4691, 5417, 6297 Chudasama D, 2823, 6979 Chueh F-S, 2691 Chun YJ, 1537 Chung F-T, 983 Chung HW, 6985 Chung J-G, 729, 795, 2077, 2691, 5417 Chung JW, 1333 Chung SS, 39 Ciarmatori A, 6805 Ciavattini A, 13 Cicha I, 5717 Cîmpean AM, 759, 3147, 5325, 6521 Citronberg J, 4983 Classe J-M, 4997 Clemente N, 13 Clemons J, 4009 Clerici E, 4109 Cleveland J, 5839 Clevert D-A, 2571 Cliby WA, 683, 6097 Cloutier A-S, 4229 Cocuzza P, 269 Coh Y-R, 159 Collettini F, 319 Colombo P, 543 Colosimo C, 3055 Comandone A, 543 Comito T, 4109 Comşa Ş, 3147 Conde-Moreno AJ, 6189, 6219 Conte M-A, 1803 Conte P, 2183 Contentin N, 2999 Conti A, 433 Cook JM, 6001 Cooperwood JS, 653 Copeland Jr RL, 1453, 1549, 3811, 4723 Cordio S, 2391 Cormio L, 2175 Corominas JM, 851 Correia-Gomes C, 4219 Cortés-Funes H, 6941 Cortez A, 6799 Cosimato V, 1017 Cosio S, Costa B, 3781 Costantini B, 3027 Costantini F, 2577 Couteau J, 4915 Couvé S, 6639 Cozzi L, 4109 Creytens D, 1835 Crisamore K, 5353 Crivelli F, 5595 Crocetti D, 2211 Csonka Á, 2105, 3245 Cuppen E, 3399 Cybulski M, 1115, 1715 Czartoryska-Arłukowicz B, 989 Czyz M, 2747 D Agostino GR, 3055, 4109 D Aloisio F, 4915 D Amico G, 5383 D Andrea A, 3041 D Orazi V, 6847 D Souza MMA, 1291 Da Pozzo E, 3781 Da Silva EM, 6971 Daber R, 3007 Daga H, 3987 Dager A, 1675 Daglar-Aday A, 5425 Dahlke M, 4215, 5515, 5701, 6793 Dai J, 3193 Daigeler A, 767 Dalal P, 2823 Dalan AB, 6057 Dalay N, 2435 Dale Uglehus R, 865 Dalgleish AG, 1499, 5827 Damaskos C, 3129 Damaskou Z, 3129 Damigos D, 1771 Damodaran C, 5773 Dams-Kozłowska H, 3275 Dandamudi RK, 4841 Danesi R, 269 Danieli D, 1743 Danieli R, 4265 Danielsen S, 935 Dank M, 5063 Danker PYW, 627 Dansonka-Mieszkowska A, 2423 Daraï E, 6799 Darb-Esfahani S, 6329 Dardanoni G, 3995 Daros M, 2901 Dartigues P, 4943 Das A, 615 Dasu A, 2841 Dauchy S, 6105 Daum O, 2241 David L, 2315, 4099 David M, 2999 Davidson SJ, 1567 Davies RS, 5615 Davis G, 4935 Davydova J, 5201 Day A, 1549 De Assumpção PP, 6971 De Brakeleer S, 6893 De Carvalho DC, 6971 De Cobelli O, 1017 De Filippi C, 3041 De Geus-Oei L-F, 5601 De Grève J, 6893 De Groot J, 5467 De Hingh IHJT, 295, 627 De Luca A, 2769 De Luca S, 2417 De Marchi L, 4733 De Masi E,

179 De Matos A, 4219 De Matos AJF, 3361 De Matthaeis N, 325 De Melo MEB, 3325 De Mey J, 6893 De Pascali SA, 739 De Rosa N, 2769 De Rose F, 4109 De Rubertis G, 3097 De Sanctis R, 543 De Sanctis V, 1783, 4171, 5693, 6239 De Sanjosé S, 851 De Sio I, 325 De Toma G, 2211 De Vicente JC, 2949 De Waele M, 1481 Dean M, 669 Decavalas G, 2321 Decoster L, 1481, 6893 Decullier E, 4997 Deguchi T, 6671 Dehais C, 2901 Dejean L, 5293 Dejima T, 6137, 6925 Del Conte A, 3563 Del Rio MC, 569 Del Vecchio MT, 5595 Delaloge S, 1729, 6105 Delangle R, 6881 Delattre J-Y, 2901 Delestre L, 5983 Delinasios GJ, 1881 Delinasios JG, 1881 Delishaj D, 269 Deliveliotis C, 3075 Delpeuch A, 457 Dempke WCM, 2503, 5745, 5797 Demura K, 6739 Den Otter W, 713, 3385 Denel-Bobrowska M, 1935 Deniwar A, 1237, 1635 Denko NC, 4625 Dennis JL, 5827 Deodato F, 3441 Deosarkar S, 2531 Derwinger K, 4073 Desar IME, 5601 Desbordes C, 5889 Deshpande C, 3007 Desideri I, 5687 Desmond F, 1311 Detti B, 3875 Dewitte A, 5983 Dhakal HP, 6111 Di Brina L, 5687 Di Cataldo V, 5687 Di Fazio P, 4697, 6127 Di Fino G, 2175 Di Loreto C, 4733 Di Muzio J, 6247 Di Paola G, 2149 Di Primio R, 433, 2113 Diamantopoulos P, 5141 Dias-Pereira P, 3361, 4219 Diaz-Cano S, 2345 Díaz-Iglesias JM, 4271 Dibenedetto G, 395 Dieckmann K-P, 117 Dietel M, 6329 Dietz A, 3917 Digiovanna MP, 1243 Diguisto C, 581 Dima S, 1613, 2229, 2315, 3519, 4099, 4125, 5097, 5123, 5649, 6877, 6913, 6919 Dimitrakopoulou A, 5141 Diorio C, 4569 Diouf M, 1803 Dittrich C, 517 Do I-G, 2465 Do Nascimento SC, 3325 Dobi Á, 4967 Doğan MB, 2709 Dogkas N, 6933 Dohlmar F, 2841 Doi K, 3033, 4419, 4453 Doki Y, 891, 2223, 6591, 6739 Dolejsova O, 4855 Doll C, 5867 Domagała-Haduch M, 4063 Domínguez-Jiménez JL, 4271 Dondajewska E, 3275 Dong Z, 4655 Donizy P, 351 Dore F, 4265 Dos S. Matias L, 935 Dos Santos NPC, 2009, 6971 Dos Santos SEB, 2009 Douik H, 1763 Dowdy SC, 683, 6097 Dowell B, 4935 Dragioti E, 1543 Drag-Zalesinska M, 6009 Dralle H, 5185 Drees J, 843 Drosou A, 6933 Drueppel D, 1709 Du Four S, 5551 Du P, 4829 Dubey A, 2431 Dubis J, 3317 Dubois S, 2999 Dudek AZ, 301, 1279, 1777 Duerinck J, 5551 Dugas T, 6411 Dumitrascu T, 5123 Dumollard J-M, 3559 Dunston GM, 1549, 2565, 3811 Duran A, 2901 Dürkop J, 5623 Durocher F, 4569 Dusek L, 3455 Duś-Szachniewicz K, 6551 Dutton S, 1641 Düzköylü Y, 2709, 5391 Dvorakova S, 2029 Dwivedi C, 3137, 5353 Dworzański J, 1657 Dybdal-Hargreaves NF, 5845 Dynda D, 4009, 4145, 5575 Dzięgiel P, 2835, 3317, 3341, 3353, 3961, 6009, 6017 Dziggel L, 5701, 6793 Ebert N, 5271 Ecke TH, 2651 Economou S, 301 Edet-Sanson A, 2999 Edlund K, 5277 Edlund P, 2493, 5491 Edvardsen K, 5745, 5797 Efferth T, 1929, 2105, 2645, 6505 Efird JT, 4243 Egami MI, 2817 Egashira A, 4859 Egawa-Takata T, 359 Eglītis J, 6379 Eguchi H, 123, 1385, 6591 Eiber M, 5679 Eichhorn ME, 2571 Eidukevičius R, 6573 Eiholm S, 2235 Einvik C, 2521 Eklund C, 2873 Ekman S, 2493, 3979, 5491 Ekshyyan O, 6411 El Sharouni SY, 5607, 6773 El Zein D, 2857 Elbabaa SK, 6391 Eldabaje R, 2487 Eldeiry D, 3175 Elhag R, 1263 Elia F, 6121 Elias D, 4943 Eliashar R, 5519 Ellerbroek SM, 5263 El-Modir A, 4841, 5567 Elshaikh MA, 4053 Elsing C, 5881 El-Zawahry A, 4145 Ema A, 1411 Emmanouilides C, 1675 Emole J, 6355 Emoto M, 2739, 4757 Encinas A, 6291 Ende P, 6723 Endo I, 697, 707, 5201, 6855 Endo T, 835, 1369 Enomoto H, 3489, 6475 Enomoto Y, 4259 Enrici RM, 4171, 5693, 6239 Entschladen F, 5277 Era T, 4479 Erben P, 3801 Ercoli A, 6951 Ergen A, 255, 5391 Ergonenc H, 1709 Erikson RL, 3235 Erker T, 2675 Ermani M, 1743, 3563 Eronat AP, 5425 Esaki M, 2255 Esaki T, 371 Escobar HM, 145, 1917, 2805 Eskelinen M, 941, 1627, 2215, 3543 Espié M, 1729 Eto S, 2071 Eucker J, 5091 Euvrard S, 2305 Evangelopoulos A, 645 Everaert H, 5551 Ezelius E, 1433 Faber A, 1389, 1951, 3801 Fabi A,

180 Fabrini MG, 269 Fadhil W, 1641 Fagotti A, 3027, 6951 Fakhrian K, 1977 Falchetto Osti M, 4171 Falchi A, 4265 Falco T, 1783 Falcone G, 3041 Falconi M, 3441 Falcou M-C, 5111 Fan H, 5533 Fan Y, 3167 Fanfani F, 3027, 6951 Fang H-Y, 2725 Fang Q, 1867 Fang W-L, 1345 Fanizzi FP, 739 Farfarelos CD, 1881 Farfarelos MC, 1881 Faria EF, 2881 Farley J, 5263 Farooqi AA, 5391 Faruque MU, 2565 Fasola G, 2391 Fasolis M, 6247 Fatela-Cantillo D, 4271 Fauske L, 6081 Favaretto A, 2183 Favuzza J, 6159 Fedele F, 487 Fedirko V, 4983 Feldheiser A, 1591 Feller AC, 2055 Fenchel K, 5745 Fend F, 3479 Fender M, 4183 Feng A-C, 1121 Feng X, 6049 Fenoglio C, 739 Ferda J, 955, 2241, 2351 Ferdinande L, 1835 Ferdová E, 955, 2241 Ferguson DM, 5211 Ferician O, 6521 Fermér C, 3767 Fernandes DCRO, 2009 Fernández-Aramburo A, 6941 Fernández-Suárez A, 4271 Fernández-Valle Á, 2949 Fernando I, 4841, 5567 Ferran N, 4871 Ferrari S, 5581 Ferrazza P, 269 Ferreira AF, 2915 Ferro M, 1017, 3055 Ferron G, 4997 Fersino S, 2149, 3055 Fetzner UK, 1297 Fiaschi AI, 3097 Fiedler E, 6841 Fiegl M, 5129 Figueira AC, 3361 Filippakis GM, 1049 Filippou D, 1675 Fillini C, 4949 Fillman S, 5353 Fillmore HL, 77 Finek J, 3455 Fineman R, 2861 Fioravanti A, 1743 Fiordoro S, 827 Fiorentino A, 2149, 3055 Fiori E, 2211 Fischer D, 333, 1189, 1197 Fischer MB, 5901, 6667 Fiscus RR, 273 Fisher C, 473 Flach A, 5479 Flægstad T, 2521 Flejmer AM, 2841 Floris R, 5117 Focan C, 6311 Fogli S, 3781 Fokas D, 5857 Fondy TP, 65 Fontoura ML, 2999 Foong YM, 6639 Forest F, 3559 Fornari F, 325 Forsberg AM, 4813 Forslund O, 913 Forte GI, 2577, 3223 Forte S, 2037 Forti LN, 1481 Fosså SD, 1619 Foster PA, 5249 Fotopoulou C, 1591 Foulis AK, 6457 Fountzilas G, 1105, 4023 Fradley M, 6355 Frakulli R, 5581 Franceschi E, 1743 Francica G, 325 Francini E, 3097 Franco P, 4155, 4177, 6247 Franquesa J, 5655 Franzese C, 4109 Frascino V, 3055 Fregatti P, 2369 Freitas NDSDC, 6971 Freundl AJ, 5717 Freyschlag CF, 4955 Frezza G, 5581 Fridrik MA, 517 Friedlander P, 1237, 1635 Friedman D, 2369 Friedman M, 3019 Friedrich M, 1189, 1197 Friedrich RE, 137, 4713, 6509, 6813 Friesland S, 5491 Frisch NK, 5905 Frydlewicz A, 3317 Fu C-Y, 1033 Fucci R, 3875 Fuchs R, 31 Fuchsova R, 3537, 4855 Fuentes R, 4871 Fujii H, 1361, 6175 Fujii S, 1065 Fujii T, 379, 3581 Fujikawa H, 2849, 5639 Fujiki F, 1251 Fujimoto D, 6261 Fujimoto T, 4419, 5851 Fujimoto Y, 2385 Fujino S, 4403 Fujioka K, 6069 Fujisawa M, 3067 Fujishita T, 1791 Fujita Masami, 359 Fujita Mitsugu, 4425 Fujita S, 1025, 3103 Fujita Y, 997, 6671 Fujito H, 1353 Fujiwara H, 2191 Fujiwara Y, 499, 4961, 5079, 6739 Fukagawa S, 4521 Fukuchi M, 505, 6183 Fukuda K, 467 Fukuda S, 5241 Fukuyama T, 3575 Fulga V, 759 Fumagalli LA, 6847 Fumagalli M, 739 Fumagalli Romario U, 4109 Furfaro I, 3875, 5687 Furugaki K, 3585 Furukawa K, 499, 4203, 4961, 5079 Furukawa Y, 1691 Furuse J, 6577 Futagawa Y, 499 Futawatari N, 3575 Fütterer JJ, 5601 Gad S, 6639 Gadducci A, 1099 Gaito S, 6805 Gajdács M, 3245 Gaksch M, 1161 Galán A, 6941 Galani V, 5857 Galanopoulos A, 5141 Galise I, 461 Gallo K, 6325 Gallo M, 2369 Gallotta V, 6951 Galmiche A, 1803 Galoforo S, 5973 Gálve E, 6941 Galzio R, 1743 Gampenrieder SP, 517 Ganne N, 1803 Gao C, 4655 Gao L, 4003 Gao Yanhua, 4593 Gao Yong, 1321 Garassino I, 4109 Garau I, 6941 Garbay J-R, 4229 García MJ, 6941 Garcia R, 6219 Gardie B, 6639 Gardner N, 5263 Garlaschi A, 2369 Garrett CR, 1567 Gärtner F, 3361 Garufi A, 395 Garzaro M, 6247 Garzino Demo P, 6247 Gasimli K, 3423 Gastl G, 5129 Gatt ME, 3019 Gattuso P, 6325 Gauthier T, 2887 Gavara G, 229 Gazala S, 1873 Gebauer B, 319 Gebauer N, 2055, 3571,

181 Geissler EK, 6655 Genovesi D, 3441 George S, 2857 Georges N, 6311 Georgiadou D, 1049 Gerdin B, 3253 Gerger A, 5737 Gerhardt T, 1867 Gerini C, 3875 Gerull S, 1085 Gerullis H, 2651 Geye HM, 365 Gezer U, 2435 Ghezzi F, 6097 Ghirtis K, 1861 Ghosh S, 1873 Giacchetti S, 1729 Giacobazzi P, 6805 Giacomarra V, 4733 Giacomelli I, 5687 Giaj Levra N, 2149 Giallongo A, 3223 Giampieri R, 2391 Gianello L, 4949 Giangregorio F, 325 Giannakopoulou N, 5141 Giercksky K-E, 3793 Gies J-P, 149 Giger-Pabst U, 2309 Giglio P, 615 Gilardi MC, 2577, 3223 Giles NM, 4707 Gilles L, 6311 Ginori A, 5595 Giordano L, 543 Giorgio A, 325 Giorgio E, 1017 Gipponi M, 2369 Girelli G, 4177 Girkontaitė I, 6573 Giuşcă SE, 5325 Gkiozos I, 1129 Gkretsi V, 1509 Glatzel M, 137, 4713, 6509 Glehen O, 4997 Gliemroth J, 5515 Glover SC, 3267 Go A, 4487 Gobet F, 4915 Gőcze K, 523, 1091 Gocze P, 523 Goda AE, 3235 Godin C, 1803 Goebell PJ, 4277 Goéré D, 4943 Goertz O, 767 Gogas H, 1105, 4023 Gögenur I, 2235 Gogou P, 1771 Göhler T, 6869 Goi T, 239 Göke A, 5873 Göke R, 5873 Gola D, 2055 Goldhahn K, 2675 Goldschmidt N, 3019 Gombos K, 523, 1091 Gomes C, 3361 Gomes TS, 2817 Gomulkiewicz A, 3961 Gondos A, 5085 Gong C-L, 4691 Gonthier C, 6799 González M, 5655 González S, 6941 González X, 6941 González-Fernández L, 6291 Gonzalez-Lopez P, 6391 González-Santiago S, 6941 Goodman M, 4983 Göransson H, 3253 Gori S, 2149 Goryca K, 2423 Goscinski MA, 3793, 5533 Goshima S, 1749 Gostout BS, 6097 Gotlieb WH, 2893 Goto K, 1697, 4259 Goto S, 4535 Gotoh M, 4003 Gottschling S, 5185 Gounaris A, 1049 Gourieux B, 457 Gouy S, 4997, 6105 Graas M-P, 6311 Grace S, 2121 Grams AE, 4955 Grandaliano G, 2175 Grant WB, 1153 Grapsa D, 1129, 1543 Gratziou C, 1129 Grauslund M, 6223 Grávalos C, 6941 Gravante S, 3041 Greco AF, 575 Greco G, 461 Greil R, 517 Greish K, 4707 Grela-Wojewoda A, 4063 Greten HJ, 1929 Greto D, 3875 Gretskaya NM, 2657 Griffioen AW, 5945 Grimminger PP, 1297 Grinberg M, 5277 Grischke E-M, 3479 Groheux D, 1729 Gross M, 5519 Gruia I, 3371 Gruia MI, 3371 Grüll H, 627, 5945 Grzegorek I, 3341, 3353 Grzegrzolka J, 3961, 6009, 6017 Gschwend JE, 5679 Gualandi S, 325 Guarini A, 461 Gude F, 569 Guemira F, 1763 Guerra G, 2769 Guidi G, 6805 Guiggi I, 1099 Guimond C, 4229 Guinebretière J-M, 5111 Gundersen POM, 1619 Gunsilius E, 2165 Guo L, 1873 Guo X, 3193 Gupta SV, 97 Gurard-Levin ZA, 5179 Gurt G, 5655 Guthrie ML, 6001 Guyon F, 4997 Guzman G, 3267 Guzman M, 2121 Györke T, 5063 Ha T-Y, 1967, 1985 Haapasalo H, 3767 Haas HS, 31 Habbel P, 5091 Hack M, 713, 3385 Hacker M, 6787 Hagedorn H, 3953, 6517 Hagel C, 137, 4713, 6509, 6813 Hagel E, 4813 Hägerbäumer P, 5333 Hagino A, 4059 Hagiwara K, 6679 Haglund C, 1843, 3767, 6163 Hagström J, 1843, 3767, 6163 Hah JH, 4235 Hajós G, 3245 Hakelius M, 3253 Hakim SG, 385, 2593 Hald ØH, 2521 Halkova T, 2029 Halling KC, 683 Hallmann S, 2651 Halon A, 351 Halter J, 1085 Hama T, 4059 Hamada H, 3379 Hamada K, 4487 Hamaguchi M, 1663 Hamaguchi T, 1815, 2255, 5055 Hamakawa H, 4551 Hamakawa T, 2223 Hamamoto J, 261 Hamamoto Y, 997 Hamdoun S, 2105 Hamid MS, 2333 Hamm B, 319 Hammad S, 5277 Hammer SE, 2805 Han CJ, 5047 Han HS, 2611 Han JH, 5631 Han L, 6001 Han S-M, 4749 Han Wenke, 4829 Han Wonshik, 6271 Han W, 6271 Han X, 6049 Hanai N, 1009 Hanazaki K, 6201 Handiri N, 1763 Hanslik J, 989 Hao Q, 4655 Hara A, 1749 Hara R, 3289 Hara S, 4881 Hara Y, 1423 Harada K, 4617 Harada K-I, 3067 Harada N, 3061, 6963 Haraldsdóttir K-H, 6147 Harati K, 767 Harazin-Lechowska A,

182 Hare F, 3091 Harimoto N, 2475, 2867, 3061, 3411, 3525, 4077, 4167 Harr BA, 5511 Hartaigh B Ó, 1161 Hartinger J, 1303 Hartke M, 635 Hartman T, 4983 Hartwig K, 319 Hartwig S, 5867 Haruki K, 499, 4961, 5079 Haruma T, 337 Harzallah L, 1763 Hasagawa K, 5821 Hasegawa H, 4425 Hasegawa K, 1997, 6475 Hasegawa T, 4681 Hasegawa Y, 1009 Hashiba T, 1423 Hashimoto D, 1583, 1647, 2157 Hashimoto N, 997 Hashimoto T, 427, 1757 Hass H, 2021 Hassani S, 6633 Hasseus B, 311 Hata A, 1025, 3103, 3885 Hata K, 2983, 5073, 6599 Hata M, 4849 Hatta Y, 5473 Hattori S, 881 Hattori Y, 3885 Hau P, 5551 Haug AR, 6787 Haug BH, 2521 Haugnes HS, 1619 Hauser S, 1575 Hayakawa A, 4487 Hayashi D, 6747 Hayashi H, 1353 Hayashi Hiromitsu, 1583, 1647, 2157, 2359, 3033 Hayashi Hideki, 6671 Hayashi Hidetoshi, 2005 Hayashi Katsuhiro, 493 Hayashi Kazuhiko, 6231 Hayashi Shinichi, 221 Hayashi Shuichiro, 3415 Hayashi Takehiro, 1423 Hayashi Takuma, 4665 Hayashi Tomoyuki, 1423 Haybaeck J, 875, 4821, 5737, 6321 Haydaroğlu Sahin H, 4807 Hazama S, 129, 997 Hazell S, 6713 He B, 3167 Hecht JR, 1567 Heck MM, 5679 Heidegger I, 2513, 3567 Heidrich-Lorsbach E, 6869 Heim D, 1085 Heinzelmann S, 5927, 5955 Hellerbrand C, 6655 Helson L, 599, 6373 Hendolin P, 2873 Hengstler JG, 5277 Henic E, 913 Henne-Bruns D, 5587 Henneman R, 4015 Henningsen M, 5263 Henriksson R, 5491 Heo DS, 175 Héquet D, 5111 Herbold T, 1297 Herbrecht R, 457 Herbst A, 5873 Hergan K, 5671 Herlea V, 2315, 5123 Herman JM, 3441 Hernández-Vallejo G, 2949 Herold-Mende C, 2681 Herranz M, 569 Herrmann T, 5443 Hertlein H, 5271 Hes O, 955, 2351, 5661 Hewicker-Trautwein M, 2805 Heying E, 5263 Hidaka S, 1073 Hidesima H, 4453 Hietanen T, 5193 Higai K, 2269 Higashi M, 6633 Higashi T, 2157 Higashida M, 6193 Higashijima J, 2071 Higgins SC, 77 Higuchi A, 2401, 4865 Higuchi K, 897 Hill EK, 6001 Hill M, 6159 Hintersteininger M, 2675 Hinz S, 2961 Hirahara F, 4849 Hirai S-I, 5201 Hirai T, 6193 Hirai Y, 2669, 5851 Hirakawa H, 1009 Hirakawa K, 563, 677, 4091, 4889, 4897, 5037, 5369 Hiramatsu M, 2385 Hiramatsu Y, 337, 3289 Hirano G, 371 Hirano H, 2935 Hirano K, 719, 3821 Hirano S, 1607 Hirano T, 6041 Hirano Y, 555 Hirasawa S, 2739 Hirashima T, 1663, 3987 Hirata H, 123, 1385, 6591 Hirato J, 5559 Hiratsuka A, 4881 Hirayama Y, 2341, 4135, 6829 Hiriyan J, 229 Hiro J, 2849, 5639 Hirohashi Y, 413 Hirono Y, 239 Hirose K, 6829 Hirose Y, 4453 Hiroshima Y, 661, 697, 5821 Hirsch T, 767 Hisakura K, 1757 Hisasue S-I, 1703 Hitzel A, 2999 Hiyoshi M, 1459, 2983 Hiyoshi Y, 401, 407 Hjelle LV, 1619 Ho H-C, 3299 Ho M-R, 1345 Hoang C, 669 Hoellen F, 1189 Hoermann K, 3801 Hoffman RM, 661, 697, 2539, 2545, 2553, 3193, 3755, 4641, 4647, 4655, 5225, 5821 Hoffmann TK, 1271 Hofheinz R-D, 3801 Hofman FN, 5607, 6773 Hojo K, 4411 Holdenrieder S, 2435 Holgersson G, 2493, 5491 Holguin F, 4871 Holick MF, 3773 Holland B, 4145, 5575 Hölscher A, 1297, 6153 Holubec L, 5661 Holzmann C, 6445 Homma S, 555 Hompland I, 5759 Honda H, 3447, 3591, 4083, 4909 Honda K, 1663 Honda Mariko, 2669, 5851 Honda Masao, 1423 Honda T, 4473 Hong DG, 2611, 5015 Hong H-N, 1967, 1985 Hong JY, 2465, 3081 Hong ME, 2465 Hong S-H, 2015 Honma K, 6909 Honma Y, 2255, 5055 Honoré C, 4943 Hoogstraat M, 3399 Hora M, 2351, 4855, 5661 Horák V, 703, 6539 Horan TC, 6001 Horas K, 6281 Horgan PG, 6457 Horie S, 1703 Horio K, 2929 Horiuchi A, 1703, 4665 Horiuchi T, 4961, 5079 Hörmann K, 1389, 1951 Horn K, 2085 Horn T, 5679 Horninger W, 3567 Hornung D, 333, 3571, 5515, 6793 Horsman MR, 2559 Horváth Á, 3245 Hosein PJ, 3431 Hosek P, 2351 Hosen N, 1251 Hoshino I, 1353 Hosoda K, 419, 445, 897 Hosomi Y, 6705 Hotta K, 4681 Houbiers G, 6311 Hrubý M, 753 Hsia T-C, 3893 Hsiao C-L, 5417, 6297 Hsiao H-H, 6615 Hsiao T-S, 4691 Hsiao Y-P, 729 Hsu C-C,

183 Hsu C-M, 2725, 3893, 4691, 4975, 5417, 6297, 6615 Hsu H-W, 191 Hsu J-F, 6615 Hsu J-L, 6583 Hsu J-T, 2263 Hsu L-H, 1121 Hsu P-C, 6297 Hsu S-C, 729, 2077, 2691 Hsu W-C, 4777 Hsu W-H, 2691 Hu P-S, 2725 Hu Q, 4077, 6591 Hu T, 4655 Hu W-P, 6075 Hualin W, 2867 Huang C-C, 1735 Huang C-Y, 191, 2725 Huang Dachuang, 531, 6639 Huang Dan, 531, 6639 Huang K-H, 1345 Huang N-K, 4975 Huang R, 3743, 5533 Huang T-C, 6583 Huang W, 2487 Huang W-K, 983 Huang Y-P, 729 Huber J, 4277 Huber KE, 6901 Huchon C, 2887 Huegel K, 5263 Hufnagl C, 517 Hug KA, 3175 Huimin BW, 6639 Hung J-S, 4207 Hung S-K, 3299 Hung S-W, 5007 Huq F, 2783, 6027 Huq F, 6027 Hur DY, 2699 Husain K, 4599 Huttenlocher S, 333, 3571 Hutterer GC, 3463 Hutzschenreuter U, 6869 Hwang D-Y, 6887 Hwang J-J, 4777 Hwang S, 1967, 1985 Hyodo I, 1757 Iacopino F, 1881 Iatì G, 4949 Ibe H, 4535 Ibrahim Y, 1635 Ichikawa D, 2191 Ichikawa Y, 697, 907 Ichiki Y, 3575 Ichimura S, 2375, 6781 Ichinoe A, 3447, 5993 Ida S, 2441 Ide H, 1703 Ide S, 1447 Ieni A, 487 Iftode C, 4109 Igarashi A, 881 Igarashi Y, 2269 Igari T, 1607 Igawa S, 6705 Igawa T, 3415 Iguchi T, 123, 1385, 6591 Ihm S-H, 5453, 6529 Iida H, 6679 Iida Michihisa, 997 Iida Miho, 2247 Iida Y, 1459 Iihara H, 6175 Iijima H, 6475 Iijima M, 2411 Iizuka N, 997 Iizuka Y, 5473 Ikawa-Yoshida A, 2441 Ikeda K, 6069 Ikeda N, 6475 Ikeda S, 1815 Ikeda T, 1691, 4077, 4167 Ikeda Y, 4859 Ikegami T, 2475, 3061, 3411, 3525, 4077, 4167 Ikemura S, 261 Ikitimur-Armutak EI, 1491 Ikoma H, 2191, 2921 Ikuta S, 4191, 4923 Iliakis T, 5141 Illig R, 4697, 6127 İlvan Ş, 5425 Ilyas M, 1641 Imai H, 1749, 5485 Imai K, 1583, 1647, 2157, 2359, 3033 Imai M, 6231 Imai Y, 1025 Imaizumi H, 505 Imamura F, 3885 Imamura Y, 2299, 4037, 5023, 6207 Imkamp F, 5443 Inagawa H, 4393, 4461, 4467, 4473, 4501, 4509 Inatani H, 493 Ingolic E, 31 Ingvar C, 6147 Inokuchi J, 6137, 6925 Inokuchi S, 6829 Inoue Akira, 5797, 6957 Inoue Asuka, 1459 Inoue K, 4191, 4923 Inoue M, 5473 Inoue R, 413 Inoue Takahiro, 4441, 4447 Inoue Takashi, 1361 Inoue Tomio, 4849 Inoue Yasuhiro, 2849, 3511, 4633, 5639 Inoue Yasutoshi, 4397, 5377 Inoue Yuriko, 6069 Inskeep B, 1285 Inui T, 4441, 4447, 4487, 4545 Ionescu M, 1613, 5123 Iordanidou L, 4251 Irato E, 487 Irie H, 2247 Iriyama N, 5473 Isaak A, 1575 Isava Á, 5655 İsbir T, 2709, 5425, 6057 Ishibashi K, 505, 6183 Ishibashi O, 1401 Ishida H, 505, 6183 Ishida T, 1025, 1691 Ishigami S, 2279, 2941, 6471 Ishiguro T, 505, 6183 Ishihara Mariko, 5299, 5341 Ishihara Masashi, 6175 Ishihara S, 1459, 2983, 5073, 6599 Ishihara Y, 2279 Ishii A, 6475 Ishii H, 2921 Ishii M, 1073 Ishii S, 1607 Ishikawa H, 1757, 5559 Ishikawa M, 4441, 4447 Ishikawa T, 907 Ishiko T, 1583, 3033 Ishikura S, 4419, 4453 Ishimaru H, 379 Ishimaru K, 3553 Ishimoto T, 4617 Ishioka K, 261 Isiko T, 1647 Isitmangil GA, 5391 Isobe A, 359 Isobe K-I, 5317 Isobe T, 389 Isohashi F, 6231 Isozaki Y, 1353 Itabashi M, 3495 Itai S, 1603 Itakura Y, 2063 Ito A, 6765 Ito Hideaki, 129 Ito Hiroshi, 129 Ito J, 6261 Ito K, 5559 Ito M, 6671 Ito Sachiko, 5317 Ito Seiji, 6747 Ito Shuhei, 401, 407, 6591 Ito Y, 6231, 6747 Ito Z, 555 Itoh J, 2385 Itoh S, 2475, 2867, 3061, 3411, 3525, 4077, 4167 Itoh Yoshinori, 6175, 6671 Itoh Yoshiyuki, 2385 Itthiwarapornkul N, 2827 Ivanova D, 6623 Ivarsson M, 5813 Iwagami S, 4617 Iwaihara Y, 4419, 4453 Iwamura M, 531 Iwasa S, 1815, 2255, 5055 Iwasaki H, 345, 967 Iwasaku M, 1025 Iwasawa S, 6705 Iwase R, 499, 4961, 5079 Iwase Y, 6481 Iwata C, 2063 Iwata Y, 6475, 6747 Izumi D, 4617 Izumi K, 221, 1603 Iżycki D, 989 Jacobs B, 3007 Jacobs JJL, 713, 3385 Jacobsen H-C, 2593 Jacobson BA, 5211 Jäger T, 6127 Jakab M, 4697 Jakšić B, 481 Jakubowicz J, 4063 James ND, 1057 Jamil B, 2991 Jamy O, 3091,

184 Jan Y-Y, 2263 Jana BRP, 4557 Janczak D, 3341, 3353 Janda J, 703, 6539 Jang HS, 5047, 6833 Jang JH, 3081 Jang WI, 5047 Jang W-I, 5103 Janik K, 2759 Janik M, 2093 Jankowska-Konsur A, 6017 Janson C, 3979 Janssen S, 4105, 4151, 4215, 5701, 5807, 6793 Jaramillo E, 4139, 4813 Jardin F, 2999 Jarosz B, 1715 Jaunalksne I, 6979 Javaid S, 1279 Jay-Dixon J, 5211 Jazvić M, 481 Jebavý L, 6539 Jebelovszky É, 4967 Jeevan D, 689 Jeleniewicz W, 1115, 1715 Jen J-F, 6075 Jeng L-B, 5417 Jeon E-H, 2049 Jeon H-S, 2611 Jeon S-R, 245 Jeong B-K, 6833 Jeong H, 6833 Jeong J-H, 2775 Jeong JY, 2775 Jeong W-J, 2049 Jernman J, 3767 Jess P, 2235 Jhanwar-Uniyal M, 689 Ji B-C, 729, 2077, 2691 Ji H-X, 4975, 5417, 6297 Ji K, 1321 Ji X, 97 Jia W, 2635 Jiang A, 2635 Jiang H-L, 2015 Jiang L, 3167 Jiang P, 2539, 2553 Jiang S, 4799 Jiang WG, 1321, 2635 Jianu V, 2169 Jin E-J, 2795 Jin J, 4829 Jing Y, 5839 Jingwi EY, 1549, 2565, 3811 Jiravova J, 3943 Jitariu AA, 5325 Jo A, 785 Jo J-S, 2465 Jo T, 2929 Jobst J, 2021 Joffe E, 2861 Johnsen SH, 865 Johnstone EC, 1641 Jöhrens K, 5867 Jonas Meyer H, 5185 Jónasson JG, 4929 Jonat W, 5623 Jones R, 1867 Jones RL, 6213 Jontell M, 311 Jordá E, 439 Joseph K, 2431 Joseph MY, 653 Joste M, 3471 Jouhi L, 1843 Judson I, 473, 6213 Juhász K, 523, 1091 Jukić T, 481 Jung CW, 3081 Jung E-J, 6887 Jung HA, 3081 Jung J, 4043 Jung JH, 2775 Jung M-J, 4741 Jung S-H, 2465 Jung W-S, 4749 Junghanss C, 1917, 2805 Juniku-Shkololli A, 1513 Junkins-Hopkins JM, 3185 Juršėnaitė J, 6573 Juzeniene A, 1171 Kablouti G, 1763 Kaczorowski M, 351 Kadioglu O, 1929, 2645, 6505 Kadono Y, 1603 Kafadar A, 3933 Kagawa Y, 2975 Kagaya H, 2909, 5299, 5341 Kahán Z, 4967 Kai M, 2341, 4135, 6829 Kaida S, 6765 Kainis E, 1129 Kaizu H, 4849 Kaji R, 1025, 3103, 3885 Kajihara M, 555 Kajiyama K, 2341, 4135, 6829, 6963 Kakava K, 6933 Kakegawa S-I, 389 Kakeji Y, 511, 4425 Kakiuchi G, 4083 Kaku Y, 6563 Kalaitzidou S, 6933 Kalala F, 5141 Kalfert D, 2455 Kalichman I, 3019, 6755 Kalli KR, 683 Kalofonos C, 2321 Kalogeras KT, 4023 Kalra S, 1851 Kaltenecker G, 6869 Kalthoff H, 2961 Kaltzidou V, 4251, 6933 Kalusová K, 5661 Kamal M, 4053 Kamata Y, 4551 Kameoka S, 3495 Kameyama K, 6671 Kamigaki T, 4535 Kaminuma T, 5559 Kamitani T, 4909 Kamiya K, 3289 Kan JY, 2447 Kan S, 555 Kanaan YM, 1453, 1549, 3811, 4723 Kanai F, 549 Kanai H, 379 Kanamoto T, 5299, 5341 Kanazawa A, 2401, 4865 Kandil E, 1237, 1635 Kane JM, 2857 Kaneda T, 3885 Kaneki E, 3447 Kanekiyo S, 997 Kaneko M, 3553 Kaneko S, 1423 Kanematsu M, 1749 Kanemitsu Y, 1815 Kang BS, 785 Kang BW, 2775, 3531 Kang H-M, 5007 Kang JG, 5453, 6529 Kang JH, 6833 Kang KM, 6833 Kang MH, 6833 Kang S, 2775 Kang S-K, 159, 4749 Kang S-W, 2663 Kang U-B, 6271 Kang W-H, 1881 Kang Y-H, 2795 Kanitakis J, 2305 Kanno T, 6563 Kanogawa N, 549 Kanomata N, 2739 Kanouta F, 4251 Kanz L, 4043 Kao P-Y, 2725 Kao S-H, 1121 Kapalschinski N, 767 Kapanen M, 5193 Kapucu A, 1491 Karagiannis GS, 2715 Karamaroudis S, 3129 Karanikas G, 6787 Karasawa K, 6231 Karatzas T, 3129 Karayannopoulou G, 2305 Karczewski M, 3317 Kardamakis D, 2321 Kärjä V, 6465 Karstens JH, 385 Kasagi Y, 2299, 5023, 6207 Kashino G, 2731 Kashiwabara K, 1065 Kashiwagi E, 6137, 6925 Kasik P, 4855 Käsmann L, 4105 Kasparek A-K, 4821 Kasper B, 6213 Kassim OO, 1453, 1549 Kastelijn EA, 5607, 6773 Kastner J, 2351 Kasuya T, 4849 Katada C, 897 Katada N, 419, 445, 897 Katagiri M, 4403 Katakami N, 1025, 3103, 3885, 6261 Katano M, 3585 Katayama Y, 2401, 4865 Kato H, 949 Kato Ken, 2255, 5055 Kato Kiyoko, 3447, 5993 Kato M, 3585 Kato R, 3103, 6261 Kato Takeshi, 2975 Kato Taku, 6671 Kato Terofumi, 4259 Katoh H, 1411,

185 Katoh S, 239 Katono K, 6705 Katra R, 2029 Katsube T, 2969, 4521, 4527 Katsuhara A, 1251 Katsura M, 1791 Katsura Y, 2975 Kattner L, 1205 Kaufeldt A, 929, 1433, 4139 Kaufner L, 1591 Kaul D, 5091 Kawago M, 2669, 5851 Kawaguchi Y, 4515 Kawahara H, 3489 Kawahara K, 1663 Kawai K, 2983, 5073, 6599 Kawai T, 4487 Kawaii S, 811 Kawakami J, 6747 Kawakami K, 4059, 6671 Kawakubo H, 467 Kawamata H, 1411 Kawamori J, 4903 Kawamura H, 5559 Kawamura M, 1447, 2385 Kawanaka H, 407, 2475, 3411, 3525, 4077, 4167 Kawanami S, 4909 Kawano H, 2441, 4859 Kawano J, 379 Kawano Y, 3447 Kawasaki K, 1361 Kawase I, 1663 Kawase M, 5915 Kawase R, 881, 1401 Kawashima S, 5851 Kay CS, 5047 Kayashima H, 6963 Kaynar MY, 3933 Kazama S, 2983, 5073, 6599 Kazazis C, 645 Kazimierczak U, 3275 Keam B, 175 Keck B, 4277 Keihas M, 3155 Kellokumpu-Lehtinen P-L, 921, 1559, 2141, 5193 Kelts JL, 805 Kemerdere R, 3933 Kemmerling R, 6127 Kenguele HM, 1453 Kenjo H, 3447 Kenmotsu H, 4259 Keramidas I, 4251 Kern P, 5479 Kerr DJ, 1641 Kerr RS, 1641 Kerr SE, 683 Kerschbaumer J, 4955 Kertmen N, 857 Kesinger JW, 47 Keskin M, 2435 Keskin O, 857 Khabra K, 6213 Khalifa M, 2601 Khan AN, 1635 Khanal A, 3437 Khandelwal A, 6411 Khare V, 1513 Khayat AS, 1465 Khayat BM, 1465 Khoa MT, 333, 3571, 5515, 5701, 6793 Kiani MF, 2531 Kidogami S, 6591 Kiesewetter F, 5717 Kiesslich T, 4697, 5737, 6127 Kijima Y, 123, 2279, 2941, 6471 Kikuchi H, 3289 Kikuchi K, 1583, 1647, 3033 Kikuchi S, 419, 445, 897 Kikugawa T, 3379 Kim B-Y, 3235 Kim C, 301 Kim CS, 5453, 6529 Kim C-Y, 5631 Kim D, 2699, 2795 Kim D-W, 175, 2049 Kim E-Y, 2663 Kim H, 3909 Kim H-C, 1333 Kim H-J, 3081 Kim HS, 3501 Kim I-A, 5631 Kim J-E, 2015 Kim JG, 2775, 3531 Kim J-H, 4741 Kim JH, 5631 Kim JM, 3925 Kim JO, 1873 Kim JP, 6833 Kim Jae Sung, 5631 Kim Jin Seok, 3081 Kim J-S, 3901 Kim JW, 5631 Kim Jin Young, 785, 3531 Kim Joo Young, 5015 Kim Kidong, 3909, 4197 Kim Kihyun, 3081 Kim Kyubo, 245 Kim K-H, 3925 Kim KH, 4235 Kim M, 5047 Kim MK, 3531 Kim M-S, 5047 Kim MS, 5103 Kim N, 1967, 1985 Kim R, 4599 Kim Sanghwa, 2015 Kim Soyeon, 175 Kim Seon Dong, 4235 Kim Sung Dong, 2049 Kim Seok-Hyung, 3925 Kim Sun-Hee, 3081 Kim Se Hyun, 5631 Kim Si Hyoung, 5453, 6529 Kim SJ, 2465, 3333 Kim S-M, 2663 Kim SY, 1537 Kim TM, 175 Kim WH, 3501 Kim WS, 2465, 3333 Kim WW, 2775 Kim Young, 1369, 835 Kim Yeunjung, 4983 Kim Y-B, 3909, 4197 Kim YH, 4235 Kim Yoon Joong, 4235 Kim Yu Jung, 5631 Kimmig R, 5479 Kimura A, 6183 Kimura H, 2935 Kimura Kana, 2385 Kimura Kayoko, 6765 Kimura Kenjiro, 5037, 5369 Kimura Kenya, 6747 Kimura Tadashi, 359 Kimura Toshihiro, 359 Kimura Yasue, 511, 2441 Kimura Youhei, 239 Kimura Yutaka, 4425 Kinashi Y, 169 King D, 4935 King M, 5567 Kinkorova J, 3537 Kinoshita S, 2287 Kinoshita T, 6747 Kinoshita Y, 4535 Kinugasa T, 4403 Kipp BR, 683 Kiran B, 5391 Kirita K, 1697 Kirkeby LT, 2235 Kis LL, 929 Kisakesen HI, 5425 Kishi K, 6705 Kishi Y, 2255 Kishikawa H, 6765 Kishikawa J, 6599 Kishimoto K, 389 Kishimoto M, 811 Kiss I, 523, 1091 Kita K, 907 Kita Y, 2279, 2941, 6471 Kitagawa H, 6201 Kitagawa T, 3217, 3861, 6063 Kitagawa Yasuhide, 1603, 5031 Kitagawa Yuko, 467 Kitahara H, 1791 Kitajima T, 4633 Kitamura H, 413 Kitamura K, 1703 Kitanaka C, 85, 6607 Kitani M, 1663 Kitayama J, 1459, 2983, 5073 Kittai A, 5149 Kiviluoto T, 6163 Kiyoi M, 2669 Kiyomatsu T, 2983, 5073, 6599 Kiyoshima K, 6137, 6925 Kiyozumi Y, 4617 Kjeller G, 311 Klairmont M, 6159 Klare P, 6869 Klee F, 5277 Kleinert R, 6153 Klein-Hitpass L, 767 Klieser E, 6127 Klimowicz AC, 669 Klocker H, 3567 Kloesch B, 2675 Klotz LV, 2571 Klussmann JP, 1271 Knief J, 2055 Knisely JPS, 6901 Ko Y-C,

186 Ko YH, 2465, 3333 Kobashigawa S, 2731 Kobayashi E, 359 Kobayashi Hiroaki, 5993 Kobayashi Hiroko, 555 Kobayashi K, 6957 Kobayashi Michiya, 6201 Kobayashi Minako, 2849 Kobayashi Nobuyuki, 1607 Kobayashi Noritada, 3575 Kobayashi Satoshi, 4865 Kobayashi Shogo, 6739 Kobayashi Sumiko, 5473 Kobayashi T, 6577 Kobayashi Y, 2005 Kobierzycki C, 3961, 6009, 6017 Kobliska A, 5263 Kocak I, 3455 Kocakova I, 3455 Koch M, 5717 Kocher F, 5129 Kodaira H, 5473 Kodani Y, 881 Kodeda K, 4073 Kodetova D, 2029 Koenig K, 5225 Koga T, 2341, 4135, 6829 Kogashiwa Y, 977, 1669 Kogo M, 6261 Koha R, 929 Kohan R, 1433 Kohchi C, 4461, 4467, 4509 Kohda H, 4441 Kohlitz P, 1777 Kohno M, 1791 Kohno N, 977, 1669 Kohnoe S, 2441 Kohoutek M, 3455 Koido S, 555 Koike I, 4849 Koizumi M, 5167 Koizumi W, 897 Kojima D, 4881 Kojima N, 4493 Kojima S, 881 Kokawa Y, 2669, 5851 Kokubo M, 3103 Kołacz J, 4063 Kolarova H, 3943 Kolb F, 4229 Kolbenschlag J, 767 Koljonen V, 1843 Kollàr A, 6213 Kołodziej P, 6551 Komatsu A, 1353 Komatsu H, 123, 1385, 6591 Komatsu K-I, 4501 Komatsu M, 6861 Komatsu S, 2191 Komoda M, 371 Komori K, 6747 Komori T, 4461 Konaka H, 1603 Kondo C, 3495 Kondo Haruhiko, 4521, 4527 Kondo Hiroshi, 1749 Kondo Hisayoshi, 1073 Kondo K, 1251 Kondo M, 1423 Kondo N, 2909 Kondo S, 4633 Kondo Tetsuro, 6705 Kondo Tomoko, 129 Kongpetch S, 6639 König P, 2165 Konishi H, 2191 Konishi I, 4665 Konishi N, 2287 Konno S, 2969 Konno H, 3289 Kontham V, 3155 Koo S, 3209 Kopkash K, 6159 Korcakova E, 2351 Kordes U, 3013 Korehisa S, 5023 Korhonen R, 941, 1627, 2215, 3543 Korica N, 1291 Koriyama C, 6633 Kormann M, 5587 Körner C, 3917 Kornprat P, 4821, 6321 Kosaka S, 389 Kosaka T, 2411, 5201 Kosaka Y, 6231 Koshida K, 5031 Koskas M, 2887, 6799 Koskela A, 5813 Kostakis A, 3129 Kostakis ID, 3129 Kostakopoulos A, 3075 Köster F, 1189, 1197 Kostopoulos A, 1377 Kosuga T, 2191 Kosumi K, 4617 Kószó R, 4967 Kotake Y, 4397, 5377 Kotarski J, 1115 Kotecki A, 5263 Kotlarski M, 3275 Koudijs MJ, 3399 Koul R, 2431 Koumakis G, 1881 Kounnis V, 5857 Kouraklis G, 3129 Kourea HP, 2321 Koutras AK, 4023 Koutsilieris M, 107, 819, 1377 Kouvaris I, 1771 Kovacs A, 311 Kovacs K, 523 Kovalská J, 703, 6539 Koyama F, 1361 Koyfman SA, 5511 Koyi H, 3979 Kozłowska A, 3275 Kozyra C, 351 Krajsová I, 6303 Kratzke RA, 5211 Krause R, 1181 Krayzler E, 1961 Kreis W, 5271 Kreuzberg B, 2241 Krieger D, 3463 Krievins D, 6979 Krishnan K, 1851 Kroell T, 4043 Kronenwett R, 4023 Ksiazkiewcz M, 2759 Kubala E, 6303 Kubicka M, 5667 Kübler H, 5679 Kubo K, 4441, 4447, 4487, 4545 Kubo N, 563, 4091, 4889, 4897, 5037, 5369 Kubota H, 6193 Kubota S, 2385 Kucera R, 3537 Kuchiike D, 4441, 4447, 4487, 4545 Küçükhüseyin Ö, 3933, 5391, 5425 Kuczyk M, 5443 Kudo K, 3033 Kuempers C, 2055 Kujala P, 921 Kulda V, 2455 Kulinczak M, 2423 Kulka J, 5063 Kulkeaw K, 4479, 4493 Kumagai A, 6819 Kumagai H, 371 Kumagai Y, 505, 6183 Kumamoto T, 6855 Kumar Sanjeev, 6097 Kumar Shant, 1881 Kumar Sheeba, 6111 Kunath F, 4277 Kunii E, 5241 Kunimasa K, 1025 Kunisada T, 4647 Kunisaki C, 5201 Kunizaki M, 1073 Künzel J, 5717 Kuo J-H, 795 Kuo K-K, 6075 Kuo T-Y, 1521 Kuo W-T, 1345 Kupryjanczyk J, 2423 Kurachi H, 85, 6607 Kurachi H, 85 Kurahara H, 2279, 2941, 6471 Kuraki T, 389 Kuramasu A, 129 Kuramitsu Y, 1941, 3217, 3861, 6063 Kuramoto K, 6607 Kuramoto M, 3033 Kuranami S, 2411 Kurashige J, 1385, 4617 Kurebayashi H, 239 Kurihara T, 1691 Kurimoto R, 6705 Kurita D, 5473 Kurita N, 2071 Kuriu Y, 2191 Kurokawa Y, 891, 2223 Kuroki H, 2157 Kuroki M, 4433 Kurono Y, 6633 Kurose H, 3415 Kurose K, 881, 1401 Kuroyama M, 2935 Kurreck A, 5091 Kurth AA, 6281 Kusaba H, 371 Kusec R,

187 Kusić Z, 481, 6335 Kust D, 481, 6335 Kusumoto T, 337 Kusunoki M, 1447, 2849, 3511, 4633, 5639 Kutarska E, 1715 Kuvaja P, 973 Kuwano H, 949, 2411, 3581, 6183 Kwak S-J, 3829 Kwasnicki A, 689 Kwiatkowska E, 3275 Kwiatkowski M, 989 Kwist KW, 1285 Kwon J-L, 3925 Kwon SK, 4235 Kwon T-K, 4235 La Porta MR, 4177 La Rosa C, 2037 Laban S, 1271 Labrie Y, 4569 Laco J, 2455 Laera L, 3097 Lage H, 5867 Lagunova Z, 1171 Lai H, 1867 Lai HC, 1339 Lai J-P, 2121 Lai K-C, 795, 2077 Lai Y-L, 5417 Lakatoš B, 2627 Lakomý R, 6303 Lama G, 1881 Lamazza A, 2211 Lamm H, 1977 Lamprecht S, 1881 Landis T, 5353 Landolfo V, 4155 Landström F, 5813 Lane J, 1321 Lanfranchi B, 6805 Lang A, 517 Lang SA, 6655 Langer R, 6213 Langfort R, 3353 Langova K, 3943 Lankat-Buttgereit B, 5873 Lansiaux A, 5983 Lapenda Lins JC, 3325 Läppchen T, 5945 Larsen SG, 3793 Larsson L, 311 Lastuvka P, 2029 Latimer B, 6411 Latinwo LM, 653 Lau S, 2893 Laurent A, 6497 Laval M, 6881 Laviolle B, 3471, 6881 Lavoue V, 6881 Lazaris AC, 1049 Lazovic D, 6281 Lazzarini R, 2113 Le DL, 2487 Le Formal A, 6639 Lea MA, 5889 Lecointre L, 4183 Lee A-S, 4975 Lee AY, 2015 Lee B, 3909, 4197 Lee C, 6271 Lee C-C, 3299 Lee DS, 5047 Lee DY, 4235 Lee E-J, 2663 Lee EJ, 6985 Lee H-B, 6271 Lee HJ, 3909 Lee HS, 3501 Lee H-W, 159, 4749 Lee J, 6271 Lee JC, 1537 Lee J-H, 2015 Lee JK, 183 Lee J-O, 5631 Lee J-S, 5631 Lee JT, 3761 Lee JW, 6271 Lee Kwang Hyuck, 183 Lee Kyung Hee, 3531 Lee K-M, 6271 Lee KT, 183 Lee K-W, 5631 Lee M-S, 3299 Lee O-J, 3925 Lee P, 615 Lee RJ, 5433 Lee SA, 3531 Lee S-H, 175 Lee Seong Jin, 5453, 6529 Lee Soo Jung, 2775 Lee T-W, 4777 Lee TY, 6985 Lee Y-C, 2447 Lee YH, 2611, 5015 Lee YS, 2611, 5015 Leese MP, 5249 Lefebvre F, 4183 Lehnhardt M, 767 Leibovici V, 5519, 6755 Lenain P, 2999 Lengyel Z, 5063 Lenze D, 3353 Lenze F, 961 Lenze U, 961 Leonard A, 843 Lepretre F, 5983 Leprêtre S, 2999 Lequerica-Fernández P, 2949 Lerner MR, 47 Leskiewicz M, 351 Lester JF, 5615 Leung GKK, 6487 Leveque D, 457 Leveque J, 3471, 6881 Lewis V, 5461 Leymarie N, 4229 Li J, 3267 Li L, 3193 Li P, 4655 Li P-K, 47 Li W, 3849 Li X, 5533 Lian T, 6411 Liang H, 5839 Liang J-T, 4207 Liang S-J, 3893 Liang Y-H, 4207 Liao C-H, 1033, 2263, 2725, 4691 Liau J-Y, 4207 Liegl-Atzwanger B, 6321 Lien J-C, 729, 2077, 2691 Lightner J, 1851 Lim DH, 3333 Lim JH, 4235 Lim JS, 5047 Lim S-C, 785 Lin A, 1777 Lin B-R, 4207 Lin C-H, 3299 Lin C-Y, 983 Lin H-H, 1521 Lin H-Y, 2691 Lin HY-H, 6615 Lin J-P, 795, 2077 Lin L-I, 4207 Lin M-L, 795, 5359, 5407 Lin P-M, 6615 Lin P-Y, 6583 Lin S-F, 6615 Lin W-C, 1345 Lin Y-C, 2447 Lin Y-L, 4207 Linam J, 2479 Linardou H, 1105, 4023 Lindahl J, 929, 1433 Lindblom A, 3155, 4813 Lindhorst SM, 615 Linē A, 6379 Link K-H, 5587 Lipinski M, 2759 Litwin M, 3317 Lityńska A, 2093 Liu C-C, 1121 Liu C-W, 1521 Liu D, 5467 Liu F, 5225 Liu Garvey, 843 Liu Ge, 5993 Liu H-C, 729, 2077, 2691, 3867 Liu J, 4829 Liu K-C, 2077 Liu L, 5317 Liu M, 3193 Liu M-C, 2447 Liu MC, 683 Liu S-P, 4691, 6297 Liu T, 3155 Liu Wen, 1917, 2805 Liu Weidong, 6475 Liu WM, 1499, 5827 Liu Yang, 53 Liu Yanhua, 4799 Liu Yishan, 3743 Liu Yi-Chang, 6615 Liu Yu-Chang, 3867, 6685 Liu Y-Y, 1033, 2263 Liv P, 5491 Livi L, 3875, 5687 Livun A, 5219 Lizalek J, 5263 Ljungman D, 4073 Llimpe FR, 2391 Llorca C, 6941 Llorente R, 6941 Lloveras B, 851 Lloyd MC, 25 Lo Re G, 3563 Lo Y-L, 6297 Lobelle J-P,

188 Lockyer MG, 6171 Lodola L, 6439 Lofts F, 575 Lohneis P, 6329 Lohr J, 2681 Loi M, 3875 Løkke C, 2521 Lonardi S, 2391 Londero AP, 4733 Longhi A, 5581 Löning T, 6445 Lopes C, 4219 Lopez-Gonzalez JS, 1529 López-Muñiz IC, 6941 Lopez-Yurda MI, 4015 Lorimier G, 4997 Loseto G, 461 Lotem M, 6755 Louandre C, 1803 Loupakis F, 2391 Lu R, 1867 Lu S, 5797 Lu Y, 1703 Luanpitpong S, 4585 Lucarelli G, 1017, 2175 Lucariello A, 2769 Lucarini G, 433, 2113 Lucidi A, 3027 Lucio F, 4949 Ludvikova M, 2455 Luedders DW, 1797 Łukawska M, 1935 Lumachi F, 3563, 4837 Lundt A, 5263 Luo H, 4453 Luo N, 4799 Luo X, 4799 Lutman RF, 543 Luton D, 6799 Lutrino SE, 2391 Luukkaala T, 921, 2141 Lux O, 2651 Ma H, 661 Ma X, 6411 Ma Y, 4655 Maawy A, 697 Mabuchi S, 359 Macdonald JR, 5945 Machioka K, 221, 1603 Mackenzie MJ, 1567 Mackiewicz A, 3275 Mackiewicz J, 3275 Madeddu G, 4265 Mae Y, 4059 Maeda K, 677, 5037, 5369 Maeda N, 891 Maeda T, 3061, 6963 Maeda Y, 997 Maehara M, 4521, 4527 Maehara S-I, 1941 Maehara Y, 401, 407, 511, 1385, 1691, 1791, 1941, 2299, 2341, 2441, 2475, 2867, 3061, 3411, 3525, 4037, 4077, 4135, 4167, 5023, 6207, 6829, 6909, 6963 Maemura K, 2279, 2941, 6471 Maeno K, 5241 Mäenpää H, 3767 Maffei N, 6805 Magli M, 3041 Magnuson A, 5813 Magnuson WJ, 365 Magnusson B, 311 Mahmood S, 2431 Mahon B, 6159 Maibaum D, 145 Maidment Iii BW, 3441 Maier GS, 6281 Maillet G, 4915 Maj J, 6017 Majois F, 6893 Makatsoris T, 1105 Makert GR, 2085 Makide K, 1459 Makino T, 1723 Makishima H, 1757 Makita K, 4535 Makiyama A, 371 Makiyama C, 371 Makovický P, 6539 Malafa M, 4599 Malandrino P, 3995 Malina L, 3943 Malinka W, 2835 Mallmann P, 3117 Mamelona J, 207 Mamoughli T, 1763 Manavi KR, 1211 Mancuso A, 5687 Manganaro L, 3041, 6341 Mangoni M, 3875 Maniewska J, 2835 Maniglia A, 6311 Manisova B, 3943 Mann M, 3167 Manome Y, 6069 Manshouri T, 5219 Manso L, 6941 Mantzaris MD, 5857 Manxhuka-Kerliu S, 1513 Manyam BV, 5511 Maolake A, 1603 Maphossa AM, 6091 Marchal F, 4997 Marchan R, 5277 Marchetti S, 543 Marcos R, 4219 Marcu M, 2169 Marczak A, 1935 Margan M-M, 759 Margarino C, 2369 Margonis GA, 19 Mariani A, 683, 6097 Marikkannu R, 3155 Maring ED, 3761 Marino A, 1017 Mariuzzi L, 4733 Markowski DN, 6445 Marmé F, 5085 Marnitz S, 2991 Marquardt P, 1181 Marrari A, 543 Marsh S, 5263 Marthinsen ABL, 935 Martin G, 3209 Martin JC, 301 Martin LJ, 207 Martin MG, 3091, 6287 Martin TA, 2635 Martini C, 3781 Martins A, 2105 Martynow D, 1041 Maruyama T, 1353 Maruzzo M, 473 März W, 1161 Marzi S, 5117 Marzinotto S, 4733 Masago K, 1025, 3103 Masaki T, 6577 Mason MD, 1321 Mason T, 3811 Masoud GN, 3849 Masuda G, 4897 Masuda K, 1997 Masuda M, 2401 Masuda N, 6705 Masuda T, 1583, 3033, 6591 Masugi Y, 2247 Masumori N, 413 Mateša N, 6335 Matesic DF, 775 Matias LDS, 6091 Matkowski R, 351 Matoušková E, 1303 Matsubara H, 1353 Matsuda D, 6909 Matsuda E, 4535 Matsuhashi N, 5485, 6175 Matsui D, 2205, 2269 Matsui H, 5559 Matsui S, 5485 Matsui T, 2269 Matsumoto A, 3379 Matsumoto H, 6193 Matsumoto Kazumasa, 531 Matsumoto Keiji, 3591, 4083, 4909 Matsumoto Kotaro, 3585 Matsumoto M, 4385 Matsumoto S, 1697 Matsumoto Takeshi, 1025 Matsumoto Takuro, 4647, 5821 Matsumoto Takuya, 6909 Matsumoto Yoshifumi, 977 Matsumoto Yoshihiro, 555 Matsuo M, 3415 Matsushita H, 2199 Matsushita R, 2063 Matsushita Y, 371 Matsuura K, 2199, 4981 Matsuyama R, 697, 6855 Matsuzaki S, 359 Matsuzaki T, 6431 Matta M, 2901 Mattiucci G, 3055, 3441 Mauad EC, 2881 Maureas V, 1771 Mauricas M, 6573 Maurizi Enrici R, 1783 Maus MKH, 1297 Maus U, 6281 Mautner V-F, 6813 Mayer B, 5587 Mayo KH, 5945 Mayr C, 4697 Mazouni C, 4229 Mazza F, 3563 Mazzarella C, 1017,

189 Mazzarella G, 2769 Mazzeo E, 6805 Mazzio EA, 1263 Mazzola R, 2149 Mazzucchelli R, 433 Mcclure G, 6411 Mccormack J, 1311 McGregor MJ, 1641 Mcguff HS, 1861 Mckallip RJ, 5231 Mckenna T, 5263 Mclachlan J, 6713 Mcmartin K, 6411 Mcmillan DC, 6457 Mcvary KT, 4145 Meattini I, 3875 Medinger M, 1085 Meeus P, 4997 Mehra R, 1243 Mehta M, 47 Mehta V, 6411 Meier-Allard N, 31 Meirovitz A, 5519 Meissnitzer MW, 5671 Meissnitzer T, 5671 Melano A, 4949 Melano M, 6247 Melichar B, 3455, 6303 Mellem J, 4765 Melpignano A, 461 Mély Y, 149 Memeo L, 2037 Mena M, 851 Mendes V, 3471 Menéndez-Rodríguez P, 569 Menghini V, 269 Menichetti A, 1099 Menon V, 615 Merchionne F, 461 Merims S, 6755 Merseburger A, 5443 Mertensotto M, 843 Messa C, 2577, 3223 Messingerová L, 2627 Mets T, 1481 Mette M, 4487, 4545 Mey V, 269 Mezani B, 5391 Miah A, 6213 Miailhe G, 6105 Mian M, 5129 Miano ST, 3097 Miao C-E, 3893 Michalak K, 2835 Michel LL, 5085 Michelsen L, 6255 Michotte A, 5551 Micke P, 3979 Mieno H, 419, 445, 897 Migoni D, 739 Mii S, 697 Milanese G, 433 Milanesi G, 739 Milano A, 5383 Miller D, 3849 Miller G, 5263 Miller R, 615 Miller RC, 3441 Miloso M, 5383 Mimori K, 123, 1385, 6591 Minafra L, 2577, 3223 Minagawa R, 2341, 4135, 6829, 6963 Minami K, 4859 Minardi D, 433 Mine S, 1607 Minier C, 4915 Minniti G, 1783, 4171, 6239 Minoia C, 461 Miracco C, 4117 Miranda S, 3361 Mirea G, 5547 Mirka H, 2351 Misawa K, 6747 Misawa T, 499, 555, 4961, 5079 Mischinger H-J, 4821, 6321 Mishima H, 4881 Mishra R, 703, 6539 Mitsudomi T, 2005 Mitsugi K, 371 Mitterhauser M, 6787 Miura K, 5473 Miura N, 1663 Miura S, 6765 Miwa S, 697 Miyagi E, 4849 Miyahara D, 4521, 4527 Miyake H, 3067 Miyaki A, 2969 Miyamoto K, 3307 Miyamoto K-I, 2063 Miyamoto N, 3987 Miyamoto S, 4433, 4521, 4527 Miyamoto Y, 1815, 2359, 4617 Miyasaka M, 2669, 5851 Miyata H, 891, 2223, 6739 Miyata K, 4433, 4521, 4527 Miyauchi J, 6765 Miyazaki A, 3067 Miyazaki K, 5031 Miyazaki S, 3289 Miyazaki T, 949 Miyazaki Y, 891, 2223 Mizokami A, 221, 1603, 1723, 5031 Mizumoto M, 1757 Mizunuma N, 4059 Mizutani K, 6671 Mlineritsch B, 517 Moan J, 1171 Mochiki E, 505, 6183 Mock A, 2681 Mogi A, 2411, 4881 Mohamed SEH, 1635 Mohammad M, 6425 Mohelnikova-Duchonova B, 3455 Mohri Y, 1447, 2849, 3511, 4633, 5639 Mojica WD, 5905 Mokry M, 875 Molina R, 5655 Møller BK, 2559 Möller C, 5813 Molnár J, 2105, 3245, 5915, 6505 Momiyama K, 2269 Momiyama M, 697 Momose M, 3495 Mondello P, 5129 Monden K, 1025 Monfrini M, 5383 Monninkhof EM, 5607 Montalto A, 4171 Monteagudo C, 439 Montenegro RC, 1465, 2009 Monterossi G, 6951 Montesinos J, 5655 Montironi R, 433 Montrone S, 269 Mooberry SL, 5845 Moon H-G, 6271 Moon K-M, 1967 Moore A, 4145 Moore RG, 6001 Moore-Medlin T, 6411 Moorhead J, 2345 Morandi L, 1743 Moretto F, 4155, 6247 Morganti AG, 3441, 5581 Mori H, 2731 Mori K, 3511, 5639 Mori Masahide, 2935, 3885 Mori Masaki, 891, 2223, 6591 Mori Masako, 555 Mori R, 697, 6855 Mori Shun, 6167 Mori Sinichiro, 6471 Mori Y, 4551 Morice P, 6105 Morii T, 2375, 6781 Morikawa K, 2731 Morimoto M, 2401, 4865 Morimoto S, 1251 Morimura R, 2191, 2921 Morinaga S, 2401, 4865 Morisaki K, 6909 Morishige M, 427 Morishita N, 1663, 3987 Morita H, 3581 Morita M, 401, 407, 2299, 2441, 4859 Morita M, 511 Morita S, 3885, 6819 Moriwaki H, 2545, 2553, 5821 Moriwaki T, 1757 Moriya H, 419, 445, 897 Moro Y, 977 Morodomi Y, 1791, 3411 Moroz K, 1635 Morrissette J, 3007 Mosbah R, 5111 Moschetta M, 6713 Moselhy J, 5773 Moser C, 6655 Motoi T, 1607 Motoki K, 1997 Motomura M, 6471 Motoyama T, 549 Motthor M, 1613 Moukharskaya J, 1851 Moulay M, 1917, 2805 Mourmouris P, 3075 Mousa S, 3175 Mousli M, 149 Mowjood R,

190 Mozet C, 3917 Mraček J, 955 Mrak K, 6321 Mrsic E, 3463 Msaouel P, 819 Msika S, 4997 Muallem MZ, 3423 Muguruma K, 563, 4091, 4889, 4897, 5037, 5369 Mühlhofer HML, 961 Mukai Y, 4849 Mukozu T, 2205, 2269 Mulder SF, 5601 Mulders PF, 5601 Müller-Uri F, 5271 Mulligan N, 1311 Multinu F, 6097 Mundhenke C, 5623 Munekage M, 6201 Munkarah A, 4053 Muñoz-Colmenero A, 4271 Murakami H, 4259, 6193 Murakami I, 389 Murakami K, 1353, 2247 Murakami M, 2983 Murakami S, 6705 Murakami T, 697 Murakawa M, 4865 Murali R, 689 Muramatsu K, 427 Murasaki C, 4397, 5377 Murata K, 1229 Murayama M, 2969 Murayama Y, 2191 Murelli F, 2369 Murgić J, 481 Murgui A, 439 Muroi H, 949 Murphy B, 615 Musa MA, 653 Muscardin L, 6121 Muto S, 1703 Muzaffar R, 2121 Mužík J, 6303 Muzzonigro G, 433 Myint SS, 6639 Myreng Lyså L, 6401 Mystakidou K, 1771 Naab TJ, 1549 Nabeki B, 2941 Naber U, 4713 Nabeshima K, 345, 967, 2739, 6167 Naccarato S, 2149 Nachbaur D, 2165 Naemura M, 4397, 5377 Nagafuji H, 1669 Nagahara H, 677, 5037 Nagai H, 2205, 2269, 6679 Nagai M, 2287 Nagamune H, 4411, 4515 Naganawa S, 2385 Nagase S, 6607 Nagashima F, 6577 Nagashima K, 2255 Nagata Kazuma, 1025, 6261 Nagata Kinya, 881 Nagata T, 719, 3821 Nagayasu T, 1073 Nagler RM, 1961 Naicker T, 4765 Naito M, 345, 967, 6167 Naitoh H, 505 Naitoh K, 4535 Naka G, 1607 Nakae Y, 1251 Nakagawa A, 6261 Nakagawa F, 1437, 4605 Nakagawa Kazuhiko, 1683 Nakagawa Keiichi, 4903 Nakagawa S, 1647, 2157 Nakahara R, 2385 Nakaji Y, 407 Nakajima A, 1703 Nakajima H, 1251 Nakajima Kenji, 1475 Nakajima Kiyokazu, 891, 2223 Nakajima M, 949 Nakajima Yoshiki, 1475 Nakajima Yoshiyuki, 1361, 2287 Nakajo A, 6471 Nakamoto T, 1361 Nakamura H, 6475 Nakamura Katsumasa, 2299, 3447, 3591, 4083, 4909 Nakamura Katsuya, 3585 Nakamura Kazunori, 1411 Nakamura Kazuyuki, 1941, 3217, 3861 Nakamura Keichiro, 337 Nakamura Kenichi, 4617 Nakamura M, 5821 Nakamura N, 4647 Nakamura R, 467 Nakamura Satoaki, 5167 Nakamura Shinji, 1361 Nakamura T, 977, 1669 Nakanishi M, 2191 Nakanishi Y, 4479, 4493 Nakano H, 4551 Nakano T, 1229, 5559 Nakanoko T, 511, 2299, 2341, 4135, 6829 Nakao T, 2071 Nakaoka E, 6041 Nakashima H, 5299, 5341 Nakashima K, 5031 Nakashima M, 1073 Nakashima T, 5031 Nakashima Y, 401, 511, 2299, 4037, 5023, 6207 Nakata J, 1251 Nakata Y, 4467, 4509 Nakayama H, 3553 Nakayama M, 6481 Nakayama N, 1411 Nakayama S, 261 Nakazawa T, 239 Nakiri M, 3415 Nalkiran I, 255 Nam KH, 3501 Nam SO, 4433, 4521, 4527 Nambara S, 123, 1385, 6591 Namikawa T, 6201 Namiki M, 221, 1603, 1723, 5031 Namur J, 6497 Nanashima A, 1073 Nanbara S, 407 Nandhikonda P, 6001 Nano R, 6439 Naoki K, 261 Nara S, 2255 Narimatsu H, 1411 Naritaka Y, 2969 Narui K, 907 Naruse T, 239 Naser W, 2601 Nasroulah F, 4003 Nass J, 2645 Nasser S, 3423 Natesan S, 229 Nathan C-AO, 6411 Nathan N, 6411 Natsugoe S, 123, 2279, 2941, 6471 Natsume S, 6747 Navarria P, 4109 Nawroth R, 5679 Ndoye A, 6881 Neal JW, 669 Negoita V, 3371 Negoro S, 3885 Nehls O, 2021 Nehoff H, 4707 Nekhai S, 1453 Nelson K, 5867 Nemoto K, 6231 Nerlich A, 3953, 6517 Nesland JM, 3743, 3793, 5533, 6111 Netíková I, 1303 Netti GS, 2175 Neumann C, 5091 Neureiter D, 4697, 5671, 6127 Newberry KJ, 5219 Newman SP, 5249 Newstead G, 4935 Neyns B, 5551, 6893 Ng S-H, 5359 Ngenazahayo A, 1917 Ngobili TA, 1285 Nguemgo-Kouam P, 1977 Nguyen DM, 3431 Niazi TM, 2893 Nicolau P, 851 Nicolay K, 5945 Nicolini C, 827 Nicosia L, 5693, 6239 Nielsen FH, 3839 Nielsen HJ, 4935 Niemiec J, 1041, 4063 Nienhuijs SW, 295 Nieri P, 3781 Niggemann B, 5277 Niho S, 1697 Niibe Y, 4903 Niimi A, 5241 Niinaka M, 2935 Nijman IJ, 3399 Nikolaou M, 2321 Nikolidakis L, 3129 Nikpayam M, 1729 Nilsson D, 3155 Nilsson J, 2493, 5491, 6091 Nilsson M, 2841 Nilsson O, 3767 Ninkovic M, 5129 Ninsontia C,

191 Nio K, 1423 Nirmal S, 5973 Nishi M, 2071, 4425 Nishi Y, 3575 Nishida H, 493 Nishida J, 6765 Nishida S, 413, 1251 Nishida T, 337 Nishigori N, 1361 Nishiguchi H, 2669, 5851 Nishiguchi S, 6475 Nishihara K, 3415 Nishikata T, 4441, 4447, 4545 Nishikawa H, 6475 Nishikawa T, 2983, 5073, 6599 Nishimiya H, 1411 Nishimura G, 6861 Nishimura N, 379 Nishimura S, 2299 Nishimura Y, 1025, 6231 Nishino K, 3885 Nishio J, 345, 967, 6167 Nishio K, 1683, 2005 Nishio M, 1009 Nishio N, 5317 Nishiwada S, 1361, 2287 Nishiyama A, 1025 Nishiyma Y, 6431 Nishizaki T, 6563 Nishizawa T, 4501 Nissi R, 973 Nitta H, 1583, 1647, 2157, 2359, 3033 Niyazi M, 1851 Njemini R, 1481 No JH, 3909, 4197 Noda M, 6471 Noda S-E, 1229 Noel N, 4915 Nogami Y, 2247 Noh D-Y, 6271 Nohara T, 1603 Nojima M, 413 Nojiri K, 6855 Nolte E, 5271 Nolte I, 145, 1917, 2805 Nomura Y, 1423 Nordback I, 6163 Nordling S, 6163 Notarnicola M, 1099 Noujaim J, 6213 Novak J, 3537, 4855 Nowakowski A, 1115, 1715 Nowicka-Kotlarska A, 3275 Nowinski D, 3253 Nowosielski M, 4955 Nozaki E, 6577 Nozawa H, 2983, 5073, 6599 Nuebling T, 4043 Nukatsuka M, 1437, 4605 Nukiwa T, 6957 Numazaki R, 4849 Nuti C, 3559 Nutt M, 4145 Nwizu TI, 5511 Nyman J, 5491 Obara S, 1361 Ocaña-Pérez E, 4271 Ochi T, 3379 Ochiai T, 2921 Ochiya T, 5201 Ochoa RE, 3431 Ocker M, 4697 Ocsovszki I, 5915 Oda H, 371 Oda Y, 2441 Odun-Ayo F, 4765 Oelkrug C, 635, 2085 Offerhaus GJ, 3399 Offidani A, 2113 Ofner A, 5873 Oga A, 129 Ogasawara N, 3415 Ogasawara S, 549, 4535 Ogata K, 3033, 4881, 6183 Ogawa C, 337, 2909 Ogawa K, 5167, 6231 Ogawa S, 3495 Ogawa Y, 6591 Ogino Y, 2205, 2269 Oguma E, 4535 Ogura K, 4881 Ogura T, 4259 Oguri T, 5241 Oguzkan Balci S, 4807 Ohashi T, 2669, 5851 Ohba M, 6705 Ohchi T, 3033, 4403 Ohga S, 2299, 3447, 3591, 4083, 4909 Ohgaki K, 401, 511, 2299, 4037, 5023, 6207 Ohgami T, 3447, 5993 Ohgino K, 261 Ohi M, 1447, 2849, 3511, 4633, 5639 Ohira M, 563, 4091, 4889, 4897, 5037, 5369 Ohkohchi N, 1757 Ohkubo H, 5241 Ohkubo Y, 4411 Ohkura K, 4411, 4515 Ohkura Y, 6577 Ohkusa T, 555 Öhman J, 311 Ohmatsu H, 1697 Ohmori M, 4509 Ohmura Y, 2975 Ohnishi K, 1757 Ohno S, 5201 Ohno T, 1757, 5559 Ohno Y, 6671 Ohori J-I, 6633 Ohshima K, 4403, 4909 Ohta M, 3289 Ohta T, 85, 6607 Ohtani H, 677, 5037 Ohtsu A, 4003 Ohuchi M, 4617 Ohue M, 6739 Ohyama M, 6563 Oikawa H, 6231 Oike T, 1229 Oishi N, 1423 Ojevwe CD, 1777 Ojevwe FO, 1777 Oji Y, 1251 Oka M, 129, 997 Oka Y, 1251 Okabe H, 1583, 1647, 2157 Okabe K, 3033 Okada F, 3217 Okada H, 1423, 3987 Okada M, 85, 6607 Okada S, 4535 Okada T, 2385 Okadome J, 6909 Okamoto Haruna, 4397, 5377 Okamoto Hideki, 493 Okamoto Hiroaki, 6705 Okamoto I, 1683 Okamoto K, 2191 Okamoto M, 555 Okamoto N, 1663, 3987 Okamoto T, 407, 1791, 3411 Okamura T, 4419, 4859 Okamura Y, 2669, 5851 Okano S, 1791 Okano T, 6481 Okay E, 2709 Oki E, 401, 407, 511, 2299, 2441, 4037, 4617, 5023, 6207, 6909 Okigami M, 3511, 4633 Okimoto T, 389 Okines A, 6713 Okita N, 5055 Okonogi N, 1229 Okuda C, 3103 Okugawa K, 3447 Okuma K, 4903 Okumichi T, 389 Okumura H, 2279, 2941, 6193, 6471 Okumura N, 5485 Okumura T, 719, 1757, 3821 Olbert P, 4277 Olbromski M, 3961 Olczak M, 2759 Oldenburg J, 1619 Olesen S-P, 3781 Olier C, 6941 Oliveira CZ, 2881 Ollonen P, 941, 1627, 2215, 3543 Olsen Jesper, 2235 Olsen Jørgen, 2235 Omori T, 6739 Omoto I, 6471 Omura T, 719 Onda K, 6041 Ong CK, 531, 6639 Ong P, 6639 Onishi H, 3585, 6231, 6577 Ono A, 4535 Ono H, 2619 Ono HA, 5201 Onozato R, 2411 Onozawa H, 505 Onyema OO, 1481 Ooi A, 6639 Ooka Y, 549 Oosaki T, 4487 Orange C, 6457 Ørbo A, 6401 Ordeig JM, 5655 Oridate N, 6861 Orlandini C, 269 Orsaria M,

192 Osada S, 1749, 5485 Oshima CTF, 2817 Oshita F, 6705 Oskay-Özcelik G, 6869 Osse EM, 4015 Ostasiewicz P, 6551 Osti MF, 1783, 5693, 6239 Oszczapowicz I, 1935 Otake A, 359 Otani K, 6599 Otawa N, 4551 Otoshi T, 6261 Otsu H, 2441 Otsubo D, 4425 Otsuji E, 2191, 2921 Otsuka K, 1025, 3103, 6261 Otsuka T, 493, 2935, 3885, 3987 Otto T, 2651 Ou Y-C, 5007 Ouldamer L, 581, 2887, 3471 Ouni N, 1763 Oura S, 2669, 5851 Owaki T, 6471 Oyen WJG, 5601 Ozakinci G, 6081 Ozasa H, 5241 Özgür E, 2435 Ozkayar O, 857 Ozturk O, 5425 Ozturk T, 5425 Pääkkö P, 973 Pace A, 5117 Pacini S, 5525 Paik JH, 6887 Palaniappan N, 5615 Palau VE, 1851 Palko-Łabuz A, 2835 Pallotta S, 3875 Palmqvist T, 935, 6091 Paloheimo L, 2873 Palombarini M, 5581 Palomo AG, 6941 Palpacuer C, 3471 Palumbo B, 3041 Palumbo I, 3041 Panait M, 3371 Pánek J, 753 Panici PB, 6341 Panizza B, 1291 Pannone G, 1861 Panyam J, 843 Pap M, 5401 Papadakis G, 4251, 6933 Papadopoulou V, 5141 Papageorgiou E, 1377 Papagerakis P, 1861 Papagerakis S, 1861 Papagrigoriadis S, 2345 Papandreou I, 4625 Papanikolaou NA, 5857 Papaoiconomou E, 819 Pappa T, 4251, 6933 Pappas A, 4251, 6933 Parayath NN, 4707 Parisi A, 487, 5581 Parisi M, 2769 Park C-W, 4749 Park GB, 2699 Park HJ, 5047, 5103 Park HY, 2775 Park J, 1339, 1867 Park JJ, 6833 Park JP, 1285 Park JS, 3081 Park J-S, 3829 Park J-Y, 2775 Park S, 2465, 3081 Park S-C, 4749 Park SC, 5047 Park S-W, 4235 Park Yong Sun, 6271 Park Youn Soo, 2663 Parpa E, 1771 Parsons PG, 1291 Partelli S, 3441 Pascale F, 6497 Paschke S, 5587 Pasello G, 2183 Pasi F, 6439 Pasqualetti F, 269 Pasquino M, 4177 Passalacqua M, 6391 Passera R, 2417 Passweg J, 1085 Pasta V, 6847 Patel MR, 5211 Patel SJ, 615 Patel VR, 5007 Paterson JK, 5905 Patsea H, 4023 Patsouris E, 1049 Paul R, 2565 Pautov M, 1613 Pavlakis K, 4023 Pavlidis N, 575 Pavlidou S, 5479 Pavlíková L, 2627 Pavone V, 461 Peccatori F, 575 Pecce V, 2037 Pecen L, 4855 Pechkova E, 827 Peciak J, 2759 Pecorari G, 4155, 6247 Pecorella I, 6341 Pectasides D, 1105, 4023 Pehlivan M, 4807 Pehlivan S, 4807 Pele KB, 5661 Pelissero A, 4949 Pellegriti G, 3995 Pellín A, 439 Pellín-Carcelén A, 439 Pengpaeng P, 201 Pennisi M, 395 Pentheroudakis G, 1105 Pento JT, 47 Péoc'h M, 3559 Pepe P, 395 Perconti G, 3223 Perdonà S, 1017 Perelló A, 6941 Peretz T, 5519, 6755 Pergolizzi S, 4949 Perrier-Trudova V, 6639 Perruolo G, 1017 Persico MG, 6439 Pesta M, 2455 Petereit DG, 365 Petr O, 4955 Petraki C, 819 Petraki K, 4023 Petrić Miše B, 4161 Petrillo M, 3027 Petrioli R, 3097 Petrirena G, 2901 Petritsch W, 6321 Petru E, 517 Petruželka L, 1303, 3455 Pfister C, 4915 Pfragner R, 31 Pham MH, 5983 Philippou A, 107 Phillips N, 2121 Phuong PC, 333, 5515 Piaskowski S, 2759 Picelli S, 3155 Pich A, 145 Pichler M, 3463, 4697, 5737 Pichler R, 2513, 3567 Piel B, 6799 Pierce CJ, 1291 Pierpaoli E, 5309 Pietzner K, 1591 Pignatelli A, 3049 Pikoulis E, 19 Pilkington GJ, 77 Piludu F, 5117 Pilz S, 1161 Pineau P, 5123 Pinggera D, 4955 Pini A, 3875 Pinilla-Ibarz J, 6355 Pinto LC, 1465 Piotrowska A, 3317, 3961 Piras B, 4265 Pircher A, 5129 Pircher M, 517 Pires I, 2915 Pires L, 6049 Pirrie S, 1057, 5567 Pirtnieks A, 6979 Pirtoli L, 4117, 5595 Pisa FE, 2391 Piscaglia F, 325 Pitkänen M, 5193 Plánská D, 6539 Pocard M, 4997 Pocheć E, 2093 Poddar N, 2121 Podder T, 4243 Podhorskaokolow M, 3961 Podhorska-Okolow M, 6009 Pogorzala M, 5667 Poh J, 6639 Pohlig F, 961 Pohlmann K, 3463 Pokrywka M, 2093 Polack S, 1189 Polanec SH, 6787 Politi E, 1543 Polliack A, 2861 Polo V, 2183 Polz-Dacewicz M, 1657 Polz-Gruszka D, 1657 Pomel C, 4997 Pompili M, 325 Pompucci A, 3055 Pontoriero A, 4949 Poon M-W,

193 Poon SL, 6639 Popa I, 5547 Popescu I, 2229, 2315, 3519, 4099, 4125, 5097, 5123, 5649, 6877, 6919, 6919 Popov D, 2873 Poprach A, 6303 Porfiri E, 1057 Porojnicu AC, 1171 Porpiglia F, 2417 Porpora MG, 6341 Porta R, 4871 Portaluri M, 3049 Possinger K, 5091 Potenza I, 4155, 6247 Potter BVL, 5249 Pottgiesser SJ, 5927 Pouliot M-C, 4569 Pozzati E, 1743 Prada J, 2915 Prado-Garcia H, 1529 Prausová J, 3455 Prenzel K, 6153 Presz M, 1641 Prgomet A, 481 Primavesi F, 6127 Principi E, 433 Priolo G, 395 Pritchard A, 1641 Proschogo N, 6027 Provinciali M, 5309 Prpić M, 481 Psaltopoulou T, 1049 Puetter C, 5479 Puła B, 2835 Pummer K, 3463 Purohit A, 5249 Pusztai L, 5179 Qi H, 4655 Queiroga FL, 2915 Quenet F, 4997 Ra J-C, 4749 Raatikainen P, 1559, 2141 Raatikainen S, 6465 Rabinovich A, 2893 Rachmut J, 5519 Rack B, 5679 Rades D, 333, 385, 3571, 4105, 4151, 4215, 5515, 5701, 5807, 6189, 6219, 6793 Rafinsk B, 5667 Ragona R, 4155, 6247 Raguse J-D, 2991 Raguse JD, 5867 Rahe ML, 5511 Rahnenführer J, 5277 Raica M, 759, 3147, 5325, 6521 Rajesh RP, 283 Rajmon R, 703 Ramanakumar AV, 2893 Ramirez JL, 4871 Ramírez MF, 5461 Ramos D, 439 Ramos JAB, 1465 Rampino M, 4155, 6247 Randone DF, 2417 Rantala J, 3155 Rao R, 6159 Rapaccini GL, 325 Rappe B, 6317 Räty S, 6163 Rauch E, 1205 Ravasi M, 5383 Ravn J, 6223 Rawendra RDS, 6583 Raza A, 5211 Razalli NH, 97 Razik E, 6009 Razzak R, 1873 Rea S, 6847 Reboun M, 2029 Recchia F, 6847 Recchia N, 6341 Rechl H, 961 Reck M, 5797 Reddemann K, 2055 Reddy L, 4765 Redekopf J, 6655 Reed MJ, 5249 Regierer AC, 5091 Regine WF, 3441 Reich A, 6017 Reichert D, 6869 Reichert K, 1189, 1197 Reid TR, 1567 Reinmuth N, 5797 Reiterits B, 6787 Rembiszewska A, 2423 Reni M, 3441 Ressler S, 517 Restaino S, 6951 Retz M, 5679 Reyes-Botero G, 2901 Reymond M-A, 2309, 6723 Rezai M, 5479 Rezniczek GA, 6723 Rhee JC, 183 Rho JK, 1537 Rhu M-H, 2663 Ribbat-Idel J, 2055 Ribeiro DA, 2817 Ribeiro-Dos-Santos Â, 6971 Ribeiro-Dos-Santos ÂKC, 2009 Ribeiro-Dos-Santos AM, 6971 Ricardi U, 4155, 4177, 6247 Riccardi L, 325 Ricchetti F, 2149 Rice A, 2823 Richard S, 6639 Richards SE, 805 Richardsen E, 865 Richter R, 3423 Richterstetter M, 4277 Ricks-Santi L, 1549, 2565, 3811 Riedl Z, 3245 Rieske P, 2759 Riess JW, 669 Rimareix F, 4229 Rinnerthaler G, 517 Rino Y, 2401 Rinta-Kiikka I, 6163 Ripamonti M, 2577, 3223 Risinger AL, 5845 Riva G, 4155, 6247 Rivera S, 1729 Rizvi S, 1567 Rizzo G, 4837 Roa WH, 1873 Rocca BJ, 5595 Rocca M, 5581 Rocha Lima CM, 3431 Röcken C, 5623 Rodali R, 6001 Röder C, 2961 Rody A, 1189, 1197, 1797 Rogenhofer S, 1575 Rogers M, 1851 Rolen K, 1 Romanini A, 3781 Romero-Garcia S, 1529 Rondak I-C, 961 Rong X, 6411 Roolf C, 1917 Rorive A, 6893 Rosati G, 2391 Rosati R, 4109 Rosell R, 4871 Roselli P, 325 Rosen DG, 6171 Rosignolo F, 2037 Rosselli M, 6847 Rossi G, 4155 Rossin R, 5945 Roth SA, 2521 Rottey S, 6893 Rougala N, 5141 Roux A, 2305 Rouzier R, 5111, 5179 Roviello G, 3097 Rowan C, 1057 Roxburgh CS, 6457 Rozendaal L, 713, 3385 Rubin K, 3253 Rubini C, 2113, 4733 Rubio CA, 929, 1433, 3485, 4139, 4813, 4929, 6365 Rubio M, 4871 Ruchlemer R, 2861 Rudat V, 333 Rudico L, 759 Ruge F, 1321 Ruggieri R, 2149 Ruggiero M, 5525 Ruibal Á, 569 Rumbo-Nava U, 1529 Russi EG, 4949 Russo G, 2577, 3223 Russo I, 4171 Russo M, 3995 Russo SM, 6901 Rütgen BC, 2805 Ruttloff J, 2651 Rwigemera A, 207 Rydlewska M, 2093 Ryoo B-Y, 1967, 1985 Ryoo HM, 3531 Rys J, 3961 Ryska A, 2455 Ryu C-G, 6887 Ryu YJ, 1333 Sadjak A, 31 Sadovska L, 6379 Sadowski D, 4009 Saeed MEM, 1929, 2645,

194 Saeki H, 401, 407, 511, 2299, 2441, 4037, 5023, 6207, 6909 Saeki N, 2619 Saga T, 6623 Sagini K, 149 Saidak Z, 1803 Saiepour D, 3253 Saif MW, 6901 Saigo K, 3307 Saigusa S, 1447, 2849, 3511, 4633 Saijo R, 5915 Saikawa Y, 467 Sainis I, 5857 Saito H, 1437, 4681, 6705 Saito K, 505, 4461 Saito S, 2909 Saito T, 123, 549, 1385, 6591 Saito TK, 6069 Saito Y, 811 Saji S, 2545, 2553, 5821 Sakagami H, 5299, 5341 Sakaguchi Y, 401 Sakai S, 2739, 3495 Sakai Y, 6475 Sakaki H, 6607 Sakakura C, 2191 Sakamaki K, 1703 Sakamoto H, 2619 Sakamoto K, 997, 1647, 2157 Sakamoto N, 4545 Sakamoto T, 4203 Sakamoto Y, 2157, 2359, 4617 Sakata M, 1437 Sakellariou S, 1049 Sakimura S, 123, 1385, 6591 Sakisaka H, 2975 Sakoda M, 6471 Sakuma Y, 6861 Sakurai H, 977, 1757 Sakurai K, 563, 4091, 4889, 4897, 5037, 5369 Sakuramoto S, 419, 445, 897 Sala M, 5655 Salama M, 3117 Saldari M, 6341 Salih HR, 4043 Salone M, 5581 Saltzman D, 843 Salvi F, 5581 Salz R, 5225 Samantas E, 4023 Sambanthamurthi R, 97 Sambasivam G, 229 Sancho IG, 6941 Sand J, 6163 Sandelin M, 3979 Sander S, 5587 Sander W, 5551 Sanders AJ, 1321, 2635 Sanguedolce F, 2175 Sano D, 6861 Sano K, 4665 Sant F, 5655 Santacaterina A, 4949 Santala M, 973, 3393 Santala S, 3393 Santamarta TR, 2949 Santella RM, 3969 Santha S, 3137 Santoni M, 433 Santoni-Rugiu E, 6223, 6731 Santoro A, 543 Santos A, 4219 Santos M, 4219 Santos S, 6971 Saptefrati L, 759 Sarfati B, 4229 Sargon M, 857 Sarici F, 857 Sasada S, 3987 Sasaki Ken, 2279, 2941, 6471 Sasaki Kinro, 949 Sasaki S, 3553 Sasaki Takeshi, 907 Sasaki Tohru, 897 Sasaki Tomikazu, 1339 Sasaki Tomonari, 3591, 4083, 4909 Sasaki Toshihide, 4487 Sasaki Y, 1749, 5485 Sas-Korczynska B, 1041, 4063 Satherley L, 1321 Sato D, 977 Sato H, 2071, 3379 Sato K, 6591 Sato N, 413 Sato S, 6855 Sato T, 261, 3379 Sato Y, 6261 Satoh T, 1683 Satomi A, 2935 Satomi R, 261 Satomura H, 949 Sauer U, 6869 Saviano A, 325 Savvidis C, 819 Sawa N, 4461 Sawada K, 359 Sawaguchi Y, 6431 Sawaki H, 1411 Saygili N, 5425 Scambia G, 3027, 6951 Scartoni D, 3875, 5687 Scartozzi M, 433 Schaller M, 1181 Schallier D, 6317 Schauwecker J, 961 Scheckenbach K, 1271 Scheckinger S, 2571 Schemme J, 2055 Schena M, 6247 Scheurlen M, 2021 Schiavone R, 3041 Schick S, 4277 Schild SE, 333, 385, 3571, 4105, 5701, 6189, 6219, 6793 Schillaci A, 2211 Schillaci O, 4265, 5117 Schillert A, 2055 Schini-Kerth VB, 149 Schirripa M, 2391 Schizas N, 645 Schlenker T, 5881 Schlitt HJ, 6655 Schmeel FC, 835, 1369, 5921 Schmeel LC, 835, 1369, 5921 Schmetzer H, 4043 Schmidt FA, 4955 Schmidt K, 6655 Schmidt M, 5277 Schmidt T, 5623 Schmidt-Wolf IGH, 835, 1369, 1575, 5921 Schmitt N, 3781 Schmitz S, 6517 Schmohl JU, 4043 Schnapauff D, 319 Schneeweiss A, 5085 Schneider J, 6291 Schöllnast H, 4821 Scholz CW, 5091 Schönhofer B, 4151 Schottel J, 843 Schramel FMNH, 5607, 6773 Schrot-Sanyan S, 5503 Schubert A, 635, 2085 Schuler B, 2645 Schuler PJ, 1271 Schultheis B, 1709 Schultz JD, 1389, 1951, 3801 Schulz C-O, 5091 Schumacher U, 5333 Schuster E, 5901, 6667 Schwach G, 31 Schwake L, 5881 Schwartz L, 5503 Sciacero P, 4177 Scialpi M, 3041, 6341 Scognamiglio U, 325 Scopa CD, 2321, 4023 Scorsetti M, 4109 Scott KA, 1499, 5827 Scuteri A, 5383 Sebastián F, 4871 Sebti S, 4599 Seccia V, 269 Seder CW, 6159, 6325 Sedláček O, 753 Sedloev T, 5027 Seeger JB, 6281 Segedin B, 6189 Segreto HRC, 2817 Sehouli J, 1591, 3423, 6329, 6869 Seino M, 85, 6607 Seino S, 85, 6607 Seiz M, 4955 Seki K, 169 Seki N, 337 Sekiguchi K, 4903 Selander T, 841, 1627, 2215, 3543 Selçuk F, 2805 Sellmann L, 5745 Selvaggio O, 2175 Semba H, 1065 Semenov A, 2873 Senadi GC, 6075 Senda Y, 6747 Sendur MA,

195 Sennazli G, 1491 Seo E-J, 1929, 6505 Seo J-Y, 3081 Seo K-W, 4749 Seo Y, 5103 Seo YS, 5047 Seong Y-S, 3829 Sergentanis TN, 1049 Serly J, 6505 Serrano S, 851 Serth J, 5443 Seth A, 2601 Setoguchi T, 3289 Settineri N, 4949 Seya T, 4385 Seyhan F, 5425 Seymer A, 5671 Sgherza N, 461 Shah BK, 1, 3437, 4131 Shah H, 1285 Shameem R, 2333 Shan S-J, 3185 Sharma N, 3441 Sharma S, 1567 Shen C, 4829 Shen M-Y, 4975 Sherbet GV, 5767 Shi B, 3175 Shiba H, 499, 4203, 4961, 5079 Shibasaki Y, 4461 Shibata K, 505 Shibata T, 2385 Shibata Y, 371, 4647 Shibutani M, 677, 5037, 5369 Shibuya K, 85 Shida A, 3575 Shigematsu K, 2929 Shigeyoshi I, 6747 Shih L-S, 1121 Shih T-C, 4975 Shih T-Y, 795 Shih W-L, 6583 Shim CS, 6985 Shimabe M, 1997 Shimada Kazuaki, 2255 Shimada Kazuhiro, 907 Shimada Keiji, 2287 Shimada M, 2071 Shimada Yutaka, 719, 1815, 3821 Shimada Yasuhiro, 2255, 5055 Shimakawa T, 2969 Shimamatsu S, 1791 Shimazaki A, 2969 Shime H, 4385 Shimizu D, 907 Shimizu M, 4647, 5821 Shimizu N, 5559 Shimizu R, 6261 Shimizu T, 1683, 6563 Shimizu Y, 6747 Shimokawa M, 3525 Shimokawa T, 6705 Shimura T, 1447, 2849, 4633, 5639 Shin I-S, 159 Shinden Y, 123, 1385, 6591 Shindo Y, 129 Shiono O, 6861 Shiota M, 6137, 6925 Shioyama Y, 3591, 4083, 4909 Shiozaki A, 2191 Shiozawa M, 2401, 4865 Shiozawa S, 2969 Shirabe K, 1691, 2475, 2867, 3061, 3411, 3525, 4077, 4167, 6963 Shirai K, 1229 Shirai Y, 499, 4961, 5079 Shiraishi K, 4903 Shiraiwa S, 4403 Shirasawa S, 4419, 4453, 4493 Shiroyama T, 1663, 3987 Shivarudraiah P, 229 Shkeir O, 1861 Sho M, 1361, 2287 Shohet JM, 3787 Shoji H, 5055 Shonka N, 5467 Shui H-A, 2725 Shvidel L, 2861 Šiaurys A, 6573 Sica G, 1881 Sicignano G, 2149 Sick E, 149 Sideris M, 2345 Sidhu PS, 6001 Sidorko M, 6001 Sieg P, 2593 Siew EY, 531, 6639 Sigal-Batikoff I, 1881 Sikic D, 4277 Silva TB, 2881 Silvaggi NR, 6001 Simonetti O, 2113 Simontacchi G, 3875, 5687 Singh ATK, 6425 Singh N, 1867 Singh NP, 1339 Singh RK, 6001 Sirén J, 6163 Sivolapenko G, 1377 Sivolella S, 4837 Siwicki JK, 2423 Skalický T, 2241 Skopeliti M, 1543 Skyttä T, 1559, 2141 Slany R, 5271 Slodkowska E, 2601 Slodnik P, 767 Smejkal J, 3537, 4855 Śmiałowska-Janiszewska A, 989 Smirnova E, 2873 Smith C, 5615 Smith L, 5467 Smolle E, 875 Snyder CS, 2545 So KS, 1537 So Y, 6985 Soares BM, 1465 Sobajima J, 505 Sobel A, 5271 Socola F, 3431 Soejima K, 261 Sogo S, 1251 Soini Y, 973, 3393, 6465 Solares C, 6291 Solass W, 1709, 2309, 6723 Soliman KFA, 1263 Solivetti FM, 6121 Sollazzo P, 6341 Soma G-I, 4393, 4461, 4467, 4509 Somlai C, 6505 Somlai K, 5063 Sommer JU, 1389, 1951 Son JW, 2611 Song G-W, 1967, 1985 Song HS, 3531 Song JH, 6833 Song KS, 3925 Song Y, 2663 Sonmez K, 1491 Sonoda K, 3447, 5993 Sonoda T, 4191, 4923 Soppa G, 2823 Sordillo LA, 6373 Sordillo PP, 599, 6373 Sørensen JB, 6223, 6255, 6731 Soroush F, 2531 Sort P, 5655 Sortica VA, 2009 Sottili M, 3875 Souda H, 1815 Souzaki R, 4433 Spaggiari P, 4109 Spaka I, 6979 Spaks A, 6979 Spanu A, 4265 Speel E-J, 1835 Speiser P, 5901, 6667 Spengler G, 2105, 3245, 5915 Spick C, 6787 Spiekermann M, 117 Spielmann RP, 5185, 6841 Spies C, 1591 Squatrito S, 3995 Srinivasan S, 5773 Sritularak B, 201 Środa-Pomianek K, 2835 Sromek M, 2423 Staebler A, 3479 Staffurth J, 5615 Stallone G, 2175 Stamatoullas A, 2999 Stánitz É, 1091 Starzec W, 989 Stasinou T, 3075 Šťastný M, 6303 Stättner S, 6127 Stauffer RG, 6425 Stec A, 1657 Stec R, 4575 Steer CJ, 3761 Steigerwalt J, 5353 Steiner G, 2675 Steiner N, 2165 Steinhoff J, 1797 Stengel C, 5249 Stenmarker M, 2841 Stenram U, 6147 Stenzel-Bembenek A, 1115 Stephan C, 2651 Stepulak A, 1115, 1715 Sterenczak KA,

196 Stern M, 1085 Sterpetti AV, 2211 Steurer M, 5129 Stevens D, 5111 Stock A-M, 5277 Stoczynska-Fidelus E, 2759 Stoecklein N, 6153 Stoecklinger A, 4697 Stoica C, 2169, 5547 Stojakovic T, 3463 Stokes M, 1311 Stokke T, 3743 Stone WL, 1851 Stotz M, 5737 Stracci F, 6341 Stracke A, 31 Straume B, 6401 Streb J, 989 Stremmel W, 5881 Strieth S, 2571 Strikic A, 4161 Stroescu C, 5123 Strohm GL, 1977 Stromberger C, 2991 Studenovský M, 753 Stupack DG, 4799 Sturiale C, 1743 Styczynski J, 5667 Su S-W, 6615 Su Y-C, 3299 Suekane S, 3415 Suenaga M, 4059 Suetsugu A, 2545, 2553, 4647, 5225, 5821 Sugae S, 907 Sugahara T, 3379 Suganami A, 1353 Sugano K, 677 Sugimachi K, 123, 1385, 6963 Sugimoto M, 6137, 6925 Sugimura K, 6739 Sugita K, 4059 Sugita Y, 5299, 5341 Sugiura Y, 4681 Sugiyama D, 4479, 4493 Sugiyama H, 555, 1251, 1607 Sugiyama K, 6041 Sugiyama M, 6577 Sugiyama T, 6671 Suh DH, 3909, 4197 Sukrong S, 2827 Sukumaran SK, 229 Sul H-J, 3925 Sule N, 2857 Sullivan CA, 6049 Sulová Z, 2627 Sumida T, 4551 Sumino Y, 2205, 2269 Sumiya Y, 4441, 4447 Sun P-H, 1321 Sun S, 6487 Sun Y, 3193, 5317 Sunagozaka H, 1423 Sunami E, 1459, 2983, 5073, 6599 Sundaram S, 3839 Sundset M, 935 Sundström M, 3979 Sunela K, 921 Sung M-W, 4235 Suo Z, 3743, 3793, 5533 Surov A, 5185, 6841 Sutani A, 389 Suto T, 3581 Suyama S, 3415 Suzuki E, 549 Suzuki G, 5167 Suzuki Hidekazu, 1663, 3987 Suzuki Hidenori, 1009 Suzuki Kazuhiro, 5559 Suzuki Kenichi, 4059 Suzuki O, 505 Suzuki Satoshi, 4425 Suzuki Shuhei, 85, 6607 Suzuki Yoshihiko, 2909 Suzuki Yoshiyuki, 1229 Suzuki Yuta, 6069 Suzuki Yuzo, 1791 Svobodova S, 3537 Sweet K, 6355 Swiercz A, 2423 Swierczynski S, 6127 Sydow VON, 5813 Sykorova V, 2029 Sylvestre E, 6881 Syrigos K, 1129, 1543 Syrjänen K, 2873 Syrjänen KJ, 2881 Syu Y-R, 2725 Szabó Tönki Á, 5915 Szczęśniak-Sięga B, 2835 Szczylik C, 4575 Szeberényi J, 5401 Szekeres K, 25 Szentmártoni G, 5063 Szigeti K, 2857 Szmit S, 989 Szolkowska M, 3353 Sztiller-Sikorska M, 2747 Szuba A, 3341, 3353 Tabata A, 4411, 4515 Tabbara IA, 5149 Tabor MK, 3185 Tabouret E, 2901 Tachibana K, 2739, 4757 Tachibana T, 6069 Tachihara M, 3885 Tachikawa R, 1025 Tada Y, 6069 Tadmor T, 2861 Taga S, 2063 Tagawa T, 1791, 3411 Tagliamonte V, 1017 Taguchi K, 4859 Taguchi S, 3379 Taguchi T, 427, 4433, 6861 Taguri M, 6855 Tahara T, 1997 Tai P, 2431 Taira K, 3987 Tajima T, 2375, 6781 Tajiri H, 555 Tak E, 1967, 1985 Takács D, 3245 Takada K, 1791 Takagi Y, 6705 Takahari D, 1815 Takahashi Hidenori, 6739 Takahashi Hiromichi, 5473 Takahashi Masahiro, 6861 Takahashi Masakazu, 949 Takahashi O, 379 Takahashi R, 1603 Takahashi S, 169 Takahashi Takao, 6175 Takahashi Toshiaki, 4259 Takahashi Tsunehiro, 467 Takahashi Tsuyoshi, 891, 2223 Takahashi W, 4903 Takahashi Yoko, 4527 Takahashi Yoshihito, 3575 Takaishi H, 467 Takakura K, 555 Takakuwa O, 5241 Takamatsu Y, 4881 Takami S, 555 Takamori H, 3033 Takano Y, 123, 1385 Takao K, 5299, 5341 Takarabe S, 6765 Takashima A, 2255, 5055 Takashima S, 1251 Takashima T, 6475 Takasu C, 2071 Takata R, 6475 Takayama K, 3103 Takechi T, 1437, 4605 Takeda H, 85, 6607 Takeda Kazuhisa, 6855 Takeda Koji, 3987 Takeda M, 1683 Takeda Yuichiro, 1607 Takeda Yutaka, 2975 Takei M, 5473 Takeishi K, 1691, 2475, 2867, 3061, 3411, 3525, 4077, 4167 Takemoto M, 6231 Takemura M, 5241 Takeno A, 2975 Takenokuchi M, 3307 Takeshita F, 5201 Takeshita Hiroaki, 1073 Takeshita Hiroki, 2191 Takeshita J, 1025, 3103 Takeshita N, 1353 Takeshita T, 881, 1401 Taketani K, 2341, 4135, 6829 Taketomi Y, 2983 Takeuchi A, 493, 6137, 6925 Takeuchi H, 467 Takezawa Y, 5559 Takiguchi S, 891, 2223 Takiguchi Y, 6705 Takii Y, 1815 Talacchi A, 1743 Talerczyk M, 989 Talvensaari-Mattila A, 973, 3393 Tamada K, 129 Tamaki T, 1009 Tamesa T, 997 Tamiya M, 1663, 3987 Tamura K, 4881 Tamura S, 2975 Tamura T, 563, 1683, 5369 Tamura Y, 1353,

197 Tan JFV, 713, 3385 Tan M-H, 6639 Tan SY, 531 Tan J, 531 Tanabe M, 907 Tanabe S, 897 Tanahashi T, 5485 Tanaka Akito, 6563 Tanaka Ayako, 1663 Tanaka H, 563, 4091, 4889, 4897, 5037, 5369 Tanaka I, 3217 Tanaka J, 2983, 5073, 6599 Tanaka Kaori, 1749 Tanaka Koji, 1447, 2849, 3511, 4633, 5639 Tanaka Kosuke, 1025 Tanaka Kuniya, 697, 6855 Tanaka M, 4535 Tanaka R, 371 Tanaka Sachiko, 6041 Tanaka Shinichi, 6909 Tanaka T, 413, 2983, 5073, 6599 Tanaka Yoshihiro, 5485 Tanaka Yuka, 4479, 4493 Tanaka Yuriko, 5317 Tandstad T, 1619 Tang D, 3193 Tang X, 4829 Tang Y, 2531 Tanguay J, 5615 Tani E, 1663 Tani S, 4191, 4923 Taniguchi D, 3411 Taniguchi H, 2975 Taniguchi K, 6855 Taniguchi T, 3307 Tanii S, 1251 Tanimura S, 4881 Tanji N, 3379 Tanoue Y, 407 Tarantini G, 461 Tarkowski R, 1115 Tatematsu Y, 4411, 4515 Tatsugami K, 6137, 6925 Tatsuki H, 3581 Tatsumi N, 1251 Tatsumi Y, 4681 Taubert H, 4277, 5271 Tavolozza M, 4265 Tawada A, 549 Tawadros PS, 3761 Tawinwung S, 4789 Teh BT, 531 Teh BT, 6639 Teixidó C, 4871 Tekautz T, 3013 Tempfer CB, 1709, 2309, 6723 Teng Lesheng, 5433 Teng Lirong, 5433 Tepel J, 2961 Ter Haar NT, 4015 Terahara A, 4903 Terai E, 3553 Terai H, 261 Terai K, 1279 Terakubo S, 5299, 5341 Teramachi H, 2063 Teraoka S, 6261 Terashima H, 1757 Terashima K, 3591 Terracciano D, 1017 Terrenato I, 5117 Terry MB, 3969 Tertipi A, 4251, 6933 Terzea D, 2169 Teske KA, 6001 Tewari AK, 5007 Thaler J, 517 Thalgott M, 5679 Theard S, 6761 Thibodeau BJ, 5973 Thierauf J, 1271 Thill M, 1189, 1197, 1797 Thoma V, 4183 Thomas MP, 5249 Thomas SA, 6761 Thomé C, 4955 Thompson MP, 1211 Thorns C, 2055 Thuy Trang N, 4215 Thway K, 6213 Tilly H, 2999 Timirci Kahraman Ö, 255 Ting C-Y, 3867 Tini P, 4117 Titopoulos H, 1675 Tixier S, 3471 To K, 1073 Tofani S, 4177 Togashi K-I, 389 Togashi Y, 2005 Toh CK, 6639 Toh Y, 4859 Tohyama K, 6193 Toiyama Y, 1447, 2849, 3511, 4633, 5639 Tőkés T, 5063 Tokuda K, 3217, 3861, 6063 Tokuhisa Y, 997 Tokumitsu Y, 997 Tokunaga K, 4487 Tokunaga M, 3861, 6063 Tokunaga R, 4617 Tokunaga S, 3987 Tokunaga T, 2071, 6679 Toldo C, 461 Tolkach Y, 5443 Toma-Dasu I, 935, 6091 Tomaschitz A, 1161 Tomatir AG, 4807 Tomatis S, 4109 Tomeh N, 6761 Tomescu D, 5539, 5543 Tomii K, 1025, 6261 Tominaga Y, 427 Tomita H, 1749 Tomoda M, 3489, 6671 Tomoyasu T, 4411 Topolcan O, 955, 2455, 3537, 4855 Torgyík L, 5063 Torigoe T, 413 Torregrosa D, 6941 Tortorella L, 3027 Tosoni A, 1743 Tóth C, 1091 Touboul C, 6799 Toussaint LG, 3209 Toya W, 4059 Toyokawa T, 563, 4091, 4889, 4897, 5037, 5369 Toyota T, 1353 Toyozumi T, 1353 Tozzi A, 4109 Tramacere F, 3049 Tranberg K-G, 6147 Trang NT, 3571, 5515, 5701 Trapani D, 6223 Trapé J, 5655 Trávníček I, 5661 Tredici G, 5383 Trendowski M, 65 Trenkle T, 2593 Třeška V, 2241, 3537 Treskova I, 3537 Triantafillou E, 4251, 6933 Trinchet J-C, 1803 Trivizaki E, 4251 Troelsen JT, 2235 Troiano F, 2175 Trombert B, 3559 Tromp E, 6773 Trong Khoa M, 4215 Trope CG, 3743 Truchot C, 149 Tryfon S, 1675 Tsagouli S, 1129 Tsai C-H, 3893, 4691 Tsai CH, 729 Tsai C-W, 2725, 3893, 4691, 4975, 5417, 6297 Tsai C-Y, 1033, 2263 Tsai J-H, 4207 Tsai M-H, 1735 Tsai SYC, 1121 Tsangaris GT, 1881 Tsapanos V, 2321 Tsartsalis D, 1543 Tseng L-H, 4207 Tsilika E, 1771 Tsitsilonis O, 1543 Tsou Y-A, 1735 Tsubamoto H, 4191, 4923 Tsubata Y, 389 Tsuboi A, 1251 Tsuchiya A, 6563 Tsuchiya H, 493 Tsuchiya T, 1073 Tsuciya H, 2063 Tsuda Y, 2299, 5023, 6207 Tsugu H, 4757 Tsuji H, 5559 Tsujita E, 1691, 3061, 6963 Tsujiwaki S, 1475 Tsukada K, 719, 3821 Tsukiyama I, 2199, 4681 Tsumura S, 1065 Tsunedomi R, 997 Tsuno NH, 1459 Tsunoda T, 4419, 4453 Tsurumi H, 4647 Tsuruta A, 6193 Tsuruta N, 3585 Tsutsumi J, 4203 Tsutsumi S, 3581 Tsutsuyama M, 6747 Tuettenberg J, 4955 Tung M-C, 5007 Tunoglu S,

198 Tuohinen S, 1559, 2141 Tupý R, 955 Turáková K, 2627 Turan S, 255, 2709, 3933, 5391 Turco E, 6805 Tuzuner MB, 5425 Tzakos AG, 5857 Tzelepi V, 2321 Uchakina O, 5231 Uchi R, 123, 1385, 6591 Uchida J, 1437, 3885 Uchida K, 4551, 4633 Uchihara T, 2867 Uchikado Y, 2279, 2941, 6471 Uchino K, 371 Uchino Y, 5473 Uchugonova A, 5225 Ueda K, 3415 Ueda Masami, 123, 1385, 6591 Ueda Michio, 6855 Ueda S, 1683 Ueda Taeko, 4521, 4527 Ueda Takeshi, 1361 Ueda Yuki, 239 Ueda Yutaka, 359 Uehara F, 697 Uemura N, 6747 Uemura T, 5241 Uenami T, 2935 Ueno M, 4865 Ueno S, 6431 Uenosono Y, 2279, 6471 Ueo Hiroaki, 123 Ueo Hiroki, 123 Uesawa Y, 2909, 5299, 5341 Ueyama J, 4681 Ueyama Y, 4551 Uhercsák G, 4967 Uhl W, 767 Uivarosi V, 3371 Ulbrich K, 753 Ulmer H, 517 Ulukaya E, 1491 Umbreit C, 1389, 1951, 3801 Umemura S, 1697 Uner A, 857 Uozaki H, 6819 Urakawa MM, 2401 Urata S, 5031 Urata Y, 3885 Uratani R, 5639 Urayama KY, 379 Ürge T, 5661 Urso L, 2183 Usami K, 1997 Ushoida M, 929, 1433 Usman A, 97 Usuda A, 2969 Usuda R, 389 Usui T, 2969 Utnes P, 2521 Uto Y, 4441, 4447, 4487, 4545 Utsumi H, 2255 Uwagawa T, 4203 Uzan C, 1729, 6105 Vaclavikova E, 2029 Vadgama JV, 39 Vairaktaris E, 1881 Valente M, 4837 Valentini V, 3055, 3441 Valeriani M, 1783, 4171, 5693, 6239 Valicsek E, 4967 Välimäki MJ, 3767 Vallianou NG, 645 Van Beijnum JR, 5945 Van Binst A-M, 5551 Van Den Brekel MWM, 4015 Van Der Graaf WTA, 5601 Van Gorp J, 1835 Van Herpen CML, 5601 Van Lieshout S, 3399 Van Mackelenbergh M, 5623 Van Monsjou HS, 4015 Van Moorselaar RJA, 713, 3385 Van Mourik TR, 5945 Van Oudheusden TR, 295, 627 Van Putte BP, 5607, 6773 Van Ramshorst B, 295 Van Steeland T, 6311 Van Stiphout RGPM, 3441 Van Velthuysen M-LF, 4015 Van Vulpen M, 5607, 6773 Van Wyk HC, 6457 Vanchiere JA, 6411 Vandenbroucke F, 6317 Vandergrift III WA, 615 Vannucci L, 703 Vanwert AL, 5353 Varga Z, 4967 Variami E, 5141 Varma AK, 615 Varthalitis I, 1105 Vasama K, 6163 Vasilescu M, 3371 Vasileva M, 5027 Vasilyev S, 2873 Vass A, 4967 Vassal F, 3559 Vassiliou S, 1881 Vaudaux S, 2999 Vcelak J, 2029 Vecchini G, 4251 Veerapong J, 2121 Vehling-Kaiser U, 6869 Veit JA, 1271 Velasco J, 6291 Velásquez JF, 5461 Velescu BS, 3371 Velidedeoğlu M, 5425 Veninga T, 6189, 6219 Venuti A, 487 Vera P, 2999 Verdorfer I, 5129 Verhagen CVM, 4015 Vernet-Tomas M, 851 Verras M, 4625 Verstovsek S, 5219 Veselý P, 1303 Vetvicka V, 5287 Vetvickova J, 5287 Vezina G, 6267 Vida F, 5655 Vidiri A, 5117, 6121 Vieira PC, 2009 Vieth M, 5333 Vigna-Taglianti R, 4949 Vigneri P, 3995 Vigneri R, 3995 Vildé A, 581 Vilhena H, 3361 Villani V, 5117 Villiotou V, 4251, 6933 Vinci V, 6341 Vincze I, 2105, 6505 Viniou N-A, 5141 Virman J, 921 Virtanen V, 1559, 2141 Vishnubhotla R, 3267 Vivanco-Allende B, 2949 Vizzielli G, 3027 Vlcek P, 2029 Voest EE, 3399 Vogel U, 2021 Vogler C, 2121 Volpin L, 1743 Von Beckerath M, 5813 Von Eisenhart-Rothe R, 961 Von Gersdorff G, 1181 Von Leffern I, 6445 Von Minckwitz G, 5479 Voss A, 5881 Vrdoljak E, 4161 Vu K, 2431 Vyzula R, 3455 Wach S, 4277, 5271 Wada N, 467 Wada T, 2063 Wadsak W, 6787 Wagner A, 4697 Wagner C, 6655 Wagner S, 145 Wakame K, 4501 Wakamori S, 2739 Wakatsuki A, 2199 Wake N, 5993 Wakelee HA, 669 Wakui N, 2269 Waldthaler C, 5129 Walji N, 4841 Walker F, 6799 Walker P, 4243 Wallwiener D, 3479 Wallwork B, 1291 Walter KA, 53 Wanderås AD, 935 Wandhöfer C, 1297 Wang B, 2531 Wang C, 4655 Wang G-J, 191 Wang H, 2475, 4077 Wang H-E, 3867 Wang Jin, 3849 Wang John, 5007 Wang Juan, 4799 Wang Junbai, 3743 Wang Junsheng, 5533 Wang J-J, 6075 Wang JY, 2447 Wang J-Y, 4691, 4975 Wang M, 5433 Wang PS, 191 Wang Rongrong, 4799 Wang Rubin, 5293 Wang S,

199 Wang S-C, 5417, 6297 Wang S-W, 191 Wang S-Y, 1033, 2263 Wang T-C, 2725 Wang Yue, 2531 Wang Yufeng, 1941, 3217, 3861 Wang Y-C, 6075 Wang Z-H, 191 Waraya M, 1411 Warnecke-Eberz U, 6153 Warren WH, 6325 Washington KN, 4723 Watanabe G, 5915 Watanabe H, 1749 Watanabe Kazuhiro, 3489 Watanabe Kazushi, 2199 Watanabe Koshiro, 6705 Watanabe Masahiko, 419, 445, 897, 1411, 3575 Watanabe Masato, 6819 Watanabe Masayuki, 4617 Watanabe N, 1697, 4259 Watanabe Satoshi, 6957 Watanabe Sho, 1607 Watanabe Takashi, 6577 Watanabe Toru, 3821 Watanabe Toshiaki, 1459, 2983, 5073, 6599 Watanabe Toshiyuki, 3553 Watanabe Y, 129 Watarai H, 6607 Watrowski R, 5901, 6667 Wattez N, 5983 Wattiez A, 5503 Webre C, 5467 Weeber F, 3399 Weeks HP, 1321 Wei C, 1321 Wei J, 4983 Weierstahl KA, 805 Weiss C, 1951, 3801 Weisser B, 5623 Wellner U, 4105 Weltermann A, 517 Wen J-G, 5533 Weng S-W, 2077 Wenzel A, 3801 Werner JA, 5499 Wesołowska O, 2835 West R, 669 Wharton R, 1641 Wheeler E, 3175 Whitaker-Dowling P, 4593 Whitehead MT, 6267 Wichmann G, 3917 Wiedower E, 6287 Wiegand S, 5499 Wieners G, 319 Wienke A, 5185, 6841 Wiezer MJ, 295 Wiggenhauser SP, 1271 Wild J, 4043 Wilhelm T, 5499 Willenbacher W, 2165 Willenbrock S, 1917, 2805 Wilsgaard T, 1619 Wilson GD, 5973 Winchester A, 1549 Winchester D, 3811 Windrichova J, 3537, 4855 Windt T, 3245 Winfield LL, 6419 Wirtz RM, 4023 Wischnik A, 6869 Wiśniewski JR, 6551 Witkiewicz W, 3317 Wlodarczyk W, 2991 Woeste A, 1189, 1197 Wojtyra P, 3961 Wolf A, 5901, 6667 Wolff J, 3013 Wolke J, 6091 Womack C, 1641 Won Y-J, 1967, 1985 Wong B, 531 Wong JC, 273 Wong STS, 6487 Wong V, 65 Woo SH, 6833 Wozniak M, 2747, 6551 Wu C-N, 5417 Wu C-W, 1345 Wu H-C, 2725, 3969 Wu H-G, 245 Wu M, 3193 Wu P-F, 1521 Wu S, 2333 Wu T-S, 5407 Wu W-H, 1809 Wu Y, 1321 Wullich B, 4277, 5271 Wyatt R, 5567 Wysocki M, 5667 Wysocki PJ, 3275 Xian S, 4707 Xie J, 5433 Xie Q, 3185 Xu B, 2857 Xu R, 5533 Yabuki K, 6861 Yabushita H, 2199 Yaegashi H, 1603 Yaegashi N, 4665 Yaghmour G, 3091 Yagi H, 3447, 5993 Yagita H, 129 Yahagi H, 5299 Yahata H, 3447 Yahya S, 5567 Yajima A, 2909 Yajima R, 3581 Yajima T, 2411 Yamada H, 4487 Yamada K, 6705 Yamada M, 6175 Yamada S, 493 Yamada Teppei, 4881 Yamada Tesshi, 1663 Yamada Tomohiro, 4551 Yamada Y, 2255, 5055 Yamagishi S-I, 1703 Yamaguchi Akio, 239 Yamaguchi Ayami, 1997 Yamaguchi H, 1459, 2983, 5073, 6599 Yamaguchi Kazuya, 5485 Yamaguchi Kentaro, 2969 Yamaguchi Norihiro, 261 Yamaguchi Nozomi, 881 Yamaguchi R, 1703 Yamaguchi Satoru, 949 Yamaguchi Shohei, 4859 Yamaguchi Tetsuji, 3821 Yamaguchi Toshiharu, 4059 Yamaguchi Toshihiko, 2935 Yamaguchi Toshihiro, 3591, 4083, 4909 Yamaguchi Y, 221 Yamakoshi Y, 1861 Yamamoto H, 6591 Yamamoto Mako, 697 Yamamoto Manabu, 4859 Yamamoto Masaaki, 891 Yamamoto Masato, 5201 Yamamoto Masayoshi, 3289 Yamamoto Michiko, 6705 Yamamoto Naoto, 2401 Yamamoto Norio, 493, 2553 Yamamoto T, 4551 Yamamoto Yoshihiro, 2199 Yamamoto Yusuke, 2921 Yamanaka N, 4191, 4923 Yamane T, 5993 Yamaoku K, 2401, 4865 Yamasaki M, 891, 2223 Yamasaki N, 1073 Yamashita Hideomi, 4903 Yamashita Hiroharu, 1459 Yamashita Keishi, 419, 445, 897, 1411 Yamashita Kimihiro, 4425 Yamashita T, 1423 Yamashita Yoichi, 3411 Yamashita Yoshinori, 389 Yamashita Yoshito, 4889, 4897 Yamashita Yuichi, 4881 Yamashita Y-I, 1691, 2475, 2867, 3061, 3525, 4077, 4167 Yamato I, 2287 Yamato M, 6481 Yamauchi H, 379 Yamauchi K, 977, 1669 Yamauchi T, 379, 4599 Yamazaki H, 3575, 5167, 6231 Yamazaki K, 1815, 4003 Yamazaki R, 6431 Yamazoe S, 5037 Yan J, 5839 Yan L, 3839 Yanaga K, 499, 3489, 4203, 4961, 5079 Yanagisawa Y, 1641 Yanar K, 5391 Yang C-K, 5007 Yang L-X, 2479, 2487 Yang M, 2539, 2553, 4655 Yang M-D, 795, 2691, 5417 Yang MH, 183 Yang M-Y, 6615 Yang Sera, 183 Yang Shuang, 5433 Yang X, 5433 Yang Y, 4829 Yang Y-H, 1809 Yang Y-L, 3167 Yang Z, 3193 Yano K, 2739, 4757 Yano M,

200 Yano S, 697 Yano Y, 2935, 3885 Yasuda Hiromi, 1447, 3511, 4633 Yasuda Hiroyuki, 261 Yasuda K, 6599 Yasuda S, 1361, 2287 Yata Y, 5851 Yatabe M, 2909 Yaylim I, 255, 2709, 3933, 5391 Ye L, 1321 Yeh C-C, 3167 Yeh C-N, 1033, 2263 Yeh K-H, 4207 Yeh T-S, 1033, 2263 Yencilek F, 6057 Yenilmez EN, 3933, 5391 Yerokun T, 6419 Yi M, 6271 Yi YW, 3829 Yigit F, 1491 Yildirim A, 6057 Yilmaz SG, 6057 Yilmaz VT, 1491 Yilmaz-Aydoğan H, 5425 Yin G, 3193 Yin TC, 2447 Ying T-H, 4691 Yoda S, 261 Yoh K, 1697, 4259, 6475 Yokobori T, 949, 2411 Yokokawa T, 4059 Yokomizo A, 6137, 6925 Yokomizo H, 2969 Yokosuka O, 549 Yokota S, 2935, 3885 Yoneda T, 2935 Yonehara A, 4479 Yonesaka K, 1683 Yoneyama K, 881, 1401 Yoo HJ, 5047, 5453, 6529 Yoo HY, 3333 Yoon S, 3531, 4741 Yoon S-Y, 1985 Yoon SY, 6985 Yörüker EE, 2435 Yoshida A, 1607 Yoshida Kazuhiro, 1749, 5485, 6175 Yoshida Ken, 5167 Yoshida Kosaku, 555 Yoshida M, 1423 Yoshida Naohiro, 4403 Yoshida Naoya, 2359, 4617 Yoshida R, 2341, 6829 Yoshida Takeshi, 1683 Yoshida Teruhiko, 2619 Yoshida Tsukihisa, 1791 Yoshida Yoichiro, 4881 Yoshida Yoshihiro, 1691 Yoshihisa H, 4757 Yoshikawa K, 2071 Yoshikawa M, 549 Yoshikawa T, 2401 Yoshimasu T, 2669, 5851 Yoshimatsu K, 2969 Yoshimura K, 129 Yoshino K, 359 Yoshino S, 129, 997 Yoshino T, 4003 Yoshioka H, 1025 Yoshioka Y, 5167, 6231 Yoshitake T, 3591, 4083, 4909 Yoshiya S, 2341, 4135, 6829, 6963 Yoshiyama A, 2375 Yoshizawa Y, 811 Yoshizuka N, 4003 Yoshizumi T, 2475, 2867, 3061, 3411, 3525, 4077, 4167 Yotsumoto F, 4433 You L, 3167 Youn H-Y, 159, 4749 Yousaf N, 473 Yu C-C, 3867 Yu C-H, 191 Yu E, 2431 Yu E-M, 5149 Yu F-S, 2077 Yu G, 65 Yu J-H, 6271 Yu JQ, 2783, 6027 Yu W, 4829 Yuan NY, 6001 Yueh T-C, 4691, 5417 Yuge K, 4403 Yukaya T, 5023 Yun HJ, 785 Yunotani S, 3585 Yvorel V, 3559 Zabel M, 6009 Zacny JP, 1777 Zage PE, 3787 Zago G, 2183 Zagouri F, 1049, 4023 Zahnd W, 4009 Zaitsu Y, 2299, 6207 Zaitu Y, 5023 Zajdel M, 2423 Zänker KS, 5277 Zaucha JM, 989 Zeillinger R, 5901, 6667 Zekaj S, 1513 Zervakis K, 5141 Zeybek U, 3933, 5391 Zhang D, 5839 Zhang Lei, 3185, 5225 Zhang Lijiang, 1321 Zhang Linna, 3787 Zhang M, 5533 Zhang Nan, 661, 697, 3755, 4641 Zhang Ning, 4829 Zhang S, 3193 Zhang X, 5293 Zhang X-Q, 6487 Zhang Yifan, 5839 Zhang Yilin, 4655 Zhang Yong, 661, 697, 3755, 4641, 5225 Zhang Z, 4053 Zhao G, 4655 Zhao M, 661, 3755, 4641, 5225 Zhao Q, 4829 Zhao W, 6049 Zhelev Z, 6623 Zheng B, 5433 Zheng L, 1861 Zhi X, 1321 Zhong Y, 3743, 5533 Zhou F, 5533 Zhou W, 4799 Zhou Y, 4557 Zhu J, 2635 Zhuang JTF, 6487 Zid Z, 1763 Zieba J, 2759 Zieker D, 6655 Zigeuner R, 3463 Zimling ZG, 6731 Zimmermann A, 5499 Zinchenko GN, 2657 Ziółkowski P, 6551 Zografos GC, 19, 1049 Zouiouch F, 1763 Zuba-Surma E, 3341 Zuziak D,

201 Errata Volume 33, No. 12, page 5301: Authors and affiliations should read: Silicate Fiber-based 3D Cell Culture System for Anticancer Drug Screening YOSHIE YAMAGUCHI 1,3*, DAWEI DENG 1*, YOSHINORI SATO 1, YUNG-TE HOU 1, RIE WATANABE 2, KOHEI SASAKI 2, MASAAKI KAWABE 2, EIICHI HIRANO 1 and TETSUO MORINAGA 1 1 Japan Bio Products Co., Ltd., Aikawa, Kurume, Fukuoka, Japan; 2 Japan Vilene Company Ltd., Koga, Ibaraki, Japan; 3 Department of Bioscience and Biotechnology, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan Volume 34, No. 5, page 2297: The affiliation of the first Author should read: JOSEPH KIM * * ROK Army, Seoul, Republic of Korea Volume 34, No. 7, page 3807: Authors and affiliations should read: HAN SUNG KANG 1, JOSEPH KIM 2, SANG-GEUN JANG 1, SUN YOUNG KWON 3, YOUNG SOO PARK 4, JEFFREY E. GREEN 5, HARK KYUN KIM 1 and JUNGSIL RO 1 1 National Cancer Center, Goyang, Republic of Korea; 2 ROK Army, Seoul, Republic of Korea; 3 Keimyung University DongSan Medical Center, Daegu, Republic of Korea; 4 Asan Medical Center, Seoul, Republic of Korea; 5 Laboratory of Cancer Biology and Genetics, National Cancer Institute, Bethesda, MD, U.S.A. Volume 34, No. 8, pages : In Figures 2 and 3 the unit of Duration should be Duration (years). Volume 34, No. 8, page 4589: The second key word should read: GcMAF Volume 34, No. 10, page 5233: Left column, the second sentence should read: CLTM1L confers resistance to apoptosis caused by genotoxic agents in association with up-regulation of the anti-apoptotic protein, B-cell lymphoma-extra large (BCL-XL) (84, 85). Volume 34, No. 10, page 5240: After Reference No. 83, please add: 84 James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, You M: Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15:33 locus. PLoS One 7(6): e36116, James MA, Vikis HG, Tate E, Rymaszewski AL, You M: CRR9/CLPTM1L regulates cell survival signaling and is require for Ras transformation and lung tumorigenesis. Cancer Res 74: ,

202 Volume 34, No. 11, page 6345: The name of the first Author should read: MUKTI N. MISHRA Volume 34, No. 12, pages : The term linked or linkage studies should be replaced by associated or association studies, throughout this paper. Volume 34, No. 2, page 7207: The name of the second Author should read: LISE M. LINDAHL Volume 34, No. 12, page 7407: The name of the first Author should read: CHIN HOCK GOH Volume 35, No. 1: In the Contents, page numbers 47, 53, 65, 77, 85, 97, 107 should be changed to: 39, 47, 53, 65, 77, 85, 97 Volume 35, No. 2, page 835: An asterisk should be added after the name of the second Author: FREDERIC CARSTEN SCHMEEL 1,2* Volume 35, No. 3, page 1271: The name of the fifth Author should read: PAUL SEVERIN WIGGENHAUSER 3 Volume 35, No. 4, page 2021: The name of the first Author should read: HOLGER G. HASS Volume 35, No. 4, page 2292: The following note should be added to the legend of Figure 3: Figure 3C was reproduced with the permission of the authors from the article J Exp Clin Cancer Res Mar 28;34(1):30. doi: /s Volume 35, No. 5, page 2601: Line 27 of right column should read: the molecular pattern of tumors found in the Saudi Arabian Volume 35, No. 5, page 2609: Table V should be replaced by: (see Table V on the next page) 7196

203 Table V. Comparison of the mutation frequency with global Minor Allelle Frequency (MAF) in 1000 genome phase 1 population. The mutations from 10 Canadian patients (20 alleles) and 10 Saudi Arabian patients (20 alleles) were compared with 1000 genome phase 1 population Minor Allele Frequency (MAF) data from 1,088 people (2,176 alleles). Only mutations found in at least 2 patients were included. SNVs predicted to be probably or potentially deleterious by PolyPhen-2 ( are shown in green. 7197

204 Volume 35, No. 5, page 2610: Acknowledgements should read: Acknowledgements This work was funded by the University of Dammam, grant # and the Canada Foundation for innovation, project # We thank Mohammad Akbari and Steven Narod for their help in designing the Breast and Ovarian Cancer Predisposing panel. The Authors thank Tanya Jorden for creating hyperlink for Table III. Volume 35, No. 5, page 3041: The names of the Authors should read: MICHELE SCIALPI 1, RAFFAELE SCHIAVONE 2, ALFREDO D ANDREA 4, ISABELLA PALUMBO 3, MICHELLE MAGLI 5, SABRINA GRAVANTE 1, GIUSEPPE FALCONE 1, CLAUDIO DE FILIPPI 2, LUCIA MANGANARO 7 and BARBARA PALUMBO 6 Volume 35, No. 6, page 3190: The Acknowledgements should read: Acknowledgements The project was supported by Dr. Jacqueline M. Junkins-Hopkin s personal finance and the Jiangxi Provincial Department of Science and Technology grant (No.20142BBA13045). We thank Mr. Jonathan Thuong for excellent technical support. Volume 35, No. 6, page 3409: The Acknowledgements should read: Acknowledgements This work received financial support through the project entitled CERO - Career profile: Romanian Researcher, grant number POSDRU/159/1.5/S/135760, cofinanced by the European Social Fund for Sectoral Operational Programme Human Resources Development Volume 35, No. 6, page 3563: Line 22 of the abstract should read: a 5-year OS of 48.8%. No difference was found between Volume 35, No. 7, page 3844: Figure 4 should be replaced by: 7198

205 Volume 35, No. 9, page 4642: Right column, first line, in the paragraph entitled: Mammary fat pad injection of 4T1-RFP cells. the words nude mice should be replaced by the words Balb/c mice. Volume 35, No. 10, page 5391: The affiliation of the 7th Author, UFUK C, AKATAY 2 should read: 2 Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey; Volume 35, No. 11, page 6050: The third line of the right column should read: lung injury (ALI) mice (38, 39). Radiation-induced muscle 7199